<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0411211258
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2021
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Squadaion
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        BENDAMUSTINE HYDROCHLORIDE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        25
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Lyophilisate for solution for injection
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        242.50
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Mylan Laboratories Limited" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Mylan Laboratories Limited
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 5165]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Viatris Arabia Limited
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Mylan Laboratories Limited
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        L01AA09
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>SQUADAION</strong></p><p>Bendamustine Hydrochloride for Injection</p><p>25 mg/vial &amp; 100 mg/vial</p><p>&nbsp;</p><p><strong>COMPOSITION</strong></p><p>Each vial contains: Bendamustine Hydrochloride 25 mg.</p><p>Each vial contains: Bendamustine Hydrochloride 100 mg.</p><p>&nbsp;</p><p><strong>EXCIPIENTS</strong></p><p>Mannitol, Tertiary butyl alcohol.</p><p>&nbsp;</p><p><strong>PRODUCT DESCRIPTION</strong></p><p>Lyophilized Powder for Injection. White to off-white lyophilized powder.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>PHARMACOLOGY</strong></p><p>Pharmacodynamic properties</p><p>Pharmacotherapeutic group: Antineoplastic agents, alkylating agents.</p><p>ATC code: L01AA09.</p><p>&nbsp;</p><p><strong>Pharmacodynamic properties</strong></p><p>Bendamustine hydrochloride is an alkylating antitumour agent with unique activity. The antineoplastic and cytocidal effect</p><p>of bendamustine hydrochloride is based essentially on a cross-linking of DNA single and double strands by alkylation.</p><p>As a result, DNA matrix functions and DNA synthesis and repair are impaired. The antitumour effect of bendamustine</p><p>hydrochloride has been demonstrated by several <em>in vitro </em>studies in different human tumour cell lines (breast cancer, nonsmall</p><p>cell and small cell lung cancer, ovarian carcinoma and different leukaemia) and <em>in vivo </em>in different experimental</p><p>tumour models with tumours of mouse, rat and human origin (melanoma, breast cancer, sarcoma, lymphoma, leukaemia</p><p>and small cell lung cancer).</p><p>Bendamustine hydrochloride showed an activity profile in human tumour cell lines different to that of other alkylating</p><p>agents. The active substance revealed no or very low cross-resistance in human tumour cell lines with different resistance</p><p>mechanisms at least in part due to a comparatively persistent DNA interaction. Additionally, it was shown in clinical studies</p><p>that there is no complete cross-resistance of bendamustine with anthracyclines, alkylating agents or rituximab. However,</p><p>the number of assessed patients is small.</p><p>&nbsp;</p><p><u>Chronic lymphocytic leukaemia</u></p><p>The indication for use in chronic lymphocytic leukaemia is supported by a single open label study comparing bendamustine</p><p>with chlorambucil. In the prospective, multi-centre, randomised study, 319 previously untreated patients with chronic</p><p>lymphocytic leukaemia stage Binet B or C requiring therapy were included. The first line therapy with bendamustine</p><p>hydrochloride 100 mg/m2 i.v. on days 1 and 2 (BEN) was compared to treatment with chlorambucil 0.8 mg/kg days 1 and</p><p>15 (CLB) for 6 cycles in both arms. Patients received allopurinol in order to prevent tumour lysis syndrome.</p><p>Patients with BEN had a significantly longer median progression free survival than patients with CLB treatment (21.5 versus</p><p>8.3 months, p &lt; 0.0001 in the latest follow-up). Overall survival was not statistically significantly different (median not</p><p>reached). The median duration of remission was 19 months with BEN and 6 months with CLB treatment (p &lt; 0.0001). The</p><p>safety evaluation in both treatment arms did not reveal any unexpected undesirable effects in nature and frequency. The</p><p>dose of BEN was reduced in 34% of the patients. Treatment with BEN was discontinued in 3.9% of patients due to allergic</p><p>reactions.</p><p>&nbsp;</p><p><u>Indolent non-Hodgkin&rsquo;s lymphomas</u></p><p>The indication for indolent non-Hodgkin&rsquo;s lymphomas relied on two uncontrolled phase II trials.</p><p>In the pivotal prospective, multi-centre, open study 100 patients with indolent B-cell non-Hodgkin/s lymphomas refractory to</p><p>rituximab mono- or combination therapy were treated with BEN single agent. Patients had received a median of 3 previous</p><p>chemotherapy or biological therapy courses. The median number of previous rituximab-containing courses was 2. The</p><p>patients had no response or there had been progression within 6 months after rituximab treatment. The dose of BEN</p><p>was 120 mg/m2 i.v. on days 1 and 2 planned for at least 6 cycles. Duration of treatment depended on response (6 cycles</p><p>planned). The overall response rate was 75% including 17% complete (CR and CRu) and 58% partial response as assessed</p><p>by independent review committee. The median duration of remission was 40 weeks. BEN was generally well tolerated when</p><p>given in this dose and schedule.</p><p>The indication is further supported by another prospective, multi-centre, open study including 77 patients. The patient</p><p>population was more heterogeneous including: indolent or transformed B-cell non-Hodgkin&rsquo;s lymphomas refractory to</p><p>rituximab mono- or combination therapy. The patients had no response or there had been progression within 6 months</p><p>or had an untoward reaction to prior rituximab treatment. Patients had received a median of 3 previous chemotherapy or</p><p>biological therapy courses. The median number of previous rituximab-containing courses had been 2. The overall response</p><p>rate was 76% with a median duration of response of 5 months (29 [95% CI 22.1, 43.1] weeks).</p><p><u>&nbsp;</u></p><p><u>Multiple myeloma</u></p><p>In a prospective, multi-centre, randomised, open study 131 patients with advanced multiple myeloma (Durie-Salmon stage</p><p>II with progression or stage III) were included. The first line therapy with bendamustine hydrochloride in combination with</p><p>prednisone (BP) was compared to treatment with melphalan and prednisone (MP). Tolerability in both treatment arms was</p><p>in line with the known safety profile of the respective medicinal products with significantly more dose reductions in the BP</p><p>arm. The dose was bendamustine hydrochloride 150 mg/m2 i.v. on days 1 and 2 or melphalan 15 mg/m2 i.v. on day 1 each</p><p>in combination with prednisone. Duration of treatment depended on response and averaged 6.8 cycles in the BP and 8.7</p><p>cycles in the MP group.</p><p>Patients with BP treatment had a longer median progression free survival than patients with MP (15 [95% CI 12-21] versus</p><p>12 [95% CI 10-14] months) (p=0.0566). The median time to treatment failure was 14 months with BP and 9 months with</p><p>MP treatment. The duration of remission was 18 months with BP and 12 months with MP treatment. The difference in overall</p><p>survival was not significantly different (35 months BP versus 33 months MP). Tolerability in both treatment arms was in line</p><p>with the known safety profile of the respective medicinal products with significantly more dose reductions in the BP arm.</p><p><strong>&nbsp;</strong></p><p><strong>Pharmacokinetic properties</strong></p><p><u>Distribution</u></p><p>The elimination half-life t1/2. after 30 min i.v. infusion of 120 mg/m2 area to 12 subjects was 28.2 minutes.</p><p>Following 30 min i.v. infusion the central volume of distribution was 19.3 l. Under steady-state conditions following i.v. bolus</p><p>injection the volume of distribution was 15.8 - 20.5 I.</p><p>More than 95% of the substance is bound to plasma proteins (primarily albumin).</p><p>Biotransformation</p><p>A major route of clearance of bendamustine is the hydrolysis to monohydroxy- and dihydroxy-bendamustine. Formation of</p><p>N-desmethyl-bendamustine and gamma-hydroxy-bendamustine by hepatic metabolism involves cytochrome P450 (CYP)</p><p>1A2 isoenzyme. Another major route of bendamustine metabolism involves conjugation with glutathione.</p><p><em>In-vitro </em>bendamustine does not inhibit CYP 1A4, CYP 2C9/10, CYP 2D6, CYP 2E1 or CYP 3A4.</p><p><u>&nbsp;</u></p><p><u>Elimination</u></p><p>The mean total clearance after 30 min i.v. infusion of 120 mg/m2 body surface area to 12 subjects was 639.4 mL/minute.</p><p>About 20% of the administered dose was recovered in urine within 24 hours. Amounts excreted in urine were in the</p><p>order monohydroxy-bendamustine &gt; bendamustine &gt; dihydroxy-bendamustine &gt; oxidised metabolite &gt; N-desmethyl</p><p>bendamustine. In the bile, primarily polar metabolites are eliminated.</p><p><u>&nbsp;</u></p><p><u>Hepatic impairment</u></p><p>In patients with 30 - 70% tumour infestation of the liver and mild hepatic impairment (serum bilirubin &lt; 1.2 mg/dL)</p><p>the pharmacokinetic behaviour was not changed. There was no significant difference to patients with normal liver and</p><p>kidney function with respect to Cmax, tmax, AUC, t1/2., volume of distribution and clearance. AUC and total body clearance of</p><p>bendamustine correlate inversely with serum bilirubin.</p><p><u>&nbsp;</u></p><p><u>Renal impairment</u></p><p>In patients with creatinine clearance &gt; 10 mL/min including dialysis dependent patients, no significant difference to patients</p><p>with normal liver and kidney function was observed with respect to Cmax, tmax, AUC, t1/2., volume of distribution and clearance.</p><p><u>Elderly subjects</u></p><p>Subjects up to 84 years of age were included in pharmacokinetic studies. Higher age does not influence the</p><p>pharmacokinetics of bendamustine.</p><p>&nbsp;</p><p><strong>Preclinical safety data</strong></p><p>Adverse reactions not observed in clinical studies, but seen in animals at exposure levels similar to clinical exposure levels</p><p>and with possible relevance to clinical use were as follows:</p><p>Histological investigations in dogs showed macroscopic visible hyperaemia of the mucosa and haemorrhagia in the</p><p>gastrointestinal tract. Microscopic investigations showed extensive changes of the lymphatic tissue indicating an</p><p>immunosuppression and tubular changes of kidneys and testis, as well as atrophic, necrotic changes of the prostate epithelium.</p><p>Animal studies showed that bendamustine is embryotoxic and teratogenic.</p><p>Bendamustine induces aberrations of the chromosomes and is mutagenic <em>in vivo </em>as well as <em>in vitro</em>. In long-term studies in</p><p>female mice bendamustine is carcinogenic.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>INDICATIONS</strong></p><p>First-line treatment of chronic lymphocytic leukaemia (Binet stage B or C) in patients for whom fludarabine combination</p><p>chemotherapy is not appropriate.</p><p>Indolent non-Hodgkin&rsquo;s lymphomas as monotherapy in patients who have progressed during or within 6 months following</p><p>treatment with rituximab or a rituximab containing regimen.</p><p>Front line treatment of multiple myeloma (Durie-Salmon stage II with progress or stage III) in combination with prednisone</p><p>for patients older than 65 years who are not eligible for autologous stem cell transplantation and who have clinical</p><p>neuropathy at time of diagnosis precluding the use of thalidomide or bortezomib containing treatment.</p><p>&nbsp;</p><p><strong>RECOMMENDED DOSE</strong></p><p><u>Posology</u></p><p><u>&nbsp;</u></p><p><u>Monotherapy for chronic lymphocytic leukaemia</u></p><p>100 mg/m2 body surface area bendamustine hydrochloride on days 1 and 2; every 4 weeks up to 6 times.</p><p>&nbsp;</p><p><u>Monotherapy for indolent non-Hodgkin&rsquo;s lymphomas refractory to rituximab</u></p><p>120 mg/m2 body surface area bendamustine hydrochloride on days 1 and 2; every 3 weeks for at least 6 times.</p><p>&nbsp;</p><p><u>Multiple myeloma</u></p><p>120 - 150 mg/m2 body surface area bendamustine hydrochloride on days 1 and 2, 60 mg/m2 body surface area prednisone</p><p>i.v. or per os on days 1 to 4; every 4 weeks for at least 3 times.</p><p>&nbsp;</p><p><u>Hepatic impairment</u></p><p>On the basis of pharmacokinetic data, no dose adjustment is necessary in patients with mild hepatic impairment (serum</p><p>bilirubin &lt; 1.2 mg/dL). A 30% dose reduction is recommended in patients with moderate hepatic impairment (serum</p><p>bilirubin 1.2 - 3.0 mg/dL).</p><p>No data is available in patients with severe hepatic impairment (serum bilirubin values of &gt; 3.0 mg/dL) (see section</p><p><strong>CONTRAINDICATIONS</strong>).</p><p>&nbsp;</p><p><u>Renal impairment</u></p><p>On the basis of pharmacokinetic data, no dose adjustment is necessary in patients with a creatinine clearance of</p><p>&gt;10 mL/min. Experience in patients with severe renal impairment is limited.</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>The safety and efficacy of bendamustine hydrochloride in children have not yet been established. Current available data is</p><p>not sufficient to make a recommendation on posology.</p><p>&nbsp;</p><p><u>Elderly patients</u></p><p>There is no evidence that dose adjustments are necessary in elderly patients (see section PHARMACOKINETIC</p><p>PROPERTIES).</p><p>&nbsp;</p><p><strong>Method of administration</strong></p><p>For intravenous infusion over 30 - 60 minutes (see section DIRECTION FOR USE).</p><p>Infusion must be administered under the supervision of a physician qualified and experienced in the use of</p><p>chemotherapeutic agents.</p><p>Poor bone marrow function is related to increased chemotherapy-induced haematological toxicity. Treatment should</p><p>not be started if leukocyte and/or platelet values dropped to &lt; 3,000/<em>&mu;</em>l or &lt; 75,000/<em>&mu;</em>l, respectively (see section</p><p>CONTRAINDICATIONS).</p><p>Treatment should be terminated or delayed if leukocyte and/or platelet values dropped to &lt; 3,000/<em>&mu;</em>l or &lt; 75,000/<em>&mu;</em>l, respectively.</p><p>Treatment can be continued after leukocyte values have increased to &gt; 4,000/<em>&mu;</em>l and platelet values to &gt; 100,000/<em>&mu;</em>l.</p><p>The leukocyte and platelet Nadir is reached after 14-20 days with regeneration after 3-5 weeks. During therapy free</p><p>intervals strict monitoring of the blood count is recommended (see section WARNINGS AND PRECAUTIONS FOR USE).</p><p>In case of non-haematological toxicity dose reductions have to be based on the worst CTC grades in the preceding cycle. A</p><p>50% dose reduction is recommended in case of CTC grade 3 toxicity. An interruption of treatment is recommended in case</p><p>of CTC grade 4 toxicity.</p><p>If a patient requires a dose modification the individually calculated reduced dose must be given on day 1 and 2 of the</p><p>respective treatment cycle.</p><p>For instructions on reconstitution of the medicinal product before administration, see section DIRECTION FOR USE.</p><p><strong>&nbsp;</strong></p><p><strong>DIRECTION FOR USE</strong></p><p>When handling Bendamustine Hydrochloride, inhalation, skin contact or contact with mucous membranes should be avoided</p><p>(wear gloves and protective clothes!). Contaminated body parts should be carefully rinsed with water and soap, the eyes</p><p>should be rinsed with physiological saline solution. If possible it is recommended to work on special safety work benches</p><p>(laminar flow) with liquid-impermeable, absorbent disposable foil. Pregnant personnel should be excluded from handling</p><p>cytostatics.</p><p>The powder for concentrate for solution for infusion has to be reconstituted with water for injection, diluted with sodium</p><p>chloride 9 mg/mL (0.9%) solution for injection and then administered by intravenous infusion. Aseptic technique is to be</p><p>used.</p><p><u>1. Reconstitution</u></p><p>Reconstitute each vial of Bendamustine Hydrochloride containing 25 mg bendamustine hydrochloride in 10 ml water for</p><p>injection by shaking;</p><p>Reconstitute each vial of Bendamustine Hydrochloride containing 100 mg bendamustine hydrochloride in 40 ml water</p><p>for injection by shaking.</p><p>The reconstituted concentrate contains 2.5 mg bendamustine hydrochloride per mL and appears as a clear colourless</p><p>solution.</p><p><u>2. Dilution</u></p><p>As soon as a clear solution is obtained (usually after 5-10 minutes) dilute the total recommended dose of Bendamustine</p><p>Hydrochloride immediately with 0.9% NaCl solution to produce a final volume of about 500 mL.</p><p>Bendamustine Hydrochloride must be diluted with 0.9% NaCl solution and not with any other injectable solution.</p><p><u>3. Administration</u></p><p>The solution is administered by intravenous infusion over 30-60 min.</p><p>The vials are for single use only.</p><p>Any unused product or waste material should be disposed of in accordance with local requirements.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>CONTRAINDICATIONS</strong></p><p>&bull; Hypersensitivity to the active substance or to any of the excipients listed in section LIST OF EXCIPIENTS.</p><p>&bull; During breast feeding</p><p>&bull; Severe hepatic impairment (serum bilirubin &gt; 3.0 mg/dL)</p><p>&bull; Jaundice</p><p>&bull; Severe bone marrow suppression and severe blood count alterations (leukocyte and/or platelet values dropped</p><p>to &lt;3,000/&mu;L or &lt;75,000/&mu;L, respectively)</p><p>&bull; Major surgery less than 30 days before start of treatment</p><p>&bull; Infections, especially involving leukocytopenia</p><p>&bull; Yellow fever vaccination</p><p>&nbsp;</p><p><strong>WARNINGS AND PRECAUTIONS FOR USE</strong></p><p><u>Myelosuppression</u></p><p>Patients treated with bendamustine hydrochloride may experience myelosuppression. In the event of treatment-related</p><p>myelosuppression, leukocytes, platelets, haemoglobin, and neutrophils must be monitored at least weekly. Prior to the</p><p>initiation of the next cycle of therapy, the following parameters are recommended: Leukocyte and/or platelet values</p><p>&gt;4,000/&mu;L or &gt;100,000/&mu;L, respectively.</p><p>&nbsp;</p><p><u>Infections</u></p><p>Serious and fatal infections have occurred with bendamustine hydrochloride, including bacterial (sepsis, pneumonia) and</p><p>opportunistic infections such as Pneumocystis jirovecii pneumonia (PJP), varicella zoster virus (VZV) and cytomegalovirus</p><p>(CMV). Treatment with bendamustine hydrochloride may cause prolonged lymphocytopenia (&lt; 600/&mu;l) and low CD4-positive</p><p>T-cell (T-helper cell) counts (&lt; 200/&mu;l) for at least 7&ndash;9 months after the completion of treatment. Lymphocytopenia</p><p>and CD4-positive T-cell depletion are more pronounced when bendamustine is combined with rituximab Patients with</p><p>lymphopenia and low CD4-positive T-cell count following treatment with bendamustine hydrochloride are more susceptible</p><p>to (opportunistic) infections. In case of low CD4-positive T-cell counts (&lt; 200/&mu;l) Pneumocystis jirovecii pneumonia</p><p>(PJP) prophylaxis should be considered. All patients should be monitored for respiratory signs and symptoms throughout</p><p>treatment. Patients should be advised to report new signs of infection, including fever or respiratory symptoms promptly.</p><p>Discontinuation of bendamustine hydrochloride should be considered if there are signs of (opportunistic) infections.</p><p><u>&nbsp;</u></p><p><u>Hepatitis B reactivation</u></p><p>Reactivation of hepatitis B in patients who are chronic carriers of this virus has occurred after these patients received</p><p>bendamustine hydrochloride. Some cases resulted in acute hepatic failure or a fatal outcome. Patients should be tested for</p><p>HBV infection before initiating treatment with bendamustine hydrochloride. Experts in liver disease and in the treatment of</p><p>hepatitis B should be consulted before treatment is initiated in patients with positive hepatitis B tests (including those with</p><p>active disease) and for patients who test positive for HBV infection during treatment. Carriers of HBV who require treatment</p><p>with bendamustine hydrochloride should be closely monitored for signs and symptoms of active HBV infection throughout</p><p>therapy and for several months following termination of therapy (see section ADVERSE REACTIONS).</p><p><u>&nbsp;</u></p><p><u>Skin reactions</u></p><p>A number of skin reactions have been reported. These events have included rash, severe cutaneous reactions and bullous</p><p>exanthema. Cases of Stevens &ndash; Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) and Drug Reaction with</p><p>Eosinophilia and Systemic Symptoms (DRESS), some fatal, have been reported with the use of bendamustine hydrochloride.</p><p>Patients should be advised of the signs and symptoms of these reactions by their prescribers and should be told to seek</p><p>medical attention immediately if they develop these symptoms. Some events occurred when bendamustine hydrochloride</p><p>was given in combination with other anticancer agents, so the precise relationship is uncertain. Where skin reactions occur,</p><p>they may be progressive and increase in severity with further treatment. If skin reactions are progressive, Bendamustine</p><p>Hydrochloride should be withheld or discontinued. For severe skin reactions with suspected relationship to bendamustine</p><p>hydrochloride, treatment should be discontinued.</p><p>&nbsp;</p><p><u>Cardiac disorders</u></p><p>During treatment with bendamustine hydrochloride the concentration of potassium in the blood of patients with cardiac</p><p>disorders must be closely monitored and potassium supplement must be given when K+ &lt;3.5 mEq/l and ECG measurement</p><p>must be performed.</p><p>Fatal cases of myocardial infarction and cardiac failure have been reported with bendamustine hydrochloride treatment.</p><p>Patients with concurrent or history of cardiac disease should be observed closely.</p><p>Nausea, vomiting</p><p>An antiemetic may be given for the symptomatic treatment of nausea and vomiting.</p><p>&nbsp;</p><p><u>Tumour lysis syndrome</u></p><p>Tumour lysis syndrome (TLS) associated with Bendamustine Hydrochloride treatment has been reported in patients</p><p>in clinical trials. The onset tends to be within 48 hours of the first dose of Bendamustine Hydrochloride and, without</p><p>intervention, may lead to acute renal failure and death. Preventive measures such as adequate hydration, close monitoring</p><p>of blood chemistry, particularly potassium and uric acid levels and the use of hypouricemic agents (allopurinol and</p><p>rasburicase) should be considered prior to therapy. There have been a few cases of Stevens &ndash; Johnson syndrome and Toxic</p><p>Epidermal Necrolysis reported when bendamustine and allopurinol were administered concomitantly.</p><p>&nbsp;</p><p><u>Anaphylaxis</u></p><p>Infusion reactions to bendamustine hydrochloride have occurred commonly in clinical trials. Symptoms are generally mild</p><p>and include fever, chills, pruritus and rash. In rare instances severe anaphylactic and anaphylactoid reactions have occurred.</p><p>Patients must be asked about symptoms suggestive of infusion reactions after their first cycle of therapy. Measures to</p><p>prevent severe reactions, including antihistamines, antipyretics and corticosteroids must be considered in subsequent</p><p>cycles in patients who have previously experienced infusion reactions.</p><p>Patients who experienced Grade 3 or worse allergic-type reactions were typically not re-challenged.</p><p>&nbsp;</p><p><u>Contraception</u></p><p>Bendamustine hydrochloride is teratogenic and mutagenic.</p><p>Women should not become pregnant during treatment. Male patients should not father a child during and up to 6 months</p><p>after treatment. They should seek advice about sperm conservation prior to treatment with bendamustine hydrochloride</p><p>because of possible irreversible infertility.</p><p>&nbsp;</p><p><u>Extravasation</u></p><p>An extravasal injection should be stopped immediately. The needle should be removed after a short aspiration.</p><p>Thereafter the affected area of tissue should be cooled. The arm should be elevated. Additional treatments like the use of</p><p>corticosteroids are not of clear benefit.</p><p>&nbsp;</p><p><strong>Effects on ability to drive and use machines</strong></p><p>Bendamustine Hydrochloride has major influence on the ability to drive and use machines. Ataxia, peripheral neuropathy and</p><p>somnolence have been reported during treatment with Bendamustine Hydrochloride (see section ADVERSE REACTIONS).</p><p>Patients should be instructed that if they experience these symptoms they should avoid potentially hazardous tasks such as</p><p>driving and using machines.</p><p><strong>INCOMPATIBILITIES</strong></p><p>This medicinal product must not be mixed with other medicinal products except those mentioned in section DIRECTION</p><p>FOR USE.</p><p>&nbsp;</p><p><strong>DRUGS INTERACTIONS</strong></p><p>No <em>in-vivo </em>interaction studies have been performed.</p><p>When Bendamustine Hydrochloride is combined with myelosuppressive agents, the effect of Bendamustine Hydrochloride</p><p>and/or the co-administered medicinal products on the bone marrow may be potentiated. Any treatment reducing the</p><p>patient&rsquo;s performance status or impairing bone marrow function can increase the toxicity of Bendamustine Hydrochloride.</p><p>Combination of Bendamustine Hydrochloride with cyclosporine or tacrolimus may result in excessive immunosuppression</p><p>with risk of lymphoproliferation.</p><p>Cytostatics can reduce antibody formation following live-virus vaccination and increase the risk of infection which may lead</p><p>to fatal outcome. This risk is increased in subjects who are already immunosuppressed by their underlying disease.</p><p>Bendamustine metabolism involves cytochrome P450 (CYP) 1A2 isoenzyme (see section PHARMACOKINETIC PROPERTIES).</p><p>Therefore, the potential for interaction with CYP1A2 inhibitors such as fluvoxamine, ciprofloxacin, acyclovir and cimetidine exists.</p><p><u>Paediatric population</u></p><p>Interaction studies have only been performed in adults.</p><p><strong>FERTILITY, PREGNANCY AND LACTATION</strong></p><p><u>Pregnancy</u></p><p>There are insufficient data from the use of Bendamustine Hydrochloride in pregnant women. In nonclinical studies</p><p>bendamustine hydrochloride was embryo-/fetolethal, teratogenic and genotoxic (see section PRECLINICAL SAFETY DATA).</p><p>During pregnancy Bendamustine Hydrochloride should not be used unless clearly necessary. The mother should be informed</p><p>about the risk to the foetus. If treatment with Bendamustine Hydrochloride is absolutely necessary during pregnancy or if</p><p>pregnancy occurs during treatment, the patient should be informed about the risks for the unborn child and be monitored</p><p>carefully. The possibility of genetic counselling should be considered.</p><p>&nbsp;</p><p><u>Fertility:</u></p><p>Women of childbearing potential must use effective methods of contraception both before and during</p><p>Bendamustine Hydrochloride therapy.</p><p>Men being treated with Bendamustine Hydrochloride are advised not to father a child during and for up to 6 months</p><p>following cessation of treatment. Advice on conservation of sperm should be sought prior to treatment because of the</p><p>possibility of irreversible infertility due to therapy with Bendamustine Hydrochloride.</p><p>&nbsp;</p><p><u>Breast feeding</u></p><p>It is not known whether bendamustine passes into the breast milk, therefore, Bendamustine Hydrochloride is</p><p>contraindicated during breast feeding (see section CONTRAINDICATIONS). Breast feeding must be discontinued during</p><p>treatment with Bendamustine Hydrochloride.</p><p><strong>ADVERSE REACTIONS</strong></p><p>The most common adverse reactions with bendamustine hydrochloride are hematological adverse reactions (leukopenia,</p><p>thrombopenia), dermatologic toxicities (allergic reactions), constitutional symptoms (fever), gastrointestinal symptoms</p><p>(nausea, vomiting).</p><p>The table below reflects the data obtained with bendamustine hydrochloride.</p><p><strong>Table 1: Adverse reactions in patients treated with bendamustine hydrochloride.</strong></p><p><img src="data:image/jpeg;base64,/9j/4AAQSkZJRgABAQEAyADIAAD/4TC2RXhpZgAATU0AKgAAAAgABgALAAIAAAAmAAAIYgESAAMAAAABAAEAAAExAAIAAAAmAAAIiAEyAAIAAAAUAAAIrodpAAQAAAABAAAIwuocAAcAAAgMAAAAVgAAEUYc6gAAAAgAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAFdpbmRvd3MgUGhvdG8gRWRpdG9yIDEwLjAuMTAwMTEuMTYzODQAV2luZG93cyBQaG90byBFZGl0b3IgMTAuMC4xMDAxMS4xNjM4NAAyMDIyOjEwOjEyIDEwOjQ4OjM0AAAGkAMAAgAAABQAABEckAQAAgAAABQAABEwkpEAAgAAAAMyOQAAkpIAAgAAAAMyOQAAoAEAAwAAAAEAAQAA6hwABwAACAwAAAkQAAAAABzqAAAACAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAMjAyMjoxMDoxMiAxMDo0Nzo1MAAyMDIyOjEwOjEyIDEwOjQ3OjUwAAAAAAYBAwADAAAAAQAGAAABGgAFAAAAAQAAEZQBGwAFAAAAAQAAEZwBKAADAAAAAQACAAACAQAEAAAAAQAAEaQCAgAEAAAAAQAAHwkAAAAAAAAAYAAAAAEAAABgAAAAAf/Y/9sAQwAIBgYHBgUIBwcHCQkICgwUDQwLCwwZEhMPFB0aHx4dGhwcICQuJyAiLCMcHCg3KSwwMTQ0NB8nOT04MjwuMzQy/9sAQwEJCQkMCwwYDQ0YMiEcITIyMjIyMjIyMjIyMjIyMjIyMjIyMjIyMjIyMjIyMjIyMjIyMjIyMjIyMjIyMjIyMjIy/8AAEQgBAACFAwEhAAIRAQMRAf/EAB8AAAEFAQEBAQEBAAAAAAAAAAABAgMEBQYHCAkKC//EALUQAAIBAwMCBAMFBQQEAAABfQECAwAEEQUSITFBBhNRYQcicRQygZGhCCNCscEVUtHwJDNicoIJChYXGBkaJSYnKCkqNDU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6g4SFhoeIiYqSk5SVlpeYmZqio6Slpqeoqaqys7S1tre4ubrCw8TFxsfIycrS09TV1tfY2drh4uPk5ebn6Onq8fLz9PX29/j5+v/EAB8BAAMBAQEBAQEBAQEAAAAAAAABAgMEBQYHCAkKC//EALURAAIBAgQEAwQHBQQEAAECdwABAgMRBAUhMQYSQVEHYXETIjKBCBRCkaGxwQkjM1LwFWJy0QoWJDThJfEXGBkaJicoKSo1Njc4OTpDREVGR0hJSlNUVVZXWFlaY2RlZmdoaWpzdHV2d3h5eoKDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uLj5OXm5+jp6vLz9PX29/j5+v/aAAwDAQACEQMRAD8A9y1WWWHTpZIZBHIBkMRkD68Hj8K4+HxFqjNvl1K18mPHmhIpN2O/WPr7UAa2nz6/ftFMlxam0LlZGBIcANg4BTrj1qE6jq41BLZLhXSRgqsyYIyuecJjr70AXI4vE/mDzJbMJuGdr847/wAHWl1ebUrKGFoLseYQN6ygY/DahNAFPSNX1C91T7Lc3IRTuUeXGwJYDOPmjxjHvWnqzXtrGGtrxywRmxIqkHBX+6pPQmgDnpPEOro+3z4cnOMo/bIOf3fsa6Gdrz+xo7mG+YTPGGBZRsyVz025x+tAGbbeIPKg/wCJndzJOTkLbwll2/ig5zmr0t49xpslxp9/KXQso86MKNwUnB+TOOnIoAyDr2ookbyXC7QwMuI2ztOMFf3fJ9fSujO+XTmuob24w0RdCyoO2RwVoA5GLxRqTbIzfWrTM+wAI+M8Y58v610mhXFzqmmrcy3bBixH7oDbx/vIDQI07CR5dOtpJG3O8SszY6kgZNFAxbn7kf8A10X+dTYHoKAFqvY/8eUX0oAsVUuLdbi6RWeRdq7gUYryD39R7UAPs7OOyiMcTSMpbdmRyx/M0y4jEt3ChZlBjflWweq96AGWulQWl21zHJcM7IEIeVmXAxzg9+OtTXaCREQkgM4GVOCOD0NAFKfQLa4iWN7i82qwYbbhgcgY5PfjHX0z1q/P9+H/AK6f0NAE1QXn/Hjcdv3bfyoA4CxF1qKlLSa6muQx3hNV4CrtwenqeR/jW9o2k6j9oV783tsIzvXbf+YrnPRhjkUAb2m/8gqz/wCuCf8AoIooAbqQ3WZABzuGMDJzn071hB7wYBjvO/WxHr7NQBs2VpuRpZvmD8qjRbCnJ68n2rGJljXEQn2AYwlrvA/HNAGhYWsk7JcPOfLOQYHgCNxkeuRzzV37LB9sH7sf6s/zoAm+yQf88hWdqUEcckbRqytsbBjTeeq9qAK1vFc3T7ElZDjrLZ7Rxj39/wBKuSaey2kcbSq05fAm8vHr/DnFAElrp8kbsbmaOZT0VYtuPxzTNSt4o7dWRGDBuDGu5uh6DvQBmZuzvG25BAyM2PX6fNzVxJYbmzkQ2Vwp8kkySRFQeP8APFAF+PS7CFt0VpCjYxlUAOKl+yQf88xQBHpnGlWYH/PBP/QRRQA+5+7H/wBdF/nU9ABXIz28EkytLDEWICgvayPnv1Bwe9AFzT4be31OMpbRK7EgyLBIuOPU8cnFbn/L4P8Armf50ATVTuoVnuoY3LbTG+drEHqvcUAM/si19Z+3/Lw/b8asz9Yv+ug/rQBNUM/34P8Arp/Q0ATVDdf8ec//AFzb+VAE1FAFXTf+QVZ/9cE/9BFFABfyiG3EpBKo6k4IHGffiq/9tW2M49/9bH/8VQBZW6d1DLaTFSOCGTn/AMernWs9QuB5sVkxDIApafbgg+gf/PFAFi00qQMxurO5PQoUue/fPz/lWg96tnNH5sEqII9oLun893tQA46xABkqQPXzY/8A4qm3V/8AZ7qKWa3ljjWN8szIB1X/AGqAF/tq29P/ACLH/wDFUh1FbhkEMMkhWQZ2vGcdf9qgC39ol/585/zT/wCKqKe4l3w/6HP/AKz1T0P+1QBL9ol/585/zT/4qorq4l+xz/6HP/q27p6f71AEv2iX/nyn/NP/AIqj7RL/AM+c/wCaf/FUAN0z/kE2fGP3Ccf8BFFADdTG6yYcjJA4AP8APisBYpELF45X3qQP9Ft8q3GD19B09KALVp/aLT+U91PDCp/iiiAx1xwSR6Vs2P8Ax5RfSgCxWfqFo95MkaTCLC5JMavkZ9GGKAI7fSDFIDNOk8fP7trdAOnsPp+VLqwY7QoO7y3xiLzOcr/D3oAy1j2MjSRSyLv+4dOXJA7fpWxD5DIjw2pt8ygENFsJ49PxoAv1DP8Afg/66f0NAE1Q3f8Ax5z/APXNv5UATUUAVdN/5BVn/wBcE/8AQRRQAmpIXsnUNGpOMGU4X8axbWwhV5Pta6XKpzt2bUI5/wDr0AXjHp53Zt7E7m3HMi8nnnp7n86mtrpYbaOMvbHaO04x/KgCX7ev9+3/AO/4/wAKj+2L9o377bG3GPPHr9KAJPt6/wB+3/7/AI/wqrdPFduiyvbmPYwIFzg8lT1H0oAjgt7K2mSWMxB0OQTeE9sd/arUl4rlMPbfKwP+vH+FAEn29f79v/3/AB/hUcl4rtGQ9t8r5/149D7UASfb1/v2/wD3/H+FRz3iyW8iB7YFlIyZx6fSgCT7ev8Aft/+/wCP8KPt6/37f/v+P8KAJLFPK0+2jLKxSJVJU5BwO1FAFbW8DS5SxAABJJbb2PeuchkMtzHF9riIkIGFv2JOOMD1+909qEB0cM2rNOomtLdIc8kSkkDP0rnrt2U8X0aNsXaDdmMp8o/hxQAkfmXcn2eCSGdmIO3+0GYjGfY9jn6/TNW9Ta4jitkuWjhm2lc/aWTPXGGA6njr70CILWS2nbZc6gIQygo0V+WYHjsfrXQTWSS+TavJKVELAOHIfgrg59aBkX9hxFt32u99MfaDT721K6S1tCHlbBVQ0mCxIPG7tQBTstOuZkMd5HcW6qxZWW+Zy3TjoOMAfrV42MccHkeZMyySEkvISwyD0PagCI6FBsC/ar3jHP2hs1dkjEVg8YLMFjIBY5J47mgCeigCK2/1A+p/maKAKusKzae+wMXHKhV3EnB7d6wIUvWnjTy7kBifmayAC/U7uxx+VAGzZ6ZdRSbru7SdcH5Fi28/XNS2un2jWkDGBC2xTk+uKAJ1sLVfuwqMelY+twSxyp9jikZynIRN479cmgBV0S9eMN9uiUsAf+PYZHH1q3a2DxXCrdyrO5VyrKpXA+TjGfXNAF77JB/c/wDHjVPVLdEsXaIMrgEhlG4jg8gE4JoAxLcalPeLEZZ4gxwGktAF6Hr82ef6Vq3Fo8OmYMpmuVziSNMnODjC55NMCjaWuqXcr5uZIFUAjzbUDd1z/F/nitYWPladItw4mkCNlwNufwzSAtfZIP7n/jxo+yQf3P8Ax40ALagLbqB0BIH5migCO/nS1gWeQ4RGyx9BzVddcsHxtuYDkZGJ06dfWgB9vq1rdyGO2ljlcc7UlQn+dVodcsYII4ZZ4o5ERFZHlUEEgY4JoAvW98l3F5tuPNTONyOpGfTrUM+oRWl1m4xCGQAGR1UHn1JoAdb6rbXUnl28kczgZ2xyoxx+Bp7SSfbYv3D/AOrfuPVfegCbzJP+eD/mP8apas+dPkEsOI8HdvwVxg5yAeRQBztvFpq3Kvcy6WyMeQkgB6cc7+P8+tbsTWNnarcWkCrbltzPGwYHAPoaAHnX9NAybu2A/wCvhP8AGrVxK5tZSIWwUPO4en1oAl8yT/ng/wCY/wAaPMk/54P+Y/xoAS15t1JGOTx+JooAZexGeERCR497Y3p1Xg8iq0ekukiOdRu3C/wsUw31+WgDQVEQAKqqAMAAYqG0VTZQEqD+7Xt7UATgAdBiqV1aG6u1xcTQlEBzGRzyeuQaAFtbBrabzDe3Mw242ybcfXgA1O3/AB+xf9c3/mtAE1Vr2Lz4PK8x495270OGXIPI96AK9vpbwTJI2oXUoU5KSbNrcHr8ue/r2p+qfJYuVO3qchwmPlP8Xb60MDmIHuJZxHBJcOwIIWO9g+bAweAvIH9PaupW3a20+WNriSfCNhpMZ6dOAKALlFAEVt/qB9T/ADNFABN1i/3x/I1LQAVDaf8AHlB/1zX+VAE1RD/j7b/rmP5mgCWoW/4/Yv8Arm/81oAmqKbrH/vigCWqWqZ+xPhWY4OAoBJ+U9jx+fFAHNhrgTI0YukZW6pawhgcHv8AT+db9tdyXNhOssM6SRx4ZpY9u447UAaVFAEVt/qB9T/M0UAE3WL/AHx/I1LQAVDaf8eUH/XNf5UATVEP+Ptv+uY/maAJahb/AI/Yv+ub/wA1oAmqKbrH/vigCWqGsJ5mmyphjuVhhU3n7p6Dv9KAOZSxJaJRaqpPG5tOYAcjJPPHFbttqEktm0E8N15pV8yPblF7456dKYjYopDIrb/UD6n+ZooAjvfN8lTCMyBvlHqcGqSzaud+bPbgZX98hyfTpQA+GXVHlVZbTy4zjc3nKdv4YqxaRyfYoP3zf6tf4R6fSgCby5P+e7f98j/Cs3ULqWxuFYSqdygYd1T17kUANsdWS5RfPuYoZGOFVZUfd0z0HqcVJqU0tltuBKDsjY4chQRle+KAK9vql7dSqkMcT8jdtuEJA7nGK1Jo5P3f75vvj+Ef4UASeXJ/z3b/AL5H+FVNRtpJ7Rot5k35Gw4Ab5TxkUAYT6LK+4HSHYkdDe8d/wDAfpW5DbPBpHl5aHbER5e4Pt69+9AEIm1nBzZrkdP3y88j29MmnW82rvMqz2gjQnl1mU4GfTHpigC/a8W6gnPJ5/E0UALN1i/3x/I1LQAVDaf8eUH/AFzX+VAE1YWvkq8bBS20BiBs5wenzf05oAqWNz5Dt9os1ZCwCu8kXyDueMdetaepXixRrcRRxXKqjfKZFCn5k7njigCtBqq+cq2uloGbrtljBwc44B9q2Zusf++KAJail+9F/v8A9DQBLUVz/wAes3+4f5UAS0UARW3+oH1P8zRQBFfTC3gExBKo2449MGqX/CQWh6EngnAV+3/AfY0AKuv2rSJGM7n6fK//AMTVu0ab7FB+6X/Vr/H7fSgCbdN/zyX/AL7/APrVg+IAkhVbpkhj2HLGLzR3Hpx160AULc24mR3nt5AG+dDYYyO4zt4+tbd1ZGQLb28FvCrRsR8gZeqfw4xQBVTQ76PLJcWqyAgo62iArjPH61cL3llaGS8kFwUffuVcHGOgAznv+dAE9rqKXrSLbqGMeN2cjr9RzS3c8kEaytDlUbJCtkng+1AFeDXbe4nWGNW3sdoDKw5/FauXDTfZZv3S/cP8ft9KAJN03/PJf++//rUbpv8Ankv/AH3/APWoAS1z9nXIwcnP5migBt5MkEaSyEKiuCSTjHWo/wC07Xj94vPT5h/jQBMLgMuVjkIPQgVFaT/6FB+6l/1a/wAPtQBN5/8A0yl/75rL1L7NNNtuJprb938rq+w98/WgCNbOxZwEur1mJ6C5Jzx9a0PN2XUKiOY7YmGSMnqtAFjz/wDplL/3zVTUpJZLNkhik808JnjnBxzQBlWenXUjubxbuE4IUxXLN3461sz3KQpGzq6IjZLN0AwepNACjUrY9HB5x1H+NLcT5tZSI5MFDzt9qAGrqlq4BWRWB6EMDn9afFexTqWhzIAcEpg4oAfanNupwRkng/U0UAVtYDHTpAud2DjCBznB7Hg/jXNrBKFkIsCWzhB/ZiA5I+916Dj/ACaEB02lbhpkIdXUgEYePYQATjjtxU9p/wAeUH/XNf5UATVmalYyX0ojR4VAQbhLCJAwyeMGgCtb6HcQXEU32i13oxJKWaqTn3HtxWs3/H7F/wBc3/mtAE1RTdY/98UAS1Vv4mnt/KRwjOSoYqGwcHnB60AULXQhHPuufsc0YXAVbRUIPrkVpzqFs5FUAKIyAB24oAyhNo7/ADSaW6P/ALVgxPT1CmtGwWz+z+ZZQpFG5PCxeXkjjkYB7UAS23+oH1P8zRQBDqPkG2AuV3Qs2HGCeMH0rNSPQIpEkSEB0Pyny34P5UAaKanaSHEbyOcZwsTn+lQ2mqWgtIVLvuVFBHlPwcD2oAlOr2QODKwOcY8tuvp0qM6nardZZpAGQbSYX55PTigCVNTtZP8AVtI/+7C5/pTWvIvtsXyT/wCrf/lg/qvtQBN9si/uT/8Afh/8KimvIsx/LP8AfH/LB/8ACgCX7ZF/cn/78P8A4VDPfwJ5bMJlUPkkwOAOD7UAL/a1lj/WN/36b/CmzahbyWs2zzWwhBxC57fSgDBjiu0mV/7PuCVfcCbqbBI5zjZ09q2LLU7qV3F5YvAq/dZA77vw2jFAF+0Ia2VhnBJPIwepooAi1GFri18lSoZztBZdwHB7VlReHGV4w4sGjU/MotQM9PfjpQBrW+nWVpIZLe1iicrtLIoBx6VWh0jTriCKaaygeR413MyAk8DrQBM2j6axy1jAT6lBmszV7REWGCG3Lxqm0KIfNCj3FAFLT7W7/tIGKEQPyfOaw2Agj7uc10zZ+2w56+U/81oBE9RTdY/98UAS1S1QE2TBV3Nzhdm7PB7d6AOV+yzLE3l2AAxtAOmfTtn3/nWxpBWDT5rUWc0TbHZpGg8tW7D8cH8hQI36KBkVt/qB9T/M0UAQanI8NoZI3RHQ5BkOFHB6n0rIj1+Rmi8y4sERj87/AGtTtAPYY5496ANiCdLpWa3vY5QpwxTacH8KLRJfsUH74/6tf4R6UATeXL/z2P8A3yKydWvbjTpkeOSBi642zSCPPXgHHWgCo/iGcQyP5tkGU4AW4D59uFyO1attJJdNbT+aBvic/KMjqvfAoEXPLl/57H/vkVU1J57ayaZJlLR/MNy8cA9cUDMgeIplZTJJYCNiMEXik47nG3+tbV1bmeNIpJN0btgjA5GDQBVHh2xC7dhx/vN/jUyaclhp80VvIwQqzHPzc496AM9dXvllMcjWHyuVYi7AI/4Dt6+2a2wk20bpcHuAoNABa5FuoJycnn8TRQAy+iM8AiWRoy52h16rweapf2PcYOdTnJyCDsTjrx096AJ7PT5rSXc99NOpBBV1UDPrwP8AOas2n/HlB/1zX+VAE1ULyWaK5BhtPtGUGRuAxyfWgB1nNLO0gmsGtwOhYg7uvp/nmpmAF7EAP+Wb/wA1oAnqhrLMmlzMudwUkbWCnoe54FAGHaT33mrcLDdXUYBDRh4mXOOnHsf5VuQXE87KJrN7dUcBdzA7uD6UCL9RXP8Ax6zf7h/lQM5b7PdcsyyDbjgaeh5J7cc1tWmqSMsEUtpeeY2A0jQ7Rn1PPFAF+2/1A+p/maKACbrF/vj+RqWgAqG0/wCPKD/rmv8AKgCaoh/x9t/1zH8zQBLULf8AH7F/1zf+a0ATVWvYvPg8oMF3nGSoOPwPBoAz7fSL63jCx6jHFzkiK1RQRV2KK4hWNbi589jLkN5YXAweOKALlRXP/HrN/uH+VAHPrB4Z8n5blUQHJBuXGPwJ4qzaWmhXs0ZtZVmltyCu2ZiVwR78jgUAa9t/qB9T/M0UAE3WL/fH8jUtABUNp/x5Qf8AXNf5UATVEP8Aj7b/AK5j+ZoAlqFv+P2L/rm/81oAmqKbrH/vigCWopfvRf7/APQ0AS1Fc/8AHrN/uH+VAHNP/aCB2DakZGOFY+Tk9eOvAq3ZWmoXD75bzUIQpBAkEeGGeny5oA2rb/UD6n+ZooAivp0tYFnkzsRssQOgweaq/wBv2GM7z0z26fnQBNFqkM6b4YppF6ZRMim2l6PsUH+jXP8Aq1/5Z+1AE324f8+1z/37qtLqsFvdAzRzRh12rvTGTyaAD+37EkAOcnp05/Wntej7bF/o1z/q3/5Z+60ATfbh/wA+1z/37qKa9H7v/Rrn74/5Z0AS/bh/z7XP/fuobjUEjCO8FwqK2WYx4AGDQBGniCwkkWNHZnf7qjBJ/Wpbi9H2aX/Rrn7h/wCWftQBzn9k3BkLNaRFT0XyG/ya6O3nS3gSGO1uAqjoIjQBYtDutlOCMk8Ecjk0UAQasdunyHODg44B5wex4P0Nc1BBGW2MGG8YVmtIAI+Qc9frQBrw2b267INaiijJyUWKMDoM/nWhaXVv9ig/fxf6tf4x6UATfarf/n4i/wC+xVac2FzcKJzbShUJG8qcc0AJ9m0fAHlWWByBhaka6t/tsX7+L/Vv/GPVaAJvtVv/AM/EX/fYqOa6t/3f7+L74/jFAEn2q3/5+Iv++xUNxPaSBEeWFkZsMpYEEYNADFg0lHV0js1ZTkEBQRzmpbi6t/ss37+L7h/jHpQBJ9qt/wDn4i/77FH2q3/5+Iv++xQAtsQ0OQQQXYgjv8xooAr6r/x4SDjkEckjse45H1Fc3DDbmSMXF1+7H3it/M7DHTAKj3oA3bK8063UW8N68pJyBI7O3055pbXVrFbaOM3Ch0RQykEEHAoAuJdwyIroXZWGQwjYgj8qgm1C2t7lTNIYwyEAsjDPP0oAcNVsjMIROPMJwF2nJ7+lK06fbYuJP9W//LNvVfagCb7QnpJ/37b/AAqOadP3fEn3x/yzb/CgCT7QnpJ/37b/AAqC6vIYUWWUukaEszNGwAAByelADRrGnldwukxnGefTP8qfNdRPZyMm9lMZIIjbB4+lAFOPS7OKZJFkv/kYMqmSQqD9Kks7G1spfMie9PGNsjSMv5HigC9bHMRIzy7dR/tGigCtqxA0+TJxwRwoY9D2PB+lcziNEV1WYZU5RbGLPpzQBZ0+zWaUSi78hosbRLaRKfw/Kq07RC6RiZSJEQfJaRyBvl9Tz27+lAF611CWxlCvLczQLwsaW6AY6DGDkYxU+uyQzGEBmcEHd5aLIQPoT/jQBTs4jc3YdrponQBt01pGoyMDg10DXMH22L99H/q3/iHqtAE32mD/AJ7R/wDfQqOa5g/d/vo/vj+IUASfaYP+e0f/AH0KrXzwXFv5H2iNfMymcg4ypHQ8GgCla6ZZRIyXM9rcxnopiRQOnp9K0JprZLOREliVRGQAGHHFAE32mD/ntH/30KPtMH/PaP8A76FABbENESCCC7YI/wB40UAMvIlnhETlgrnaSrEHkHoR0qm+hW7nJur/ANx9rk5Hp1oAu21qlojKkkz7jnMsrOfwya5W4uI4JW3XCxsyJhRfTR5+UZ+VRgH6UAa+gwW8kQuo7iWWQEq/+lPImTz3x/KofErxK1r50kCAscGdmC5wf7v9e1AFW3WTUvMNjKJUVudmozJj04xx9K6FV2XFuvzcQsPmOT1Xqe9AFmopv+Wf++KAJail+9F/v/0NAEtRXP8Ax6zf7h/lQBLRQBFB/qz/AL7/APoRooAJusf++KloAK5qSzvpAjxR3hQqhBju1Qfd7AjigDSt9Nf9xM9zdpIoXdGZQQcf3scH3qtr8gjeDMroCD92cRZ/E0CKmm2j3ski/bb2PYclkvFfnpjjp0/Sugbi9hH/AEyf+a0DJ6im/wCWf++KAJail+9F/v8A9DQBLUVz/wAes3+4f5UAS0UARQf6s/77/wDoRooAbcyJEsbyOqKHGSxwKT7dZ/8AP1B/38FAB9utP+fqD/v4KhtL60+xQf6VB/q1/wCWg9KAJvt1p/z9Qf8AfwVi67cwyGIxSJLtUkhDGxH4N/SgCppuoSWMsrGF3Vx93dCuP++T/nNb32+0a7hb7TCMxPwZBxyvvQBP9utP+fqD/v4KjmvrT93/AKVB98f8tBQBJ9utP+fqD/v4KjlvrTdF/pUH3/8AnoPQ0ASfbrT/AJ+oP+/gqO4vrT7LL/pUH3D/AMtB6UASfbrT/n6g/wC/go+3Wn/P1B/38FADrZg0O5SCpdiCDwfmNFAEOqQvcWEkUcQlZhjYxwDx35HFc/Fo13vQSacgjJG8LcvnA44+f0JoA1V0u1S5W4WyuhIrbgfPzznPTfirlu80dtEjWsoZUAPzJ1x/vUAS+dJ/z6y/mn/xVR+ZL54b7LLjbjqnr/vUASedJ/z6y/mn/wAVUTPMbqN/ssu0IwPzJ1JX/a9jQBL50n/PrL+af/FVHJJK2zFrLwwJ5T/4qgCTzpP+fWX80/8AiqZJJKzRkWsvytk8p6H/AGqAH+dJ/wA+sv5p/wDFVHNJK8Eiray5ZSBynp/vUAUVs71V2i81Agfdz5JI/Hv+NWrQXNuhWU3Vx0wZPLBH5EUAWoAwi+ZSpLMcHtkk0UAf/9kA/+Ex6Gh0dHA6Ly9ucy5hZG9iZS5jb20veGFwLzEuMC8APD94cGFja2V0IGJlZ2luPSfvu78nIGlkPSdXNU0wTXBDZWhpSHpyZVN6TlRjemtjOWQnPz4NCjx4OnhtcG1ldGEgeG1sbnM6eD0iYWRvYmU6bnM6bWV0YS8iPjxyZGY6UkRGIHhtbG5zOnJkZj0iaHR0cDovL3d3dy53My5vcmcvMTk5OS8wMi8yMi1yZGYtc3ludGF4LW5zIyI+PHJkZjpEZXNjcmlwdGlvbiByZGY6YWJvdXQ9InV1aWQ6ZmFmNWJkZDUtYmEzZC0xMWRhLWFkMzEtZDMzZDc1MTgyZjFiIiB4bWxuczp4bXA9Imh0dHA6Ly9ucy5hZG9iZS5jb20veGFwLzEuMC8iPjx4bXA6Q3JlYXRvclRvb2w+V2luZG93cyBQaG90byBFZGl0b3IgMTAuMC4xMDAxMS4xNjM4NDwveG1wOkNyZWF0b3JUb29sPjx4bXA6Q3JlYXRlRGF0ZT4yMDIyLTEwLTEyVDEwOjQ3OjUwLjI4NzwveG1wOkNyZWF0ZURhdGU+PC9yZGY6RGVzY3JpcHRpb24+PC9yZGY6UkRGPjwveDp4bXBtZXRhPg0KICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgPD94cGFja2V0IGVuZD0ndyc/Pv/bAEMAAwICAwICAwMDAwQDAwQFCAUFBAQFCgcHBggMCgwMCwoLCw0OEhANDhEOCwsQFhARExQVFRUMDxcYFhQYEhQVFP/bAEMBAwQEBQQFCQUFCRQNCw0UFBQUFBQUFBQUFBQUFBQUFBQUFBQUFBQUFBQUFBQUFBQUFBQUFBQUFBQUFBQUFBQUFP/AABEIBccDAQMBIgACEQEDEQH/xAAfAAABBQEBAQEBAQAAAAAAAAAAAQIDBAUGBwgJCgv/xAC1EAACAQMDAgQDBQUEBAAAAX0BAgMABBEFEiExQQYTUWEHInEUMoGRoQgjQrHBFVLR8CQzYnKCCQoWFxgZGiUmJygpKjQ1Njc4OTpDREVGR0hJSlNUVVZXWFlaY2RlZmdoaWpzdHV2d3h5eoOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4eLj5OXm5+jp6vHy8/T19vf4+fr/xAAfAQADAQEBAQEBAQEBAAAAAAAAAQIDBAUGBwgJCgv/xAC1EQACAQIEBAMEBwUEBAABAncAAQIDEQQFITEGEkFRB2FxEyIygQgUQpGhscEJIzNS8BVictEKFiQ04SXxFxgZGiYnKCkqNTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqCg4SFhoeIiYqSk5SVlpeYmZqio6Slpqeoqaqys7S1tre4ubrCw8TFxsfIycrS09TV1tfY2dri4+Tl5ufo6ery8/T19vf4+fr/2gAMAwEAAhEDEQA/AP1TooooAKKKKAG9OrUmX9F/Ovnfx1b+N/FX7SU/hHSfifrHg/RE8LR6yLXS9P02Y+Ybt4Sd1zbSNyAO+OK1x8EfHrTbV+P3jZgw3L/xKdCx24P+gZ7jtQB7jl/Rfzoy/ov514dL8EfHcSqx/aE8ZIFBZmbSdCK4HXn7BxTpPgf49VSy/H7xooXvJpOhlfqcWAoeiuC1dj2/L+i/nRl/Rfzrw4fBLx60ZP8AwvzxsjcZU6ToZwcZIH/Ev+b8KkX4G+O9mf8Ahf8A41JOcH+ytCG76D+z/wCtD0Enc9ty/ov50Zf0X868Ob4J+OvMjjP7QPjSKR921H0rQdz467R9gqX/AIUT49/6L943/wDBVoX/AMrqBntmX9F/OjL+i/nXif8Awonx7/0X7xv/AOCrQv8A5XUv/CifHn/RfvG//gq0L/5XUAe15f0X86Mv6L+deJH4GePN6/8AF/8Axtsbt/ZOhkj/AMp/4Uv/AAovx7/0X7xt/wCCvQv/AJXUD3PbMv6L+dGX9F/OvE/+FF+PP+i/eNv/AAV6F/8AK6uT+KXw5+JHgX4Z+LfEtl8ePFtzeaPpV5qMNvPpWiCORoYnkCEjT84O0UEp3Vz6Yy/ov50Zf0X86+efBHwr+IHifwfoWrXHx58ZRT6hYQ3TxxaVoe1WkiViM/YD0LfjitYfBHx9sBPx88ZhcBg66TofPsf9A7/SkM9wy/ov50Zf0X868T/4UX49/wCi/eN//BVoX/yupf8AhRPj3/ov3jb/AMFWhf8AyuoA9ry/ov50Zf0X868U/wCFE+Pf+i/eNv8AwVaF/wDK6k/4UV49/wCi/eNv/BVoX/yupiPbMv6L+dGX9F/OvE/+FFePf+i/eNv/AAVaF/8AK6j/AIUT49/6L942/wDBVoX/AMrqBntmX9F/OjL+i/nXif8Awonx7/0X7xt/4KtC/wDldR/worx7/wBF+8bf+CvQv/ldQB7Zl/Rfzoy/ov514p/worx5/wBF+8b/APgr0L/5XUn/AAonx7/0X7xv/wCCrQv/AJXUlqB7Zl/Rfzoy/ov514n/AMKJ8e/9F+8b/wDgq0L/AOV1ed+NPCfxM8O/FT4ceGLX47+LZbDxRJqCXE82j6KJIfs9t5yeWPsGDu6HNMD6wy/ov50Zf0X868PHwP8AHjQgr+0B40MmATnStCOAfYWH9eaVPgj473fvPj943ABAIXSNDHJ6Yzp/IoA9vy/ov50Zf0X868T/AOFFePf+i/eNv/BVoX/yuo/4UZ486f8AC/fG3/gr0L/5XUAe2Zf0X86Mv6L+deJ/8KM8edP+F++Nv/BXoX/yuo/4UT49/wCi/eN//BVoX/yuoA9sy/ov50Zf0X868T/4UT49/wCi/eN//BVoX/yuo/4UT49/6L943/8ABVoX/wArqAPbMv6L+dGX9F/OvE/+FE+Pf+i/eN//AAVaF/8AK6j/AIUT49/6L943/wDBVoX/AMrqAPbMv6L+dGX9F/OvE/8AhRPj3/ov3jf/AMFWhf8Ayurhfjh4N+I3wu+DXjjxfp3x28XXl9oei3mp28d5pOi+S8kMLvscLp4YZKjoe1AH1Nl/Rfzoy/ov514Pp/wZ+IF1YwTt8ffGRMqpJ8uk6HgAqDt5sB1JFTt8E/HrXEka/H7xh8uG2rpehlgCe4+wenSgNj3HL+i/nRl/RfzrxP8A4UZ48P8AzX3xsP8AuF6F/wDK6j/hRXj3/ov3jb/wVaF/8rqVxJ3Vz2zL+i/nRl/RfzrxP/hRfj3/AKL942/8Fehf/K6j/hRnj0f8198bH/uF6F/8rqE7uwdbHtmX9F/OjL+i/nXif/Ci/Hv/AEX3xt/4K9C/+V1L/wAKJ8e/9F+8b/8Agq0L/wCV1MLnteX9F/OjL+i/nXin/CifHv8A0X7xv/4KtC/+V1J/wonx7/0X7xv/AOCrQv8A5XUDPbMv6L+dGX9F/OvE/wDhRPj3/ov3jf8A8FWhf/K6j/hRfj3/AKL942/8Fehf/K6gPM9sy/ov50Zf0X86+Ufgf4P+JvxN+H6eINU+PHiuwuTqOpWTW9vo+iqii2v57ZTl7HPKxKT/ALTH0rvD8E/H0cyBvj741Ze6jSNDUtx0BOn4zSF0ue5Zf0X86Mv6L+deJ/8ACivHv/RfvG3/AIKtC/8AldR/worx7/0X7xt/4KtC/wDldRfWwz2zL+i/nRl/RfzrxP8A4UV49/6L942/8FWhf/K6j/hRPj3/AKL943/8FWhf/K6n1sB7Zl/Rfzoy/ov514n/AMKJ8e/9F+8b/wDgq0L/AOV1H/CifHv/AEX7xv8A+CrQv/ldQB7Zl/Rfzoy/ov514n/wonx7/wBF+8b/APgq0L/5XUf8KJ8e/wDRfvG//gq0L/5XUAe2Zf0X86Mv6L+deJ/8KJ8e/wDRfvG//gq0L/5XV574r8J/EvQfi14C8KQfHXxZNZa9banNd3D6PowkjNtHAY/LH2HB3GY5zmgD6uy/ov50Zf0X868P/wCFI+OxIFH7QXjJmA3FG0nQwcep/wBA4FKvwP8AH21WHx/8aSK2fmGk6HjB6EYsKYz2/L+i/nRl/RfzrxP/AIUX49/6L942/wDBXoX/AMrqP+FE+Pf+i/eN/wDwVaF/8rqWwvI9sy/ov50Zf0X868T/AOFE+Pf+i/eN/wDwVaF/8rqP+FF+PR/zX3xt/wCCvQv/AJXUCbse2Zf0X86Mv6L+deJ/8KL8e/8ARffG3/gr0L/5XUf8KJ8e/wDRfvG//gq0L/5XUlqrjPbMv6L+dGX9F/OvE/8AhRPj3/ov3jf/AMFWhf8Ayuo/4UT49/6L943/APBVoX/yupge2Zf0X86Mv6L+deJ/8KJ8e/8ARfvG/wD4KtC/+V1H/Ci/Hp/5r942/wDBVoX/AMrqBntmX9F/OjL+i/nXyl8CPB/xO+KnwztPEeofHXxVa3VxeX1t5dtpGjCMC3vJ7cH5rEn5hEDXdn4KeO/lKfH/AMaOhBO4aVoRGBj0sOvDdM0m7E9LnuWX9F/OjL+i/nXiJ+B/j35Qfj94zAPA26ToeSff/iX9BSN8EfHew7fj742POM/2ToXXn108DByPypvQfY9vy/ov50Zf0X868V/4UT47LcfH/wAbY/7BWhf/ACvpv/CifHv/AEX7xv8A+CrQv/ldR1sI9sy/ov50Zf0X868T/wCFE+Pf+i/eN/8AwVaF/wDK6j/hRfj0f8198bf+CvQv/ldQM9sy/ov50Zf0X868T/4UX48b/mvvjb/wV6F/8rqP+FE+Pf8Aov3jf/wVaF/8rqBbntmX9F/OjL+i/nXif/CifHv/AEX7xv8A+CrQv/ldR/wonx7/ANF+8b/+CrQv/ldQM9t/4FTq+XfiJpPxD+E1x4D1VPjP4k8S2WoeLNJ0i9sb7StHWGaG4uUjdN0NmjrlSRlWyM5BFfUVABRRRQAUUUUAFFFFABRRRQB4fBGq/tp3SgbR/wAIBEfl4/5iUhr4/wDif4+vPg/+2V8WfHA1W8Notk2hLDLIfJSWXSPtUG30PmW2ARzlsV9hQ/8AJ6t1/wBk/i/9OMlUvHH7IXgn4ha94i1XWn1SS417VNN1e5gjnTyo5rJCkaxgx52OrEPuzkHjbQF7I+L/AIA/GbxP+zd4Dh+HOiXUdzq9x411nT7nU7vSr3W2t1toYSES2tv3kheRiu4Nhc5NdT8b/wBpj4j/ABa+DnjfSU0e08IR6Z8P4NZ8Qwajbzx33n3EzxqkJ+Uw7REz/Mp++BX03qn7G/g+8murm01zxNoutNr994hh1nS9QSC6s5rxFS4ghbydvkuqL8rAsMZDAnNVPGn7C/w+8Waatg2oeItFtH0OPw5cRaXqCL9utY3LxecZI2LyBiTuPXODkUO1ncUHaV/63Pknxp4R0/xFeftEeKpLm5i8QeDfCvh3U9F1O1vpoJLO6XTzKzKykKFY8EMDmuT+MmpDxF4q+MHia+0fxAviv+z/AA0+neL7KR4bbw/LNAjNLdMjqyJuYk4jbNfbvif9hrwh4q8Savqd94s8YQ2WtW9ja6zoNpqEUdhqENrH5cKSqsPmEEdcPzXQeJv2SvBni2x+I9jdXGqW9r4+trK01KO1kjUWsVqoWJYMx/u8qADu3VUpxtzCguVI+Uv2tvixb6L+0hoesSeKYrWT4Z2mi3LWJvhE2oG7uUN0qR/8tf8ARst3x2xX1h+058YvE3wr8A6VrHhW0W7tr3Uo7e91xrCTUI9MtWDlp/s0LCSbBCrhexzWTrX7EPwx8RL48/ty0m1nVPGABn1S/S3lvLBVgECizfyh5IRQOx/Gu18TfA/TfFXgfw94cm1/xBplx4bS3Wx13Trtba+jeKMxiTfsKPuUnIZCvfGaHayK6tnzX4m/bW8ceFfDdnq00vhfV7bWPBGpajpN3oqySwXGtW92kcMasxBCPFNETCw3q+QTW5H+018T1+NT+AdauPC/g69kuI7Gwt9b025Q6irWu5ru3uVYxOyzf8uvDEcb8074qfsjJqF98FfBXhTQJ5fDPhjxN/wkGr+ILrUIfMEbSPLLC6k+Y7zSCNjtXZ8o6dK9f1L9lbwprHxCj8W3mp+ILpI9Xj8QR6HNeBtPj1CNdqXCxFN6tjnAcAnkgnmpEtT4x+Dv7TXj/wCHXwd8AeH49bTV9Y1yfXryPUn0O+1eWCC1nwbZobeR3ZnlJ/eA7Yx13V2XjL9ub4uaXpPiDW7LQvD+mQ6B4U0PxDqGi6tZXH2pZ7qbyZ7cHzFMe08/MrMuOhr2+z/Yc8GaXo+n2Gn+KPGmmtplze3On3ltqaJcWFveDFzaI3lYMD4J2tuZTyrA81a1/wDYg8AeINL8Saa97r9tZeIdF07w/cR297EfLtrJi0JjLxMd5IyxckemKpW6lLRmp+zz8YPFnjbx18U/Cfi/+yptQ8J6hYxwXej28kUM0N3aJcIpV2ZsqGxuzzmu0/aEUf8ACg/ihnnPhnU+p/6c5KTwT8H9F+H/AI48c+LtOubmTUPGD2TXa3DoYo/s1uLeMRBV3AFQCQSR6Yp/7Qn/ACQP4n/9i1qf/pHJSlrsRFWVjyL9ofwze+L/ANgrU4NNMqapaeFbXUrSRGPmCS3jiuBg9TnyyMHg55zXzz/w0xqth8RfGnxN0KNruTXL/wAN+DNIuri0nv4LXzbD7VdzfZrcb53Vvl2oyntX3d8P9Hg1z4M+GtPvMS29zoVrDKqnhla3QMPoQT+deP8Agn9hj4d+CfhHB8PdKv8AxAtpZ65/wkNprX2uIanbX65RJVkSIJlVG0bkII61nT0b5v61KnqkkedeGf2qvjP438W/DbwtpugaPo+s65/bS6hJ4j0u8sElisZYVS5ghdvNQSRuxCOCAzAFsKa6n4LftMeOviH8WNA8C6jDpK3+nXPiCLxO1tbSD5bO4jitmjBb93u8+IndnOTXo/hH9mXwp4J8UeD/ABBY6hrlzqHhuHUUhkvbtJBcSXrLJcS3LbMmQlMgqVUZbj5hXH/AD4Lav4d/aE+MHxM1vQ30BfEVxBaaTZzXcU7tDGo86ceWz7BI4U4Yhjj5lXitU05r5/mZST5H8h2ufHT4m+IPjd428O+BNP8AD15ongefSYdRtNS8yO61A3a75fKlLKkflpyuQ288VwkX7Y3j2TxHp+rGx0UeDda17XfDllYG1m+228lhDK0dw82/awd4SrRmNcBs7+K9m8bfsn+CviD8QbvxZfzaxDNqE1jPqulWt2EsdVezbdam6jKbm2HoFYAjg5HFUrX9jbwPB4xm1/7TrQQz315baIb0f2dY3d4jJdXNvFs3Kzh24ZioLZAB5rOCatzf1qjaprfl/rR/qfONn+2d8cJvCsd80Hg1pbr4cN49ikFjcnyxFLskgwJcHd/453zWr44/bY+Ken/8JVrOiWHheLRdB0/w1qctpqMFwZWXUkQyR+ar7cISfnx+Fe32/wCxL4Hg0W30z7frwgh8Et4GH+kwZFiz+Yz58n/XFud33e23FNvv2KfA+paL4msDqOvBNfsNH0+7b7TDlE00AW8kZ8nO44G9j97HG2r01+f6/wCaEttf60R5cv7XnxHh1bUvA1ynhweNX8cweE7TV4raQ6fFHNb/AGjzHh83czovy4EnPesqx/bE+KXirVNM8P6QPD9nrcNv4lt9UuJrCSaH7TpT4WSOMTBgsg/hLZr3LXv2RPBWsXPie+k1PX7bU9a1+DxMNUtp08/Tb2GPyla2by/kxHxhw+epyabof7HPgbRJ9Gls5dXjk0yy1SyDvdK5uW1A5up7jMZ3zZJ2t09ulHb+ui/UDoPhj8TNW+LH7OPhjxtJe2nhPVta0aHU5LjyRPBbEgOx2MeUIGME7gDjO7mtf4QfEzUfiHpd+91p8bfYZUgj1jT939n6oCOZrZnAbb7fMB2eTrUOhfAvQ/DfwTsPhdYX18mgWNillb3k0dvNcKqHcrnfCYWYEZ5jI9q6HwZ4RvPCdvLa3HinWvEoJBVtXS1UW4A4Vfs8EOV9jmk/ibWwHXV4h8WkU/tHfAZSinM2t8lQSP8AQM8Ht+Fe4V4h8Wv+TkPgL/121z/030AeYftAeGLb4rftU+Bvhx4hurtPCX/CIarqzWNtdS20ct0sscccjeW4YiMElQTgZ4ArjNR/aK8WfC7QrXwp4F8W6N4+svBfgI+Kr/xHq0Ek0mtRx3MlulsuyXETAIxaU+YdyAbOTX0t8ZP2efD/AMYrzR9UudW17w1rujxXFra6t4bvltbtIZ1CywlmVlKsAOCDjtiuN8QfsQ/DnXNJ0bTbb+2fDdpZaJ/wj9xDod/5Iv8ATy4dre4ZlYupfc5YFXJJ5pr+vuYv6/FfoeK6/wDtqfE9vEmtajoVv4ZHhiz8R6BpMVjqNtP9oeLU7WJ1JmVwoKMzE8d/TFX7X9rL4r6hrWh+FIz4Yj8T3HjnUvCU959il+xyJBb+Ysqxed5iY925r2bVP2QfA+qahrM5u9ZtY9Y8Q6X4jmgglhEcVxYqscEKfuvliIQBgSxODhlyKkt/2TfBdn4ttfEcd9rL3dv4pvPFRjaeHy5bm5iEMiOBDuMYUEKgO7d1Y9pbSlf0/T/JkKLs1/XX/NHhPgH9uP4hfYfCniDxXpWhXOh61oWvXklrpsM0NxBPpe/dIC7EFJcD9396PuTVPXv23fih4M8N6hHq0fhi68QXXhTSvF+mvaWc0dvbxXV4lu9rOGlyWXJPmD/vivevDf7GXgHw7F4UtFutYvbPwzbatZQ211cRMt1DqGftCT7Yhn73yBChGed1Za/sK+BV8N6polxq3ijUBe21lZDUL7UEmureztZkmhtYWaPaI9w53AsfU1TajL+u7/QNXFHQfs8/F7xb448Z/FXwp4uOlT6h4P1S2torzR7eSGKaOe2SdR5bO5GNxGd2a95rzvwN8I9H8AeLPGviKxurqa88XXUF3fpcMrQRyQwiFViAUFRwCdxavRaG1fQqN+olFLRSKErx39sL93+yn8YSvyn/AIRPUzleD/x7SV7HXjv7Yv8Ayaj8Yv8AsUtS/wDSaSgDz79vS5mh/ZJ1K4heS3uJLzR1MkLFSm69tw3I6D1rxv4ifGbxL8If2ivjLfeHjZTXVxe+DNLij1TzZLdUuFlWUqoIwSNgGOuM9a+x/HXw10P4yfCmfwn4hguJtI1S0iinWB2jkjK7JFYEcghkU/h715hD+xX4LbQby11LW/FGqXt/qun61ea3qmoRz3sstmf9GjZmh2BFHUKoPv3pqSi9fL80Ve+h5npP7WXxK1rXE+HkLeHIvHc/jy/8JQ63/Z0zaebe1tEuXmMHnbhJtYgL5mKs+PP2pPi/4chm05dF8MaR4i8N+DLrxfr0dy5u7e/EE7IILZklXyhIkTPvPmbfMCkZU16dqH7Hvg++uNZ1CHUvENlrd94mk8WRatp93FFc2d68CwsICY8BCiYKyBz8xyTxjP1P9hn4cX2g6NpVlqPiDQbfT9Nm0mWXStTEcup2c8vnSx3TsjFy8pkbeu1vnYBgDiofRf18P+YtNjxrXP21vihJqmt6xoFt4YPhmx1Dw1bRWOpW0/2hxqtvG2DMrBRseTPT9K1rX9q/4rXmpWHhVG8LjxUfiRe+Bprz7FL9kaGO0E6XIi87eCM4xuwcV7Dq37HPgjVJPEKJPq9rHrF9pOpTW9vPGkUcmnBPs8ceYm2oRGgbJZjjgrk5sWf7JPg6w8WJ4iS91c36eMpvGoVpovL+3Sw+S8f+qz5O3kLndn+OrvHdeX6f5MXRnz34Y/bs+Ium6N4W8ReKtO0G90bVdK8TTS22mQTQzpcaT5nzguxGyXyziP7y9zR4q/bc+J/gXwD4jn1WPwxc+IpfCWj+M9DktbSaO2S3u7yO3ktpg8pMjL5mfMUr90/JXuWj/sWfD/SbXwbZvPrN/aeGl1xbe1ubiN4bmPVC/wBrimIiXco8xwgUocHksRkUT+wt4DufA/iXwrd614o1Jdc0+x0uW/v79Jbu1sLWYTQW0LGPaEDBuWVie5OBTVr6/wBasatp5G/+z/8AGDxb42+IXxW8GeLjpb6j4P1Gzjhu9Jt5IY54bi2E6jZIzNx0zmveq858E/B3RfAPjjxv4t0+6u2vvF8lo95DPInko0MXlJ5QC5AIPcn2r0ak2r6E/adgpBjFOpMVPUZ8pfDtjb/sQePZY2ZJYX8aPHIpO5WGpakQc+oPP1ANfOX7Id/B4V8YeFtV0LT9T8D7fhi+ratb+Jb54LHxBdhVAukBaULErKzNJww3j5MYr6v/AGcvDtr42/Zg1LQbp7hLTV9W8U2FxJCoWSOObV9QUsAw6gN+tXp/2PPBNxbeG7a4u9cu7fQ/Ctx4Ogt5p02T2UyKrecVjzuwi/MpC9cjmlG65r9dvua/UrS6PnW+/bs+JGleG/Gyxnwzr+qabY6LqGn6na6ddWlpL9tvPs7wokrbplHVZxhT3Fb/AI1/bD+K/gn4jXvhB9G0zWtZ8ORWDapY6BoWoagupyXL73WKaMbbTyYv+e27celekyfsI+BLqzv7S78ReK9Ve+07TtOllvr+GSRYbG48+2UZg+T5vlKqACq9A3J7Pxp+y/4S8cePrjxXcajrljd362n9q2Gn6h9ntNWW1ffb/aU2lzs3AZVlJHDZHFVpoQ/ibPal6U6qqyMqNkt0BOcbhn6DH8801bhpVyjMeeDxgkZyvQkYIwcii2twuXKKg8w/3jj14x0+n41D9pZWIZmUb8blwceg5HfpgZPP40B/X6F2iqf2p2fYjoxxnr+A49yDzVvvQFxa8O+Jkaf8NR/BMbFwdO8RHp6R2WMenQV7gc14l8Sv+TpPgj/2DfEf/ouzpJ3GfPf7ZHja8+Bvxj8U+IY7mWG18WfDHUtMsY3c7BqcEqeWVHQMUmUcf3KyvAv7SvjL4X69pHwy0LQ5NX03wbNougajaxaFf3dzeLPBG1xdvexgw2/lGTOx1JbacV9Q/tAfsx+D/wBox/CreK5tTU+GdQGoW39nzxxb243JLvRsxHauQuDx1qHXf2WPCWtfEybxr/aWu6bLdXdpfX+i2V+IdOv7i2G23kmiCZJUYXAYBuMgkVV7FbtHg+h/tV/GOb4W6n8RtQtfCq+GNL8XR6HNBb287XUlquovbzzt8+2P5XjA68xk9GFexeAfjh4o8TfAf4i+Pby3s0l0251x9ESGFjG1tatKkPm8/M2+Bt231FZfxC/Z9XwT+yz44+HvgrRdS8VXGum7khtZr23hkhnupCxbzCI1WONzuwoLBQAucAjtfhf8F4PCv7POh/DDUXHlRaH/AGVfyWcg3GSSErcSKSD826RjnnlsnNNNSRnJ2Z4FeftQfF+x+D/gvxRqepeBdE1TxLp0+s21lFp17qE88EdtDIIoLeJwzMzOzPIWCRqyZzR4T/bI+InizXG1KPStCtvCmnfD/TfG+rxuzm4UywzPJBAc4+YqvLZ2bec5r2HXv2QfB2taP4L0wat4i0x/CWly6PZXun3qxXE1jKixSwztsw6sqJ0C4wMYq38Ov2V/Bfw3uJvsc+q6rBceFrTwpNa6rNE0c9lbqyoGVY0PmMHYMxwOeAKzWidwZwP7Jf7Tfjb41+KJLLxFpWdIvPD8Gt2ur2ug3unWsMzOFezWS5G24Kq8b+ah2nJwMCvrCvH/AIP/ALO3h34K3Vxd6Xqmv6zMLGDS7eTXL8XAsLOHdstoQFUKi7iTuDN0G4gAD1ZZWCnLt0B5A3DjB4A65/PtV6PYUb9S1RSbqdSLEpPoKWkFAj54/ZsjX/hlXpj99r/f/qI3v+Jr4e/Zl+I2peHZ/gD4d1zVL2/k0y9vdetWnkZvPsLnT7iQKM9QlxDMvtxX3T+y3ps2q/sxQWEMhjnmutdhV5FHDNqd4Aa4XTf2Jjomr/DHVU1aymvPh3ZTadp26CRlubeRGUpchcF9pZirJt+8cis4p+8mVJXikeT+Kv2qvib48+E+oRXkmh6SvjPwDqnibSJ9Ltplm0yO3k/eQO5nxKzxHAkHlmOTkoRXY/HC98QW/wDwTAlv9W1c32qjw7p1z/aMUTwOFeaBlGTI7bljbYWzlj8wxXT+E/2If+EZs9TsV1O1vbC40qbQ7a3vnlmTSbKV/MkgtQCNis3OX3nHGccV0Wsfsv6/4g/Z3/4VBqXipL3w39kis/7QnDNqPkxzLJGvmf6v5VRUB29B1q3tIlaTieX6X+2P488XeA/Dfi/w+PD1tpfirx9a+FtLsbq2kluLazIdJZboLKNsrMolCDonHWrXhf8Aa6+I/jRvDXgyym8MWfjnUvEviLRJtZmspm0/ydLXc0yQ+buJcdB5nGOc1119+xteX/jKXXV8RW1nLJ4g07xS+mWaMtr9vtEKCTy2ywEik+YwbL9RtPNVJ/2LtQkhH2XxO2maoniDU/EdvrVoZI7y0mv023EUZYbTEy8FCC3+1VSkrJkRvztHmNx+358SNT8FwX+laLoia1rvhmzvdDtJLeV4xqJ1OSyuUchsugEfmJt6BhuzXQL+2Z8QPF3iDTP+EWfQE0PVPE2i+Hba5u7GSXabrSftdy52zDcUkkQKB/cx3Ndwn7GrReIPhTqNlcaTpy/Di3kg0i0ghn+zyLIAW84Fyz/ON33hgk53Zql4J/Yhm8B+HPDWkadrtrNa+HfEw8VWU14jPL9rCbBFIOnlBeAqYYdmoi1ez7/kxu7Sa7X+89V/Za+LHiL4ufDK41PxPDZwa5Y6xf6TM1jC0UU32a5eHzBGzFlztzgmvaa8R+C/wb1/4L6TcaNZ32l3mlXmq3Wr3m+CUTNLcSmSVIzuxgEnbuBznmvb6XkOIlFLRQUeIftTxI2i/DslVJ/4WD4ebkdxex4Ne314n+1N/wAgX4d/9j/4f/8AS1K9soAKKKKACiiigAooooAKKKKAPEYf+T1br/sn8X/pxkrxz4o/tVeNvDPxH8bXGmPoi+D/AAVr+i6Bf6Td2TNPfG98ve6TiTKsnm/KNmDt5zXscP8Ayerdf9k/i/8ATjJT/FP7K/gTxb8R28Xail/He3F3aahd2MGoSJZ6hcWw/cSSwA4Yp+vfNLqv66oD5xsf2pPjFdeFZtVnufDsFpqvxAXwLosi2EjzQO126i4nUHbtCKEVVGT1OTzWxD+0x8Rl8H6vb3niHw9pXiC38aaj4eSeLSJrueWC1i3iOzsYSxkfuWlkUKvJr0n4jfsy6TpXwX1Lwp4V8N33ifzvEp8Q/Z21n+zbuK6eczPPb3Pl4V0YkoGGOxaub+Df7Gtra+DQ3jSPU9E1qLxTe+ILBtL1p2uLVLgeW0Mt0CTJ5kfyyd8dCKa6X8v0/wCCJ76ef6nltv8AtifFXxb4Z0nUdKv9C0a6/wCFeXfim5t5tNa4Vrm1vTGw4lHlCRUIw24DtivoD4qftAa34Z/Zx8E+MdNtbKLxD4qm0exha7Uvb2U17s/eMo5ZV3Hgc81Y0L9in4feH9N+wwHVjB/wjt34UCyXYc/YbiZ5XGShPmAu2G9/y7jxD8BfC3ir4T2Hw91OG7uNFsIbeO1dbox3MLQY8mdZEIIdSAc9++aelmv63f8AwCbP+vRfqfKfjTxN470f9pT4Tz+M9U8K3OseH7Dxaw1W1laGxmjjskeGS8QFmgAySyjeQpz1qbw7+1h8X73TviFp+nWNj4z1/T9A0vWtLutO8PXVqJlubnyZzbwSMJLqNF3vG5Ee/ZjHNe2R/sT/AA2jurK6uI9WvZ7WDVYbme6vzLJfnUIRDdS3BYZYmNQq4IAHamad+w/8PbGyv7Z7rxFfx6lpdnpL/wBoavLI6Q2svm27I+AyPGRxggdR0JoZb6WPIbr9qb4lyfDmx1HSdZ0fV9Mh16703U/Fmm+Gb2WTS4IoFkjW9004e3k3sAxBZQhQjkmvq34P+Lrjx18N/Duv3d9pOoT6lYxXDXuhNI9jMWH34jIisATnCtyO9edn9jHwJHYxLBe+I7fXFvp9Sn8UQ6tKmqTzzRLFIzzAbWDIiLt27RtGADzXrfgPwHofwx8I6Z4a8P2QsNH06IQ21sju+xR/tMSxPXkkk9zVJrla6kyT0sdCVU4OMc5pTErBgRkMCDnnI9KdtFLULYoasarnAxu5PPtivPP2hP8AkgfxP/7FrU//AEjkr0WvOv2hf+SB/E//ALFnU/8A0jkoAi8N6De+IvgV4e0rTtcvPDt9NotkI9Q06OCSa2/cp0WVGjbj+8pr5N+DmtX9p/wTzt9Htb2e913xTq+oeGLa8uHPmPPeapNb+aR3Ko7OfXac19m/CeNW+FfhBGUFBo1l8uOP9QhrivB/7NPhTwbo/g/SrP8AtOWw8Larda3p8NzcowW5naVm83C/NtM8hUDuR1wKmwHi954Hvfh/+278LbCLxDqGq6P/AMIlqyabo1ysS2+miGO1TFvsUH5tq5Mm4nHJryj9nma407xt+z54xjjvI/EXxA1LxIPE1zNKzyXcUYd40kJJVlRlUKFAA7Yr7j1T4TaNrnxU0L4gyG4TWtH066021CyqIZIpyjOzKBycoP8APXl/Af7LPgX4b+Of+Eo0lNQNxC1y9hZ3moPNaacbhy8/2aInC7mJ+gOBgcVcdJJvzFJXi16HsflIy7SoK/3SOKc0KMuwqNn93t+VOpaQxnlJtI24B5OOOfX60GNSoGMAdMHFPooAZ5KblIXBXOMdOetAhRf4e+eeafRQA3avTAx0oVFXOFAz1wOtOooAK8Q+LX/JyHwF/wCu2uf+m+vb68Q+LX/JyHwF/wCu2uf+m+gDX+MPjDUfA0unajpviG0+1TIbeLwrfQlzqjYyfJ8lGmWQA9QGTHUKPmrxD42Wet3X7Tn7NniC+1jWLSw1LU52fwneCL7NYSrpsrE7lUM8gOd25iB2xX0V4z+F58Za5a6rb+Jda8PXMMRhd9K8hGdeoGZYXI59MVW8QfB3RfFeueAda1O7v7nUfBdw9zptw0qL9oke3MDNNhcOWViflC8mjqB45rmg6j8W/id8YNesNf1Dwx/wjulQ+FdP1jTY4TMkmwXd4sYmV1GfMgjJAzleCCK8J+GtlH40+EX7HfgXWYZ9S8J682qSala3DExXjQRSSRLKAQSAx3AZr7m8GfDXR/A3hrUtF04TPFqV3eX11NMwaWWa5kZ5DuGBkFgoHGAgHauEm/ZR8DTfDjwn4MgudXtLfwrM0mj6nY35hvraRkbcVkXg5V+jAjpx3pW3+QteZM+EvALP8V9Ifwx4zN1qWj+FvAfiTUNIguJWPkTW+pSQQ3BOSTJFHH8hJON2R617d8dfEHivxP8A8E4vB3iGPWv7L1ue00W4v7h42eS5JkjUlcHIZnZHJHUDB4OK9y1b9jH4Zal4d0PR7aDVvD9rpGny6XHJpOpyW8sttK2+aGaTJMgZuSSc9cEV3Xj74FeFfiB8JZfhvf2k0Hhg28NtDDYyeVJBHCVMYR+o2lF56nHOaHqn8gtsfM2r/tQfEnw74q1DNxol34d8L+KNH8F6lZNZvHeX73cUYkvI38zCESS/Ki5BC8mvt+vCf+GPvAcnjKz8R3Y1q9vI57S9uoJtTZ7S+vLWPy7e8uYjw86r/EOCcEgnmvd6ttCSd2woooqSgrx39sX/AJNR+MX/AGKWpf8ApNJXsVeO/ti/8mo/GL/sUtS/9JpKAOr8U3jWvw/F0niaPwvJBFFONWvI0eKHAQnzlkIBBBII3K2DwQea+fvjpr3in4n/ALJ/xDv01LU/CD6XZXE0WpaJF5cGuWy2+cxrPE0kUMmexB9HYfNX0R4k8IxeN/BsOkXd3cWAZIJFuLTyWnV0IZWHmo65DAHOOorHv/g5b694A8SeEdf8Ra9r1j4gt5LW6mvJ4VljjddrCJo4lVcjuVznnOaiSbTsHW54pqUa+MfAX7N3w+gVSNU/s/W9QhUAILGwtkmZWUdFac20f/Aj71H+zdompeG/2vvj7p+peJNU8WXMNnobpfagsCEI8c7bAkKIi4I25CgnGT617j4Z+D+heF/EOk67ZtdT3mkeH18N2PmTqVjthIGZsAffYxx5Y/3cYHNYniP4F6XcXfxV17Spb5PE/jnSo9Mume6MMaGG3eKExsqkxcSZLc881o93IT3ufH/7U051LxF+0h4yupbpNa+HqeGm8LX0UzA6aZGSeR4sH935jMQ3Hzd81g2mtajb3nhj4qRrM3jq++Ml7oVxd+cxk/ssQzKLTZnaIlCKwj7EZ65r63b9j7wVri6Bc682oajqkGm6bZastvqEi22s/Y1Ahlu4yf3oVwG7Z6NuHFblj+yr4B0/4lf8JbFa3huIdRm1lNJkvXbTEv5omjluhbZ2iVkZhubIGchQcGpi1ZX/AK6jTPlT9lZZPD/j39nTXrQXbap498Na5eeKruWQubySORJY5pyxOWVmKr12g7RgcVq/Ff4oeMfgf+0R+0D42tdXt9Xt9C8K6TPbaLcW5EW+4uXhgRm3jGxzvZurA4HAxX0x8M/2WPAvwl8VQ69oqal9qtbaey02G+1F57bTIJ5BJNHaIxPlhmA65PYYHFSePP2XfA/xG8XeIPEGuJeyPr2kroup2cN6y211CjFoWZBg70LEqQeCacnzNNdP87/kJdTG/Z6+Jni7xF48+Ifgbxpfafqmq+FJrFo9V0u1+yrdw3NuZQHjMjlSp9MV7/Xm3wm+B/h34QrqsujtqOpahqsyXF/qms3zXd5cOkYjTdIewQYAGB+Nek03boCCiiikM8C/ZZR5v2dZANRk02Q614lP9oAozW+dZv8AEvzgodvXDAj1FN0PxV4h+KOg+JfDVv4gmis7e2RrX4geGLRI4rg+ZhxEs6SRtIFGHaMsmScFDwIf2X9Ih8Sfs33OmTSiO3uta8T27yRIpMe/W78cI4IPXuDXpXg34eT+DluDceKte163aMRx22qPAyWqgYARYYUHFID4++FepXs//BPLwt4ZjuZJvEHjS9k8NW0jHewkur2dZpOe6wi5cnr8tdvrvhe78H/t4fDe3i1u91PQ5fC2rS6bodxFCtrpiRLboFtvLRSCcD5nyfevY/Bv7OPhLwPpXgbTbCW/e18IX13f6ZFc3AJ8+4EhdnGz5yBNLgDGNx9OOj1T4U6LrXxV0L4g3AuBrui6fcadaRxyhYfJuChfem3JO5BznjB4pPoyWfDH7Ocslr41/Zu8YW093/wkfxA1HxRH4mujOwOoJGsjRq/PzrGVXaeq4OMVY/aySfWPF37SHia+e6GsfD/S9Bm8MzrcMF09nPnPIgBwhcjBz1r6Z/4Y98E+H5Ne1PRE1RdRns9Tg0qGTU5Fh0c3sZE5swBiAuT1O7bn5cDiqbfsY+C9etNBk8Tzaxe6na6Tp+l6s0OoyR2+u/ZBmIXKEky7WycnBPQlhxVN7+Qo7X7/AOaPknVfEGqWttafFuEzt8QD8Y38Py6gJ2Mx0sQOgtNucbNoB2da7D9lWF/DvxK/Zz1awN4uoePPCmu3nie5a4ZvtsiuksU82SQ0gdiNwwefSvqhP2T/AIet4/PiwWt95n9oHV/7F+2sdMGomIxG7Nt93zdjEf3e+Aean+F37LvgT4Q+KhrWh/2hJeWtrLaafbX+ovNFpdvLIJJYreNvuIzAHJLMOgIHFVGS6/1ugab1X9a3Pmn4yfFbxj8Df2lvjb43i1iHU7TQvA1hd23h+aAiD95cyRRKx8wAFXzIzDlgdor339n74qeNda+I/wAQvAPji803VdT8OLp97a6lplr9lWaC6iLhZEMj4KsNoxyQMmtvx7+y/wCCPiN421jxNrq308mr6EfDupWaXrC2ubQMXj3IP41ZiysOQTkc81tfCH4G+GPg6urzaNc6lqd/qzQvf6nrN+93dTmGPy4gWPZV4AGB3681K8/61NH/AF9yPSzXiPxK/wCTpPgj/wBg3xH/AOi7Ovbq8R+JX/J0nwR/7BviP/0XZ0rCKfxx/au0b4O+MdB8FxaFf6/411yMy6dYwmO2tW9We6ndIwM5+7ub/YryD9rTTvH+qfDj4Y+IPE2rHw/f/wDCXaRFfeG9Du0uNNmEt8Cm+ZolkYom0HawRix4wBX1t44+G/hb4laPLpXinQbHXtPk6w3sIcA+qk8qfdSDXB6n+zV4N1b4daN4H36hF4e0bVYdYs0/tB5pYZYpzNGgeXeTGpPCk4CgL90Ypi1OW8YaXN8Tv2ndO0SzvrjSYPBXh6bUV1CzjRnhvb4m3i4kVlysUUxwQRgjivlW3vtW0L9nn4jaDPrup61LqXxjHhzUtWvCFuLu1kubeOTeY8YMifKQMcHHFfoD4X+HOm+FPEHinXYHu5tR8R3UV1evdSByvlxCKOOMDoqoMfUk8kknil/Zh8ES+D/FvhqWK7u9N8T69N4jvHF2Y5lvHkWQNCy4KFGjQj6c5qk7NfL80S02v67HB/sh2cXhTxt8cfBulK1t4Y8P+JoYtKs1k3R2qy2iPJHEpPyAMSce9eL/ALXaR+KPiR8drnUVumk8F/D6y1Hw68dwyNZXbzTu11FgjYxKRqWPPy+mRX0Zp/7L+n+ENW8HzeF7zUrZdP1+TXNau73UJHn1RpLd43Evy4l5EfBwBt4xk1r/ABV/Zb8DfFzxRLr2vjURd3FhHpeoQ2WoPaw6haxyGVIbkL95Q5J+XB5wcjiofT+uli46Xv8A1rf8j4Yh8Uanr1lqXxbvluE+INn8WdI0e3vPPdZlsmggR7VVBwI2VpCYhwd2T0Fdb+zRJcaf4v8A2aPF8ckyeJfiAPFH/CT3jXDltR8kuyCcZx+6IAXHSvra7/ZN+H918Sv+EveG8Nx9th1f+w1vGXS/7QhiEUV79mBx5ioAOuD1IJ5pfh7+yr4B+GXi6HxJpMN809p9q/sy1vr5prXSxcuZLj7Gh/1e9ic9euBgcVpdf16EpPqe0U+kpagoSkHenUmKBHgv7Jl4mnfs42N0ytILfUNadlzksRql3/hXz78H/ix8Qb7wd8ONF8FXmjWPibx5pmueOtT1nXoGuFaRbnMVsF8xMDMqIzH7qJkc5NfQX7Kv2v8A4Zus0tIbW8umv9aEMU87Rwux1S8+UuEZgPfZmvIPCf7JnibU/AegeGfFPhqxtLvwlNqWm6Xqul+L7i0mutLuJC3lO0do2UKOqYfDfu84GeTZNgyD40ftZfEb4bzWF4L/AMNytptnobazoGkWFzqJWa8kVJ3uLtf3VrF86m3G9ml703S/2qPicvxEs3u5dLl8NTfFm6+H/wDZi6fic23lu8U4nEm3K4HGOe+a6PxF+xrba4skMHhWx0O0ktdNtJrHS/Gl4kMkdgUNqzRtYkNIvl7cnr1OTzW1b/szXlvc288fhrTXmg8YyeOog/iqfb/aTxGNgf8AiXf6vBPyUcy93+uqIlez/roeN+Ef21vibpfhvwd4r8UtouqaL4g0vxXcvpttZNBLDJpHnSIRL5pB8xUVcYxx6nNY3xb+O3xP8VfA34heG9d1jSlub/4c2Hjmy1DR7B4GtYLh8S2ZYy8kAYSQfMfQ17fov7JMXh/TfC+nx+E9Ju7PwvDrFvZx3fiyb97Hqe77UJiunAnO9tmMEZpNG/Y/t9H8KeJvDsnhfT9Sstf0tNDuLi98aXktxa6bExMNpb/6D8scZKgAde+aHa/9d3/wDVtOzj5/n/kcx+1RHq1r+yX8L0nv7fWNa/4SDw+FvJLcxxmXzFwdi54B7dPWuf1z9sz4jeG5ZfBF09rdeMYPGd14duNZ0rQJ71fssNss/mRWUTF2kO8DGcbVJ6817V4t+AviDxv8KNC8Ca5oljqGkaNJaywTTeMbgXUjQHKtNMNPznjqoFYP/DKcsPh+302Hw/bxaomtyeIV8Rx+NrxdUW8dSjyif7Bz+7Yrtxtx26U29W/O/wCREYtRSfb8rnrf7PPjzxH8TPhDoOu+LNDuPD+v3CSJeWVxZSWrBkkaMP5Mh3oG2ghWyQOteq15V8LfDOtfD7Q9I8L2vh7RNM8OachgM1v4iuLy5UhWIJElqm92JUsTID85PYZ9SZjxik97hHYfRTFJOM0+knco8T/am/5Avw7/AOx/8P8A/pale2V4n+1N/wAgX4d/9j/4f/8AS1K9spgFFFFABRRRQAUUUUAFFFFAHiMP/J6t1/2T+L/04yV7aFC9BgeleJQ/8nq3X/ZP4v8A04yV7dQAxolY5I+vvxjn1pRGo6Dvn9c06igCP7PHuzsBP/1sYp2we/506igBoRVxgcDpTfJQDAUDnPHHbGfyqSigBvlruDbRuHAbHP50u0Zz3paKACiiigArzr9oX/kgfxP/AOxZ1P8A9I5K9Frzr9oX/kgfxP8A+xZ1P/0jkoA1/hL/AMku8I/9gey/9J466zYPf061yfwl/wCSXeEf+wPZf+k8dddQAwxq3JznnnJ70rRqxBI5HQ06igAooooAKKKKACiiigAooooAK8Q+LX/JyHwF/wCu2uf+m+vb68Q+LX/JyHwF/wCu2uf+m+gCz8av2mPCvwX1zRfD15Df69401kOdJ8O6TbBrm7Az91nZY1H+0zduleFftj658TNV/ZmPirUbi4+Gt1Bq1nDeeGrG7iuZLuCS9gWNZroL+6ZQxY+Xwc4JI4r6w+IXwp8H/FfQzo/i/wAOaf4g07JKw3sIYoT1KN95D7qQa868Qfst+HNf+DM3wxl1jXRoJuYrmO6nvhc3VqsdwlxHArzK37oFFXBzwMdKBalP4vNfeOPjl8OPAlheSWS6fDeeLb2WPDKnkx/ZbVG9R5115m08HyuQRXylqnjfxr4H+Cv7TYv/ABbqOs+IbfxvZ6LDryEQzLFL9ljLJ5YAiAVmHyAYz68195aP8ObHTPiLr3jSOa7n1PV7O1sJPtDJ5UUMBcqkQAyNzSMSWJJOOeBjhp/2WfB2oaN8StKv7jVLux8f6iuqanEZo1+yyqE2rCVUFMNGh+bd0qk7Ma8zkP2Y4n8F/Gn43+ArS71KXw3oV1pt1YR311JcmE3Fr5kyq0jMcFhnGeO2K+nGiRlYMNwbqG5Fea/B/wCB+k/CGPXLm21XVtf1rXJY59S1bWJY5Li4dE2JkRqiLheMKoFem1PQlJ9RnlrjHP5nNPoooKCiiigArx39sX/k1H4xf9ilqX/pNJXsVeO/ti/8mo/GL/sUtS/9JpKAOm8afEzw78H/AIYv4r8U6gulaFp9rG010sTyKuQBgIoLHmvPPBfxX8b/AB00zUbvQvDdz8N/C15ZeZpXivU5Lee9mk3LiRbM5UR4J5kOfavZ49Lstb8OwWmo2dvf2k0EayW9zEskbjHQqQQa4P4d/s5+DvhN4s1HWPB9ndeHoL+PbPo9lcsummTIPnLb7tiNwPugfSgD5k+EPjfxBp37AupytrF5q/jXWtZvtEtL+SUm4e9u9Qa2jkVuxAcvx02nFdV4i0XxF4D/AG1Pgdop8a3l94Vk0fVYbfQdqqlssFlBGNzgb5SzktukZiOxFereDf2X/Dng3QfB+hwX+rT6d4Z1yfxFBHcTRfv7uRp2/fbUHyIZSV245xnOK6bxR8H9J8W/FTwR8Qbu8u4NY8IxXsVtbwPH5Mi3SKkolBTccBBtwR096YH593HxQ8S+FfB/hL4v2euarL4o8Sa14usdS+0X0rW8kFvDeG1jaEsUxCbdCvy/L2r2T9lia+8JfGjwJpEesazd2Piv4VQ+INUivr+a5STURcxI10PMZsOyy4wMDA4Fe06V+xr4G0vxhLrEs2qX+mfadQvLXw7eTobC0lvVdbto0VA7bxI4w7kLu+ULWv8ABn9mPw78F9YGr6bqus69dwabHodjLrNxHL9h05H3rbxCNFBAbnc2WPc8Ypxsr3M5Rbasey7RThGoYkDk4z+FLtFLUGg3YOe/1PFOoopgFFFFAHz9+zDrlj4X/ZzutY1Kb7Lp2n654mvLqaaNtyRR61fs7bRkkjHuab8Mf2kr/wCO+rWVz4B8H3s3gC4LiXxlqkkVskuFfH2e2J8yT5wF+cLxWj+x7Alx8B4RIvmBvEPiQMrchh/bd+CCO4rX0r9mfwJ4X+I9v408OaXN4X1gsxuotFma3tL7Kkf6RCuI26n+Hrz1pdwPDv2c/F2s/D3xh+07f+OfFE/ib/hGNSt7qS+uFSMGKOxMjBI0ARMAhcKBkjvXDePPDnjrwf8AD39mXUrvxZe241rx5o82s6CFRfPuru5ku5C8mN4Cf6rYCFxzjNfSmrfsu+G9Vj+J0R1LVli+IV5bXeqKs0Qz5KovlRYThHVCGzzzxXUfFj4QaL8WE8KJq17dWKeFdfs/Elqti8aBprfd5aSllY+W2TkLhunNP/gAdnqt0un6Rd3IUSCCJplXZkHapbA/Kvys1D4neLPh18HfAPxM0bxFrEniTxz4X8T3mtXNxqEsimaH57Z0jZiqGHO1dqjb2xX6P+B/BWsaP8SPiLrd/qdxc6VrVxaNYWc1350dskcGyQKoA8vc3bmvO9F/Yi+Hmi3F4l5PrGr6NJZ3unWGj3twpttNt7w7rlINiB/nPd2Yr/CRQ935jjpFJnyV4+1bW/hn46sPhpoOs6+vh/xbbeEn1CObVbiWeNri78m6aORnLKZl5cgjNfVn7Ht5cafrHxf8HLdXl3ofhnxbJY6UL+4e4eC3aBJRGruSxCliOSe9WLf9h/wa2gavpupa14k1i/vksI4NdvLuL7bYLYtutBAyRKo2Nz84bd/Fur0z4P8Awh0j4Q6PqFnp19eapfapevqWp6hqMiPcXVywAZzsVVXhRwqgDsKuTVlYhX6noHlqCxA5bGTn0p1LRUFBXiHxK/5Ok+CP/YN8R/8Aouzr2+vEPiV/ydJ8Ef8AsG+I/wD0XZ0Ae30wxK27Izu68+2KfRQBGYUOBtwB0xxinbR9KdRQBH5Cc/L168nn6+tP2gcDgUtFADdoxjHHp2o2gdBTqKACiiigApitTqao5pkvc+dv2bPEUXg/9lE6xJE80OmyeIbxokJBZYtSvCVHua8P8Hfty/E7xH4P1/WLTwLFrzroMGuWH9n6HqUEdoWnjWa3cy/8fRjjkEu6DaGCYFe8fsv2L6p+zHHYpZR3rXV5rsP2e6maGKTfqd2GRnVGZARnnYT9a4DQf2PdZ0PQdR0gNNfQSWEOn6Z9o8b3G7R7WKYzRRW+zTlXCv0LhiVGxiVG2oi90y3seZ+Pvjd8RfinpHwd1Lw74v8ADcYb4hx6Sb/QILpYbxRCxQz2xmWW3RQZQ9u5LErGwOCczeCf2ifHukz2mg+FNK8NWk2u+KvFgefVnvZ4h9iHmRTDdKWXd/EAQD/AEr0e6/Y/1680O1gkgik1yLxLH4vl8Sv4wc38mopH5atk6T5W0IAuBHjA6VY0L9k3VfD/AIj03WLTTbSa50++1jUBHP4ndVLakuyVM/2WOFHC/wDj2ab6W/rb9RaWscx8L/20fiD4oi0u51vRPCtnaaz4Cu/F2nMlzLbR28tvJ5LR3UzllCM3zZUAoDg7jXl3xn/al+JPxC+CfxV0lNY0OyvfDF74euF17QbO/sEuYbu6jO2JZJPMG2QY8zO2RASANy17Hb/sUzx6Po+lTaNa3tppvhK68ILFJ4sdfPt55BI8hI0sHzFf5gR8hJHyUXX7F+r6n4b8baTqRn1s+LrXTba7vdQ8Xt9ogFgQ1tJARpIVXyq7lIK/KOK0TXNf+t7/AJB0SKkf7ZnjK3+Nlz4SGnW+tWej+I7PwvqkNhoN8ZZmeFDcX6XKs0EEaSEgQuzOU5zXJ/Df43eOPjV8f/2fPGGsw6VpHhjXB4nk0200l5hN9ngUxBLoM215coWygC16npf7MPiPTvGK+IiitJLd22sahpr+MJEs9Q1GGIRpcyxrpgYFto3IrBD/AHapeBP2S9Y+HPjTwn4j0ywhaPwtLfyaPo914wklsrJLxWE0aY0rfsJdmGWyCcZxikmkl8vyt+Y4v+vkee/tHeMvHfgv9rLxN4rsNX0vUbLwX8OZtf0nR7mC4aHczyRMSiTqrSlufMYFdmFChgGrstW/ai+MVrp2iacNK8H2niW+8J3vjiVpDcT20djAqFLUDdGTOxJ3v9xM8ZrrviX+zn4g+J/ijxTruraTpdtc+IfCx8KXEdr4mkWOG3MxmaaMtppIkBY4LZGOMYqr48/Zl8QePrTw5EdOg0G60XR38PjUtH8Wywz3OnuqrLbShtLIKMFH3MEdiKyhdJJ9v8xytpb+tjy3xD+3p8SntfEXiPw/oXhn/hGtE0vw9qk1jqSzi7YaiEEkXmq4T92xP7zbgdw1fQ/7Ofxm8W/ELXPiVoHjG00uHUvCOrraJdaOHSCeCWFZoyVkLMHUMQRnFeaax+xtc6tY+K7GLw7p+nWPiKz0iwlhtfFMmLeDTWBt0iL6WTyQNxfJ/ukV6N8N/hl4q+Gnizxzr9homkXN74wv49QvI7jxPLJHHIkYj2RFdOUgcfxZNayt0M1fqaH7U3/IF+Hf/Y/+H/8A0tSvbK8T/am/5Avw7/7H/wAP/wDpale2VJQUUUUAFFFFABRRRQAUUUUAeIw/8nq3X/ZP4v8A04yV7dXiMP8Ayerdf9k/i/8ATjJXt1ABRRRQAUUUUAFFFFABRRRQAUUUUAFedftC/wDJA/if/wBizqf/AKRyV6LXnX7Qv/JA/if/ANizqf8A6RyUAa/wl/5Jd4R/7A9l/wCk8dddXI/CX/kl3hH/ALA9l/6Tx111ABRRRQAUUUUAFFFFABRRRQAUUUUAFeIfFr/k5D4C/wDXbXP/AE317fXiHxa/5OQ+Av8A121z/wBN9AHt9R+ShGMcemTipKKAG+Wu7OOfWjy1znH+c5p1FADGjDdSw+jEU+iigAooooAKKKKACvHf2xf+TUfjF/2KWpf+k0lexV47+2L/AMmo/GL/ALFLUv8A0mkoA9T0f/kE2X/XGP8AkKu7F3bto3dM96paP/yCbL/rjH/IVfoAaI1XAAwBwMUGNW7fjnmnUUANWNYwAo2qBgKOg/Cjy12hQMADAxxinUUAFFFFABRRRQAUUUUAeI/scf8AJB7f/sYvEn/p8v69s8tecKBnr714n+xx/wAkHt/+xi8Sf+ny/r26gCMwoeq5GScfXOf5mnLGq5AGOc06igBnlJ8p2j5eB7fSlWNFZmVVDN1IHJp1FAEYt413AIoDdVxwfwpxjVgARkD1p1FABRRRQAV4h8Sv+TpPgj/2DfEf/ouzr2+vEPiV/wAnSfBH/sG+I/8A0XZ0Ae30UUUAFFFFABRRRQAUUUUAFFFFACUi06kFAj55/ZeGor+zHEdKa3XUVvNdW0NwX8kMNUvMF9vzL+BFfHvwl+Lnxiay+AeqDWLXxFqV1o/i25FvqGp3K29zHC4Cvd7Q4eRdrBVAwNy4x3+zP2UJJ4/2b7Vreze7uxqWtsbZZQjSMdVu/wCPpzXkfgX9kvU/AbeFTbWmu3dp4ZttastMs7q8sV8mLUsb0ZkYZZGZip5J4ycAYmO7X9bA+/b/ADOa1j/gpVeQ2Ph27sPDeltdN4c07X77Tp7mY3F21zIyvaWmxG+dQpfdJxivpz46/F7Uvhv4L0rVtI/sCCa6vI7V7rxRqK2VrbRvGz+Zz880gwv7qPcx3HnivBdD/ZD1Lwvp+iWeiy+MNFKaLaaBq7aXqmnwS6pb20zSxMXyXQ5dlYoyko2MnpXrPxk8C+JPi8nhW4j0bVNB1XwzqcWsabqdjf2UpMux43UpKGUgq7DlT1yOQKuUk3p/WpEL8t3/AFoeO2n7f2t/8IPp3iq+8MaVp9nf+GNf1K3CvI6vqum3Lw/Zw7FPklVQ4GN4710et/tgeL/B/j3wpoWvaF4XaDV7zS9JurCx1Z5tRSa6iVpJxCgYRRpIxVUlZXkHQisO+/Y3bVvh54K8KXOm63cx+FfENxrqXP2+y8+78+dpp7aTDAAOGIJHP4Vr+JP2W9T13xzfeJI7DxBp9neeILPxPJoi32ntbve26BFyxUyfMAON2AeQAeaXmWzzD4T/ABa1+6+Inwvuba8vpLdb3xnFNpd1rU7295NbnMSs8rkAA9C3yr2ArP8AjF+2P4t8bfCH4gaL/wASvS9e0i30XUrfU/COrTPbP51/Gklp5+FD4yUMkbMjg8V6Xpv7HclvZ2FpdaFrU1lbJ4hR4hfWK+Yuq/6wZDA/L/DWXefsY6nqWi6jpl43iPUzeaRp2ivdXF5pqTW8Nlcie3X5MAgqAMH6nnmqVuo1o79P+D/kVviN+0J4v17UNE8Na1bDwn4h8M/EvRNPv10G/ma3urO4gMsaPlUZlZTtKniu0+AP7c0/xq+KuleHxpGlpo2rjUvsUtjcTSXlr9nf939pGwR/vU+YbW4qMfss6lNM17f2HiLVNXm8V2Xiq81S8v7BZJ5bZdqQYjVQIwvAIANdB8KfgZ4h+EniSzu9PtfFV5oWnG9Ol+Gp9Wslsrb7S+6UNsAMm0/c3lsA4GKHboQk+Zt7H1IYUZSCMg4zknt0pVhVVIGcHPcnqcmqOl3l5eWMEt5ZnT7ph81s0iyH/vocVo1JZ4n+1N/yBfh3/wBj/wCH/wD0tSvbK8T/AGpv+QL8O/8Asf8Aw/8A+lqV7ZQAUUUUAFFFFABRRRQAUUUUAeIw/wDJ6t1/2T+L/wBOMle3V4bBJu/bMu3IdW/4V/EegIx/aMh7E84r2/8A4E35f/WoAfRTP+BN+X/1qP8AgTfl/wDWoAfRTP8AgTfl/wDWo/4E35f/AFqAH0Uz/gTfl/8AWo/4E35f/WoAfRTP+BN+X/1qP+BN+X/1qAH0Uz/gTfl/9aj/AIE35f8A1qAH151+0L/yQP4n/wDYs6n/AOkclehf8Cb8v/rV5x+0PMF+APxOZsgf8IzqhbkDgWso4JGMkUAbnwl/5Jd4R/7A9l/6Tx111cb8KJD/AMKx8HBCkinSLVWeMnaCIUArr/8AgTfl/wDWoAfRTP8AgTfl/wDWo/4E35f/AFqAH0Uz/gTfl/8AWo/4E35f/WoAfRTP+BN+X/1qP+BN+X/1qAH0Uz/gTfl/9aj/AIE35f8A1qAH0Uz/AIE35f8A1qP+BN+X/wBagB9eIfFr/k5D4C/9dtc/9N9e2f8AAm/L/wCtXiXxXO/9or4Gtko8c2tldw6/6Bg4Xqe3SgD3Cimf8Cb8v/rUf8Cb8v8A61AD6KZ/wJvy/wDrUf8AAm/L/wCtQA+imf8AAm/L/wCtR/wJvy/+tQA+imf8Cb8v/rUf8Cb8v/rUAPopn/Am/L/61H/Am/L/AOtQA+vHf2xf+TUfjF/2KWpf+k0lev8A/Am/L/61eN/tfMzfsr/F6OQMM+EtUJKAEAC2kxk8cn0oA9Y0f/kE2X/XGP8AkKv1naVIF0+0XDY8mPsfT6Ve/wCBN+X/ANagB9FM/wCBN+X/ANaj/gTfl/8AWoAfRTP+BN+X/wBaj/gTfl/9agB9FM/4E35f/Wo/4E35f/WoAfRTP+BN+X/1qP8AgTfl/wDWoAfRTP8AgTfl/wDWo/4E35f/AFqAPFP2OP8Akg9v/wBjF4k/9Pl/Xt1eG/sft5fwRiiBbK+JPEa/OAuf+J3fZ456E4Pv7V7f/wACb8v/AK1AD6KZ/wACb8v/AK1H/Am/L/61AD6KZ/wJvy/+tR/wJvy/+tQA+imf8Cb8v/rUf8Cb8v8A61AD6KZ/wJvy/wDrUf8AAm/L/wCtQA+vEPiV/wAnSfBH/sG+I/8A0XZ17Z/wJvy/+tXh3xKYt+1L8GDv2hdO8RBc4yf3dl0HVsYOcetAHulFM/4E35f/AFqP+BN+X/1qAH0Uz/gTfl/9aj/gTfl/9agB9FM/4E35f/Wo/wCBN+X/ANagB9FM/wCBN+X/ANaj/gTfl/8AWoAfRTP+BN+X/wBaj/gTfl/9agB9MVqP+BN+X/1qTaPVvy/+tTFqeBfsu61B4c/Zij1K/iEdrZ3muTPF1GxdTvGP6V4R4J/ac8e+Pfjn4X8R3mjXGk6Lf/DvU9c03w3baupi1Ii4jEBd3CIk204LN8ozxXtv7NFoNU/Zb+xy276jDd3OuwTW9vIgklV9SvE2oWdVDsMKAzrg9e9eH6f+x5rkOmrYakfHGraZH4OvvBlnbLaaPbvb2k8itGwcahtLrhckr8/+zRC0Xd+f5P8AUozPjJ+2l418V/Br4mL4XtNK0DxP4Uu9C+0azoesm8h8q8uIwIoZfJXMit8kgIxjzME4Fex+Mv2tvEHgD4peG/CHiTwzoMEeoapY6PObXxCsl601wibrmG2EeVtkdiu6VkY9hXnGpfsoeINW8L+PtG1GHxZdz+KLDRbMX1vp+jW5tH0xw0LBFvwrK2B+7IyOTnk1oah+zF4svvGD67PD4smWfxJpniq9tWstG3XF9ZqFJMn9obhDIFGIwQIyM4c80u3y/T/Jk9z3H9lzxfqHiLwv4p8Oa3fTanq3hDxJfaLNeXT75J4klMtu5Y8k+VIi5PPyc8817d5KblJXJXOCeSM189fsi6JrMfh/xrruueGNZ8K3virxFea2LfVfJWRYZXIijKI7OrrGikh1XmXA3YGPoX/gTfl/9ajoPq2J5K7VHzYXp8x/yadtAYsBgnqfWk/4E35f/Wo/4E35f/WoABGqsCBjAwMccelIsKKmxV2r6LxS/wDAm/L/AOtR/wACb8v/AK1AAsKKqhVCqvRV4A/Cn0z/AIE35f8A1qP+BN+X/wBagDxb9qb/AJAvw7/7H/w//wClqV7ZXh/7U286J8NgOGPj/wAPlhkdr1M8mvcKACiiigAooooAKKKKACiiigD5Z8cfCPR/iH+2Zcx6jqHiawQeBorgf2Jr95p/zi/kXOYJUOMfw9Paups/2bfAup3l9aWfi/4hXF3pzrBdwp8RdaLxSMisN4+1HB2srVfgAX9tS6wAP+Lfxdv+ojJXmWoSX918ftQ0S21zUNKsdS8cJa3jaVdtBPMi+HfNVWIOcB4k564XPUmgDtdS/Z78AaTrulaPeeNfH1vqeqmRbKzb4ia3vm2DLlR9q6KDyTgZKDqedZf2U/Cfl718T/EZ1b7jf8LC1vB+p+1cflXztp+t6tp0yeOBqepar4r0f4c+JHtrie/kkZntNQEELsgbY7FeX3KcuATkgGu9sPEXja01a20C91DVNK0nVdW0eycXWtJc6hEslvcPIxmiYvEJ3ihAGQRuk2kDZg/r8bE8x2mrfs9/D3w/cXEWo+OviDbyx2c160L/ABF1jzEt0IDz7BdbiFJVc4xl1GCa04f2WfB1xax3CeK/iQYJBw//AAsDW/8Avr/j6rx3x7pv9l+KvEOsad4z1rVbzSPAPiEwarHqk8LQvDd+WFYBtrNCDgs4wzKshyVBHS6T4w8RDULLxC2uaq12vjaz8N/2d9ob7IbOSGIuvlfdztk8/wA0/NldvA4prX+vOxdj0Jv2UfCyhifEvxE54Qf8LD1sZ+ubrrTm/ZN8KbsDxR8Rge274g60f0+1CvCdB8ReMrLwX4Mmi8eanb6r4o8G3st1ea9fvJbpdi7skt3B2/uCy3MkYfkgbSVc5Ne3fCjxbNpvgbx0mtX2sWF14evJlvYNemF9Npi/ZI5VVJwzfaIyGEgdip+cqQCKbjYXWxK37KnhVCA3iX4iKc8qfiHreSMY4/0rqTinf8Mo+FTE7jxN8RMEblP/AAsPW8D8ftXT8K8Im8aeK7W21jSE17xBp8V9p3he/trrUNT869aS61U27zkAMlv5i7P3auyDH3RXX2Oqa7efFW7+Hlx4q8QW+gWviK9YX41BvtgVNKtbmKDzjl9m+eV9pGcR4ORxSatbzDrY7fQv2cfAviTS7XUtL8X/ABEv9OuN2y5i+IetEHDbeP8ASvXNaf8Awyj4P/6Gr4jf+HD1r/5Kqx+yepT9nvwckcq3KeRIy3AcFZR5znf8vTntXstLrYDxL/hlHwf/ANDV8Rv/AA4etf8AyVXFfHD9mTw1pPwX+IV9D4g8etPZ6Bf3EK3HjrVpog62khUmN7kowz2YEHuK+oq86/aFz/woP4n8n/kWdT7/APTnJQB5L4V/Z68Fab8LfDmu6x4v8fabB/ZVpNcSHx9q8UBZokAOFuQB8xXgADgV1v8Awyv4SaMSf8JL8RETAw//AAsPXNrY6sf9K4z+vbFZXxUZP+GM4VeWIxvoumbZGJVesGOv0rhra+1bUNY0+7uvFXiKQ61418Q+Hbqz/tErAbKOG9ZYYsEbWQ26bHGGHz4IoA7nwz+zz8P/ABlYSajofjn4g6pZea0azW/xE1l4iynlVIuhkD689jWp/wAMq+EvkX/hKPiNnO0MPiDrZ3H3IusA188eGNU8T6F8NPCOg+Hb7xBb2um/D23123u/7eWBIrqRiry3JnI3RR7FxCNygSH5fuEew+Fby88ealqmpeIfG+q6TeS+JLzRBpVjcPHa3NvHaEpAiqw8s/8ALx5wIbHBbacU1rqHkXdM+BPw11+5t7bTvHfj65lmsk1KIW/xG1lzLauzLHKv+lEFWI4wc1t/8Mo+FTHk+JfiSuB8x/4WDrfH0H2nnFfOvw68Qaz4N8CeBdG0jVtSstM1Hwr4dilaW+lc25utW8md0J3CJ1j34fgJ7YFehw3Ws6r8WLDwO/i3Xk0G18S6nYrcR38q3M0C6ZDciNp/vSBJJHXcG3KVwT2osHWx2fir9nn4f+CdEvNa1/xr8QdJ0ezVpbi9m+ImsrFCgJwWJu++R+VQ3XwE+HGn30ttd+P/AB3byW+nnUpkf4jayNluG5mZvteAg6Zrn/FWoT+Nf2EkuNenbVpryxtUvGulD+cBdRxNu/hOQM/rXlHiaa407VPFfhC8eSSTwfomnaLfSzuC0umDV43Ekq9Sr2kgy3T5H7jNJauwHsmn/Cv4Q6r4du9as/id40n0mxH+lX3/AAsvWAkO4fLvzdjGeq8fMfWtLwr8B/hx47sJL7w943+IGrWsbmF5LX4ia0QkgUNsbN0CrYZeCK5v4w6PpWufFzxRZz6tHoUVzpfhyMXSwCeMal/acj2Cyx4CujGLYfmGUbHyn5q9P+DviW4vvGPjzQ9Z0nStP8UaZdwNqV/opf7NfCaBTFJ8wykgVArRktj5SHbJpLVXAp/8Mo+D/wDoaviN/wCHD1r/AOSqP+GUfB//AENXxG/8OHrX/wAlV7bRTA8S/wCGUfB//Q1fEb/w4etf/JVeSfEn9mvw1p/xy+Denx6/46Md3NqwkaXxxqskq+XZb18uRrgvF83J2Fc98ivsivEPi1/ych8B+T802uZ5P/QPoAd/wyj4P/6Gr4jf+HD1r/5Ko/4ZR8H/APQ1fEb/AMOHrX/yVXttFAHiX/DKPg//AKGr4jf+HD1r/wCSqP8AhlHwf/0NXxG/8OHrX/yVXttFAHiX/DKPg/8A6Gr4jf8Ahw9a/wDkqj/hlHwf/wBDV8Rv/Dh61/8AJVe20UAeJf8ADKPg/wD6Gr4jf+HD1r/5Ko/4ZR8H/wDQ1fEb/wAOHrX/AMlV7bRQB4l/wyj4P/6Gr4jf+HD1r/5Ko/4ZR8H/APQ1fEb/AMOHrX/yVXttFAHiX/DKPg//AKGr4jf+HD1r/wCSq8v/AGov2afC/hn9m/4navBrnjq6nsvDd/cxJfeONVuYTItu5XfFLcMjj2YEH0r69rxz9sJdn7J/xgAJwPCWpY5P/PtJQByOtfAf4feCvCcWteIfGnxC0rT4Y4fOuJ/H+tqFLbQqhVuieWYDFHhL4I/DTx5YyX3h3x9451e2jl8t2g+Imt4Rto/dsPteVY70bkd19eeg/aQe+T4I2Q00Ryah/amh/ZopnkSOWT7fblEZgrHDMApz2NcHrHgbxZY/Fzwve69rq+HrrxvrjQahZeEr6aKIQW2lXTIplZEeSR3Clm2qQEXBG0YAO8/4ZS8KF41Pib4jrno3/Cwtb+b/AMmv8KX/AIZR8JD/AJmb4mHnZ/yP+t9fX/j6/XpXgNn8TPiLq2jC1tb7VL6bQvC099BqUuuxWqG6XUry3We837RNGFtUVh8/DZ25ZTXod98Qtdt76eN9cvAqfFG204Dz2wLd7OOVoOn+qyS2M4ycdBil1t/W6X6ieiv/AFtf9Duv+GUvCfyt/wAJR8SNq53D/hP9c5x1/wCXr8qQfspeEmcr/wAJR8SlcDeU/wCFga1nHt/pX9a8P8P3XiLVPCXh3UJfH3ipZtS8DavrUudRcEXtm8Ahf7vCp5x4HD7fmDV0ek/EbxRq2hy+MZ9aul1Cy17QNJsdOWZltLm2uYbJpy0QAVzIbmbDjp5S4Iw2bUbtr+t2v0Fzf18k/wBT01f2UfCaht/iv4jYYbg3/Cwda+QAYPP2rGM880o/ZS8JNsx4q+I3GN3/ABcHWzn/AMmunv0rymTxBrU/wu03x0PHOsL4nmt7jxBdeHY52khuorO+jeVEjDZURxbodqcOGywLDNR6x4o8V+ItD/4SS18RazcaRfS67qcdho+pCG+FlHOsVpdW6swSeGNQHMTOgIn5DYGCxR3lx8B/hva3D2b/ABA8evcLexaa6J8RdZaRbp08xIsC7wGZPmww6dK3n/ZR8Jou7/hJ/iUyr12/EDWiT/5Nc/hXjWhXyaX4/wBV8R6br+sD+1vHGhrPNd305jlt5tLilwYjIUCklzgcDO0YUYr0T9nrxFrH/CbJpXiHW9T1jUb3w/8A2ot19tW703UE+0BRdWzFg8PEip5flopABBYhjStYDpf+GUfB/wD0NXxG/wDDh61/8lUf8Mo+D/8AoaviN/4cPWv/AJKr22ikB8a/sx/s3+GNV+D6anfeI/HNhJDq2v28htfGuq2sSpDq95GWKx3KqCVRSzYyxG5iSSa7Lwj8HfhX48ku08NfEXxxrktqiiaO1+JOsvs3/ckOLrO1uzAFTUXwTh0q4/Y58Sxa5NLY6PLd+LIr64syTJBbtquoLJIp5OQmW+tcr408beIfhhpdzpT22j6jr8fh21TRvFvh2MW850/7bb2zJNG+VhO2dGSRSYyS7BVCGmlcD1T/AIZS8LMuf+Ek+JS8Lu/4uDrffrgfaecU9f2UfCjIGj8T/EeQ/wB1viDrYz9f9K4rzKxvPE974k8NeGtX8Qa1oNhP4uudOSzGti5v/I/sppvss1xE5bPnK0m4ncEKLnJNYdn8QPFM+h6X4h1LxZql3o+i26rc3GmXyi6sQmp3MK315bZVbiCaCFM5fcgEhCZKkDVgPV9F/Zw8E+ILe5uLDxX8RbmOGWW3YR/EPWW2yxO8ckeftY+YMuD2BHBI5rV/4ZR8H/8AQ1fEb/w4etf/ACVXil94w8VXGhXeo/8ACTalc6ZpNx4mmvrPS9REOo2Sx6nLHBexo7BJ4YkjMX2d3H3sKGFfZGkaimoaTa3kUrTwyxI6SsoUyAgfMQOmfSkB5F/wyj4P/wChq+I3/hw9a/8Akqj/AIZR8H/9DV8Rv/Dh61/8lV7bRQB4l/wyj4P/AOhq+I3/AIcPWv8A5Ko/4ZR8H/8AQ1fEb/w4etf/ACVXttFAHiX/AAyj4P8A+hq+I3/hw9a/+Sq8l8e/s2eGrL9oj4S6bFr/AI5MN3Za4XaTxvqjzLsjtceXI1wXjzuOdhXd/FnAr7Hrw/4lcftSfBPk/Np3iInk9o7PFAHGeLPhn8H/AABrsGkeI/iZ470jULmD7XHb3vxD1tCItxXfu+04VMq3LV10f7LPg6YRSx+LfiLJHMokjK/ELWyjqcYIIuumWHfpXO/EzTfFOvfH/wAQ6N4btNFZNS8Dw2txea1NIohEl5coGiRI3WQjrsZk6jmuLtYdb+Ht9qaWPi/xBeHwx4u8PeGbWzuL/wD0U2klpYJKJIuhaQzseRlTtK4JJpgeuf8ADKXhJfNJ8T/Ebj/qoWt/L/5Nf401f2UvCnluP+Eo+I28/wDVQdbO3pnpdexxn1rwS4+JXxGPwq1fxM2p6lp0+peFdT1GZ7jW4pAbmN42jlsokfdCsY3xsBsGGGQWUmu4+IHijXNV+L2qaHZeJdS07TZPEPhrTn/s+/dZIYZYLqSZFYZGXKKCfbrSA9Ej/ZV8Iybivif4jbW4Vh8QtbIB/wDArrR/wyj4SV1U+KviMxUbmH/CwtayR9PtXSvEG+IHivwT4fsPENr4u1fVb2WTxlp4h1K6aeMrYfavsv7vu0f2dctjc3zbieK6DxXrXiDw7qlv4Z0rxbr17p12/hi6OpLfFpllu7+WGb97g/u5o0TC5wu4FVFUlzNITdrs9An/AGa/BVrqlnplx4r+I0GoXyySW8P/AAsLWiWVNu/b/pXIXeuc+vetFf2UPCbbB/wlHxFDLyyn4ha2Sf8AybFeMS/EDVvBesaxaXvivWLbStF/4SmGK+mma7uUhhhs2jbLMDOUMpKbum3BOK9Y/Z/1vXH8W+O9B1dtRjstPj0uWytdWvvtk6ia3dnDyncS7Fd5QMwB4BxxS6J9x9WjQ/4ZR8H/APQ1fEb/AMOHrX/yVR/wyj4P/wChq+I3/hw9a/8AkqvbaKQHiX/DKPg//oaviN/4cPWv/kqj/hlHwf8A9DV8Rv8Aw4etf/JVe20UAfHH7Kv7NvhrxF8E9KvJ9d8cQSnUtXULZ+NtUt412ajdRqVjiuFVTtUZIALH5jlua9cX9lXwirMw8V/EUMwAJ/4WFrPYYH/L16Uz9jvLfs+6QxLbv7T1ruf+grd17dQB4mf2U/B7NubxR8Q3O3Z83xA1kjGMdDdelIf2UfB7KoPin4iYUlh/xcLWep6n/j6r22igDxI/so+DmYk+KfiIWO4Fj8QdZzzjPP2rvgZ9cUf8Mo+D/wDoaviN/wCHD1r/AOSq9tooA8S/4ZR8H/8AQ1fEb/w4etf/ACVR/wAMo+D/APoaviN/4cPWv/kqvbaKAPEv+GUfB/8A0NXxG/8ADh61/wDJVH/DKPg//oaviN/4cPWv/kqvbaKAPEv+GUfB/wD0NXxG/wDDh61/8lUf8Mo+D/8AoaviN/4cPWv/AJKr22igD5H+NXwB0TwHN8ONU0/WvGWoTx+PtBwuteLNRv4Rm8jz+7nndD/3zX1xXiP7Uyj+xfh3xn/iv/D/AF/6/Y69uoAKKKKACiiigAooooAKKKKAPEYf+T1br/sn8X/pxkruodD8J3fiS+v4IdMu9ZsbsT3UkbK8tvObcxhpMH5G8livOODmuFh/5PVuv+yfxf8Apxkrhtc8Qa/q3x0n8LWfiW80mzn8Y/ZJf7N8qORrb+wPtfl7iucebznrnvS/4H5oR7VHovgjwvq+m2TRaRp2o6hDc21pZyMkclzE7ia4SNGPzjcd74B9ant/hL4Ns9Ek0OHwnpK6RcyLPPa/Zl2NIvKOwIySuBgn7uBjFfIUPizWLK6t/iFc6vqOo+JdF+H3iK4WSZlWOR7S/wDIjd0UBQx6vgcnk5Nd03iT4pLa32kiXU4IFvNMC2t/rmlLrV5E8U5uUt3jldFZvJDoJNrMN4BGCULX/rzC3c94vPhr4E1CTTdJuPD2iy3Om2U0NpaNCm6GzmHlSqo67XX5W7E9atzeCvB2l+JoNfn0rSbXXGZbaG8mijWdiQVVA3c7eB3xxXyrBr083iq58Yv4/wBcgvE8FyW39ptYt5kcw1T7L5TWXmeX5qv8n38eZ8+dvFWNautb8aZ0bW9X1y1i0T4laTZ20dxqUbXUUc1vDJskkgyCweRvlJJGfpRqv681/mM+mNL8D+Adc0jTk0/S9H1LTNPtp9LtVt445o0t2dRNbjkgrviTcvqg9K2vD/gnw94V0dtJ0jSrPT9NYu7wQRBUkLgBy5xhyygZLZJwM+tfLfh7x14m17SbyyHiPUNEXR9K8Q+IEniSBDNNDqtzDCXLKf3aKh3D/loH57VasviV4v1KTU/Fv/CT6hZ/Y/EHhuxOht5X2JIb6LTxMkgKbx811IQc54/J6y0/rdkt2aZ9Caf8HfA2mxhbXwlpdqrKiKq2gG5UlEqBuOQkihlB4XHGBxWjrXws8IeJIblNW8NaZqS3F2L+UXdssm64CLH5nzA4bYirx1UY6E1438D/ABd4km+ITad4l129urq+0q4vYkAgn03U0S5RftVlcRtlFRZI1MTjOJA2cqa+jqbvoCd22Z2h+H9N8M6TDpulWMGn2EIIjt7dAiICSSAB05JrSpKWp63KCvOv2hf+SB/E/wD7FnU//SOSvRa86/aF/wCSB/E//sWdT/8ASOSmBH4bj0WX4HeGP+EoNjDpbaRY/aFvzttx+7j2g7yMfNt6+ldHH4M8PRiLZpFoUhu31CM+WMJcSq6ySrxwxWR8kf3z61498TYPK/YxtkiXltF0rITjvb+nSuFuviT4u8NqPFkfiW/1WNfFmv6T/ZM4iW3eGCC9lhj2hQ28G2QDnJz+cSlypvtqFtvN2Pf9b8C/D2G18P2eraTowtrN0tNHiu0j2o3VYos/7gO3odo4OK3E+H/h2HxG3iJNGs115uX1Fbcee/y7SS3XJX5fpx04r5t1KbUvsvwqudQ8aS+JLjVNS0TVJdNuI42mt5XjuHknjKdInDEBduF8r73Jzjat8a/GGk/DHwdq1lq7zanN4Q1jUppJtu1p454Y0uGG3GIg7HbjBzyDir1V1/WyJW6fdX/Fnv8AZ+E/hd4Xa40e3svDemvcJHYy2CtEHAmkaSKEx9hI28qO56Z4x02k/DnwpocOmpYaFp9idNaV7Zo7dUMTSqVlYEjOXBIY9+9fMk1tqfgf43XlmniK814Xmv8Ahi2a71BI5bjy3hvWYOdi7eVBXHO3vWTD8XfHXhLwD4Y1tfFeo6vfa/4Y1fUpE1JIdtvLDc2scE6ps4VVnYkMSGx0FNXasPrc+vF8DeH28Mf8I6dItDoYQJ9g8jbDtDBgNv1AP4U2X4e+G59f1LW5dFs5dW1OzGnXt28YZ7i2BOInz95eTwfU15r8JbrWdM+LHj7w3e+LbrxPYabZaXNYi9dGlhaZJjKZGRQCWKKcdlAx3z7ZihqwzkNO+EPgnSfD+oaHaeFdJh0i/bddWYtUMcxxgbgRzgcD0HTFafhPwL4e8CaabDw9o1no9mZGmaKzhCB3b7zNjlieOTnoPQVuYpalaKwBRRRTAK8Q+LX/ACch8Bf+u2uf+m+vb68Q+LX/ACch8Bf+u2uf+m+gD2+iiigAooooAKKKKACiiigAooooAK8d/bF/5NR+MX/Ypal/6TSV7FXjv7Yv/JqPxi/7FLUv/SaSgDvH0DTfEXhmytdTtU1O2BtrhVuFVx5kZjkjI3d9yqR71cvPD+nard2F9e2Mc95pkrXFlcTKrG3kZHjYx8nadkjoSOoP0rz3426r/Y/wr028+z2l2Dqejq0d2Gx+8voEH3CDxuryrwj8VvFEfiQ6VpC6FpGlw3XiLVNQDWU08stvZ6qseIcTjDyIxG4/IPvhdvy1LdtAPoKX4ReCpodPik8LaU8WnyNLaRtaqVhZmDMVGO7AE+4zRcfCXwbc+KG8SyeGtNbX2kSY6j9nXzvMTG193XcAAM9ccdK8Hvv2iPHWgaLo+pXqaTdxarotp4p2w27L9ksvtdvHeQtmT5jHFcq4lH9x/k5FQ6x+1B4m+2TR2DWUVvcNrN7psy6Fe6gZbaymS2jikSAkhpJTI3mD5dqAYzVNdRM+hbf4b+F7W1gt4tCslhgs5NPjTyhhbeQgvGP9liBn6VWT4a+EIdZtdVXw5po1axWNLa6+yJ50SopSMBtpOAA2303HGM1514R+K3jX4gaxf3Gl2Flptho82nxX+k6jEy3L/aLaKeYiTdiJovOA2MpJ2HO3Irnv2ZfE8+uappcZ020s/M8D6Xen7Ksow0l1dgIN7HKgL94/MfWhd2Fj1HxN8LrAaL4l/wCEY0jR9P1rXoJLW4vLq3yjrID5jMF5IOeV6EgGmaN8E/B1n4C8K+HNR0iy1mz8N2EOnWkt1AGZFjjWNsHrhtg3DODjnNejeWo9euepo8pT29P0OaUdGUcxN8MfCdx4gXXJNAsW1hZYZhfeUBNviXbG27r8q8D24qbwz8OPC3gu4vrjQfD+n6RNetuuGs7dY/MOSecD1Zj9Sa6OlpiCiiigDw39kG3iu/gCkM8SSwy+IPEiSRuoKup1u/BBHQgjjFegaH8G/Avhmx1Gz0vwlo9ja6lF9nvIYrNAs8WMeW4xymCfl6cnjk1wf7HH/JB7f/sYvEn/AKfL+vbqAPIfF/7PvhvxRceD7GHSLKDw5oupT6hdab5I8u6ZrWaAEj+8C4O7r8o54FdlefCbwZfXGkz3HhfSpJNJjSKxJtE/0dEIKKgxgBSAQO3brXUtGrbQc/KcjBIp9AHHX3wd8Eaotut74X0y8W3nnuYhcW6yBJJn8yZhnP33+Zh0J5rr0jWNQqKFVQAFXgADoBTqKACiiigAooooAK8Q+JX/ACdJ8Ef+wb4j/wDRdnXt9eH/ABL/AOTpPgj/ANg3xH/6Ls6APWY9B03+25dcS0hOpzWq2Zv1UecYQzMsYOPuhnY/jWNrWh+EbET3uq2um2iz6hb3M1zdBU8y6UxpC7MTy2UiC/7q14x8b/EXiS18eeNf7M8ZX+hw6D4HXXbewthCFa5Es+HfeCWUiEKwXj5h3rmNQ8TeLNQXxN4gl8VXwjt/Gmh6VbaLiIW0CzSadJID8u8v+8cDcTtz8uO06vVAfSFr8MfCtjNqs0Hh7TY5NUV47xhAv71H5dG45VmJJXoSxJ5NVtF+D/gnQHV9N8MaZYlXilHk2qqRJGHEbse7KJHwevPsK+efDureL/EfizSLObx7rFtaav4s8TaRdRQiE+XBZSXH2dYiYydy+SNx77uawZPjJ411X4b+HPEkGvand61pui6JNqQtbeGK0tp7m6CvJOX+eZpY8DyUj+TIOctkOKfUD62j8A+H4pop49GsQ8M1xcwvsHyyT7vObp/Hvfd67jVHTvhX4N0W2+z2HhrTbW2F3DfGKG1VR9oiYNFIMDhkKgr6duprwGTxB4v03TfEPj+78ZajLY6H44bTZdN8yMWS6Ul6IHPC7twRw2S2fk9zXZaH4s1hv2a9Q8Yah4hvNOvNUjudSstQjtlupLO3uJma1RIflWU+W0QXdzubmm07NoOqR6ReeCvB1neSXF7pelQy31xMrLcRxg3D3KhJUIPDGTaoI74q74Z+HPhrwbJNNomhafpU1xCkFzLaxBDIiZ2huPmxk4z24r5Q8QXWt+Md2h67q2uWEeifErRLS1WXU4pLpI5oYHZJJIcgsJGkODkjdgYGBUev/FTxpD4d17S7XxZNZ6p4FtdQj1K7LA75m1JIbCSYEYGbZJHx0Pmcg4GH1F5M+xr7xFZabdWUN7fW1jNfyfZ7SC4dVeeUKXKpz852qTtXJ4rQMwZlIf5f/Qvpxz+FfLGpeOvE3hP4pW3h9dW1DxDZaf4mikinvBE80qS6JeTtah1AGA0aOvfEuM8Cn6b4u15fh/4X1e5+JWqXWqeMLDTbk6TZWdu9zLJPMC32Is6LboysYwXBCjD7iVNCV3YZ9MXGvWNpqFrYzXsKX1yGMVu0iK8gXG5gpOTjcPzrTr5M+E/irWfEXxU8DvrMl1dXdjdeLNMU3k8ctwsMN1bxoGaMAO6Y2nHbmvrOhqwHiP7HP/JvOkf9hPWv/Trd17dXiP7HP/JvOkf9hPWv/Trd17dSAKKKKACiiigAooooAKKKKACiiigDxP8Aam/5Avw7/wCx/wDD/wD6WpXtleJ/tTf8gX4d/wDY/wDh/wD9LUr2ygAooooAKKKKACiiigAooooA8Rh/5PVuv+yfxf8Apxkr0c/DTwy3iL+3TpMLat9s+3/amZi3n/Z/s2/rj/VfLjGO+M815xD/AMnq3X/ZP4v/AE4yV7dSA5LTPhP4S0dkNroluoS1uLLZIWkVoZ5fOmRlYkMHk+Y5B9OnFUY/gb4Fh0dtMXw9ALU3CXYYyyGVJkUrHIsu7erIpKqVYbVJUYBxXd0UtQOBvPgL8P8AUIbSKfwtYtFa2UunRooZQbeRtzxuAfnBf58tkh/nBDc01vgL4EfT76yOgR+RfTwXVzi4mDyzw7fKnL793mrsX95nccck16BRRqBwd18DPAt9Y21nP4ctZba3e4dEZn58+Uyzox3ZdJJCWaNsqc8jHFal18MfC94L4S6PARfXdtfXIUsolmt/L8hzg/weVHgdPl6da6iiqQHJ+GfhV4T8G6tNqejaLb2F9MhiM0ZYlYywZkTJOxSyhiq4BPJGSTXWUUUAFFFFABXnX7Qv/JA/if8A9izqf/pHJXotedftC/8AJA/if/2LOp/+kclADvCHh3TPE3wU8N6TrMAuNNm0ax8+FpWjXCRRsDuUgjBUd+1SaT4N8F6vHBdabDp99FbanPqqzQTeciXsm4TSHDHLkPIMHgbunFebfE+8m0/9jN5YLuWD/inbCN7iPKGKBxAkjAnnITec9f0rifixcP8ACH4nahB4B+w+FDeeHtLN0bW1iMMbtq0UEbmPbgZie5BYDJCjGCAaNHoxPY+gdN+CPgfR1iWy8P28CQ3MN1Eqs+I3i3eUqgt8sab32xj5F3HCio7H4C/DzT7q6uIfCen77pLiKVZEMkflzlTMioxKqjFF+VQAMcAV47N4x8dt8TLf4fr41mh8vxJJYvrhsLX7RPbNo73qRhfL8sMkgA3BOQOQaw4fjp491bwr4n1BNbNjceDPDz6lMVsISmr3Ed7ewEyblOyN1sR8se05mbDcLSV23cdj3fTPgj8PvDGy9tNAtLSRbu2u/tEkjljNEHSAlmY52id1APHzfSjXPhHoLeF103S9IsrZ7TTbvT9PN4JLi2ijnA81JY93zo+xc7s5xXzx8Sv+Ez+I2h+MLq88baxpmnaf4607SbXR7CztIhHGZ7F1LyPEzsyM7EANjnDbxXYw/FLxVEulwtrs0q/8LA1DQJpZYohI1rHbTuqEBcHa0asTjPy9ccVT93+vNL9QWv8AXlc7b4P/AAxj+FN14o1/VU03SzqcdpA9vY3cktvHDAjLGTJPhy7GRup4BQV6/Nc/Z455pnWGGMEs5IwqgZLH8K+KLr4peOl+HGhTar4pGtvr/gm08QH7ZY2wWG6F7aLJ5aiIAowuuPMDYKgjBHHQfEHxh4wvF8caPrviTUdFtdSstci05ILS2msryCKJmha0ukVisyohWRJ8E4cjaQDUzfKm35/g7CWt/wCulz6wt9Uiup3ghuIZpU2eYkcis0QYFgWx0yBxxzV7Jr468J+LPEXhi/s/DFhrLrJqC+FdMXWfsdu00Sy291JK+4RhZGKwLGu9SFJB5NfTvgF9R/sF4tS1+38R3kN1NCb6BEQMqzMqq4QBRKFAVgAAGB4qno2uwXOqooopDCvEPi1/ych8Bf8Artrn/pvr2+vEPi1/ych8Bf8Artrn/pvoA9vooooAKKKKACiiigAooooAKKKKACvHf2xf+TUfjF/2KWpf+k0lexV47+2L/wAmo/GL/sUtS/8ASaSgCX4u6Fq/ir4e6DpekWTzTzappM09wJo447aCG6huJJXDsu4bYyNse488Vf8ADfwS0Dwv4jOsxSX91cuNTRku5I2iIv7sXMwOEDH5wFXnhRzk81qeMPH1j8MfAdtr2qW15e20QtrZ4NPg86R5JnjiX5cgH5nH5muVn/aN0iOayshofiJteudQm0z+wFtU+1xTw2/2orJ+92ANCQyvv2H+9Ra4FnSv2dfDemWGrWE2oavqFve6O3h62S+nif7FYNktBBhAQCcZZ9zfKgzhVw21/Z58P6b4d0DTLHUtY0ltBsJdNTULOaMXVxbysrzLMxiILMyht6gOGyQwJOa0f7TXhdtI0vVrW11O5sLywj1a9uEtVH9mWjyNEHuAXGD5iOmE3/6tz0FbC/G/QlSKMWeogS+I38KKoii/4+xGzs/3/wDV4Vvm6/7NGuweZE/wJ0Aa8uow3epwW7G2uZdFFwv2W6nto1SCV1IL71WNASGG7au7OKl+HvwX0P4Z3UF1pdzf3Elvo9roSm6kSX/R4JJJEztVfnYzEn+HngVyEP7Xfh6402K/Xw14rME2jf8ACRp/oUf/ACDl/wBZP/rf+WeV3L1P8G6upX47eH18RR6WsGpPYzXcGntrQiU2i3M0KyRQE794dkZG3bNnzY3ZNPyFc9Uor59vv2tNC1bwhqd/p1nruiI2g6hrGnarqFhC8Vx9kAEyxoJsu6My/K2xW7PXZW/x20pvFGn6DLp+ro13dJpserNapHZvem2a48gZffnYhGQCmfl35qbNDPUKKKKYBRRRQB4j+xx/yQe3/wCxi8Sf+ny/r26vEf2OP+SD2/8A2MXiT/0+X9e3UAFFFFABRRRQAUUUUAFFFFABXh/xL/5Ok+CP/YN8R/8Aouzr3CvEPiV/ydJ8Ef8AsG+I/wD0XZ0nsBoeIvgPpHjL4yT+KdcsrLUNNXRbexitZNwk8xLiWQlsEboyGXKnIPOQea7a4+F/he6j1BJNHiZdQ1GLVrnDuC91G0TRy5ByCDBF0wPl6cnPTeWm7dsXdjbnHOPSn0LYDlrD4Y+F9LvLO7tdJjhuLO8u7+CRXfKT3JJuJB83Vyxz9TjFYE37OXw3uLGzs5fClo9taWcdhDGXk+WGNt0QzuyShJKscsuTgjJr0iih36AeT/Ej4Wrr3wp8V+EPC9rp9l/wkS3Ed694ZHCG4BE0oKhv3o3EhRjnBBFdk/w/0W88EQ+FdRsYdQ0RLVLM2c67o2iVQqqQeuABgnkEA9ea6QxqwAIzik8tdpXHB68mhXtqHW5wTfAfwI2mX1i3h+M299PDc3ObibzJJ4QBHMX37vNGB+8zuOOSa80179n3UvFGhfFzz10i21/x9Laq8cEkhtkt7dY403SbNxdkDt9zqa+isUnlr6U+wdbnHaT8H/BuiR2gs9At4vst8+pQlmdytw0bRFyWJJ/duyAHIVTgAADFSP4DeAYbG4s4/DVtHBM8b4R5A0RjbdH5LBswhGJKiMqFJJGMmu9paWtwOP0H4Q+D/DOqW2oaXokNld2z3EkMkbviNpwomYLuxl9i5OOSM9ea7CiimB4j+xz/AMm86R/2E9a/9Ot3Xt1eI/sc/wDJvOkf9hPWv/Trd17dQAUUUUAFFFFABRRRQAUUUUAFFFFAHif7U3/IF+Hf/Y/+H/8A0tSvbK8T/am/5Avw7/7H/wAP/wDpale2UAFFFFABRRRQAUUUUAFFFFAHiMP/ACerdf8AZP4v/TjJXt1eIw/8nq3X/ZP4v/TjJXt1ABRRRQAUUUUAFFFFABRRRQAUUUUAFedftC/8kD+J/wD2LOp/+kclei151+0L/wAkD+J//Ys6n/6RyUAT+C9Ks9Y+C3huw1WGG9srnQ7SK5huPmjkVoUDAgkDH4/SuN+IH7OOjX3w71TQ/D1g32nVLrT3urrUr2e6neOG8ik2+bK7OqqqvhVIAycDNVPHN8ND/ZD0+5WK3l8rRdMCpLAkkfPkKfkYFehPbvXLW3xL8faleWctx4hhi03VvFWueF47e1sE8yzjgjvDDN5rAq0q/Zf4gUO7kGjrcDqfEv7POi6xqngaPR7f/iTaTrV5qOqXH9p3H2yWV7Oa3VhcbjJv3lVPzgqox04rt9Q+A/gW/t9Lt5dCQWum2q2McUdzNGr26uHWKXa485NwLbZNwJZifvNn5c+HfxC8TeAfhf4J8P8AhmS+1bU4/CKeJ2NpoBvH1K6mYqkDyRKBErBH3O37wkqS5IYn2nwr4w8c/Ea+1jUrbxBaeHNIj1m60M6TPZo08Sxw4EkcjZDXHnc7Gym3jGeaVtbgd9f/AAm8I69o+uaRLYF7HWrtdRvo4LyaNjODGUlR1YMhHlRlShULt4I5zWX9n/wOviJNc/sidtSS7N+sjaldMguDA0DS+WZdm4xuyk7ec5OTzXy98K/HWveDfCfgu0hms7/VtS8JeHbW01a/sYpJoDfakLUJI6KpdI1cYXODsyQa9Mb4neO734kWXw9h8TRWdzFrV7pk2stpcTT3USadBeRMsediuPOKl9uz5fu1TVybO56pefAHwNd6fZadLo7yWdnpUeiW8P2mXEVmkkcgjzvyRvhjOWJPy4zgmnQ/A3wRJqF5qZ0bz5b5Ll3Sa6kktla5DC4eOPfsjaQO+5kCkhjzXA6l8Stb8SfsmW3ii7lgh17VbG2tZLiy3xxB57hLdnAzkfeJrM0n4xeJJfirNomj2WoNoen+I10CSwh0WRrRLU26F7r7bjZ5izEnbuxs+Xbu+ap8mN6bHqFr+z34Hs9MuLBNKmaG4jsonklv7mScC0LG1KzNIZEaMu2GVgecEkV2fhvwrpXhHSU0zSbRbSyR2k8sMzkuzFmdmYlmYsSSxJJNeNfGT4ieMbXWPE+neENUstMk8O+F5PEDNc26zm7kYyrFGct8iARMxbrkr2DZ9a8I61Nq3hrSLy5k3y3FpDI8iphZGaNWJXHbk01dt3FKSi0u50NFIelFJO5QteIfFr/k5D4C/wDXbXP/AE317fXiHxa/5OQ+Av8A121z/wBN9MD2+iiigAooooAKKKKACiiigAooooAK8d/bF/5NR+MX/Ypal/6TSV7FXjv7Yv8Ayaj8Yv8AsUtS/wDSaSgCn+0g18vwNtTpyQXOonVNDW284ZR5v7RtdmfYsBn2rN0H4ReJpPiZpHjfVl0mzuZtautQv7a1uHmCRvpos4EjdkTzDlVLZAwOnevarGwtr3Q7KK4gjni8uJhHIoZQRtKkA9CCoI9CM1pCCNWLBAGPVu/XNNMD5Esv2UdWisbBb3S9F1iW60iDS52ubq4WGx8q7uZPM8pQBcApdkeUwTkEZxXUz/BHxofFkUMUeljw9F4xPimO7N0/2lVktnjeLyvL2naztyXyeK+kvJTj73Hfcc9Mc+v+TQsCKuAMfic9c9aXW/8AW6f6A9Vb+trfqfM9n+z74stfB+maOP7M86D4dXvhgyfaH4vJPJ2n7n3PlbJ6nvVzS/gZ4os5P7F36eNBuvEGn+JLi8+1SNcQzW6WzGAR7COZLVD5m/GJD8tfR3lrnO0ZximfZo927bznPWmm07/1vf8AUm39fK36Hy3q37O3jC8+Fug+HlfTfttr4X13SJJBcvs+03hhMBHyZCZQ7iOR2xWnd/A/xdfeP9J1u8Gn6rHp3iNdWh1ObU5vtEdkbd4TBHD5eyMJ5jNlWBc8ggjNfSnlrtxtG3GMY4pDGrbfvfL0wxA6Y/GhtvcsfRRRSEFFFFAHiP7HH/JB7f8A7GLxJ/6fL+vbq8R/Y4/5IPb/APYxeJP/AE+X9e3UAFFFFABRRRQAUUUUAFFFFABXiHxK/wCTpPgj/wBg3xH/AOi7Ovb68Q+JX/J0nwR/7BviP/0XZ0Ae30UUUAFFFFABRRRQAUUUUAFFFFABRRRQB4j+xz/ybzpH/YT1r/063de3V4j+xz/ybzpH/YT1r/063de3UAFFFFABRRRQAUUUUAFFFFABRRRQB4n+1N/yBfh3/wBj/wCH/wD0tSvbK8T/AGpv+QL8O/8Asf8Aw/8A+lqV7ZQAUUUUAFFFFABRRRQAUUUUAeIw/wDJ6t1/2T+L/wBOMle3V4jD/wAnq3X/AGT+L/04yV7dQAUUUUAFFFFABRRRQAUUUUAFFFFABXnX7Qv/ACQP4n/9izqf/pHJXotedftC/wDJA/if/wBizqf/AKRyUAVtB8H6Z44+APh3QNXE50250awEoSQJINscbr83TqqirUXwd8NQtZlbeWRrXWLzXk3S7iLm585Ze/I/fvhenFec/FO+n0/9i0T2SNLdJoGnMsSuQcnyM8jnua4nxR8ZPFXhP4r+I9W1fw5N4Xvv7H0bTrK1e4/tGPE+oTRi4ZIMkgZkyi8tsGKVwPb5v2ffCM+m6RYCC8jt9N00aOI4L14vtVmCCILgrgugK8A9Nzf3mzft/gr4YtfFh1yK0vFnN22ofZvtLGz+0tD5LTeSTjeY/l3YzivJtB+L/wARfFnjHw74asJbbRxNNqrXer61oF1BJdW1qbRo5IraRo2UstyU5PBUn+HacNv2lvG/g/wHpnijxI2j366zoWo6hZ2tjZSxyQzW0iKoZgzlg6zKTheCnvQ7getaP+zT4G0fTEsY0vrq2Sxh02BLq/kJit4pjPEqNnKlZCWDD5h0zgAVt6N8FvD+h32k6jbi/m1Oxurm++13F07yTz3EYjleUk8koAB2XAwBXkn/AAvjxy2k3qw213cWVpq0FvJ4lPhO+jdLR7WSR3Fg4WRyksfls6Flw4O3g16XY+ML7X/gva+Jh4n0TTL2awS8l1mzi+26eFUAyOqMyMybc8MQynjtS1EWfEHwjsT8G7nwHpcrWlklqYrSa4YyNEyuJIznOThgDz6Uun/CXRpfElr4nuLO7tdRlmXUZtNS7c2gvREIvtBjztMmwBd2MnGTzzXkGj/GL4nS+H/LuptPg1mx8NXHi+ZbvSzGZoDLILW1ZBKPKYxx5dhvwzADhTnU0341eK/EfjaPTxLZeHdP1h0/sq31OxlH2q1ksfNW4gusmOScTf8ALqVDbOaai2FiT40fA3UfFGjyaVodlealHc6Jd6NJqVzr81tcIJ3DgXHB82JeW7uNzKBhmB9k8IeDU8I28givrm78yOGMq8zMiiKFY/kUnamdoPygV8mfD343eL/B3wn8J6PaXkniHVLfwwNc3p4fur+S+Z5XSG0H2ff5Z/dS/O/PK/Lwa97+E3jrxR4+8deODdXGn23hnRNQXTbfT47Q/bC5tLa4DSS+ZgFTKw2eX/F14qtUh6No9hY06kwKWkIK8Q+LX/JyHwF/67a5/wCm+vb68Q+LX/JyHwF/67a5/wCm+gZ7fRRRQAUUUUAFFFFABRRRQAUUUUAFeO/ti/8AJqPxi/7FLUv/AEmkr2KvHf2xf+TUfjF/2KWpf+k0lAHqej/8gmy/64x/yFX6oaP/AMgmy/64x/yFX6ACiiigAooooAKKKKACiiigAooooA8R/Y4/5IPb/wDYxeJP/T5f17dXiP7HH/JB7f8A7GLxJ/6fL+vbqACiiigAooooAKKKKACiiigArxD4lf8AJ0nwR/7BviP/ANF2de314h8Sv+TpPgj/ANg3xH/6Ls6APb6KKKACiiigAooooAKKKKACiiigAooooA8R/Y5/5N50j/sJ61/6dbuvbq8R/Y5/5N50j/sJ61/6dbuvbqACiiigAooooAKKKKACiiigAooooA8T/am/5Avw7/7H/wAP/wDpale2V4n+1N/yBfh3/wBj/wCH/wD0tSvbKACiiigAooooAKKKKACiiigDxGH/AJPVuv8Asn8X/pxkr26vEYf+T1br/sn8X/pxkr26gAooooAKKKKACiiigAooooAKKKKACvOv2hf+SB/E/wD7FnU//SOSvRa86/aF/wCSB/E//sWdT/8ASOSgCto/g+y+IXwE8P6Dfm6XT73RbFZHtyqSsBHGw6jjkCpPFfwV8PeM9evtc1Ca6XUJbW2tFmtZUja2NtOZ4JEO04lSUlgenJBBHFY9x46m+HP7OOga3BapeX8WmaZa2scxwkksxhhiyfTc6k1zHjL42eO/hXcapH4r0zRp7ZdE1S+065sY5VF9PbpDJEm1nYoGWWQGM/NmLIbBqXugO/0r4L6LoviLRdbN5e3uq6et8omupEdrg3Qh81n+X+7bxqFUAAAADAFeefB/9mWwtfhfZaX4t/tCe6m0m50y40ye+WS2sI7iQSTLb7ARksqnduJUDAIHFct4W+I3xG0H4i+KtG1TUNFn1nXNf0/StOt5LS5S1sZ/7LS5mdQbgl4xHGR5alSZCcttrV1T9ofxxdRzW2k6foK6lpOla9dX73kczwvcaZeJbYh2uG8uXcTlj8nfdVPYD1JvgXYtbo58ReIP7bW/W+GvC7QXe4QeQBjy/JK+XkFfLwSSxyxJLfEPwJ0XWvhOPh/DqWr6Hov7vdc6dcRi5kKy+Y29pVdXEjfeDKQwJB4OK8yv/wBpbX/DOm6lNr0GhRXdzaaHeaXcwCUQwR6lcNbqJ2JLOI2RjuQDf2Aqx4d/aG8WeOL600Pw7aaJPq8bao93qU8FylrdxWvkeV9mTcHzJ9qjyzEhdkmN+KCdzuNX/Z+07xNb+Vq3ifxBqF+bOXTbvU/Nt4bm9spG3vaztHAq7N2TlArDJwRk5ux/A3QI/FEOrLdaksEWoDU4tHFyBaxXQhEKzIoXep8oMNoYLyflzXlUf7T3iWLR/A2ragnh+CLWLLQprzT7YXEtwz3zRpMykNtto4zKhTzd3mfdDDrVXwL8WvFtjo91onh8affahZt4k1qV9XkmmEsMGqypHbRFWXDfeXechdoG05p7FdD0ey/Zj8P6ZpVtp9tq2u28FvYSaQ0kN4I5LiwaQyJaO4TJRSzYcHf8z/N8xz0Vv8Mf7I1KW70PVby1F3r/APbd9H521JT5CQNBwnKHy0OO23ivJ7H9pbW/EV3b6PZ6bYm91jUrN7GORJAW0i40xr0yn5uJFEckefu5Tpk1zGi/tFeObH4bXOqaXYeG7PR/DvgnTteeC7W6mllmntJZFhjYyFigMane5LHoTnmmk3cOlz7Gor5/+Inx58T+F/GWuaTZWVium6dc6XDcalLaTXC6dBdQXDyXNwkbbiiPAij7ijzPmbivUPhx4ym8Y+B9F1m5kspp7q33yyaTN9ot3bJAeNgDwwUtt6rnaeai4HYV4h8Wv+TkPgL/ANdtc/8ATfXt9eIfFr/k5D4C/wDXbXP/AE30wPb6KKKACiiigAooooAKKKKACiiigArx39sX/k1H4xf9ilqX/pNJXsVeO/ti/wDJqPxi/wCxS1L/ANJpKAPU9H/5BNl/1xj/AJCr9UNH/wCQTZf9cY/5Cr9ABRRRQAUUUUAFFFFABRRRQAUUUUAeI/scf8kHt/8AsYvEn/p8v69urxH9jj/kg9v/ANjF4k/9Pl/Xt1ABRRRQAUUUUAFFFFABRRRQAV4h8Sv+TpPgj/2DfEf/AKLs69vrxD4lf8nSfBH/ALBviP8A9F2dAHt9FFFABRRRQAUUUUAFFFFABRRRQAUUUUAeI/sc/wDJvOkf9hPWv/Trd17dXiP7HP8AybzpH/YT1r/063de3UAFFFFABRRRQAUUUUAFFFFABRRRQB4n+1N/yBfh3/2P/h//ANLUr2yvE/2pv+QL8O/+x/8AD/8A6WpXtlABRRRQAUUUUAFFFFABRRRQB4jD/wAnq3X/AGT+L/04yV7dXiMP/J6t1/2T+L/04yV7dQAUUUUAFFFFABRRRQAUUUUAFFFFABXnX7Qv/JA/if8A9izqf/pHJXotedftC/8AJA/if/2LOp/+kclAFDRfBNl8QP2f/Dvh7U5pIYLvQ7FDNC4VklWKF45I8gjKuqkZHUd+a4L4qfA6419vCelx3Gr63e3Hi6DX9V1yZkjRLeKIJNE5QKqo8KrGEVQG7jPJ0fiJql/oP7G0N7pF1NFfwaBppint5DE6cQDKlcY4J6VneIf2mL/wZqt5ofiO18P6JrX9tx6RHqV1qbxacEks/taPKXRX3BPkC45foVWkwOy1n4D2l94u13xBbeINU0zU9RurfVIfs/lMbO8igNuJYy0Z3B4WZGRsrjoB1qCL9nTQYY5/9O1CS5uNI1LSb25fYWuft0iSXE5ypw+9SdowozwuK4W2/as17XNG1PWtG8O6beaRo+gx63qRbUmDPi4uoZooGCbWwLRpFYkAq3NdFc/HzVU+KOl+Fja6LbQ6pqFxYWKfa2nugFs5biK5lWMMqo/lkbGKuKb1VgN7UP2e9E1JpXS+vI7wWmlWdtcbELWcmnTSTW86fL94NJyPutjpXLfEr4Z6jov9k3ul3PibW9dC6kLjWNLmtWuT9oEZaFoJBsEbGFVUxgeV5fXLMT46vxQ8fN8EZ7qXWoT4mj8C69qkWqC4uAoWK6jVVMe7BmUcB8cduM16R/wvDWvA954iivYYTeR6jp1he63f3Nx/Ztl5mmRztcMhLmGMtmMYwpdlJYkk00rshaGr4L/ZVj0vwPoml3XiLVNNu47LRTqdva+U8c97YRwBJg7oznHkouC207eQcnPTyfs5ad/Z8kFnr2saXczjUY7i5s5YvMmgvrs3M0PzxkAK5OxwA4BOG5rE+OXjHVb79l99elS80G9uG0x500G/eaeIPeQCVYZoGyxILKCpzzXEaD40uvCV/wCK7yw1bXoPD+ka5ojW2k+Jri6N/HFPiC7JW5zK0TK4ZA2QHjfGMU30Zb2PYf8Ahn3wz/wsKy8YW3n201n4f/sC3tEC+THDgqrAY3bgjMvXGDWZpP7Nvh7R/BOueGXvb++07V/D9n4buWYRrKkNvC0SOCqg72Ls3pk9K9o8pN2dozndnHfGM/lR5a88YzwSDgmp6sS2PGLT9nn7Jql9rv8Awm2uDxFdSWsn9rRfZowGhjliXdCsYiYOkzAqUIJIPUA10fgX4c3Xw9vdOsLDUblvC1lpssbWdwIyz3klwZGuflXIJ3ScDC/NwOBXonkpz8vBOcfl/hSeQm8MFwwOc5+v+JoGSV4h8Wv+TkPgL/121z/0317fXiHxa/5OQ+Av/XbXP/TfQB7fRRRQAUUUUAFFFFABRRRQAUUUUAFeO/ti/wDJqPxi/wCxS1L/ANJpK9irx39sX/k1H4xf9ilqX/pNJQB6no//ACCbL/rjH/IVfqho/wDyCbL/AK4x/wAhV+gAooooAKKKKACiiigAooooAKKKKAPEf2OP+SD2/wD2MXiT/wBPl/Xt1eI/scf8kHt/+xi8Sf8Ap8v69uoAKKKKACiiigAooooAKKKKACvEPiV/ydJ8Ef8AsG+I/wD0XZ17fXiHxK/5Ok+CP/YN8R/+i7OgD2+iiigAooooAKKKKACiiigAooooAKKKKAPEf2Of+TedI/7Cetf+nW7r26vEf2Of+TedI/7Cetf+nW7r26gAooooAKKKKACiiigAooooAKKKKAPE/wBqb/kC/Dv/ALH/AMP/APpale2V4n+1N/yBfh3/ANj/AOH/AP0tSvbKACiiigAooooAKKKKACiiigDw1ZAn7Z11K0gjX/hAoo/mOPm/tGQ9x6V7dvb0X/vr/wCtXzD43+CvgT4o/tm3UHi3wnpXiCL/AIQSGbbf2yyfN9vkXPPtTpvgH+y/Dd+LLR/A/hFLnwrEk2sR/YRmzR42dWfPYhGI+nvQB9Ob29F/76/+tRvb0X/vr/61eHR/sX/AiWFJV+F/hdo2XeHFmpUrnOc49Kd/wxd8CWZlHwr8M/X7AOOO3Hzc0Ae3729F/wC+v/rUb29F/wC+v/rV8+6t+yf+zxoV9pFpf/DfwtbTarcm1s0exAaWTy5JNn4Kh/KtM/sW/AvzIgfhZ4Wj3ZyrWS5P05oA9v3t6L/31/8AWo3t6L/31/8AWrw3/hi/4Fhxj4VeGpM8eWlkmV9zz26cU7/hi/4EqzA/CvwySOSv2AZ/D1oWornuG9vRf++v/rUb29F/76/+tXiA/Yt+BXy7vhb4aB9rBRu/A81P/wAMUfAj/olXhn/wCWgLntG9vRf++v8A61G9vRf++v8A61eL/wDDFHwI/wCiVeGf/AJaP+GKPgR/0Srwz/4BLQM9o3t6L/31/wDWrzn9oORn+AfxNAUknw1qiEDBIY2sgGcZ/QGud/4Yo+BH/RKvDP8A4BLXDfHD9j/4K6H8F/iBqWn/AAz8O2WoWHh7UZrW6gs1WSF1tJCCrDkc0Ael2fguL4kfs76J4amupLCK+0awie4RA7Ltjicjbxz8oFQat8C0v/GV74vsdfn0vxBNqMWpW0sUKtFG6WX2Ro2UnMqNH82OORXH/DP9jn4Jap8PfDF7d/DHw5PdzaXaTSTPZruLmGNic9ufSul/4Yo+BPP/ABavw0TxybIE8dBn09qAOUvfgLrWvfEzxDpV14i1y38N3nhOx0e+1CRFkk1RTd3rzRtMwIV9smMKBhZyBgAAdXYfs7xad4ssNVt/EkiWdh4gm8RW2mmyiKpPLFJDOu/7xXErhOfk3c7sDCf8MTfAbcW/4VR4XJIwf9AXHXOceue/Wl/4Yo+BHmb/APhVXhndgDP2FegOQPpmgDLtP2X4V8O3WiXXiS6msp/DuqeHIJPIVbiGC9mEhO8EBmjwOD1xWhY/AfUdPu7/AFW18Z3UGsXV3b3d1ItiPstz5VkLVoprfdtlBVVfJYkOoxjFSj9ir4EiPZ/wqrwzszu2/YVxn1x60v8AwxX8Cd4b/hVXhnK52/6Cvy5OePTnnimhFnVfgLbN8DbX4b6drE1ja2wt5IdSnhWaVJIblLkMEyq/eTgAAAfTFYWvfBPU7xZ7jVdZn8S654g1DSY9UmjtltrO2s7KY3OyKIFtgysoy7sd0uM4wK0/+GK/gTu3f8Kr8M7sg5+wr1BJ/mx/OkH7E/wIGMfCvw3wCB/oY4z1/wA+vNDKPaN7ei/99f8A1qN7ei/99f8A1q8X/wCGKPgR/wBEq8M/+AS0f8MUfAj/AKJV4Z/8AlpCPaN7ei/99f8A1qN7ei/99f8A1q8X/wCGKPgR/wBEq8M/+AS0f8MUfAj/AKJV4Z/8AloA9o3t6L/31/8AWrxD4sSlf2jfgQWUDbPreS7Y/wCXHaNuARyT3Iqf/hij4Ef9Eq8M/wDgEteRfEv9k/4PaX8evgzplp8OtBttO1SbWPttrHagRz7LLcm5ehw3Pv3zQJu2p9i729F/76/+tRvb0X/vr/61fKXjr4P/ALKvwz1aHTvEngfw3p11MokjiGiSz7wxbaA0cbDPH3evFdfpP7H/AMBNa02yv7T4ZeGpbW6iW4SX+zfL3oyZBCsMgcg880k7q43o7Hv29vRf++v/AK1G9vRf++v/AK1eH/8ADGHwKJyPhX4XZfayX8aX/hin4FCTafhb4b+5n/jxX/D+tPYD2/e3ov8A31/9aje3ov8A31/9avDv+GL/AIFNIi/8Ks8NJxvK/YByvOOSOvTjrWfrn7Jv7PfhrTxf6r8NfC9jY74o/PlslX53ZURduM5ZnApAfQO9vRf++v8A61G9vRf++v8A61eID9i34FEH/i1fhnIzuH2AZH0/zzWdqX7JHwC03UtOsJvhf4Zjub9mSBDYBjIyozsFwOyjPOMjpzTA+gN7ei/99f8A1qN7ei/99f8A1q8QX9i34FMo/wCLWeF9wO0j7GpGfrip/wDhij4Ef9Eq8M/+AS0Ae0b29F/76/8ArV49+19uk/ZX+LyDc27wnqmcLz/x7SbR1z+lQf8ADFHwI/6JV4Z/8Alry39qP9kj4NeEv2bfihrGjfDfQNN1XTfDOoXNneW9oFlgkW2kIZW6j6dKAPq3SWCabaIZI9whj7+31q7vb0X/AL6/+tXzT4o/Zr/Zu+G/gk+JvEvgHwppej2cMP2i+msMpHuKqv3fdhTdU/Z9/Zh0XXPC+i3/AIE8I2+q+JvMbSLX7GGa7EcfmSbMDkBe/emB9Mb29F/76/8ArUb29F/76/8ArV4cv7FvwLXj/hVvhlv9prEAZxj+fas24/ZP/Z7ttcsdFk+GnhePVLyGW4it2s18xoo2jV2AxjgzRf8AfftRYD6D3t6L/wB9f/Wo3t6L/wB9f/WrxD/hi34EnJHws8M5xnabAcD6dc+1Z2h/slfs/eJLOW5074aeFbmKG5ns5THZA7ZopGjkX6qytxS62A+gN7ei/wDfX/1qN7ei/wDfX/1q8N/4Yv8AgU2MfC3wzycA/YVwec4HqcVm61+yn+zz4dtUutS+G3hW0gmmitYi1iCDLJIsSL06mR1WjrYVz6E3t6L/AN9f/Wo3t6L/AN9f/Wrw5f2LfgUqsf8AhVvhlwDnd9gAAX29ao6h+yX+z7pNxYQXnwy8K2099N5FvFLZoGd9jPtHPXZHI3/AGp2A9/3t6L/31/8AWo3t6L/31/8AWrwDQ/2Sv2ffEel2+paf8M/DFzY3A/dzLp+3PO37rLkc+ta//DFHwI/6JV4Z/wDAJaQyr+x/dBPgfbIBj/ifeJHHPBA1u9B5wT1YZ9+mRXuW9vRf++v/AK1fHn7K/wCyf8HvFXwdttT1f4daDqGoDXdeg+0T2oZ9kWr3kUYz/sxoqj0AxXrf/DFHwI/6JV4Z/wDAJaAPaN7ei/8AfX/1qN7ei/8AfX/1q8X/AOGKPgR/0Srwz/4BLR/wxR8CP+iVeGf/AACWgD2je3ov/fX/ANaje3ov/fX/ANavF/8Ahij4Ef8ARKvDP/gEtH/DFHwI/wCiVeGf/AJaAPaN7ei/99f/AFqN7ei/99f/AFq8X/4Yo+BH/RKvDP8A4BLR/wAMUfAj/olXhn/wCWgD2je3ov8A31/9aje3ov8A31/9avF/+GKPgR/0Srwz/wCAS0f8MUfAj/olXhn/AMAloA9o3t6L/wB9f/Wrw/4kzbv2nvgu67SPsPiFAxJOP3VrnbgYP3TncRjtmrH/AAxR8CP+iVeGf/AJa8j8f/sn/B6w/aL+EWkW/wAOtBi0zUdO11ru0W0HlzGKO18rcO+3e2PTPsKAPsTe3ov/AH1/9aje3ov/AH1/9avF/wDhij4Ef9Eq8M/+AS0f8MUfAj/olXhn/wAAloA9o3t6L/31/wDWo3t6L/31/wDWrxf/AIYo+BH/AESrwz/4BLR/wxR8CP8AolXhn/wCWgD2je3ov/fX/wBaje3ov/fX/wBavF/+GKPgR/0Srwz/AOAS0f8ADFHwI/6JV4Z/8AloA9o3t6L/AN9f/Wo3t6L/AN9f/Wrxf/hij4Ef9Eq8M/8AgEtH/DFHwI/6JV4Z/wDAJaAPaN7ei/8AfX/1qN7ei/8AfX/1q8X/AOGKPgR/0Srwz/4BLR/wxR8CP+iVeGf/AACWgD2je3ov/fX/ANaje3ov/fX/ANavF/8Ahij4Ef8ARKvDP/gEtH/DFHwI/wCiVeGf/AJaAIP2O5iv7P8ApKbMFdS1ksCcn/kJ3TDp6hh2r2/e3ov/AH1/9avj79lv9lH4P+LPgjpeq6z8O9C1LUm1LVgbu4tQ0mI9SuUQbuvCxoPwr1n/AIYo+BH/AESrwz/4BLQB7Rvb0X/vr/61G9vRf++v/rV4v/wxR8CP+iVeGf8AwCWj/hij4Ef9Eq8M/wDgEtAHtG9vRf8Avr/61G9vRf8Avr/61eL/APDFHwI/6JV4Z/8AAJaP+GKPgR/0Srwz/wCAS0Ae0b29F/76/wDrUb29F/76/wDrV4v/AMMUfAj/AKJV4Z/8Alo/4Yo+BH/RKvDP/gEtAHtG9vRf++v/AK1G9vRf++v/AK1eL/8ADFHwI/6JV4Z/8Alo/wCGKPgR/wBEq8M/+AS0Ae0b29F/76/+tRvb0X/vr/61eL/8MUfAj/olXhn/AMAlo/4Yo+BH/RKvDP8A4BLQBB+1JM02kfDURbCG8e6DIRuydq3iZx2/Wvc6+SfjZ+zX8Lvhnc/DnX/CngXRdA1lfHehQi+sbYRybHvI9wyPWvragAooooAKKKKACiiigAooooA8Rh/5PVuv+yfxf+nGSvnj497PButfHfxksiNZXav4e1dtm1GS50e3+zM2TztuEVAeCPObBr6Hh/5PVuv+yfxf+nGSu6uNA8F+LI/FWlXWmaPqsc86R65avbxyLI/lo6faFIwxCCPBbOMCjyA+cLLxX4zm+IV5qNpcFV07xNb6ZHHda00UM1mLJC0EVnsKkykl1YnOeAwHFcx4k8da3pvwz07ULXxXqkd34h8DHWdXuGvnxZ3ZurRVljUsTAMzzptXYPkHy5Vq+zV8C+HI9ei11dA01dajjEKagtpGJwgAAXfjdgAAAZ4Fee/FX4W+D9Q8B69okMGi+Fp/Fs8FrLfraRRm7uGlVkV8Aea7ENjOeST3OVcDxLxJq/8Awi/xMtIIdd1DUvCui+KUuob65upb+WCZ9Av5LgRyNu83bgSbMn5nwABxWXpuu+J/O1Tw/b+IrzTRqej6De2ses+IZ3lvpZrqVZY2uAh+xy3EaIu2IlUZvlzX13Y/Dfwppdvb29p4a0m2t7edruGKKyjVY5mUq0qgLgOVJXd1wcdKp2/wf8C2trPbQeD9Egt54BbSRxWESK0QIOzAX7uQDjpnnrTTA+VJtb1DxE0Wmx6x4s09dM8PeKvMszq7mb7XBc2/l4uI3HnpH5pCuSxIXDhhWlDqHiKCLUNCs/GF1Feav4e8Mah/xNdVli8+6uLidbmOGVQzW4uFhEYaNfkZvlVetfVEHw98MWcUMVv4e02CGG2ms4o4rVFVIJWDSxKAMBHYAso4OOabcfDvwvdWstrN4e0ya2ltYrF4ntEKvbxEmKIjHKISSq9ATkc0Rsrtks4z9n/WJNU8E3SSHUkn0/U7y0kt9YuhcvbFJMCJLgZ82NRwHJLHuTXq9cZLqXhL4a2KWSTab4b0+xtJrw2sZS3iit4yvnSkcKFUuhY+/vXYK245B+Wm31GlYfRSUmTUXGOrzr9oX/kgfxP/AOxZ1P8A9I5K7WXWLeK8WzMq/a3RpEtwf3jIpVWYD0BYfnXFftC/8kD+J/8A2LOp/wDpHJTTuBr/AAl/5Jd4R/7A9l/6Tx111cj8Jf8Akl3hH/sD2X/pPHXXUwCiiigAooooAKKKKACiiigAooooAK8O+LX/ACcf8Bf+u2t/+kFe414h8Wh/xkh8Bf8Artrn/pvpieqsXf2gdhb4bqzKxbxpp2wMwAYgSZHPfrxXkUXjzVHuvDto3iK4+0N4/wDFFpLA16+8xRwak0SEb8+WpRSqsCApUjotfWGoaDp2rfZvttlBefZpVnh89A/lyLnDrnowyeevNZC/DPwimvSa2vhnSRrMjmR9QFlH9oZypUsZMbslWYE55B5rNe7FIb3ufGPna9pvw7udTHjbxa98nwptPEqudXuSgv1D4m+914GY/uHHINei3XivXW8Sajri6xf/ANtR+O7LQodK+3SeQ2nSQ2+8fZt2wnZLJPu2ZyMbscV9GN8OfCzWTWh8O6WbVtPXSTD9kTabNc4tsY/1Qyfk+7z0qjpOh+DNa8Qy65Yado93rViTYyalFbobiNlUKYzJjdwrAYz0qua+n9boP6/A+PvFnxG11fg34Te18Tap/asvw71u5m23kn2kXEb2gV3Oc+YoaXk4K557V7x8afD8HhX4H2+nQXuo3y/25o7NcalePczs8mq2zbzIzdC3zYHAHAAHFekD4OeA9183/CGaDu1ASC7P9mw/vxIQZFf5fmVyq7geGxzmuk1bRNP12zNpqNnDfWpZXMFwgdNysGU4PHBUEfShO+oHxtqWseKG1vXvB8XjS70SfwaNXM2p319LjN7dxf2Ykx3Z2mGR1V/+We3dxinXnjXV9NmsdOj1vVPCN5p2q6vBfS6nqR1SKwlOjmdCJgxNxEMmXEh8xGOMAcV9C+FfhLDpvizxz4h1uLT9Wu/FbQQXUItSIBawRtHDEVctuY7zu7dscCursvhn4S021tbW18M6Tb21q0rQwx2UYWMyJskIGOrL8p9RweKpOwHln7POqXtvqHibQNYl1BNTsWs5ZbOfUzqtsokj4mhuXAk2ysrHZIAUx2BFe8Vi+G/BegeDbOS00DRbDRLWRt7w6fbpAhb1woAz/gPStqhgFeO/ti/8mo/GL/sUtS/9JpK9irx39sX/AJNR+MX/AGKWpf8ApNJSAzP2mtMg1j4FwabdrHcWN5qGi2U25giukmo2ySEqeMbea+bfCcc/j34jeALLUL2RX8E3q+ARdQuyz/bYrC/F1IpDDaSkVo2Bzl/rX3Uuh6frnh+wt9Rsob2BVglEdwgcBkKsp57gqp/Coo/APhyzuHuLXQdNgu2vm1MzR2iKxu2Uo05OP9YVJBfrjvTTsB8aab4+8Z+JNAsLmC+1XU1019F8F6tCmqtbeZfRSTNes8qkrE7MLeMy8OPMyGBqTxF4i8X+HbGG/N75uo6doPiy2gvLa/e8NlbjUbBAGuHVdzwrySQ33PvV9NeAfhDY+G/DOtabrltYa7Lr+rXGs6mv2PbbSXE0qsdsLlvlUImGYk8A55rqLf4f+GrNLdItB02NLe1msrdEsowIoJWzLEvGArELuXocc5quYD5q1jVbyx+KEHgK217Vz4Eu9bsEvtRGpymaOSbT72ZoFus+YqtLb2xOW480qMFlrz+01rUPBPh24stC8TanLH4vuvEPhbTbhLx2DamdaCW824HAm8t7lt3UiPnNfaq/C/wevhuXw/8A8IvpH9gzSCWTSzZRm2dxtIZosbSQUXBI42j0rk/EPwdtdY8QeDxawaZpXh/w7qT67HplvZbDNfeXKiybwdqqGmLnC7ianqmD2seCeIfEmr+GNU8RyXHibVLldStdeg03VdP1Z3i3W0E5W2ls3AeCaDyz++QEP5XzEbxVTWNSuY7bTrS21y/8QaJcReDNbnuNRu5bsveSarFmRC2TH5iKrFOEGMgCvprxZ8JfD+uaZ4sFhoemadr2t6fc6dJq0NlGk7CWErl5Au5gCe5NP8H/AAh8M+F/DdlpEegaWDCbW5nZbOP97dQgbJjxy6lQQ3UUK122TbSx8sX3jrV7q/F7pPi6/wBD0rxNouvTwa1rWrPKJJlubZYn+zKu22jTzXRTEd3QsCykVfmsV8SeJPBGk6vc65pt/ovjyBLnT5PEFxdJab9JnlCQXauDLGzANumG4eYUwMkH6q/4VT4MF3c3X/CKaN9quZZJpp/sMW93kz5jFtuctk59cnNC/CnwZHo0Gkr4V0caXb3K3sVn9ij8qO4XG2ZVxgSDA+cc+9VdAlY+V/hv4iuvE2g2aeKPGmt+HbTRfC0Oo2+oQ30ys9w17dCWaQDi42CGBPLYPkP0zzX2grE9a5tvhj4QaPS428L6O0elAiwRrGMra5JJ8sbfk5JPHfmulAA6VLdyjxL9jj/kg9v/ANjF4k/9Pl/Xt1eI/scf8kHt/wDsYvEn/p8v69upAFFFFABRRRQAUUUUAFFFFABXiHxK/wCTpPgj/wBg3xH/AOi7Ovb68Q+JX/J0nwR/7BviP/0XZ0Ae30UUUAFFFFABRRRQAUUUUAFFFFABRRRQB4j+xz/ybzpH/YT1r/063de3V4j+xz/ybzpH/YT1r/063de3UAFFFFABRRRQAUUUUAFFFFABRRRQB4n+1N/yBfh3/wBj/wCH/wD0tSvbK8T/AGpv+QL8O/8Asf8Aw/8A+lqV7ZQAUUUUAFFFFABRRRQAUUUUAeIw/wDJ6t1/2T+L/wBOMlcBfeJPEXgX4kfE3xLYX0A0dfFui2d1pKWSsbyO5gsrVy8h5Rk80MvIBZcHIOK7+H/k9W6/7J/F/wCnGSukuPgN4Uu/G1/4mmt7x76/ure+u4PtbCznngVVhd4M7WKhVxkdRnrzS+0gPBl/aQ+IN94L8ReKLK31BrGTw7rGpwtJoDJa6ZPbHNqsc5G248xMhvmbLjjavFafib4h+JND8ULofiLULHXks9c8O3NrPJpyReT9qW5LxqCDhlMB8tx8y7sE16xL+zn4MmsdYs3tb17PUrW7shbNfOYrSG6bfcLaoTiLeepABA4BA4q/f/B7wlqfii51SRWuNTWXTrqaPztwU2fmCBimeOJJM/3qrRN3Dpc8A8QfHr4l6R4G0vxOmvafOuveCL/xRb2yafGqWU6fZWjiBLZkREnbk5JK85r3H4XeK/Elx468beG/EGopqi6ObG5t7tbRLdlS4hZmjcK33VZDg9eeSa8z8O/s0y614heDxJpT6T4fj0W/0ZLOLW3ulYXE8LhrXKgwxBYjw2GzNjooFex6l8MbaTxJJrmm3U+n6he39jd308MrKJ0t1ZRGVBxtcOwIxg55zgU3boS+5wXx68feMvDfie+tPDeuW+lW9j4P1PxBIk9itx5k1u8IiXkZCHewb0zXNj4yeMrS513S9S8TWVnIbXQ9Qt9Qj0kzyxi9afzba2gj3GV8WzBN4Y5Zi2Qhr2jxX8MdF8ZX91e6nDNJPdaNdeH5WRh81pOVMgx7lF568Vlan8CfDGqahFqDJdw6ksdjHb3cV26TQG0EqxFXBzkLPMCe4kYHg0dNRs+YfFnxK1XxJo93retxWlxrmm+DvGdk9vf6fEd/2e/toY/Ot9zoSyqN6kbd3GMV6pqnxX8bXGsf2nperW1votv4003wrLpclghZ4nEBnm3li24tMVABxsXI55rtb39nPwHZ6LeWdwtzb6Td2epafKZb58bNRkjM4Ls3LNIqkMcnPeuF8XfC5vEnxnia3lsrO3TxFpusvLHr7bXNtAAoNlni4cqyj/lmYowxO/IMtp2iv61RXS5g6F8dviDZ+HfDmrav4h0sJ4i8Pavfq9/p/lRadNbTRLFIwi3SOCsgBQKSW6Vc034yfEDWPElv4ZtdaeDf4wg0dtW1DSEiuGspdKmuwRDjCvvVSpcKdo+ZDXq0/wCzn4LvtB0rQ7mzuJNN0e1u7K2g+1MNkVwyO4DA5yDGhDfeUjg8mnaL8DvCVn4ki1qKW/vtYs9QTUJZ7rUmnkN4tq1vulyThvJmAwMcEceq0/r1v+Qk7nkfwx1rxN45+NHw/wBa1XXZ5bmHQPENpd29pbQwxXBtdVhtzJsZS48zap4YbSOMDNe3ftC/8kD+J/8A2LOp/wDpHJUWh/A/w34e1TQdRsBd2lzox1A2rJdttk+2zCecMudpBkAbBGAelS/tC/8AJA/if/2LOp/+kclP0A1/hL/yS7wj/wBgey/9J4666uR+Ev8AyS7wj/2B7L/0njrrqACiiigAooooAKKKKACiiigAooooAK8Q+LX/ACch8Bf+u2uf+m+vb68Q+LX/ACch8Bf+u2uf+m+gCt8dviX4x8D61bz2V1DofhiGz8+TWJbE3lt9q81R5N2I90sMOzJ81UHU5K7Ru4jxB8dvHdnFrml2+o2yav4fTxLqF/N5MRza20SPp4wVwN4u7bkDJ2HOea9t8b/Bzw94+vXu9TTUPMnshp12LK8eFb+2DM4imUMA6hnc89ncZwxB4nSPgjHrHj34pa1runLp+n+LNPg0CG1S6Dyy20aPHLOCOELq0QUdR5QLc0AcddfGL4gaTrqeF7jX7K4vtcGgvZamunRr9h+3SzJMqR7sOFW3ZlLg4Z8HcOKwPAep+O9J+IE/hTS/EenW8mp+KNfutTvlsElM32eOyeLam4bGO8hh0GelfQOvfAvwz4juLu5uIbtLme1s7RLiG5aOSH7JI8ttKjKwKtG7swwe5yDTPCvwJ8MeDdWs9T09b64vrWW7nF1fXzzSGS68v7Qzs2S5fyo/vZxt4xk5qNk7vsB4V4l/aC+Ifh34Z2Pi1dSsZn8UeGbvXLG2ksMLpMsbwGOMEcyIYpiGLZIddw+X5a3rz4ofEXwz4p1W2uvEltqdppHi7R9DaM6QiG7jvvs/mDKvx5fmnYQQTn591eiyfs1eCZtP1Gxks76SzvLOewjge/dktLeZxJLHbAn5AzgH1GABgcVu6n8HNB1S8v7mdLh5r3VrHWpm8zG64tDF5IGCMD9zHnGM45zzmdLJAeXfCX4zeJvHnjWwkW11Gbw/qN3qtpL5miPBaWa280iWzJc4Ak37Pm+Y5ZwBtwRX0hXAeHvhDoHhfxN/a9nDe+cpumtrZ7h3t7Y3EnmTlEJIBd8sfQlsdTnv6ACiiigArx39sX/k1H4xf9ilqX/pNJXsVeO/ti/8mo/GL/sUtS/9JpKANz4iePrj4a/DeHWbe1jv3V7W1LOzCCHzHRDO7KCRFGCZGOM7RXmmoftQavoWh6hqWoaJps8f/CP3uqaXcaVfi7t9Tmt7gQqsLoDlJfMgYZAZQ+CM1634i8M3nibwraWFlq82j3C/Z5Y7+z5LSRsrBWBBDxOFwQcgg4INeH+MPgO6658ONEso77ULhvFtx4m13UI7ExWawvunkib+CNWljt1EYYsdmSc5JAN+D9oTX7HWSda0TTLbw8niO48NXE0F1I1yk0ds0/nCLZt8vCEY355riNU+PfjK1vLbxvd6MiadN4Cvtd07RrW/mkjuh9otNiyjYNswRwNw4/eH049hm+ANlcSHzdRZkPimbxMR5A5aWBomiPPPLsc9efYVyM37K815pp0++8a3N1ZR+GJvC1hG9jGDbWzvCy5IbMrBItvUZ4PUZqlbqBavP2gvFOhya1caroWkxWPhuWyTXRb37yNH9qdSPKZokDeTE8bPnrv4qhaftAeMdY161tNO8L6C0GpeINU0DT7i41GXPm2hkxPJ+74RkixgfNurr/GHwJi8Va5ql1/bt1aaVrzWbatpSwqyXJtSrRFJP+WWVVVfg7gBt21Y0n4Hw6TrGj6h/asrrp2v6r4gaMw4DvfCcGM4P8HnjB6krnrSdugHmWsftoWen+HdI1GVNH0128PL4h1HT9W1QW9wytI6fZ7XCHzXJim29M4i/v8AH07ayC6ghmUlQ67/AMTXiWg/s2zeFdL0qz0bxff6bMmjroeoXENtGHuLZZpJlZTuzDKPOlUSAsPm+70r0/wraavZza7Hqd0bm1Oo7dOjEar5Fr5UeEyoBb5vMOWyeevSkB09FFFABRRRQB4j+xx/yQe3/wCxi8Sf+ny/r26vEf2OP+SD2/8A2MXiT/0+X9e3UAFFFFABRRRQAUUUUAFFFFABXiHxK/5Ok+CP/YN8R/8Aouzr2+vEPiV/ydJ8Ef8AsG+I/wD0XZ0Ae30UUUAFFFFABRRRQAUUUUAFFFFABRRRQB4j+xz/AMm86R/2E9a/9Ot3Xt1eI/sc/wDJvOkf9hPWv/Trd17dQAUUUUAFFFFABRRRQAUUUUAFFFFAHif7U3/IF+Hf/Y/+H/8A0tSvbK8T/am/5Avw7/7H/wAP/wDpale2UAFFFFABRRRQAUUUUAFFFFAHiMP/ACepd/8AZP4v/TjJXNeMvi54k0n4vWFrperT6jpZ8RWmh3em22mxra2iSwqzrLcSAO9xllYLCxAX7wrpYf8Ak9W6/wCyfxf+nGSuh1T4J+EdW8QXGpT2tx9sfULbVzFHeSxRLdRYVJxErKm8rGFJwdwHOam13/XdCex4Fp3xy+I/h3wJp3iS/wDEEeuzax4K1PWorKaxhijs7m3nto4ZdyKCyEXILBiQ235Qten/AAX0XVNJ+OfxMh1rxD/wk90um6JtupbSO3nXH2z/AFiIqqOTlcD7uM5rsrf4D+CYNK0/Tf7IjexsNJuNDt4XldgllOUMsPLchjGnJyRt4Iq34F+Ffhz4dahqV5o/2o32qQw29zc3+oS3cswhD+WCZXJ+QSP+DegGNNLv+urJ7WPC9W+NXjC38Fabexa5Cl2194uicfZYyZFsUvPswyVw3lGGPJH3ivOectT4k/Euzf8Asq21648QXN9ouh66JY7Gziu4knmlW7S0QgJIxSMsqyBjkPg8CvX5f2b/AALNfTXb6dfM8st3N5f9ozeTG90JBcGOPftj8wSyZ2Afe9hibVfgn4P1maKW7sJkvbWzs7C3mhvJUlt0tSzwtCykMGRpn+fqd2DwamGjs+pUlzaI8XtPih428UQxRaL49aGHT/Dmq6tLcy6JDFNcXFre+VFDcxyIPJKr8sqqF55UqKseHfj3418Z+JLfVLG11cadDqenW0uk2+mRtZvby2tvJPI87YdZFa4LBVYcRAFWL112ofsw6DqXxE06eS1uB4Zh0W8s5Vj1OZJ55p7iOSZJnVg8yyAPv8xmDZweMV6Q/wAGfCsnihNbOnfvlnhuvs/nyi2M8SbIpmg3eU0ijGHKlgUQ5yikXzRsn3KbTvY8B1jx14t1D4I2XjS88T6deW+u2tlejRbyxhYWrvqVqoMQ2ZMSxuyM0m8hijAjpXPaZql/8OfF3ijX31KTVpJfH+ofaBqGn2nnCO30WaZUSRIg44WJQQcgAgcMQfoqP9nrwPHBPCNOuWgkCqkTXczJAq3CXISIFsRL50aPtTaCVGRWkfg54TbUlv2sVa6XVJtZ3NK5Bu5YDbySFS2DmIldpG3uBnms3q7rt/kHRo+ftL+NHxKm8LxSST6lFJrUeiR2+rappUFuthcXt7HBKYY1/wBZFslGzzAxDLyzV6f+znY32n618XLfUNXGtXEfi583Sosbn/iX2XDqoCq3HQACt21/Z+8D2+g6tpEdhcy2V7Bb2cm6+lkeGK3ffAkTF8xCJ/mVUICnkCuk8C/DPQ/h1bapFotvIBqd2b+8a4uJJ3mnMaRl2aRmOdkaDrjj1JqusvX/ACJWiOr8se/fue9eeftC/wDJA/if/wBizqf/AKRyV6LXmv7QUjS/AX4kgKytJ4Z1NBnBG77JL3BPTBFIZufCX/kl3hH/ALA9l/6Tx111cj8Jf+SXeEf+wPZf+k8dddSuAUUUUwCiiigAooooAKKKKACiiigArxD4tf8AJyHwF/67a5/6b69vrxD4tf8AJyHwF/67a5/6b6APbfLXABUEDpnmmiFACMcEkkZOOc5/nUlFADPLX5uPvdaVowyspyQ3Xk06igBNo468e9N8tcKMcL0p9FADfLXkY4PUU6iigAooooAK8d/bF/5NR+MX/Ypal/6TSV7FXjv7Yv8Ayaj8Yv8AsUtS/wDSaSgDsde8XWvgnwXbaxdxXUyRJbxpa2NuZ5JHkKRxxoiDklmxk8DOTwK5mL4+aHdaXHPa6brd1qM19eWI0iG2827Elt/rwAH2YUbDw/O7C5Jqx8TvD+t+JfhtZWPh+5FtcPNZySxpeNaSXNqs0TzQpcL80W9AwyuDg4GK8o8G/BXxj4E8QQ+ItJ0TRXuodX1idNKTUCIxbXiWxU+cYv8AWRSwAMCOcEjqaAPTrf8AaB8KXWm6ne25mmtNOuNNtZWW3GS975Yt8AsCuPNXcG6VzfgP9ou51bRr2fWPDOsxatJrmpaZYaRZRQS3E8cE0o3hFnbYUjiy+8rliQm4FRXPeIPg78RbnUNYglOl6pHruoaHqV9qjXTQbWszAJ08jYQQ3lfL89Ubr9n7xDdahaS3OmWd9FpOu63fQ21rrk9q13Dfv5u4yRKrRvG+E2sWBxkdqAPadY+L3h7R/hTF8QWa8uvD8lrb3kb2kJefy5iqoQhPUbxnBrm7T9pTwzca4NNl0fX7OZdWXRLh7nTRHHb3bx+ZCrncceYpG303jftqLxN8Kby6/Z0h8B6dBYW19DBYxCG2DpaAxTxPIqbyzFQEbGSc8Vk6p8HNbu/FWr3qmxWK68f6f4jGHC7rSGyt4Tn5eXDRdDmgDpE/aO8J/YtIukh1J4dS0tNWiVbbc+17iO2jiYA/655pUVU74bnisnVf2hrOPxV4bUTjSNFk/thdbj1KAxXFo1lbxyFW5OMeZuym7KsmK8d8IfBW58dad8SbTTzY39vpfii1i0OSG9kiiurK3uzqRt/Nh5jG65mhDZIDRLjG0Y67WP2ZNV1yxSzSz0/Q4L6LXRdFLqa5eM3lvBBAHeVmaeTEWWbIUBQABgUCPQpv2gLLUb/SLG2j1PQdRuNUsoJbLVtNBlaC4WQxN8sn7pHMTDe2WU9Uql4f/aFfxn8W/DOiaPaXUfh7UNN1K7N5fWRiW78iW2jSWF8nEe+V1wRk5DdK52/+EfjTxh8QNH8W6vZ6fp1zbXWj27WttftNm1tWunmm3FAfne5UKvUBfmzUvwn+EnjTwl4o+HkWqQaV/Yvg7RNR0cXlvdPLc3wkeAW8mwoDGTHEd+5m+YUDPo+iiigDxH9jj/kg9v8A9jF4k/8AT5f17dXiP7HH/JB7f/sYvEn/AKfL+vbqACiiigAooooAKKKKACiiigArxD4lf8nSfBH/ALBviP8A9F2de314h8Sv+TpPgj/2DfEf/ouzoA9vooooAKKKKACiiigAooooAKKKKACiiigDxH9jn/k3nSP+wnrX/p1u69urxH9jn/k3nSP+wnrX/p1u69uoAKKKKACiiigAooooAKKKKACiiigDxP8Aam/5Avw7/wCx/wDD/wD6WpXtleJ/tTf8gX4d/wDY/wDh/wD9LUr2ygAooooAKKKKACiiigAooooA8Rh/5PUu/wDsn8X/AKcZK47xh4g+0/ES6u5re3n+x+NtH8MW8c0SuIIhbi4Z48g7Xb7TjjH3a7GH/k9W6/7J/F/6cZK1Jvg9BffETUdQvI2k0m7v9P8AEETRygFNSt0aLGOpUxrE2fVcUuv9d0J7HjFr+0X4/wDDvhXSfEmsXul6rHq/hvWL+DT47MRCK6tJ444Pm35IYS5kycfIduK0fixqnjTwj4g8OahrGq2WtyaTb6xeWN1Bb7JAw0mSXF1CP3YKuBs55UZOTzXrS/s++D20nTtPuI7m+07TtPvdOWG4uWIeC7bdMCwIIPowIK8bSKjg/Z78JC+t767e91fUAZjJfaheF5btJbY2rB2GMhYGKjGPXk81Stzf13f6BHp/XY8+8RfHTxdYyW1pYXFn9p1Hw94cmtmuIFeOC61C9e3lmcBgW2hQVUfKW4xXns/iDxL4B8TeNb6aXS9S1m18Vatcrqc1gVb9z4bilicDOQflCuBwAMdK94s/2Z/CVra6pDcXGtXxvbCz00Pe6nLLJbx2kzy2hjbduVo2fcMHkrls0rfsyeEWhuluf7XvZ7u7ur2e4nvd7vNc2YtJ2yRwGiAO3oG6YHFO+t0Pqzzuf40fEDRbqDQ7zU9KvdQ1600CfT9RWzESae9/cyQyqybzv2rFvUnqz4PGBXoHw8+JGvR+F/iZf+KLq11K48Kavd2sUtrF9nElvDawzJvU5w7F2zj14pfiH8ENOl0uS40qynvtUWy0/T7eFdR+xuEtJ/NhaGTHyyoeQT8p7g81Y+BHw5ufCHhvxFb6zCyXWtavc6jLbXF39qm8uVUjVZpMYd2WLe2Om7AwOKiV3FpfL8BI46L4jfEbRfD/AIO8T6rrOj3WiatNpc17bw2pSa3W6dopI15wYEaS3ZXLbztkz0rnLX49fEGSx0TXL68sNI0DUEN1ZX0+mSvaTb751SG7ljVzbILUwFJCBukfkkKwrsPiB+z3Y2fwr8T+HPC9lqGrajrWmLoVtPfaj89hbxhvJCM5B8uFmJG3c5zyTjjqLz9nXwrqljYW1xLeW9rBYWumXtvZXRjg1G2tiWgjuF/iCknkYJBKkkcU+rfmMxv2bYdS07RPiFPqevy60Y/FmqBPtCIiQiOTaRlQDgjseB2ry6+/aU8dWNjqcUGp6bqt5PpFhqtlfR6VLBZebLqUVrLFBvKyXEG2T5X27j619JeFPhrpnhG78StYvdNb67ey391ZzuGiWaU5kZMjPzHtnA7YriIf2WfCVvaW1mtxrJtLexh0yKGS/LrHbQ3MdxBGgOdoVol5HJxzmgDkLf4teP7z4gSfD1NZ0+O/i1+W1bxB/Zu7/RU0yG88vyt+zzS84XOcbFJ61V8Mw3MP7CPjNbtY5NRj0TxHHcG04/eCS8Hyk+lep6x8C/Dut63fa217qNhrFxqaaq17Y3hilhlW2S1ZAy/wtCgQg5HGRzycT4jeA9L+Gv7Kvj/w3ojSx6daeGNY8lbuV5Su+GZ3LMTubLMxySTz+FAHe/CX/kl3hH/sD2X/AKTx111cj8Jf+SXeEf8AsD2X/pPHXXUkgCiiimAUUUUAFFFFABRRRQAUUUUAFeIfFr/k5D4C/wDXbXP/AE317fXiHxa/5OQ+Av8A121z/wBN9AHt9FFFABRRRQAUUUUAFFFFABRRRQAV47+2L/yaj8Yv+xS1L/0mkr2KvHf2xf8Ak1H4xf8AYpal/wCk0lAHUeMPHMHw78C6brNxC12GuNOsCEOwk3E8Vurc9g0uatzfEfwvDqWqWR8T6Sl5pUL3GoQG6QtbRR48xpF3fJtyOWPGeRxXHfG/TbnWPhLpdvZ2lzeyf2toZMUMYkk8tb+1ZmxhugQtn2rwO8+FHivWNN8R6PKniK91m3fxXPbQ/wBnxQ2LNd/avJY3HlhphL5y7VEgIwN3QYAPprxp8WNH8G3ukQLKuo32oX9lafZYZvmijupdiTsMcpnPX+7x3rRvPil4QsbVbm78S6Pa2rXMlks1zexRobiItvjyxHzJt5XqM818o+OvD/ib4meImm0Gy8SaCk8fhK0/taXRbhJ7Vor26+0MElQKRF5gLAjHQ/dp0ng/xPDY+HdOv7LWNKh0DQ9Z8K6iuh6Ctyt9cSSQGOWMSxNxcxISZRgB8gv1pgfVOsfFDwn4f1mTTNU8T6Pp2p9Psd5fxxSKMbsBCwYfJhs46MCM8Corf4qaFqV5oa6TqOn6tY6ktywvbbUYmRBCqs+AD85AYZ25296+b9U+GGpWuk+KdPfw5fXZ+3eBoIWezM8xjtpbQy/MqhWMexi7L8o5ztpuueD/ABLa+KNeu9N8JTamv9p+K57eyu7KRYLlprC2MaNgcxzSK4B/iJ70mB9P+C/E/hTXtONv4S1LSb+ztcL5ekyoYYSwLDhDhQcE/nXU+UhAyoPGOnb0r54/Z40jV7f4i+O7q7t9bbTNQ0zRxbXGqaV/Z0TMizrMkUflpgKHUfMC/ua+iqBEX2aIkkxqSSScj1xn+QpWt42GCuVznaTx+X+fWpKKBhRRRQB4j+xx/wAkHt/+xi8Sf+ny/r26vEf2OP8Akg9v/wBjF4k/9Pl/Xt1ABRRRQAUUUUAFFFFABRRRQAV4h8Sv+TpPgj/2DfEf/ouzr2+vEPiV/wAnSfBH/sG+I/8A0XZ0Ae30UUUAFFFFABRRRQAUUUUAFFFFABRRRQB4j+xz/wAm86R/2E9a/wDTrd17dXiP7HP/ACbzpH/YT1r/ANOt3Xt1ABRRRQAUUUUAFFFFABRRRQAUUUUAeJ/tTf8AIF+Hf/Y/+H//AEtSvbK8T/am/wCQL8O/+x/8P/8Apale2UAFFFFABRRRQAUUUUAFFFFAHiMP/J6t1/2T+L/04yVi+IvjB4u8P+KvFt4DoreF/D+vaXpTWP2V/tU0N3HbKWEolwu17gPzHyFK1rws6/tmSE7Nz+AY13crn/iYScAE/jVXR/gjc618WfHuu69Nqlpo9zrOn31rp0N0ptNR+y20HlSSrsLDbLGW2ggEjkGjrcOh5z8TPjZ4k8QfBvVry++yf2P4x8Ja3f6VHZW8iXFmLePeoaUth98J38iPDcVvat+0J4y0WS80BLTSRrmmXOptMixv5f8AZ9vpq3UEn+s4Zmnt1bB6k13V3+y74YvNN1XTZdU1mTT7jTb3TbSB7iL/AIlUN02+Zbc+Xkbj3kLlR8owvFctrfwe1bWviB8UvE1rp11aNd+E28OaVHdTIwu7ho33T4DfICqW6ZfaT+FNWu2wW1jK8RfF7xlp+gS3HiKTTF1Kw0rSPFtsdMWW3EUctwYp7WXMriX5DIPMGByCEyAa+pQoVcDOPrXzzZ/s/tZ/Dmw0me51TVtV1G20nStTl1WWN2tbG3dZpYU2oA4A81cnexaTkkAY+hNz/wB1f++j/hTdugC+WmwpsXaRjbjjHpQ0StgEZx05PFJuf+6v/fR/wo3P/dX/AL6P+FSAvkovQbed3y8ZOc54pWjVsbhkdME8H6+tN3P/AHV/76P+FG5/7q/99H/CgB3lrxlQcdPam+Qm4tg54/iPYkj+Zo3P/dX/AL6P+FG5/wC6v/fR/wAKAHCNQxIGCevNeeftDc/AH4nr0H/CM6n04/5dJDXoO5/7q/8AfR/wrzr9oVwvwG+JaO4JfwzqRO0gED7JIOBzkk9KANv4S/8AJLvCP/YHsv8A0njrrq434TyAfC/wknmKJRo9nuRiMofIQYP0Ndduf+6v/fR/woAkoqPc/wDdX/vo/wCFG5/7q/8AfR/woAkoqPc/91f++j/hRuf+6v8A30f8KAJKKj3P/dX/AL6P+FG5/wC6v/fR/wAKAJKKj3P/AHV/76P+FG5/7q/99H/CgCSio9z/AN1f++j/AIUbn/ur/wB9H/CgCSvEPi1/ych8Bf8Artrn/pvr2vc/91f++j/hXiPxYLn9on4EyYyBNrYVlI2jNhx9c9O3WgD3Kio9z/3V/wC+j/hRuf8Aur/30f8ACgCSio9z/wB1f++j/hRuf+6v/fR/woAkoqPc/wDdX/vo/wCFG5/7q/8AfR/woAkoqPc/91f++j/hRuf+6v8A30f8KAJKKj3P/dX/AL6P+FG5/wC6v/fR/wAKAJK8d/bF/wCTUfjF/wBilqX/AKTSV69uf+6v/fR/wrx39r5yf2U/i3nDq3hTUkZieG/0aQDGM8kkdqAPVtHUDSbHrxBGASST0FXPs8ZOSik53cjuMYP14HPtVLS2ZdNtEKrkQx9z6fSru5/7q/8AfR/woAVoY2ADIpGc8juRj+RNHkptwF28EfLxjPXGOlJuf+6v/fR/wo3P/dX/AL6P+FJ36AAt412gIMKCo9ge304H5UoiUYAHC9B265pNz/3V/wC+j/hRuf8Aur/30f8AChX6gH2dOeMZ64JH4/X3qSo9z/3V/wC+j/hRuf8Aur/30f8ACmBJRUe5/wC6v/fR/wAKNz/3V/76P+FAElFR7n/ur/30f8KNz/3V/wC+j/hQB4r+xx/yQe3/AOxi8Sf+ny/r26vDf2Py6/A21AUhT4g8RHH11u+O7nHGensa9u3P/dX/AL6P+FAElFR7n/ur/wB9H/Cjc/8AdX/vo/4UASUVHuf+6v8A30f8KNz/AN1f++j/AIUASUVHuf8Aur/30f8ACjc/91f++j/hQBJRUe5/7q/99H/Cjc/91f8Avo/4UASV4h8Sv+TpPgj/ANg3xH/6Ls69r3P/AHV/76P+FeI/EfdL+1B8GCvzMmneIV3KQQrGO04I/Pv/AAmgD3Kio9z/AN1f++j/AIUbn/ur/wB9H/CgCSio9z/3V/76P+FG5/7q/wDfR/woAkoqPc/91f8Avo/4Ubn/ALq/99H/AAoAkoqPc/8AdX/vo/4Ubn/ur/30f8KAJKKj3P8A3V/76P8AhRuf+6v/AH0f8KAJKKj3P/dX/vo/4Ubn/ur/AN9H/CgDxX9jn/k3nSP+wnrX/p1u69urw79jtn/4UFpEZXZjUdYcjuVbVbsqecYyuD/wKvbdz/3V/wC+j/hQBJRUe5/7q/8AfR/wo3P/AHV/76P+FAElFR7n/ur/AN9H/Cjc/wDdX/vo/wCFAElFR7n/ALq/99H/AAo3P/dX/vo/4UASUVHuf+6v/fR/wo3P/dX/AL6P+FAElFR7n/ur/wB9H/Cjc/8AdX/vo/4UAeL/ALU3/IF+Hf8A2P8A4f8A/S1K9srw/wDaiZm0r4dKVc/8V/oPygdxdqwHTGOBk5r3CgAooooAKKKKACiiigAoopjNtOSfloA858efs3/C74oa8Nb8WeBNE8QauIxD9tvrRZJdgyQu49uTx71z3/DFfwJ6/wDCqfDGc7i32BcnnPJ7j2r0M/EbwuHI/wCEn0bAwCpvosg43DHzdxT/APhY/hX/AKGfRv8AwPi/+KpXA84/4Yq+BW2Nf+FW+HNsZUr/AKIOCOnem/8ADEvwG3Ow+E/hYF+uNPQd849hnt9PSvSP+FjeFf8AoZ9G/wDA+L/4ql/4WP4V/wChn0b/AMD4v/iqE7jsebL+xP8AAdc4+FPhjkYObFTxx/gPx5p3/DFXwJ/6JV4Z/wDAFa9H/wCFj+Ff+hn0b/wPi/8AiqP+Fj+Ff+hn0b/wPi/+KpiPOP8Ahir4E/8ARKvDP/gCtH/DFXwJ/wCiVeGf/AFa9H/4WP4V/wChn0b/AMD4v/iqP+Fj+Ff+hn0b/wAD4v8A4qgDzj/hir4E/wDRKvDP/gCtH/DFXwJ/6JV4Z/8AAFa9H/4WP4V/6GfRv/A+L/4qj/hY/hX/AKGfRv8AwPi/+KoA84/4Yq+BP/RKvDP/AIArR/wxV8Cf+iVeGf8AwBWvR/8AhY/hX/oZ9G/8D4v/AIqj/hY/hX/oZ9G/8D4v/iqAPOP+GKvgT/0Srwz/AOAK05f2LfgUpBHwq8MYxt2/YFwRgjBHQjk8GvRf+Fj+Ff8AoZ9G/wDA+L/4qom+JPhcfN/wlGilcZG2/iO4A8kfN68UAefD9iv4FLGY1+FXhlE5+VLBV9PT6Ck/4Yq+BP8A0Srwz/4ArXo//Cx/Cv8A0M+jf+B8X/xVJ/wsbwr/ANDPo3/gfF/8VQI85/4Yq+BP/RKvDP8A4ArR/wAMVfAn/olXhn/wBWvR/wDhY/hX/oZ9G/8AA+L/AOKpP+FjeFf+hn0f/wAD4v8A4qlcex5z/wAMVfAn/olXhn/wBWj/AIYq+BP/AESrwz/4ArXo/wDwsfwr/wBDPo3/AIHxf/FUf8LH8K/9DPo3/gfF/wDFUAecf8MVfAn/AKJV4Z/8AVo/4Yq+BP8A0Srwz/4ArXo//Cx/Cv8A0M+jf+B8X/xVH/Cx/Cv/AEM+jf8AgfF/8VTA84/4Yq+BP/RKvDP/AIArR/wxV8Cf+iVeGf8AwBWvR/8AhY/hX/oZ9G/8D4v/AIqmH4j+FuP+Kn0f/wAD4v8A4qgTdlc87/4Yq+BP/RKvDP8A4ArR/wAMVfAn/olXhn/wBWvRv+FjeFv+hn0b/wAD4v8A4ql/4WP4V/6GfRv/AAPi/wDiqBnnH/DFXwJ/6JV4Z/8AAFaB+xV8CA+8/Cnwuz5Lb2sFZsnrya9H/wCFj+Ff+hn0b/wPi/8AiqZ/wsjwt5eP+Eo0XfnGft8WM/8AfXTPFK4Hnf8AwxV8Cf8AolXhn/wBWj/hir4E/wDRKvDP/gCtej/8LH8K/wDQz6N/4Hxf/FUn/CxvCv8A0M+jf+B8X/xVMDzn/hir4E/9Eq8M/wDgCtH/AAxV8Cf+iVeGf/AFa9G/4WN4V/6GfRv/AAPi/wDiqX/hY/hX/oZ9G/8AA+L/AOKoA84/4Yq+BP8A0Srwz/4ArR/wxV8Cf+iVeGf/AABWvR/+Fj+Ff+hn0b/wPi/+Ko/4WP4V/wChn0b/AMD4v/iqAPOP+GKvgT/0Srwz/wCAK0f8MVfAn/olXhn/AMAVr0f/AIWP4V/6GfRv/A+L/wCKo/4WP4V/6GfRv/A+L/4qk3YDzj/hir4E/wDRKvDP/gCtH/DFXwJ/6JV4Z/8AAFa9H/4WP4V/6GfRv/A+L/4qj/hY/hX/AKGfRv8AwPi/+KoTuB5x/wAMVfAn/olXhn/wBWg/sV/Ag/8ANKPC+c5JGnoC2QQQx7jk8HivR/8AhY/hX/oZ9G/8D4v/AIqov+FleF2Kr/wk+i784IF/FjIwWGd3oy0wPPo/2K/gVHs2/CrwyNihV/0FeAOlJ/wxV8Cf+iVeGf8AwBWvR/8AhY/hX/oZ9G/8D4v/AIqj/hY/hX/oZ9G/8D4v/iqAPOP+GKvgT/0Srwz/AOAK0f8ADFXwJ/6JV4Z/8AVr0f8A4WP4V/6GfRv/AAPi/wDiqT/hY/hXj/ip9H/8D4v/AIqgT0Vzzn/hir4E/wDRKvDP/gCtH/DFXwJ/6JV4Z/8AAFa9G/4WP4W/6GfRv/A+L/4ql/4WP4V/6GfRv/A+L/4qgfkecf8ADFXwJ/6JV4Z/8AVo/wCGKvgT/wBEq8M/+AK16P8A8LH8K/8AQz6N/wCB8X/xVH/Cx/Cv/Qz6N/4Hxf8AxVAHnH/DFXwJ/wCiVeGf/AFaP+GKvgT/ANEq8M/+AK16P/wsfwr/ANDPo3/gfF/8VR/wsfwr/wBDPo3/AIHxf/FUAecf8MVfAn/olXhn/wAAVo/4Yq+BP/RKvDP/AIArXo//AAsfwr/0M+jf+B8X/wAVSH4jeFv+hn0f/wAD4v8A4qgT01POm/Yr+BLKiN8KfDDImSqNYKVGevHTn+fNJ/wxV8Cf+iVeGf8AwBWvQV+JHhjcf+Kp0Xdx8rX8WMZJz97rjP8A3zUn/Cx/C2f+Rn0fH/X/ABf/ABVK4X0uedf8MVfAn/olXhn/AMAVo/4Yq+BP/RKvDP8A4ArXov8Awsfwtu/5GfR8f9f8X/xVO/4WP4V/6GfRv/A+L/4qmFzzj/hir4E/9Eq8M/8AgCtH/DFXwJ/6JV4Z/wDAFa9H/wCFj+Ff+hn0b/wPi/8AiqP+Fj+Ff+hn0b/wPi/+KoGecf8ADFXwJ/6JV4Z/8AVo/wCGKvgT/wBEq8M/+AK16P8A8LH8K/8AQz6N/wCB8X/xVH/Cx/Cv/Qz6N/4Hxf8AxVAHnH/DFXwJ/wCiVeGf/AFaP+GKvgT/ANEq8M/+AK16P/wsfwr/ANDPo3/gfF/8VR/wsfwr/wBDPo3/AIHxf/FUm7Aecf8ADFXwJ/6JV4Z/8AVob9ir4EOpVvhT4XIOR/x4LxkEHHpkHnFej/8ACx/Cv/Qz6N/4Hxf/ABVRj4keFzkf8JTorYyTtv4uAen8VCdweh55/wAMVfAn/olXhn/wBWj/AIYq+BP/AESrwz/4ArXo3/CxvCv/AEM+jf8AgfF/8VS/8LH8K/8AQz6N/wCB8X/xVMVzzj/hir4E/wDRKvDP/gCtH/DFXwJ/6JV4Z/8AAFa9H/4WP4V/6GfRv/A+L/4qj/hY/hX/AKGfRv8AwPi/+KoGecf8MVfAn/olXhn/AMAVo/4Yq+BP/RKvDP8A4ArXo/8Awsfwr/0M+jf+B8X/AMVR/wALH8K/9DPo3/gfF/8AFUAecf8ADFXwJ/6JV4Z/8AVo/wCGKvgT/wBEq8M/+AK16P8A8LH8K/8AQz6N/wCB8X/xVH/Cx/Cv/Qz6N/4Hxf8AxVAHnH/DFXwJ/wCiVeGf/AFaP+GKvgT/ANEq8M/+AK16P/wsfwr/ANDPo3/gfF/8VR/wsfwr/wBDPo3/AIHxf/FUAecf8MVfAn/olXhn/wAAVo/4Yq+BP/RKvDP/AIArXo//AAsfwr/0M+jf+B8X/wAVR/wsfwr/ANDPo3/gfF/8VQB5uv7FHwHUIB8KPC+xPup/Z6FR07dO1L/wxV8Cf+iVeGf/AABWvQl+JHhhGff4p0Ux8kML6LIB6Z+b/e/IVL/wsfwr/wBDPo3/AIHxf/FUAecf8MVfAn/olXhn/wAAVo/4Yq+BP/RKvDP/AIArXo//AAsfwr/0M+jf+B8X/wAVR/wsfwr/ANDPo3/gfF/8VQB5x/wxV8Cf+iVeGf8AwBWj/hir4E/9Eq8M/wDgCtej/wDCx/Cv/Qz6N/4Hxf8AxVH/AAsfwr/0M+jf+B8X/wAVQB5x/wAMVfAn/olXhn/wBWj/AIYq+BP/AESrwz/4ArXo/wDwsfwr/wBDPo3/AIHxf/FUf8LH8K/9DPo3/gfF/wDFUAecf8MVfAn/AKJV4Z/8AVo/4Yq+BP8A0Srwz/4ArXo//Cx/Cv8A0M+jf+B8X/xVH/Cx/Cv/AEM+jf8AgfF/8VQB5x/wxV8Cf+iVeGf/AABWj/hir4E/9Eq8M/8AgCtej/8ACx/Cv/Qz6N/4Hxf/ABVH/Cx/Cv8A0M+jf+B8X/xVAHDaH+yL8GPDOuadrOlfDXw7p2q6fcJd2t5b2apLHKhyj7hySD0zmvXa5lviN4VDAHxToy7fvH7dDz/49W7a3Ud7awXFvMs1vMgkjlQghlIyrA+mKALNFFFABRRRQAUUUUAFUtQkKWM5BwVidh9QOKu1R1L/AI8Ln/rjJ/Kl1uI+bvhL4H+Hnhr9kfwV4u1LwN4fvxY+B7HVro/2TbvNPs09JHyShJY88+9ZP/CxPhnpdvPJ4k+Ctj4duGs7TUbO1uNN02Q3VvPcJBuRoyw+RpIy2T/HW1oymH/gnvpQTzAW+GUAjUD5jjSUAXjPJNfPOpalYXdi8fhrxzcfE63m8L6ZFqNxcXEF0NGdNQs9lujwKiLu3ysyFWc+SMtU043qSTKl8MWuv/APttPhX8MpLjyF8HeEmuvL3/Z/7Mtd2MZBxsz079KYPhj8L2XzB4O8KlI5DHIY9It3VGB2kMwTC8+uOlfJ2pRSL4k+waUIn+M3/CT6xJyg+2/2YYrhYWwRn7Pg2uD9zk+9c/eR+HrhtGHhaKM6Fa6bYw+PYUjJXcJ8f6YABvkU/M+7+VXK0RyTitf66H1p4F8O/Czx9feIYdP+H3h5YtHvmsZJZNGtSkrL1eNlUgrW+vwt+F8kM0kfhLwhILc7Z9um2rCM+hwnBzxzivLv2ZZtCh0P4pXPhi2jl8PDXLuW2h01QEmiCZUQspHBOccd6+UNQk0LWNSv/sK6V5et6J5F5o+jWZiEVx9sj/czOWZpph87MxJIB4XGKtRu7GcnyJtn6Bf8Ks+GP2OS6/4Q3wj9kRtpuf7MtfL64+9sxnPGM9a5r4Y+H/hj8UfCcmvWHw78OW1st9d2IE2k2p3G3uHgZuE6EoTXz3r2h+HPC/j/AFG21azstP8AhbZ+MN2o2tzAF09Y5NJIiJGBGi+aUJDYG7nrXuP7GaW0fwPgFlGqWf8AbWsSQcMAIjqE5TlgGOUYHJFUorlbNGrHpH/Ck/h3/wBCF4Z/8E9v/wDEUf8ACk/h3/0IXhn/AME9v/8AEV2tFYp3JOK/4Un8O/8AoQvDP/gnt/8A4ij/AIUn8O/+hC8M/wDgnt//AIiu1opgcV/wpP4d/wDQheGf/BPb/wDxFeV/Hz4O+AtO0jwm9r4I8O27P4t0OBjHpMC5jfUEDrwnQgnP1r6JryX9on/kC+EP+xy0D/04RUAV9U8J/DLSfiJofhOT4d6C93q9rcXMU39i23loINu7J2d94rbm+FPwzhvILd/BvhSO4n/1du2l2gcgdSAVyfQ4zXnHxr+JHh34Z/tAfDfV/E+s22haX/ZeqW5u764CxEt5O3PPGdhrxf4gXNl44+Olxq6eKtPMeoXmgSeEng0cXuo39mskbyPp9yZ49iLL5gldUfCHLBuKmPvNMpr3Wz6b8WeCPhh4V8Larr0ngfwvdW2n21xdGGDSLUvIIEd5EHy9fkIx2I5qTQ/Afww1vQ7TVE8EeGIYbi2S4Kz6PaqYQy5UP8o259/zr4+8Q61Zt4bbwsLqSXxBYa343ub/AE9QfPjiljv3iEoAygdXidQwAOOcjK1b0Ga80TwS2leP3t7/AFGa50nVNSvdzeTd6G42LGynJ8qKT5HUcfxE4q42cmvQU7JW6o+w2+Gfwvjtknbwf4Q8uQfunbTbVEkPsSvftyakf4U/DSGRYp/BvhGCWVS8SHTLbeyjqQDGOn0NfFLSeAY/H0UmswWh+HtxHrR8PK8W6zTIQB7ZSNpyxPl4K4/h3UzUfDmu3PiS1i8V69p+manJp+mSaDb3WjLeavOo+8lpK1xH5JH8fytUwXNr3/zsRzK7j2/4H+Z9pyfDH4cGK6Fp4D8K39zBE0ggj0y13sQOEI2/KScckYGag0r4d/DnUbCykn8AeFdOu7mGOb7HPplmzpu/gO0EEjuQSPSvkzS/CdjpVt4V1K302OHW7++8R299fLGPPkiWOTbvfOWUNsKg8cfWuSh1iwhb4d3U66Z4f1/TZ/C6xx3Fu0mqXtv+78yZZ2dTDCPn3KFG7PLHit40+bS+rLkuWPN/XY+r/iDefB74b/ErwH4N1fwDoKXvjK5ntbO4XRbYwwvGilQ58vjeWCr/ALXFYz+JfhjeEWmjfCHS9a119T1LToNIg0ywjkn+wyLFPJvkwioGdeS1J+0t4Hk+IPxT8G6VaOItTk0XWGsrgknyLpBBJbyYxwVdCRz2rxv9nv4iW9j4g0T4qeLY/wDhEtB1G+8UafeXGobUjs7ue+gmSKViw2FhDN3YfIOaiFnON+z/AOANr3Wj2G68WfDC7s9Hfw38H9P8TX99aT30mn22kWMUttDDL5UxfzAuGST5cV6h4V+HPw08X+GdN1u08B+HI7W9gSdBNoUEbgHsVKZBr5k09dD8P6LpmpeKNb1P4darqU+r6voPiy1uhErxXd68sdk8MoKyM8ZhfYy5JY4K19MfBX4gXfivwnoNr4mC2vjP+zIb26sfJMbKrllSQqem4oeM4qIp+8n0Mtb3Zv8A/Ck/h3/0IXhn/wAE9v8A/EV5XJ8HvAS/tOW9kPBHhz7G3hGSYwf2Tb7PMF6mGxs68nmvofNeSzZ/4aptcdf+EMl/9LY6j4dS7nN6s3wo0W28eTS/DjQ54/B0Cz3xj0ezzKGR2AQY44XvXY6b8OfhjqEdmf8AhCfCaSXMCTpbnTLXzfnG5Rt2enfPavnH4vfDm98Tap+0FqieJ9e0eOy020b7HpksK294ogkLJN5kbs3Hy9VP481xHjLWLBviRpV5DJpvh3xNpGv6TGsXkNLql1CYIx58lwzhltw0nleWoCsy9Qflq/tOJP2ebza+4+y0+GHwvmlcQ+D/AAq/l5EgGkWxER9Xwny46YOKdD8LPhlNMsUfg/wfLKxZUjGm2uWwc8YQ8gen6V8FaToLz/CPxbNJq0Opa4ngy4s/EOlaXoP2Ro75ru3EiajMLhjJdCTztg8sEoXO75Vx6jq3gHQ/D/jzxNPpOk21mdM+IGgw6TJbQqgt4ZrW3acRAHCq7SSCTH3sHOapq39edhRd032PqRvhX8MlkkVvCHhAPGB50f8AZlr+5Hcn5PyyBWfrXgn4V6Ho+o38ngvwlcvaRSyi1t9NtWlkCBjtA2feO018ea1/Z83hLUrfTbdJPiJBoviI+MZCp8+EtH8q3LdCWbmPJBHbFdtpvwf8Jad4y1DytEtdlj8NI7mB2XcDKfNy/JO5/mPzH16UlrFyNEr28z6H8HeC/hd4w8J6drtt4I8LxwXVqlw8c2l2heDcu4eYQuB0x2rWX4YfC/7DHenwf4PFpIfluP7NtfLwT8vzbMcj3r40u/D+leAYtNS18OabbWF14Ss21SO5R0tgTd4N1dIrIZkA528jH8VUfAd14UtFitPE2paTqPgGz8S6m7yLaJa6Y8klput9kGNgiY8puPzfw5q+Tz/rYl6f18z7Zk+Ffwxt2gWfwf4UheUhUjk0m13MfQYXk9vlzWl/wpP4d/8AQheGf/BPb/8AxFfnboOgi+0XTLe71+x0S1uNHjh8MQSaOL3Up2F/OJTpzvcRhJVCxnOwnA+uf0r8P+JbXXm1C3tbtbq502b7JebYynlzeWr7efZ1/OpasCdzG/4Un8O/+hC8M/8Agnt//iK8s/aT+DvgLTfhX59r4I8OW0/9vaGvmRaTArYfVrNXGQndSQfY19EV5N+1B/ySP/uYNA/9PFnUjMb4saH8PPhXoWn35+Feh69c6hqEWm2thZaXZRyySPuwcyBVx8tN8AaZ8L/GljqBufhxoPh7UNNujZXthqmk2Sywyg5AyoKsHX7pFH7Vdrqd94V8H2ukahHpupTeKLFYbua2+0pCf3nzeUGQuR/d3D618/ftF/D2y8F2N9aeJtT0u91/XbW91STX9V0xmWecDC2dnbmXYsmPulmdh2AoHa59XP8AC34YQzeS/g/wn57f6uB9Itkkk/3QU+bPbApJPhb8MFmlgPg/wqkkbbJP+JVaboifu7ht4z2yK+L7fSdN1/QvFfiRYIb3WrKz8NGx1SSPzLiKUR/OYzgFdrckDg9810+j+FfC3i7wdr/hubQzc/FuFtWur/ULePE1ifNk8k3HzBn3JsCZD4xxinODikzO/MrI+iPEej/CDwr4i0LRdQ8H+FYr/Wr1rC1jXSLdv3ogkmwfkGPlj9OrAda6GH4W/DKZ5tng3wm5iO2RF0m2/dnOMMdnynH8JwecV8daRFo/ixfhf8T9d0izgvvE3iy6uvtWp2schgH9nz28ADvyivcQqwz1LbhtPNcV4sXQ5/h1pEGmLHJf2nhuOD4hCIFWbUTq+ljF4FyWnLC6bDMG2D72Kvl6GtuZn31/wq74X/Zxcf8ACJeEfsq8tN/ZVrt64xu24zn29utI3ws+GMJj83wh4Tj8zDIDpdrlgTxj5OhIIGM57V8f+MLDSrya+vfDuoeH9H+DbeMYik99pv2zQt39l4dvJDxx+Sbj5fv483n73FZVr4BsLjSPEtzqML6w2m+Bbe50m71HT0g+z/6fcujRRGSQJsTYAQ+4Y4HNSot3Jl7qufZFn8O/h7JNqgv/AIeeFtJt7ObyYri506z23B27twwDtGP4TzW3H8Gfh1KAU8C+F3UjchTSLchh9dlfF3jq4s5PEHiTTfEVlpsdrqOpuRrmuW5uoIZlsUZI44jIA8sjEhWYHPZWr6v/AGW9R/tL4EeESt21462QjeV2ywYZ4OST+ZpJXTfYz51p5nUf8KT+Hf8A0IXhn/wT2/8A8RTf+FJ/Dz/oQ/DP/gnt/wD4iu1JO2kqfMp9j5n+Cfw5+H2n/BXVdav/AAN4euzp+ueJHZpNKgZikWr3yhclOgUYA7AYo+GOu/Drx9rmnabqXwd0jwrLq2j/ANu6S2oWFhKt9aDy9zqYg23b50ed39+tn4YxSt+zb4sSNDcStqXitVjUffZtXv8AFfKmlzG98GaI3g/xbqXj2dfAUVnrefKmfQbdJLFpbeM28aFS6eepUlpD5QO/NKjrKd+n/BJqacqXX/gH3Efhn8L2tVn/AOER8HiFmYicaba+XhTlhu24yFBzz2NPk+F3wwht4JZfB/hSBJmRY3k0i2VXLdFBKYyenGa+SjoPhLxj8QdBh8MaXaap8LrvxpaLbW1vGTp80i6VOLhohzHIm4RqQuVZxgg5OeEvdFaSH+z9W1zTfDugRWOo6bokV9o51JjcrfyAxWK+fDtnA2EffOB9avlt8y/I+9bz4R/DfT41mufBfhOCFsfNLpNsq57KGKgHNNh+FPwzum8uLwb4TeRlDhU0m2Lbf723YTg9q8x+PWgx6x4R+Eem6rbSarE3iDTo54NQhBab5CSXUNjI4yv6+vi2g+G7PwdceG9U0vQY2unvPEFlJbw/I89uiZjti4bcsZP3QCAO2KfLqo9xn1lH8L/hfMksieE/B7xQkLJIumWuxWztKs2whTk9DzTo/hj8LpZBHH4Q8IO2C5LaZajKgZJA2dh19O9fB+l2Ohaxb+INJsJtJlstYh0Ge4sdDszbQJILvMylgxLNEfkdyS2OWK16t4k+Fuj6TB8fr3RdBtbN7HUrGBPssbJ5Vh5EDXgQAfLmNpclOWJ5J4xP2VLuNK59NQ/C34ZXCo0Pg3wjMr7ihXTLZlcDrgiPGQeuM4HJp1v8J/hncrGYPCXhKfzIjJHt0m1feufvDavzAdOPWvjTxtfWfhvTfEvj74ZQJP4S0jxMlrpCaYgNqzXmmPZzNb7BhYjcy2uSuMlZB15r0v8AZD8F3Hhv4meIfDM8ZktPhzaf2FYTOHHnLc3MtzvDMMPtga25H97FOwNNH0h/wpT4d/8AQheGf/BPb/8AxFeWfHD4O+ArO8+G62/gjw7AJ/F1pbyiLSoF3xmKZipwnIyi/lX0RivJvjx/x/fDD/sdLL/0RcUhLzKt74V+GVn8RLXwi3w78Pi5udPbUkvP7Gtmi2K+0rgJnNU/AOk/Crx54UtNei8DeFdOt7qWaOKC90y0ErbJGToqnnK9Bk1zPxi8CTePv2ifDcEOva14aFv4duw95oMsKS/6zhMzROnP0r5c8QJaQ/BvRNH1D7BbX1no2ozafqetIbi8u5heSbYbZN6xQz/xMyKZB2FaRs73Gfeknwm+Gq3X2ZvBnhNLny9/knS7XdgHLHb5ecAd8YqFfhv8Km5/4RLweU3BNy6daY3E7cfd9e3X0zXx5bWNz4k+Kk9zea/ZRa3caxpt7pdrp+jC41O7sDaxsri8a4jC2hPmB/kYDPX0zLH4Z6F/wgGmM2iWZuX+E2r3kw+zHLXccsTQT9eJEPmbGHzrn5cVDTT/AK7XF1t6fi0v1Ptub4U/DOK6jtG8H+E0u5E81IZNLtFZ1HXC7c49SARXNfDvQ/hX8RPDI1m38AeHLGMyToYLrSrRZAkUzRNLjbwm5G5NfOmr+XN4ivU1JYpPidda34Xm8KuRuvBpfl2fntC33lhDi+Mm0Y45XgYwNS02+0rwX4L+xWCN/wAJpdan4OuDECGJl1YyrIcgceV9qP0A9sVKLj/Xkn+pm23Zn2DqPw3+HNlZXj2/gbwrqF5bW7XDWcWm2YdsLuCD5eMjoSMe9Taf8Nfhle29qH8GeE7W7miSY28umWbOFK7j91cEY/iXivjHxVYaN4e8QeOdM0mK31jVpLLWklhkha11zTIvI2hZ25821Y/6s4UDsBXSfDWTT9L+MHhSVEXVdfubi2ZrK6tzb6taReRseSFwWMlnn1AHvSUbmz2PsP8A4Un8O/8AoQvDP/gnt/8A4ij/AIUn8O/+hC8M/wDgnt//AIiu0GaWpJOK/wCFJ/Dv/oQvDP8A4J7f/wCIo/4Un8O/+hC8M/8Agnt//iK7WigD53+FPwg8B3XxK+NUM3gnw7LDb+J7SKGN9KgZY0OiaaxVQU4G5mbA7sT3Nep/8KT+Hf8A0IXhn/wT2/8A8RXNfCL/AJKj8cv+xrsv/TFpdetUAcV/wpP4d/8AQheGf/BPb/8AxFH/AApP4d/9CF4Z/wDBPb//ABFdrRQBxX/Ck/h3/wBCF4Z/8E9v/wDEUf8ACk/h3/0IXhn/AME9v/8AEV2tFAHFf8KT+Hf/AEIXhn/wT2//AMRR/wAKT+Hf/QheGf8AwT2//wARXa0UAcV/wpP4d/8AQheGf/BPb/8AxFH/AApP4d/9CF4Z/wDBPb//ABFdrRQBxX/Ck/h3/wBCF4Z/8E9v/wDEUf8ACk/h3/0IXhn/AME9v/8AEV2tFAHmviT4J/DxfDeqSDwH4ZDpbSSKw0i34YISD9z1p37O48z9n34ZM5Z2fwvpgZmYkn/RI+/rz1rsvEv/ACK+rf8AXnL/AOizXHfs6/8AJvfwv/7FjTP/AEkjoA9HooooAKKKKACiiigAqjqX/Hjc/wDXGT+VXqo6l/x43P8A1xk/lS8gPG/gz4ktPA/7HXgHXLuGSWy03wJp9/NDDGu544rCN3ULjHIFer6LqkOtaXbX8Q/c3UMd0sUwAZAyhhz04/mOteAaMuP+CeekA+awHwuh/wBUTvBGkoAoxySTXi1robL8SIfAItytg+np8Q0k8lvKjQ6ULMr/AL/2gNJ65OamNnKf9dwaiowt1f8Al+rPvfHlsQN2MAdew7depz1qFmCquf3Qc5ZSoByQWx1xkDOeua/OyL4ZeFbTwrcXEWjwLcr8ONO1kAxAkX5kfN1gn/XhQB5v3q6DxN/wjl38TPHreZaD4l/b9Bk8PzJzfZMEBl+zc+ZgqZdwQYOec4GNZU9LLf8A4NjPm5r+i/FJn2l8PfHdn8RfDcWs6bb3MNs0skKxXiBJCyMVY8EjHHBBwfWpvF3jTTfA9nb32rSFI57mK0hdUMh82U7EXAyQCcEnGMZyBXwlo+k6V4H0Pwj4ls9IeW+1KPW4dUa1d4J9SjByscrowYop6LnHtXPQaP4HutG8ZWV6vhHVvDlrqmganGNLskTT4RI22eRUcyApj/WybsnuM1XJeX9dzey1b2P0a0XWG1SO8klsr7TvIuXiAvlT96q4PmoFdso2PlJ54PArVMe3YeW52r1B5znn/wDV9a+DrGPwS+rIPGdppc/wtTXdaK2UgjbTlnEMZgYDPljC+Ysf19ea9k+OVvoer/s2eHUaeXwr4elk0x0XxNbSXUUcIw62+qK0oPkbcLJl2xms7csfu/Ixhe1nufRrXLqu4sDt+c7cAFcdT1wM5PXOB3qlr2vW/hrQ7/VtSuvs1lZwPdStsyVReScAZIx2AJ9zX573UIi8OeFrbw/ob2mlePpr7wHJFZTPNZsi6issctq/y4tRAb9osjaqkKGChQL+r+FvDS+LvH2irY6b4nvry28QJPH9mKaxa7EcqmoQEv51qCP9HbC9U2hsnNOPLFPuWffOi+IYfEmi2eq2D+ZZXarNE7IVPllc8qRnOeNvB+laD3G12VSWfAYrx8o9eeo496/N4aTod7f6Cmnaz4Z0KyttN0p/DcVpobXeoM+6M3IsPLuYYo5TNvWYgMcH5+K3dB+FvhrWtW8Oz6rolrdS6tqXiBNUNxEGFykaZHnAnDqD91WyPahRuTza2P0GWYyLlWViRvXachh9a8s/aJ/5Avg//sctA/8AThFU37N9xLcfA/wm8kk0khtSm6Yl3UB2GCeCeAKg/aI/5AvhD/sctA/9OEVJ6BGV9Rnxj+PA+DMVjeXPgnxT4lsbySCFLvQxZtGk0rrHDEUnuY3BZnA4X8a0PA/xah8ceKLzw9N4f1rw7rWn6Za6ncWepG3BWO4kmjTJgmkViDAx+ViMMOc1zf7VUnmfDfTEiDMyeJtDG2N9nTUYCf4TwApb8K8O/aS8KaTqvxE+Mmu3Vkl1qmi+EdCvNMvtgZ7S4F3fMJYDn5ZMIg3LggHHQ0qdlBFyjzJ/11SPtPOSdse8DOOgBB59AM8nH8xSsxUgAKGYknZ29W6dT05NfDcvgvQIfDPizxBq2mxyade/Ei5sPE11dZdDpguZBsYk/Jb+Z5e8EAEZyMVxt14a8PeJLzxJGthZ3ngvTdA8SXXhxt+63jiin3wvbk8BEb/VvjC9FIFR8T5Y7tfpf9TPSL5ujf62/Q+z/iY3hvwX4i0Xx7rBv3vbM/2Naw2pR48TyDLMh9Co5ByAOlemtt+8V5UZzznHX/Ir88fF2h+HfDPhTXLD7AlroN/YaBqOqwxN5Ykcy5uJmHO6Vl+85+Zu5Nbps/CS619nvF0eH4Df25cDCkf2TuFt8gzjy9ol56Y7dOK1ilKHMu/+X63Mou87eV/vv/wD7qEaxrFlg5X5RjAzx0+ueuMZrL8SeJrLwf4c1bXNUlK6fp8LTTtCrSbUXkkIoJz7DmvhjwfL4UVrI/Fixm1yy/svb4QtWd/t8v8ApUi7bX5lcTbRGcxuDgdaq654LtPE0vxK8Gahokd5p3gHSNXntbLUIBMzNepHLC6hgfnVRMoPX5RUzvGMrdr/AJHTFNzUX3X9feff1nqlvqlja3cJZobmFZY2ZSrYYcYBwV49h+FWnkTdESvJI2gHGBnBJ+m7pnntX58eG/8AhFvtED6DHosPjkeIvD0fhFtNEW5NJH2P7ULZYzzbn/TfN2Eg/wASrgYwLFrKH4cC8+GF3BB4/wDsvihfFUumK7XnkefMIhdBGV8hkXyjgFsfu8Vc4ODfk7fgv8zJN2TfVH6T7VXCr8y8R7S3A4JPGOuD0rn5IbSz8cJcDS7pru7slhm1LINvHGkjFI2DSZBLO2NqHr16V8N+H/CWg6lZ6TptrqHhjXvCd74r0tTY+GtHfTdFLG0nMqRBrqfzGYrGJeAjY+YHJpPD99aeD7vWrOPSpbrStNt/ElpBpcDNCiRLfbURCjArEi88EY7YrOK11K3Vz9BxcfKDuBBOwMvzZb3A6fnXls7f8ZU2p/6kyX/0tjryP9iJ9L0/xB8RtL0jU9CntFuLK5htPDlqLWwTzIdzmCPzJGKbuMljXrs2P+GqrUY4/wCENl/9LY60lFRYK+q7Fjxp8ePD3gP4oeEvA2pQXbaz4mDfZZoIlMMYTP8ArW3ZGScD1Jr0RzGqqxLqqtwpJAzjqT+uelfD3xovfFXibxr8QfG+iaHpmpaN4SvNOto9QuNWeCe3azkE84hhFu63AfO07nWn6HZ6TD420vxtY6aX16++I1zAmoW5IuHtH0/Pkl92RHnjHTNZ7KMev/BRfK+e3Rr8Um2fbysGUfKwbJG1SAQTyfxwc/TNI0fmLv8ALbk42nrknqfofTOBX5fTX0M9nqdz4Sl8P6GniHQLW71fS7G3kl+xxDWLT7UNRkMvm3k0UM8omLMhWMHG2vT/AAn4A8Oa7qvhLRru98P+KfCDeK9QlgstK0b7DoaqNLGBaxG5mWSAuGG7cBv3/LwKq3NFP+t7GOy/rtc+5ta1ZtE0u6ul0+61NreIyC1sVTzZtvZAzKo9tzDp3q3azC6ijmETx+ZGCBIAG6ZCnBxxk+3vX526JpNloXw40q8sLdra71fwDcTapeKn764aKdBF5pJyzqhIXPK9sGtvXtb0Zvjn4W1oDw/ous2viO10+5E0byaxdW4g2tPLM0p2WxP3YlUKe5pxhd8t97/mx68/L2P0B+zx7cbQVIxg88elcZ8RPhwnxGtbOFfE2u+GLu1Z2jutCuIlcq6bGDpNHLHICpI+dDjtiuk0LxFY+JNJh1HTLhb2yl+5ND8wNaflqeCMjGMdsVFnGTRoc94L8K6f4G8MWWh6WWFlYps3S8ueSST6k56960tL8Pafo11qNzZwGKbUJ/tV03mM3mSbFj3YJIHyoo4wOPrWhsXOcc06mAV5N+1B/wAkj/7mDQP/AE8Wdes15N+1B/ySP/uYNA/9PFnQB6t5K4wckZJwWJ6/056UnkINwA27uu0kE+9SUUAMaNWGCMj0PSsDxZ4fXxJ4f1DTF1W60ZrqIxPeWJh8+FSO3mo6/iVOO1dFTQiqMAAD2qZXasBzngvwlp3gfwjpvh7TMrpumQiCMSD5toz19ScnJPJ5PJqp8Qvh/Z/ErwvNoWqT3C2U0ttOxgIR90M6TDqD1Majp0z6muv2g84GaZ5KZzjB9jih3vdDG+TGQFK5GMc88UeWgIUL3z+PWpdopNgznHNPUREkMaMMLyOnJ4z/APqp4hXk5PXP3jTtozmloFZBTRzTqRaPIZ5F+zSyH4SzMw2qniLxFuB54Gs31d34c8V6B4u08Xugaxput2W9rdp9PnSaIup/eR5Qn515yvUd68r+DsdzffAPX7azvLrTbp9a8Tqt5bJE01u/9sX3IEilCQexUivmrwD8Q/G/w6+C/wAM4vD3i3WL6HS/D/h24v7L+yNO+xQpezxqBczuqyyKySYiSFUcbSXlc5NOCTlJre6X5/5FOOiufdMPjDw9c3iWkOsWDXU0k8UdtHdx+a0sOPPULn78e4b8fdz82K6DyULbsHPrk8dOB7cDivhH4ifErX7bUL3xFBPHbaxoV54wFhKtpChXyY4jGSpTDsCo+ZgSe5Nd58QPjJ8Qre8vrHRtf/s2T7FobxXUljBMsTXT4lk2lMkkdjwOwFEVeCn3VyZrks31PrL7OnHGMcjB6cY49KTyItwOxcglgccgnqRXyJpvxY+K9v8AFQaebjXNU0XSdah0O7uLmHRrbTboMgLSPIXSf7QSRtSFSvPSvr/FDTspCTuM8lFUD5sD/aP6+tJ9nj2/d756nPXP+fyqSlqLMZEYV2qu0YHTHb6elKsKR/dXb2447AfyAqSiqdwEryf48n/Tfhh/2Oll/wCiLivWa8m+PP8Ax+/DD/sdLL/0RcUK/UWp6r5aZzjnGM556560n2eP5ht4bqMnHOc8fiak2ilqhkYhjUsQgBb73HWmLDGjYC46/ryanpuwdaQiuLZOVIJB65YnPsfbnpXG+IvhvZ+KvF3h/W9U1PUGTRZTcWelZi+ytcbGTzyNnmF9rsNu/bznbnmu72imiNVOeemPvGgENWJEzjPJz940fZ49xbaM5z+I7/X3qTFLTGFFFFTqAUUUUwPJfhF/yVH45f8AY12X/pi0uvWq8l+EX/JUfjl/2Ndl/wCmLS69aoAKKKKACiiigAooooAKKKKACiiigDJ8S/8AIr6t/wBecv8A6LNcd+zr/wAm9/C//sWNM/8ASSOux8S/8ivq3/XnL/6LNcd+zr/yb38L/wDsWNM/9JI6APR6KKKACiiigAooooASqOp/8eNx/wBcZP5VeqjqX/Hhc/8AXGT+VAbannP7NEMc37MvwphlRZI5PCGkoyOMhgbKLIIPUVnww+E/DPxm1nU9S8S3N74kubKysYtNuYlEVnazSSCKNRHGDseSOU7nzjOCeBXK+F/F2p+Bv2BNB8R6LH5msaT8NrW9sw6AgzR6YjJwQc/MBwRzXi88t94D+NV3NpPi/V9XlurbwfFPezXjzvIk17e+bEW5O2TccL0GfYUJaNoUly0nN9NfyPuloI9u3yYwGTy3yONozgdOeprk/Dnw30rw74x8T+JYZXvL7XpYZ5Y7jbshKRCNQnGVyAOtfIlz8UvGfhFtSe48T61canriuba+S5a40y4g+3xwm4tuD9nMccnQKQduSDW3Hq/ieT45Wfw5tfHHiZtAtdXd2ulu3NxNG1okzQNNglwJCeQcjOM44p2dr9wjDddnb8j621jXtD0PUdGsNQuLa1vdSkaGwt2U/vZAu5lQ4wOOvrWnHZ2sZI8iCMyLt8soAWXqQR35r4S8VeItftz4Y8btr+p3evte6uV066ut0NoY4to2oWwm0dSFFS2viz4j2vhFre58TXui3Grf2Pfbk1v+0LqJriZFkdd0a7I3BOEJyPalZ20LejUe590TW1vJb4lgilQNu2SKPmfsQSaszWkFxbtDNEk0TdY5FDL9MGvkzw5q2v8AhL44Q2d74r1fV9F/tpNGsp49Ra4hQG3ybW6tyoMblxnzeT2zjivrrHFUzNfE0ef678LLTxN428M6/d6hdG08PsZrDRxHELYTmNo/PBC78hHZdudvOcZrtl021G7ECruBU7RjjBGOPY/y9BVhoUbBKjI4B7in1DuyupTOl2e2JfssJWJt8YKA7DnIK+nPpTlsoFZG8tdyghSecZ64+vf1qzRtFVcVtbleG1hhTZHEqRgYCKMKOfT8a8t/aI/5AvhD/sctA/8AThFXrWBXk37RH/IF8If9jl4f/wDThHSElY7fUvFWj2fiXT/Dt1cRtqt/FJc2ls8Z+cRFSzZxjILKa0mtYZml8yMESKEfzF3bgMnByORyfbnivJPHcot/2lvhzJJIURdG1YtmTCbv9HwvIPWvIvF3xD8V2fxa17wRB4kvgbW8vfFMMyylydH/ALMcxJuBx5QvQBg9cYPHFStEl/Wmv5I1Wp9c/YbWRCpRJEbL7TyORgnB7Hn8eetItnb2yoI4I4kjGEEa7QoLZIAA4z39e9fB/wDb3jDTfCeoai3j7xVLNZ+BdD8VkNqZO6+meYSjGf8AVkIuYvu8V2PiTxj4ms/HXjzXrXxVqMt1oviLSLCx8PrdMbaa3nitfOzBuww/fs2VGRjgitfZuPqv87HOnzJ27fmrr8z6q8N+ItG8baMuqaPNDf6ZcgqsyqVVyrFdpBHTt09a1GsbSSGOA2EbQMMlWjXaufUetfB3gnxZ4j+GXhXwzq+ka5fzLrWl67cTWd5cmWDzIChRol6AoSc4rT8SeKPE2i694X8M2PjzXH0bV7nSLvUNUkv5Gmhaf78SzD7gfHIJwO2KFTd7L+tbfoaNLVr+kfcP2S2m8l/IhdIzujZY1Pln1U9j9BXHeDvhvaeDdU8R6vNeT61q3iCdZbu5vUiB2Iu1IR5caqFQZAyMnvXyfq3jv4halrUHg3T9Qv7uz0661aOG/PiL7DcyLCkZiDXIRmk2GTnA5285qW18ceOLqyv/ABJeeNby4v8ASpPDixW2n3pfT5RcviXMYx5vmDpmla91/Xf80S76JbvT5n2Not1puuK01lFFKLWR7Jy1syFHRsMF3BcgZPzDg9qofDn4dWPwy8LW+g6dJJJbQy3MizSxr5mZpnmx8oAwC7DpjgV8b+PviZ4ovPCfiyPTfEetx61oj+JNSgNvqf2K3ijtrgLFJK20GRUYoghHBDkkHFfbPgvUpda8JaJqE8vmTXdlDO8i/LuZ1VicduSeO1Sm5XY52jJx82vuNyOyghUBIlRQdwCjAB9fryaibT7Ta4+zx4YMG+Uchjlh9CRz696tEnbRtBFC7h3SKkdpBDhUTYqoFABOAucgfSvMZv8Ak6q1/wCxNl/9LY69Y8tfT2ryeb/k6q1/7EyX/wBLY6UmX1udF/wtLwn/AG5ruijWLf8AtbRbVbzVbEq+63hYffI285/GtrR7zT9Y0uy1DS/IubG7Vbu3miQhJFZcqwIHBI9fWvib4zovgf4p/FX4hbPJtQlro+oybASIJoJAsj8/KEk2NyOcYPBIp+j+NPiFPdaVdWV+NF0XQIPDlnBLd64be1limgjMoe0CHzC4k2hyygbeMGlD39OpHN+9jH1Pty5t9P09Lq6liSKMIzTzFOQmP72MngevGKTSZrC80+1ubFoZrGSFbiBoVAUq4JEisMAbgx5Hr718eQ+OtY8WeFfCFlfeI9Vlh1bQ/GEt80V2YpJfs9wFiLYbKlUOMAcZrnPh7c+IfBfw48Qanpvi7xK1l4W8BaTf2FhcXbtDFczWk2+SQOOVXYr7TkAjp2q4x5nLyt+NyJSUXB9Hf9D7wazt2XyhAmwLtChRgLxwB6cDjpTXs7S5YrJaw3Dbldm2KfmHQkHkEdielfFXibV/EWj/ABE8N+BrLx/rz6BqOqaXNLrMmpStNumtrp2t/PU52s0CnGeNwxiqWpfEP4la5LF4a0/U7+4sNHh1Z49WbxCLGW6WG5eOJ5JdjecUQAkZOe+aOVxXMuprGO99z7b0DQ7LwxpqabYW/wBm0+2GEQlm/U0ui+ILfxFafatOm8+BJGidmhdDuU4IAYL+fSvjbT/GnjSa/vfElx4w1Oe90/XtJ077Lb3hfT2jnTM37oYyCfunrXPeKfih4nu/Bt/Np/iPWk13Rk1DUJZLfU/sNpa263exWICgzYPybTkY5xnmpveSXcS1TfY/QKisfwvqUmqeHdJvZn8yS5tYpWbAGWZASeK2KezsCd1cK8m/ag/5JH/3MGgf+nizr1mvJv2oP+SR/wDcwaB/6eLOgZ6zRRRQAUUUUAFFFFABRRRQAUUUUAFNzxTqTaKQHkP7NtpFefCe/gmQSQyeJvEqujdCDrl+DVO9/ZI+Gl5p9pYnRr+GztbC102OC11S4hTyLY5tgwSQb3iP3JGy69mrR/Zj/wCSXzn+94n8SZ/8Hl/XrO0elGqWgLbU80m/Z+8DXTu0+l/aSz30jefcyyZa8AFyfmc/fAH+7/DisrSf2XfAGhm5aLT9UunuDbmV7zVrm5Y+QcxDMkjEBT2HXvmvX9o9KUKF6Cn5dBP3tzzy5+B/hC78ejxfLZyvqnmLOV+1zC3aVRhZWgD+UZAOjlNw9a9Epu0bt2OadQMKKKKACiiigAryb48/8fvww/7HSy/9EXFes15N8ef+P34Yf9jpZf8Aoi4oA9ZooooAKKKKACiiigAooooAKKKKACiiigDyX4Rf8lR+OX/Y12X/AKYtLr1qvJfhF/yVH45f9jXZf+mLS69aoAKKKKACiiigAooooAKKKKACiiigDJ8S/wDIr6t/15y/+izXHfs6/wDJvfwv/wCxY0z/ANJI67HxL/yK+rf9ecv/AKLNcd+zr/yb38L/APsWNM/9JI6APR6KKKACiiigAooooAKo6l/x43P/AFxk/lV6qOpf8eNz/wBcZP5UAfNH7P8A8YYU/Zx+Guk3Hw+8ZajAnhfTrORodG82CdVsolLJ8/zIR/OptHX4daBMZdP+BnjC3k823m3f2GzHdA7vCeZT9xpHIHQZ9hXSfCzxTN4H/Yl8E+I4LRbyfSfh7ZahHatwJWi01H8v2Bxjiui0z9pHwJJb2Kal4u0TTdVeFDdafJdKWgmMKytH9Qrj69qmN7tA/h12ZwVpfeAbC81a6t/gd4uin1WNobxhoBPmIzbiuDJhQTz8uKs+Hdf8FeEmsG0f4KeMbB7CSSa2eLQTujdwAxBMmTkAdenavRL39oL4e6fo+n6vceMNKj0zUPMNrdNcr5cnlttlC9ztPXir1n8a/BOpQ6nLbeKdMmj0sK14Y7hP3Kt91jz0J4yM1Urx0YX/AB/4Y8n/ALU8Cf8ACTTeIT8EfGD6zM7SPdvoRZtzDDEAyYG4dcDnvmjSdU8C6HpVxptj8EvGUFjPOlxLANDYqzowZCcydFIBA6DsK9b1z4xeDfDcl5HqvinTbBrV0WUTXCKVLLuVcZOSRVa++OXgXTND0zWLvxbptvpWo7ha3bzrsmCnazA88A+uKV7qwfoebv4o8HSeMv8AhK2+DHjNvEGB/praEScgYDbfM27v9rGfeuv/AOGhP+qcePv/AASf/Z12nib4gaD4N8PrreuatZ6ZpTbdt3cPtT5l3DB6tkegrKh+M3g66tL68i8TadJaWcEFxPIswIhjmZ0iZ+ONzxyD/gNNX0Qm0lcwP+GhP+qcePv/AASf/Z0f8NCf9U48ff8Agk/+zqj4+/aq8BeBvDnjTUB4k07U9Q8L2Ut7d6bbTqZRtJAQj1Z8R5BI3HnFdDpf7QHgTVZtAto/E+npf67bx3NjZvJiSRZAdgx0BODwSO1Cu1cb0VzM/wCGhP8AqnHj7/wSf/Z0f8NCf9U48ff+CT/7Ortx+0h8NbWa/il8baKGsd32jbdA7NjbZP8Avk9cZrvtO1a31azt7uzmW4tp18yOSPlStOwrrS55p/w0J/1Tjx9/4JP/ALOvMvjt8bm1LRfCoHgPxrbeV4s0Wc/aNGxuCXkT7B8/326KO5r6l59a8m/aKRW0XwdlQ2PGegEZGef7Qi5pDOL8fa54J+KUljJ4q+C3jTWpbHd9nkuNFYMm7bnkSgnOxevpXJeDksNH+JmseJbr4a+LlsbjQk8Padp9v4bkPl2KyPI6zM7EkszDgHtX15ULWsTMGZAxByCecHj/AAFHUNeh89t4o8IPay2zfBnxmYJtOi0h0/sM/NZxljHB/rPuAu3HvXIeG7Xw/pPxQ8U+M9R+GPjW/vtUu7a806Q+G3H2NY7aGDaAJMEgqTyM9+1fW+0UeWP1z19sUXdxWtt/X9LQ+fbfxl4UtfsIi+DfjNEsYZLe2j/sI7Yo5MeYFXzMDdgZPU96858beE/B3iPSdJ0zRPhJ4w0axh1iDU76FvDb4uEi6oSZc49MdO2K+yqbsHpQm0xnzdqGp+BNV8OafoN38EPGE+kae5ktrVtCO2NiMEg+Zk5HXJ575q7N4u8JTw3ULfBrxl5V00DTqugbRIYTmLdiTnYenpX0LRtA4o63F1TPmfVrj4fa8sa6j8DfF14iSzzBJdBJUvMS0pYeZhtxOSDkZx6Cuw0f40WXh/SbPTNP+GPj62sbOJIIIV0Y4RFACjJkyeAOte0FQRiij0Fa7uzyX/hoP/qnHj7/AMEn/wBnS/8ADQn/AFTjx9/4JP8A7OvWaWgZ5L/w0J/1Tjx9/wCCT/7OvNJPjcf+GkrS/wD+EC8a/wDIpyweR/Y373/j9j+fG/7nvX1JXkk2P+GqLXgZ/wCEMl5xz/x+x8UDOY1jxp4U8QWuvW+o/BnxjeQa8oXVI5fD4IuwF2jf8/OBVH+2PA7eIdI10/BLxgdX0mCO2sbz+wTvhij/ANWo/eche2c47V1HiL463mhW/wAUXWxglfwfbQy26SShWu2dHPz/AN0ZUdMV1Wm/F7wzeaLb38+v6fZgXEVhcL5wJju3iDiDp97DA/QfWpirq66C6c3yPKdJ1LwHoXiO417T/gj4wtdYn84Pdx6Ed2JTmUL+8woc9QuM1N4R1zwT4Es9QtNC+CfjDTrXUIFtrqGPQSVmiXdiNgZD8oDsMdMHFek6L8dvAvirSdQ1LR/F+lX1hp9uLu6uI5lKQxMpIkbkfJ0OR6Y6mnD48eAP7FsNZbxlpK6ZdTtbwzi5XbLIq7inIyG2/Ntxmi0rXE0tD558ZeFfB+uWvhay0n4S+MdM0ix1pdWvbU+HJMzKtvMiru83cuC642kV22pal4D1fR9M0u8+CHjCew00EWkLaEcRgghhkSZIOTnJOe+a9Us/jZ4H1htWjsvFmlTyaZE0l20c4dbdRwXc5wFDcduahb4//D5fDcevv4x0uPSJJmhW7a4VULj+HnnJHPStNeVFN2OCfxp4Vk83d8HPGpEs8d04/sM4aSMYRv8AWfwjp2FY2pv8O9ajVL/4F+LrtV8wAS6ETxI29wf3nILc4PAPSvWpvjx4Bgg0KZ/F2meVra+Zp8q3CFbhc/w+vpxXE65+1NofhXxVonh3VL7S1v8AWL+6tIpra6EsUHlRb180joS3y+1TyttWJTu7I09O+OFtpOn2tla/DPx/FbWsaxQp/YxO1VGAMmTJ49at/wDDQn/VOPH3/gk/+zrV0D4yaBe+E4tUvfEWiiWIQR3clvdhrZZpW2ookI5DH7vHNcDN+1/4Q8M+KNA0HxLr+jWr6pY3l+2pW92GtIlhuFiVCzAcnL/N0HltmjV62Hs+U6n/AIaE/wCqcePv/BJ/9nXmX7RXxvbUvhf5DeA/GltjWdFmMl1o/lx/Jqlm+3O88t91fVuK+itO8Uafqmt6hpFpqMNzf6ekL3cKnLRLKrNGemMsFJ+grgf2nkWP4SDaoGPEGgY4/wCoxZ0eQJ3F/wCGhP8AqnHj7/wSf/Z0f8NCf9U48ff+CT/7OvWqKBnkv/DQn/VOPH3/AIJP/s6P+GhP+qcePv8AwSf/AGdetUUAeS/8NCf9U48ff+CT/wCzo/4aE/6px4+/8En/ANnXrVFAHkv/AA0J/wBU48ff+CT/AOzo/wCGhP8AqnHj7/wSf/Z161RQB5L/AMNCf9U48ff+CT/7Oj/hoT/qnHj7/wAEn/2detUUAeS/8NCf9U48ff8Agk/+zo/4aE/6px4+/wDBJ/8AZ161RQB8sfs7/G5tP+Hb26+A/Glzu8Qa/P5tro3mRjfrF6+3O8crkq3o3Fem/wDDQn/VOPH3/gk/+zqL9mtkb4TzyMoXb4k8Rs2R/wBRq+J/UZrm/g7+1Za+PX+I0/iS1tPC2l+FrtpYL2a4ylxppkmiS6YkcAyW8q8egpLW4m7HU/8ADQn/AFTjx9/4JP8A7Oj/AIaE/wCqcePv/BJ/9nWl/wANAeAT4dn13/hMtGGkW9x9nnvPtA2RyZ4jI6liPT69KXUfj/8AD/SY9PlvfGekW0WowJdWhknVfNiYkBh6glWHbGKY1qZn/DQn/VOPH3/gk/8As6P+GhP+qcePv/BJ/wDZ1D4b/aM8O6l478QeFtT1bT9L1LT79LW1hef57lGi3q3TAz9ak+KH7RGgeCfh/ceIdI1LTtau2g8+xs/tGPtYEgRtuB2P8qrlYr62Hf8ADQn/AFTjx9/4JP8A7Oj/AIaE/wCqcePv/BJ/9nW/pfxm8H6p4iPh+HxTpUmupDvk05ZQJRhdzEAnOAO2M1xnjr9rTwB4Q8K3mtQeIbDVltNSttMkhs5wzmSWVYyF9SPn9jt61LulsPd2NT/hoT/qnHj7/wAEn/2dH/DQn/VOPH3/AIJP/s6mt/j54X0/T77U9c8U6FZ6UuoNZWtxFdhwflRgJO4fDglcfKrAk16LY6jHqVnDcWlxHcW8yrJFPGwZZEYZDKRwadnuTzI80/4aE/6px4+/8En/ANnXmnxo+Nzahe/DsDwF41t/s/iy1nPn6NjzcRXA2R/vOX9q+pDXk3x6Vftvwwyqn/itLPGRnH7i4OR6H3pFB/w0J/1Tjx9/4JP/ALOj/hoT/qnHj7/wSf8A2dUf2lPjxffA/wAM6Pe6Tow17U9Qvlh+xSNt2W68zzcf3F5/Guo1L44eCtFvrPT9U8UaZp+pXUUNxHazzoknlyfdYqScD8admO1jF/4aE/6px4+/8En/ANnR/wANCf8AVOPH3/gk/wDs66RfjB4PfxafC48T6YfEKrvOmrKDMF27sbc5Jx2xn2ri/Gf7T/hfT/h74m8ReFtW03xTc6Ja/a2tbW44ZAyqzsQDtQFx8wzSJbsrmh/w0J/1Tjx9/wCCT/7Oj/hoT/qnHj7/AMEn/wBnW/oHxk8I+KDZppnibTbuW6uWs4khnTLTpGJGi2kgh9mWA/u81ycP7Snh9vHniPTbjUdPh8LaRpNvfnxDHcbozM9zcwPA3GNym3zwTndVKLYX0uXf+GhP+qcePv8AwSf/AGdH/DQn/VOPH3/gk/8As61J/j54AtfDOneI5vGOmR6HqDNHaXnnqUnYNtYLjn5TwcgY71yU37U3hy68ea74QsNS0tdU0z7Lte9uhElz5v3th6HH1pdbBJ8qbfQ2f+GhP+qcePv/AASf/Z0f8NCf9U48ff8Agk/+zrptB+K3hbxJ4lvdA0vxHZX+s2uTNYxyBpY/XKgDp7E12dDVgTueTf8ADQn/AFTjx9/4JP8A7Oj/AIaE/wCqcePv/BJ/9nXrVFIZ8t/Cz43fZviF8ZLj/hAfG0puPEtrN5cOjlpI8aPpsYSQb+H+Qtj+66HvXpX/AA0J/wBU48ff+CT/AOzo+EZ/4uf8cVwAB4rszwMddC0vOfXoPyr1qgDyX/hoT/qnHj7/AMEn/wBnR/w0J/1Tjx9/4JP/ALOvWqKAPJf+GhP+qcePv/BJ/wDZ0f8ADQn/AFTjx9/4JP8A7OvWqKAPJf8AhoT/AKpx4+/8En/2dH/DQn/VOPH3/gk/+zr1qigDyX/hoT/qnHj7/wAEn/2dH/DQn/VOPH3/AIJP/s69aooA8l/4aE/6px4+/wDBJ/8AZ0f8NCf9U48ff+CT/wCzr1qigDxbxD8efO8L6vj4d+Pk/wBDl/5gn/TM/wC3XRfs6/8AJvfwv/7FjTP/AEkjrsPE3zeF9Xzn/jzl7/8ATM1x/wCzr/yb38L/APsWNM/9JI6APR6KKKACiiigAooooAKoakP9Buf+uMn8qv1R1L/jxuf+uMn8qOgXa2Pnvwrps2rf8E/9B0+wikvbm6+GVtDFFCT5ju+loqAe5rzvw78N9fuLjUJrvwtfSTv450G4EstuzP8AZYtKtlkkLEZ8tXVlPoa98/ZpkWL9mf4UyyssKR+ENJaQsQqpiyiOSfQVhWX7TWheIPiHqvh7w9f+HtX06zTT5V1aPXohG0lxPNC0A2qy+YpgJCbssW24XrRFtOVutvwdwlL3Ffpf8TxvRfhn4oj8SQ3N14Y1SWKD/hM/J86B2Ef2m53Wu3I+Xev3MUXnwp8Uro97b2nhvUIJG8B6fZReVbFdtxDdb2iGBxJt7jnFfUtj8UPCGqalqlhZ+KtCvNQ0dWk1K3g1CF5LVV6tKgctEobj5hxVWH4zfD+40e21eLxv4ffTromO2vI9Wh8mVsKdquX2l/mB25zzWsptvX+t/wDMXVSW6v8Anc+YNK8Oa541+MY16fwbrllow13TJAupaXLb5jitdrMRJjI3etYV58J/FGmvZX+p2fjCzsDDqun/AGHw7bb2mkkut0JmV4JcRuv8Q6dnr6h1z4+eHNL+IXh7whpup6VrGpahNJFewwalH52nxomQ8kQ3EEn+8FresPjJ8P77Sb3VYPHHh250+xmS2vLu31OBooJicLHKQx2OT/CxBrO70fb/AIBX2m3u/wDNnl/xR8JXWm/B7wBZNo3iD7Rov2PfceHz9vvtNMUGwZQIxucP8rbU6c14vc+EfEzeJvhDpWo6H/ZY8aMbHWIVtDAWisL5r+Fposny2khWUEZIXzcelfXuj/FzwPrmtQ6JpfjPw/fazPF9oi0+11SCSd4v76orFiMfN0rUm+Heg3HjKDxVLaTS65BAbaCaS7maOFCct5cRfy0ZuhZVDEcEkcURk4u5EldOJ8Yax4B8V3Gl+PPD3h/wxrq2lxoHiFZrHWrDEdjc3D74o7O6CItzFO/PlqGZT1ar0XgHXPEXj67uLjTfHEdtrmoaPqenaalv9hsBbwR2/mC7LwM8TRvFzHlN2Txyc/cJt0bHy9M8ZOOeuR3oaFGUgg9+hI601J2SZUtVY+N/DPwt8Q2OpeDpbjwvestv/wAJP53mWhPk+dLuh6rxv6rX0F8AtJv9F+D/AIUsNRtLiwvIrJY5IbjiRG5616L9nTngnP8AtH1z/wDq9KcIVGTz1zyxNHM0mjOUFJxb6CnmvJ/2if8AkC+EP+xy8P8A/pwjr1naK8m/aJ/5AvhD/scvD/8A6cI6n1ND1qiiigAooooAKKKKACiiigAooooAKKKKAErySf8A5Ootv+xMl/8AS2OvXK8lmH/GVdqO3/CGS/8ApbHQI8T+K/wAh8dal8btcvvDWrXWry2dtHpEkNzdwrdskLj5Y43CSfMR94HrWXfeC761/aE0/RJbZ00gaGni2aV0XabyC1ksW3jGBgyxuD1OzvXrMv7T1pa/FT4geCJdCxL4U0gatDdtOdt4QH8xP9X8hUKT34rlv+Fiw/2nrfijw14Fh1NpdEs9T8TXV9rc+8W88RkWC0Ta6khScriIHjviojJxTktv+Awi1dQ87/ijwfS/Auv/ABg+C/w0u/Duj+INEsvDfgyys78RWRgl1DN/p1wUtVdWSc+Va3DZAK7pVHcpXrPgv4X3l1418H60+heJr7TpPFV5qT3HieHNyR/Z3krdSwiGMW5Mny4Mee/Wu60D4sT6Iq6F8P8AwQ2seBvCkdhpdzHDeyG8jjlijKfZ4PKk89Y4ZY2bzJIzw4AkKivovyE2qCC23BG4k9O9dNSXN00f+ZEdUvRfkfn/AK58LvGeq6fq3hzw9oGv6bpkMLSXEV/YlZ7Bvtscxg065ZVW6VoxMwADY2gH0rtvBvwxvrjxN4X1mPSfFV1YzeJhctdeI7Yeeyi02CSW3WCJYI89yDzX2U1ujYyCcEEcnjH+fxo8lM52jdjG7vj61nfSxctT4Hj8A+JdBtoZI/CGtx65dGW3hih0/wC2WF0v2vekd2Nubfj/AJattHtXS23g3xZod9oOoXfhjU38nxJrUkyW1pLckpNZeXG52A/u9/Q+tfauwelJ5S7cEZHuc04ycbWElZ3Phbwj8GfE9t4u+FmmN4Y1CDw/qOn2l1rU09sVW0ubBpHgSbjgs3lnt0961vCfwt1Sa88C6brvhjUl0vVvDXifQLxzYOzWT3V6ksRm2r+6V0Q7ScdT/eOftPyUIIIyCMHPeqOr6BZ65pN3p10s32W6haCT7PcSQPtYEHa8bKyHk4ZSCOxFTzOy+f4pr9R29658+fsQxaprXw71Txd4gt/I17WdQ+zXAKjdiyhjsQQccqzWzuP+uhx1ru/2oP8Akkf/AHMGgf8Ap4s69B8L+EtK8F6DZaNo1r9j02ziEMEPmvIVUZ6sxLMckkkkk55NefftQf8AJI/+5g0D/wBPFnTk+aTYorlVj1miiipKCiiigAooooAKKKKACiiigAoopuaQHzx8Pta1TRf2X/F2p6JptxqmrQ6n4plsrG2USSTTf2vf7EAwP4sV4Z4s/Z9+Inw88Lw6V5jeNrDUvAL6DPDp+jyI1tNazwzQib94/nF/OuRzsJ2n1NfTf7Otwln8J7+4uJmSGLxL4leSSY4IUa3fkn8q2G+OXw6htILseOvCwhuboWccg1aBFmuCqOsSvvwXKyIduc4dT3xRHSUiZdEeCePPDXinSfiV4lvLTw9q50O71XTpJ77R9MS6vURNN2FoAUbln/duw5UdCK8z8Hwax4V/sbw7f+EPEF1rU3ga905bWbTZpJIrl7mUxmQA8KNxxJ93n71fb1x8TPCNr4ui8Jy+KNJi8USqsqaPJfRi8dWGQVhLbiuOcivOfHHxr+E/g5ta8et4j0PUte0WBNMvP7P1aNpolMhxCyB8A72J+cZ/lR05v62sXHrFb/8ABPINH+EPifT9DurW78PzXVzD4o0eQTPbFjJGluI5XHy/6sdyK5XUvh5r2tXfxl0G00aS5h8No+n6RHbqJTKtzOJmZAMMpUBxweM19V6Z8cvCEmj6hrOp+J/DFh4bimjig1KTXITG/mR71WU8LE5z93J46dKi0XxN8KfhPK8cXinRtLutck+3p/aeuK8t+8pJDxvPKWcEkj5DtGeAK11Mo7Xfn+Z8z654P8ceJPiPpDS+HtfhvI77U7eWKDTxDpsMMtpIlu6OiASP5mzczuQMfwZrqdQ/4SHxF8CDotp8M9Y02fw9a6Jb3E0tlIt5cSwXUL3EcUPl7rhFRWYshIYkhd2a+v4jG3lsgyHTKuvpxx9PapDZwtyVyT1JJyRnOM+nt0qXKS28vwNIvW58X6bo+u+E/jBqXj+98Ia9q+gTXuvQ21jHpc8lxIbqHTTDI1uV37GFtMmcfLyG219aeDY518L6R9q02HRp/skXm6daKPKt3C8xqMYAU8DHpW+sEaYCrgDoPSj7OnoeoP3j2o5naz6aEcuw9q8n+PP/AB+/DD/sdLL/ANEXFesV5P8AHn/j9+GH/Y6WX/oi4qS+p5/8bvhv4v8Ai58WorLS75fD+k6VoE6tfXumG8innuPlMcREseSF615HbfDrxjq3w68dR33hPUn1OLwrYaZbmS0bzJpbeV1byDtzkqAa+zPE3xB8MeCZrKDxFrum6HPeyCO0h1G7ihMzZwBEGYbz0+UZPPSuI8A/H7w9428Za34YvNQ0vSPEemarNZ2mkvqKG6u440U+aIW2t91myF3KM/eNXGTWw5PT+umv6HgXiTRvE9z8VNMvdS0PxN/xL/EguHjsdMVdOjs/smxLnzVjG+Yy8OTISo/uV59Y+FdX+J/wN8ODR/B+p79J8HXthJcNZv5eoST3MHlJCdv+kDZG0ny5x0r7ptPiV4P1ttW0+08VaLey6TGx1SGHUInezUEhjMFYmPGDyxGO9cJ4c+LXgXQW8BeF/AV9o+s+F9Se7so7vSdUWeKxWCB5idwL5HHdhtHPIoTb3/rdE3Vtf66/qeP/ABs8Pav4Ltfi145sdGkF1oOuaNr2jRmMAXXlWVvb3RjYjDgxySJkYJYYrDk+GPi3wLeWA03QtQvLdPDmhWt3q1lp4vLlGWa6e6eAFGHnKXjPyhvvmvrbWPD3hP4waBYG7ePxBogljvrY2d+4t5yuSufKcCVO+18qTjI4rsPssRjdCuVbOQTkckn+Zpxk43DeLSPhT4Z6N4h+HNxpuuX3grxXrdnHqGvRJp9zpsks8rXU+6B50CYCSDrJjavda6L4heGfFGoeIfE0MXhDVbWTVYdEngj0y3eezi8v/XKsqgKCnsOe+a+yhbxq5cIA56sBgmnCFFXaFAHoOKnmvJNhL3lJd/8AgHzh+z5a6r4bl0rwlqHgm9jvtLF79p8SalZmGJS0p8ryZNpEu5cA7XXFfSNN8tfSn0Sd2JK1woooqSjyX4Rf8lR+OX/Y12X/AKYtLr1qvJfhF/yVH45f9jXZf+mLS69aoAKKKKACiiigAooooAKKKKACiiigDJ8S/wDIr6t/15y/+izXHfs6/wDJvfwv/wCxY0z/ANJI67HxL/yK+rf9ecv/AKLNcd+zr/yb38L/APsWNM/9JI6APR6KKKACiiigAooooAKoakP9Buf+uMn8qv1S1P8A48bn/rjJ/KmGvQ+e/Dvh3V/FP/BP3QdE0FWbW7/4b2tpZIkhUtM2mIqruHI5714/fafe+Lvig2qeHvAniHT9LZPCcBe78Pz2IMltdXPnR4ZFH7pGQFvur1GEO6vqD9mEZ/Zr+Ew/veEtJzz/ANOcdemmBCMYwM5wpI75/wA+tKLcRTvODg+un5f5H5+XngrxLfWN7oPh/wAOa5NpGmxtLeWWt6TJFc6WPt0cstna3SxIl9G6+dsKh2G0Zeuw0LwXP4z/AGgtI8WjwlqsXgy41mW5s49W0ae38iRLKGPzngkjDQlnQlSyJmvtIW0axhAgCAY2jpjpjHpS/Z03M2DuYYJyapu402r+ev4WPgnXvBGv6rDpPhOx8N+IovEem3+sSXeqRaTMsBSeM+T/AKUyeUwbIxknb3xTdM+F+o+IPCUUo03xv4gaM6NbTw+J9Kt7aEMk6PNFFaw2MLPGgJ/fgupz96vvdrWFgQY1YNnIIHORg5/Cl8lOfl69c/h/gKV2loU5OTuz5GXw7qOg/tCJb6N4a1SO1m8Rx3l5p2paMZ9PC+RsbULO+jVRFJt/5YySN67Aa+vaZ5S9cZ/E+mKfRdtak9bhRRRSAKKKKACvJf2if+QL4Q/7HLw//wCnCOvWq8l/aJ/5AvhD/scvD/8A6cI6APWqKKKACiiigAooooAKKKKACiiigAooooAK8ll/5Ostf+xMl/8AS2OvWq8ll/5Ostf+xMl/9LY6APBPjx4B8WLqXxY8YaD4bnvtW0trOTTYFtJc6jbmCVLmKHjltrH7u7rnrVzRW1j4ZeF/EGl3fh/X7zUPFfhfS4NNXTtLuLnbfJZfZ2gmdIytqVco2+fYPnPpX2L9nj3A7ckdMknsRn64JpFt0VdoBx/vGos+SUe5HL+8U32/yPibxd4Z1XwvHFp+leEfEWi/FfSbTTdL8MeIPDsF3JZarbxRRjbqM0SfZ2jWTzwyXABCAFME5r7aj3bMMctTVtYlx8p4GOST+P196l2jOe9auTluEY8v3IWiiipLCiiigAooooAK8m/ag/5JH/3MGgf+nizr1mvJv2oP+SR/9zBoH/p4s6APWaKKKACiiigAooooAKKKKACiiigAplPpKT7AfP8A8K7eS+/Zt8WQojXEsmreLI0SIlixOr36jH514P4q+E+o6V4Z8D2kuneMdK0m8+HEGhf2X4V0G2nlkvnVFmtLgzWlwLPeDHmT5FBiYs5Kg19Ofs1FV+Fc7Ywq+JfEeAOBga1fVl/CH9pPR/idqHj2K707/hGrfwnf+Qt1qF4giu7bzJYlvFZgu2NpIp1yeu33qYwipScf60a/UmXT+uqf6Hz18QPCvid/F9rpn9jeJNMuLPxDZCC20nQfMs7u3Nl5S391fQwZuJjIdrHzBsHLRqBurbt4b3VvgVceF7L4XalFrGgaDbWl9q1xpUqz+ek677WFfL8y5G0NJmJivOPavqWH4peB10O51keMdCOjW03lTX51OA28Mh+bY8m/apI5wxz3p+ofErwdpcenS33inSLaO+2vZebqMQFyGJQGP5v3gJPbIFXe0HFdf0Vv0Kj8XN/W9z5StdM1LTPiz/wnV94f8Qah4SttUJFsvh+9e4bfZxxrILUxeb8r7+cd/pWTovwr8S2Pg7xW174f1K6vLjwiy2rSWDl18y88xYFJXO9U7dq+o/Dfxv8ADmreN9e8M3Goadpep6XdJa29vPfRiW/BXdujjOCcD0LVN8TPjbofw98Bz+J4ri01tBF59vbwXYU3QB2t5ZUNnB9q15pGa1VvX8za8B+KLfUo5tGjt7yG+0mC3S6W6hMeGdM8Ek575rs64vR/GPhGbxFc6XYa7oreJJQsl1YW99C118qZJeMHdgL3x36VzXjr9pHwR4I8PT683ibR9T063vYNOmWx1G3YxzSSqh3Nv6rk/Ljdw3Hpm7lxWtj1miuQm+JWgNcS2Gn+IdGv9Y+xi7h05b+LzpEK7llIUkiMgg79uAOelcj48/aC0j4f+B7HV9RutN/tu8htZotBj1aBpZRNIiZjbrKi7idyKd2OKm/by/EOqXc9dryb48/8fvww/wCx0sv/AERcV6nHIZIgwPJFeWfHn/j9+GH/AGOll/6IuKfkM8t/ac0G8bxzaappmka3NqTaR/Z1rc2mkHVdO1Aedu+yXMaoWtxn/lsJY65PRPhx4oe1L/8ACNXGmarcePReSlLWXZBEII1D7sZaIHucr/tV9qeSm3btyM559c5pDAhz8vU5P14/wpqTQPax8Ba98PfEHinwjp3h7S/CGtWmr+G9Cv7XWZbjTpLePU5ZJQPJhkkUJcmVhu3o5C9+uK6D4xeDfEP7Q2q+HE8EeHdY+HVrJeXatrd5oz28t8BpZULdRvFHJFGSfIDSMGYZ2la+3fs6ZBwRg54JFHkpxhcY6Y475quZvcm2ljifhPrVx4i+H+hXtxolx4bla2WKbSLpHia1dBtaMBlHCuNqn+JQDXdUzyU3A45+tPqW7jQUUUUhhRRRQAUUUUAeS/CL/kqPxy/7Guy/9MWl161Xkvwi/wCSo/HL/sa7L/0xaXXrVABRRRQAUUUUAFFFFABRRRQAUUUUAZPiX/kV9W/685f/AEWa479nX/k3v4X/APYsaZ/6SR12PiX/AJFfVv8Arzl/9FmuO/Z1/wCTe/hf/wBixpn/AKSR0Aej0UUUAFFFFABRRRQAVS1L/jxuf+uMn8qu1S1L/jxuf+uMn8qAPPP2X/8Ak2v4Sf8AYpaT/wCkcdeoV5f+y/8A8m1/CT/sUtJ/9I469QoAKKKKACiiigAooooAKKKKACiiigAryX9on/kC+EP+xy8P/wDpwjr1qvJf2if+QL4Q/wCxy8P/APpwjoA9aooooAKKKKACiiigAooooAKKKKACiiigAryWX/k6y1/7EyX/ANLY69aryWX/AJOstf8AsTJf/S2OgD1qiiigAooooAKKKKACiiigAooooAK8m/ag/wCSR/8AcwaB/wCnizr1mvJv2oP+SR/9zBoH/p4s6APWaKKKACiiigAooooAKKKKACiiigAoopuelJgfPHgDxRc+C/2XfF+u2NpcXl3p+p+KriC1hhMkski6xflQFHUk44xXzv4l+D/xA+FvhefQ9UsbTXrHWvAA0eWXQrC4EqT2txHKnngtJveT7VdnA4+U19Yfs3lbf4UzzTSlIovEniJ2YsQFVdZvs59R9a7n/hNfDzRxv/b2ntFK7QxyfbIwGk2g7EOeWwwOOvNOPuykTLZI+SPG+kXXhv4heI4INAm0vw7ea1pol1W30U3LWGNO2+bbwtEyFnk/d7yuV6k5rzzwZLp+n2ei6RrWiX+o6jceBb3S7S3uNMkeYXH2l8eaCnyscDDjgdq/QRvFGlx6rHpbarYxam4BWxa6QTkMODszn36V57448YfD/wAF6hffES91a3ub/SrRdMnW2vY2KoZDhGQHg72NHn/WxcX9n+tz500T4b6jp9hfS3ujSz63D4o0bOofZSJXiWDYxDAZAB6469653WvCOsXn/C19BgsJp4/BdvJZadbwxMeLqeOZGRR82dm9fbPrivtfS/iJpupRahdXV3aafpMJjWDUZr6Ly5wybt4PRSPQ1neFtJ8HfDOe7FvrUYvteuGvZLnUNRSSe6dz8pVmPK9lHStdU0+3+VjKPf8Arc+QtY0vXtc+JWjvFpd5o2pR6hqdjJp9lo5it4Wa0kWKRrhIgZC77DuclRjjvXQaoNJ8QfAlLTS/ANzFe6PZ6KmrXk2mMs5kivIvtMCrszOUw7Fl3htxxX22FVo8D5lYEDuKf9ljEgfb8w755/zzU8zSsvL8C4vW/wDXc+Ftc0d9WutQ0XTdAvj4qk8XX2tpqEenSxAaRJYSbHEhTaB5XlwCL724Y21iapotxo/w5vtI1vw/ql5q+r6b4VOkKLCaYQpD9njuI2wn7vy28xmz0zx0FfoKbdGzkfrR9nj2428fXms0uXby/Alxu030v+JFaxtHbKD1xXmHx5/4/fhh/wBjpZf+iLivWNo9K8n+PP8Ax+/DD/sdLL/0RcU2222ykktj1miiigYUUUUAFFFFABRRRQAUUUUAFFFFAHkvwi/5Kj8cv+xrsv8A0xaXXrVeS/CL/kqPxy/7Guy/9MWl161QAUUUUAFFFFABRRRQAUUUUAFFFFAGT4l/5FfVv+vOX/0Wa479nX/k3v4X/wDYsaZ/6SR12PiX/kV9W/685f8A0Wa479nX/k3v4X/9ixpn/pJHQB6PRRRQAUUUUAFFFFABVLUv+PG5/wCuMn8quVR1In+z7j/rjJ/KgOtjz79l/wD5Nr+En/YpaT/6Rx16hXy/+zr8SvHNj+z58NIbb4U6vqVpD4Z0yG3uoNY05BcItnHiQK8ylc46GvRv+Fp/EL/oi+v/APg70r/5Jo6XFfqetUV5L/wtP4hf9EX1/wD8Hek//JNL/wALS+IX/RF9f/8AB3pP/wAk1PMM9Zoryb/haXxC/wCiL6//AODvSf8A5Jo/4Wl8Qv8Aoi+v/wDg70n/AOSaadwPWaK8m/4Wl8Qv+iL6/wD+DvSf/kmk/wCFp/EL/oi+v/8Ag70n/wCSaAPWqK8l/wCFp/EL/oi+v/8Ag70n/wCSaX/haXxC/wCiL6//AODvSf8A5Jo8gPWaK8m/4Wl8Qv8Aoi+v/wDg70n/AOSaP+FpfEP/AKIvr/8A4O9J/wDkmhuwHrNeS/tE/wDIF8If9jl4f/8AThHS/wDC0viF/wBEX1//AMHek/8AyTXmHx2+I3jvUNE8J/afhTq2neV4r0WY7tY01/MkW+jKQjE3Vz/F0FAtj6ooryX/AIWn8Qv+iL6//wCDrSf/AJJo/wCFp/EL/oi+v/8Ag70n/wCSaYz1qivJf+Fp/EL/AKIvr/8A4O9J/wDkml/4Wn8Qv+iL6/8A+DvSf/kmgR6zRXk3/C0/iF/0RfX/APwd6T/8k0f8LT+IX/RF9f8A/B3pP/yTQM9Zoryb/hafxC/6Ivr/AP4O9J/+SaP+FpfEL/oi+v8A/g70n/5JpXA9Zoryb/haXxC/6Ivr/wD4O9J/+SaP+FpfEL/oi+v/APg70n/5Jpges0V5N/wtL4hf9EX1/wD8Hek//JNH/C0viF/0RfX/APwd6T/8k0Aes15LL/ydZa/9iZL/AOlsdL/wtL4hf9EX1/8A8Hek/wDyTXmUnxH8df8ADSVrd/8ACp9W+1f8InLF9h/tnTvN8v7bH++z5+3H+z1oA+pqK8l/4Wn8Qv8Aoi+vf+DvSf8A5Jpf+FpfEL/oi+v/APg70n/5JoA9Zoryb/haXxC/6Ivr/wD4O9J/+SaT/hafxC/6Ixr/AP4O9J/+SaAPWqK8l/4Wn8Qv+iMa/wD+DvSf/kml/wCFpfEL/oi+v/8Ag70n/wCSaAPWaK8m/wCFpfEL/oi+v/8Ag70n/wCSaP8AhaXxC/6Ivr//AIO9J/8AkmgD1mivJv8AhaXxC/6Ivr//AIO9J/8Akmj/AIWl8Qv+iL6//wCDvSf/AJJoA9Zryb9qD/kkf/cwaB/6eLOj/haXxC/6Ivr/AP4O9J/+Sa8x/aG+I3jnUvhl5dz8KdX061Gt6K/2ifWdObJTVLR14jmb75G32oA+p6K8m/4Wl8Qv+iL6/wD+DvSf/kmj/haXxC/6Ivr/AP4O9J/+SaAPWaK8m/4Wl8Qv+iL6/wD+DvSf/kmj/haXxC/6Ivr/AP4O9J/+SaAPWaK8m/4Wl8Qv+iL6/wD+DvSf/kmj/haXxC/6Ivr/AP4O9J/+SaAPWaK8m/4Wl8Qv+iL6/wD+DvSf/kmj/haXxC/6Ivr/AP4O9J/+SaAPWaK8m/4Wl8Qv+iL6/wD+DvSf/kmj/haXxC/6Ivr/AP4O9J/+SaAPWaZ1ryn/AIWl8Qv+iL6//wCDvSf/AJJpB8UviF/0RfX/APwd6T/8k0nZ6MDmfhdHJcfs2+Lkt0Z5pNW8VoiqTlmOsX4GK+ZfFHw0s9D8N+BLZ7hdB0a++HNva28cGhpeTXGqFFSQgttMVywMO2UkH92eeTn3D9n34jeObP4evBb/AAn1bUbQ+IPEEnnQ6xpy4ZtYvWeLDzr9xiYif4vvCvTR8TPH20D/AIUrr+Acgf23pWP/AEpqUuWUvP8A4IpK9v67Hyp8SPtQ+JGmRvbPpGt2niKytfL/ALLLXlxC1kVW8kudzBQZCqFVIUYzjPNaMcHhXxB+z3qmlWnguaXxNpmkWba5ftZFXEy3YEkbhwS0pCu2QCcHrxX01/wszx/v3/8ACl/EG7BH/Id0rv8A9vPt+FB+JXj5gP8Aiyuv+x/tzSsjgjOftPXk/nVN+64jWkr/ANb3PmaG10ePx2+vaxpzv8M5NRdJ1+wn7O7PaxiFjHtxjdv42456dKyNO8A3N54V8Q3Oq6Jc3d/H4P8AP09pbVi0C/bPMQJ6ME6HrX1f/wALK8ffNn4K6+dxJOdc0rv/ANvNL/wsvx9/0RTXum3/AJDWk9PT/j56VpzpkpWS/rrc9E8M+b/YGlGViJjbxmQHuxUE/rWzXkX/AAszx+NuPgrr42nI/wCJ3pXpj/n59Kf/AMLS+IX/AERfX/8Awd6T/wDJNQ2EVbQ9aoryX/hafxC/6Ixr/wD4O9K/+SaX/haXxC/6Ivr/AP4O9J/+SaSdyj1mvJvjz/x+/DD/ALHSy/8ARFxR/wALS+IX/RF9f/8AB3pP/wAk15j8bPiR47uL74di5+E+rWfleLbSWDdrGnP9pkEVwBEMT/KcfxHimB9T0V5N/wALS+IX/RF9f/8AB3pP/wAk0n/C0/iF/wBEX1//AMHek/8AyTQHWx61RXkv/C0/iF/0RfX/APwd6T/8k0v/AAtL4hf9EX1//wAHek//ACTQHWx6zRXk3/C0viF/0RfX/wDwd6T/APJNH/C0viH/ANEX1/8A8Hek/wDyTSbsB6zRXk3/AAtL4hf9EX1//wAHek//ACTR/wALS+IX/RF9f/8AB3pP/wAk0Aes0V5N/wALS+IX/RF9f/8AB3pP/wAk0f8AC0viF/0RfX//AAd6T/8AJNMD1mivJv8AhaXxC/6Ivr//AIO9J/8Akmj/AIWl8Qv+iL6//wCDvSf/AJJoAT4Rf8lR+OX/AGNdl/6YtLr1qvlj4X/EjxzD8QvjHNbfCfVrySbxNayXKLrGnKbVxo2mr5RzN83yKsmR2lx1Fenf8LS+IX/RF9f/APB3pP8A8k0Aes0V5N/wtL4hf9EX1/8A8Hek/wDyTR/wtL4hf9EX1/8A8Hek/wDyTQB6zRXk3/C0viF/0RfX/wDwd6T/APJNH/C0viF/0RfX/wDwd6T/APJNAHrNFeTf8LS+IX/RF9f/APB3pP8A8k0f8LS+IX/RF9f/APB3pP8A8k0Aes0V5N/wtL4hf9EX1/8A8Hek/wDyTR/wtL4hf9EX1/8A8Hek/wDyTQB6zRXk3/C0viF/0RfX/wDwd6T/APJNH/C0viF/0RfX/wDwd6T/APJNAHofiX/kV9W/685f/RZrjv2df+Te/hf/ANixpn/pJHXOeIfij4/l8L6t/wAWa1xM2cvXWdL/AOeZ/wCnmuj/AGdf+Te/hf8A9ixpn/pJHQB6PRRRQAUUUUAFFFFACVS1L/kH3P8A1xk/lV2qOo5/s+5z/wA8ZP5UuqF1PCfhz4kvfA/7DvhTxFp0Kyalpfw9s9QgSbGySSPTUdUYr1G4CsT4dftT6pr2h/DbUPEMFror6hp2qP4oimheP7Fc2aQswTLHaCGZhnOVkQ1reCfD+oeJ/wBg3wxoml25n1PUPhxa2VpbCUIXmfTEVF3NgDkjnivI/iZ+yz468QeNrGDR7K1h0C98LzpeO1wsf2XVvstvBxtfcEkWCNWMSn7lKHxSuXpaC82fQj/tVfDiHw7/AGzc6zeWFr9rishHeaZdRXHmSqzRfuGj8za4RtrbcGtHT/2iPBN9psN+NSuoYbi/bTolubG4hbz1XcUKvGpUY+bLV4foPwP8SGTSNQg8EapoCnX9OmuLXXPEkmr33kwQTI0kskl5NH5KGQbI42DHutaHjf8AZ38VeKvjp4ovIYBD4R1bSprlLwzRjbqUlr9nVdu7ftA53beverdlp/W1yU+aWh6xpP7Tnw/1fIj1a5gdrmK2hS5066hMzSttiaPfEvmIx/5aJuT/AGqm179ozwN4dN6lxqd9cXFrfyadLa2Om3NzMs0S7pQEjiYlVHV/uD+9Xz3r3wl+IviMaNrkvgm602fwjYWVhFpralZNLqfkz75DAwn2RZH3fNZaSb4U+PtQtNT1i8+G2pRX9z4jvdUtLfR9ftIdVso5YdkUhl+0CGRWP343LewaqUebYdtLn1F4g+LHhvw34RsvE93qDPo14sbWrWlvNcTXXmf6pYoY1aR2b+6FzXNWn7TngC80XV9VTV7lLPS9P/tO786wnjeGBZnhcshTO9XRgY/vdPl555vx94C8Sat8DfDOk6n4e/4SnW9Pa2ub630a8TTbpJI/vSWMqvFHHMh6ZdF6+teKeLfhz4yhvfg9Z640puvEGsXOjarBdSwveDThdLqKibyMrJNss2jdlLKfNOSSaUbc3KFvdue6eM/2sPCGjaD4rm0qbUNS1XR7G+mht10y6EV3NbL+9iil8oq7RsQsmzd5fzbsbTVzQ/2pvB15p3httTn1XSdS1a2tpZbO60a8QWTTMqJ57GICHe7gJ5hXeOVzXkOpfBvx5ea74tsdH8MS+HNO1SDXEvGfU4LjSdRkuYZFt5bSFpWmtJSSpk+WNMibiTeDWXH8D/E+sa3Dd6j8PdelOsWukxtFc+Kvs1hYtbBI5vtVvaXyrcZWHzECLLuLfPtpQtzSTFNq0bHucn7WXw7ivJLcajqkxXz9rQ6LeOJvJbE3lYj/AHnl/wAWzdXqPh3xDY+J9FttW065+1afdJ5sMo7rXzN4X+CPjHSG8Gs+jeWmn/8ACQ/aNl3Eph+0nMO3Dfxn8v48V7f8EfDupeEfhb4a0bVLYWmo2NmIbi38xH2N7FMqaI2lcme8Uup6AR9fzryX9oZVTRfB20BdvjHQFG3jj7fGMfTHavWeSteT/tEf8gTwh/2OXh//ANOEVQtyi14u+Jlx4Z+L3gzw7Ld2cGiaxYX0801xlJBLEYfL+c/Jht7cda4zwV+1Voi+C4dX8YagltdXOp6tbQx6Vp9zcqltaXckQnkWISFUCeSzyMVQF+duK1fip8GbD4m/GLwXqXiDwvpniPwxpun6hFeLrEFvcwxSP5PksI5M/MdrfNjIrwC1/Zs8TeH7HRpl8DX+p6bbW/iDTLbRvD/iT+yEt0udSNzZyTGC6hV7RosK8as2BjEfHFprqUtj6ef9ojwP/wAJnZ+GE1aaa+upltY7qKyuJLP7Q0XmrC1yqeUrmP5tpcGuF1D9rDR/+FqaLpFjeqfDL6fqNzqF/Pp1yoZ7doQDbOVAmT52yUD5zxXmt58EPiJB418Ox3Phm+1Sy0HW7D7Bf2OvKul2ekraeQYLe0muA/mRyfM7yIzsv3WY/LVK1+Efxd0vT/Buk6R4Xm0m58I+Hb3Rl1htTtAt9vlhKGILLvTzFRsb1XY3pVpRlv8A1oTDW59Aw/tOeBm0G51N7zVo3tryPT5dPk0W7S+Fw67kRbQx+c2R/dU1yOoftdaHpvxIs7KW6Z/CV1of9opPb6bdS3iTLNsfzEVCY41X75dF2d8V5b4V+DnxA8K+IL/xRZfDzVFjg1u01eHTNU8QW15qF3Gtr5UwNw9yy+aJPmAdwnYNjiu71r4e/Evxtq2ta1rnh+zgudT8IS2As7W4i2rOZt6QHdLy4H8X3P8Aao5YrZ/1ZExe9z1qP4++DZfE0WhJqzvdSMka3H2Sf7J5rqrLH9o2eVuww+XdmvSto9/zr4x8A/s3+IvD/jiw/tLwnqWoE6ra6y2tXXiaZdMto44YUaIWUd0A1ypQ7XMRU/xMa+z6UrdAV+om36/nRt+v50tFQUJt+v50bfr+dLRQAm36/nXkkyr/AMNU2o2jH/CHStjHf7bHz9a9crySb/k6q1/7EyX/ANLY6V7BuY9x+0PbeFfGXjGx8UO1vYaZe2Nhp8djYzXE1xLOjkLtQMx5Ufw1euP2q/h5aaXY3z6tftFdLLKyx6TdvLaJHL5cpukEWbYRv8rNLgDFcT4k+EXiy++Ll9rMeiq2kSeJNIv0ma4hC/ZoARIxTdnKgn3Oa8+174H/ABFt4L6Sw8H3765Ncas2l61per20clsZ598QvY5phHPaN1ePbJJ/s0+3mZU73dz6R/4X74N/4TaXwl/aVyNVR2jE32OX7K0yxtKbcT7fK83YpPlbt+O1cna/tofCu+sYr2PWNSS2kto75ZG0a8x9jf8A5e/9V/qF/jm+4n8ZFeeWnwn8fR6nYeE7jQWl0y28WTeLJPFC31t9lmV7eRhaxw+Z54fzJPLw0ZTywTv6LWZafAX4gQfCzT9FOggajD8J/wDhGWt/tkG77d/zw3+bjH+19z/aqoqL3/rRs0Wp7veftKeA7XxfL4aOq3R1SG6js5GGm3X2aOaWMPCkk/l+Wu8Mu35uayrP9pjwpo/hnSL7WtXm1KW8jaQXWj6RdPAyK20ysArGGPP8chVfevNpvgn40kTxjENG+TUPEejXlspuocTWsFvBHKx+bqmw+5/hrivEXwQ+J83w8tPDlx4Z1fWbNtMuEt9P07XoLOO2vmnkfzrnMyedkbNijeox84HNVyx6Pt+Sf6lXXJLuv+Cfb1ldx31pFcRtuimRZEOezDirW36/nXNeCEurbwXo0V5ZyWV3DaQxS280iOVZVAPzIzKenZq6aoZnDWKbE2/X86Nv1/OlopFibfr+deS/tQIv/CoyCoI/t/QRhhkY/tizr1uvJv2oP+SR/wDcwaB/6eLOgD1jb9fzo2/X86WigBNv1/Ojb9fzpaKAE2/X86Nv1/OlooATb9fzo2/X86WigBNv1/Ojb9fzpaKAG7fr+dIq/wCc06kWgR4h8CdWOg/AvV9RS2NxJZ614nnWG3Gd5j1i+woH4AD6VlfCz4y+Jrnw2fGHizXfD2q+CrnQ/wC2G1TR4TbrpUowfssqvM7ynaxO/CcxsCF4rY+B8OoyfAnWY9KuLe01Rtb8TrbzzKHjSX+2L8KxHQgNg8gj2rxrxB8D/G/jy81LWNP+H8Hw81N9E2axB9ttYoPEOppcWs8JxbSyARL5My+bKFfEpBQg1nTvzSuTK+iR7cf2pvAK2Ed0+paosst01ktg2iXgu/NWHziPs3l+bgx/P06Uuj/tVfDfWrW8vLXXrg2lrp/9pySzafcRo1uG2s8ZKfvdp+9s3be+2vMtN+GPjfxV8atL+Imo+Fbjw/AdQw+lT3trLLaRJp/lLLIYpGRmkk+T5GbanWsL/hQvj7/hXegaOdBBvLXwjfaZJA13AV+0Szb1jBMvp/EPlq4rXUm7im30Pd9P/aS8Capo+pajDq91FHp7RxzW9xpt1Dcs0i7k8uF41eXcPu7FbNYEH7TGjal46sEstSiHhaTR7u9upLq3eC5t5YXQZaN9r4wT8u3NcD4t+DfjK48ZT67Z6Obz+zpdGvobBbmBJb37PBtlhiZpFCup6M+1D61yesfs1+O/G114t1G50+TTJPEtpqExsZL2HfZPPLEyQvJFKf3jKr/NHlB2YVdux0JLZn0I37T3gOLRv7Qlv9QhH2qKz+ySaPeLdeZL/qh5BiEmH/hbbg1Dd/tRfD610/S7xdYvLlNRNw0cVvpV3LNCsDbZ2miWLfCsbcOZFG3POK8j8M/A3xBHe6Tq9r4H1DQmOvaTPcQa54gl1bUPJt/9bJLNNeTJ5K/wRxsG/wBmm+F/h38TvhT4r1LxHonhA+IbnU11iwgtTf20QtGlv/PtbmTfKv7gj7yx7nH92olo0Yq7Ul10PdIvj14NufFcfhyHWpH1CeaKBJhZTm0WaRFkS3+0bPKEzRsGEZfdznb2r0oL9fzr5F0n4D+IYfjJqF3qXha41IXXiS38RHxBH4guIdJt0W1iDp/Z8d4C1ys0R8stAUCOGL5+SvpP4feNG8ceD9N1w2Jsjdxbzb/aI5mQ+haMlP1q5WsrDvebtsdRt+v515N8dlEd58M9gC7/ABlZo2P4lMFwSD6jNetV5N8ef+P34Yf9jpZf+iLipKM/4qeLvG6fE3QPCfg7W9J0l77T7m+eTVdMe8DtER+7yk0Xlg56nNR/Dv8AaS0bxD4ZWXxFN/Y+t2tpc319BDFI0IhgmMLsGK+uDt+9UHxUsvF2jfFrw14t0DwZqvjKCz0u4sfK0+7sYTHLIeHl+0TxEr/uZNeI/Fb4Ma/4d8H/AA107bCus63rs+maxFFJ/q4L9i8hVgPnMbFeR6daSdyZO0Wz6J0n9pPwNrOtjTLbVpvM2sftE9jPFbFlj80xid0WPzBH8zR7twx92qlj+1d8OdSi1CSHVr9HsLa3u5LafSbuGaSO4fy7fy0eIGXzG+55W7d2zXivjj4NeMrrxJ4kt9K0Sfwro1wLw3+sSalbzaRcWzWjRpKlu8rTQ3XAy6LGhA5Y1xuoeG/Efxq8TTi18KywXOieHPDk39m2Ou20NxqFvDfSSyG2ubafbGJlVvLLSxn92NxjzVW1sPaNz688PfHLwp4kuNLt7W9uo7jURdmKG6s5oZV+zKjTJIjJmN1EqfI+1uelY1j+098PtTu9JhtNbuJ11VYZLa4i066eFFmTMPnSCLZCX7LIyk14zpfwp8ZeCbrwt4l0f4fXs4S71qSXQhr63d/D9shgWKa4ubu8kWSQG3HmCKRgN3yh+Sed8C/A34k+E7LwPDa+DpNK8RWdjo8F9qtrqlrJp5jhEYnhvoGlJlmUeZsmijbr9/pTjZ6Py/X/ACH0bPd7X9prwjo3hvRr7Wdfn1N7yJ7gXWj6NdPB5Ibb50oCMYI8/wAchVfevZbO6jvbSG4jYlJUWReezdK+H9e+CfxQuPhzaeGbjwzq2s2zaLLBBp+n67b2cUF6JpHMt1mZPP3jy9g/eKMfOF5r6q+GPiK81Sxl0u90i60i70eO3tJY7mSN/NbywdwaNmHFLl63Jk+WXKd9t+v50bfr+dBPpS0ihNv1/Ojb9fzpaKAPI/hHGrfFL44ZUNt8V2eN3OP+JHpZ4/EA/hXre36/nXk3wi/5Kj8cv+xrsv8A0xaXXrVACbfr+dG36/nS0UAJt+v50bfr+dLRQAm36/nRt+v50tFACbfr+dG36/nS0UAJt+v50bfr+dLRQBj+Jl3eF9WJLZ+xy9GI/wCWZrkP2df+Te/hf/2LGmf+kkddj4l/5FfVv+vOX/0Wa479nX/k3v4X/wDYsaZ/6SR0Aej0UUUAFFFFABRRRQAlUtS/48bk/wDTGT+VXqoaiP8AQbr/AK4yfyoF1PMP2c7q00P9l74X3d5MkNna+D9LkllfASNFso2Le3FcPbftWWfiD4kXmkaRqWnW3hy3j0fZeajpV5HM0l5c3MZTym2N8wgiCPs2AyElscVP4M8F3XxC/YC8N+G7GZra/wBZ+G1lZQyKTlHk0yNVx75Ned33gXx542+JS+IIvAepeHbZD4YthHdSW+P9FurlrhsRu2UVWQZ9MdqcYXbbHKPLTtDc9/s/2ivh1dXGo7PEcKpp9u0ssk1rNEhjRtrtC7RhZ1DFR+73c1Uk/ae+Gy6fp90/iSSGK/nNtBDPpl2kzSALmPyTEsisVdTyvvXztdfB34hXzahp2k+Frzw/ptuovLqxvL2O4s5bhL6KdYtPZnMkKOFbKuyrz0rr/DPw18Xa98erTx/eeErrRtPvNQecWmoNCslrGllDEJJgkjgsWQ8rzVcsYv8Ar+tgit7nf65+09oFv8SPDXhzSdQtriK8uZ4dSurm1uIViWOPf+6kZVjfHRsM2M9q3v8Ahpr4bL4f1DWT4gMOm2ciR3E0mnXMfzSNtR1Ro8urno6gqf7xrwHXPhH431i30zwfH4XukFjd6tLLr32iH7PIs6Zi+fd5nzHr8lN0T4F+JLjw3ZmDwfrUOoW8mkW1yviLXpb2WRbefdI8QknaMRIOigA1lGLUG2DS5kkfRuh/H7wL4g8TWOg6drExv7geXGsulXcMW/aGEPnPEsaSY/5Zlt/H3a7O48F6BN4mt/EUmi2L+ILeA20OqG3X7THESCYxLjcFOORnBr53j+H3irT/ANoRtS0vw3e6TZ3Oti8vbs3kculXtsINok8p3MiXQPdFAr6i2hutVZWTRLvdoYI0LiTaN4BUH2OOP0FBt42YNt5ByD6GpNoFLQNeY3y1K4I4pvlIykEAgnJHrUlJgUvQYYryb9oj/kCeEP8AscvD/wD6cI69aryX9on/AJAvhD/scvD/AP6cI6EB6x5ajPHXqc8/nTdoz0x9OKkpNoodwIRbxr0Xng5JycgYyT3OOM05LeNFCrGqryAAMdetSbRS0rdwIfs6ccdOBz29Pp7U9YVUY5P+8xP86fRVARNbozA4bg54YgVLRRQAUUUUAFFFFABXkkh/4yqtf+xMl/8AS2OvW68ll/5Ortf+xMl/9LY6AOJ8afGH4j2Pjj4hL4eXwtP4f8G29pNJZ6jZ3H2u8WVWaT/SVnCRbQh6wtXVWP7Qnh61sdT1K+vJrvTree1j8rRdFvru4tmlt0lCziFJN3ytneOMcda4Dxrpfjqz+IPxXsNG8E6nqsXi2zsrPTtWEkMdhGypOkzTEyb1wHA+5zXOax4D8c/D/Q/FegaP4Y1rUtH1nUtOsbjUNImgFxFpsVjGk0kW+ZDljHJH6gvuGGwaa63+ROvQ9psf2kvAWo3XhyCPUNUaPxAYE0q4bw7frbzmUBkjM/k+WpwMkMVwp/GszRv2pPBdrpeiJrvim2l1O8soL1p9N0u9Fo0cryRxyElH8lGaMjMhXFc9Y3Wt6z8bNBlvPhp4ks/CuhabBDoiqtr5VrdTqPNluF8/CmKMpGNm/G+TuBjyrwz8AfHdj4D8XadcaDdNqN54G03SYYXuISv2qO9vJWT73TbJH9Me9KK7l7Rb9P8Ag/gfUN78cvA+m+MJPDV1rcdrqseUYy2swtwyp5nl/aNnk7wnz7N+7H8NZNr+018NbrT766TxCxjt5IoniOm3guJpJf8AV+TCYvMnVuzRKwrwW5/Z+15fGmtwTeE9Y8RCXWJ9Vgnu9flj0MI0HCfZVnH73d+63eXjbVK0+F/jWTT2jm8D6+/he0a2RLS41Bf7XspY92XsJxLuaJPl2rIyL6CmorqSvhT7/wBfkfYXhHxdpXjjRbbV9HvReafcco5jZcezKw3K3sa6KvMPgLpHiPSfh7Zx+JoWt9QWaQiObyxP5P8AAZzGArSeuBXp9GnQYUUUUgCvJv2oP+SR/wDcwaB/6eLOvWa8m/ag/wCSR/8AcwaB/wCnizoA9ZooooAKKKKACiiigAooooAKKKKAEpFp1NWgR5F+zPth+E864Eap4j8RliAAB/xOr4niuI+En7VUvigfE2/8cxab4d8O+HLg32m3luXP2nSGmnihnlGXyzG3kOE4xj1q/wDD+81u1/Zk8YTeGbNtW12PVPFX9n2ysqebP/a9+EXn/axXg3xV+Afin4J/DuSe21e98ZaJH4Bk0G8W6gtY47QwSRSW+PLjQsDvnG4kt8xOaKaV3cJ3itD3nxt+1h4f0e38JXei3f2nTL/xAmkas11pd4l1DG1vJKrRW7RrI7tsTbhWDKxIDV1t7+0Z4A0/w7pWtv4gd7DUlZ7WWPT7qSQohCu0kaRF4gpDbt6rt77a8fj+H3jHxl8W/C/juTwxd6NZf23YvPbTPEZFhg0+4jaY7JG4Mku1W+9jHOMVlWPw38c+DrabUf8AhC7jWjfadqujLp8MkKmN5p5XilkDSYCMGTJHzf7NXJJWJhLVc2x79H+0R8PJvE3/AAj8XiHdqXmpbgC0uDDuK7lXz9nl5I/2qx7b9pDwdpGl2LeI/FFtdXV20wDaVpN4YliSTYZJBiQxIDwZZCqHsa8i8OfAnxjovhq4sJbAyXC+JNMvlk86PiGKDZK/3sfKe3Q1yfib4PfEq68GX2gTeGNdu7G4t7yW1t9N1KK3HnteeYDclXBcbPuLnb7VKavYuKTg5PdH3RDNFcQxyx/Okihl/wB1ulTeSjZyM56/4fT2rC8Jb4fDejC4ja3mazhjaKXh1YJyD710ND3sRFuSuyN4lYYI4+tOWNY1CqoVQMBQMAD6UtLU6lhXk3x5/wCP34Yf9jpZf+iLivWa8l+PH/H98MP+x0sv/RFxQwMj4rfEDx3Z/ESx8L+Drjw7Y7tHm1W4n1/Tri53+W+DGvlzx4BB6/MKyfD3xw+FniTU/Ceua/b2Vl42urQW0V8dKkmewaRgpia7WNlgV2Hy75BmrnxR+CrfEr45aFe6jb6snhqHRJ7a4n0vU5rMyStLkRSGF1Lpt/hYlfavLPjN8J/F0mvNp+leGNY1HQ9Jl0ufR7bTLyOOwgt7d90gMTuvmSFufn3Y7YoirO3cqVpWseyyftM/DW8027uG1l7y0tLz7C6W+k3lyZJgzqYo0WEs7jaxZUVsLz05qtoPxH+C3wt03TX8OxaX4Y07X2+2D+xtFeCGQbvLEtx5UQWBd38c20cHnrXnFn4B8c+H/g/4T0lfD+o/ZW8R6nd61Z6LcR2999llmumgZJBIApJeIuUcEKPrXk/h/wDZp8VW+ivBqfgzxLeHUtDOixWNt4hezs4GW9u5f9NMM6GS2aO4ibdy/wAmNnNayiud/ImW7t8j6y8WftFeCtDm8Q2DXk13qmjxzv5Een3UkU0sMfmNFHKkTK8q90Tc6/3a818DftpaJ4g8VWUetINH0W88P6dq8bDS7wzpcTTTRSCXMf7uFSi7ZXVVP96sdvhf4wtfiZqltpXhi80nTr671Sa+le6jn0u5hmtZEhlt45HaWK6c+X5hChTtfOaxNH+E/jfWPBevxXXhTUtMu5fh5pehpaXRhKyXdvPP5iDY78EOGx0HbFTTSd3Ly/X/AIBnJOK5V/Wq/wCCfSv/AAu/wQvio+Gm11ItVJKmRoJRbbwrM0f2lk8neAp+Tfu9qwJP2iPCGvW8S+HfE1nbzvf28Lyarp13GkkcrbQUVlQuHH3ZB+7/ANqvCvDv7O+v2Pii7sL/AMJX2qv/AGxfapFd6pr8p0MLPDIUT7Ik4zKDJ5e7y8d+vNJpPwq8f3F1Z2tp4b1iy0SyutOdLfWpIriSCRJcyrbytIZBaqvRHYkdsVHKlbU0veTaPpbw18ePBXjDxLL4d0bXGvNWjMnymxuI4pvL/wBZ5MrRiOXb/sM1ei18aeF9E8eeHfilpvjLxJ4S8QXR0kakNRvJNRia0cv9w20G/bGnvgE19c6Hqx1jRrK/8povtFvHceU3Vd6g7fqKp26ERbbdzTooopFnkvwi/wCSo/HL/sa7L/0xaXXrVeS/CL/kqPxy/wCxrsv/AExaXXrVABRRRQAUUUUAFFFFABRRRQAUUUUAZPiX/kV9W/685f8A0Wa479nX/k3v4X/9ixpn/pJHXY+Jf+RX1b/rzl/9FmuO/Z1/5N7+F/8A2LGmf+kkdAHo9FFFABRRRQAUUUUAFUdS/wCPG6/64yfyq9VLU/8Ajxuf+uMn8qBHnf7MPP7NvwlJ6/8ACJaT/wCkcVemmGNgQyKwK7TuGcj0rzP9mD/k2v4S/wDYpaT/AOkcdeoUAr9RpjG4HHOc8HHbHPrTfLTrt5znP45qSk2igY3C9hik8tcEY6+/T6elP2ijbSYhu0c+/qafSbaWhDCiiimAUUUUAFeS/tE/8gXwh/2OXh//ANOEdetV5L+0T/yBfCH/AGOXh/8A9OEdAHrVFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFeSy/8nWWv/YmS/8ApbHXrVeSy/8AJ1lr/wBiZL/6Wx0Aer+UpznJBGCCSR+VKIwCTzknPU+3T06U6igBgjVVUAcKMDvRsHOPx5p9JjFLXoAzy13bjnP1NI1vGxBKAn1/Pg+vU1JjNLS1Aj8mP5PlHy/dHYfhUlFFNX6gFFFFMAryb9qD/kkf/cwaB/6eLOvWa8m/ag/5JH/3MGgf+nizoA9ZooooAKKKKACiiigAooooAKKKKAEpop9JtpageR/syorfDGaQqC3/AAkviNc+w1y/r0rXPDuneJtJuNM1Wzjv9PuBtmt5xuWQbg2CO4yBxXm/7Mf/ACS2X/sZ/En/AKe7+vW6YtepAtpHGu1YwBtC/gOg+lP8uPk7QSRtJxyR6GpKTaKBjSqtnryc9ab5Cc9TnJ+8f09KkwKMUANES5zjJznn8qfRRSAKKKKYCV5P8eP+P34Yf9jpZf8Aoi4r1mvJvjx/x+/DD/sdLL/0RcVMtgM34q/ErxtonxC07wz4Rg0F1m0ufU7iXWBPwsT4KL5bDaSP4m4q34V/aL8Ja3o/hpdT1aDSda1eJJPsnz/u2bOMtghd38O48+9YHxO+EN18Qvjpok9zca5ZaJH4fuLWe70m4+ziRmmyIXPcbexryjxZ+z/daX8Stb0vTfD3ia60G/XT10pdPvGh0uMRffFyANy7e2DzTprXUc9bcp7y3x98Ja1q1hb6J4k0ibGoNaX/ANo8xT8ok3RxuAAzgxnI54FYfi79qXwenw18SeKvCGt2viC40nTl1H7ON6xNEWCiTopdAT1X1HtXlsfwt8S6T8KPBKT6Dc29xZeKdW1XUEjALQQyfa9sh554dcZrgNB8H+KPi18CfD9xpnhXVYE034eR6KsMiADUpZ5bSVXjBPKCOCRvrJj0rWMVLmv0JndJM+vU+PngSbw7c66PEkB0yK8GnuXhl3LcMNwQpjcflw3A+7lulLcfHjwBp02mwzeJ7Uy6jaLqNpjcfMt2DKJOBwuVYfN0PWvnn4pfCDxDL8Y9a8VR6X4jXQrPxJZ6hjw3II7ueI6P9n8yH3WT5Gwfu8dK0vBPwl8T+F5rq807wzNaXMXgS4tLCDUXW8H2x7m5m8mUt3JdPl+72x2rGT5tP62HG7dj1HxL+0j4d/4RtNT8I3tvr0qX9rZTwMjpsjmcKG2sAeQPlP3TXte1WABz1zwT+tfCel/DvxnqWt6zMnhfxIFvn0V2vNYG4sYJs3AABwAq9FAwOwr7vUcCtOVRX9dkYxcudp9P+CRzQxzqySIHRhhlboR6H1HtTkiSPhV2j0HTpj+VOxS1JsFFFFAHkvwi/wCSo/HL/sa7L/0xaXXrVeS/CL/kqPxy/wCxrsv/AExaXXrVABRRRQAUUUUAFFFFABRRRQAUUUUAZPiX/kV9W/685f8A0Wa479nX/k3v4X/9ixpn/pJHXY+Jf+RX1b/rzl/9FmuO/Z1/5N7+F/8A2LGmf+kkdAHo9FFFABRRRQAUUUUAFUtS/wCPG5/64yfyq7VLUv8Ajxuf+uMn8qAPPP2X/wDk2v4Sf9ilpP8A6Rx16hXl/wCy/wD8m1/CT/sUtJ/9I469QoAKKKKACiiigAooooAKKKKACiiigAryX9on/kC+EP8AscvD/wD6cI69aryX9on/AJAvhD/scvD/AP6cI6APWqKKKACiiigAooooAKKKKACiiigAooooAK8ll/5Ostf+xMl/9LY69aryWX/k6y1/7EyX/wBLY6APWqKKKACiiigAooooAKKKKACiiigAryb9qD/kkf8A3MGgf+nizr1mvJv2oP8Akkf/AHMGgf8Ap4s6APWaKKKACiiigAooooAKKKKACiiigAooooA8k/Zj/wCSXS/9jP4k/wDT3f163Xkn7Mf/ACS6X/sZ/En/AKe7+vW6ACiiigAooooAKKKKACiiigAryb48f8fnww/7HSz/APRFxXrNeTfHn/j9+GH/AGOll/6IuKT2A6fxl8UvCXw8uLG18R69Z6Jcag3+ix3kyRmVs42jkd8dePeof+FseC28TDw4PEVgdb8lpzp/njzSgXcxK5547EZ9q8T/AGlPD+rSeNrbU9F0PXLzU5dJNhDe6bp5v7S5Hm7vsl3EqkxqTz5u5B2rzzwv8LfE6+Lby21nSPFzakutXGtiG3RY9FhRrfhxM0BeaTPy+UsobPelrpYUro+mrX41fDfxJpurNbeLNK1CytIGk1BUuEYRxngk88jJxxnlqr6V8Vfhj4P+HejXNj4p0vT/AAnbldOsZkuA0UflKEEIYknKgDqffpXzFqHwl1v+wPAkFx4H1ueyg8GSW92mmweXdW8v221YYUjmZQjSCM9eRkjit/wxD4n0XWPD3jXXvC2t6t4dsdV1ONVh0ScanPHPbRrBdy2QQOrZ3wkKo67umK1tpv8A1cmeyPozWfjp8PtBkMV/400e1maKK5VZL1dyxyqfLc4JwrbCQ3Q4rqdN8Rabq99eWdpfQz3en7BcwB/nt2ZA6Bx6lGB/Gvkv4H/s+6i3h3x/onifRJ9Ou9Y8JafpcV3NEo8ljFdN5ET4JzCJIlIzgED3z6N+xd9t1/4W3njXWLF7DWfE2oSXlzDKysypGi28YJA5GyEEZ9aiFnddv8/8hOWiZ9DlQ1SUxc7qko1KS6hRRRQUFFFFAHkvwi/5Kj8cv+xrsv8A0xaXXrVeS/CL/kqPxy/7Guy/9MWl161QAUUUUAFFFFABRRRQAUUUUAFFFFAGT4l/5FfVv+vOX/0Wa479nX/k3v4X/wDYsaZ/6SR12PiX/kV9W/685f8A0Wa479nX/k3v4X/9ixpn/pJHQB6PRRRQAUUUUAFFFFABVLUv+PG5/wCuMn8qu1S1L/jxuf8ArjJ/KgDzz9l//k2v4Sf9ilpP/pHHXqFeX/sv/wDJtfwk/wCxS0n/ANI469QoAKKKKACiiigAooooAKKKKACiiigAryX9on/kC+EP+xy8P/8Apwjr1qvJf2if+QL4Q/7HLw//AOnCOgD1qiiigAooooAKKKKACiiigAooooAKKKKACvJZf+TrLX/sTJf/AEtjr1qvJZf+TrLX/sTJf/S2OgD1qiiigAooooAKKKKACiiigAooooAK8m/ag/5JH/3MGgf+nizr1mvJv2oP+SR/9zBoH/p4s6APWaKKKACiiigAooooAKKKKACiiigAooooA8k/Zj/5JdL/ANjP4k/9Pd/XrdeSfsx/8kul/wCxn8Sf+nu/r1ugAooooAKKKKACiiigAooooAK8m+PP/H78MP8AsdLL/wBEXFes15L8ef8Aj++GH/Y6WX/oi4oA6nxZ8SvB3gaaCDxT4o0Xw7LcfNDHrGowW3nc5yodhnB74p2ofEjwlpetafo154m0Wy1nUAZbLTp7+OKe7APBjjJDPnr8oPtmvHfjh4Q1DXviNcXKaHPqUEXg3UIbaZLN3iinJ+RVOOJD2Arw6w+FuvNqEWmatD44t7vVNM0M2dhpOl2kVpI0EfzrPeS2czW5ib1ljz2q4q456JM+2G8eeGJoobj+39LxIZfLlW9jG/yiTIAQeQuw7uwxzWKvxw+HTR2dwvjvw0yX9wLK1k/ti323E7bCIom34dz5iYUZPzr0zXyhpOja5cWuheFz4T8QxXeif8JN9pnn0W5FqPO87yfLuNuyXzN4+6XrR13wYPCHg+0tbrwJqOoWes/DGPw5aWem6KblrfUGQFoZljQ+T5haHLyYQeSN7Lis3s7/ANaN/oY35pJf1ul+p9N65448BeItcvPAV74w0tNZvN1ncaHa60ttqG/YJSAsUiyofLZWypB2sM53DHNXHxs+GPwm+HPiN9E1/Q73TvBdiWutP03UYZJbcIuEif5/lkYgL8xyWr5y0XTNSvvEHjnwZDo+o3fjGDxroFy+q2+nubOKK0sNMM7vdbdkY2JKNjspYSkJuzisnT/DfinxJaatJNoPiJtZvfAGr6XJpMegfYtNsrzOfsNlsgVWQNysgZw55V3q/ZqOi3f+SZsrJ2f9a2Pp/wACftXeC/GHiifR5Nd0XT1lhtJ9Kmm1aAtqfnxCTbEuRkruVeM5r0218c6DqH2YW3iDTpTeSSW9qIbuJjNIn3gnq47jmvj3VvCmpeJPC/jnUrHwzrAe8/4Rk2z3OjzxXA8nyfNwjxrJxsO/5a1fC8aeAf2ifFQ1PTrp/DvhRDq1vPbwF/LuNS+8FjVjwvr1FOydkupK+HmPtCimKxp9Zcwwooopp3A8l+EX/JUfjl/2Ndl/6YtLr1qvJfhF/wAlR+OX/Y12X/pi0uvWqYBRRRQAUUUUAFFFFABRRRQAUUUUAZPiX/kV9W/685f/AEWa479nX/k3v4X/APYsaZ/6SR12PiX/AJFfVv8Arzl/9FmuO/Z1/wCTe/hf/wBixpn/AKSR0Aej0UUUAFFFFABRRRQAVS1L/jxuf+uMn8qu1S1L/jxuf+uMn8qAPPP2X/8Ak2v4Sf8AYpaT/wCkcdeoV5f+y/8A8m1/CT/sUtJ/9I469QoAKKKKACiiigAooooAKKKKACiiigAryX9on/kC+EP+xy8P/wDpwjr1qvJf2if+QL4Q/wCxy8P/APpwjoA9aooooAKKKKACiiigAooooAKKKKACiiigAryWX/k6y1/7EyX/ANLY69aryWX/AJOstf8AsTJf/S2OgD1qiiigAooooAKKKKACiiigAooooAK8m/ag/wCSR/8AcwaB/wCnizr1mvJv2oP+SR/9zBoH/p4s6APWaKKKACiiigAooooAKKKKACiiigAooooA8k/Zj/5JdL/2M/iT/wBPd/XrdeSfsx/8kul/7GfxJ/6e7+vW6ACiiigAooooAKKKKACiiigAryX48f8AH98MP+x0sv8A0RcV61Xk3x5/4/fhh/2Oll/6IuKAsaPxi+NXhz4G6DZ6t4jS/ltbu+hsY10+Dzn8x22qSMjgdSa7eOYTKhBxyCzc7eeg5IyTkY4NfLX7Tlpr3xG+J9j4Y0Pw7Z+IE0jQLq9ukvr9bWNHnHlI4Ox8sp+YeleNalNF4+8I+KfEt6rtr+h+E9Mjs5mlYSWd5HI8bSRYHDcA5q4xbTsFuaSSPuSP4i2Gpanf2OnWl9qN5YX8Vjc/ZrcH7OzgEFixGEA5YjoOOtWvHXjiw+Hfhx9c1VLhrFLiCBvs8ZkkDTSrEh2kjGWdc45GelfFet6Jo/hz4keMn0VNPsvFEvjXSp91u4WeaB40OS4OWVnJYg8ZqlcWvgbUf2e47e0W8uPGmpWGkSeK5Ipj5a3cmp2gmFwN+BdeYzbWIJAQ1LjdL1t96Ere0aPufw/4N0XwvrWv6jpkH2W8167XUNRYSM32iZYYodxBJwfLhjXAwPlz1Jzg6p8VNMs/Gd54YTTtVvtVs7e1v5PsscTosVxO0KOGZx91lYt/dXnmvlCPTfDuj/FjW/CPiGa1074S6b4xuvNsLqfyrOOZtFsJYI2+bbsMk1xL6eZ83UAjkYdW1aTSTfXd5cy3n9ieESkl1M3meQdZm8oFsZYlHG7OcDjpWsYqU9X0X4/8Ab2b9D9FVLbN2cDHKEEn9P8ACuR0H4W+GtHuNZuo9Me9l1mZZbua/na9MrDoQ0jNhB2UYHH3a+NNH0i58O2Wia94czD4u1KXxQnneaxeRo/9WhJBwB/CRiud07w//aljYwtr9hcwancaTJf2fh21uII3m34kae4aaTFxjqBxWUI2lbt+rEl7iP0bEku3CsN391sA44yT79enFUtB1xtc05Lo2t5YCR5P3V4qLKAp2k4XPGemefaviT4naP4d0nxRqdrdSxWniHS/E+m2eh2bXLK4sf7qoP8Almfrz3NY/wAOdT8JtM3/AAsiSe8sLK1vLzQIIblhKJhfSLIbYq4Jl2+WRjHT604QvG/9dw2jc/QtWDdKdUEY2rxU1JgndXPJvhF/yVH45f8AY12X/pi0uvWq8l+EX/JUfjl/2Ndl/wCmLS69apDCiiigAooooAKKKKACiiigAooooAyfEv8AyK+rf9ecv/os1x37Ov8Ayb38L/8AsWNM/wDSSOux8S/8ivq3/XnL/wCizXHfs6/8m9/C/wD7FjTP/SSOgD0eiiigAooooAKKKKACqWpf8eNz/wBcZP5VdqlqX/Hjc/8AXGT+VAHnn7L/APybX8JP+xS0n/0jjr1CvL/2X/8Ak2v4Sf8AYpaT/wCkcdeoUAFFFFABRRRQAUUUUAFFFFABRRRQAV5L+0T/AMgXwh/2OXh//wBOEdetV5L+0T/yBfCH/Y5eH/8A04R0AetUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAV5LL/AMnWWv8A2Jkv/pbHXrVeSy/8nWWv/YmS/wDpbHQB61RRRQAUUUUAFFFFABRRRQAUUUUAFeTftQf8kj/7mDQP/TxZ16zXk37UH/JI/wDuYNA/9PFnQB6zRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHkn7Mf/JLpf8AsZ/En/p7v69bryT9mP8A5JdL/wBjP4k/9Pd/XrdABRRRQAUUUUAFFFFABRRRQAV5N8ef+P34Yf8AY6WX/oi4r1mvJfjx/wAfvww/7HSy/wDRFxQB6c1vaw3huQkYu5F27uA7gdBnuKpR6JpixzD7BaRRzjD7YlCuuSRkY54J6+tfMn7V14Lbxtp93Nq0j29jphnl0iG8ezuceZjz7dgQsj448ts/SvO9Q1bVb3xZ4l8Jpq2prBoljd+J0mlkdWENxa4iEmDxtk5C9PaiN5K6/qwS938PxPt6TSNNkvWvTp9ob1QG+0bELsBgrlsZ7DB7YrnfCOveGfE2peKNP0qxRZNH1KO11H/R1jRp9kdwrg/xbfMVt3UHp0FfHtwbrwjpf9k6fqGpx6LqWi+GLjWJri9kd44pbny7qVWZiyfJySpCjtioPAvhPSNW+NkfhvTdTurjwxN461NVFpqMm6eNNDhOySVWy6iRFxg8qPrWsYK7u/65l+hF/dc/T8rn3Vc6LpeoLPDdabZzpK++eGWNGWRiNod1I5JVQATzgYqdtH0+VY92n2rfIqhWhXgIdyr06KeR6dq/Pf4leILvT/h1qer2OtXzeNb+LxZH4hs1vJCbe2hS8+zN5ef3Ko8dqqsADiTOa6bxR4di8I33iu80y81BJNIu/DM1k017IwD3boLk4LYbcCcg5C5+XFZxjZaPf/hhr3kl3PuSPTrCNo9llbrLHuZFCKGXd94j0z39aLfw7pdoHEOm2kIeXzmEcCqGkznecDls9+tfGHhXUvEV18eodV1XxDYWN0viu9tJLVp7pro2UYk8uJ4QPJRNuxvNPPGM9a+07DUYtX02O7sLiG7ilTdHNG2Yz+IpuLSWo9m4nlPiv9n+z8WfESz8Rajrtw1il1Fevor2sRjaaP7h87b5gA/u7tp9DXqTeHNKkMRbTrRmhbdGxhUlWJySDjqTWhtpalXSsMQKF4p1JjNLS1A8l+EX/JUfjl/2Ndl/6YtLr1qvJfhF/wAlR+OX/Y12X/pi0uvWqYBRRRQAUUUUAFFFFABRRRQAUUUUAZPiX/kV9W/685f/AEWa479nX/k3v4X/APYsaZ/6SR12PiX/AJFfVv8Arzl/9FmuO/Z1/wCTe/hf/wBixpn/AKSR0Aej0UUUAFFFFABRRRQAVS1L/jxuf+uMn8qu1S1L/jxuf+uMn8qAPPP2X/8Ak2v4Sf8AYpaT/wCkcdeoV5f+y/8A8m1/CT/sUtJ/9I469QoAKKKKACiiigAooooAKKKKACiiigAryX9on/kC+EP+xy8P/wDpwjr1qvJf2if+QL4Q/wCxy8P/APpwjoA9aooooAKKKKACiiigAooooAKKKKACiiigAryWX/k6y1/7EyX/ANLY69aryWX/AJOstf8AsTJf/S2OgD1qiiigAooooAKKKKACiiigAooooAK8m/ag/wCSR/8AcwaB/wCnizr1mvJv2oP+SR/9zBoH/p4s6APWaKKKACiiigAooooAKKKKACiiigAooooA8k/Zj/5JdL/2M/iT/wBPd/XrdeSfsx/8kul/7GfxJ/6e7+vW6ACiiigAooooAKKKKACiiigAryX48f8AH58L/wDsdLP/ANEXFetV5N8ef+P34Yf9jpZf+iLigZa8XeMPh6PiZ4b8GeJYLG98UalBLdaZDe2ay5WM5YqzA7SPasn4XeHND8U+IfEnj6HUl8QHWQ2mf8eAt0hggYqYCjcv82fmbNeYftKeHZtT+N/hzVtN2ya9oGgz6zYoZNrM0UvzcDnaV4I6H0rxHwz4s8R+OvCmh/2PdJYaFcWusa1HdX2s3WmeU32rKkGCJ3kKL/yyZVU9yamml16DkuZP5H6BXHhbSJopYptJs5Y5bf7FIjQJhrfkCI8f6sZHy9BUOj+DPD2h+X/Z2gabpwhlM8P2Wzji2MUCFhtUbSVwpxyQMV8cWPxC19dDnS88WzXWrnxn4ZijxfTRm6jkW28xo4jhtsh3nbjkHBTNP8G6XPqkXg9PEPijxFHpnibxprsWomfW7mMJHbS37W9sHV0MSb1JzwSVVCT0reNNpLX+tGKVoxu9tD6pSPwVJ8RNW8PppOnP4mu9OS+v99km64tpHMREjY+bOw5U8H0rp5vDWk3EUwn0yxlMxRpQ8CsGZMFe3OMDHpXwHb+LNevtR0x9Rv7yKK/0nS9AutZim8u4bSz4ivIEmD5wjyQLETIeglyGB5rtrO+vNS8ff8ILeeIdUj+H1jqGtPYap/a1wtxJJb29rJGv2oSb2Eby3AOS2fL5rGmuenf/ABfg/wDgk9XHtb8UfVcem+HbzxdqyxaLbwa99nEU+prZIHlRv4PN25foNwJwPzra8N6DZeF9DtNI09SlpaR+Uqn+tfA/gPx74j1LwNo9teeJtYbSr3TdAt7+8OoyRzeVM8gllEu/5N42ZkUpjHUZNdb8XNc0ePwrcaD4I8Va5qsei2moX0Vxq/iK6tYLdoeiiVVElyw/gEjlW7sa0UbNrzt/X3kRvUeh9haP440vXta1rSLK68y/0Z40vVZCoTeu4Yz7V0lfNH7I+s3OvXPi++u5Wuri4TS5JJ5HVzKxtcMSQT3r6XokrMVOXNcKKKKg1PJfhF/yVH45f9jXZf8Api0uvWq8l+EX/JUfjl/2Ndl/6YtLr1qgAooooAKKKKACiiigAooooAKKKKAMnxL/AMivq3/XnL/6LNcd+zr/AMm9/C//ALFjTP8A0kjrsfEv/Ir6t/15y/8Aos1x37Ov/Jvfwv8A+xY0z/0kjoA9HooooAKKKKACiiigAqlqX/Hjc/8AXGT+VXapal/x43P/AFxk/lQB55+y/wD8m1/CT/sUtJ/9I469Qry/9l//AJNr+En/AGKWk/8ApHHXqFABRRRQAUUUUAFFFFABRRRQAUUUUAFeS/tE/wDIF8If9jl4f/8AThHXrVeS/tE/8gXwh/2OXh//ANOEdAHrVFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFeSy/wDJ1lr/ANiZL/6Wx161Xksv/J1lr/2Jkv8A6Wx0AetUUUUAFFFFABRRRQAUUUUAFFFFABXk37UH/JI/+5g0D/08Wdes15N+1B/ySP8A7mDQP/TxZ0Aes0UUUAFFFFABRRRQAUUUUAFFFFABRRRQB5J+zH/yS6X/ALGfxJ/6e7+vW68k/Zj/AOSXS/8AYz+JP/T3f163QAUUUUAFFFFABRRRQAUUUUAFeTfHn/j9+GH/AGOll/6IuK9Zryb48/8AH78MP+x0sv8A0RcUAdpr0ei6Na3fiPVLS3V7O0kZ76S3DzRwbcupYAnb1+Uce1cd4e0H4WfEHTrKzsPCuj6jpdisWoWVvc+HwkEfnjessIkiADN3K8jvXlv7Ss15rnijW9Eudb1HRdI0/wAJ3erRfYdSnsxNdbtvzmIgyhR0j7+leQ6PrfinVI4NC0zxJcLZxWGgMujw6zNpj3Q+zOZYra5iPySMqhtgKbyOtXTp3Umy5xaSPtfUvhj4O1rXI9dvvCeg6hrkYj8vU59Ohkuo/LO6PbKy7vlYAjkYPIpL74f+EtY8OHQL7w1o17os0hnfS7myiltjIWMjt5RXaWLbmJA+8Sepr4z/AOFja34k8K+LdTtfFniy3bwb4fju9E+06lJDNcXQnuEl+1pFKRdEGONMOCMHOMnNdDFceIdavtTu9S8YeJbSDWviHFoEsUOq3EAsrJreF/KgKFSheVI03IcjzHwRk5TTjZX3/wA0v1MXK3xf1bU+l/D9h4D8bWOqx6fo+k6jZWvneHLlX01VEa27kPaOHXBjVySFxs9BXNfEv4AW/ijwxomheFk8N+GNM0qWQxaVfeGIb/TirBdrJbh4/LePGUZWAzwQQcV8t6PN4mjvLPwZ4W1W6vdLuNf8X3VxfXHim40Z3NteRBGkvIYZJH8sSOdg+V9vzHiug8Kah4t8WaD478RXvxPu4tR0vR9Ijs7mLVLmDS/OubGFpJ9gUPiTeVWQxhlY7tnFQ4vl5ltp+Jo4+8o9Xf8AB2Pqfwh8FfC3g/wLa+Fv7D07UbCKxjsLmS6s42a7hTkLIpUhwD0U5ArC8Yr8H9B17wX4D8QaJ4dGo3xkPh7R5tHSRUKjLGECIpCR68Vifs265JHbeJPD2qX2rLqum6r9nOn63qb6lJbO0Ify47uUl5lIy/zYK5xXhfx91y/1L4x+JPE1h4R1vV18Dz6dFb6zYyWq2luytuufNEk6ycKcfKrU5N86fcmm1dn2F4L0/wAIaY1/a+FrHSrFrWUW13BpVvHEYnAwEbYB0HrXUCYsm4bvpgenp1/DrXw1Bp+nWN/47/sTVfFM2p+JfE4htUj8V3lhbTA2/mgSXALNEoXklNrE8Bqw7P4peLxofwttbjxxqqnWprrTvEEttdzSGzs0vBGl2sxIO4kpD5pIOHLYyM1dnKSXfQcY2Vj7w0bxFb69HPLZmZlhna1dZbd4SsiNhvldQSB/e6HHFaxbbzncvtXwh4m8ba9rfhfUNLh1vxGmsafd+I78OniW50u0t7e1uEjDSTRqZpvL3KVh3Kp3nk4GPrX4Q+KJ/Evw38J397erd6neaPZ3120ZjDFpYlYsVXgKWLdB/DxWcffjzL1/P/IUnytJ9TC+EX/JUfjl/wBjXZf+mLS69aryT4RZ/wCFofHL/sarP/0xaXXrdCd1cfWwUUUUwCiiigAooooAKKKKACiiigDJ8S/8ivq3/XnL/wCizXHfs6/8m9/C/wD7FjTP/SSOux8S/wDIr6t/15y/+izXHfs6/wDJvfwv/wCxY0z/ANJI6APR6KKKACiiigAooooAKpal/wAeNz/1xk/lV2qWpf8AHjc/9cZP5UAeefsv/wDJtfwk/wCxS0n/ANI469Qry/8AZf8A+Ta/hJ/2KWk/+kcdeoUAFFFFABRRRQAUUUUAFFFFABRRRQAV5L+0T/yBfCH/AGOXh/8A9OEdetV5L+0T/wAgXwh/2OXh/wD9OEdAHrVFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFeSy/8nWWv/YmS/wDpbHXrVeSy/wDJ1lr/ANiZL/6Wx0AetUUUUAFFFFABRRRQAUUUUAFFFFABXk37UH/JI/8AuYNA/wDTxZ16zXk37UH/ACSP/uYNA/8ATxZ0Aes0UUUAFFFFABRRRQAUUUUAFFFFABRRRQB5J+zH/wAkul/7GfxJ/wCnu/r1uvJP2Y/+SXS/9jP4k/8AT3f163QAUUUUAFFFFABRRRQAUUUUAFeTfHn/AI/vhh/2Oll/6IuK9ZryX48/8f3ww/7HSz/9EXFA0rlD44eJfhJpmo6Xp3xLsrC/u5kaWytrjSJtQlMatgsBHG5A3V0f/Cp/h74v0HfJ4Q0W/wBPvobdis2nJiWOJSIBh1GNgJ256A15f8Wm8Xj9pbwrJ4RGgjUm8OXKl9bWVoNnm548sgg59K4T4leKvF9n4u8e6ivibUtPvPD0Ghz22n6dOwspJpN/nKU3fNG2Bt3E1cbtOwSuldn0vffCTwJfTaMbrwlpDyaRxp2bBWFpyGxD8uE5GcDqc1c1H4b+FtU0fVdKvdA0y+sNUna71G2ntUeO5lOMyOh6vwOeowMdK+XJvifq+ifC3xP8Qm8caknjS5/tgW3hd7gTWu+3MqxokWCYgioshPGc4ORxWHJ4q8f6LYx6Nq/iO70OzvNe8OIlxDrxvbyNbqZ1uHkn2KBHKFAVByuO1RyydteqX4oxnNRg5vomz6Y1L4b/AAt3aZ4Du/CuiFHFxq9ppMmnIYsoVWWdcrtDgzrznPIrrz4H8PTDU4n0OwxqcSxXymAH7SioEVZRj5wFUKMk8DFfEtxDqXir4rJp1x4n11H8NaZ4tttM1+31Ai+nigl0503TdXCM4jOOuznqTV5fi54t17UPBmvafrWtXE9vdaFaavDNfmC0Sa6ghd4ltcAy7w7OXckDOBgcVpGm5Rgl9r/Nr9C5y9m5N9L/AINf5n0Foem/CmysdH/4R82Hh/SNGnuL+NdOtRbQRvEPKlLttwCDwfXGORXcaXpvg/VG1/SrTSLLyrpkuNTtxZ7Y7tpEzubjEuVA9a+KNeuL/VPhtqOiHU73TdOm07XruS3tZWjV5Y77cGO1gTkduh9K6qPUvFdsda8L6J4p1GeC1utJjtbOfU2tr2eA2eZEguDnY5PqalWmr91p97X6GNN7+TsfUd78DPh3qDXUtx4F0W4lkVEYtYRbnCD5ACRwB0GMccdKs6X8Efh/otjf2Vh4M0OztL8YuoYbGNUm5z8wA5Oec+uD1FZXwA18+Ivhfot22pXeqyMHV579P325XIKs2SG29Mjrj616btqdUbo4rUfgv4D1aOzjvfCOj3aWdzJeW4ms0bypnOXdcjgsQM+uBnpR4Y+G2h+C/EVzqWk2dtp5m02206K2tYVihiigaRlUbR0zL39PpXa03yU+YbeGIJ+ox/gKFpogeurPJ/hH/wAlR+OX/Y1Wf/pi0uvW68k+EX/JUfjl/wBjXZ/+mLS69bpAFFFFMYUUUUAFFFFABRRRQAUUUUAZPiX/AJFfVv8Arzl/9FmuO/Z1/wCTe/hf/wBixpn/AKSR12PiX/kV9W/685f/AEWa479nX/k3v4X/APYsaZ/6SR0Aej0UUUAFFFFABRRRQAVS1L/jxuf+uMn8quVS1I5sLn/rjJ/KgD5w/Z1/aO+Hehfs/fDHT7zxTbRXdl4a0y2uI/Jmfa4s4/lDLHg/WvRf+Gpvhd/0N1v/AOA0/wD8bqr+zzqVroH7K/wz1G9fybK28FabcTsx4CLYxM5PrwOpqTwT8dj4o8R2enal4bvvDdtqVk+p6Ze6hLCUu7Vdu58IzeWR5kfDnnf7Ur7iJv8Ahqb4Xf8AQ3W//gNP/wDG6P8Ahqb4Xf8AQ3W//gNP/wDG69BXXLKaFJory3kidjtkjkUqcDcRnOM4965PxP8AF3TvDXibQ9B8oalfar9oCfY54yYjEm8bwT8u4dM0DXvIyv8Ahqb4Xf8AQ3W//gNP/wDG6P8Ahqb4Xf8AQ3W//gNP/wDG67bTPFEF5b6d9peHTb67RZBZ3E0bPk9UXDfMR/eAwav2+r2V5dS2tve281zDjzYY5FZ0z03KOV/EUxPQ86/4am+F3/Q3W/8A4DT/APxuj/hqb4Xf9Ddb/wDgNP8A/G63PiT8UtM+Geix6hqBaXdPBCtrEyCZhLMkQcKTyoLZOBnFaukeLI77T4bnURFosss8kMdrdTRbpNjsnDKzBs4DDHPtQtVco47/AIam+F3/AEN1v/4DT/8Axuj/AIam+F3/AEN1v/4DT/8AxuvQ5Naso72S2e7t1njQuYfNTfgDJO3Of6Vmav4003R9FvtTmvLdoLW3e4IWVCWAVmABzj5gBjvyKlysr2Ecf/w1N8Lv+hut/wDwGn/+N0f8NTfC7/obrf8A8Bp//jddR4N8fWHi/wAMaHrCTQ2R1a1W7hs7iVBLgjp17d8A1sHxBYxpO73tqPJbEq+auYwem7ONp+tU9HZkKSaTXU8//wCGpvhd/wBDdb/+A0//AMbrzL48ftIfDjVNE8I/ZvFNrLjxXotxzFMnyR3sZY8x9Qe3evpuKaOWMOkqyRkb1kTBBWvLP2iI1/sXwh158Z+Hz1P/AD/xD8sdqCiX/hqb4Xf9Ddb/APgNP/8AG6P+Gpvhd/0N1v8A+A0//wAbr1baPSjaPSgZ5T/w1N8Lv+hut/8AwGn/APjdH/DU3wu/6G63/wDAaf8A+N16ttHpRtHpQB5T/wANTfC7/obrf/wGn/8AjdH/AA1N8Lv+hut//Aaf/wCN16ttHpRtHpQB5T/w1N8Lv+hut/8AwGn/APjdH/DU3wu/6G63/wDAaf8A+N16ttHpRtHpQB5T/wANTfC7/obrf/wGn/8AjdH/AA1N8Lv+hut//Aaf/wCN16ttHpRtHpQB5T/w1N8Lv+hut/8AwGn/APjdH/DU3wu/6G63/wDAaf8A+N16ttHpRtHpQB5T/wANTfC7/obrf/wGn/8AjdeZyftIfDf/AIaUtNQ/4Sm2+zf8InLb+Z5U33/tkfG3y8496+oto9K8lkjX/hqq1GOP+EMlHX/p9j/X3oAk/wCGpvhd/wBDdb/+A0//AMbo/wCGpvhd/wBDdb/+A0//AMbqv49+Py+D9e1XT7DwtqniOHRo4p9WutPMYFpG5yPkdlMhx2TdXotn4h07UPKEF/E0ksQuEhZ0EnlkZ3beuAOelAHBf8NTfC7/AKG63/8AAaf/AON0f8NTfC7/AKG63/8AAaf/AON13uoeJdO0+zlumvrXyY+GJkX73ZRjqT2Xqe1cf8LvjJZfE3wtZ+IksZNG0e80611GK4vZoSFWdC2xtrHYVOOTwe1Gtm7bA9LeZS/4am+F3/Q3W/8A4DT/APxuj/hqb4Xf9Ddb/wDgNP8A/G69Cm1qzt7dJ5ry1jgkC+VIZVAkz6ZPc8Dk1oKyMqFWDq3RhigDy3/hqb4Xf9Ddb/8AgNP/APG6P+Gpvhd/0N1v/wCA0/8A8br1baPSjaPSgDyn/hqb4Xf9Ddb/APgNP/8AG6P+Gpvhd/0N1v8A+A0//wAbr1baPSjaPSgDyn/hqb4Xf9Ddb/8AgNP/APG68z/aH/aO+HOufC/7Ja+KrV7n+3NFbYYZkH7vVLORuTH2XkevSvqLaPSvJf2oIV/4VLu53f2/4fGcnOBrNn/k+vek3YCT/hqb4Xf9Ddb/APgNP/8AG6P+Gpvhd/0N1v8A+A0//wAbrW+K/wAUv+FZQ+HUt9EuvEWoa5qCaZaWlrPDCWkZWYEtIygcKaPh98WtP8eaBdahLbv4fu7G+fTL3T9SkRXguUI3R7gSGOOmOtVbS4eZk/8ADU3wu/6G63/8Bp//AI3R/wANTfC7/obrf/wGn/8AjddjrvjK20nT7ma0WHV7uNPMWwguYkmZe/DEdKvx63Ztcy2xvLdp4181k81AyrjPzDOQAO+MVMnypsDz/wD4am+F3/Q3W/8A4DT/APxuj/hqb4Xf9Ddb/wDgNP8A/G69AXXrFo5JBfWjwxssTyJKCFkJ27T1AOcYGc1yvjf4taT4Lt9FZ5lvpNW1K106GO1ljkdGuHCRuyg8oGYcjtzmnr+Nv6+8Unypt9DJ/wCGpvhd/wBDdb/+A0//AMbo/wCGpvhd/wBDdb/+A0//AMbrsNL8WxXVhbz6iI9GluZJIY7e6ljD7lZh2br8p+UZI/CqXgr4h2njXVPE9jbQXEMmgah/Zs7TKB5kgRW3DjphhR38hOSTS7nOf8NTfC7/AKG63/8AAaf/AON0f8NTfC7/AKG63/8AAaf/AON16mMc8U/aPSgadzyn/hqb4Xf9Ddb/APgNP/8AG6P+Gpvhd/0N1v8A+A0//wAbr1baPSjaPSgZ8t/s8/tG/DrQ/h69nd+KrWO4PiHX5AiwzPlZNYvZI2yI+6HOPU4r07/hqb4Xf9Ddb/8AgNP/APG6i/ZjiU/C+UkZb/hJvEgzk5wNcviB9BgcenFet7R6UAeU/wDDU3wu/wChut//AAGn/wDjdH/DU3wu/wChut//AAGn/wDjderbR6UbR6UAeU/8NTfC7/obrf8A8Bp//jdH/DU3wu/6G63/APAaf/43Xq20elG0elAHlP8Aw1N8Lv8Aobrf/wABp/8A43R/w1N8Lv8Aobrf/wABp/8A43Xq20elG0elAHlP/DU3wu/6G63/APAaf/43R/w1N8Lv+hut/wDwGn/+N16ttHpRtHpQB5T/AMNTfC7/AKG63/8AAaf/AON15j8av2j/AIc6pffDz7L4qtZfsfiu1uZ8xTJtQRXAyMx8n2r6k2j0ryX48Rr9s+GIxw3jSzzz1zBcHB9R7UAcV4+8a/s6fFG7s7rxVdaZrN1ZhlgmmtroOgY5IyqgkZ7HirEfxG/Z8jsb6yF/pptL2OGG4he2uWWRIc+UCCv8OTiun+M3x01T4R6hpsUXgHVfE1lf3MdnHeWN1bxATSfdTbIyn8a73QPE39qWdr9vSLR9TaLfPpctzFLPb8ZIfYcZA5yOKIvS43fqeOWnxI/Z8sda1HVobzSkv9RDi6l+yXBEm8AP8pTALBRkgDPfqa4fxpcfArWvC+keH9A1jTNK0y28QWWr3lu9rcnz1hmLMpZkzyCcc8dsV7946+LWl+BbCzv5iL23utVtdKK20kbNFJPMkSsTuxtBJJB5rqbXWLK+WGWG8guo5h5kMkMilZFAHzKQTkDcMkcVLbWvn+WpEoqS5e+h4jpfxM+AGjQ2cNnf6bDHZ2tzZwD7LcsY4rhkadQSmfnMaEnqdvWsa41r9mW8mhmmXRnkhSCOM/ZLkYWEKsQwFwdoRQD6CvomPWLWeS3SC9tXeZPOjTeD5kePvDnp33YIpv8AbljNC8sV7avDEw86RJV/dj368k8YODzRzNWt/Vv6YRXNq+v6nhn/AAsT9nzyXhN3pZieGe3Km0uDmOZt0o+5/Eec9R2xWcde/ZnOiXGk40cWNx5fmILS5DEomxDv27gQvGQc16/8QvippPw/8NnWZpBfoZIVjtbWSMyyCSZIcqN3zKpbJxWrpPjGO8hle+hTSQl41nH9qnj/AH+OjJtY8n+71qo3smv66/qVGPKmzz3w7+0B8GfCekW2l6Nr9hpunWw2w21vZzqiDOTgbPWtP/hqb4Xf9Ddb/wDgNP8A/G69OWaOSEShwYiA6uvIKnpVjaPSlrfUNOh5T/w1N8Lv+hut/wDwGn/+N0f8NTfC7/obrf8A8Bp//jderbR6UbR6UwPlv4X/ALRvw5sfiF8YrybxXbx29/4ktZ7eQQykug0bTIgceX8p8wOOf7or07/hqb4Xf9Ddb/8AgNP/APG6j+Ecan4m/HJCMp/wllmdp5HOhaWT+GecepJ70QftD6DcfHjUvhclrdrqlhpg1Oe+kVVtQuV3IGPVgrqx9qXkBJ/w1N8Lv+hut/8AwGn/APjdH/DU3wu/6G63/wDAaf8A+N1u+Dfi14d8e+GYdc0m+iktZjIsaSOsbO8f3lAatex8VW13Z6e9zLHpV5dDeljeSRrM3O0KBu5yfTNNak8yu0cX/wANTfC7/obrf/wGn/8AjdH/AA1N8Lv+hut//Aaf/wCN1seHfitp3iK38V3W17CHw/fz2E5umVUYxKrFw3QAhu5rh7f9p62m+H0vjWXw9cWuhfZ/tdu7Xls7TxGVEBwrnaxLHg9O9Gt7FS91OTOg/wCGpvhd/wBDdb/+A0//AMbo/wCGpvhd/wBDdb/+A0//AMbrv28QWJt4biO8tXtpH2CbzV2cKWbn1AViRnjBz0rybxr+01p/gOKU6ro97HNFo+r620UTwt+4sZY4yNwcjMglV1HbaQeaIpydkv6tcqMebY2v+Gpvhd/0N1v/AOA0/wD8bo/4am+F3/Q3W/8A4DT/APxuu6t/EljcQxf6bBDI8C3DRzOokRCu4llz8uBzkjFc34K+LmlfEC10/UdFHn6NcwyyyX0ksS/ZyjbdrpuJHNHWxlzWVzJ/4am+F3/Q3W//AIDT/wDxuj/hqb4Xf9Ddb/8AgNP/APG6799d0+O0jmOpW/2dztW58xNpIGTz93JFXI7yO4t4pYirpIMiRGBT3+YZFBfWx5F4k/ai+FzeGNWx4ut/+POX/l2n/wCeZ/6Z10f7Ov8Ayb38L/8AsWNM/wDSSOuw8SDb4X1bH/PnL/6LNcf+zr/yb38L/wDsWNM/9JI6APR6KKKACiiigAooooASqOoDGn3P/XGT+VX6pal/x43P/XGT+VHUOtz5/wDB/hu68afsD+HtFsC0d5qnw1t7OLaefMk0xEXH4muH+IX7QWk+IPhnaaPoGi23iewt9JgGvNcyOi6SxubaFY7lUKsNu6V3j44hHOK9z/ZhQN+zZ8JMj/mUtJ/9I469MNnCzMxjUsw2kkdR6fT2qV1LjLZy3X/A/wAj89/h34R8P+LPEGj+G5ja65oq+O7i4a1stP8AslkYWsdwPkDP7otwvPPeoYLXwzb6p4a0+K2iTx/D/b/9sQiL/SRvixHvOMjI/wBXkNX6HrbxrjC4xyPaneWm0DaAB09vpT7GNOPJdvd/5n5r6lq2nre+C98eleHtdsLjRfJS4tWk1O9g7zLMzDyYV7qFAPdjXvX7N8/hZfEGn2V1ozz/ABOhn1EavqFum24tEMsmBdNkF8rsCZDfnX1cYwc9ehH3j3pDAhGMHGMYycYqrlS1Vj4Z+PLaFB408YW/iGGG48Yz+INGuNC3qWuVslliLeVjcdoIcuFC9a8/8QR6NY+D9PvNSEN1dwzeJPsek6vbEQ6qz6tIQllIAXhvQvMZ2M2OOlfpP5K7SMcHqM0vlrweeuepqY+7HlLb3PgHXlt7jU9Qt5raK3+Lh8V3d1OiZN5HoZ0+QqA33jb+T5a9NnmD15qR/CPgnwP4G+GZ8TaXZaf4Vu/BNy+66iyr6rJDB8zZwzz4U7DgEc4xX3yIVCgcnHqxPfNNFrGABt6dOT/nNVe0XHv/AJNfqYuLc1Lol/kfmr4J8OXl5e+H4tR1yLSL1odBOgWNvoq3erNAsUfmPaym4j8lN+/zMqx59gK6m+8DeFbPwHFr2pC00m5m8UajJNqes2DXVhcpvx5N0xICgj7jEkV+gDWsTsSyAll2n3Hp9KesKqMYyOvJz3zVVJc8kxRp8qSXZHm/7Pt99u+DPha4+yPYD7IB9nuJzKyDPQuQCfxFUP2iP+QJ4P8A+xy8P/8Apwjr1fy1445HAryj9oj/AJAnhD/scvD/AP6cI6l7miPWqKKKQwooooAKKKKACiiigAooooAKKKKACvJZf+TrLX/sTJf/AEtjr1qvJZf+TrLX/sTJf/S2OgDzzUvihZfBP4kfE8ayu/VtZeyudD0/cfM1NxDtMMOAWZg3bBryHXtWgn/aA0DUrq1sfDevw+K47W40+K3ka72SWZVbiS4dgVhklKRogUI2PlBb5a+x/iB4+sPhvpUOq6lDcXVtLeQWMaWg3yGWWQIuEJAbB5POR2FdDldrGQZQhslhkHOOvPPT8vSlF6KX9bh0Pgzwb4J8G+DvCvwf1DxPptra+G7rw3qwmmv4yRJq5kt/szsWwzzFPtXlrgbccEcVg/Dy8TSfhfZxatp9i+l3PhrwdZzajrNtI9jZIYJT9puIiy71jKIPLZlVtw5FfcvxC+Jdj4Dm8PW72Goave+ItQGlWNtp/lK5cxSzMxaWSNQqRwyscEt8uFVmIB63arMPM2xkElVyMH5hgj8QP++utaKTUWl1f5Nv9fwJk9n2/r9D86vhXdeDdJRovHEdp4i8MWKazbabZtZiINejUJHWG2jLYjdkMIjXjG44Ir9ENBeKTSdP8iB7WB4RIsExPmR+xz9e9T+ckmVZRliCAo3H72M8cZ6HjpXNeIviRpnh3XYtEdbi+12aymv4bG1jDM0cf3juOFHsCRn3qObmG9NWdrRWfb6kLiyWd91oWjEhjnADp8oJDD1GecE/WpWuGSMuzYC9uAeuPXHP4UBdW5i3RTaWkMWvJv2oP+SR/wDcwaB/6eLOvWa8m/ag/wCSR/8AcwaB/wCnizoaugOZ/am0/VdSuPhpbaJeJpuoP4ng8u7nsvtcUAWGUFvKDoW4Y9xXhnxy+EsngnXrSPxF4ss5NK1Gzvru61LV9H+2Ldam5zsgg86MLKV+4N7H3r7lUKvBGZFPmBOc5OQTn05I6Vw3jj4saf4J8Q6bo8umahqF3fW8135liI1iiijA8ySRmkXAA6Y3N6A076IT2PkO/wDAcH/Ct/i5quoWFxd6zaRadFBfahbAXJXZkgKWKpg9Tgk9810XhnWvCuhQ6/DqfhW78Q/FK0uNRlufsxeK6it/JyhmfcH8kr8nGV3fw19XfDrxpF8RfC9trtvpl1pVlduxhjv/ACfMljU7RIBFJIArdgSGGOQK273UDY2M0q2stzJDG0ohtwu6UgcBFJ6semSB70TbaaRMZKyZ+buk2GjavJrWi6fPpGpaHqt/4PufJ0Wy+yWgJvykqRqrElkJRZJD83HJz8teheJtJ8K+H/iPLos+n2tr40i+JOlSaXbrGVmXSFW2WMKFzttsK2cDbv8A4a+4rG4e9s4Z5LWa3knRXe3nIEkRIHynazAMMc4OM9DUs2xomMrKDtLYJ4BPTv68dRk1rOfNbTZr9P8AIU0pxku9/wArH5qeLLq0X4dz2d5Fp2jahaWF9eaZf39k9zPev/a90zx2oMgELxqAXkQFwGA3AcV9h/s5ztcap8S7jeZI5vEO6Nssd4+zQLu/NDXuRgjDE7Rk4/TpS/Z4+flznrnmsnvJ90/xsDh70WulvwTFXqakpNopaC1ogooooGeSfsx/8kul/wCxn8Sf+nu/r1uvJP2Y/wDkl0v/AGM/iT/0939et0AFFFFABRRRQAUUUUAFFFFABXkvx4/4/vhh/wBjpZ/+iLivWq8m+PP/AB+/DD/sdLL/ANEXFIDL/aYjVtN8CqOHTxVprs2WyieYQXyATxXy38StRhm+NL3mkLZ6P4m/t28sWs7e1f7cFNpsSSe6J3MJD92JRt9N1fof5a4xjimfZ4zjKBsHIzzSV0rev6F8ytY+CZl+H3iT4Y+E9P8ADPhhH3av4bh1++t4mSCa5F1EskEn3d86kMzkruqn49t7z4V+E9d8UeHbBLb+zfGeq+H7S1tVO2C31C0jSERKAAEW68jCgYG4gccV+gfkpuzjn1zzXE+OvhlYfEG70P8AtLUr4abpd5Ffvptu8QhupomV4WmYoZPlZVOFYA45zWrab12e/o7X/IzjeLT7a/g1+p8seH9B8G/C7x9r/hnxB4afX/Fun3OkQeFLW3UreNp0On28fmxS7kIhSUXRk2hQMcq3FeQWf9jaxpviaGwfSbePWvC2nNcaPodkYBBcDVEE0Usm5nnnjQkszEuAeQtfp55CbgduOMUjW8bZyCSe+45HTp6dBUqT5r/1tYcfdSXbQ/P74zeG/CPhTVPF2i6hpdpBq02oaE/hiwMZ817VTbmXyM4B/eeYZACOvsKwvHi2c2meK9L1eCxtQdU164tdZ1e0e9LSj7tvboxCrM3aRhuHYCv0faFGYMV+YDAPoMg4/QflQsEartCKF6YA4561Sm0kv66FN3VjhPgnqS6l8IvBl0shk3aTbtKzEltwiAYHIBzurv6Z5a4xjj07U+pbbdyFogooopDPJfhDz8Tvjge58WWv6aFplfMenx+LbjXtC+Kl5peizeGNS8Y3SyXklzMbyayuFa1jDW5h2BcJCf8AW8bc9Sc/Tnwh/wCSofHEdv8AhK7P9dC0uvVTbo2cgn6sfXNLrcZ+fXwn8DeD/EWseF9N/sjTZLnStM1oXVuluEW3uw+E81MDbx0yWrmPHV9aSfDjRbWeLTdIv9L0iyn0+5u7BptQvVF1lvspaQLCka/ekQE+1fpaLdAcgdiOvr1o+zoWyVycY69s5qk7NPtb8LmXK7t97/ofN3wTt4Nc8E/F5ZLaO4tNQ1m7Ch1DCZTbRAMVbg8/nXzjqvhiy0X4PvHBpJ06wk+HUfnwWdr5YZzfxiTKqR85HJPWv0fMKNuyM7uozwen+FN+yRFWUqWVjkqzEj6c9uOnSpu+a6/rcuolODj5/wCR8EN4S8J+NvjR4ah0bTrPUfhleeLIVt4rOPFlJKNFvftDcZDKWaFSAFDOMHOTnlNasJ7fwfrttDEhSPw/8SdsKrjfnV43ROmcY+bH5Zr9I/s8YCjH3enJ79/rz1pfs6ZBxnHTmto1HF3/AK2sXBqDX9d/8z8+J5tFvvjj4KuJ7LSdJvh4oNjeaeLASX93E9lJEs9xMzn9xMNnlx7dnGQpNczp+j2Vr4R0LTfDFraWN7a6VeLq1vpdqiuuL6MyK21VwfL3gE7jznriv0sNvG2QUDAgg7ueD1H6UfZo+u3BznI4PXNRzO93/Whny+7Y+DbDw14V8XfELTbfQ9PstQ+GNx4ltXsrW2gDWLOtricYwVZQ3baBX0d+ylapp/wjgs0IRYb26WONM4WMSnaMED+HHNeyi3RSSB19zTvLG3aeR7mk9XcST5mzL8S/8ivq3/XnL/6LNcd+zr/yb38L/wDsWNM/9JI67HxL/wAivq3/AF5y/wDos1x37Ov/ACb38L/+xY0z/wBJI6RZ6PRRRQAUUUUAFFFFABVLUv8Ajxuf+uMn8qu1S1L/AI8bn/rjJ/KgDzz9l/8A5Nr+En/YpaT/AOkcdeoV5f8Asv8A/Jtfwk/7FLSf/SOOvUKACiiigAooooAKKKKACiiigAooooAK8l/aJ/5AvhD/ALHLw/8A+nCOvWq8l/aJ/wCQL4Q/7HLw/wD+nCOgD1qiiigAooooAKKKKACiiigAooooAKKKKACvJZf+TrLX/sTJf/S2OvWq8kl/5Oqtf+xNl/8AS2OjbUD5p+OsHhST4heK/wDhJDYr44k8Q6PFosl6p+1jThJGXW3HDFM+ZlRgHPOeKydY0U3WvfEXwnfNqGm6P4DtNUmXULS0e5kjGpmMxyqhKl1VftW7HoPavvl4YvmmkRI3YbTI33gByOcep/8Ar1x3gv4a2fhHWNf1ea9uNb1bWpla5ur6OISiFRhIQsaKuxA/pk5yxNKmtEvUL9PNHxh4M8I+CvE3jT4b21t4Y8J3tpYfEGdFvNCtVl0SdToks7NYKQyxL5scPmRoxUTIGO5ua43VvEmiat8OPCegwahDdanpfgDXbLWreKYCe0f7XZDZKM5SRQrEbmHU1+h2teK9I8O+IvDXh+WOSO41me4hsPssI8tWigeWTJzx8oIHH3q6SO0t42DxqqfKT8oA64y2ffaPyq/acrv/AFqmv1M37ysv61b/AFPhTxRoPh3wZ4q1nQprPTtI+G8PiLRW8Q6eQsWmrA+mFnkuFYBRG8hTfvXkjmsP4y6P8IpJNAv9K8P6fpWmtoWqrokmoQxNI88bgRfZXcswH/PIRnA7AV+g62sTKw8lGy2x0wCGwQOfw7UklrbzwrH5UMqKA0auoK4HTH6VOrWv9aWKklJWPhW5j02fxFJcTNbP8U11PTpNGYyf6WNM8rBCfxm3A/1mAqHvV/4A6L4b8A658N/EkFpBpN7qSa/LrN3DCsckyrM7L5zDl9pAxuzX3C1hb+csvkoZR/y0x83THX6VX1DRbS+s5bWSBfIkRo2Rcr8rZ3AEYxnPOKqLtv8A1oQ4e5yoWw1KHVtPtb20n8+1uVWSORMYKFcg1fqtYabbaXY21naxCG2to1iijUnCqowB+XrVqkaK4V5N+1B/ySP/ALmDQP8A08Wdes15N+1B/wAkj/7mDQP/AE8WdIZw37ZEE974c8IQ3l5pOm+GW1oDV7jxJZve6UI/Lcg3MSTw7ot4HDuBxXhdn8J/CfiJfCUWs6PovjGJvDetPZ32peHY4kMS/wDHuYUkkl8uEZ/dAyZHYCv0BltYpsiRA4PBDcg9eCO/U0fZYtqjYMKcqOw+npSeun9diJJvY/Oy6l8MfDD4e31l5Gn+GYtW+H8UVtZwxfZ47y48/c/looUSsR1IBJ702RdB0nxlqL2r2eua7dw3rXE4U2+u6Z/oWAlwBvNzZnohwiA8jnmv0SNhbtsJhQ7F2Lx0X0+lL9ht/ML+Sm8/xY546U/5vP8AzuHKuVI/Pi4XS5Y7FNTisB8TY4PD0PgkncbxbTy4vMW1GNwVWMpkCfwn5gvbsv2dvC+j+GfHHwl1LTLFLDUNZg8VDVL2JfLkvNl4nlicg/NtySmegOFwK+1PsNuXDmJS6jCt3Uc8A9up6UqWMEe0rEqlQQpUYKg4yB6ZwOlNu7bBRsStTqSlpFhRRRQAUUUUAeSfsx/8kul/7GfxJ/6e7+vW68k/Zj/5JdL/ANjP4k/9Pd/XrdABRRRQAUUUUAFFFFABRRRQAV5N8ef+P34Yf9jpZf8Aoi4r1mvJvjz/AMfvww/7HSy/9EXFAHrNFFFABTTGpIJGSOlOooAKKKKACiiigAooooAKKKKAPJfhF/yVH45f9jXZf+mLS69aryX4Rf8AJUfjl/2Ndl/6YtLr1qgAooooAKKKKACiiigAooooAKKKKAMnxL/yK+rf9ecv/os1x37Ov/Jvfwv/AOxY0z/0kjrsfEv/ACK+rf8AXnL/AOizXHfs6/8AJvfwv/7FjTP/AEkjoA9HooooAKKKKACiiigAqlqX/Hjc/wDXGT+VXapal/x43P8A1xk/lQB55+y//wAm1/CT/sUtJ/8ASOOvUK8v/Zf/AOTa/hJ/2KWk/wDpHHXqFABRRRQAUUUUAFFFFABRRRQAUUUUAFeS/tE/8gXwh/2OXh//ANOEdetV5L+0T/yBfCH/AGOXh/8A9OEdAHrVFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFeSTf8nVWv/Ymy/8ApbHXrdeSS/8AJ1Vr/wBibL/6Wx0nsLqfP/xIvLLSv2hru8N7aaxqU2pWlnHbLK9tqttG6Z8uP5iJ7Un7/wAny9sVwV144u9Q8J6HBoOsvd6ppvwz1ZL2C0ucyxkXFqkiyEt/rQqsQPyr9ApNM05tQW+a1tpNRQeWJ3VRKMjGN3XBHasLxCfDvw/8P654judOtLS3s7Oa6vJLa1QSPGq7pCcfeyByD6U4yUVdj5XKWh8q3nhf4SeMviX8OvD/AIXsYb/wuur3sd3CsrHT3kGkylPKBfgBSpbGPm967fwl4oks/wBhWw1LUorzVWGiiKfN3IjszSeWCZ1w4VerEc4zX0F4bttIuNJ0u50uxtba1eIXVuscKRsgdQdwUDglWAP1rI0nxtoF9JYaA0UljNqltdSW2m3kKxySRwyLHL8mcAEyJgd8nNTP3rxRnHv3PhbR4NNnsfEnhmTxP4dXRbHxXBPb6aRN/Yl2G0+MtF/rP3UZfeFZiwJPsK+0v2d9TTWvgt4XuraO4t4jahRHfs00qj0LZBP41seJ4PB3hHQzPqmnafa6UZIbYqbNDGrF9sQIC9A5AA6DNbHh3VoNWs3a0tJbOGGV7dVlhCKdp5KgHGw9jVp3jct9zoGp1VvOdnAG3bnjLct6/lTkmZ+OjdSpIyv5VKH0uT0UmeKWn1sAV5N+1B/ySP8A7mDQP/TxZ16zXk37UH/JI/8AuYNA/wDTxZ0Aes0V558Xvjd4a+Ceh6Rqvia4uILHU9Rg0uCW3iDkzS52AjsDg81BqHx98Kab8XtI+G8t3I/ifVNPl1SCGOIlBAndm7Ejmmk3oh2PSqKrecYydz5GC5LEDav/ANanSXCqoLyLEv8AeLDB+malO4ieiq7SNhSJVIXhhkc8evt16VS1jWk0fS76+nDiCyhaeUqATtVdxA564pOSjqxpX0NWiuR8H+PrXxtpkF9p6XMdlcWVtqMF1c25RJIZl3IevUDqO1S3njzT7LxtYeFZZXTV7+zlvYY9oK+WhVTz9Wq7O/KZqacVPodTRUZYhl/WpKRYUUUUAeSfsx/8kul/7GfxJ/6e7+vW68k/Zj/5JdL/ANjP4k/9Pd/XrdABRRRQAUUUUAFFFFABRRRQAV5N8ef+P34Yf9jpZf8Aoi4r1mvJvjz/AMfvww/7HSy/9EXFAHrNFFFABRRRQAUUUUAFFFFABRRRQAUUUUAeS/CL/kqPxy/7Guy/9MWl161Xkvwi/wCSo/HL/sa7L/0xaXXrVABRRRQAUUUUAFFFFABRRRQAUUUUAZPiX/kV9W/685f/AEWa479nX/k3v4X/APYsaZ/6SR12PiX/AJFfVv8Arzl/9FmuO/Z1/wCTe/hf/wBixpn/AKSR0Aej0UUUAFFFFABRRRQAVS1L/jxuf+uMn8qu1S1L/jxuf+uMn8qAPPP2X/8Ak2v4Sf8AYpaT/wCkcdeoV5f+y/8A8m1/CT/sUtJ/9I469QoAKKKKACiiigAooooAKKKKACiiigAryX9on/kC+EP+xy8P/wDpwjr1qvJf2if+QL4Q/wCxy8P/APpwjoA9aooooAKKKKACiiigAooooAKKKKACiiigArySb/k6q1/7E2X/ANLY69arySTJ/aotf+xMl/8AS2Opeug1a54H8StStIfiV8Tb6DWr5fFml32knR7L7W6hnJcuqxA4kBUDsa81+IPiaK+17XdQs72G0ttUtfElrLp82ovcXNwsFrOB5kTNsjUtCCioFYq2TmvtzRfg/o+mfEXXfFtzFb3+p6m1vJE09kpNoYlK5jc8jIY9MVs3Pw78LXk8t5P4Y0S4upHMvnTafEWZiu3czFc5OSM9cHFEvh/r+ugQlyS5n3R8ZT3UcPiXxVd2uuTyeM9K1fwkmg2aX0gVoZIrJZUEIbbIHXzDJlTjtisa2k0Sz1TwN4w8RLqV9cQeHPGU0Vxb3zi4lkjv0aOKMFseYEaUKMdx/dXH1pa/DTw14C8aa/4yvrSO9vte1KxS0EOliV7A+TFaxhGVWZFyu4uCAucngV3TeDNBmgtWk0TS5/IZ5IDJaIQpkHzMMr8pYnnFaqVnzev4q36kpWtHsj8+9f0uy1Twz470XU7nTrzR0n8N38VvY6xNOtr5l587vK7k52/f52L1AB5rrfDc2n6qyaNrmu3EHgqPUfEJhulvXRA8MmIY/PDhiVH3VLYPoa+z7T4Z+E7W3ntovC2i29rPH5MsMNhEEmjzu2ONmCuecdKdL8OfCsmijTG8MaLJYLIZRaNYxCFWJyW27cZz1OOe9Pm92z/rRL9AvzI+F7q91XWfCvijxRrGoapDr2i6Ro09iY7uRAsjyf63y1IRiy8FWBHtXovwe8VWuk/GGG5vte/tZdSlvManDfSll2JkRXls7EQFOzBVB75r6ym8M6PN5sMul6fi4RUkXyFJZVHyj7vIHb0rmdZ0jwRb+IX0u4sdL0/xB4htpUMsNmn2m7QDEgZ9mWAH9481m2tA+zY7a2vo7u2SaJvNilVXR4+QVboauVj6Pp8Gi6TZabab/JtYUjRXzuKIMDJx1pNP8QRarfalZwrcRXFg6pIZoGVGZl3AoxHzrjuKXW4LY2a8m/ag/wCSR/8AcwaB/wCnizr1JpWGBwGxnYSMkV5b+1B/ySP/ALmDQP8A08WdFyjz39t7wv8A8J14Y8D+H9se7UNfWOEyFsLKLecxnjpiQRnPtjoTn5v+Hcd78aPiFofikS3dle6xZ6ppNpcPIY5Ea1tPJzuGCo3/ADADg981+hHiW902ym0xtStJLtpLoJbFbXzvLl2uQ3Q7MAH5jj61leKtN0fwj4V1HUooNL0Y6fFLcx3n9nCRLbI+ZvLUgknvgjNUqns3f1/Jjlsj478J+KpfiZb6Zreu6tf2nhW91a20HUrhrprURm1hw+5sjywZOSeM9OlWPC+t6ZqesW0Pj7Xby38Jadp9/caDcQ3ssRujHOgTyyDmaQISEVtwbqQTX0v8GPAfhz/hTOmWDQDX9I1INeudY0oRG5eU7i8tu4OCTz81dxceBfD2oW9jBcaDptzb2DiSzimtEZbcjGPLBX93yB93HSlqtH/WxK95XR8UnxLJffGjw5rmkXcum2l/q2p2Ui3mpTSahLt06fb5kJASJXcRBBtDEjryc5/hzw1pEXw18Br4m8QahbaZqPw1vfEEt1dapKnnaowtwPm3YfakrhIx97BJBNfXfipvh3ousajcapomm3GuQ2n9s3EcOmJPdGOMkedjYWLbiRnrXT3ngnw1rWmadZXugaXd6faY+x2txZRyRQADAKKVIX5fQU9JU9et/wAmg0umz4b0PXFjsND0C5kvbqG+0nwva2q3Gova2ELmxndmuHRlZIyIR90jc5A6cV3P7LusXOreL/AMk+o/2xLBo+sWX2rzd5QR3wXad2W4Cggk5NfVlz4J8NX9vNa3Wh6XPbyJDC9vJZxum2PPlKQV5C5O3P3cnGK0dM8IaFosyTafo2n2MqbtsltapGw3HLcgdz19afN+85/61Ryxo2pqF9dPwZpH7xqSjaOtLUHSlYKKKKYzyT9mP/kl0v8A2M/iT/0939et15J+zH/yS6X/ALGfxJ/6e7+vW6ACiiigAooooAKKKKACiiigAryb48/8fvww/wCx0sv/AERcV6zXk3x5/wCP34Yf9jpZf+iLigD1miiigAooooAKKKKACiiigAooooAKKKKAPJfhF/yVH45f9jXZf+mLS69aryX4Rf8AJUfjl/2Ndl/6YtLr1qgAooooAKKKKACiiigAooooAKKKKAMnxL/yK+rf9ecv/os1x37Ov/Jvfwv/AOxY0z/0kjrsfEv/ACK+rf8AXnL/AOizXHfs6/8AJvfwv/7FjTP/AEkjoA9HooooAKKKKACiiigAqlqX/Hjc/wDXGT+VXapal/x43P8A1xk/lQB55+y//wAm1/CT/sUtJ/8ASOOvUK8v/Zf/AOTa/hJ/2KWk/wDpHHXqFABRRRQAUUUUAFFFFABRRRQAUUUUAFeS/tE/8gXwh/2OXh//ANOEdetV5L+0T/yBfCH/AGOXh/8A9OEdAHrVFFFABRRRQAUUUUAFFFFABRRRQAUUUUAJXksn/J1Vr/2Jsv8A6Wx163Xkkv8AydVa/wDYmS/+lsdIR4L8ZvFV7H8YrPUtH1W+sxYeJ9K0e5mvtclQt5zoGihsAgiKMGOZHJI7AVw114k8SeCvB9r4t0XxDr9z4m1WXxWrx3d7NcxOIDdNDshZyv7swLnYB1r6u8dT/Ca2+JPh/RvFmj6BdeM/EgK6cL7SVuLm6WIBiDIYztCkDG49uK6vVvh5o19pE1lYWNppVwY7hbW8t7SFpLRpw4kki3KQCdxYjoehGCaqMlGkrq4Sjd8p8da9qUngvxb4j0nw54v1m/0pZPAcqrcatc3RiM+tMs6ZZ3O2SNRuXdja5XbgBam8OeI7nwTp+jeJ77xD4gvTqGmeMJNVEOqyXLSxWtz+78uKRmSJkXhNq5/vZr2L9n/4N+EtA1Txsry+HPEeqx31jZ6lBpXhNdKsraa0AuYGEJZw0265E/nK5+ZlKgFQB6xqOm+EfC+lxXV/YaPYWNm7pFNLbxokX2hlWVVyPk8x2CsB1zzmrqW0iv62QRmubn6W/wCAeI/sr3GrWvxF8aaZfXkz6c2l6dfwWsuvXOreT5ofcXmmAy7YGdgCjHAFeZaf4k1zQdDHiPw94i1TVvFN1q2vRXEFzqktyhhiDhQsJkKIisoIYjJx1NfVXw18P/DrT9Q1g+C/D+haXPp8o027k0rSUtCpChhFvVAHADjAXIGaqfCv4F+Hvhc9zdJaaffa9eXV3cvq5sI4rmRJZC5RpMFsDdjrz3zWMtbWJ+Fv1PkbRdY8Y6e2h2eoeK7ay0HxEumvq0On+Ir68u9kr4kkaaWKMWgYdVjbI7YrsPHOl+G4/H3hLUPCuta5rVxokesw2st1rFy5jnit8iKM7h5yo/JJLg9NzdK+m9L8GeAbZ9e8L2XhHSYbaZVn1LT49FENrdbjlS2YxFMc+52+1arfDfwhLa6VZyeF9Fa00dhJYWzWEWyxYDhoE2YQ+hXBrRWaHJM+KvEWralpfhvT9M0DxprU9jrOjaTqeq6nHq8008N5Le26F0di4j3K8xKcIPLHArZ8V6fqqeOvEXg6w8U6pc6dY67GttoF34hvrSW9t00rc8cN8DmORH/eBSyox4JUcV9hab8K/Bei2s9tp/hHQrG2uLhbuWG202GNJJl5WVlVQC4PRuoo8Q/CvwV4ut72DXfCGha1BfTJcXUeoabDOtxKi7UkkDqdzKvAY5IHApS1aa/rVDjonc5r4F+K7LxF8MfB81vfXV3cXGkQXKrqhX7cYyoBaUDGDu6kAKccVU/ag/5JH/3MGgf+nizrr7HwTpen+LBrdtGbe6XTY9LjjhiVI1hRiw6DkDIwM4GOBXIftQf8kj/7mDQP/TxZ0MSvfUyv2jNY1DSbz4cLp95PZi88Tx2syw3JiE6G3nzHJ6pwODxXyq2ly3Xwx0r+0fEPiC/XxB4W1K51KKbWLtoXaJ8B4vn+VVHTbjPfNfc3xB1TwzoOjHWfFEMP2SzlVo3ltWuGEpDKoijVWd5MO2Aisevpxz/geb4b/EXQw+gaRp0tlZF7N7W70f7HPaDOWja3miV4wT/CyqDT05Wuv/Aa/UqXvLT+up8ra1qFx4f1nwtN4c1PVLGDR59F0+4kvfEd47SrL95ILMlllVu8kzMR2ArT0PT7nUG8PS694q8RLYa74p1Kw1dpNbuYljt4/M8iNWVk8sb9h3YBOOTzX1dq3wq8D69ex3upeCtB1a+WBYRPd6VbyyrEv3I9zrkKOw6CsTxN/wAK4Wxv/BmqaHpuo2cP2eWbRX0RrqEmaTbHI0aRMpDPxu24BGTxS7f1/WxNN2pv+ulv1Pk74sW+hRah4i8TeF/E3iK+lh+HGpvp2szaxcxXDSR3Xk7idyKVU/KN68j5uvzV1uu+JNatfEmq+JU1nWD4rsfHNj4ctdMXUpPsw06SC3MoNtnY48uSe4Lgb/3YwQPlr6m1z4Y+EPEjWDar4O0TVf7Pha2tGvNOhlNrEU2GOPcp2qV+UhcAjipZvAPhU+Ko/Eb+GdGHiNYvskOstYxfaxHjHliUjeFxxtBxRzLkjb+tb/8AAJlG+n9fDb89T5i/ZZ1C60PUvhzeah4k1S8j1/4fJqmpyatqct0k0ySR7XLSyMIyqS4+TaDt5Jr7EiuBNHHKh3Rum4YryvSLP4dfFDRdf0TQrK3Wz02G48LXElrpPkRQRZ2S2sEkkQidFYbSI9yKRjGa6Cb4jeHvCd8miXd5NazQ3EFiiyW0xV5ZV3IiPsw/HUgnB4JzVTa6f1d/8GxUYct/62svz1O7oqo07rs+YZ/unGT7detTeYSp5UMOfw9/So62KJaKKKAPJP2Y/wDkl0v/AGM/iT/0939et15J+zH/AMkul/7GfxJ/6e7+vW6ACiiigAooooAKKKKACiiigAryb48/8fvww/7HSy/9EXFes15N8ef+P34Yf9jpZf8Aoi4oA9ZooooAKKKKACiiigAooooAKKKKACiiigDyX4Rf8lR+OX/Y12X/AKYtLr1qvJfhF/yVH45f9jXZf+mLS69aoAKKKKACiiigAooooAKKKKACiiigDJ8S/wDIr6t/15y/+izXHfs6/wDJvfwv/wCxY0z/ANJI67HxL/yK+rf9ecv/AKLNcd+zr/yb38L/APsWNM/9JI6APR6KKKACiiigAooooAKpal/x43P/AFxk/lV2qWp/8eNz/wBcZP5UAeefsv8A/Jtfwk/7FLSf/SOOvUK+X/2df2jPBWi/s/fDSwurvVhc2PhrTLaeOPw9qEux0s48jckDKw46r616V/w098Pv+ghq3/hOal/8j0PQVz1aivKf+Gnvh9/0ENW/8JzUv/kej/hp74ff9BDVv/Cc1L/5HpJ3GerUV5T/AMNPfD7/AKCGrf8AhOal/wDI9J/w098P/wDoIat/4Tmpf/I9AdbHq9FeUf8ADT3w/wAf8hDVs/8AYual/wDI9H/DT3w+/wCghq//AITmpf8AyPRcOtj1eivKP+Gnvh9/0ENX/wDCc1L/AOR6X/hp74ff9BDVv/Cc1L/5HoTuB6tRXlP/AA098Pv+ghq3/hOal/8AI9H/AA098Pv+ghq3/hOal/8AI9MD1avJf2if+QL4Q/7HLw//AOnCOpP+Gnvh9/0ENW/8JzUv/kevLvjl+0V4I1rRfCf2a91V/J8U6LdNnw9qKbkjvYyx+aDt/d6nFAH1PRXlP/DT3w+/6CGrf+E5qX/yPR/w098Pv+ghq3/hOal/8j0AerUV5T/w098Pv+ghq3/hOal/8j0f8NPfD7/oIat/4Tmpf/I9AHq1FeU/8NPfD7/oIat/4Tmpf/I9H/DT3w+/6CGrf+E5qX/yPQB6tRXlP/DT3w+/6CGrf+E5qX/yPR/w098Pv+ghq3/hOal/8j0AerUV5T/w098Pv+ghq3/hOal/8j0f8NPfD7/oIat/4Tmpf/I9AHq1FeU/8NPfD7/oIat/4Tmpf/I9H/DT3w+/6CGrf+E5qX/yPQB6tXkk3/J1Vr/2Jsv/AKWx1L/w098Pv+f/AFb/AMJzUv8A5Hry+T9orwN/w0haap9t1b7J/wAItLa7/wDhHdR+/wDbY/l2/Z8/8C6Ut9OgmeZfHzxHqN78XPEfjOy8Kavq1v4FudNjt9c08262tuEkM94JQ86yH5Cq/KjdKv68df13w34u1u0+IHimCa9+IVhodt9k1a4EVnaPdWu4QLnBJVmHIPBIr3H/AIXJ8HPsOqWQtboWeqO0l9br4W1AR3TMoVjIv2fDZAA59KqQ/E74IQaeLGPTJY7NbuK/EC+FNQCi4jKFJQPs/DAxpz3xzV07QSjLZf5ompeTvH+tGeH2Ph658D+PvF+oaZ4k8RW80fxM0jQ2abWbllurabTrCJhMpJEzkMoEjhiuxdu3LZ5XxDqurfFD4Z+I9P8AEHiLXZ4PAFtpvh6+lh1m4g+0akmqeVNNcPHIm9jFHC25skeaSMHmvpub4ufBqaaWVrWd5Jb9NUdn8Jai267RVVJ/+Pf74CIA3UbR6Vxnw98XfDXRPD3jC38UT3XiPUPFuoyalq9vB4L1SK2mkdVVUSGSFjwqLyxzkZPPNRGWi7q36f8ABK5f3nN0/wCC3/kcXpOk3Pgnx9qWtaVr/iCCYfEG10b7LLqsz29zbPZoWEsRLCVzsX533Nx1HOcbQ21zU7Pw/dXHjvxiDq2jaxqN2v8Abl2uJbVt0OMP8iIfvbcbuhyK980/4k/A3SbGGys9Jkt7SGdLlIY/Cd+FEqJsWQj7PywXjceami+KnwSh8rZpbKIoZLdP+KRvvljk/wBYn/Ht0buO/ehK1l2VvwHHRa/1rc8P/wCFk634gaHS7vxBrl3d6tYaKltaWOuNpYmnlTLhpgGeFGP32iGT2Ne/fso69qviT4O2dxquqNql/BfXVuLiS4kuThJCFTzJfmkwvG4nNYuo+PPgJq1jLZ3ugrc2sojV4pPCF8VIjGIx/wAe3RR09O1a3hn40fB7wXYy2Wg211o9pLI0skNl4W1CJWdvvMQLfkmqWisN6s9xoryn/hp74ff9BDVv/Cc1L/5Ho/4ae+H3/QQ1b/wnNS/+R6Qj1Py1yDjoMDk/57V5T+1B/wAkj/7mDQP/AE8WdP8A+Gnvh9/0ENW/8JzUv/kevL/2hv2ivBOufC82dvear9q/tvRn2yeHtRiH7vVLN25eBfTA9SaAO4/aEUrrXwxuJWQ6bB4rt2umZgRjypdvB+VQH2HJP8znzr40+NNF1bXdS8N+E11rT/Ecl/Ol3NpurnRra6kjt/MeWS5gzKwj+7tBQsxwcivSvEHx4+FHirTJdO1gX2p6fMMSWt14Z1F425zypt8Z965uTxf+z9L4dsdBbw8n9jWMpmtrEeEL8RRSEYLgC36nue/U0DPF9F8XeLvEmix6zP4t1oahpXgsakLaz1CZIppxNtErlf8AWDGfv5qvqckvw98Ra/d6L4o1y+updP8ADUlzfzahNcToZLj54xKWZ9rDgpnaBwABXv8AofxO+B/hmIxaTpLadGbf7IUtvCN8gMO7d5ZAtuVzzjpWdpPiz9n3QYZI9N8OR2CSNGz/AGfwffJuMbbkyRbfwnkChbr+u5kk1Bx/rp/keFa18VfFvh/Vtd8Q+H9a1aWx1bQtfvLNNS1+a9lnltWG2X7IUWGzERDKEiyGXlmZuK+pPgzY6LoZ1nSdL8W634ouVtrG7u7XVNSnvmtPMjJV0mlLPmUBm278DYNqoOK5K18Yfs/WOuNrNv4cjh1VpJJjeJ4PvhIXkUrIxP2bqysQfUGtTwf8WPgt8P7GSy8NafNoVpJKZ5IdP8KX8SvIcAuwW35bA6nmhfDY0qe9a3n+R8z6BYroPgJ9D0HX/FK6rc634u1JA/i+7sLVIrO/eLzJbgO0hK/I5iRgsheRnLEAjQsPHWt+KtO0W41fWb66lj1jw9Mhad8I8mneYSoAIXe/PHVuTk817xqPjj4CatbW1ve6F9qgtrybUIo5fCV+yrcTOzyyY+z8l2Zic9c1JpXxA+BGhwxRafopso4pY5kWDwjfph412xni3/hHA9O1He/kU3eV15/meIx/E7xPdfDXwkIfE+pLqk3g7UZ55Y72SSfzg+I5AAdxcD+9imeJpvHOlazPYWHi6+FlpOkafqq6tq3i+9tmE8pQSO0McEpuRuJXY+FAP3Qa9msfFP7PWm3F/Pa+Gobee/V47qSPwdfBplc5ZWP2bOCe1aGsfEr4G+INQ0u+1PSG1C90sBbG4uvCV/I9uoxgITb5AGBx0q7rmuY8r5pPuz3TT5JXsbYzPumMal2wBkkc1cryZf2mvh4vS+1YcY/5FzUv/jFP/wCGnvh9/wBBDVv/AAnNS/8AkepZSutyL9mP/kl0v/Yz+JP/AE939et18r/s9ftFeCNE+HrWV1earFcHX9euNo8Pai42S6teSoeIOpQk4/h+6ea9S/4ae+H3/QQ1b/wnNS/+R6RR6tRXlP8Aw098Pv8AoIat/wCE5qX/AMj0f8NPfD7/AKCGrf8AhOal/wDI9JuwHq1FeU/8NPfD7/oIat/4Tmpf/I9H/DT3w+/6CGrf+E5qX/yPQncD1aivKf8Ahp74ff8AQQ1b/wAJzUv/AJHo/wCGnvh9/wBBDVv/AAnNS/8AkemB6tRXlP8Aw098Pv8AoIat/wCE5qX/AMj0f8NPfD7/AKCGrf8AhOal/wDI9AHq1eTfHn/j9+GH/Y6WX/oi4p//AA098Pv+ghq3/hOal/8AI9eXfGj9ozwRqV94AEF5q0ws/FVpdSn/AIR7UU8tBFcDdzB83+6vNAH1PRXlP/DT3w+/6CGrf+E5qX/yPSf8NPfD7/oIat/4Tmpf/I9J6Aer0V5R/wANPfD7/oIat/4Tmpf/ACPS/wDDT3w+/wCghq3/AITmpf8AyPRcD1aivKf+Gnvh9/0ENW/8JzUv/kej/hp74ff9BDVv/Cc1L/5HpgerUV5T/wANPfD7/oIat/4Tmpf/ACPR/wANPfD7/oIat/4Tmpf/ACPQB6tRXlP/AA098Pv+ghq3/hOal/8AI9H/AA098Pv+ghq3/hOal/8AI9AHq1FeU/8ADT3w+/6CGrf+E5qX/wAj0f8ADT3w+/6CGrf+E5qX/wAj0AR/CL/kqPxy/wCxrsv/AExaXXrVfLHwx/aK8E6b8RPjFc3F5qsa3/iS1uLdf+Ee1F98Y0jTYs8QfKd8ci4b0DdDXqP/AA098Pv+ghq3/hOal/8AI9AHq1FeU/8ADT3w+/6CGrf+E5qX/wAj0f8ADT3w+/6CGrf+E5qX/wAj0AerUV5T/wANPfD7/oIat/4Tmpf/ACPR/wANPfD7/oIat/4Tmpf/ACPQB6tRXlP/AA098Pv+ghq3/hOal/8AI9H/AA098Pv+ghq3/hOal/8AI9AHq1FeU/8ADT3w+/6CGrf+E5qX/wAj0f8ADT3w+/6CGrf+E5qX/wAj0AerUV5T/wANPfD7/oIat/4Tmpf/ACPR/wANPfD7/oIat/4Tmpf/ACPQB6B4l/5FfVv+vOX/ANFmuO/Z1/5N7+F//YsaZ/6SR1zviT9pv4ff8Ivq3/Ew1bH2OX/mXNS/55n/AKd66L9nX/k3v4X/APYsaZ/6SR0Aej0UUUAFFFFABRRRQAVR1L/jxuv+uEn8qvVR1L/jxuv+uMn8qYjxD4Y+NF+Gv7FPgfxVJZy6pHovgTTr17a3YZlVLGNsDd3x3612U3xm0ODx83h6e4gs7VNIg1eXU7meOKKMTSskMfzdS4RjWH8B9Ct/E/7Jfw50e5hSSC78EaZA6uMhlexjUj8RkfjXyl4FXVrzwCNZ8VaJJDOdb0/wlcajq2mG6+xQ2Fo6G78lgQ6tcbwoYEHzOegxFNNt3HLVKx95XHjLQ7eys7qTWNNjtrs4guGukVJCTwFJ+8CeOKfJ4s0O11M6fPrNjHfqhma1kuIxIqY3Eleu0DvX552lvZ2ngDw9O63F5f6db6nYW9nq2nSNDfsbx9kMe1f3E/AYMu0AdOK9P8I/Yra38WaDq3gu6vfiNeXmpXKPJExmtLV4MwnzMfOgHy7A2fx5q5xaV0EV3Pp34jfFjTPh/wCGjq7RLqOZYkS2tpEMjI8uwSAZ+5nvW6PGnh97uaxXWtPN9EjGWBbiMvFtG5tw/hwPWvgvUNTHi7+x/wCyba/u/wCyfDOnWF3ut5I8XK3n7xfmHP8AeqLx7JLq/wARWmTT2sb6aXV7W+0iz058xhrVxE0k23Mu9gO5x2xVcusX3Id4uS7H6DaZrWm6xayT6ffW19BGcGaGVXQHG7qOMYNedWvx2sdY8dan4c0W1tdXWyj02Y6jBfxeQy3c00OAf7yGAnb1bcMVx+reCZ9J/Y2utG8K2L2OqzeGEAit8pO0xtwp5HO7NeCQ2eh658WZtQ8GaO1voMuoeDoX+zWLIrSx3VyWbbtAyisu5uo9eam2sn2H/wAu79T7kt/GGiXbX8MGr6bPNp/F2sd3GWtxnGZB/Dxzz9Kb/wAJt4e8i0u/7f0n7JckpDJ9sj2SngfK2fmIPHH976V8CQaLcR6dqOk6BYXOqWkNtHc67JLYPb3tpAmrW81xZXTAAXMhjeYKRliI+tdn4O8I6P4x/aM0zUNO0YXXw9k1nULjSYTauLeN10+xR3SMqBGokSUhSMZJOKbWiZcY6WfQ+p9Y+L2iaX480PwtDPBqN7qX2jzTa3EZ+x+SqsfMHX5t34V0EPjbw/cWc16mvaS9nDIIWmW8j8tZD/AzdA3oO9fBXiDQft9roehaNp00XxBsbfxANVuUtXWd5JAApLBedwA2fN2q7pPgi08RaFB5Et54l0i71bRra9SDR47K2jkXqDGnJYfxyHila6uD0aXc+7bHxdoeo332Oz1ewu71k8wW0VxG7+X137Qc4xXA/tFRK2ieDc5+Xxp4fYcnr/aEY/lXh3hPSdP8M/tHfYtE0qSZzrMj3FpLYPFPZxiLAliuFwHh/wCmbE/SvdP2iP8AkCeD/wDscvD/AP6cI6LWJvq0eseWv90flR5a/wB0flTqKQxvlr/dH5UeWv8AdH5U6igBvlr/AHR+VHlr/dH5U6igBvlr/dH5UeWv90flTqKAG+Wv90flR5a/3R+VOooAb5a/3R+VHlr/AHR+VOooAb5a/wB0flXk0ij/AIastTj/AJkuVfw+2x161XkkxP8Aw1Tan/qTJf8A0tjoAsa18arfRbf4gSyaVK48JWySyFZFxcllZht4+X7veuv0vxppGpaLaakL61it7kRjLzJlJHRWER/28HOK+Tvi58I5PF+p/HzXft3iGzmh0+3S2tLO5dba4ZIpMlkAzJ9BWfeeHb+D436d4UbT57XRZ9Nj8bl2UYE0FjJaupH8JEhtWx0OTx1pxaaZLvZPzt+S/U+xrHxnoupQ3Fxba5p1zBbQiW4kt7uOSOFcbgxIPAIyeewFct4p+OXg/wALXnhO2udctJV8U3zadYTW9xE0TuI5JGcNuxt/d7M8/M6Dua+FfC+nweIfhl8PrrwVaS/2fpfhTTG8XpDbPGLlP7S0yZ0lwvzE20V3yMnAI6Gu91DTNNvfFWm+J9O0YP4Cf4iB9MkexJihifRfKaREK/JCbodlAyAeorR0uXr/AFew4u6v/W1z7UTxtoEhvlj1jTWksTi6RrqMNbnjiT+7yyjn1pn/AAnnhv8AsuTU/wC3tJ/sxHEZvvtkXkB+m0vuxkmvzx03wPeXvgVVu7/UdT1m00z7NrNjHpEcCwyfbLb5buQYe5J2sysCSQeTivRfGvhWx0fxJ4yint5fDulW2u6bc2839mG60xJF09MiWAAqY3JIJUcHnrzUNWvqVY+wf+E709dSuo2mtf7Mt7Nbz+0vtUfltubaB9M/xdKnuPH3hq0sI7241/R7eynDGC5kvIhHIFGW2tuw2B1xXwjb6fqd5NpV9faBNpPhu3stPl1OFYpGRrAXeJMKQW2kc+WOa6fw74Sh8TeNoZv7Ca58JTX2t3ej2ckBWGNPsuEaNGXEeT0U8e1VKFupDlaLkfcVvPBcWsM8cyywuqusqgEOp6Yqz5a/3R+VeNfs1+Iov+FY+E/DUzynW7TRbe5miuUdSqFmVcluc/LXs9RaxQ3y1/uj8q8m/aeXb8JcqWVv7f8AD43BiDj+2bPv/nNet15N+1B/ySP/ALmDQP8A08WdID1fy1/uj8qPLX+6Pyp1FADfLX+6Pyo8tf7o/KnUUAN8tf7o/Kjy1/uj8qdRQA3y1/uj8qPLX+6Pyp1FADfLX+6Pyo8tf7o/KnUUAN8tf7o/Kjy1/uj8qdTeaQHkn7NKovwsuZCOf+En8Stuzzzrl8x59MjpTPg3+0NpPxh1PxxaWum3GmR+FtRaxNzeFQt5EN4W5Xj5Y2aGYAn+5XL/AA78VXHgn9l3xd4gtoTeXWm6p4quIoIY2k8x11i/2gKPmOT296+ddS+GHxC+GOl2ej6nZ290mq+B4LO4OhRTebcNYXkdxJ5+48SSRXN3wOPlxRH3ri2t5n3np/i7RNW2/wBn6vpl95oYxmC6jkB27d3TrgMD+Nc1/wALr8IH4gReEl1qyfUJNP8A7TDrdQlPJ3467vTn/d5r5x1Dxh4NsfiF4V8WeHvC13pPg62l1O0l1K1sXS2vJpbSEL+725QbkMX3R81ea2PhiWPwR4Ye2sGh1vVfAYtrK6NhukaVbndIgJT/AFiwc4bHpRdcrk+haV1c/QPRfEGmeIrYy6bqVjqMatteWymWVQwOWXI9q1/LX+6Pyr5q/ZH0Sys5vEd9pmrzaraXX2VFuP7NhsLctHHjbFGnXj7xPNfS9W1YhO43y1/uj8qPLX+6Pyp1FSMb5a/3R+VHlr/dH5U6igBuxf7o/KvJfj1GrXvwuyM7fGtmR9fIuDXrleTfHj/j9+GH/Y6WX/oi4pO/QCD4mfGnU/BPi608P6N4SbxJcy6ZLqkr/bo7URRo2NvzKct7Ungn9o3w1428QLpqPHpkT6dbX0Vzezxxea0xZREqtzuBX9a5P4seD9e8XftD+HrbR9ZufDcJ8OXMd1dx6Wt0HDyfcyw2g+45968o+LHwetPDUfxDs7PR3uTpfhnTo9O1J7UzSidZizujdQ2SfpnimvMqS5l7vl+aPp/wz8XNL1yz165vzDoUOl6rNpYe/nSMStGqtuDHjDBvwpNL+MWh6n4/13wjJPBY3+miyeKSW4j/ANM+0CRlWMfSPGf9od6+Ptf0PUWvBNqt62heHP8AhJtZMs15o4vY2ke3i8kGJ+7YdQ2No7YqjbeGotLtfEuhS6NqY8dX2jeGodBn1GyJuzMpkLNuUDBQ7N/zcY9zVq1jlu729fzZ9dXvx+0bSfFln4b1E2VjrOpS6gmnW8upW+24S1ZFLk5+TcW4VueH9K67SPHel340y3ur2wstXvbZbkab9rjkl2ld2Vx94Y5yO1fGs/h+1tPGltqWq6azFtf8cQmWazaZvOlmiNuAwXIJIfy2+7ycdapfDWxGi+NPBJTTpW1iU6Nv0m/s2SVYlsUiNzb3IX93EATvjJ98ZpUVzc1y6rty2P0BCL/dH5Uvlr/dH5Uq0tR1NEN8tf7o/Kjy1/uj8qdRTGN8tf7o/Kjy1/uj8qdRQB5J8Ih/xc745J/D/wAJZZnH10LSh/7KP19TXrPlr/dH5V5P8Iv+So/HL/sa7L/0xaXXrVADfLX+6Pyo8tf7o/KnUUAN8tf7o/Kjy1/uj8qdRQA3y1/uj8qPLX+6Pyp1FADfLX+6Pyo8tf7o/KnUUAN8tf7o/Kjy1/uj8qdRQBkeJAP+EX1bgf8AHnL2/wCmZrj/ANnX/k3v4X/9ixpn/pJHXY+Jf+RX1b/rzl/9FmuO/Z1/5N7+F/8A2LGmf+kkdAHo9FFFABRRRQAUUUUAFUtS/wCPG5/64yfyq7VLUv8Ajxuf+uMn8qAPPP2YP+Ta/hKP+pR0kf8AknFXpZto2ZSVztGMEnHUHJHQnIHJ5/OvNP2X/wDk2v4Sf9ilpP8A6Rx16hQAzyU4+Xocj688/XmmeWoI5b7u37x/x6+9TU3aKBO/Qj8lcthQCTk4HU0rQJIrKc/N33EEdeh7de1SYooDrcasSKoAUADAGOOnQUzZHz8o6g/jnOfrzU1N2D0oXmBF5cX/ADzXltx46n1+tSeWvBxnjHJpfLFLtFALzG+Wu7djB9jjP19aTYrBsjIPUZ4p+0UYo6DGNGhwdoznOffGK8p/aI/5AvhD/scvD/8A6cI69ZxXk37RP/IF8If9jl4f/wDThHQB61RRRQAUUUUAFFFFABRRRQAUUUUAFFFFACV5JP8A8nUW3/YmS/8ApbHXrdeSy8/tVWv/AGJsv/pbHSbE90WNY+NGl6Xa+PZZbS8kXwfAs940ZTMgZHYbPm44HenaH4M8Nahrmo+MDqN5c3uvWkVq5vLhdltCyqwgQbRsJyjFT8xwO3FfOnxj+G914u1T4/auPEuv6Oljp9pGtnpc0KW92ohkDCcPGzPx7r/WqN1odxB8bLTwSLPGkSabD44M235ZXhsXt5Fcf3lkFo2Tycn1OSCWre//AABPZLrf/I+t/h7p2g+DfB2keG9BvIp9M0WzitUP2pZTFCkY2M7D1AX0yDmtptWsFsUuWvbdLRlLRzecoiwoxww4xgZ61+a+nWdrrXwd8In4cTwQWNr4N0638a3MFkXy51DTSftUS4Zm+zx3bYLZ8oY3bOa9L8FfDfw74k8UeCrGa6tPF/hC88XahMsdrpa2Gk3O3S8gW0IkkRod/GHYAuHA4AraVN3vJ6/8El6JJf1ofXPgv4qeG/Hel32qWGoxRW1pqM+mT/aHCYmikZMdeclQQc89u9dHLrGnWskUE17bRSzKvlwNIpMpbhdq4BYE9Melfnc3hvR9Fn/sZLrwx4T0DT/EniJNTj1HS47mJHe5P2ITQCWIoxiJEbMR6qrHmukvvAqf8I/rlxqNrPrGpaX4V0f7Le6lZmK7hYXPzMqBpPKYL1wTU8i3ZUrxsfceoeJorO1uRbmLUdQtovNWzhukV2OMKh3N1PqQB3qW2161uI7Fbu5t7C6uoRMtrJOm8ZUFlXn5gOcnGK+BdTk02x1jxJBaRQ67qt/DfPfSeS9vrGmgpnN0w3rPEx+4xIH+zWvqkenRzS2F6qf8LLubjRpfDq7S139jWOPcVPXyR8/mEBQc8rxWdPUctGm9j7gsYtKn1m9u7SWGbUpYolmKTZfYhJRSvO0ZJB4roq+MP2d/DNn4Z8dfCy5sNNW0l1TR9be/uVGHnb7XuQSnPJx0z0r7Pq5EQv1CvJv2oP8Akkf/AHMGgf8Ap4s69Zryb9qD/kkf/cwaB/6eLOpND1miiigAooooAKKKKACiiigAooooAKQfWlpvuOlJ3A8g/Zt2f8KylJfJbxJ4hYj7oAGs33XHUfWu4v8AxRHDLp6WcK6vHNfC2mmtbhCbYFZHLtlhwNq5A5w3TAxXkPw8ttTuP2Y/GVtoUhbW5L/xVHa7QMiY6tqAUjj+929q8Z0HUvh7qUvws/4V7orQm01vRl1TVLFGitp7v7LeK0MgTrcIT+9Yru+ePO7ioTd5XHL4U/X8EfaMviDTYYN/221ESvhm80KgJzjc2cAn369qtNfWimUmePy02q53jaC2Nuef4sjGa+DPBvhPwX4L8B/CnV/F2k2kXhGfTtWbVzqCExzXpkj+zeZuwGyu8RgnC54Aqb4ieKtH0n/hM9Njs73QbnWh4ZudI0W9eQ3XkK8IbHLZKBDvwz1ryRl7rFJO9l/W59f+Dfipo3jSHV5AVsBp2q3GlN9umiXzHibazRkMeME+9aFj8UND1DxxqvhWG7zqmlW0V3dhhgIkn3MDqff+73r4K8eNYSaX4u0vVY9LsRNqWuzW+salYNdGaRTlba3QyBRMx6SYdvatG903RJrm8uWsbQXV54Z0O7ubhLdVuprMf8fbI4G44/jydx9KqUUrtdBu3Q+/xr1mtvHcvfWy2zEhZWmTDYHPPQ+vBqaHVra5ggmt7uC5imPySQsHV/Xbg8/hmvhXR/CfhTx98VvB9vpunWmofDO48VXkujwW0ebC4VdOfeyqPl8sOABhetdv8DvDrwftEa34US2e30r4fi+nsg2Vjjj1FomiCY6bVS5GO2KlK7S7kv3Y8x9hUUwE0+pTuMK8m+PP/H78MP8AsdLL/wBEXFes15N8ef8Aj9+GH/Y6WX/oi4pgereUnHyg4GOeeKZ5ceSCucjac9x1wampu0ZzTDUj8tORyM9cMR70v2ePcGKhiDkFucfT0/Cn7RTqQrDGiWRQGyQGDDk9Qc03yFyTjJPqf8+lS0UbbBa4gpaKKBhRRRQAUUUUAeS/CL/kqPxy/wCxrsv/AExaXXrVeS/CL/kqPxy/7Guy/wDTFpdetUAFFFFABRRRQAUUUUAFFFFABRRRQBk+Jf8AkV9W/wCvOX/0Wa479nX/AJN7+F//AGLGmf8ApJHXY+Jf+RX1b/rzl/8ARZrjv2df+Te/hf8A9ixpn/pJHQB6PRRRQAUUUUAFFFFABVLUv+PG5/64yfyq7VLUv+PG5/64yfyoA88/Zf8A+Ta/hJ/2KWk/+kcdeoV5f+y//wAm1/CT/sUtJ/8ASOOvUKACiiigAooooAKKKKACiiigAooooAK8l/aJ/wCQL4Q/7HLw/wD+nCOvWq8l/aJ/5AvhD/scvD//AKcI6APWqKKKACiiigAooooAKKKKACiiigAooooAK8lk/wCTq7X/ALE2X/0tjr1qvJZf+TrLX/sTJf8A0tjoEz1TyUB4XnAUnuQM4B9eprg4fhVp0PjLX/Edxealf6hqdk2nL9qaBYbS3bBaOEJGGAJCnL7jwOa9BxTTGrZyP1pO/QZyngHwZZfD/wAF6F4UsHuWsdIsYtPtnnZTK8cShVYlcDgAcY/Cuq8hC5YjLe5PH+H/ANc+tKsKIAFXAXoBT6q76kpdyPyEGMKFGMYHHHp9KFhSNQqjao6AHgew9vapKKRQwQqoIGQDx1PHGOPT8KPJXuM8Y55p9FGwEQt414C469OMZ649KloooAK8m/ag/wCSR/8AcwaB/wCnizr1mvJv2oP+SR/9zBoH/p4s6APWaKKKACiiigAooooAKKKKACiiigBKRfu0tNX5qV+iF1PHf2dbn+z/AIS3UkyqoTxH4klcoSQQNaviSPX8xXVfCn4iW/xX8C6X4ttNNv8AStO1OMT2a6p5SzTW74Mc2I2YKHXDBSQwzggEVwPwc0Cx1v8AZ/8AEOm39jDqWn3et+J45bO4jEkcitrN9kMD97PvXxGtn4Q0P4U/DuWCz8MeFda0nwz4Y1m01C6iJvr7zLmOWeazcuqWxB3maZUJbP7xgBwo+/z38v1KcUlFI/Q5fipbR+KNK8OX+i6lpd5qtxeW9jLcLG0ciW+399lX3Kj7vkyAT3213vOxQBhxn5yc7RnOeo4r89PHkM+pab4hSzgkvWuLzxsI/JH9/wAvHfv29aseJ9a8MfE5tXhsdTttZ0yez8MWt1Jp9wCsb+Zh0DAk8Dqc59c1pypx5vQmp7jv3ufoE0gXcNrHaCSq559vQk+/PNTNaxMclOQcg9CM9cen4V8F2vgmy0f9oVLYX+g6DqWneILeLRtKs9AebWRpy/6pY5Tdpssz/GUiKj1r74pWXKn3BEb26SKVI+XOSMnB+tcV4L+HFp4M1bxJqS6ldaxq+uXK3F5eX3lBlCAiGILGiDYgLY4ycnJOa7qmeWpGCMj35qdegPVWDd1p9N2inUxhXk3x5/4/fhh/2Oll/wCiLivWa8m+PP8Ax+/DD/sdLL/0RcUAes0UUUAFFFFABRRRQAUUUUAFFFFABRRRQB5L8Iv+So/HL/sa7L/0xaXXrVeS/CL/AJKj8cv+xrsv/TFpdetUAFFFFABRRRQAUUUUAFFFFABRRRQBk+Jf+RX1b/rzl/8ARZrjv2df+Te/hf8A9ixpn/pJHXY+Jf8AkV9W/wCvOX/0Wa479nX/AJN7+F//AGLGmf8ApJHQB6PRRRQAUUUUAFFFFABVLUv+PG5/64yfyq7VLU/+PG5/64yfyoA+bv2d/jFrWm/s+/DOzi+FnjK++zeGtNtxdWiaf5Euyzj/AHkfmXisUPYmvRP+F6a3/wBEd8f/APfGm/8AybXKeA9dvPB/7CvhbW9Nm8nUNN+HFrd205VZDHJHpisrYYEHBA4Ixx0rkfh/+0XdeHfELrrvxCtPH/h//hHY9VvbiyhtPO027aSONLZfs4VX8xnfaGBPyDnmlF80nFdBSfLFSfX/AIH+Z6z/AML01v8A6I74/wD++NN/+TaP+F6a3/0R3x//AN8ab/8AJtZcv7VHhpdJSV9M12LV5bmW0GgCyQ6gskcSyMCm8rgIwfdnG3tSzftXeEoNUa0Wy1q5hjS0kur+GxU21mtzt8nzWLgjO4dqqwzT/wCF6a3/ANEd8f8A/fGm/wDybR/wvTW/+iO+P/8AvjTf/k2sHTv2mPD+mi1tJrnXPE15qN5eJbCy0yMSIIfvx7VYDC+p5NZnjj9rex0zwv4sl0bQNebxBpenHUbSwvrJY2uYN23zlXcT5YPc4PtRYUXzbHY/8L01v/ojvj//AL403/5No/4Xprf/AER3x/8A98ab/wDJtZWnftQ6J52m2eoaVrNvdvHaDUJhap5OnzXAHlRzHf8AIX7dcbhmpPC/7Uvhjxb4gstNtbDW7eO81O60e31C4tESzkubcSmRPN39hA3/AH0KQJ3VzR/4Xprf/RHfH/8A3xpv/wAm0f8AC9Nb/wCiO+P/APvjTf8A5Nrsfh/46sPiJ4T0/wARaWbg6dfbjC08YVioZlDYx0O3P/Aq6ih6OzDc8m/4Xprf/RHfH/8A3xpv/wAm0f8AC9Nb/wCiO+P/APvjTf8A5Nr1migZ5N/wvTW/+iO+P/8AvjTf/k2vM/jp8YtZ1LRfCwPwr8aWnleK9Fn/ANITT23BLyN9g8u8b526KO5NfUteSftFxq2i+Dtwzt8Z6ARn1/tCLmgB3/C9Nb/6I74//wC+NN/+TaP+F6a3/wBEd8f/APfGm/8AybXrNFAHk3/C9Nb/AOiO+P8A/vjTf/k2j/hemt/9Ed8f/wDfGm//ACbXrNFAHk3/AAvTW/8Aojvj/wD7403/AOTaP+F6a3/0R3x//wB8ab/8m16zRQB5N/wvTW/+iO+P/wDvjTf/AJNo/wCF6a3/ANEd8f8A/fGm/wDybXrNFAHk3/C9Nb/6I74//wC+NN/+TaP+F6a3/wBEd8f/APfGm/8AybXrNFAHk3/C9Nb/AOiO+P8A/vjTf/k2j/hemt/9Ed8f/wDfGm//ACbXrNFAHk3/AAvTW/8Aojvj/wD7403/AOTa80k+MWsf8NJWl/8A8Kp8aY/4ROWD7Ps0/wA3/j9j+fP23y9nvur6krySUf8AGVVrx/zJko/8nY+KTdlcB3/C9Nb/AOiO+P8A/vjTf/k2j/hemt/9Ed8f/wDfGm//ACbXmPxJ+KXj3w34o+IusWXitYdK8KmxktvDx063kjvFk3b4zJjzS7Y+UKR0r0i7/aG0G50e0ezkvIrvVL690ewLWoObu2jkdyQT9zEZwfamtUmBN/wvTW/+iO+P/wDvjTf/AJNo/wCF6a3/ANEd8f8A/fGm/wDybXnvw/8A2yNFX4eeGbnxOupX2sSaRpF3quoWViv2aOW/jBg6NgFnyMDiu5P7THhv/hH21BbDXH1FtVk0ZdA+yJ9v+1oNzRbd+z7vzZ3/AHTmqcWnZk8yspdyz/wvTW/+iO+P/wDvjTf/AJNo/wCF6a3/ANEd8f8A/fGm/wDybWBdftgeDoJoY0sdbuQbKDUZ3t7RCLaCSaSImX5/lKNGd3pW/rX7R3h3QvE9no15Ya3brdTLbQ6k9httJZmj3iJWLbmbHoMe9KzvYbaQf8L01v8A6I74/wD++NN/+TaP+F6a3/0R3x//AN8ab/8AJtZnhn9qzwp4mmtvKsdbsra6tbm9gutQs0ihlit1zL5bb+SK9P8ACvii28ZeGNP12xLpZ38C3EfnrtKqy5HFFrAnc4P/AIXprf8A0R3x/wD98ab/APJtH/C9Nb/6I74//wC+NN/+Ta9Y7UtSncZ5N/wvTW/+iO+P/wDvjTf/AJNrzP8AaG+MWtaj8MfIm+FfjOz/AOJzos/mXaaeIzs1Szk25jvG5b7q+rcV9S15L+09Gq/CMbRtx4g0DG3j/mMWdMBf+F6a3/0R3x//AN8ab/8AJtH/AAvTW/8Aojvj/wD7403/AOTa9ZooA8m/4Xprf/RHfH//AHxpv/ybR/wvTW/+iO+P/wDvjTf/AJNr1migDyb/AIXprf8A0R3x/wD98ab/APJtH/C9Nb/6I74//wC+NN/+Ta9ZooA8m/4Xprf/AER3x/8A98ab/wDJtH/C9Nb/AOiO+P8A/vjTf/k2vWaKAPJv+F6a3/0R3x//AN8ab/8AJtH/AAvTW/8Aojvj/wD7403/AOTa9ZooA8m/4Xprf/RHfH//AH703/5NpB8ctbH/ADR3x/8A9+9N/wDk2vWqNopCPln9n/4vazY/DyS1j+FfjK/Emva9MZLNNPMQ36vePszJeLyoJRvRuBxXobfGDUJG3P8ABTxy77dhZoNMJK+h/wBN5FT/ALMcat8LpsjdnxP4k68/8xy+/wABXrm0VLWjt1Gr9Tx5fjNqaElfgx48Qli52R6YOSRk8XvfHPrQvxl1NWyPgz49H+z5em44ORx9txnNewbR6Uu0elW762E9dzyH/hdWrGQSf8Kb8fbx0bZpuf8A0tqX/hemt/8ARHfH/wD3xpv/AMm16ztFFAHk3/C9Nb/6I74//wC+NN/+TaP+F6a3/wBEd8f/APfGm/8AybXrNFAzyb/hemt/9Ed8f/8AfGm//JtH/C9Nb/6I74//AO+NN/8Ak2vWaKAPJv8Ahemt/wDRHfH/AP3xpv8A8m15r8aPjFrN9efDzPwr8Z2n2bxZazn7THp583EVwNke295f2NfUdeSfHhB9s+GAxj/is7P8MwXBP40m7AO/4Xprf/RHfH//AHxpv/ybR/wvTW/+iO+P/wDvjTf/AJNrm/jJ4u8Xr8TtN0Tw/wCMY/CenR6BcavNM1nbTJNJHJgK5lUlVI7qRU3hH9p7SZvhxJrPiGO8g1DTdLg1DU/sttlFSWTy1ePnn1x6U4+8tByTjY3v+F6a3/0R3x//AN8ab/8AJtH/AAvTW/8Aojvj/wD7403/AOTa4zQP2oI9FGpQ+IINT1q/n12+s9MtdHtIpZGhghSXbgMOik8nmui0v9qzwVqul32pF9UsbC20lNaimurEx/bLZm2qYck+YS2FwMcsKFdxUu5nGSkrr+tbGj/wvTW/+iO+P/8AvjTf/k2j/hemt/8ARHfH/wD3xpv/AMm1kN+1d4bhS1t20LxP/btxeyaeNA/s9Pt6ypbfaCCu/ZgxfMDvqfVv2qPC+neG9C16DTNc1HRtUtI759QtrHMNjA7bd05LDaQf4Rk0dyzQ/wCF6a3/ANEd8f8A/fGm/wDybR/wvTW/+iO+P/8AvjTf/k2qC/tVeEW1TWLcWusG20rUYtLu782X+jRTSMqoN+eQS4z6V3/gvx9pvjptWXS2nkXS76SwuJJYwoMidQvqPenbS4jj/wDhemt/9Ed8f/8AfGm//JtH/C9Nb/6I74//AO+NN/8Ak2vV6dSA8m/4Xprf/RHfH/8A3xpv/wAm0f8AC9Nb/wCiO+P/APvjTf8A5Nr1migZ8u/C34xava/ED4xXB+FPjSU3HiS1naOBdPMkONH06MJIDecv8hbEe75JEPevSf8Ahemt/wDRHfH/AP3xpv8A8m0nwj/5Kd8ch0H/AAldoeOOuhaXk/oPyFeR6T8afHOk3yeJNV8UC+0WXxnf6A/h9tOt1aK0hecLKjoBIWAhHXP3uaCuV8rl2PXf+F6a3/0R3x//AN8ab/8AJtH/AAvTW/8Aojvj/wD7403/AOTazPDv7VnhDxBYXF08Wq6VDDp66msl9ahRc27P5YeHaW3/ADemK0fD/wC0d4a8Sa1Z6QsWpaZrEty9pJp+oQIksLCPzAzqrNgEfdwec0v6/Qle8rod/wAL01v/AKI74/8A++NN/wDk2j/hemt/9Ed8f/8AfGm//JtYWpfteeELGGyljstcu1ns59RbyLSNvKt4ZvJmeT5/l2tWhb/tReFJtH1W+MOqRSWD2yLYTWyC5u/tG7yPITf8/mbTt6ZptSV9B21SLv8AwvTW/wDojvj/AP7403/5No/4Xprf/RHfH/8A3xpv/wAm1lX37Vfhmzh05V0vxBdapd/bv+JRbWCNeQm08vz1lj8z5SPNQ9elcV8QP2sl0fQ7rX/CX9peLILibw2beztbKExw2+oTbVfeWDF5FyME4VinTJp2fT+rk32PSv8Ahemt/wDRHfH/AP3xpv8A8m0f8L01v/ojvj//AL403/5NrldJ/an0XT9BjnuRr2uXct9qXmwppkSXNpb2tw8UxeNXHyRMAm8ZJxkgmvedPuhqFnDcIcJLGrjj1puLi2h7Ox5h/wAL01v/AKI74/8A++NN/wDk2j/hemt/9Ed8f/8AfGm//Jtes0VFwPFvEPxq1qbwvq3/ABaHx8n+hy/waZ/zzP8A0+10f7Ov/Jvfwv8A+xY0z/0kjrsPE3zeF9Xz/wA+cv8A6LNcf+zr/wAm9/C//sWNM/8ASSOmB6PRRRQAUUUUAFFFFABVHUv+PC5/64yfyq9VHUv+PC5/64yfypS2DqeFfD/w3feLP2F/C+gaYAb/AFH4c2tlbpN08yTTURMn6muH+Kn7Keq+KIvDtvoWnaPaw2/h+Kz1KOMrAt1cwXNpcQxMEUfuyLeVcjkb69G+C3iyy8C/sc/DnX9QdlsdL8D6XeuWkO5lSwjJHAJ7frWP8Mf2xvBnjzWWt7zV9P0SzmstOkspLi6+eae5WQtA2eAVMW3PQ7uDRs24/P8AEmTVoxf9bHGz/s/+IbfQZFtPAHh+BLrUZL86LY33lXNufJhiSUXh5LfuyTnqODkcVzXh/wCHvxC1bxZ408DXSWuq3lzp+jxanrUl5jyHjjidsgjdJ90DjpX1VN8XvBdr4ju9Bn8T6ems2ds1zPZ+eCyRopLt74GcjOfl6daw5vj18LdPtU1ubxTocMdxIITe+cu5nGMKWGeeB7cdapNq7ZUbtr5nnHgH4C+L/DPijSb2We1tYbT+1ALiOYl188/uTjPX1PWuF039mvx415r882jaXZXV/wCG7vSbjUpL4yS3988++O4fjhWHpjHoK+lrz4yeCrPxFDoUvijT49cljE0dm0+WYMNwBGMdO2c4qjZfGrwrYadoba74i0mwv9Wj3QRW9yXil+bbujOMkZx1xTb1sZQfIjxw/Bz4g6tHdaLNpMOn6P4kuNLvr+8bU1km057by/Njxj593lJtK+h3ZyayPit4H1/4b/sn6vGzW1v41sPEdzrGiqswL3M8upPLGi/3neKRlIHGD0r6b8YfEbwv8PdNg1DxNrFrolrJlI5J2IRvl3EKcfNx6VyusfGH4W3F9pVnqfiPw/dXcgt77ThMUkVFlLJDIhOQhJVucihNvYv4YsvfCWzu/CFungb7AYdN8N6Xp1vbX2SRdkxOsh59GiB/4FXpVeO+Ovj/AKN4V8eeGfCWn3NjqevanrUWlXFl55ElrG8MsrS9MEjbH8uc/Ma9hHQVHN7R83QduXQWiiimMK8l/aJ/5AvhD/scvD//AKcI69aryX9on/kC+EP+xy8P/wDpwjoA9aooooAKKKKACiiigAooooAKKKKACiiigAryST/k6q1/7E2X/wBLY69bryWT/k6y1/7EyX/0tjpWuMxdH/Z70e8+NXjLxl4i0OyvheTWUuk3E2XaNo4zk7c4yHJxkcZ4rzqH4HfECPxro1m2l6R/wjum+I9W1hL77WPMmiurWeNE8rblcNL2YV6x8Wv2gNA+GFzHpi6lY3fia4vrO2TSZJzvCTSogbGMD7xPaunm+LHg+30+K8l8SabHZ3H2gRTm4G1vI3edz22eW4b0x6mnF3Wm1v8AIS0t6nzf4b/Zk8cab8PX0WWGzF29r4OjaNbsBC2m3Hm3fQYxx8o6Hge1dlqHwh8aaN4ouvFGl2drqd7b+MrnXrbS2vBGLi0msfs3DsMLIDzz24rU8eftVeGtNm8A23hbW9H1qTxdrp0mCaeeRYYVSNpJmLIpYPwiICBkyKenNeiXfxl8EWuj2eqTeKNP+wXFnNqMdz54EcltGyLLLnH3FMqc+4racpTnzPrr+X+RjKK5En0/W6PnfRf2YfGel6Z47iY2z3XiLw99mWP7WMC+lvbi4ljDY4jUSgZ71H4w/Z38f654rtL86Xpurz2mrQ3NtqsmoECGy8jyxBHG33Qp9Bk+9fRNv8cPAl34butej8V6a2kWcqwz3hlwqs2CF65yRz05FcJ4w/aw8GeHvEml6Ja6/pM0uqabPe2t9dXQW3VkfHlysMlc/pjms+a75v67lyild+n4Kx5f8avhzq/h/wCA/wAMvDkN5ar4uttRhsRCZPmlhnfE4RfQpwfT619eaTpsWi6Pa2USBYbaFYURegRRgD8BXFT+PfAt34o0jS9UvtEk8V+WsttDJsadSy7gImI4JHoQau+GfjF4O8aasdM0LxJp+pXo3FoYJCzHY218cYOD6UfFewvhjc7j+GnU3+GnVmjQK8m/ag/5JH/3MGgf+nizr1mvJv2oP+SR/wDcwaB/6eLOqA9ZooooAKKKKACiiigAooooAKKKKACiiigDyT9mP/kl0v8A2M/iT/0939et15J+zH/yS6X/ALGfxJ/6e7+vW6ACiiigAooooAKKKKACiiigAryb48/8fvww/wCx0sv/AERcV6zXk3x5/wCP34Yf9jpZf+iLikBnfET4F2PxK+NOh654g0m31Tw7YaPNAY5WYEzGXcoYKRvXb/C2R7V598cPgn4y1S+8WWfgvQNOvNI8QaLa6WGku1tRYmCTg7SDuBXsK7f4yftDxfDf4g+GvCNpJpSahrNvPdyXGsTyRQxJGmRyqnGaZ4U/aY0W98fX3hnWr/TbFo7XT57G4t5WaO9a4RztjJHTKjbnGauEWmpx6FKTT/rujlfDPwJ8UaX4q06/ljtvLg1jVr4v9qBYJc2IgiwdueSB0rCP7Mvi648I+HNJzZRTaX4Lt9LdlnwHv7e7t7mOMgDBjYREEn+pr3i5+N/gKGLVJJPFmmpHpzOl06zhvJIfYQdp67/l2j5qZc/HbwDaJoU8/i/TVj1hTJYss4xOu7bkYPZvl/3vypRk9Jdf+H/zOdUlFf13ueV+H/g7411f43ab8RNZsbTSmm1eae606G9Wc21sNMNrGd4ADSM/J29B7V51r37MnxEvPAen+Hm0rTdehh8PDT7WNtRMMWmXazSSNLs4Dlh5ag4O3HNfRbfHDwroNlc3XifxLoOmRrql3psDR3TMiG3cqyvlRiVcjcOg9a9Jt5obqOK4jAlR1Do0fPytyD+NCRorRTX9bnzfcfD2+8JfAH4lQeKo9O0i4vrq71OALIrRA5WWLPqQUUDOeld/+y/4fvNB+Cfhj+1Vk/te8txf3hbIYyzcsW9+leo6loun6xaNa39lb3ts33obiMOh5zyDVqOFI1CooRVGAqjAFTG6vcJapWHdqdSYpaFcoKKKKYHkvwj/AOSo/HL/ALGuy/8ATFpdcd8Mf2cNM8N2fi3UdW0TTZfGN9qmq3VtfSFpCkdxNIYSu4kK20qMgA9eeTXY/CL/AJKj8cv+xrsv/TFpderG3Ruo7Y69qT1C7tZHyL4k/ZZ8S+KPBulaNdJZOYPC0Glys1webiO488oTj7h6Z60ab+z/AOLPDeo6V4l0DwVoGj31rfmU+Hre8wzRGDydzXOMMc/MMg47V9d+SuCPm65+8fXNL5Y9/XqfTFO7/r1v+YKyVl/WiX6Hx94S/Zw8c6boLx6ha20V6/hfUNNeOC9DK1xcX3nhCSOQB3rT1f4A+MU8RT69a2lndXVnH4cuLS3e7A86Sx87zo2OOQd42k19W+Wu3HP5nNNNujdj/wB9GtHVndtf1q/8xvVnzH4L+B3iq0+IFt4vvIbOzm1CbW72/smuVcWMl1FbxwJlV/eDFt8+D1bNcXoX7NXjzRfhhcaQ9rbTalDpnhFIbc3gbz5NLm33UZbG0ZGNrDkkAk5Ar7R8hBjAxzng475pfKXk88+9TzSj8Pl+BKvuz4x1D9n34hSeD44k8Oabeam+o65PbXEOq+Rd6W93eSyxTicYDKFZN0YHJHQmvrfwvpt1pvh3TLO9m865gtoklkwF3OB8x4rVNrCzIzRqzIcqzDJU+oPaneWu1hjhuTzSbu2+43q7jj2paKKlIDJ8S/8AIr6t/wBecv8A6LNcd+zr/wAm9/C//sWNM/8ASSOux8S/8ivq3/XnL/6LNcd+zr/yb38L/wDsWNM/9JI6YHo9FFFABRRRQAUUUUAFUdS/48Ln/rjJ/KrtUdS/48bn/rjJ/Kl5C6nj3wX02XUv2M/AllAAJ7jwFYRRhVAG5tOjA46dTXz34Z8C+IdX+HHiiRvCeuWN3/wj/hPT7eO/0uS2nL2s2LiNN+MKp+bjt7V9Kfs6alDpH7Lfwsv7+4gsreHwfpMk0srfu40WyjZmz6YzW3a/HP4d3ssMdr488OzSTXf2CPy9UgfzJ+vlD5/v45x+hoj7nPydbGbipOEpdLny542+Gfiu80O88IReFtQl1aHxDq3iFtYS0P2ea2nhu/KCThfLZyJY12ElxgfKDWv8VfBPie1+F3hrw3p/hnWIrN/C8kBh0HTQ8v23A2QTERsUi/FK+o/+FheFm8VS+GB4j0j/AISaOL7YdHe8j+1iLGRJ5Jbdtx/F04+teaT/ALT2hah4s1XR/Dmq+HdasbCxtbp9XOtpHaK8tz9naKSVQyxsCMgAkk/Lt71Su9up08z0TWx5j8JbHxL4RsZ9AvPhveateao1veQ6hfWRjtrWLyNrmSV1bbKhHEeNx/vVS+Hvh7xL8PWgnvPh7feIp9a0X7LaW81kzQ2863EjMtyxX9wGUx8vj7v1r6h0r4m+E9a8VXfhux8UaLceJLRN13pFvfxSXMGPvExg7gP9ph+FWfFvj3w54AtYb3xL4h0nw9YzS+Qlxql4ltG0mNxG5yFzgHj2605Sbd31OblvZHlv7SFvrc1p4QisNO1S40l55Uv7nw/YC8vbVzDtiCDY2xC/ysy4IHOa+cfCfwr8Vy/CfxxazeEdagvpvBuj6dALu1b7TLdQ3VyJ1yRlioZG+lfS1x+1N4RufiB4h8H6Zq2hy63oosXYXmrwQJOtww3CM5JJVfm24+YtHg/Nx3ei/FLwd4l1y50XTPFej3+sWofz7C21COSaNUZlfcoOcqVYN/dPB9aFJwi09jSXwtd9P1/Q+cbjwjrFt450HQpfCetXl1F8SJ9el1mGwJs/sEsMxWY3G3YNu8R7M7hwevNfYy/dFePa1+0F4Yhs7K68M61ovjAya9Z6NfLpOpRyrZG4lMe5/L34Zf7pxnafu17COgrOClGmovZf5IHLml8vzbf6i0UUVQwryX9on/kC+EP+xy8P/wDpwjr1qvJf2if+QL4Q/wCxy8P/APpwjoA9aooooAKKKKACiiigAooooAKKKKACiiigAryWX/k6y1/7EyX/ANLY69aryWX/AJOstf8AsTJf/S2OmB4n8V/CusSeLPE+mHwnrGuSaz4i0rUrHVLLTjPaLaxtEHV5AhWPYA/AIznJzXL3Pw5vtZ8ffGDw5ceH7jVdG8PWl1Ppljp8oD3R1J4ZGVP7sgaCYhTwfMIII4r7q+zpxxkjuSc9c9fSuf8ACfw78P8Agd9Tk0exaCbU7o3t5NNcSzyTyn+JnkZmwOy5wOwFTH3Y29R9vU+U/B/hTxRq/jDwLqVzoWoXGkWvjR719V1PSGsr2W2Gh3EJmvIyFA2ymOIMQudqjBwK8/1DwN4v1jwP4d8Lr4I1qO78OeC9Z0e6WbSpBA8kl1aERxEf68MsX8GelfoULWJcYQDBLcccnqf1p/lLtxjj35rVTaa8l+jX6kSV1b0Pj7xd4D17TfiJqniO38O6le6Np/iDR9QeCxtDI93Emn+XM8SBQJdjdlBBPaqfxY0/xN4ht9J1a1+Hl9YW+oaJqVrFYaXp80kiSySAx+aEjXyd69d+OtfZhhjZXBRWD8MCM7uMc0phUjGCB7Eis9ba/wBaW/IJRUlY+LZ/AfiCCd/CzeGdUlvdR1ew1W21Y2jG2s4YogHDT48tHUDG0HB9OtdJ8Fvh7rfh/Vvhdd3uhXVi9n/bf26V7Zg0XmSyMglbHOTsxn0r6uEajPyjk5Pv2prWsTKQUUg9cjr9fWqjJxv/AF0t+hPL7nKh38OafSbaWpLCvJv2oP8Akkf/AHMGgf8Ap4s69Zryb9qD/kkf/cwaB/6eLOgZ6zRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHkn7Mf/ACS6X/sZ/En/AKe7+vW68k/Zj/5JdL/2M/iT/wBPd/XrdABRRRQAUUUUAFFFFABRRRQAV5N8ef8Aj9+GH/Y6WX/oi4r1mvJvjz/x+/DD/sdLL/0RcUAct8fvCeta5420+bTtOur+OPw5q0Jlt0JxJJFhUznglsY7jtXhUPgPxR9i8UeHD4N1s6nr+h6LaWOsf2bL9njljjPmmWX+Ex5OOK+9fLXGMY5zxxSeUuScck5PJ9MVrGo4JpB/X4p/ofHuk/DvWPCvw/0XVD4c1K8fTvHN3rOo6bb2rtd39sZZAsgixufkxvgjtXC6l4E8YWMmt6vpvgzXItc1w3r6ZYyWbXNlcwyXpkS1v49u61PyLKJiy4MpB4AA++0hSNdqqFX+6OlIbeM54+8QTgkZrJXtqO70t/W/+Z8NeIPAfiXTbG9uW8Ma/aX517xI1lfaLYm7jK3U4eOGe0VTut5Qo/fjhccnmvsPwHHfW/g3QY9UtVsdTFjBHc28DbxDIE+ZQe+Dmui+zx7g235l6HuKcsarnA6+9O+liZXk7vu/xHNS0lLSGFFFFABRRRQB5L8Iv+So/HL/ALGuy/8ATFpdetV5J8I/+SofHL/sa7P/ANMWl10Oj/GjwP4h8UXnhvSvGmhaj4itXaGfSba/hkuYJFYqytErbgVOQwPTb2oDpc7qisvVNattFsXvdRvIbG1i2+ZLKwCDccDk9OcVehk8+FHV+HTI/wAaA8yaim7qTdSuA+iovMIU80/cKBdLjqKKKYwooooAyfEv/Ir6t/15y/8Aos1x37Ov/Jvfwv8A+xY0z/0kjrsfEv8AyK+rf9ecv/os1x37Ov8Ayb38L/8AsWNM/wDSSOgD0eiiigAooooAKKKKAEqhqA26fc/9cZP5VoVR1L/jxuf+uMn8qVri8z578NaXNqn/AAT/ANAsLWCe6uJvhjbwxwwoGkdzpaKqgepJrzPxR8L9V87xZLa+FbsSr4b8HW9ps01uHhvJHlRBt4Magb8fdAwdgr6E/ZnZYf2ZfhRJJJ5Xl+ENILsz4C4sojkn0FZ1r+0bpOtePNT8PeHpNK1mGzhsLj+049bh+zsbqeaExBlDAyI0LHZu+YsAMdaI3jfl6ilrFOfQ+aNa+DXivWL3xPoGfG114gk1vWNRs0W1gttJSCWG48iT7b9kLSuVl8vyFuAQ/JVAKd4i0XUvF1xqEukeBvElmYfDWjWEhvdBuLUyXUN9tmCb0G8hecpuJHXivtSz+InhbUJtUt7XxJo893paFr6G3v43NqoPPm4YbPT5sYqqvxW8GTaXDqkXi/QP7KuG2W96upwNBK+CdqPv2k8qeD3rWM5RafZ3NHNyR8reEND8Sal8cvCs11aeJNGmt59SinjtfDqw6XpXmRfunhZbcLNuf/lqzyIPWut+NPgrW/Ddn4WurzX/ABh4z1m3e5Fr4hh0SC+VN8WFt5rO0tVDxycjeoUr/fr1/Wfjh4d0/wAeeH/Cun6hp+s6jqU7w3ENpqEZks8Lu3yRjJ5HqVrpLT4k+EL2xu7u38VaTc2VrKtrcTw6jFJGkrHasbODgOT/AA5z7VLk7JLorEWadj491Twv4pjn1bS7nwXqOn3mpaX4X8u10zSbqazX7PcsbhFlRWVQiMo2M+7Famg+AfEui6P4NntfCMlzqNpqnjGZ7e6sH8m4aU3nkLc8cxzfuwCeoIBzX1fpXxC8H6xrMek6Z4m0e91S6h+1x2dnfQyTSIcHzRGpLFeAd5BHvXU/Z49xO3r2ycdu34CiUpOL80wkuZcj7pn57eG/DPiG+8fW9/Hovi6+trr/AIRKUXGqeFZLKOI215eNcwxolvEkUURkjUcDK/ON6/PX6Gr90fSo3tY5FKleGOTjjPTr+VS0cz5bP+tF/kKzlPnfZL7rhRRRUlBXkv7RP/IF8If9jl4f/wDThHXrVeS/tE/8gXwh/wBjl4f/APThHQB61RRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXksv/J1lr/2Jkv/AKWx161Xksv/ACdZa/8AYmS/+lsdAHrVFFFABRRRQAUUUUAFFFFABRRRQAV5N+1B/wAkj/7mDQP/AE8Wdes15N+1B/ySP/uYNA/9PFnQB6zRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHkn7Mf/JLpf+xn8Sf+nu/r1uvJP2Y/+SXS/wDYz+JP/T3f163QAUUUUAFFFFABRRRQAUUUUAFeTfHn/j9+GH/Y6WX/AKIuK9Zryb48/wDH78MP+x0sv/RFxQB6zRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHknwj/5Kh8cv+xqs/wD0xaXXzl4WtfFHi/Sr620jwrc2Vv4d8da9rf8Awlkk1p9niWOe63Q26CVpXdmcdYUj469K+jvhH/yVH45f9jXZf+mLS67Dw/4F8P8AhXR7+z02zSHT7y6ub66jmkZ1aSeQyTOS5OMkk4HA7AUhvWLi+v8Akz5K8f8AxK8Q+Lvh3Y2Wp6o1zY6j4QttUuRJbwgyXP24L5ihUGOMf7PtVrQfH3xM1jVLVIvH15YW1x4jutGSxg02xkENuiZUws0JYuD/AByFl/2a9x039ln4baat69votwfttqtq8bavdSqbZZPNWJA8pEce/namB+FdLp/wU8GaVJA1poqwtDfSamhFxMT9pcYaQ5fnI7Hj2qk1Hf8ArW/5E7RUF0/yS/M+efD/AMYPiF8QNE0PToPF03h7U7bQ9R1a91SLT7QteSW1y8CxukkToitgElACccbaxPCvx9+JHiGxg8ZTeKWh06PXdC09tAj0+2NrJDdxw/aC0hi87O52K7XBXPzbq+iNU/Zx8AahoumaNJo0sNjp8kslubXU7m2kzLIZJUZ45FaRXJJKuSD3Fa4+A/gdbWa2TQljt5b+01Mxx3U6hbi12/Z3XD/KE2L8q4U45ByapcvX+vev+RaaPlDx5+0N8RvD48X6hpHibWL3Srnw/wCIr7Sr++0rTobSOey2+W9lGitKyRlirG6c7ypIUDiu18bfEP4k/DHWo/Dd548bWdV8WaZpzaDcT6ZaxfZL06hHFebAsIDRiG5jYCQOyiIknk59Tv8A9kn4X6p9q+1aNcSx3MV3bvCdVvBGIbnd9ohRBNtSJy7MY1AXcd2MgEL42+EF342+Mfw612ew0+LQfBzT31tO1y7XT3UsJh8tY/L2rGB+8Lh9xKjKd6d43T9fz/yJfwpI9hjZtnzHLVLSeWPSnVm9yVfqFFFFBRk+Jf8AkV9W/wCvOX/0Wa479nX/AJN7+F//AGLGmf8ApJHXY+Jf+RX1b/rzl/8ARZrjv2df+Te/hf8A9ixpn/pJHQB6PRRRQAUUUUAFFFFABVDUh/oNz/1xk/lV+qWp/wDHjc/9cZP5Uw16Hz54e0HWPEn/AAT90LR9ADf23ffDe1tbUI5UiV9MRVwfXJrxXULODxN8TX1Pwv4P1W20ll8Hxs7aVJbAywXNyXTDIoxGjKG9B9a+qf2X1H/DNfwlHP8AyKeknr/05x16asCIMKNoyTgHuTk/rSi3EU/fg4Prp+X+R+e154V1i6j1TQ/D2kapfW0ETT3sd/YNDf6XELyOSW2SZYwt1vQTbWXzG+Uc11fh/wAJweNv2iNN8RW/hu5j8ETazJPY/a9Mkjj3JZRR71jkjUxgurcHj2r7d+zx7Su3j69OMcen4U7yl3Fuc4x1OKpu+402r+f+Vj8/PE3hu7updD0Ky0K/h8ZWOpa1PfX8WmyqMPERH+/CbSCOg38dqZpXw1k1/wAD4jHiXxJbq+j2d5bato8NnCWSdGmt1ihgTzCoJ/eMD16mv0GWFUAAB49znpjk96Qwoc/L2xnvj6/gKOZpWRTk5O7Pj618Pr4d/aGe10bQbua3ufEKXM2j6lpp8iBTBsN5b3Kx7VXb/wAsi+O+M19i1GIUXcQuC3U9zxjNSUrtpXJ63CiiikAUUUUAFeS/tE/8gXwh/wBjl4f/APThHXrVeS/tE/8AIF8If9jl4f8A/ThHQB61RRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXksv/J1lr/2Jkv8A6Wx161Xksv8AydZa/wDYmS/+lsdAHrVFFFABRRRQAUUUUAFFFFABRRRQAV5N+1B/ySP/ALmDQP8A08Wdes15N+1B/wAkj/7mDQP/AE8WdAHrNFFFABRRRQAUUUUAFFFFABRRRQAUUUUAeSfsx/8AJLpf+xn8Sf8Ap7v69bryT9mP/kl0v/Yz+JP/AE939et0AFFFFABRRRQAUUUUAFFFFABXk3x5/wCP34Yf9jpZf+iLivWa8m+PP/H78MP+x0sv/RFxQB6zRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHkvwi/wCSo/HL/sa7L/0xaXXkHjr9orXrzxV4s8HXL6RJp9xpus28X9mxTiayaCL7stwx8p5Gz9yNf3fcmvXvhH/yVD45f9jXZ/8Api0uuRuP2Sre41ZJl8Y6zFpsUmp/ZNP2QssEd9HtnXcV3H5uQSTjtilYpNRTbOK8H/tIax4V8M6boM2mW9xqVjLaoitE7NNYPaec8gy2d4PFL4d/bG8R6npOq376DDeJJbLLpjW2m3dtHHK0nliCd58I7/7UbBa9Rsv2YfDdr490TxPNPdzXGl6F/Yi2xIEU6bdvmN/00xxmqcP7K+mtpl5pepeJNa1a2a1Sz08MUjXTYlfeoTaBuO7nc2W7ZxV6W1Jdrnnvir4neJLr4h+FdF8RxaXbeIPD+t+ZPLYyyW1jNDJbO8TfOSRwBw2elV7X9r3xq2h+JCtj4b1fVrKPS7iwezhure1uFu7nyCn71i0m3r5qlVPpXpEn7K+mahtn1jX9U1zUpLuS7vtRkEccl1+5MKxEKAMBSQMD9az7P9kWGHB1DxtrWr4ttPs/38cI/dWc/mxLwvXtnqe5NEbX1Jvb+vM9x8Pyar/Y9v8A20bJ9UA/0g2AYQqfYMd1a3lrx14zjk96aFBxnPy+5p2TU8yewx9FMzTqVxi0UUUwMnxL/wAivq3/AF5y/wDos1x37Ov/ACb38L/+xY0z/wBJI67HxL/yK+rf9ecv/os1x37Ov/Jvfwv/AOxY0z/0kjoA9HooooAKKKKACiiigAqlqX/Hjc/9cZP5VdqlqX/Hjc/9cZP5UAeefsv/APJtfwk/7FLSf/SOOvUK8v8A2X/+Ta/hJ/2KWk/+kcdeoUAFFFFABRRRQAUUUUAFFFFABRRRQAV5L+0T/wAgXwh/2OXh/wD9OEdetV5L+0T/AMgXwh/2OXh//wBOEdAHrVFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFeSy/8AJ1lr/wBiZL/6Wx161Xksv/J1lr/2Jkv/AKWx0AetUUUUAFFFFABRRRQAUUUUAFFFFABXk37UH/JI/wDuYNA/9PFnXrNeTftQf8kj/wC5g0D/ANPFnQB6zRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHkn7Mf8AyS6X/sZ/En/p7v69bryT9mP/AJJdL/2M/iT/ANPd/XrdABRRRQAUUUUAFFFFABRRRQAV5N8ef+P34Yf9jpZf+iLivWa8m+PP/H78MP8AsdLL/wBEXFAHrNFFFABRRRQAUUUUAFFFFABRRRQAUUUUAeSfCP8A5Kh8cv8Asa7P/wBMWl1yXwn/AGlrfxBqmq6J4lFzFqS63qtlbXaae8dmYrad8RCTJzIIgD0ye9dd8I/+So/HL/sa7L/0xaXXmNn8D/G9rb6YbPybO+tvFWu6sbiKVM+TdmUwyEBuSSV/LHSgHrFo9Asf2nvBl4dWVl1aznsY4pTa3mnvHLMsjMsTwoRlyxU+lJeftVeELPT9Pm+xa9Ld38k8MemxaVI11HJCu6VZE7bR7184337LPjXXtYGo6n4QljI0+zW7ebX1ll1C6gnZ5AXD7kEgdtgUgLnntXofhj4C+ILLXvD99D4Ys9Es0m1We402K/N1NbLPBthEsksrb5GPUqdtXG3UR6joX7T3gfxFBqV1BdXkFta6f/aaSTWrRi4t/wC/ECfmO7jp1qC6/al8G2ujWl7cLqlpPcaimljT5tPkW8WcxtIoMAO7BCmvJdW/Zr8YazpOlwG1tlktvCMumcyDC3H23zkTHTG3/Ct23+EHjPxF8VtL8eavpB0mWfW7O7utMa5im+zQ29rNHv3KzKzEuv3eaHo1b+tUO139/wCTNDxh+11p01hp9z4VttUkWLxLY6PqBn0x/mV7jy5Yos9ZO3tXXX37VXg+z8LW2urFrM9oTeG7SHSpXlsUtW23LXA4EYQ9Tk+wNcrb/BnxOPDNna/ZofPT4i/8JK/78f8AHqb0y7v++T9371edeNv2f/iBrVr4g06PR49c0PVbnxE9tpw1VbeK2uLqffZ3kwDDegA/1Y6elYU17sYPf/gIh+7Ob6J/qz3fxV+1F4M8I6lBa3T6lOjPaRyXVnZNNDA9y0YgWQj7pbzUP0rW8M/Hzwv4s8Zf8I/p8moNM/mfZ7mSxcW135f+sEEmPm298ivknxdZ634StdX8MjTLMXOt6z4Yur1V1SAT6bNGtlE8TxBsuMQswZdyr1NeqfA39n3VPh7490qa88Lw2kemC9x4gl1SSeS6877nkQeaRD/t/uxmt9HFSRbspcp9W0UUVAGT4l/5FfVv+vOX/wBFmuO/Z1/5N7+F/wD2LGmf+kkddj4l/wCRX1b/AK85f/RZrjv2df8Ak3v4X/8AYsaZ/wCkkdAHo9FFFABRRRQAUUUUAFUtS/48bn/rjJ/KrlU9S/48bn/rjJ/KgD5q/Z28O/Fe4/Z/+GEun/EPw7ZaY3hXTHihk8KPNJDE1pGUzL9uVX2rxuC89xXocfhz4uySKIfij4YmdRko3g9yCP8AaAvwV/P8K5Lwf4nvPBf7AvhrX9PD/b9L+HFpeW/ZlkTTEK49CDXG6bc+CPg7q2nv4Yvv+EY8ZQ+GJLm7j1jTr610vXDsgJurm7EJW5mjLAfI7ufOIOSBiVK9/wCu7/QaTdvM9l/4Q/4x/wDRUPDf/hFSf/J9J/wiXxjZkYfE7wzhThk/4QuXBOMf9BDOM814nZ/tTfEG48O63G1rbi60jXotLuvEbeFb+OCG3ktVuFnl0zzzcxqd6xnc4xnf04rB1X4ufEnT/Hmr+NdP13w1qH2fwTa6gNJggkmsmZ7naxEy3IHPXfjpxjNauLV/63V/1F1sfRf/AAh/xj/6Kh4b/wDCKk/+T6ZB4X+MVw0jD4n+GCqEoVXwXJ94df8AmImvMdV+PHxM0WPW7y6m8Ktb+F1sZNXt4bO4JuluNmfIlM+ItmT/AKwNv7bawbD45eMjrF5pvhFPCOjW5/tTUJZ73T7iTPkbMDCzx435P07YqXoK92l3Pbf+ET+Maq6/8LO8Ms7EAH/hC5MIf/Bh0NO/4Q/4x/8ARUPDf/hFSf8AyfXzbqHx/wDGPh3xhN42t9RsJLDWvDOhta6NFo17ebLi8m8qMjy5iZQjZYiOMs/3BtPzV12oftLfEez8L29xcWC6FBFf3Vtc+K9d8HapbWjIkSSQu9lJJHLbxyMzxGV5GSMx7iSGFTJqMXJ9Abt/Xlf9T1+bw18YowvmfE7wtbrnYC3gyUlju2rknUcZY44qb/hD/jL/ANFO8L/+EXL/APLCvnLWvG3jKLx14w1rVbrw9reh3Nx4LA0RrOWaCKS6vUj3QzCfBKbmbPl7ZMpgDa+7tdF/aO+IDX41HUB4WXQrrVNd0mGCWGe3NqbGSXy7ma63uDGUj+ZRECB83tW3s2lcUZcx6m3hn4vL5b/8LR8MeU5GGPg98E4xtH/EwHU81J/wiHxi/wCin+G//CLk/wDk+vnfWPjh4i+JGk3mi63Pp+pGx1bR7q11Gz0S60uKeOaTnYtxI5lQdpVwregr7cC8Dlv++jWdtFImM1J2PK/+EP8AjH/0VDw3/wCEVJ/8n15j8dPDHxVj0fwo2ofEPw/cRt4r0QIIfCbwYlN5Hsb5r45Cvz5fU92r6l2D3/M15L+0Qu3QvB6gkAeM9BPBx11CLNI0GN4b+Lkcio/xR8No0n3N/g9hnA3Nt/0/JwPahfDfxekjLL8U/C5UFlZv+EOf5Sp2n/l/PINeR/tYR6pY/Gz4a+KdHllS58L2mpaxPDAxzdW8awiaEjvmJmOeozwRXPaF8ada8E/DvVrzwhqWjK994j8QXsEcujXuq3N0kcwYLHbwMmyMFxvmeRUT5ODmpcrfdc05HZP5H0H/AMIf8Y/+ioeG/wDwipP/AJPo/wCEP+Mf/RUPDf8A4RUn/wAn15dY/tSeJdT8G6vrq2VnbG2vvDMEMTwSv8mpJZmQPhuMG5fZj/Y3Vmaj+1l4u8L6h4um16DR7Uael0tv4beyuodRhZJlhglWUuVvY5CwJFum7+7urVxcd+9vy/zMISU4qS6nsn/CH/GP/oqHhv8A8IqT/wCT6X/hD/jKOvxO8L/+EXL/APLCvHrP9pL4gTeHb5buay029F7HHaapeeB9bt2vInj37LbTXYTyyBvkyXC/x9OK9w+BnxD1D4pfCvw/4l1K1hgvb+FnmjhRo1yrbSVRiSoyOjHNLldm+xV9UjKHhr4uhUH/AAtLwyxkfKP/AMIdJtYZ+7/x/wCM9utS/wDCH/GP/oqHhv8A8IqT/wCT6+cf7SXw/eQ+CpIVnsfCvijU9Wnttow1vDH9phJX+6X7dD06cV0ut/tNfEnw2vhjTLxvCs2teKhpt3pk0VlcrDBBc3kNu8UsZn3PIv2iM71Zep/d8U4Rc7W6uw3o7HtP/CI/GRHy3xN8MlP+xNk/+T6Z/wAIv8YOv/Cz/DO3AOP+EPfptxnP2/oTznFeXeH/AI8/EIeINJtPEVp4dvNNm17UfDk40+xlgm822tJbpbkmSdlRGWMjy+ePm39q8itfHXiZvDv/AAkZk8Onwx/wqvS9RPhP+y5f7PxLM4VM/a+ocZ3Yztwud3zVMVzRjNbS/wAm/wBGJ+6m3/WtvzPrL/hD/jKenxO8L/8AhFy//LCk/wCEP+Mf/RUPDf8A4RUn/wAn15Xp/wC0d45s/FUN3qSaDJ4Xk8Wah4XFja2UovM28M0wl81psZIgI2eX/F1rf+FPxm8e+KPHXha3146G2ieJNBm1i2t9NtpY57cq6BUMryssowx+ZVXr0pxXNFSXVX/C5M5qCu/61sdr/wAIf8Y/+ioeG/8AwipP/k+vMJPC/wAVv+GkrWP/AIWJ4e/tL/hFJf8ASP8AhE32eV9rjG3yvt27OefMzjtivqMj5sZOPqa8pkH/ABlVajJx/wAIZLxk4/4/oz0qLlkDaD8XFby/+FoeGDI3UDwi3y5+71vx1+hpy+Hfi/J+7i+J/hhn3gZbwdISAV3AMov/AE+leNePPhz4b8WePPjxrWsabZy63pFhYTadrCxKLuycRzFDFMPnTlF4UjOOaNG+OXiCz0XWLiCXQNC164v9NtJrm60e9vry6Z9OSZiLO3bfdS7mYCPdEFRSWOeafVx7W/F2Bay5T2z/AIQ/4x/9FQ8N/wDhFSf/ACfUH/CO/F0SoD8U/C4wrOV/4Q5/nVSQT/yEPUr27e9eT+Gf2kviP43t/C76bb6Dpzz+GtR1zUxf2kzSM9neC3KQxLMCok6/Mx2d81xz/EL4q3mu+HviFLN4UttdPw+vdfNtHp9xJD9mBgl8j/XhvM5P7zt2SShaq/r+F/8AJmSqJ28/80v1PpD/AIQ/4x/9FQ8N/wDhFSf/ACfR/wAIf8Y/+ioeG/8AwipP/k+vLdU/ac8WSLq/iTTINKXwl4bl0u21axuInkvrhrtITuhkWULHtM643Rtu29qz/h7+1l4w8axtq39lR2/h/UNNutQtr6+8OapZ2OleWVWJZ79wYrveSf8AUKvtuquX+vxNVqrnsX/CH/GP/oqHhv8A8IqT/wCT6P8AhD/jH/0VDw3/AOEVJ/8AJ9c/+zh8ZvEXxM1HxZpniE2882jS24hvINHutJ8+OVC6N9nnkkfaR0k3Yb0Fe77B7/maTVhHlH/CH/GP/oqHhv8A8IqT/wCT6P8AhD/jH/0VDw3/AOEVJ/8AJ9er7B7/AJmjYPf8zSGeUf8ACH/GP/oqHhv/AMIqT/5PrzT9obwt8VLf4YmXVPiHoF5a/wBr6MPJt/CjwHzf7UtPLbLXzdHwcd+lfUWwe/5mvJ/2n+PhKCCQR4h0A8Ej/mM2dAC/8If8Y/8AoqHhv/wipP8A5Po/4Q/4x/8ARUPDf/hFSf8AyfXq+we/5mjYPf8AM0AeUf8ACH/GP/oqHhv/AMIqT/5Po/4Q/wCMf/RUPDf/AIRUn/yfXq+we/5mjYPf8zQB5R/wh/xj/wCioeG//CKk/wDk+j/hD/jH/wBFQ8N/+EVJ/wDJ9er7B7/maNg9/wAzQB5R/wAIf8Y/+ioeG/8AwipP/k+j/hD/AIx/9FQ8N/8AhFSf/J9er7B7/maNg9/zNAHlH/CH/GP/AKKh4b/8IqT/AOT6P+EP+Mf/AEVDw3/4RUn/AMn16vsHv+Zo2D3/ADNAHlH/AAh/xj/6Kh4b/wDCKk/+T6P+EP8AjH/0VDw3/wCEVJ/8n16vsHv+Zo2D3/M0AfLH7PPhn4rTfD9n034h+Hba1PiDxADFN4Ueb94usXfmHK3wPzPvOM/JnYdxGa9Q/wCEP+Mf/RUPDf8A4RUn/wAn0z9mVd3wvlLFif8AhJ/Eh5J7a5f161sHv+ZoA8o/4Q/4x/8ARUPDf/hFSf8AyfR/wh/xj/6Kh4b/APCKk/8Ak+vV9g9/zNGwe/5mgDyj/hD/AIx/9FQ8N/8AhFSf/J9H/CH/ABj/AOioeG//AAipP/k+vV9g9/zNGwe/5mgDyj/hD/jH/wBFQ8N/+EVJ/wDJ9H/CH/GP/oqHhv8A8IqT/wCT69X2D3/M0bB7/maAPKP+EP8AjH/0VDw3/wCEVJ/8n0f8If8AGP8A6Kh4b/8ACKk/+T69X2D3/M0bB7/maAPKP+EP+Mf/AEVDw3/4RUn/AMn15j8aPDPxWjvvh39t+Ifh65DeLLTyTD4TeIRS+VcAMd18d4x/yzHze9fUuwe/5mvJfjxGFvPhkBkBvGln3PGYLg8en4Um7ANbw78X1ZQ3xN8LIzAuFPg+T7o6nb/aGaRfDfxd+Rx8U/C7q2cAeDnwecdRfnoa4j4w+Jtd8M/tIeHJNE8H6r4wnufDdzCbTTZ7aF0PmffLTzRR9P8AaryLwr8efFPwx+BXhibQzpNtcrb313d6PfaZdanqJ/0qRdoNvIkcCZA/fSOw9qqPvJspxtqfTX/CH/GP/oqHhv8A8IqT/wCT6P8AhD/jH/0VDw3/AOEVJ/8AJ9eT+H/2o/GniT4hG3sPD11d6CuoJp8tpb+GNTl8pDArm6GoqDbEb3VfJxnH8dc/b/tJfGKbw3Bqpk8G/wCl+DLvxjEn9mXfyLauoa2P+k8mUOv7z+D+5JRs7P8ArS/5IlanvH/CH/GP/oqHhv8A8IqT/wCT6P8AhD/jH/0VDw3/AOEVJ/8AJ9ec6h+0l4sm1TUdd0y10tfB2garo+j6rp1xG8l/cPfLbMZYZllCosYvYflaJi+x8bcisXR/jv8AGPxE3hdrX/hDbRPEmuX+mWq3Frct9lhtvOzJLifmU7F/dj061XI7X/ra/wCTM3NI9bj8OfGCWPcvxM8KlAQrMPCEnysDtZeNQPINS/8ACH/GP/oqHhv/AMIqT/5PrwX4T/Ebxd8ObjUEkvNCuPDGq+LNct0E0MtvLbypJK/mSXAZ1WP92f3Yi3e9amg/tVeMJ5ta0me50bUtQBsl07VI9FvdPs1a5fA3pcS75o0H/LVfLEnYCpasVza2PYm8K/GQt8nxN8McHZhvBknXHU/8TAfpUn/CH/GP/oqHhv8A8IqT/wCT68T1r4+eKNH1EjxXpXhnXLvQ9fuLFLi2gmhUBLfzElVTNIYS3+1ur3X4O6z4+1/Q7fVvFtxoNza6haQ3dl/Y0E1u8XmAExyq8kgfAP8ArFZc/wBynFcyuOT5bFb/AIQ/4x/9FQ8N/wDhFSf/ACfR/wAIf8Y/+ioeG/8AwipP/k+vVdvufzNO2D1P5mpA+W/hl4Y+KsnxE+MSWnxC8PQTxeJbQXcr+FXl8+T+x9NbIAvh5WIyqYO7kb+h216X/wAIX8Yf+in+G+mP+RKk/wDk+j4Rru+Jvxwjydq+LbNgMnqdD0on+Qr1nYPf8zQM8l/4Qn4wDp8T/Dg5B/5EyX/5YUf8IV8YBwPid4bHG3/kS5en/gfXrWwe/wCZo2D3/M0AeTf8IX8YM5/4Wb4az/2JMn/yfTP+EI+L4ZT/AMLN8N/L0/4ouXA4xwPt9eubB7/maPLHv+ZpO4Hkf/CE/F//AKKZ4Z67v+RKk6+v/H/1pT4L+MJH/JT/AA53/wCZMl/+WFet+WPf8zR5Y9/zNLXdC9Twy8+DPxB1DXbfW7nxj4JuNZtgVg1GX4f7riIHqEkN9uXPsa2v+EL+MI6fE/w2Pp4Ll/8Ak+vWfLHv+Zo2D3/M0126B5nlH/CH/GP/AKKh4b/8IqT/AOT6P+EP+Mf/AEVDw3/4RUn/AMn16vsHv+Zo2D3/ADNMZ4x4i8HfF/8A4RvVs/Evw6V+xy8f8Ic//PM/9P8AXRfs6/8AJvfwv/7FjTP/AEkjrr/E0at4V1dSPl+xyj/yGa5D9nX/AJN7+F//AGLGmf8ApJHQB6PRRRQAUUUUAFFFFACVR1I/8S+4/wCuMn8qv1R1ID7Bc8f8sZP5UdQ6nmH7POk2mvfsr/DPTb+EXNle+DdMguIXJxIj2MasueoyD2rlbz9kDw7rv2FtX8X+KtdXT7CfTNNF5d2ubC3kMDARFLdd7I9vGVkk3Of4mbpWr8G/Gen/AA//AGNvh/4p1ORo9K0jwJp2o3EgHJjSwjYj8hXlLfGrxRcfGe/XxNpeoeH7Frbw2tvo9jrskkSyXN3dr5+9EVT8qqJItuTtGTwKVr35Rr3Y8z6Hplp+yrZ2eoajqNv8RPGEPiG6vY9RbWBLZefHOIVgYhPs3lFWjRV2FCoxlQDk02b9kPwqLS0tLLVvEGl20emppksdrPAwuY0l85Hl8yFsOJPm/d7eaytP/a8iubLWtSufDgi0m0LQWU0OpRyT3Nx9oW3SCeDYGtndmUqrZ+tPm/am1iPxJZeE5PAHn+M5L82s+mR6qjRW6GNZFm83ysldrjnZVyuTFNLX+up1viz9nfQPGHiR7+bVdY02C4jt4tS0yzmiEGpLDjyhIWjaT5cD/Vume+aTTf2cfDWi6xc38F5qYeZb5ColiAxdY80Y8vtgbfSvL/FX7Rmry+MvBmsPpt3ofghLvUFmv4NTEwvFt4+RJAoBX5vUtVjT/wBuKy1LQbi+h8N2t/qivavaaXo+uw3xmhuGVUaSRE2wyKWG6M5I9ajXcLWkv68jsL79lHw7qEOnwx63r1gljplppifY5rbdMbZt9vdMz25Pno3OQdh7qavSfsz6W9qtzZeL/Euk6+0k8t34hspbP7VfNNHGkhnRrYwHKwxgBIl27flxzVHwf+0ZqPib4kN4Xl8IC0a2uk0++ZtSD3VtKYt+/wCz+UGaHt5uVHtXvPkoW3FQW7HvSd3Hbv8AmHk/L8kjwNv2SfC6T2sWn6zr2laLFbaNbNpFpJEbd/7NmWSzf95EzjG3YyhgrLgkZAar+o/su+ENZ0M6RqFxqlxYf2jqmpPCbhOZNRMvnpkICFBmYrg5yckmva/s0e5SRkr0JJ9/8TS+Sm4ttyT/APW/wFXzMSVtjwe3/ZR0uGeWe/8AGXibWJZFs0LX0trwtrJviVQluu0BflIGN38WTzXvQAwKb5KDoMdf1OTUlJfCkHLZ3CvJP2if+QL4Q/7HLQP/AE4RV63Xkv7RH/IF8If9jl4f/wDThHQUdJr3w40/xJ420jxFdPO1xplldWcUDFPImSfaHDDG7jYo/wAnPkvh39i3wl4S8P6VpWg+IfEmk22njUoEngubfzpbO+Km4tXLQfLECiYKgSLtGHFfRrQozBio3Kcg9xSrGq5AUDPX3o1Tuh3Z86x/sc6HH/ZtrH4w8UR2NmNLNzYxyWirfS2DKbaadhb7s7IkUrGVU7RkEjNa037KfhzVrmcajrviLVdJW3uItN0y8miEOmGdlaVoGEQkySin94zbcfLjJr3MRKowM4znqfXNHlr83HLHJp80n8RKSWiPDm/ZZ0iV49Ql8XeJZfEMc3mjxJJNam8VfL8vylH2byVTZ/EIw3fOea2vhr8H5/hbNoum6Vruo3fhjTbadTa3kiFpJJJt6swjiXcVGeT616x5a7i20biMbsc0GNW4IyPelrdhbqeTv+z54ZX4peIfHk013NrGuaYulXNm0w+yrEBjeiBd3mEcHLc5rnbT9lHQIWtft2u+INWNlPZ/YTqE1sxgt7WVZY4BsgGY9yqSWzIcDLcV70I1XGBwOg7Uz7PHuZsYLdefbFNNx2B66nkTfs9+HxdWl2L/AFUmz8Q3viGJTNDhJrm3kglAGzAjCyu6jqCfpWDN+yP4dm0fTdMj1/xFZWlp4Zh8Kzxwz2zG8s4m3x+azQEiQMSd0ZQHoRjFe+eQnPHXrz+FHkpxx06VKulb+v63CXvRa/re55E37POgJFbDz9RvFtfEFz4kSOSWLbNNMsitCfk4h2yYx1968z+Afwl8UaD8UbPU9Us/Eel6PoekzabbW+sahZ3MAEkoZVtBb/vCgVR81yPN9a+qPs8ZLHBG7OcEjrj/AAFL5KnGQTj3NO9thSXNFrzBvvf59K8pk/5Oqtf+xMl/9LY69Z2g15NJ/wAnV2v/AGJkv/pbHUq/UZn+K/2cdM8XeMPEGsP4u8QWVhr0dvDrPh6zazFndJCGAVnNubhMh25jlXrTdY/Zr8P6pql1qlnrGraBq0mpQ6nHeacYM20q2rWpSNZYXVkeF3Q7g3UEYIBGDq2ia78X/Hnj21tfFGteHZ/Dpgs9ITTrySCGOZldjLIiELKCAOJAw9qsXX7R194b16WyuvDIn8OWV9HoEviAXixFtQMSsFFuI8CMswj3+ZndwEpxva3X+rfjYG7a/wBbGt4M/Zo0LwUgjt9U1a7RNJvtDX7TJEWFvdXHnyHKRgkqQNpOT/eya0H/AGfPD72dlaPqGpGK08LTeE13yIWNnIqqZMlM+YAq/N93j7vNecaT+2FcL4Nk17WvAVxoqTeG4PE2nww6gJhLbSSxxFZH8pfKKNIrMSCNpzzVfXPjv491fxV8Mv7N8O6faWmpanfWuoRx6950E0SWhm32862/7xAuG34X5x5eO9VbRpef6r/NEe7e6/rb/I7jU/2YfDd9qVsX1vXLbSyLQXmjrPB9n1OS2VRA8mYi6soRciJow+PmDUlr+yj4WW2vLCbXPEV9pnkSW2nafcXEYi0iN2DstuwiDckA/vWkNcJ4L/asuIvC2nzWfg/UL3RdP0Ww1bVNQ1HWhJc29vcDgktGTOwHUnYeK6rWP2mryw+I1n4RPhi3gk1ESjSpZtZiNxKVTKPJbojmNGP3WLfhUu6LUk9jT0j9ny98G3GoaloPjfX7zV9WuLM6hdalNAQyw/ISqxwKAdvG0AKepGea9yr4x+Gv7TGtab4Y8P65430+5m1qbRrm4ihs9W82O6/0nYoKGNFDdt2M16TcftQa1b3VnojeBj/wmMupLp9xo/8AayeXAXiZ4387yslGCHnZxWkk9AR9C0VxHwm+JB+KXgmz8QCwbTJJnkimsWmWYwyRyNGy7wADyprt6gYV5N+1B/ySP/uYNA/9PFnXrNeTftQf8kj/AO5g0D/08WdAHrNFFFABRRRQAUUUUAFFFFABRRRQAUUUUAeSfsx/8kul/wCxn8Sf+nu/r1uvJP2Y/wDkl0v/AGM/iT/0939et0AFFFFABRRRQAUUUUAFFFFACV5N8eP+P74Yf9jpZf8Aoi4r1qvJvjz/AMfvww/7HSy/9EXFIDqLz4d2N94+t/FkslydQg059MRcp5YjZtxbpuzn3ryu8/Y98MXWmrp9n4l8RaTaPaXFhcx2E1spu4JJTKUlLW527XYkbNp7HI4rqPil8arjwLra6Vo/h0+I9VWybUruP7SbfyrVX2kqRG+9/wDY4+tcHeftreHY/GFhpkUGnNpd01vA91PqscV4ZZ13KI7MrukRR947hinZ2si3tqdVof7MOg6BrEd1/bviG809HF4dLuGt/srXwiWEXZVIQxl2Io258vjO3OTTo/2Y/C8Oix6d/aOqfZ4fDF54Vjm82IEWlwVMj/cx5g2Jz9zj7vNcrpv7YEd5pmt6tP4X8vTbUyQ2c1pqSTS3NwtwtvHBMmwC2eRnBVWY/WrLftNeIv8AhJrTwmPAMbeM5r6Syn0v+20+z27LaC5V/P8AJyUdQy58v73FOV3/AF8vyZnfl/r5nS3H7NuhX2u212NY1gaYklpPcaCs0P2G7urRESC4lHl+YJFEcf8Aq3VT5a5BwMaeifAjRPD8fhsW15qDjw/qN3qVmJJIx+8uN/mJJhOUG8/dx19q8Svv2ndZt/G134w0zRr3VPC9v4Hi1fUNLm1MwCydLueOcqgRxJKPK2jbjcF7V6Fq37T0fh/4m6f4Y1XRIbWy1O4aC0ul1mOS9bFu1wJXtQuY4WVCA5b8Kd3b+umn6EOOmv8AXupmvqP7MPhPWNLfTr651Oe0l1O+1OaBnjzJJdiRZEJCZ2ATNjnjPJPbjvFv7Ma+HfD97qOnar4s8aaxDaW9nDaz31lDPHDA+6JrZjAqrKg6bvlb+INWZ4i/akutQ0XbqXg7UdH0nUtLGr6fqFlrOLiS3E0UWOIwY2y6kq2QRwc5rPi+PHinT/GGtxeIdJvJNHtPEVrZ2f8AZ2tMJY1eHeFeIRhpQR1BY5os21/WzDmV/wCvU3PhX+znc69plzqPj19agubnWbrVIoNTurd70xy2/kFLp4E8oP3AiIA7V6j8LfgrpfwyvL24j1jVvEl3Nbw2cd1rUkMj21rCP3dunlxpuA7swZjxljWV8E/jnN8XmupG0OCwso0Ettd2eqJexyDdt2yEKrRzf7BB+teyeWvAxjHT2qVeKH8T9BeBxS0lLQWeS/CL/kqPxy/7Guy/9MWl161Xkvwi/wCSo/HL/sa7L/0xaXXrVABRRRQAUUUUAFFFFABRRRQAUUUUAZPiX/kV9W/685f/AEWa479nX/k3v4X/APYsaZ/6SR12PiX/AJFfVv8Arzl/9FmuO/Z1/wCTe/hf/wBixpn/AKSR0Aej0UUUAFFFFABRRRQAVR1L/jwuf+uMn8qvVS1L/jxuf+uMn8qAPFPhT4QtPiH+xX4H8KXsnl2ms+A7DTppFH+rEunomQO+M1y6/szeL9e8YL4g8S+KtLudQjGiIFsrGSIbLCeaQn5nPMnm8ivTv2X41H7Nfwl4/wCZS0n9bOI16c0CMMc9c8MaItx2CWsXE+XNS/ZJ1nxBqU8+seKLWSWCF4rG+tLN47m7lFws8Ul6d22UpsUDaF6V0Xhb9nnWYPiHZeOdf1ixuNb+1PcXi6dZtDDIgtlgjjjUsSANinDZzjvzX0B9nTbgjcuCMMSQc9c0v2dPmOCCxycEjtinzN7h0a/rY+ZL/wDZS1bVdQsdJl8SWZ8G2Nzey2lkbFmuVW4HzDzd2wbW5GF5q7b/ALOXiObwzb6dqvifTkjhm09EXT7JraD7PbzK4yN24yuEUEkkce9fRzW6N1B7dGI6HNKIUVtwRQcYzjt6U+ZpaD63PCtS+Amu6t8WrPxLd67Yy6XaamNVg/0Nl1FQFwLXzwwUw57Fd3viveKj8hPTjrjJx1zn86kpXbWoutwooopAFFFFABXkv7RP/IF8If8AY5eH/wD04R161Xkv7RP/ACBfCH/Y5eH/AP04R0AetUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAV5LL/ydZa/9iZL/AOlsdetV5JL/AMnVWv8A2Jkv/pbHSegGT44+C/irVPEHim58NeJbXQ9L8V28MGqpcQO1xEY1KGa3dXwrFTjB4rnbv9l29+2Xmk22uWsfgmfV4te/s+SzcXK3Mcaqg83dt2B0V8bdxI5J5rM+IXijWbP4yavaat4x1jwNI0lqnhtpA50i8H8YkA4Zy3y4OOOfejwv+0h4stvEnjbTtV8LjU7o+Km0LQbW3vY0+0MttHMVyV4Hlb5cnPHy9a0ine6/rVfqS1f+vJmppv7Mms6Lofh6007xDb2eoaP4Pg8NLcJbH55YpYJPMIzgxOICrIQeGqrpP7MPiHSJNK1Oz13SLXWIPEFxrFxbQWEqWMcU9v8AZ2jgiDh1+X5/mb74I6VJq37YVtY6X9ttfCGoaiLXSL3WNXVbmNP7PWzuPIuUOR87owzgeldPD+0XPNp/idH8GXsOq6OLWT7DNexoJLe4VmjmklPyxKArb852+9Jtr3l/Wv8AmTtv1/yX6WPHPBX7PHi3T/FGqeA4Ncsm0K18O6NpuoXsmnyHzxEzl1ifdhGKgcNururX9mLXtL8ZQ6hp/iHSjotvrcurNDd6ezXUm9NpiMokxtU/d4+WsS8/ah8ReMNd8CT+H/C8sejXx1iHUYxqMQdJbRNrmNiuCY2J/wB7PHSsO3/aO8SM2qedpeqf8IbHo2l3MOorqUK3yyTTbWbheSx65604803ZjdoWv1Oltf2P9Xn0a302/wDEtnt0y0ltdKuLWzcNGxuPPVpQzcgdMDiuo0P9nfWpPFll4s8QazY3OvjVFvrtrG0eOGSJYGhWONWY4wXY/Nnr7VueDP2hIvG3xCuPD1t4evobOKaezOqtOjos8R5VovvJn+Fjwa9l8lfn4IL/AHiCQemKT5lZlJp7HkHwn8B+JfhpdWfhV7i1vvDqw6heSXCWxTM014ZI06/wo7fXPfivYqjkgSVdrruG0ryex61JQ5XGFeTftQf8kj/7mDQP/TxZ16zXk37UH/JI/wDuYNA/9PFnUges0UUUAFFFFABRRRQAUUUUAFFFFABRRRQB5J+zH/yS6X/sZ/En/p7v69bryT9mP/kl0v8A2M/iT/0939et0AFFFFABRRRQAUUUUAFFFFABXk3x5/4/fhh/2Oll/wCiLivWa8m+PP8Ax+/DD/sdLL/0RcUAZ/xb+D+reLvEkmteHdasdGvNQ0uTw/qTX9qZ1ktJGziMKynzM92JFcv4d/ZbvvBesQx+HfEFlp/hyV7WS722BGob4F2AJKGwoccNkcdsVvfFrVr3XPiZo/g0eKbrwlpX9lzatfahYXItp9qtsUBzwEB65rD1f48ah8GvBOkya7ZR+LisEst7rtleQxxsqy7VHOfNdkwx2elVsrly6Gbffsn654i1bUb3VPFFolwsDxade2Vk0czym4WeOS8XO2YpsQDAHT61geIvhL4/0X4weCdft9V0248W61ql9d390LOY6bbRx6aYo4fK37iDuLAls7zjpXoFl+0x/wAJHrer6ZoHha6v4rdprRLz7XHlp1tvPw0RG4IRxvPFcd8Gv2stb1bw/otv4s8JXMN0nh//AISLU9dhuozbRWO+UGfbtz0jPy9aV7u39d/0M5JtaeRryfsoPD4X1/RYdctzLqfg5vDTTz2hbN1JPPPLcnB5DPccr7dao3P7Keu/8JFbXcWtaRPottrLasqSWj/bLgS27QSQvLuxtXexjGMDPPStKb9pCLUzpFlq+h6x4T1C8v8ASbm0t472Nzc2l3NsiJYLnBOQ8X3h0BFUde/aw1LUvC+sT6X4PubK6fTtYfS7ye7j8uWWyfy5iBtyCPve9F3GN/N/ncSkpz5Fv/wLfkzy7wT8Nte+LWuWPhxNYWLS9A8Pvponm0aa3ltGF1GQkpc7ZJdsI5j+XivY9e/Zn1rXfE13Nb+JbW10mXVbXVodtmwuoZYIPJZQ+7YATz92szSf2vo9C0PQofEukRR6mLG1n1SQatbB4pJyqoVjJ+fcWLYHAq54p/aovL7SfFy+GPDNzc/YLe+S11RbqPiaCPJMsRXdGM/dz97tVc0uZJef5kQWt/62sWvDvwa8b/DzWNV8UQ6rpeo69Pbx6fHBp9i0UUsfnBjPOGk5k2/3cCvo+vkzwz+0rqWj2Ol3eraDqeoeIr220q1+wJqcbQl7v7rjjg+9dtqH7UN3ZeBf7fj8F3Ms9vfT2Oo2s+owwJaPEu5v3rcOSPuqBk0vesrl7SaPeGZl6KzBv4hjK/hUteE/Af4lXPxM8beLNRjnmGk3Gm6RqFlbzHiATwu7j3zgdemOMV7tSasKMlJXR5L8Iv8AkqPxy/7Guy/9MWl161Xkvwi/5Kj8cv8Asa7L/wBMWl161SLCiiigAooooAKKKKACiiigAooooAyfEv8AyK+rf9ecv/os1x37Ov8Ayb38L/8AsWNM/wDSSOux8S/8ivq3/XnL/wCizXHfs6/8m9/C/wD7FjTP/SSOgD0eiiigAooooAKKKKACqWpf8eNz/wBcZP5VdqlqX/Hjc/8AXGT+VAHnn7L/APybX8JP+xS0n/0jjr1CvL/2X/8Ak2v4Sf8AYpaT/wCkcdeoUAFFFFABRRRQAUUUUAFFFFABRRRQAV5L+0T/AMgXwh/2OXh//wBOEdetV5L+0T/yBfCH/Y5eH/8A04R0AetUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAV5JL/AMnVWv8A2Jkv/pbHXrdeSy/8nV2v/YmS/wDpbHSeodTmvih8GfGnjT/hKdEttY0yTwn4jMRuPt8crXdiQMMbfaNuffqPasWf9nHxRpfi7UPEOiavpM80Wurr+mHVEmJSRrP7JNHKFGCpT5lZfm3d+9fS6xqoUAbQvQDgUxbdI12qCB6bjxVJ2/rzT/Qd3qu/+Vj5b/4ZP1hvD/iK2fXLX7ZrfhPW9Jupm3mOO+1G4895AM8RoeOPmPrWr4u/Zs1rWtY1LUdP1TTSLj+xvL0+9jd7ab7AkyPHOAv3H80cDj5OlfR620a9Bj2ycdc9KFt442YqgG7r6Hknp9San7Nv63uS/f1lv/wEv0PlrQP2Y/F/h610kW2p+H5brT9V1a6aHyZVt2gv2ycDbw6HkAcVXvP2U/FLabBplpq+jvZtpWn6feTXEUqyiS2n8zfGAMEH3r6v8lNu3bgelHkocZGcdOelWpOMuZCkudrm6Hz/AOFfgT4m0v4t2/iO9vdJisLWaeVLvTY3ivbtJPuw3AChGC+uM+9fQVMMEbKQUBDdQeh+tSUuZtJPoCik9AooopFBXk37UH/JI/8AuYNA/wDTxZ16zXk37UH/ACSP/uYNA/8ATxZ0Aes0UUUAFFFFABRRRQAUUUUAFFFFABRRRQB5J+zH/wAkul/7GfxJ/wCnu/r1uvJP2Y/+SXS/9jP4k/8AT3f163QAUUUUAFFFFABRRRQAUUUUAFeTfHn/AI/fhh/2Oll/6IuK9ZryX49f8f3wx/7HSy/9EXFIZB8T/hZq3ijxNpXiXQjpNxdx2cumXtjr0Pm29xbSNuGQA2Src46H9K8Y/wCGM/Fdv4StdHg1fw5cs1hcWbfaIJRFaNJP5vm2yBcK2Pl6DHavRfi98ZtY+Gnxk022WwvdY0GPw9c6jPY2jQjlHx5haQg5A4xnFXtf/aa0zw9qWgyXPhnWl0LVI7MR64yRJbo1zgxKFd1kkx/EYwwXPNEr8o5OyOf8N/s7+Lrfxpo2sarrGkxRae3mS3WkxyxXtx+48r7PIcbZIs87mBb8Kh+GP7M+u+HtO1jSfEeqWF5pt54U/wCEViawWVZJE8ydvNkBGFO2XHy1tv8AtaaAtvqlzJomsJpkNpeXVjd/uWOoLbBvOVEWQumNrf60JVWH9rewW9mgvvBevad9lk09b6S4WFhbRXrbbaU4f5t5/hHzjutEo8z/AK7NfqTzNbd/yszDg/Zt8Yavqnh/VPEusaa2p6G+kWtkumpKI3tLK4813kJHEkmeg4Fai/sy6t/YWgWEmr2r/wBnJrySOVY7xf8A3Pf5e/rW+/7T+jR+JbnT30TVv7Jju73TbXXCsf2a/vLWN3ngjXfvyPKkAdl2fIfmrE0H9rSPxZN4dstN8CeKhc69pz6lYSXEcKj7ONv72Qb/AJR8w4ptOzXm395nGMadTm9PwsjFs/2YvFMOpWd5KfCUk9xaWdrqNxPZPczRNbOAj2vmIwXcgAbPTqMHmrV/+zX4l1jxZqt9da3plraSw3lv9t0+KWO9uxMMRrdKAI32DowG4djUHwN/aY1HUvh9oUHiTw5rl/4jm0b+0LaeJLeT+18MqSmMRvmPDOv+tVcj5uldbpf7Ulnq2kzG38K6m/iGLUf7LXw8lzbPctNt3EB1kMOMd99OXNTn/XccVZ2/rZHG6b+y74n+3aJqGo6no6vpbaQpW1im+dbL73G3+L1qTxB+y/4hvLp7i0vNBu5Z9QvrhLTV7aSWBEnXaJPu8zIvRj+dbkf7Ymi3emW93D4Z1hpdk1xeWhaFJbKGKXYZHDyLuyf4Vya910vUoNX0231C1k860nRZ4ZE58xGXIbHbrTu2lfoVdKep5H+zn8EdW+DsN/Hqmp2mqGaw06xVrNGAH2WKSPPzeoZfyr3GomjUsGwc/U+uakpOXMyYx5VY8m+EX/JUfjl/2Ndl/wCmLS69aryX4Rf8lR+OX/Y12X/pi0uvWqRYUUUUAFFFFABRRRQAUUUUAFFFFAGT4l/5FfVv+vOX/wBFmuO/Z1/5N7+F/wD2LGmf+kkddj4l/wCRX1b/AK85f/RZrjv2df8Ak3v4X/8AYsaZ/wCkkdAHo9FFFABRRRQAUUUUAFUtS/48bn/rjJ/KrtUdRz9huv8ArjJ/KgDz39l8j/hmz4S/9ilpP/pHHXp24V8wfs7/AA08S3vwB+Gl3b/GbxlpttJ4V0ueKzt7XQzBEhtIyETzdOaQoBxl3J9TWxo8cHiKzvrvSv2otd1Gz0+UWt3c2s3hiSOGdm2pHIy6aQjFvlAIBJ6Ckne4H0PuFG4V4vN8O9ft7qytpv2gfG0Fxebvs8Elt4dEk20fOEH9l/MRkdM1o/8ACnvF3/RcvH3/AIA+H/8A5VUwPV9wo3CvKP8AhT3i7/ouXj7/AMAfD/8A8qqX/hTvi3/ouXj7/wAAvD//AMqqVwPVtwo3CvGrP4d65fTXMEH7QHjS5ms5AtwkNv4dYxEjcBJ/xK/l4rQ/4U34t/6Ll4//APALw/8A/KqmB6ruFG4V5V/wpvxb/wBFy8f/APgF4f8A/lVR/wAKb8W/9Fy8f/8AgF4f/wDlVQB6ruFG4V5V/wAKb8W/9Fy8f/8AgF4f/wDlVR/wpvxb/wBFy8f/APgF4f8A/lVQB6ruFeT/ALROP7E8If8AY5eH/wD04RU//hTfi3/ouXj/AP8AALw//wDKqvMvjt8K/FVjo/hQ3Pxh8Z36zeLNFhjF1baGnls15Htl+TTVy6Nyqn5SeCGFAH1FuFG4V5V/wpvxb/0XLx//AOAXh/8A+VVH/Cm/Fv8A0XLx/wD+AXh//wCVVAHqu4UbhXlX/Cm/Fv8A0XLx/wD+AXh//wCVVH/Cm/Fv/RcvH/8A4BeH/wD5VUAeq7hRuFeVf8Kb8W/9Fy8f/wDgF4f/APlVR/wpvxb/ANFy8f8A/gF4f/8AlVQB6ruFG4V5V/wpvxb/ANFy8f8A/gF4f/8AlVR/wpvxb/0XLx//AOAXh/8A+VVAHqu4UbhXlX/Cm/Fv/RcvH/8A4BeH/wD5VUf8Kb8W/wDRcvH/AP4BeH//AJVUAeq7hRuFeVf8Kb8W/wDRcvH/AP4BeH//AJVUf8Kb8W/9Fy8f/wDgF4f/APlVQB6ruFeUybf+GpLRsfN/whkvP/b7HS/8Kb8W/wDRcvH/AP4BeH//AJVV5pJ8K/FH/DR9raf8Lj8Z/af+ETkm+2fZdD88J9rQeVt/s3Zszzu27sjGcUCbsfUG4UbhXiV54I1fTdUsdMuf2hfGNvqOobxZ2s8PhxZLgp9/Yn9l5bb3x0qez+Hevao0ws/2gPGtz5MxgkMFt4dYK4xlD/xK+G+ZePele6uHWx7NuFG4V5P/AMKf8Xcf8Xy8ff8AgD4f/wDlVS/8Ke8XdP8AheXj7/wB8P8A/wAqqfWwubS56vuFG4V4xqXw613RxAb39oHxtZee/lQ/arbw5F5r9kTdpYy3tWh/wp3xdx/xfLx9/wCAPh//AOVVC1diutj1fcKNwrxLxH4I1Xwdpc2q67+0V4v0XSrc/vrzUovDkECezSNpgC/iag07wvfa3HZPpv7SHinUE1AO9m9knhuVbhVOWMW3TTvwvXGaV7kuVlc903CjcK8atvhvr15fXFpb/tAeOJ7q22+fBHa+HC8W7puH9l8Ve/4U94t/6Ll4+/8AAHw//wDKqmNux6vuFeU/tOYPwk56f8JBoH/p5s6P+FO+Lf8AouXj7/wB8P8A/wAqq8x/aE+Fnim1+GfmTfGPxnqUf9taLF9muLXQ/LEjapaqshMemo37tismM4O3BBBIoGfUm4UbhXlX/Cm/Fv8A0XLx/wD+AXh//wCVVH/Cm/Fv/RcvH/8A4BeH/wD5VUAeq7hRuFeVf8Kb8W/9Fy8f/wDgF4f/APlVR/wpvxb/ANFy8f8A/gF4f/8AlVQB6ruFG4V5V/wpvxb/ANFy8f8A/gF4f/8AlVR/wpvxb/0XLx//AOAXh/8A+VVAHqu4UbhXlX/Cm/Fv/RcvH/8A4BeH/wD5VUf8Kb8W/wDRcvH/AP4BeH//AJVUAeq7hRuFeVf8Kb8W/wDRcvH/AP4BeH//AJVUf8Kb8W/9Fy8f/wDgF4f/APlVQB6ruFG4V5V/wpvxb/0XLx//AOAXh/8A+VVJ/wAKc8W/9Fy8ff8AgF4f/wDlVSAb+zGR/wAKtl/7GfxJ/wCnu/r1jcK+VvgL8NvEn/Ctby6X4y+MtJsbfXvEG/ybXQ/L+TVrsPMTLprEeYQ8rDOFLYUAACui8GLafEW8urPwt+1Prnia9tUEk9tos3hi6khU8BpFj01igPvin1sK+lz6H3CjcK8o/wCFP+Lf+i5ePv8AwB8P/wDyqrKj8C61NqaWCftB+MXvZkeSG1SHw4ZHVTtZgv8AZeSAaQnKyue2bhRuFeUf8Kd8W8/8Xy8ff+AXh/8A+VVL/wAKd8Xcf8Xy8ff+APh//wCVVMrrY9W3CjcK8p/4U74u5/4vl4+/8AfD/wD8qqX/AIU34t/6Ll4//wDALw//APKqjpcD1XcKNwryr/hTfi3/AKLl4/8A/ALw/wD/ACqo/wCFN+Lf+i5eP/8AwC8P/wDyqoA9V3CvJ/jxj7d8Mf8Asc7L/wBJ7in/APCm/Fv/AEXLx/8A+AXh/wD+VVeafGz4VeKLO4+Hol+MXjO9M3i2yjja6ttDQ27eVOPNj2aaNz/7LZHJ4pMZ6D8RvhRq3jPxhLrFndWlrBJ4du9HCSSSCQTTHKvwmNgNeLa7+yV4wkSJIj4W1AxW+lsL69lnW5tGtf8AWwWxED7Y5O7DBPdK9wHwX8WAAf8AC8/iDwdw/wBE0DP/AKav0pB8FfFY/wCa5/EHt/y6aB2/7hVHSwS1VvI8f0r9kfWdN0HxJo8Fj4J0pprTUIbTVtPslW/vWu9237XN5O+Py97fcZ9+ecYFdLr37NviLVx4oEOoaZH/AGvbeG4YiXkJibTpvMmI+TjcOFx1/i213Z+Cnikrt/4Xh4+Azniy8PjP1/4lXP8AWj/hSvir/ouHj7rn/jy8P9un/MK7fpVczV7dTPlTtfuedXX7NviuW+/sZ7zRx4I0/W9V8R2Eoll+2PcXkd3iCSLy9iRo99Md4d2bZHlCM463wb8Fda0DVvA9zc3dnNHofg8+HLjynf55T5PzplOU/dnk881sf8KV8V7lP/C8viDlRgH7JoH/AMqqT/hSfirbt/4Xn8QgN27i10AY+n/Eq6e3Sp2vbr/w36jqRVR3l/Wqf6Hkl9+yn4ru/AfhPRYdb06G90fw+dKlmaaUpJL50MgQZTIRljKFvvYIGMVzGsfDvV/gXPF4v1R/BPhf/ieLe2ltBc3FvpaK0OxoZ5ltcRkn7spQhvQV9B/8KV8VYI/4Xj4/IIwQbPw+ePT/AJBXSl/4Uv4ryT/wvL4gHJzzZ+Hzj6f8SrirqSlUlzP+tblfab/rZL9D5t+Gn7OeseNPDei+Kjong/V7u9tbyFpvElmLj7Er3G+O6s0eB959jsU+tfbGi2TaXpdnayOrvBbxxMyKFDFRjgAAAewFecL8FfFasx/4Xl8QfmOebTQCBxjgf2Vx+FL/AMKW8V5U/wDC8fH+VJI/0Pw/36/8wqkS1eVz1csOKXcK8q/4U34t/wCi5eP/APwC8P8A/wAqqP8AhTfi3/ouXj//AMAvD/8A8qqlDGfCPH/C0Pjj/wBjXZ/+mLS69Y3Cvl/4X/CnxPcePvjBHF8ZPGlvLF4mtopbi2tNCMk7DRtNYSSh9OKh8OEwgUbYkONzMx6VNGkm8Uf8IzH+0x4iPiRVLPpO/wANfbFGDz5H9mbsDn/vn60XGe97hRuFeRRfCnxRcKjw/Hbx9LFJnbIll4eYcdemlVP/AMKc8W/9Fy8ff+APh/8A+VVPpcV9bHq24UbhXlP/AAp3xb/0XLx9/wCAXh//AOVVH/CnfFv/AEXLx9/4BeH/AP5VUdLjPVtwo3CvKf8AhTni3/ouXj7/AMAfD/8A8qqX/hTfi3/ouXj/AP8AALw//wDKqgPM9V3CjcK8q/4U34t/6Ll4/wD/AAC8P/8Ayqo/4U34t/6Ll4//APALw/8A/KqgD1XcKNwryr/hTfi3/ouXj/8A8AvD/wD8qqP+FN+Lf+i5eP8A/wAAvD//AMqqAO/8TN/xS+r/APXnL/6LNch+zr/yb38L/wDsWNM/9JI653xB8IfFdv4c1V5fjf48njFpIShsdAAPye2mA10X7Ov/ACb38L/+xY0z/wBJI6APR6KKKACiiigAooooAKo6l/x43P8A1xk/lV6qGpf8eNz/ANcZP5UdRPY8M+H9rY6p+w54Vs9W1VNB025+H1lBPqYPy2yNp0YaQf7mSfwrw34u36+B/AeraX4t8LWNl4rtNE05dP1Xw3cmW11PT7bUISdsRwYnR3BCsCD5hCnAwPpb9nfRrHX/ANlX4YaXqNrHd6fd+DNLgnt5FyskbWMYZT7EUth+zD4GsrO9t5bXUdRF1HHA0moanPcypDHKJkijeR2aOMSKrbFIXgDGOKhaNj3S/rseGW/x68W65ovh/wATHUY7O4vYfEEx0yWygaXSWt7dfJhdmQsHV1Zn5+beMfLgV6F8A/HfjHUPHMei+J/Ev/CRR3nhm01z99ZW9v8AZ5HZ1dYjFGu9CQOWz0rtNQ+BXw91Lxte6ncWe7Wb2GaW4gS8kTzFljSCSTyQwHKx7dwHriuo0D4W6B4Z1qDVLCy8m8t9Mj0eKQyyPttEYusQDMRgMSc9fetoOKTT6jqSTty/1r/kfOWtfGzxpY/FBvsPiG+vPDkz6lbSCbS7KLT7d4IdyrA3Ny7qerSEI390Vz0fx2+I/h/T9GhvfF39qXfibRLe7guZtOtIhp08l0kJZAkQDgAk/PkV77f/ALMnw+k1o65NaX1tPHcSXyLHqU8cNvJIu2VkjD7F3jhsD5u+avzfs++CNSsbOCTTZpbe10v+x4D9pc7bfcGUKd3BBAO4c+9ZppJ36f5A2tLHI/s0abqGj+Mvi7b6pq8mvXy69Fuv5oo4pZB9mjwJEiVUDcngKOtfQHlp/dX8q4f4cfCzQfhdFqUehJcCTVJ/tV5NeXUtxJPKFChmaRmbOAB17V2+48U5NLX0/wAiU73XYXy0/ur+VHlp/dX8qQMcnNOpdbAJ5af3V/Kjy0/ur+VOopjG+Wn91fyryb9ohR/YXhFccHxloH/pwir1uvJf2if+QL4Q/wCxy8P/APpwjoA9Y8tP7q/lR5af3V/KnUUAN8tP7q/lR5af3V/KnUUAN8tP7q/lR5af3V/KnUUAN8tP7q/lR5af3V/KnUUAN8tP7q/lR5af3V/KnUUAN8tP7q/lR5af3V/KnUUAN8tP7q/lXksij/hqi1THy/8ACGy8f9v0Zr1yvJJv+TqrX/sTZf8A0tjpdRHzH+0d8QNLh/aLPiaUXbX3gGbTIbOSGxu5oR50ub7dMkbRRYi4O5lzXYeD/EXiK+8W6p4R8M+JJPDQ1vxRq2ovrNvawXDlIbW2cRR+cjRkszgk7MhU4r6DvPhf4M07w34l03UI/K0vxJdPJqa3l0x+0SSYQgszZGeMBSPaudj/AGfPh34g0P7BZR3Bghvpbr7bp+qTJcpdFBHJiZW3DKgKVDYIHSnC3Lr5iqfEpLujwXQvj38R/EWg+JvFw8T+Tb+GNK0a+k0W10y2eC+eWSdLjczIZVRxCCu1xtLZ5Hy03WP2nPidpl94i8WWWkalfeH7XUdb06PTrpNMh04x2aziKWBvNF4826EO6spUqXwFwK9Y0X9lfQYvilrepXunxQ+HBaaVBpWl2d3IkTfZPNIE8QIRwCUYBgQDkjkk13M3wD8Ef8JBfa5c2UsjXX2l5LS4vZHsozOpW4kWBm8tGkUkOygE7jnqaqTUdfX9Ap2SSl0f+Z5frXiTxX4L0/wmuq+P7fxNf6lrOniW3udPso7iyEkMzSqBGgIQsqlTs3jB+c81W+EPxf8AFfiL4y2On3WualrnhfWrG5vrO4vNMsrS2kMb4/0NYszGIA/eldie1em+Gf2e/AOn6ZZ/Ybee9tlurfULee51Ca5JEassKh2ckxqHYKn3BnpWf/wyt4OsRJdaN/aWm36wyQWkn9pXOLSOQ5aONPMwi56KBgdsVOkJNv1/ImUW6em+n6j/AI/aDNr6+EptNvdLj1zT9RF5p2n6ymLbUdqZaFmAPlk8fNg9OlfMvjj4wp4G8R+HtU8P+Cr3Tdbsr/VbXVNMt7g3kFpdG3zJc7icPAi/Nwq88ba+wvHHgPwzrvhOytvE93LDDpOx4tWN41pcW0qjAlWdWUo2O4NYmj/Bz4c+G7ixiVITe2sFxKZLu9aSa5SZQk08rM5aXduA8xySOgIqYaXv/Wg6nvR0PGtY+JnjC38SXmi6N4via6utW8Pad/bsWn2uZEud/myKPKw+cDbuBr2j9n3xdrninwTdnxFdjVNQ0/WtQ0s6gYUiknjgndFeVI1VEcgAYUAcVjeCfhX8I7PSWvfD95Y6hY2NzBeSXUes/aUtZrYnySzCQhdmSNucc9K7v4a2fhW10e9bwfd2t/pl5eXF/NdWd4t1G9xM5eQlgzHPPTNaaN6GaT1T62O0Ea5+6Pyryj9qCNf+FR9M/wDE/wBAH/lYsv8ACvWTwa8o/ag/5JH/ANzBoH/p4s6k3PV/LT+6v5UeWn91fyp1FADfLT+6v5UeWn91fyp1FADfLT+6v5UeWn91fyp1FADfLT+6v5UeWn91fyp1FADfLT+6v5UeWn91fyp1FADPLT+6v5U3YuPuj8qlplJh1PAPhphf2Z/FpHyk6n4sPy8D/kLageleWaD4y+IPg/8AZj8M3Gm+GtF8D3U0PhzSbDWre9TUnmSee2icyQtAgT5JHY5Lcn2Fe2fs/wCn22q/BXULO+G+yutf8SxzKSV/dtrF+CMjkcHrXPfD34JfCPUtNXSfDniK48VaXa/Znj09fFk2pQ2rQSxzQuqGdgm1o4+g5Bwcg4qqfu1Jylto/uM5e9y28zlNS+IPxD8P/ESX4Xy+MZL/AFi91OxmsdcNhZrcppr2sjzN5IiEZxJbSclSR5o54GPIvhxo/izStL8H3Ol+PdT+3WvhbW72C6mt7OZ2iWbcsa5h2MrH+JgWHrX1RL8K73X/ANpKHx9qGn2Fta6Josmk6dPb3XmTXJmYM5lTyx5e0Djk/ePrWjpP7Ongrw+0ptdPvXWS3urQpNfzSosNyczIis5CKx7KBt/hxStr66/gVK0tPT+vxPAdD/aH+J/i7xJZ3mn2eoHTrJtNiuI4Y9Lj0q6M6ZczTTSCdGJ+6IgR7U/S/iX8T9cvNADfEG4sotd/tXAg0exfyPsqPLH5W6E53KAreZnHavfYf2cvA9rqllqsWm3sctqsaiEX0vlSeWMRmWLfskKjoXDH3pyfCnwJoD2TPB9mTTRcyRma8dRGLsETZ+bndkjnp2quZJ3f9bEu/LJ+h89eKv2hfHEugaBrWleIb5ru10mxvtW07TdJsmsUMjgM9xPKDIocB8LEqlc96+zlYSMgClcc/Mo+Y4Pyn06g14jrP7Nvwq1RrbTb1bi3aS3TT47CHWJYvNWLLom1XG9k3Ehmyy54Ir07wb4Ok8L3mvmS6muodRvvtkQllZ/KXyIo9oyTjlG/OiVkki3rNtbHVeWn91fyo8tP7q/lTqKkY3y0/ur+VeT/AB4QC8+GAAwP+EzsgPb9xcGvWq8m+PP/AB+/DD/sdLL/ANEXFAHq/lp/dX8qPLT+6v5U6igBvlp/dX8qPLT+6v5U6igBvlp/dX8qPLT+6v5U6igBvlp/dX8qPLT+6v5U6igBvlp/dX8qPLT+6v5U6igBvlp/dX8qPLT+6v5U6igDyP4RKP8AhaPxx4zjxXZkZ5wToWl5P6D8hXjdnp9r4P1a1jv7O28ReDtU8U3V3o/i/TLox3+l6lMZx+/ib5ZGjZ5VDHIAUFlNezfCP/kqHxy/7Guz/wDTFpdWLf8AZ98IWvin+3xBeGUXjaibGTUZ3sEuWB8yZbYt5QdsnLbc8k9TUPdFRaW58m+BfHHxE8H+B/DfhjwxrHibWLqSwv8AVJbi1sdJ3RskuxY2a5EapAPvMTl/9uu/uvj/APEPT/EkXhu6mhXW76S11G3hgiglzYiDzbpY9iNuweMnJ9DXsk37L/gS4s0tlh1RLdZJJoUh1u7QRpJ9+BcScQN3jHy+1dN/wpXwf/wmOneKv7Hi/tnTtObSrW43v+6tWGCgXdt5H8RG73rSMk4ie9z5Lj/aB+Lc3hG91t7vUNJi1TT/ALZaTa1b6RHHZv8AaUTNtHE7SyRBWKsZ1yG6Guu174mfE7S28Q+H7bxJeak+k+II7OfVrGw086olq1r5reXA6LDIUk4bCZ2c17Rb/sx+A4Yb6I6deSxXSeXtmvpZBCm8OUh3MfJUsAxWPaCeoqxrv7Png7xHdXt3NaajbXt3eC/e6s9Rmt5RP5PkbleN1ZQY/lKggHqQTzRpdEQi/euV/B/xMvbn4P8Ah3xNDZXvj69u4YhKmhQQwySnGHkEc7xBACPmUnIY4HFdH4K8eX/i68uoL3wP4g8J/Zz97XBZ4l/3DBcy5rc8LeE9L8H+H7TRNKs47LT7VdsUCksBzkkkkliTySSSSck1r+UnBK7iDkbucUn8TYRutxfLT+6v5UeWn91fyp1FBQ3y0/ur+VHlp/dX8qdRQBkeJFC+FdWAzj7HL3P/ADzNcf8As6/8m9/C/wD7FjTP/SSOux8S/wDIr6t/15y/+izXHfs6/wDJvfwv/wCxY0z/ANJI6APR6KKKACiiigAooooAKo6l/wAeFz/1xk/lV6qOpf8AHhc/9cZP5UXsgPFfhXrGsaD+xf4K1DQreC61u08BWE1lbzShI2mWwjMYLnjBOOTXn3gn47eNJPEHhXSNS1drya88Rx6dqMd/pK2d5Zo+nTXDwPEBgEOi7XAOVHJNeo/AfwzYeMP2R/hxoeqQrPp2oeCNMtpo1JA2PYxhsEHI4PBHI7YqJf2W/CElgElutcbVVu476HXJL8m/t5I42iUJLtwqqjMoGMEGnFxjfm62CTvZLz/L/M8Bt/HfjrxR4+1HxdY6xb6Vq2l+F9QkPmWEcn2iO3v7pVR+MKuFUMy4bjrXpngH4reO/iRbat4sh8R6Zo2g6fcmy/sS5tF3TFYdxYSH5tzHlQDg10sf7HfgK3jsFgm1uAW1rNZfutQZTcQSyPLLHIQvzBnkcn646Yroo/2cvA8fir+21guUG8S/2etziyLhdoYxdCQO9Gz/AK7jlqtP60X6nhnjL4s+L/Gnwyt7H+249POq+CbnVZ7i3tk3rNHNtym5T8uOKrXXxm8deAofC1vZ+I/+EhgtIdKg1G3/ALKhjitzcdRc3GeH/uiMDNe1aH+y34L0Jr3y/wC2LuO6spdNK3l+ZBbW0jbnjQHoCefbtVO4/ZD8GXFusU2peI5I1EDMv9ok+Y8P+qkb5fmZe2fypxtqn1M2nuui/wAjyrRf2iPiHoVjpniTWb+312w1L+38aTHYLF9n+xSy+ThgAx3rGRyTTPDXx6+KWoTaVoV7Nd6bJ4jm02Ow8QanpFvA9u9wJ3mRYAxBQLCPLZgSS2CTXvWmfs9+DNPtdKtFhmvINO+2eRFcT7x/pO/zsnqc+Y/XpnjGBWZF+zJ4Rt9HubDzNcnuJPs5i1KXUma9tPIYtD5Eh+7sJOPY46cVLa5/K6C1+Zx63/Q838M/HvxjceLU8O32pQXU2n6b4ojvLyO3jUTz6fPapBOVC/J8s7Ky8LuHSqPgX47fETVfE3hKTXNSjsNI1RNNSA/2fG9tetNbI8wklUZim8wkKoIBHavUtQ/Zd8F6ppel2wfVreTT/tok1CC/dLi5+1MrXQnfrIJGRSc9xxinaX+y34J0PVtKurV9UFnp/wBmI037aTZtJbxiOGWSM9WVVAz3PJyeaKdkry7fq3+TQ5xbfu9/8j2haWmil5qb9Sha8l/aJ/5AvhD/ALHLw/8A+nCOvWq8l/aJ/wCQL4Q/7HLw/wD+nCOmB61RRRTAKKKKACiiigAooooAKKKKACiiigAryWb/AJOrtf8AsTJf/S2OvWq8ll/5Ortf+xMl/wDS2OgDxT49eKfEvjC/8QIupxWnhrw54l0ewOmtbp5k8jTIxkeTbkDLdAcVk6p8cvH2jrez2d5b6BolvqOrme+h0tZ41aG62RLcKBuSJl481cfWvoXxZ+zz4V8ceIn1m/n1GOSaeC6uba0vSttNLCQY2dO5BA9j3rL1b9lnwbqkdwFOsWK3TzPfJZ35UXccr75Ldx3QtzjjHQYqYpxSTHLWHL1ujgIfjh4yn1K08TDVbd/DNz4om8KrocNopcMkEm2dJfvM3nRZwSVKNnFcd4b+InxR+IXw68LQ6j4u0+3vNf8ABl14mu5bXSY/LEQSFVhClchXLszMPmGeCOK+gYf2dfB9v4wTXoluo40la7TTluMWSXTReU0yx44fy+Mj69aq6h+zP4PuvC/hXQozqtha+HdOOkWU1ndlblrNkVWhlcDlSEXr6ZzVS96Ml1e33Mhrt3/VHzp4L+OPjfSdB8K6P4WsdRk07QdF0YTpFpsE0Fz56o8nnXDPmLahJXGMk85rrYPil8WdQ8EXXiQa6iw3eu3NgkOn6fBLNaWsbuBNGjk+YQANw56V7C37NHg37Vpjr9vjgsILa3kt471lS8S3YNCLoD/WbSBz1I4ORxV+/wDgD4XuvDNtoENxqGnLbXMt5BeWd6Uuo5ZCTIVbHAYk5UDHPSnP3r28/wAyIxkopPy/JHkvxs1g/E79iXXpdT1a11T+1LNYZb6xiKiUmYKQqHlHx614Rrnii4h16Tw1d3Qk1DQ/DraHqDMx3xwm8tgsm7qRscDP+x9a+4m+Cnhp/hufA5guf7FOC2JcTMQ24Ev3Oe5rI1T9nPwVq/jrWvFlxpzSaxrOkDRbv97iOW3DBg2B0bIHzDnitYShGTbWho9UkeM/F7wTDP8AEnxD4U0O603w/Z3uiWN60FwDFZy3UN/GYInRSB+++dG/vA+ten/AHUbCbWPHGnS+HpPB/iW3uLebWdJW7FzaKXjYRy25GFVG8t8jaPue9aVr+zl4UGhatpV7NqupTao0LyahqF2ZLxTCcxFZABt2HkAV0fw8+F+kfDn+05rC4vtWvdSZHvdT1K6+0XM5QEIGbA4G5sAccniso6Rs9ybM7dq8o/ag/wCSR/8AcwaB/wCnizr1ivJ/2oP+SR/9zBoH/p4s6RZ6zRRRQAUUUUAFFFFABRRRQAUUUUAFN9DTqZSewHhXwd4/Z68Q8kf8TbxRjBx01i/xXhFvrln8HPhd8CfGWh6TavqcfgW7mvIreMKbuCLS4pQzAYDnzFg+dgfvdeTX0R+zzZRap8Hb6zuOYbjxB4kt5PLPAB1m/BOaPB37Mng7wbYpaOdR122j0g6DBHrl0blbezKBHhTKjarKqjA9BjFOOjnfr/k/+AZ3+FrZf8A8Kt/jh8W5mstJdpLB9Q1LS47fVNe0iCDYlxHc+bHHBGzEhfLTa5HOOeproNY+KHxRtfGVxYReLLZbRPFcPhlY/wCy4TxLbbxLnbneG5x09q9d0b9nPwpo9xaSyy6rqt7aX1vfW93qd6ZpY/IDiKINjIiUSP8AL785wK17r4I+GLvUpNQktZnuX1tNeZllwBdLFsVx2wBRF7L+tl/wS5attf1vb9D578SftBeObXwBGbbxPFJ4lsZL8TR6XpMNxLfx2z489wx2RQ4+8QAR2rA1Dxd4q/4SfxP4vfxDDLHd6Noc76VNZRSQRCbuNyHpX0NrX7MXgrVLRonl1S23pcJOba9KvcRTHM0b56ox6imt+y74Sle2MkurMkWn29g6C8wsscH+pDDHVfXv3zRpzK/dfdZkyvZpdf8ANHz14T8SeMvBfxY1lBq8Wtx3XjDVYIrfVLaFTA8WneeAsoQFQRxwRXtn7M3xH8TeLp9Ws/FWstdapb29tcXGn32miyurKZ2dXj2rgSRZUbJB1rfm/Zj8E3PjKbxRKL+S6muJLt7Zr1jamWSLyXfZ2Jj+Xj69earWH7OWl+EYVfQ9X1JNTNzYFr7Ub1pJjaWk3mi334zswWXHvzWvNHlSe9vx1Lunse1UUUViAV5N8ef+P34Yf9jpZf8Aoi4r1mvJvjz/AMfvww/7HSy/9EXFMD1miiigAooooAKKKKACiiigAooooAKKKKAPJfhF/wAlR+OX/Y12X/pi0usL41fEab4c/FDwXcTX93FoUWmapf3ttCQxn8oQ7Qc+m9vzrd+EX/JUfjl/2Ndl/wCmLS64TVv2afFHjDVHtvE/iOC+0W0sdSstMubdWW9X7Xtw0xPyt5exenXHOeaFvf8ArYaMT4iftFeI7zRdLtbPw/faH4nXWLCYabDfpMbqzn37cuAAA+BwOldD/wANb3M0kFlZ+Bby71tWvo7yw/tGILbNarufMuNrZHoKrp+zh4p17WIdZ8S6zpX9qQXOnxxx6ekqwra2xOPvH77ZPsM8Vd0f9mnVNL8ZX+tNqVmyXV3qs6ARkNEt0uxMH2Xj/wCvTSVrEK99R2kftbaf4i8SaZY6d4bup9NeO1N3evdxxzWjTdP9HK7nVf4mBwKrap+19Fovh7VNcv8AwndW+nQ6Zd6vpUou4z/aUVu21l+7+6J+9zn5eaxR+yr4kuptBsrjX9LbTNOS1SS9W3kS/i8rrFGwwGik7hs1Fq37KnijxB4Vl8P3/iDSl07TNEvNI8OvFDIZEW4bBkuQeDsTC4X8apJdSj2b4W/Fa58fax4i0bUdCm8P6xopgaW3muEn3QzKzRPuQAfMEbivSq848HfDu88L/EPxV4imvY5YNZtrCNIlL/I1usynv0IdeOnFej0pW6Eq/UKKKKkoKKKKAMnxL/yK+rf9ecv/AKLNcd+zr/yb38L/APsWNM/9JI67HxL/AMivq3/XnL/6LNcd+zr/AMm9/C//ALFjTP8A0kjoA9HooooAKKKKACiiigAqjqX/AB4XP/XGT+VXqo6kP9Auf+uMn8qA6HiPwzutTsf2J/Blxo3kR6vH4AsJLfzGIjVxp8ZBz6ZryXwD+0N4j8J+C31DXNMsJvEX9leHRNqU+oXH2DN3FIwuLgmMeSqhF3lV+857Cvc/2f8ARV179k/4a6bIQq3XgfS7fkdN1jGD/OuN8M/st654V0mT7P4+VdZt7fTbW0vF0ULAkNkk6Ik0QnxKHWY7hvTkA8HBCiviv1tb5GVSMpOPL03Kl1+1T4gt9Q8NWDeGtNhu763S4l8y+bypwbhoSto/l7ZGCr5m0kHaU9TWtc/tWf2V4fXWL3R40ij1u/0u4VZ8mOO2V2Mg45yAKzx+x7LbaDBo0fjFRpFwztqljNpCyxOzXBmZrRTLi1b5vLyN5C4x0FWH/ZBe61Q28vjSd/CbaleamdHayzMXuIzG6G483kLk/wAHetbxNFe7ND4A/tPR/GzxFfaOItNeWGwXUkbSbs3SpEz7RHMSq7ZfZSRXHfEP4s+JfFPi3QVsbG3tPClp4sXRzfR3rLcXJj/1hMYAxG3scivYPhZ8KtU8DlZdT8Xz6/DFaJZ2Ft9mFvFbW6/MMorsskv/AE0GM+lcne/s0Xt34kF3D40kg8MDWW1xdEGmEuJ26qJTJwh9NlZy3TRLTs0cL4P/AGpL5bjQNH03w7bJEbcXDQ6hqUq3F6GuXhcWjvGVlZSASpYEdq2tQ/av1rRtHvPEV54YtU8OXsWrroMi3chluZ7BZmKTLs/dCQQS7du/7vvVt/2Sbu40u10WTxs83htSr3envpm55GE7TBreUy/uGO4AsoYnHJJqe4/ZQe7sdQ0y68WyzaAkOqx6PYmwHmWMt+sqSSPKJf3hRZ5RGMRgb+cnFU2hQTi1f+tTz34zfHr4g698I/G1hF4bs9C1KDwW+vahcxalJvs7a5WRbYwlU5kzDNu9Ng9a6Rv2wLfTPG9v4aiSxvY7WeDSpka8Y6jJcSRKyyrEAQYlZgrMzAjOa6f4lfsvz+M9OvrPSvF6eHBrHhqLwrqj/wBlCf7TbxmQo8eZV8twZpf7+d3OcCtO2/Z+v7HxFqU9p4untPD+o3kN9d6bb2+yWe5jt1hIaYSZMTbFYx7Oo681XMrmktlb+tEefL+1x42XwR4X1y98JaHpD+JEmnsZb7UpRaeXGmQskixnZI5+6h/OvpjwzrE+teHdP1G7h+xzXFukskIdXCEjJwR1rxq4/Zrv7H4a+F/CWj+L1sV0OzfT5Wu9KW4tL2Fxgl4DIoD46Yf5e2K9b8D+FbfwL4R0rQrWZ57XT7YQrPMfmcjoTS90Ur6WOjJryb9on/kC+EP+xy8P/wDpwjr1mvJv2if+QL4Q/wCxy8P/APpwjrNIZ61RRRTAKKKKACiiigAooooAKKKKACiiigAryWX/AJOstf8AsTJf/S2OvWq8juCR+1TbEdf+EMl/9LY6APWtg2kc4PvRtHHXjpzVdZXdflcMMfeU9PpxzTt0mOcK3Py549qCbk20de+c0eWN2ec/U4qBZmZh8x6Z+7j889BU+Tto6XGncXaNxPf60bQOnFQGYhCM/PjOdpOPrjvVil0uPyG7FxjHHp2o8sDaBkBenJp1FMBjRhs5Lc+jEUpUN6/madRQAV5N+1B/ySP/ALmDQP8A08Wdes15N+1B/wAkj/7mDQP/AE8WdAHrNFFFABRRRQAUUUUAFFFFABRRRQAU30NOpvcelJgeCfC+4kt/2b/FVxExinXU/FTK6cYK6tqBBGPevnj4c/FaL4a+H9E8T/DxrrxfYW/g2zHiS3n1GWSP+1ZZ7OKDEkrvskYSXJMa/LwPavpb4G6MviH4H6zpDym3S813xLbGRcOyB9YvwT6d61dX+C0eqfA/TPh42rS7NOt9Pt/7QaAsZVtHhfd5e7GWEWOvBJxTj7spX8v1IavyW8zjb39o3xH4f0vxYdY8NWqaloWp6NYNDBdyGNjfPCC2dnRBOPrtrldc+PHijxLe2Ei+EtNhsl8U3Hh7TLhtZli33MYlHmsFQBo8Rnhsj2rtPiN+zfqPjjxdq+o2ni7+yNI1afTLrUtL/s7z3klsZFZPKl81fL3hEB3BugNXbf8AZxghtdMtP7c3R2Pii58T4a3yCJvO/c8ycAeb979K0jy2v5/5f8E2Ti9fX8mec/BL9obxhY/DzS4vElpY6tqUfhq91lLpbty1yIHcAH5OMhQPwrpfD/7UWqeIvHGgaNHodjBBd29pcS2z35+2us6Z8yFSoWSND97nPtVRf2S9UsfDtjY6f4/Wx+yadd6V9qfRY3zZTkkIR53DqSf3g4Pda2B+zNePdaHDc+NLm60PSXtLv7HNYBrlZ4BhXgnMm6EOOqbWJ9TVJxvr/Wr/AEIku39aL9T6EDBulOVQB+vWuW8Cf2/D4aH/AAkTCbUxPNllRR+78xtgwgI4XaK6n0rF6MSHUVXWRmVCr+YrfxLjApomdmBVWIBIZcAHPbHqKTdguWq8m+PP/H78MP8AsdLL/wBEXFeq5ODzXlXx4/4/Phh/2Oll/wCiLimPrY9ZooooAKKKKACiiigAooooAKKKKACiiigDyX4Rf8lR+OX/AGNdl/6YtLrZm+NvgK21nUtKl8YaPBqmnPEl1bTXa7rXeyqu/nAyT1Przisb4Rf8lR+OX/Y12X/pi0uvnuP4cavrHiLXPDlr4W1jT9KlttZE0Ou6Vug0y4lYOk1pfhESVJWAPlqXYdzR1sB9PeIPjT4C8JXU9prXjDTNLu7eTEsN5eIjglFk24brhWU+oFZPxG/aD8JeBPBs2tHXNOuJ57F73T7WS7VftqDp5RBO/nj5c8186fBHw3rXja1+HHjS/wBBuri41bUtSvr+VoPMSBDEsUOdx5GxFAz6Z65NYmmeC/EXg/wJLBq/g3XtTfVfDM2n2kNnpM95LHcrd79kgRD5RYfxPsWnZWbfQHorn1bovx68F3ukQT3ninSLe7W0inu7X7Wu+2LopZX54OWGBVq6+PHw+svD9nrlx400ZNGvHZIL5bweXJIq7mVT7Dk818z6b8K9ZtfA/iDVJvC2ofaYfEek6nPA1kfPvLSCOHzVT5csBsbjvjnNX/D3gHXdY+KVr4ql8PX9poeoazq9/ZJeWMkLW8Tad5Mbukq5t97dnwAemKfLG9v62uS5WjzH0rpPxi8Ha5/az6Z4p0q9i0yBbm9kjukcW0ZXcJH5GE2gcjPLVo+D/iFoHxE01NQ8M63aazYGR4jcWbiUblAyOD8pG4HkdMetfF978GfF2ofDHw/pthomrWVzb/DmCGVYrRknM8V7aSyQEsu0zskUgVD2JGzFe1fA+aDwIdf1nULXxlKnijxDb2kF94nt0S5uT9kjCzNAsEDW8YaNosOgJKBjnfwcq3Xn+Gg+tj6OoooqRhRRRQBk+Jf+RX1b/rzl/wDRZrjv2df+Te/hf/2LGmf+kkddj4l/5FfVv+vOX/0Wa479nX/k3v4X/wDYsaZ/6SR0Aej0UUUAFFFFABRRRQAVS1L/AI8bn/rjJ/KrtUtS/wCPG5/64yfyoA87/ZhUH9mv4T9fm8J6STz/ANOcVen7B057dz2rzH9l/wD5Nr+En/YpaT/6Rx16hSd+gEYhRSpAIxzwSM/X1/Gj7PHtK7F2f3ccdc9PrUlFCv1AbsHPfd1yaNo6Y4p1FMBhiVmDEfN6/l/gKTyI9ytsXcuQDjkZ61JRQAzy12FcYGMcHFKqBRgdPrTqKAG7Bgjt060MisVJGSpyKdRQAV5L+0T/AMgXwh/2OXh//wBOEdetV5L+0T/yBfCH/Y5eH/8A04R0AetUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAleSTc/tUWv/YmS/8ApbHXrleSyD/jKu1H/UmS/wDpbHQI8w+IPijWbXwb+0W8Or30L6WEFi0dy6m1zDuPl4Py888VhfEj9oT4l6h4V8SWnhXwjp1lb+Htb03S7jWr7WyjXAkNpJtjiFtITuWYq/OUz8u8jNeneO/2ftT8T614ot9P8X22l+HfF5j/ALa0y40zzrqXYu1vs03moIsrx8ySY68UzWP2bJL7wf410ax8Rrbya9r0Gt2UtxpzTRWckP2fCPGJQZB/oo6NH9787i0nr5fmVpyJddfxMHRvjfrNvqV9oOi+FRfeLbzXLy3NpqHiGb7Fi1t4JriUXDQMypulCJGsQ3dTsq54+/ap1f4a654Xs9e8JadpqaqbFLmzvPElv/akT3EixSeTawpIJY4ZGAeRpEX0Jqb/AIZt8Qafer4h0fxdZ6d4xGr3epi/m0VprbF3bR29whgE4brDHIjeblSuGLAnOTrX7J+u30c0WnePUlt74aTNf3Wt2Dahe3F1YFNjNOZkJRvL+ZcbgRkMKUbaX/rQhKyZWg/aE1rxb/wjOpaj4JuNN0m58TTaVp0lp4hKS3Uka3J8ySNYwpXNuPlZyP3nTiuu+DP7Slz8UvHWueF7zSNJsL/TLZbzdouvJqkW1mdRFM6wokcoIG4I0gHrVO7/AGYVvvAfhrwxL4iwmk6zdarLeQWm13E4nBVRv/dYFx1O77tXfhP8A9f+HvjCHXb/AMWWWsRwaOmixWdporWgjtkcvGwPnud5Ykv/AHu23pVXjqUtj3eiiisgCiiimAV5N+1B/wAkj/7mDQP/AE8Wdes15N+1B/ySP/uYNA/9PFnQB6zRRRQAUUUUAFFFFABRRRQAUUUUAJTVbpT6ao6UnsLqeBfCyZ7P9m3xVPbsYJ11TxW6yRfKwYatqBBBHcGvkG8+J/j+T9j3wp4Vj8Ya4PG+n6w1zqOvi6l+2vYRW6X6sZd+/DLd2sWc84r7M+Ceiv4g+BeuaSJfs/23XPE1uszAMF36xfjOAewNeff8MPWP27VtQHiPZPqPg2z8LYNh+6hmhWNHu9pl6yLDENnUbRlqun7sp83YiSb5GvP9DoL79rBPCvxM/wCEW13SNPtdOWO6IntdbS81ONIIGmWSe1ijKwpIisUJmLnugrRt/j94tt7Hw9qet/D+303SdcvLS20+8h1xZ/luN2PNQwoySjA+RVdeT89Ycf7KOpf29Esviyzk0CPVtQ1F9NfSS11dx3gdbhJLgzZPEmF+T5Rw26rsn7NPiqfQ4LW8+Jayz6S9rJomNLZLO0S2zgzwC4HnSHJy4MeM8AUo7ijfl+85Pxf+0RN/wsPQdYkjurHS9DvddsZrO11DMd81uqLGzKMA7mJ65xXTan+1J4i0MQ6Rf+ArO38Wz3ljaWmljWW8p0uf9W/nfZsgr/Emzj1qrD+x7PqkMD+IPGbavNLLqk87xaV5IeS9IbIHmsE8sgY7cc1z/wATfgX40sLXQ9UbXv8AhIfF1xrmk28V9ZaE0dpa2kB4MkPnPtB48wmRVOeAKvS50Saex0nij9rTVPDXhS81Sfwtotnd6bdS2Oqxar4nW3hjnRQ6w2r+Qz3UkkbhkxEoOcEirOoftXatHqF7dWvg2GTwrpttpV7qGqXGrCK4SG9TduitvKIfy/4t0iVUv/2RdXuL+51q38Y2MWv6paX0Gs3kuhGRLg3SqrGCJpiYdoRR8xkzj3Nc94R+APijUPGnivwxfa2tp4VGm6FZ6kyaCyLqi24kGLWUzYjyI/3nD/fFS+Vpo5qnNdcvn+R1/iv9oqe78L+RbaI1vNqPiHWPDkEq3RGw2lnd3CT8J1b7Ljy+vzda5rS/2mNS+Gvhn4X6drGlWN3Bqem6NDLe3fiEJqd29x5UTvb2flytKqSSDe0kkZGeCa29U/ZT1m+8RQ7PGVsnhm317U9cg0z+x2+0xyXtpcQSK8/n4dVaYshWNTyQcgVS1H9kPV/7Nt9P07xta2tjJBoomt7jRDcSNPpgj8kIftICRN5I3J1B5EmeaKainK/WxrV1nGUdtf8AgHqHwU+LWt/Fy11PU7nw3DoWiwXk1lazjUftEty0MrRu+wRDapKjq2ab8ef+P34Yf9jpZf8Aoi4ra+E/w5b4a+EW0CW+XVi13cXZk+zeSpWaZpNu3JHG41i/Hn/j9+GH/Y6WX/oi4ola90Z0+ZR97c9ZoooqTUKKKKACiiigAooooAKKKKACiiigDyX4Rf8AJUfjl/2Ndl/6YtLrlf8AhdyfETxnqXw0vvhj8QtNnljV7y6kuLG3SG1lZlWQS29+JVQlD9zLDutdV8Iv+So/HL/sa7L/ANMWl14r8evt83xA+Kn2CKQwyeG9ES5eMsC9v9ulM6qQOMxswIHr60JXkg5XJaH1N4f0jTfDGiWui6RbC1sLGJY4rdG+WJBwoBJPJ6/Mcnuafbao13q17af2XdxxW6Rn+0JkRYZ93VU+bcSvOcqB718HeKnsbfwr4mt/hMhFumqWw8GpoDBLVJvsf+mGIgEeUfunCrl6Zcf2BIsjWQ83wSI9Bi1dbnAQWjDE4nOPlBb7ykMDTcOZtDtZWZ92eKvE9t4W8M6prlzG1zBp0TzSRWxUyqFHIG4hd2OxIHvXLfC34q3PxOsVvZ/AviLwnay26T2d1rj2Wy4STbt2/Z7iVkJ3Dh1WuEjk8If8M2eMn8DwyaN4XSC7S0Bmzaqi9ZLb5nCwHsFwvB+UV87ap4r8J61+z74ds9R+MNv8QrGDUfDv9oaRONOxpkAurdGUNawo33eMOWohHmqSgt9F95mvelFep93XWuSx69Y6aumXVzFMJpHv0jRoLYoFIWTLhgzbxt2qwOOorDt/GWja78StU8HvYySazoVha6000sKPConaeNDE2S28GKYH5VwD33EV8S6nDqVrqfiCPwAYYNEi07xUng9NKA2CE2dif9FVDgr5yzMqoMc4AwABj+JLfwevi7X1+Hl34c0/wJcW3hddeuBay3GkRRedqBnNxFFKm/5xAsql1HB8zG5suOuq2aT+/wD4cqPwKT6n6S/aJEOGA25UBm4znPUY+npn1qUzEKCo3LjO7+v4/wCQa+CfAXw/0PxB4v8AhtpN99h8R6JDZeJrnSlt9OfT9PdUubaSNLOLz5t1qp3mImRgFPC1yPh/4X+E2+GulyNo0CXj/Du81SbMQJa8i/1M/XiVf4JByv8ACBRbRv8Arr/kPpf0/F2P0gW4wq5csnP7zA5/Lpjvmud+H/xDs/iR4eOr6XDMkHnSw+XdBUfcjbTwrN3r4Y+K2vaffa9pV9dTaJpXijTYdDePUdV82fVbots3taSNKDCi5PmGNSD3avqb9lOfz/hLvAkVDqd7JzJ5j4M5YdB3BpWDrY9X8S/8ivq3/XnL/wCizXHfs6/8m9/C/wD7FjTP/SSOuw8S/wDIs6t/15y/+izXH/s6/wDJvfwv/wCxY0z/ANJI6m4Ho9FFFMAooooAKKKKACqWpf8AHjc/9cZP5VdqlqX/AB43P/XGT+VAHnn7L/8AybX8JP8AsUtJ/wDSOOvUK8v/AGX/APk2v4Sf9ilpP/pHHXqFABRRRQAUUUUAFFFFABRRRQAUUUUAFeS/tE/8gXwh/wBjl4f/APThHXrVeS/tE/8AIF8If9jl4f8A/ThHQB61RRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXksv/J1lr/2Jkv8A6Wx161Xksv8AydZa/wDYmS/+lsdAHrBjVl2lRj0pPLXvk8YwSSPy/Cn0UARmBD1GenBJI4ORx9aUwoxyVBP/AOv/ABNPooAb5aggjIx7n/Pem+ShXaVyPfmpKKACiiigAooooAK8m/ag/wCSR/8AcwaB/wCnizr1mvJv2oP+SR/9zBoH/p4s6APWaKKKACiiigAooooAKKKKACiiigApvpTqaO1J7C6ngnwpuJLH9nHxRd27mG5i1TxW6SpwysNW1Agg+xFeK/BD4q3WmX/h250HVfF3ippPAr6tr+k+Kb662z3QFqI5bZ74gAAtcF2jJjKkEk8V7r8E9JOv/AvXNIEpha91vxPaiXGdhk1e/Ab8M1zPjT9lq98U+GfA2mQ+IYbC78O+GW8PzS+Q2y75szu6/c3WxBRs5Dkc5OXF8jk5f1oxWbcO2v6FK1/bOhutCnnj0DTxqya4uhoP+EhiOlyu1ulwHW98raAVYKuUGWOKzZP2hvEuh+Pta1+bw3qFx4cj0fSbm8sbjUzGNOM8hQsibCJGz1OEz3rVsf2bPHGm3Hia/XXvDTXGu6xb6pPpf9lSf2e221SB4ym/PDIrRnqMfNnmrOk/sl6hpnhXWNJbxJE8upaPYaZ5phclWt5/OLE7snI4pqSX9eSFKN7W8z6Pt2S6gjccrIgb68d/Wp1iRfuqBxjj09PpXI+BX19f7UttZijWO1uDDYMiFPNhXjcc5611TStn7rKgzuY9R9KT10RSuOa3jbf8g+Y5b0P1pwjXuN3Ofm5pu5twGGwOrcYqWoTGRPbxyAhkBXBBHYg9c+tHkLt24yvcdj16/nQN23rn/azmn9s0732AasQXgcc5615V8ef+P34Yf9jpZf8Aoi4r1ftmvKPjz/x+/DD/ALHSy/8ARFxQgPWaKKKoAooooAKKKKACiiigAooooAKKKKAPJfhF/wAlR+OX/Y12X/pi0uu1Pivw9Pa3d4NUsJLa3f7JdXK3EbJHJnAhc7vvZcfKfX3rifhH/wAlQ+OX/Y12f/pi0uviy8uG8D6f4/Se8kbS/GfjeWaBCPkiv7bWkhdR6bodjY6fu+BycuMeZ6lxi2mz9JobeGNU8uNV2524Hqcn8zTTp9sVYGCMhwAwK9QDkA+wJr410b9pb4mNJf8AiNtMu5fD89rfyQ2tzZW8NrA0X+qMM2/zZf8AaypxXW+LPHHxO8LeE/DQg8e6bqWqa/qOnJGz6XALi2juPvIUU7Sn91iN3vT5HeyZB9MOltDE4eNEjiTOSowF71xXi74c6F8UND0qLzUSygv7TVIptP2FZfImWREyBgo2wflXhN98WvHVta3epalrMd5o39uyeFJdLFpGhL7dvn+Yqhg2fmxnb7Vy/wAK/iv4x8L+FfC/g20urWK61W20h9JMsceUgaaRL1fu/NsWPOTkjcMYoUfeTW+n5XJ2iu6Psm8k0zSNPku7k21pbRqQ0s+ERVPUc9Af1xVxNNtI8hLWFVYEMqoAGBySCO+SSfxr4u8V/HDx1p+g+Of+Eg1SBLlLG7u7XRNR0qGSPZHcokctrKq7Z4zESWVtzBzgV6R8N/i1401T44XOh+IdUW0sri71JLLTJbFPs1zbQsBBJaXSAF32BmkRySp346DGag42S7X+4SkpbdD2vxN408K+B1t18Qa7o2gwuPkOqXsVtuGOihyOOMfRcVit8ZPhsNNiuE8b+FzYl2hWYarbeWSAGKKd/Jwy8CvMvElpp/jbxV8bJNX0+HUG8P6bHp9p9qjEixobFpyyA8A7rhhu6/L14FecavocWg+Gv2f00HwHZeJnmtrmWTT5ZY7NZH+zRfOzMrAtwOSM8VKejXkn99zRfxIRfW/4H1Zp/izwn4kYGx1XRtV8y3NwPs9zFOWh4+f5ScpwOelbGl6tp2qQ7rC6trtMKSLeVXGD0PFfEnjp7zwh8ck8dzaWnhuHRfDVta6vpUd0r21tazBxgEAKQrAc7e1d7+yvqA0zxB4Z0+1Kmx1nws14RGowGiufLU568rxWsVe67f5nMqm39bJH054k/wCRX1b/AK9Jf/RZrj/2df8Ak3v4X/8AYsaZ/wCkkddh4l/5FfVv+vSX/wBFmuP/AGdf+Te/hf8A9ixpn/pJHUdToPR6KKKoAooooAKKKKACqWpf8eNz/wBcZP5VdqlqX/Hjc/8AXGT+VAHnn7L/APybX8JP+xS0n/0jjr1CvL/2X/8Ak2v4Sf8AYpaT/wCkcdeoUAFFFFABRRRQAUUUUAFFFFABRRRQAV5L+0T/AMgXwh/2OXh//wBOEdetV5L+0T/yBfCH/Y5eH/8A04R0AetUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAV5LL/AMnWWv8A2Jkv/pbHXrVeSy/8nWWv/YmS/wDpbHQB61RRRQAUUUUAFFFFABRRRQAUUUUAFeTftQf8kj/7mDQP/TxZ16zXk37UH/JI/wDuYNA/9PFnQB6zRRRQAUUUUAFFFFABRRRQAUUUUAFN9KdSCk9gPBvhPfT6d+zl4mu7eTyrmHVfFUscgAyrLq1+QfwIrxjR/wBsCzW3+Ft/b6vqeumx8HXupeJbNIXUzyRQWhZyzoA5U+e+U64969w+CejP4g+AuvaXHL5b32teKII2x93frF+B/OsnWfhHbeHfCvgK48Satbnw/wCDvC91o2q3EoZhOktrBC0icEtkI3Ud/Woh7zlf+tyL2nBepNrX7T0dr4w/sDQvC1z4gvDqi6VDJHdxxrMzWa3jMCR2Vip96yb/APbO0C1W0EejSSNHa/atWV7yOJ9P/esmwIwzM+VbhfSvKPh74G8ZaP8AD74DXNnPb3fi2+1e91WS51K1kWMI1q4RZQOUIiEY5549znvbT9kHVNJ1C0v7K58PX95fwRw6vPqlgZ2gfz2meayLo21iHYYPHPbArWSXT+tBJ+9JC/FH9pTXdSt3t/C/h/UreDTPEtnpkupR3CLHfMx4ijH3sNxnGMVtX37Tmlyaho99q2la1ocun3V/Z39j5yOIpreLeUbH38juK1m/Z11H+zdQs11OxBn8VQa4sgiI2xp1Uf3X+lc1r37JGpeItXup7jVbOGGbV9U1H92jeZsuYPLjUehXuRz9acLJ3f8AWhsrdTN/4ae1rw/408XatrXhfWrextdP0qW10EzIz77mUxlgV4Ocp1z04rvm/agNrqvk6h4XurCwttTt9D1W+N3G66fqFx5fkwFQuXz50PzDj5/auVm/Zx8b+IL27vPEGtaFHdSRaTCkOmxzBRFZXAkYncOS20evStvxH+zvr2seLtXittY0+38Iaz4gtPEl8oD/ANoJNB5eI4jgrsbyY/cbeKltRSQO3QzLr9p6HxR4T1W9Tw5rWk6TG9q9neWNzEZZg99FasjKP9USZAdr87d5GMCu5+Gv7QifEjxZe6Xa+Hb630uN7yG31VpkffJazeTMssQG6E55Xd94dK8pvP2T/FGqT3zXesaJZzXFtb2xOmxSwR6myX9vdefcRhQgm2W8i5UHiQ13PgP4GeJvDfxY/wCEr1S80nyLeO7iMmkRvFc6qJpt8ZvFwEZoh0bBJ7mm1syT33+GvKPjz/x+/DD/ALHSy/8ARFxXrFeT/Hn/AI/fhh/2Oll/6IuKnqB6zRRRTAKKKKACiiigAooooAKKKKACiiigDyX4Rf8AJUfjl/2Ndl/6YtLqPX/2Z/A/ijQYtJv9PnktYtdfxJGPtTKReNMZmO4c7C7E4/DoMVJ8Iv8AkqPxy/7Guy/9MWl16w0YZcHOPqRR1uF3ayPJtP8A2cPBVhql/evZXFyl0k8YsLi6aW1s1n/1whRuI93+yBjtiotE/Zq8H6EYHjl1K7mt7+G+hku7+R3Rov8AVRg5ztXsK9e2j/JpdoJzTu73DoeXSfAHwhN4qm8QyG/ZppjcvZG9b7GZSu0v5XTdjv179a47T/gBFZ/GXwTqltpaW/hrwbpdxaWM8135sszzDbsK9wB3PPvk19BYFNaFWyeRkYOCR/k1CureX+QHizfsreBJ4b+G4ivri1u4Z4IYJr5njskmcSSraqeI9zgH2xxW34d+A3hTwz4s/wCEmsWvJJknubq0s7i7Y2dnLcEtO8UR4QuWbOOxI6GvT9g4FLtHNPWy9LCskebf8K8LeO/Ft6yg6B4k0yK3vY8kSCVBLGxHflGUcelUvFf7P/hvxVovhfTjeappo8OI0dheaXfvb3MasgRhvHXIA65r1Ro1kABHGQeuOhzR5anHt0pNaA77o8th/Z98KnTdStb2S91p9S0f+xryfU7ozSTW+ScljznLEg54qt8LfgrbfDXxI81jA1to2naVFo2kRyTGaVYd+92cnuX55r1vy1wR2PvSLbxo5dUVWPVgME/Wq66Byq5meJf+RX1b/r0l/wDRZrj/ANnX/k3v4X/9ixpn/pJHXYeJf+RX1b/r0l/9FmuP/Z1/5N7+F/8A2LGmf+kkdAdT0eiiigYUUUUAFFFFABVLUv8Ajxuf+uMn8qu1S1L/AI8bn/rjJ/KgDzz9l/8A5Nr+En/YpaT/AOkcdeoV5f8Asv8A/Jtfwk/7FLSf/SOOvUKACiiigAooooAKKKKACiiigAooooAK8l/aJ/5AvhD/ALHLw/8A+nCOvWq8l/aJ/wCQL4Q/7HLw/wD+nCOgD1qiiigAooooAKKKKACiiigAooooAKKKKACvJZf+TrLX/sTJf/S2OvWq8ll/5Ostf+xMl/8AS2OgD1qiiigAooooAKKKKACiiigAooooAK8m/ag/5JH/ANzBoH/p4s69Zryb9qD/AJJH/wBzBoH/AKeLOgD1miiigAooooAKKKKACiiigAooooAKKKKAPI/2Y0H/AAq6b38T+I+/prd8BXrAjVWJ2jOMZ74ryj9mP/kl0v8A2M/iT/0939etYzS9BETQpI2SvOc5Bwak8sen50uMUtCuAzyV27cHH1Ofrn196FjVFCjJx0LMSfzNPood+gxhjVjkrz60i28alSEGVzg+mfSpKKVu4EZhQrgjIxjkn0xSiJApXaMd+PXrT6KoAryb48/8fvww/wCx0sv/AERcV6zXk3x5/wCP34Yf9jpZf+iLigD1miiigAooooAKKKKACiiigAooooAKKKKAPJfhF/yVH45f9jXZf+mLS69aryT4R/8AJUPjn/2NVn/6YtLrzi3+OnxFsf7T8V6hPoM3guy8WSeHZtPisJIruGH7WbZZxcNMyudxU4MSU4pyfKh293mPqKivJ9H/AGlPAWualBY2euXM801//ZUcg0y5WF7obsoJGi2fwn+Kl1/9pbwH4ds2vL3WbhLZZZ4Ha30y5uTA0LbZWkWKNiqKf+Wn3P8AaosQpX/r+ux6vRXB+JPjJ4W8I+BbTxlquqm18OXPkmO8+zSvv87b5OFVS3zb17Vj6f8AtHeC9S8QWGjx6lcRXt6yRqJ9Lu4YopG3bYpJZIlSOVsDbG5VzkfLSd07WKWqueqUV5HZftP/AA91CbVvL8QvDDptpLfSSXWmXUEc1vEyrLJBI8YW4AZlX90TjcOtct4l/a+0G11fwJb6NZ6rqEGu64+j6gj6Jfx3WnMLSSfEkDQb0fIiOxgPkfzM7FJp2YH0LRXjFh+0p4T0vwz4fvtd8R/apNTtftf2jTtGvBCkW7b50q7Ha2jzn5pSB8p+atOx/aR8Cal40Xwvb6vcvqhvX05W/s25+zPcoAxi8/yvK34Dcbuxos72DzPVKKbninUgMnxL/wAivq3/AF5y/wDos1x37Ov/ACb38L/+xY0z/wBJI67HxL/yK+rf9ecv/os1x37Ov/Jvfwv/AOxY0z/0kjoA9HooooAKKKKACiiigAqlqX/Hjc/9cZP5VdqlqX/Hjc/9cZP5UAeefsv/APJtfwk/7FLSf/SOOvUK8v8A2X/+Ta/hJ/2KWk/+kcdeoUAFFFFABRRRQAUUUUAFFFFABRRRQAV5L+0T/wAgXwh/2OXh/wD9OEdetV5L+0T/AMgXwh/2OXh//wBOEdAHrVFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFeSy/8AJ1lr/wBiZL/6Wx161Xksv/J1lr/2Jkv/AKWx0AetUUUUAFFFFABRRRQAUUUUAFFFFABXk37UH/JI/wDuYNA/9PFnXrNeTftQf8kj/wC5g0D/ANPFnQB6zRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHkn7Mf8AyS6X/sZ/En/p7v69bryT9mP/AJJdL/2M/iT/ANPd/XrdABRRRQAUUUUAFFFFABRRRQAV5N8ef+P34Yf9jpZf+iLivWa8m+PP/H78MP8AsdLL/wBEXFAHrNFFFABRRRQAUUUUAFFFFABRRRQAUUUUAeSfCP8A5Kh8c/8AsarP/wBMWl15Db+APHGrQ6v4FufBV7p2k33jOXXZPEUt7ZC1ktVuxcxhFjuHmd2CgENEgFevfCP/AJKh8cv+xrs//TFpdeoRqvCgbcYyMcfhxTjJwmpL+uv6BK7g1/XU+XJfhT4u8PfDvw2Lbw/Nqep6H4xm12fRobm2Wa5ti823y5ZJFjBw6/6xh3rzG48P+LPhr/wlWsar4Z/4mWtaLqsMmix6xZi4tbeSff57l5lV48dfL3kdw1fYer/EnS/Dt7JFrEF/pca3tvp8M8sOYriaUblEZQtkAD5s9Kx7OHwR8d9Pe81DwzZ63HpepSWiNrWnwzNBLH95kLFgBz1B/CiN0uXurfl/kT8PKu3/AAWcHqHgfWPFX7Nfw40fS7Jru8ij0eaWN3RCkMRiZmIdlydqiuR1T4A61J8YtVvl8OX2sx33ia016DWLjxDdLpdpHFFFlGsYr1A9wrwsUZ4inz4ZiOK+rLVVt4VVYkiCKF8tT8qDHQcDjj0FLtZV3ZKtna23pz3Ix+P9aJTd3Lvr+X+SKirJRZ8Ja18A/id4q8QLqd94b1abXF0u9jvNT1XxBDcQX90t/a3duLeMTuYLZ0szGoVFYbvnjH3q9l8VWvxM8c6h4D8UXngyWzGh+MDfL4ftr21/tCHTzp9xblp2+0/Z3k8+TOEl/wBWcfeyte8axrH9lfYIzaT3v2y4+z74AD5ZAZi8hJACjackcjsKuLMpO1cqYzhY9mMcEA47DIOOlVzPr/XUItr3l/V9D4y0r4I/ELwp4JW0j8KXGrahrng//hFrqOO8tcaTN507+dKZJB5iYuB/q9z/ACdK6nwr8CfGeg2fh6yfS2dLPx3/AGzI32qLH2TyZU88jdycsvy/f/2a+qmZuhfknCjOD0/Xjmuck8cWcfj6Pwe0VwuqyWB1PzFUGEReYyAbyQdxK9Np4FJTd1b+upUm5Jp/10/Q6yn157r3xes/DWuW2mXmj6xuur1bG1uEgiMN1K0e8CM+ZkjHqB3rqtD1qTWtJgvjaz2QlVv3N4FEqEMVwyqSOo7E1OrbM1JbDvEv/Ir6t/15y/8Aos1x37Ov/Jvfwv8A+xY0z/0kjrrvEjH/AIRvVvT7HL/6LNcj+zr/AMm9/C//ALFjTP8A0kjpFHo9FFFMAooooAKKKKACqWpf8eNz/wBcZP5VdqlqX/Hjc/8AXGT+VAHnn7L/APybX8JP+xS0n/0jjr1CvL/2X/8Ak2v4Sf8AYpaT/wCkcdeoUAFFFFABRRRQAUUUUAFFFFABRRRQAV5L+0T/AMgXwh/2OXh//wBOEdetV5L+0T/yBfCH/Y5eH/8A04R0AetUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAV5LL/AMnWWv8A2Jkv/pbHXrVeSy/8nWWv/YmS/wDpbHQB61RRRQAUUUUAFFFFABRRRQAUUUUAFeTftQf8kj/7mDQP/TxZ16zXk37UH/JI/wDuYNA/9PFnQB6zRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHkn7Mf/JLpf8AsZ/En/p7v69bryT9mP8A5JdL/wBjP4k/9Pd/XrdABRRRQAUUUUAFFFFABRRRQAV5N8ef+P34Yf8AY6WX/oi4r1mvJvjz/wAfvww/7HSy/wDRFxQB6zRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHknwj/5Kh8cv+xrs/8A0xaXXxj4417W/BniPxJc2pmuI/htqN3ZlQ8h886m9wIV6fOFBteTnbk4xzX2f8I/+So/HL/sa7L/ANMWl16OdKspftG6ytpBclWcmMESleVLnHJBxjPTHFA+jR+f2peCNEs7TWLHxHbwX+naT4k0CP7RfOJI7dTaZkYknK88EjrXZfCXwro+g+O/Bmt6TtgvNR8U6tbSXVtKwaeDZuSJjjhM846V9mXmm6beRzxXNnDIlw6s4khBErDlSRj5iMd6ztAvtC1a6u7fS/sUsmkzvBcRww7Wt58YIHHBxnkVXNr/AF2REvekmfIv7Q8Oral8b9cjm1nSdINpZ2J8PvfWk1xf+a/+uNltljQv7AOB6Vz3iia2e+ub06xJb/E2TxDqNvq13ayM15BpqwSKQsRbPkhPLYAHGRX3bdaVY31xDc3NnFJdQgtFPJEC8furY4P0pG0XT2uHuvsULXbpg3CxDzWXjgtjJ+h61nLVcpre8ub+tFY+C/hve2GmeLfC+i6QLeaOHxVpRuL/AMO3B/sy+ZrK9w20s5S4LIpkU/3hzXPafp03hT4deA7vw5LPb3mteA9UudbvYpnWa6jTUdPRnkbGS6xT3G3uOcYwCP0F0e30KRrq10y3sGNrcbblLaNA0UuwEBgF+9tcdecGrq6TpqhEFhbokCNEqLAAERvvIox91sDI6HArRSTu/wCtjFaRt6fmfB/iqXwXZ+KrCxtry1b4RyeM7FNsd0xsVZ9LlMsYkL7Cu9Yj143HGKyF8Kaf4ibxS+owefYaN4U1a48OSSyuTFDFd3D2kqDHAQbNh6rjivsr4i/D3wxq134KW7dNJg03XftdvZW9oPKu5zBLH5brt6Yc/N2wPbHoP9l2Sxso0+0EZh+zr+7ABi/55kY4X26Veis/62sayklr/W7Pg+DVLq8+JVtcXV7JNI19pjNcPKCxL6buck56huM1yGr69YXXh3Rb1rqw0zWdHXTpY9Q1KaSS+u1kuskwLuxGiL984zX6S/2Lp4kWQWVuHVg4YRgEMF2g/gOKhl8K6NcS+bLpNlJL5Zi3tboTsJyVzjp7UuZXZzundt+RF4jbPhfVgP8Anzl/9ANcl+zr/wAm9/C//sWNM/8ASSOuv8SRqvhfViBj/Q5f/RZrkP2df+Te/hf/ANixpn/pJHUM0UbHo9FFFIoKKKKACiiigAqlqX/Hjc/9cZP5VdqlqX/Hjc/9cZP5UAeefsv/APJtfwk/7FLSf/SOOvUK8v8A2X/+Ta/hJ/2KWk/+kcdeoUAFFFFABRRRQAUUUUAFFFFABRRRQAV5L+0T/wAgXwh/2OXh/wD9OEdetV5L+0T/AMgXwh/2OXh//wBOEdAHrVFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFeSy/8AJ1lr/wBiZL/6Wx161Xksv/J1lr/2Jkv/AKWx0AetUUUUAFFFFABRRRQAUUUUAFFFFABXk37UH/JI/wDuYNA/9PFnXrNeTftQf8kj/wC5g0D/ANPFnQB6zRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHkn7Mf8AyS6X/sZ/En/p7v69bryT9mP/AJJdL/2M/iT/ANPd/XrdABRRRQAUUUUAFFFFABRRRQAV5N8ef+P34Yf9jpZf+iLivWa8m+PP/H78MP8AsdLL/wBEXFAHrNFFFABRRRQAUUUUAFFFFABRRRQAUUUUAeS/CL/kqPxy/wCxrsv/AExaXXz5qvxa8VQ+OL/UdH8QatdaBqNvrnkS3TxrbSS2qfu2hh+8iI/ynP3h6V9B/CL/AJKj8cv+xrsv/TFpdaNz+zn8OLrWptWl8LWxv5jcFpRLKo/frtnAUPtAcfeAAB6nmplcqLS3Pl9fiR428O32n6GfGmr3kHiDR9LubjUryRPNs3mmdZZLcYwnAAwwwOwFet/s6Wc+gaf8WYIdY/tO4ttduEj1C8mDszBMh5CvTmvWNQ+C/grVrd4brQYZUexTTWPmSBvs6MWVNwbPBJO7O73q34R+GPhnwHpV/p2g6THY2d/K011HveQzOwwxZnYk5HvVNqwmfH9v8UPGfhDS7m+1XxLqqahpMUOv3ljdXEVxb6haifEs1vKg4gKcbWO4fWk1r4k+ONS0mLxDN4r1W20KWPUNWD6TcQtNZotyY7eZ4WUM9vsQnaDk7+c1774s+AOk2XgnxFo/gjQ9KsNQ1y2+y3P9qXE5gjt2Pzqgw4UDsqgCtlP2efBd54e8LaXq+iw6v/wjtlDYW7NJJGNqhQdwVgHBwDh8j9aINNp9rEO6+9nyra6x4k8O+KPGFt4Xv9e1qbxb8QY7SWSHUIrdmiOkRXWI2fiMkqE542DH3qL/AOI3xLuPDXim4vPF9/Yaj4V8KT6tHHptzFdJLcQ6ldQRvM6qQ5EVugdBwzb8HgV9fax8A/AOvXGqzXvh2KSTVJIpbry55ow0keNjqFcBGGANyYJHBJFWJPgf4Fl02awbw5amzm0saNJDl9r2YZnER+bkbnZs9csTnmq5la39fDb8xuzTSPnG58feJvC/iu70NvEup6pFa+LNKiH2uRPNMdxp8lxJCDjIUv8Adx9Old9+zlrN9r2n6H4g1fx1qF7rHiSykum8P3jRyRxhWwTGAPk2jjB616/cfCzwrdan/aM2jQSXvnw3XnMzbvNijMcbdeqoSBUXhf4ReEfBWtX+raJosdhf33+vlSWRhjOSFVmKoM9lAFEZb38vyX6hP3lp5fqdaKfSYpakZk+Jf+RX1b/rzl/9FmuO/Z1/5N7+F/8A2LGmf+kkddj4l/5FfVv+vOX/ANFmuO/Z1/5N7+F//YsaZ/6SR0Aej0UUUAFFFFABRRRQAVS1L/jxuf8ArjJ/KrtUtS/48bn/AK4yfyoA88/Zf/5Nr+En/YpaT/6Rx16hXl/7L/8AybX8JP8AsUtJ/wDSOOvUKACiiigAooooAKKKKACiiigAooooAK8l/aJ/5AvhD/scvD//AKcI69aryX9on/kC+EP+xy8P/wDpwjoA9aooooAKKKKACiiigAooooAKKKKACiiigAryWX/k6y1/7EyX/wBLY69aryWX/k6y1/7EyX/0tjoA9aooooAKKKKACiiigAooooAKKKKACvJv2oP+SR/9zBoH/p4s69Zryb9qD/kkf/cwaB/6eLOgD1miiigAooooAKKKKACiiigAooooAKKKKAPJP2Y/+SXS/wDYz+JP/T3f163Xkn7Mf/JLpf8AsZ/En/p7v69boAKKKKACiiigAooooAKKKKACvJvjz/x+/DD/ALHSy/8ARFxXrNeTfHn/AI/fhh/2Oll/6IuKAPWaKKKACiiigAooooAKKKKACiiigAooooA8l+EX/JUfjl/2Ndl/6YtLrzz/AIaw8QySeJ7q18KadqGlaO90jGLVGW6hNvKiubmHyj5IaNi6fM4b1Feh/CL/AJKj8cv+xrsv/TFpdcP4g+AjaTrmoeLvFviC58TadY2N9bW8Gn+HpbjV/JugA8TyxPI9woAARFiUcfMDS2d3sVG3UXVf2ofEVx4jTTPDXhGy1KKe/msre4vdTMIcxQJK5+SJ+MsRVfwz+1hrWsaPNqd54UtLeCbQptYsYbfUjLIzRNteOUeUNmT/AHd9VfgP+zxe6T8Nfh9PrGoXdjrGji9vb23vIGaWSS5GCG+ZdhAUetTeKv2cLjw38OXNprF5q9zpnhe50a3it7AtNcu77/NwGb5iewok0lK3yE+ljmfiZ+0N8Q7vwzY2UOhab4a1m6m0u/ikXWHkhmsriZIwhk+zffDkqwx05rrdQ/am1nRZHv8AUPCtuPDb3lxo9vf2+pEzyX0MbM6+V5WPKZ0ZFfO7vsqroP7NOv8AiXwTb3Wu+LBH4ols9N+x3S6K8CWS27CVY5YTNvd2IG/DRnI9a0Lj9l/VdSmn0688X20vhn7TdanFpcOjtE6XsyMhcSNcn92rO7qmzPP3yMUNcrSRKWmv9aW/M5//AIa88Z2djcXV/wCAdNjjsdI0/wARXhh1xm26fdllUx/6N804KH92fl/2673Tf2hNV1T4zap4Lg0Kx/s/T7z7DPcSakFv4v8ARvP+1PalADbfw7xIDu4xWbqH7Lf23Q9Y07/hIto1DwvpnhoSfYQPL+xvI4mGJOrmT7vbHWtO++AOoax8UtM8R6h4rN3ouman/atlYSabm9t5vI8ryUvPN4t/4/L8rr/HWkrOzREL638vyR7hninUmKWs+poFFFFMDJ8S/wDIr6t/15y/+izXHfs6/wDJvfwv/wCxY0z/ANJI67HxL/yK+rf9ecv/AKLNcd+zr/yb38L/APsWNM/9JI6APR6KKKACiiigAooooAKpal/x43P/AFxk/lV2qWpf8eNz/wBcZP5UAeefsv8A/Jtfwk/7FLSf/SOOvUK8v/Zf/wCTa/hJ/wBilpP/AKRx16hQAUUUUAFFFFABRRRQAUUUUAFFFFABXkv7RP8AyBfCH/Y5eH//AE4R161Xkv7RP/IF8If9jl4f/wDThHQB61RRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXksv8AydZa/wDYmS/+lsdetV5LL/ydZa/9iZL/AOlsdAHrVFFFABRRRQAUUUUAFFFFABRRRQAV5N+1B/ySP/uYNA/9PFnXrNeTftQf8kj/AO5g0D/08WdAHrNFFFABRRRQAUUUUAFFFFABRRRQAUUUUAeSfsx/8kul/wCxn8Sf+nu/r1uvJP2Y/wDkl0v/AGM/iT/0939et0AFFFFABRRRQAUUUUAFFFFABXk3x5/4/fhh/wBjpZf+iLivWa8m+PP/AB+/DD/sdLL/ANEXFAHrNFFFABRRRQAUUUUAFFFFABRRRQAUUUUAeS/CL/kqPxy/7Guy/wDTFpdcb4m+M/jLVPFmm6D4Nl8PaZBe6zeaRFfavYT3YBtIQZCIo54jzMGj612Xwi/5Kj8cv+xrsv8A0xaXXiegaf4h8L6loVzZeH9S8SL4b8Y67JqFrprxNcKly7vC22SRAQ28UAdQvx18feJJfDfhzSJvDOi+KLjWdQ0jUbzUNPubq0VrXoYYknicb/8Aafis7wz8cvin8SvE2k6D4dbwbpuopDdfb9QvdOubu2leGTy/Mt0W5ibyz7u1VY/2er7xtrvhXUPGXhK11Oyvtd1TVdT0q8WOaO1S4H7pZQwOSv8AsYrgpvgLeaT4w0pPEfwf1Dx34P0k6hZabYWZtJY7aNrjfGVSSZOPr1ojvqNntmsfFX4jt4+1Xwt4dXwvf6hoNpa3V7p91FJBcaq0vMn2VjcbYFX1k83NSab8YPHfinxtrtv4ftNDl0fQtYh0e+0GdGGreUwj33ayiZY1UeZwuxt23qK5D4p+D9e8ZWv9nf8ACsrieSO3tl8MatZLBHcaDKPvJNJvDIqeiGQHvmovF3gfxt4i8S2EN74Lnk8bWGpWh0/4gWDw28Bsl8vzVmYSCUk/vMxlCDkc8Cqjur/1sS3ZG/4o/ak1nw7D4Wgt/CB1nUrjXJtC1ZbNgIrUxuyFyXZfKjYCCQSNuULJgjNfSyoGGD+eefzrx/4C2KPb+ONXJ+0WWqeKruS1kI/5ZrHDbsQD2aS3Yn1Jz15r2QADpUr4UJbi0UUUFBRRRQBk+Jf+RX1b/rzl/wDRZrjv2df+Te/hf/2LGmf+kkddj4l/5FfVv+vOX/0Wa479nX/k3v4X/wDYsaZ/6SR0Aej0UUUAFFFFABRRRQAVBcwiaF4+u5Sp+h61PSbRuz3oA+M/gd8eD4Z+Ffg7w/c/EXwvpz6LYRaN9nm8K380ubZjbqTIl1sbckW7j1rvf+Gj7T/orPhP/wAI+/8A/kyul/Z7v/7K/Zz0y+KszQDUJsHnDC6uDxnp+FYHw3/aI8T6vqXg7/hLtM0PTdM8VWM99Z3GlXksptlii8w/aPMRcZXnjvSuEvdjzEP/AA0faf8ARWfCf/hH3/8A8mUf8NH2n/RWfCf/AIR9/wD/ACZXpEPx78AzaCdbi8aaQ+l+ctr9oe5XYJm4Rex5IbHHPapoPjl4HmXRnHivTWTWN/8AZ5W4U/atjoj+X3ba8qKeB1p6v+vmK55j/wANH2n/AEVnwn/4R9//APJlH/DR9p/0Vnwn/wCEff8A/wAmV6hZ/G/wNe3GtRxeLdMZtFTdqANygFuMldzHPTcpHGecetc38N/2i9B8eeIvFGnrqenizsNVh0vTbqKfc1672yT4xgYfDHinFOWyKascn/w0faf9FZ8J/wDhH3//AMmUf8NH2n/RWfCf/hH3/wD8mV6hqnxw8D6LFayXvinT4VuppLaBvtCFZZkbayDnrn1wPeuEt/2rPDmq+LNa0W01jRbNtI1O3spZdQu9iXEbrudon6EgUJNtKxJlf8NH2n/RWfCf/hH3/wD8mUf8NH2n/RWfCf8A4R9//wDJlesTfGDwbBDHK3ijTts1j/aMf75f9R0EnXoTx9a1vC3jTSPG2kQ6poeoxalYTlkSa2JZdwzlTkAqenUUldoDxH/ho+0/6Kz4T/8ACPv/AP5Mo/4aPtP+is+E/wDwj7//AOTK+jmpcf5zQM+cP+Gj7T/orPhP/wAI+/8A/kyvOPjl+0Bbah4PsLlfiV4YvbjTNd0vUo7eDwnfxGbyb2BgNz3WB1J9xwOa+1sf5zXkn7USqvwZ1MgD/kI6V1Gf+YjbY/Lt6HnrQBxf/DR9p/0Vnwn/AOEff/8AyZR/w0faf9FZ8J/+Eff/APyZX0fj/OaMf5zQB84f8NH2n/RWfCf/AIR9/wD/ACZR/wANH2n/AEVnwn/4R9//APJlfR+P85ox/nNAHzh/w0faf9FZ8J/+Eff/APyZR/w0faf9FZ8J/wDhH3//AMmV9H4/zmjH+c0AfOH/AA0faf8ARWfCf/hH3/8A8mUf8NH2n/RWfCf/AIR9/wD/ACZX0fj/ADmjH+c0AfOH/DR9p/0Vnwn/AOEff/8AyZR/w0faf9FZ8J/+Eff/APyZX0fj/OaMf5zQB84f8NH2n/RWfCf/AIR9/wD/ACZR/wANH2n/AEVnwn/4R9//APJlfR+P85ox/nNAHzh/w0faf9FZ8J/+Eff/APyZXm+o/tAW9t8ftB1SH4leGZxfeHr+ze6bwnfiO3EN1akDb9qy5cyP8w+VfL5+8K+18f5zXkvipQP2mPhqoACnwv4iXGO32jSOPpwPyoA4r/ho+0/6Kz4T/wDCPv8A/wCTKP8Aho+0/wCis+E//CPv/wD5Mrd+N37RFz8JPHXgjQ4NI/tO11q62aldO5X7BbmRYkmOOxkcLz/dNdlrXx08B6DrFxpV/wCLdNs7+3IWaF5huRtu7b9SO1KPvRUhN2djzD/ho+0/6Kz4T/8ACPv/AP5Mo/4aPtP+is+E/wDwj7//AOTK9P1D45eBdJ0Gz1y88XaTBpN7u+zXbXI8uTb97ByScfQVJffG3wNpetW+iXPizTE1aby9ls1ym8iT7jHBwAfrVWfQVzyz/ho+0/6Kz4T/APCPv/8A5Mo/4aPtP+is+E//AAj7/wD+TK9Wj+MPg5ta1TSD4r0tdT0wO17b/aV3W4Rdz7xn5SBnufumsdf2kPh7deTFYeL9H1C9uk3WdvDeL/pJwv3D3HzLzSH28zgf+Gj7T/orPhP/AMI+/wD/AJMo/wCGj7T/AKKz4T/8I+//APkyup+Dn7Svhj4pfDrTvEM+s6dpupLpMGq6tpyXO8acrruYSEgEAEOufUD1ro5fjt4Di8Jw+JpPGWlR6BJL9nGoLMDEZMdFb8Qee1Erx3GeZ/8ADR9p/wBFZ8J/+Eff/wDyZR/w0faf9FZ8J/8AhH3/AP8AJle/6ZrFprWnxXtjcrd2kyrJFNAwZXU9MVoY/wA5oejswPnD/ho+0/6Kz4T/APCPv/8A5Mrzf9oD9oC31P4Qa3J/wsrwzeyac1rrEdrB4Tv4jcNa3Udwke9rrCbnhCc19r4/zmvJf2qlX/hm/wCI52qSdGuQcjPY/wCJoA4r/ho+0/6Kz4T/APCPv/8A5Mo/4aPtP+is+E//AAj7/wD+TK+j8f5zRj/OaAPnD/ho+0/6Kz4T/wDCPv8A/wCTKP8Aho+0/wCis+E//CPv/wD5Mr6Px/nNGP8AOaAPnD/ho+0/6Kz4T/8ACPv/AP5Mo/4aPtP+is+E/wDwj7//AOTK+j8f5zRj/OaAPnD/AIaPtP8AorPhP/wj7/8A+TKP+Gj7T/orPhP/AMI+/wD/AJMr6Px/nNGP85oA+cP+Gj7T/orPhP8A8I+//wDkyj/ho+0/6Kz4T/8ACPv/AP5Mr6Px/nNGP85oA+cP+Gj7T/orPhP/AMI+/wD/AJMo/wCGj7T/AKKz4T/8I+//APkyvo/H+c0Y/wA5oA+Kfgj+0DbaH4W1HSl+JHhi0EHiHWNjTeFL9/O82+nuDLxdfICZThDyvftXo/8Aw0faf9FZ8J/+Eff/APyZXa/s9xqLHx2Nq4bxnrRPHX/SK9ax/nNAHzh/w0faf9FZ8J/+Eff/APyZR/w0faf9FZ8J/wDhH3//AMmV9H4/zmjH+c0AfOH/AA0faf8ARWfCf/hH3/8A8mUf8NH2n/RWfCf/AIR9/wD/ACZX0fj/ADmjH+c0AfOH/DR9p/0Vnwn/AOEff/8AyZR/w0faf9FZ8J/+Eff/APyZX0fj/OaMf5zQB84f8NH2n/RWfCf/AIR9/wD/ACZR/wANH2n/AEVnwn/4R9//APJlfR+P85ox/nNAHzh/w0faf9FZ8J/+Eff/APyZXm/xm/aBguLLwrf/APCyfDN/LpfijSrhbeDwpfxAB7hLV5CWujuCLcvJtHLeXtHNfa+P85ryX9pDH/CF+HTtUt/wmXhkZZQSP+J1Z9M9D70AcV/w0faf9FZ8J/8AhH3/AP8AJlH/AA0faf8ARWfCf/hH3/8A8mV6R46+K/8Awg/xG8L6HdxQR6Pqem6pqF3qM0hH2ZbNYGPHoRMf++a4j4qftdeEPBvw5ufEfh7XtG8QXK3drZpD9r2xI08iosjuOkYVmfOPmCnFJe80l6BZ3S7md/w0faf9FZ8J/wDhH3//AMmUf8NH2n/RWfCf/hH3/wD8mV6fpPxo8Jahq39hHxNpsniGO3+0XFjb3Ks8YChmIBwSAD6Z4PFcFrv7ZHw9s/GWl+G9L8RafqlxqNpdTpdxThoIWiTcFcjsefpT6CuZv/DR9p/0Vnwn/wCEff8A/wAmUf8ADR9p/wBFZ8J/+Eff/wDyZWzY/tEz3Hip9JuDoNtbxJYyi8/tImO4EyZdYvl5Ofu+taPwn/ag8EfFTR7y5tdds7e6tWuXltWnG9YoHw8gyBlfeq5WVbS5yv8Aw0faf9FZ8J/+Eff/APyZR/w0faf9FZ8J/wDhH3//AMmV79pOs2uuaXZ6jY3UdzZ3cSzW88bZSRWXcD+VaOP85qfIlO584f8ADR9p/wBFZ8J/+Eff/wDyZR/w0faf9FZ8J/8AhH3/AP8AJlfR+P8AOaMf5zQM+cP+Gj7T/orPhP8A8I+//wDkyj/ho+0/6Kz4T/8ACPv/AP5Mr6Px/nNGP85oA+KPAf7QFvpHxT+KKJ8SfDKR6hqNlqctzP4Uv2DyHT4bcxxot0CNgtYj82d3mHFd3a/HTRrO9u7yD4n+D4bq7YNPMng2/DSEAKCT9s9FH5V6H8Po1/4X18XDtGWj0dj7kW74Nes4/wA5oA+b/wDho2z/AOiseE+uf+RPv/8A5MpP+Gi7PKn/AIWz4UG3gY8IagB/6WV9I4/zmjH+c0AfN3/DRVlkH/hbPhPI6f8AFH3/AP8AJlI37RNi3J+K/hMnGM/8Iff5x6f8flfSWP8AOaTaKl36AfM2m/HnSdJtIraz+KPhC2t4s7I4/B1+AMnJP/H51zzmrf8Aw0faf9FZ8J/+Eff/APyZX0dtFLj/ADmmB84f8NH2n/RWfCf/AIR9/wD/ACZR/wANH2n/AEVnwn/4R9//APJlfR+P85ox/nNMD5w/4aPtP+is+E//AAj7/wD+TKP+Gj7T/orPhP8A8I+//wDkyvo/H+c0Y/zmgD5n1D9oax1S1uNP/wCFseE0Fwhj3f8ACH3/AN0jBH/H56V6P+zDqS6t+zj8MrlEMaf8I5p6hPYWyAfpXqBUHHXjpzXk/wCyif8AjG34Zf8AYvWX/ooD+QFAHrVFFFABRRRQAUUUUAFFFNBoA8R+A8M9x+zTZRo2+ea31JQcDljcT44r5y8S/s469p3wz8GReGND1qy8Q6roF5Yat5ktxcC0ZrdpIwRKzCA+YAvyAZ+704r6d/ZjKWvwH8PtJIEiR7xmZuiqLufOa6fSvi94E16YrpnjHQtRZblbE/ZNUhlP2lmwkICuTvJz8vX2qU2np/W/+ZXSzPj/AFbw3N4as9P8TS6H4s1Kyn8U+HIyviSFft83kSPuSO1WCMnZvGDty/Yiu1+Gfw01q6+O2neKLzw/qFlpWoWniS6s3vrEwHTjPNpwgSQFco7iGeQK20jJwoxXuHi3xl8LtdutBt9f8S+H5JV1INpqzapErfboHHyIA/zOGUjZknORg1k+Ff2pPhz4ht/GN2/ivRdFsvCupHTb+a81KARgAfLICJMKrNuVdwB3RsuMiru1Jvrr9zSTMNpSb2f/AAWfMGofCzxprHhPwLo9r4T1Sy1DwJpotddMlq6pqkiX1nMyW74zcbktpWyhP+sIHWunOj6xceNta8a2vgPxHa6ND44s9WSybRZUuHtU0sQF4rcJvJ3gc4r6i1D41eANFv8AT7HU/Gvhywu9Qijks7e41aFXuUkJEbxhmBdW2nDAEHBrY8M+OvD3jbTbi/8AD2uafrthFK0L3WmXKXEUbrgkF1JUEbgfpWqqzjo/N/e7s3ck2fInw50bxL4L8QXXiLUfAGt63FrdrfWUGl3ViWPmtdyOomUriKJ02D592McYya0/FXgnxFqvj7VNPufCN+qz+J9JvxJb2UjWP2ZYNkxE2PLGw9gee9fSsXxj8B315rNpb+NPDs11o8ZfVY4dVgZ7FB95pgHzGB6nGKS1+MngG88P6hrMHjnw/Lo+nssd5qMeqwmG1LcxiWTdtTI/vEZqIVHGUX/Wr/pGa3Z8eD4I+PL7w34mbVNO121TQdWs7Ox/s6LddXGmxXDXEjQo6lXDZUbcOOOlfTP7NvhuTw74Y1yeSHWIv7T1We/V/EUw+2zBsDzHQRR+SDtHyFeMe9XPBPxotfHfgHxL4ss7W3eLSZbuKJoblZY51gUMreYAMbyBxjik+Hv7RHgbx14BtfEcnibRdP8ALtbe51O3fUY3GmSThdsUrnAVgzhfmAOe1KLdmn5fkHxWaPWWp1cPD8ZPA82r6NpaeM9EfUNVVmsLUajB5t4FO1vLTdufB67RT9O+LXg/Wta1fStO8XaPfapowLapY2t7FJLYquN5mQEtGAeCT93PNR1sUdrXkn7Un/JGNT/7COlf+nG2rP8AEf7WXw60GTwe0PizR9UtPEuqvpUF5aalbtBCyozFmbfhsMEj+UnLSLWj+1B83wX1XP8Az/aUfx/tG3qraXDrY9aooopAFFFFABRRRQAUUUUAFFFFABRRRQAleS+Kv+Tmvhp/2LHiP/0o0ivW68l8Vf8AJzXw0/7FjxH/AOlGkUdQ6njXxl+Enj34seO/iZq2kXX9lWdrpNtpumQ3mlmf7fJCTcBoJDKirmUlPut/KsnS/BPibX3g1a+8Jaj9tvPGmm6i73tsxcILXbI5JH+qDde1faXlrx149zz9fWhoUZcFRjG3Ht6Uo6KxLV3c+E9Z+GPiTTrz+0L2w8WWekteapbRW/huzWa5kaaX9yZUeCQrGU43BAB/eq7f/BvxFZ+GfG9nD4W1GV/7M0CDT1k/0lgY9+/bKEAk24XfsVcV9weWvJ2jJ5NN8lOODx7n3/xrWNSUE0uouXQ+IJPAHifUtN03w1F4S1OPUdF1PXNR1DVvsriC7triK4WBY5yNlw5Fwg2oSB5fSu98AfCu80vxL4Iu28OyW0Nn8Mxp7t9lK+TfZgygOOJcI3PWvqLyE3A45Bz16nGOfWkNvG24bB8xyccc+v196y7+f+TX6jte3l/w5+f2qfA/xbqPw2+GFhbeH9U0270jwDpsF8bOyPmxvBfWU1xBh1IM5SGRlU8nLAqQSK6oeEPEGm21zdWOl+NJtI1rWpbi61a6skl1xdtvFHGUg+zobdHZZFzt/hB6nNfbPkpx8oJBzkjnPrSCFF6AgZBxk4GBjp6cdK0qTc7+d/xdwjFR2/roePfso6Pf+HfgB4N0fV7G+0rU7GySCa31CJ4pQy9M7gK9lqMQRq2RGoPqBUlKcnOcpvrqUFeS/tWf8m2/Eb/sD3P8q9aryX9qz/k234jf9ge5/lUgetUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB5L+z3/AMefjn/scta/9Ka9aryX9nv/AI8/HP8A2OWtf+lNetUAFFFFABRRRQAUUUUAFFFFACV5L+0h/wAiX4d/7HPwx/6erOvW68l/aS/5Erw7/wBjn4Y/9PVnSaT3E0cN+1D4L1zxV4hsJ9I0m81OKPwj4ltW8mBmHnTW0SwxdPvuQ+31x9K808ZfDHxLJqUj2Xha/kgfRvBdu6x2hw01rqMrT5AXkxxv82f4cDpivtj7LD18tQc54GOemfrS/Z48Y28Zz1p026TvHujTnbcb9D4j034Q6/8A8J7q1lqNp4yvpk8Qanqgyqw6PHDKk4hnjcwFriQq6p5XmZB755q9ceA9Z8M+D/hO9r4XvxJaeHdWtbtbOweWVbqe3CRCbyh/Ee56dsV9n+SndQec8/XNOaNWBBFNNr7rGSVnzLfU+GbH4a+LovEnhK5l8N6mYbOfQDIGt22r5QxJxjAC9/Ssfx5oviTw/wCA9J+xaFqVl4g/4Si90G4W6tpY1lt76ZkjeN5Avmpko3ybwMV9++SnykjO05Fc7r3w58P+J9c0jVtUsXvLzSXMlkHuZRDE5x83kh/LY/KMFlJGOKtzu1cuT5tetkaGg6LbeHtFstMtoUjtrSFYI0QYVUVdoAHsOK1abtGCOx606s3vclaIKKKKBhRRRQB5N8P/APkvHxZ/65aR/wCk8les15N8P/8AkvHxZ/65aR/6TyV6zQAUUUUAFFFFABRRRQAUUUUAFFFFABXkv7KH/Jtnwy/7F+y/9FCvWq8l/ZQ/5Ns+GX/Yv2X/AKKFAHrVFFFABRRRQAUUUUAFNWnU2mJnh/wJtV1D9mq0tUgk1ESi/RoLeURtIDeXGQHPAzz0r5wGi61pfw31/VbLRNcaz8H6daappt9rmjtpuoCS2m837A0rJHHd4X5ROi7W/vvX1F+zJs/4UToDyMqIJL5ugVVX7ZN26dK5P4qfFTwf8QNen8ABrDxJarZSX149r4o+w26PHLGn2a5aJ84bzBlJOD3Q0o3voNv3bnhup+B9c0XwvouqaX4X1y58Sa5oJmksF0ybU9L1We6uWuZLW72RlrRkLY89pUXnpxitPxN4f1p/GF5dTW/jDRLPTPiDPqt5qHh7w62oN5M2l/Z4Lm1D2s8Vyolyp2RySR7mJCEk19fW/jXwtcatc+HIde0t9VsYhJcaUt5F9oijABy8Jbci4/vAVStPip4I1HRZdYtvGGgTaRHK9u2oQ6lA0IkA3NGZA5XcAGyM9j6Uczk7+X5tf5Gco8yd+n+X+TPju1+D+t2XhnxnZR+EvEMlvN4U0m2tYdRtRdXEjf2lczPDmCCOHequmYkQCIYGSK+jPgz4f1DQviN8XLibSriytb7U7OWyeVCkM6jT4Axj+Ucb1IPvWz4w+Ofh3wz4i8K6LYajput6xrWp21ibGDUohPbRTRu6zGJdzbcLxwARjLV00XxI8I3sWrPB4n0e5j0p0iv5ItRicWLFsKJvmAiOexwafNe7Xb9UytItP0/BW/Q+I7jRPE+s31x9p8NeLEv20DU7VtIs/CsltpVjOz4S3gaK3UOSOkm91/267LxB4D1nRPiNpmuP4Tvn8O6cdFvNQtdL0x5ywji2uyQxrul2t95FR3/2a+prX4qeCrzUrDTrfxfoNxqOoHNnax6nB5tzznEaB9zkD0B967FbeNedvOSwJJOCeuPSp7P+t7/qFrSZ86/B3Sbpvgp48VNE1HRpdS1LVJ7KwvNPktLmRWGExA6hxntx9K8Ck8Aa/wCNvBvhCOy8Ea1ZWWh+HNM0LVtP1DQ7i0M8wvrWVkRHQCWJVSXcU3RgHrxX6E+WvPXn3pv2ePcrbeVzt9s9auMnFv5fgOOiS7Hxh8Rvhjqknxq8Q2AXxhLYatqOiXWk6b4e021TSxFbPGS9xfPZyGARNvfYJIywJVdx6cNN4U1zxNr6t4h8J+LtQR/Cmv6deaRp+hjT7Gxle4s5FtrJxBscskchErPIJXJXePuV+hP2ePoFwM7sKSOT/nP15oNvG3VcjuD3+tJSd/v/ABVhvr8j4e0GHxBJrHh/XZ9D1vVNLs/GNvMdZl8NXFjqV9a/2bNAZLmyWMSfI7JH5iRBWCqSpQBh9F/tPf8AJFtV/wCv3Sv/AE429ereSmCMcH36cY49K8o/ak+X4L6pj/oIaUPw/tG2p811Z/1ol+gutz1uiiipGFFFFABRRRQAUUUUAFFFFABRRRQAV5L4q/5Oa+Gf/YseI/8A0o0ivWq8l8Vf8nNfDP8A7FjxH/6UaRQB61RRRQAUUUUAFFFFABRRRQAUUUUAFeS/tWf8m2/Eb/sD3P8AKvWq8l/as/5Nt+I3/YHuf5UAetUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB5L+z3/AMefjn/scta/9Ka9aryX9nv/AI8/HP8A2OWtf+lNetUAFFFFABRRRQAUUUUAFFFFABXkv7SX/IleHP8Asc/DH/p6s69aryX9pL/kSvDn/Y5+GP8A09WdAHrVFFFABRRRQAUUUUAFFFFABRRRQAUUUUAeTfD/AP5Lx8Wf+uWkf+k8les15N8P/wDkvHxZ/wCuWkf+k8les0AFFFFABRRRQAUUUUAFFFFABRRRQAV5L+yh/wAm2fDL/sX7L/0UK9aryX9lD/k2z4Zf9i/Zf+ihQB61RRRQAUUUUAFFFFABTTTqb1ouJnhnwUsp779l2K2tGKXc1tqSQsOof7TcbP1r5a1rRZtWsNPtNH8H6wmoad4IXTL/ADossO28F5a7snb8zfIWyvPvXvHwA8ZfEex+FWlW+l/DWz1KxhmvfIvH8RRwGbF3OB+7aEkce9ei/wDCbfFTv8KLM+58VxE/n5FVCThKwPWDifL/AI58J+IrrxF4s0XwlpWqT3+of22ZEvbR4ZtHMlq+ya3v1QRvFKyIojZjt875QMDFnUPCtt8RPi54Z1PRvC12vgyPUfDtnPb3GmSwwvdW8GqGWUxuikrEssC+Z9w7Rhs19L/8Jt8VdxP/AAqizyRjP/CVxf8AxigeNviqvT4U2Y/7muL/AOMUlJqy7W/O4PVNPrf8VY+dfGnh25j8Rf2BHoepS+LP+Fhy3sWoW+lTeQlnJby/Z2E2NgVVKKF34XHABrkdF+GOp3nw1uLKWLxJqmr2+h2ejX1lfaPDbxwym7jBtlEcCyXGBvO/fIOfpX1x/wAJt8VeMfCiy4/6muH/AOMUf8Jt8VSjL/wqiz2nj/ka4v8A4xUxvCLS8v8AIJe9Z/1vc8M8TeFB4Z+LkEeg+H7ofaryxeTSZdM/0O6VI/muIbhY/wDRyndXkKt3Br7PryP/AITb4q8/8Wos+Tn/AJGuL0x/zw4qT/hPPix/0Smz/wDCqh/+MVXM5JDesrnrNFeTf8J58WP+iU2f/hVQ/wDxij/hPPix/wBEps//AAqof/jFID1mivJv+E8+LH/RKbP/AMKqH/4xR/wnnxY/6JTZ/wDhVQ//ABigD1mvJP2pP+SMan/2EdK/9ONtTv8AhPPix/0Smz/8KqH/AOMV5l+0R40+JWofCO/ivPhraWds19phNwviOObpqFvjhYRQB9TUV5N/wnnxY/6JTZ/+FVD/APGKP+E8+LH/AESmz/8ACqh/+MUAes0V5N/wnnxY/wCiU2f/AIVUP/xij/hPPix/0Smz/wDCqh/+MUAes0V5N/wnnxY/6JTZ/wDhVQ//ABij/hPPix/0Smz/APCqh/8AjFAHrNFeTf8ACefFj/olNn/4VUP/AMYo/wCE8+LH/RKbP/wqof8A4xQB6zRXk3/CefFj/olNn/4VUP8A8Yo/4Tz4sf8ARKbP/wAKqH/4xQB6zRXk3/CefFj/AKJTZ/8AhVQ//GKP+E8+LH/RKbP/AMKqH/4xQB6zXkvir/k5r4Z/9ix4j/8ASjSKX/hPPix/0Smz/wDCqh/+MV5l4n8bfEhf2ifAEj/De1+3xeHNdFvZ/wDCRxfv42uNL8xy3k4BXEfHfefSgD6moryb/hPPix/0Smz/APCqh/8AjFH/AAnnxY/6JTZ/+FVD/wDGKAPWaK8m/wCE8+LH/RKbP/wqof8A4xR/wnnxY/6JTZ/+FVD/APGKAPWaK8m/4Tz4sf8ARKbP/wAKqH/4xR/wnnxY/wCiU2f/AIVUP/xigD1mivJv+E8+LH/RKbP/AMKqH/4xR/wnnxY/6JTZ/wDhVQ//ABigD1mivJv+E8+LH/RKbP8A8KqH/wCMUf8ACefFj/olNn/4VUP/AMYoA9ZryX9qz/k234jf9ge5/lS/8J58WP8AolNn/wCFVD/8YrzL9pPxt8Srz4C+OIb34a2ljZTaPc+fdf8ACRxzCDj+6IQTQB9TUV5N/wAJ58WP+iU2f/hVQ/8Axij/AITz4sf9Eps//Cqh/wDjFAHrNFeTf8J58WP+iU2f/hVQ/wDxij/hPPix/wBEps//AAqof/jFAHrNFeTf8J58WP8AolNn/wCFVD/8Yo/4Tz4sf9Eps/8Awqof/jFAHrNFeTf8J58WP+iU2f8A4VUP/wAYo/4Tz4sf9Eps/wDwqof/AIxQB6zRXk3/AAnnxY/6JTZ/+FVD/wDGKP8AhPPix/0Smz/8KqH/AOMUAes0V5N/wnnxY/6JTZ/+FVD/APGKP+E8+LH/AESmz/8ACqh/+MUAJ+z3/wAefjn/ALHLWv8A0pr1qvlj4E+NviTb2Pjj7J8N7a+/4q3VpJD/AMJHEnlyNcfNGMwc7fXvXp3/AAnnxY/6JTZ/+FVD/wDGKAPWaK8m/wCE8+LH/RKbP/wqof8A4xR/wnnxY/6JTZ/+FVD/APGKAPWaK8m/4Tz4sf8ARKbP/wAKqH/4xR/wnnxY/wCiU2f/AIVUP/xigD1mivJv+E8+LH/RKbP/AMKqH/4xR/wnnxY/6JTZ/wDhVQ//ABigD1mivJv+E8+LH/RKbP8A8KqH/wCMUf8ACefFj/olNn/4VUP/AMYoA9ZryX9pL/kSvDn/AGOfhj/09WdL/wAJ58WP+iU2f/hVQ/8AxivMfj/40+Jdx4P8PJefDa1s1/4SzQJty+Io5SJE1W0eKPiEfff5M/jQB9T0V5N/wnnxY/6JTZ/+FVD/APGKP+E8+LH/AESmz/8ACqh/+MUAes0V5N/wnnxY/wCiU2f/AIVUP/xij/hPPix/0Smz/wDCqh/+MUAes0V5N/wnnxY/6JTZ/wDhVQ//ABij/hPPix/0Smz/APCqh/8AjFAHrNFeTf8ACefFj/olNn/4VUP/AMYo/wCE8+LH/RKbP/wqof8A4xQB6zRXk3/CefFj/olNn/4VUP8A8Yo/4Tz4sf8ARKbP/wAKqH/4xQB6zRXk3/CefFj/AKJTZ/8AhVQ//GKP+E8+LH/RKbP/AMKqH/4xQAfD/wD5Lx8Wf+uWkf8ApPJXrNfLXgfxx8SIvjX8TpYPhta3F3KukrcW58SRAQD7PJt58jnP6V6X/wAJ58WP+iVWf/hVQ/8AxijyA9aoryX/AITz4sf9Eqs//Cqh/wDjFJ/wnnxY/wCiVWf/AIVUP/xilfWwHrdFeSf8J58WP+iVWf8A4VUP/wAYpf8AhPvixx/xaqz/APCqh/8AjFMV9LnrVFeS/wDCffFjn/i1Vn/4VUP/AMYo/wCE9+LH/RKrP/wqof8A4xQN6HrVFeS/8J58WP8AolVn/wCFVD/8Ypf+E8+LH/RKbP8A8KqH/wCMUriues0V5N/wnnxY/wCiU2f/AIVUP/xij/hPPix/0Smz/wDCqh/+MUJ3Ges15L+yh/ybZ8Mv+xfsv/RQpf8AhPPix/0Smz/8KqH/AOMU39k3n9mv4Zf9i9Zf+ihTA9booooAKKKKACiiigBKarU6mqtBL3PFv2fbp9N/Zq06eAiKWGLUZIyoHysLm4IOPrXFaD+1Q2oWnwjeXxBo0smsrcy+IEhKvIix2sz/ACoD8nzIp/Cu1+Adm2ofs36daxf6yaLUI1H+0bifFeS6z+yPd6h4I+GunWHhzR9M1PTbW9g1e8t44o5Q0tnLGm51G6T53Xof0rOGnM2a6aLueuP+1X4NtdEu9Tuxq9rHby2kRgl0yRZpRcyeXA8ackqzU+8/af8ADFroX9qiz16dkubi0udNg01nubOSBQ0wnXIEe1XQnJ6dM183eLvhVq/w4+H9tq6eCrPQdXGueF7K3tZ9SN1NezxaimW8wyvsjZmIVFxgdq6nxD8D/iF4i1XVtYn0druz8UXd/c3Phsa35UdtM9raW9pNcOjjzViFvISi7/v+o43t7vMu7X3JMxV3bz/yf6npS/tV2EPxL1zTbu0u4PCtj4f0/V4dYFqTDK1y7hRvz/EPKVOOWLjtUXiv9qOGHUfCLaPa6oLefWptO1bTJtP/AOJjGVgMqx+UemQV5BzxXm7fAHx9d6XpkH9h26sPCnh60IbUYyYrzTLprhrd8n5/NDMA4+Vc5961734XfEmTx5afEI+FIDfTeIBqlzoJ1WHzYbZLFbbiTPlGQsAfvdvrVVFHRIpf5fkjoviH+09H/Yt7qnhHXN0yafZXiWFxpx+RZL4QyEk8+ZjK7TxxnGa6WP8AaU0Pw74fl1HULnVvEeb24jcaXpRP2RIv9YX6Dy1/vk8143N+zH45ms9UlWytReahY2zfZ/taALMdS+1Sx5z0SP5Qf61a8Q/AP4hXXh+bSJNJTVdNu5NSJ0mPV1giSSf/AFVxJhh5gX+537g03yaRE027I9du/wBrbwNaahc2gk1a6W1ht7ie7trAtDFHMu6PzH6DcK9I8MfEDS/GF94gs9Kma5m0O7FldHGF84oH2g98Blr578B/BvWPC/wj8f2XjC0stFt9R0e0tvmuUkX9xblSWKccnp+ld3+yHo+qWHwR0XUdZ8ga5rkjapfyRDiR3AUEf8ARB+FRa97dCFJrc9yopvanVBqFeSftSKP+FL6mMDA1DSxjHHOo21et15J+1J/yRjU/+wjpX/pxtqAPW6KKKACiiigAooooAKKKKACiiigAooooAK8i8UwoP2mPhmu35R4b8Rvj3+0aV+nzHjp09BXrteS+Kv8Ak5r4Z/8AYseI/wD0o0igD1qiiigAooooAKKKKACiiigAooooAK8j/asRW/Zw+IzFRu/sa4G7HOMV65Xkv7Vn/JtvxG/7A9z/ACoA9aooooAKKKKACiiigAooooAKKKKACiiigDyT9n1Q1j44DAEL4y1oc/8AXz39a9bryX9nv/jz8c/9jlrX/pTXrVABRRRQAUUUUAFFFFABRRRQAV5J+0goHg3w62AW/wCEz8Mdef8AmM2Yr1uvJf2kv+RK8Of9jn4Y/wDT1Z0AetUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB5L8PVC/Hj4tYGMx6SxI6km3k715p4j/agvdF0P4jQS69o9n4l0PxB9isLCUL5htv3P3lzlj87dOea9M+H/APyXj4s/9ctI/wDSeSvKvEX7NN3rHhn4mM/hfRZvEeqeJjqGlXUkMRm+zfuORIRuX7rcZppail8DZ6neftJeFdN8Q3uk3A1JFt3niOoNaN9laaKJpWhR8cvsVjjHtVTRP2oPCmveH7rV4rfWbWGOxt9RjguNNdZ7iCYqsbwpklwxZRx0zzXh+s/s96l4b1DxLdzeGIDZx3mp62PE1xqLOZFkt5SIktzKdku9j83l428VF4c+HfxD8dfDTRdestL/ALFu7XwlpOlWcFrqcYl1a2E8M90VlVhsMkUYRS21h5hPB5pxSlzGXM04rv8A5r9D07xB+1hB/aHgKPQNJ1O8j1fxFNourRy6c3nWJitnkZCm75XOFcZLfIrntWx4Z/ac8PtpeiRTXGp+JLi6tY72e+0/S2xBDIzIrzIP9X86lcYPSvLPC3wT8b+HbzS7qLwclra6f49fxJBpv9rwylLOXTzaE+Y7HMke47snncdvWrnwt+EnxU+EM2nnSdHsZ7rVtIsdNvbqe6jMWlPDLMztguWcMsg4XcN1K/uo01u0/wCtWemfH/4ua34E1vwFpGixXUY17VFt7m8t7D7V5UYXcwx06VV1n9qXw7cWOswWs2saBfWKRzLNqGkNiWIyohaJCcydT6V0nxY8Daz4q8QeA7zStu7Rr6W4nZmGIswFV46Hk9818zal+zh8S9WcySeF1k1CbTha3eqTa2kjTzi8Egl2sxAi2KPlABoiryTew1u2z3j4b/tALqHiDWtH8QXjSXMniG+sNKaG0wBBBEj7ZMdwCeevvV0ftZeBmvhb+ZqYK2X9ozTfYW8q3t/MZN8jZ+XlGry9vgp488OeJY/Eel6DaavNB4l1HUBpwvoomktbmAQ7i5OMggNg+lUvCv7Mvi68+H/i7Rdat7fTJtc8L/2b5nniQi48+aTZkdvnFazUb6DPor4cfGDRfiY2oR6f9ssrqxWOW5stUtWt5445d3lPhgMqwRsH2rva8I/Z3+F9z4Dutc1S58K2nhSXULe0tltPtpu7iYw+ZucymV8IfM+RM/KOte71kwCvJf2T+P2bPhl/2L1l/wCihXrVeS/sof8AJtnwy/7F+y/9FCkB61RRRQAUUUUAFFFFACUi06kxigR49+zPKlp8A9AnllEaQvePJIemFu5wf0Fee69+1dZ6l46aw0fUl0zw3b6LLfyalqOjXClpUuYUV4tyr5kZVmGU3Lz96uz+BOhtr37M1ppMUnltdR6jEj5xy13cY5rwrWPgj8TvEdrp1o/g+TTbfQvCY0KO7m1O1K3kiXULB4lSUlVKIzZfac8VVKMeZue3/AYS+B23Poa5+OXw41zWLzRL+4Dtp8sk5uLzT5GsxNbAO5jnZPLaSPAPyMWGMjFU5f2qPh5Z6b9pn1W8sma8t7IWd5pl1DdSSTxyPbjymiEm2Xy2CPtw+w4Jrxrxl8AfHvjLWPFGladoR8LWerDVPtWoNfR3Gl3q3EMiQvBbs5mguSfK3sFjXhvatRPhT478bfFnw3451Dwn/wAI0tnfaPaTaTLeWzytbWkd/wCfc7opSDH5l7Gqp94hOVpKKikm+339Q+zc7jxt+09pll4m8MaNoTTG5vNdt9N1Ge/0u5SG3ieCWR4xIwVBONsQKbs/N92uhX9qf4drper6jNqtxaWemwrczTXWm3CLNC0ioJIcp+/XLLzHuryzxR8JfHuoa4/huz8NPPosnjWXxA/iRb+2SP7PNDMHHlGTzPMSSQKAFxgD0rktD/Zt8T2PgG70uLwXLZanp2lwact3qniKS9e/lW6hkL20cl00VvFsjLbGVGzxtpQ95Xl/Wg/+D+b/AEPsTwn4ss/Gmgw6vpqXX2ScZX7VBLBJ/wB8OqmtloUfbuUNg7hu5wfUelV9Ot2h0+0jb7yAA9qvYFLbYOpnatoem+ILGWy1TT7XUrOQYe3u4VljYe6sCKtWtnb2VvFBBCkEMShY441AVABgBR2GPSp9oo2inqJLQRu1OpKWkMK8k/ak/wCSMan/ANhHSv8A0421et15J+1J/wAkY1P/ALCOlf8ApxtqYHrdFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFeS+Kv+Tmvhn/ANix4j/9KNIr1qvJfFX/ACc18M/+xY8R/wDpRpFAHrVFFFABRRRQAUUUUAFFFFABRRRQAV5L+1Z/ybb8Rv8AsD3P8q9aryX9qz/k234jf9ge5/lQB61RRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHkv7Pf/Hn45/7HLWv/AEpr1qvJf2e/+PPxz/2OWtf+lNetUAFFFFABRRRQAUUUUAFFFFABXkv7SX/IleHP+xz8Mf8Ap6s69aryX9pL/kSvDn/Y5+GP/T1Z0AetUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB5N8P/wDkvHxZ/wCuWkf+k8leq+WmQ2xcgYBxyB6V5V8P/wDkvHxZ/wCuWkf+k8lesbaQEE1nBcwywzRLNDMpSSOQbldTkEEHggg4qO1sbawgigtoVt7eFFjihhGxI1UYCqo4AA4wPb0q3ik2CmKxGqoM4ydwAIZiRx9acsKqMcn/AHmJ7Y/z+dO8selOoAbsGc856dTRsU44+6cinUUDGNErYyDgdsnHTHTvSiNAMBVAznp39adRU+gEfkIduVzt6f4/X3qSiimr9QCvJf2UP+TbPhl/2L9l/wCihXrVeS/sof8AJtnwy/7F+y/9FCmB61RRRQAUUUUAFFFFABRSUmTQB8wfs+aJ8V7z4RaNJofi/wAG2GmGe9Ntaah4TvLmaEC8nxvmXU4g/wCEa16A3hn40K4c/EDwGHb5Q7eBb3jnIA/4nAxz2yaz/gVqD6b+zTZ3iJve3j1GTbjO5hcznp35rxbw34m+Hfwr0vwh45ury/0rxzc6TPrWovDplyw15ZYXcwT3JiKOyMBjLblxwBmoUlK/kNx92577/wAIx8bOcfEHwCMnPHgS/wCvt/xOeP8A659aVvDfxs2sp8f/AA/wRt/5EO+6en/IZrxmx/ax+IF54WmuI9H097+a80VLW8u9C1LTbQJeXiW8sW252PK0eSRIu1T6UmuftceL9H1L/hEZI9JPi631HU7KfUrTQ9Q1KzlFotsfktLVmmjLm7VdzOQnlktu3Cr5XZW6kXsj2f8A4Rz42MMH4geAGHH3vAl+en/cZpG8PfGuNwP+Fh+AlzkbD4FvjuPLcf8AE5GTweK86sf2iviB4guNTu7TR9B8M6Ppvh6w1i6XxMlzDcwS3MbkwSLkFCjLn7pZvuBd3zVw1r8atW+KviHwZba59hFxovjyG1+2Wmn3OnRXcbabNMCYJ3dxw4GGOKuMHJtLoEdv67XPoEaD8bgvzfEHwApxubPge9IUfX+2BTf7D+ODF/8Ai4Hw/TYcHPge955/7DJxketeeftM+PvFeoWfjDwp4cXSYLTTdCW/1SbUo5jOUd8BYmjcBCFBbLZrkF+OmveCLe+h0LTNE023Weztb3xBe2V1dW8BFtuU3MUTqyl2+Xcdir1NZQTkDkk0j3b/AIR/44f9FB8Af+EHf/8Ay4o/4R/44f8ARQfAH/hB3/8A8uK81uf2lvGMlte+ILWDQH8L6DFZNqnkK9xJdmfljbzCUIEVfmB2vu6cVX0f9oL4o+JLyzgtLTwxaDWfEV5oulyPbzT7Et/MdpJts4zlYyvy9+elaW1sVH320uh6cuh/G9o+PiF4BLZ4P/CCXuM5OVyNZPTBFSf8I/8AHD/ooPgD/wAIO/8A/lxXzH8P/j/4p+HPgHRvD2m2dn/b01z4g1S5zouoass4i1OZBbwfYwWQF3C+bISIx1DV6R/w0p8TtU0X4ga/pvhWxi0fw7PY28NnNY3Ut+PtFrZXEkkqI2SLdLqVnRUyfL2/KQdz5Xdr+uwvtcp6p/wj/wAcP+ig+AP/AAg7/wD+XFeY/tD6P8Xh8I7+bUfGngu/sje6dm3tfBt3byFvt0GwiQ6s6gBsHGOQMdTXrPwV+ImpfELwX/ad9eaTqUq3E1v9t0JZBDMEP3hG5Z4n/wCmTknpzWf+1EgX4Makf4l1HScEnJ41K2I5+tQCdx7aJ8bPlI+IXgEknaV/4Qa9/rrIwfbmgaD8blQv/wALE+H7Jjdu/wCEFveP/Kz0/GvGv29tNv72f4XXumzSRXGk6rPq+FP31iVGZSO4wTweK82sfiXO/wC0Z4z+LGjXMV/aSeHpLWwgunPk4gaNXYFMZyZOvX5aI+8W42t5n1h/wj/xw/6KD4A/8IO//wDlxR/wj/xw/wCig+AP/CDv/wD5cVwHiD9ozxd/wsB/BWi22ipq142mR6feX0EslujXEE8snmBJVL7RCB8u371T+MfjR8S/Dt1qGkwWvhp9a8OaI2t6wWhuGgvE8xlijgbevlO6ozHd5mw8fvKbVidjuP8AhH/jh/0UHwB/4Qd//wDLimHQPjesXzfEPwD6Bh4FvOeMDrrOMk159ov7S3ijV/iT/Z8sehaVoM43WdlqkU1tezwGxF0l3HcljFNHkMjxxxFwPmz2rzXUfjt4h+J95a6Dry6TcHTte8O6jDqGm2VzZxFZ7yaNk2zuxljUQMfNXCyBuAKcY8zSJcrRcj6O/wCEf+OH/RQfAH/hB3//AMuKP+Ef+OH/AEUHwB/4Qd//APLivU4nJQE9alqethp8yueT/wDCP/HD/ooPgD/wg7//AOXFH/CP/HD/AKKD4A/8IO//APlxXrFFAzyf/hH/AI4f9FB8Af8AhB3/AP8ALij/AIR/44f9FB8Af+EHf/8Ay4r1iigDyf8A4R/44f8ARQfAH/hB3/8A8uK8u8RaX8Xm/aH+H6nxt4La+/4R7XvIuP8AhDLxYlj8/TN6mP8AtXMhb91tcOoUK24NvXb9U15J4qH/ABk58NTlufDHiMH5jg/6RpHb/OMn1o8wGtovxwwM+P8AwCnOMt4EvcZ+o1k4B96cuhfG3BcfEXwAY8bwzeA777v/AIOBXz98f9N8N6r8bPH8V3oN5rfjaTQLOHw7c2GjXF3NYXB3lWWeOMrByAcs6ZrdT9o7xdpvij/hFdcj8Pa3aGzvYJRbWl1utpre38z99cyOscjk8PFGoZPU0LVXA9lj0H43uV/4uD4EAH97wHe/N+I1nFOPh/43q2T8QvAG3/sQ77/5cV4lH+0h4v0TR2n0TSvDdr4d0XSNP1C5t5YZvOled8PHGVm2psH9/dX07421u70nwDrWq248q6t7CS5j3YO1lQsBj61TTSuLrY4xdB+OOST4+8B+mD4EveD2xjWTxQ2hfG6NFLfEX4f4bAVj4FvRuPYf8hnqa+cPiV8M/Dej/srz+ObK5j0Lxlq/hKSbU2jnjjm1uaa1EjfaWAzLtJ356gDjArudU+LHiK3uovDni+w8O6nfaf4h0CKO6t4pEhWG83c4aYsZI9jfMcoe60SXLv8A1rYmUlG3nf8ABXPVP7D+N7ZA+IfgAMMHb/wg15yOeeNY+ox/s9al/wCEf+OH/RQfAH/hB3//AMuK+TPhj8RNe+Hum6FrGjWRvLz/AIV7pUWZreW6FrE+p3aG4mgiZXkRFO9ghDduwr7E+Cvj/VfiF4Bh1jUptJvLo3M0C3OhMfs1yscpTzFVnZo845RjuX3pW/X8HYrrb0/FXM7/AIR/44f9FB8Af+EHf/8Ay4o/4R/44f8ARQfAH/hB3/8A8uK9YopDPJ/+Ef8Ajh/0UHwB/wCEHf8A/wAuK8y/aS0n4ux/AXxy+peNfBV/p50i4862tfBl5byOMcgStqrrGfdlP0r6lryT9qobf2bfiLycjRrjBzz0oAf/AMI/8cP+ig+AP/CDv/8A5cUf8I/8cP8AooPgD/wg7/8A+XFesUUAeT/8I/8AHD/ooPgD/wAIO/8A/lxR/wAI/wDHD/ooPgD/AMIO/wD/AJcV6xRQB5P/AMI/8cP+ig+AP/CDv/8A5cUf8I/8cP8AooPgD/wg7/8A+XFesUUAeT/8I/8AHD/ooPgD/wAIO/8A/lxR/wAI/wDHD/ooPgD/AMIO/wD/AJcV6xRQB5P/AMI/8cP+ig+AP/CDv/8A5cUf8I/8cP8AooPgD/wg7/8A+XFesUUAeT/8I/8AHD/ooPgD/wAIO/8A/lxR/wAI/wDHD/ooPgD/AMIO/wD/AJcV6xRQB8sfArSfi9Jp/jNrPxv4Ktf+Kq1XzBceDLyUvL9o+d1xqqbUPPyHLJ3Y16f/AMI/8cP+ig+AP/CDv/8A5cVH+z3GPsPjsHJDeNNaJBJ5/wBI/l7V65QB5P8A8I/8cP8AooPgD/wg7/8A+XFH/CP/ABw/6KD4A/8ACDv/AP5cV6xRQB5P/wAI/wDHD/ooPgD/AMIO/wD/AJcUf8I/8cP+ig+AP/CDv/8A5cV6xRQB5P8A8I/8cP8AooPgD/wg7/8A+XFH/CP/ABw/6KD4A/8ACDv/AP5cV6xRQB5P/wAI/wDHD/ooPgD/AMIO/wD/AJcUf8I/8cP+ig+AP/CDv/8A5cV6xRQB5P8A8I/8cP8AooPgD/wg7/8A+XFeY/tAaP8AF6PwnoQvfGvgy6jPizw/5Yt/Bt3GRKNVtPLbP9qvlVfDMn3nXKqVY7q+pq8k/aSB/wCEL8OEMwI8aeGeVYg861Z5H0PTHpxQA1tF+NyYZviD4ARSCR/xQ163HX/oMg5+gpy6H8btoY/ET4f7P73/AAgt709T/wATnvXhn7cUcul/FT4M+K4buS0PhG4v9euFj+ZpreKWzWdOe3kyyt7beOlcN4Z+IepeHfjx8W/irprw6nHqVtawafDePmH7PHqr2AdCvQN5LNkf36Fq0kVbS59WNoXxujHzfETwCW/u/wDCCXuSQM4H/E554o/sP43eZtHxC8Abv4VbwLe/MPXjWf6V494++IGueMPjLY6FbfY9Pk0PxA0FhN9nlaNjLpKzjzkDAy4ZiPlx2pf2TfFuvajc+DbTxGNJ1O+m8MverqsUUiXRXz3QKS0r54A59qvlevl/lclansf/AAj/AMcP+ig+AP8Awg7/AP8AlxR/wj/xw/6KD4A/8IO//wDlxXD6x+0Z4osfE2o6gllpQ8D2XiD/AIRogwy/bXuNn+u8zd5ezf8ALs27v9qsPw7+0B8U/E2k6K8UfhOyv9Ygu9Stg9ncTRRWtuWDJIROMStgc/dTvuqVrHm/ra4m7NJ9T1T/AIR/44f9FB8Af+EHf/8Ay4o/4R/44f8ARQfAH/hB3/8A8uK8Z8Qftb+LdJ8J+EfERfw5Gl9p1ve32kw2F3d3Lb5WRmWRHEVtHhTh5Wb6V0/gz9oLx3q/jrRbfU7HQl8O6v4m1Lw5BHbxzC6U28M80cxlZ/L+YQ48vbn3p8rukF9/I7//AIR/44f9FB8Af+EHf/8Ay4o/4R/44f8ARQfAH/hB3/8A8uK9VVjin1ILVXPJ/wDhH/jh/wBFB8Af+EHf/wDy4o/4R/44f9FB8Af+EHf/APy4r1iigZ8seBdI+L//AAuv4nxw+N/BMd8qaWLmaTwZdyRyf6O+3ZGurBo8DP3mbf2xXp//AAj/AMcP+ig+AP8Awg7/AP8AlxTfh6uPjx8WxuYgx6OdrMSAfs8nQHp+FetUAeT/APCP/HD/AKKD4A/8IO//APlxR/wj/wAcP+ig+AP/AAg7/wD+XFesUUAeT/8ACP8Axw/6KD4A/wDCDv8A/wCXFH/CP/HD/ooPgD/wg7//AOXFesUUAeT/APCP/HD/AKKD4A/8IO//APlxR/wj/wAcP+ig+AP/AAg7/wD+XFesUUAeT/8ACP8Axw/6KD4A/wDCDv8A/wCXFH/CP/HD/ooPgD/wg7//AOXFesUUAeT/APCP/HD/AKKD4A/8IO//APlxR/wj/wAcP+ig+AP/AAg7/wD+XFesUUAeT/8ACP8Axw/6KD4A/wDCDv8A/wCXFM/ZMBH7NPwxD8t/wj1ln/v2K9bryX9lElv2bvhkT1/4R+y/9FCgD1qiiigAooooAKKKKACmGn03rR1uJnkX7MtvHffATQYZl3xO99Gy+qm7nBH5Vzzfsn6PqV1o8eoeKtY1TRdHeY6do8hhWCGCWMpJFlUDOpyfvE47Yra/Zvvhafs+6XcRY3w/2hMI29rqcgV5Ev7Xni9X1jT49O8P6pqcS2s9pNa/aYbVfNulhaN2Zv3pBYHcnymptroNXtZnptt+zHpz6fbW+q+Ltc1u6t7zS54767eIMsVjOJ7eLCoFIOADIRvbHLGnav8As2adca1e67pHijVPD2s3WpXl2uo2axOyw3UEMdxbKGUqEP2aJtwAZSgwRiuZsf2g/GuoaqvhJLHw+vjIeIrrRXui0x03ZDZreGTG7fyjFev3uKufBPxhq+h/ss2+uyNaTa1AmpTldSuiLdXF7LlXkxkYyFAHoK0d0ufsZS3Ue500n7NfhyXTfEFhBdXdvZaxp1hpgj3K5t47MN5JVjkty38RNZ2h/sw2mmeIxrd74s17V79tbh124a6EAWe5itmtwSscagBlAJUcDHTmuM8G/tSeJvGmNC07TtHu/EreIf7GhvPKngsZIfsaXfneW580HaSuM9eelcJ4B+PnjrwP4Dns7bTtNuW0qw1DxDfyajLIS4GoTgwwlT6AD5s4FPWMuZ7spaPl7f5WPoL4rfs92PxMv7m7TxFq3hptQsf7Lvv7M8gi5gB3IP3iNtIPdcEjjpWdqX7L1g11eX2n+L9a0a/uD891b+RIvliDyWV45UZHBX+8Dzz15rjLz47axql1b6X4g0bS7i5t9Z0wxyafLKsQt7mLehyW5cD+E8e1ZV5+0x4lvNEWXWvDuky6LrMOp/YoraSRZ1+znK+cxOPnP9zGKzj7q/ruNxunLseg2/7Jmg28sEdhrmqWuhPFBHqOkL5bW+peVyC5I3AHuFIB6HIrXuf2ddMbw5p9jYa5qGl6hpur3Gtabq1uIWlt55mk3qEdGRhtkdMMp4PsMefWPx+8V3fiq18N2Wm6TpluLG02Wl60wuCskO4TRuTsdUP8I+Y965z4L/GD4opZ+C/DdyPDmqS32mahq0+q3M06kRQXSowOT1JY89var13IhLVW6no1j+yRpmkaPYWumeK9asryFNSgu9QiWA3F7b3tx9omhcshAy+MOMOvZhW/H+zvo1jo/irTtM1bUtOXXNTtdRElrMokspbeG3SLy+MMf9Fib95uz3zXgPjj9pLxz4x+HnxM0rTpNFttW0fSrXVbfUtJNyYNktyySR7mYEuu0EMp2/hXc6X8YvFFn4s8S+GtM0nw+3ji+8VR6RLdtJObF2j0a3upZNhYuNv3MDA5Q9SSa95ev/BKUvf/AK7XPb/hj8Mrb4a6XqEC6ld6vf6jdvfX2o3SxpLcTt95ysaqoz6AYrn/ANqT/kjGp/8AYR0r/wBONtXjK/te+LtSXWrjS9C0OO38O6THf62t1LJ5jTC7ubaaGDaR0NuSpbOd1ev/ALSFx/aXwPv5Adokv9JIP11C1/xqOWVtQXu6HR/EL4X6V8RNS0e61Se6j/swXCLDAVAcTRBXByDngDpXnPhz9jvwj4V8LWOhQX19/Z9jpdxpwdiitIsrbzI2B1U8+/eug+OHj0eBfEXhOWPT4b24mjv3haeV1EZihDHgHByPWvnz4sfHr4geLPhTrelXdtomjXWqaFDrEE1lLPuhheVEZHO75X5IwKzppybsbcr0bPYbT9k23huL6+uvHXiK68QTm1kg1eQW/nW8sAZUZR5QRvkYLhlIODnPNXL79lPSbjS4LOy8W65pcr2s9jq81vJGzarDNI0kizFlO0lnYhk2kA4BAGK8t8J+N9c+Dul+No7WbQ7OeDXIbPy9Ref7NEFtQ5EUaMXfgDpVi4/bC8bXXhOXxBp3hrSntdL8Pxa5qdvNJIskjG5kgaKHB4z5ZILdO9a2d0u/+X/AM5rlv/XWx6VrP7J+ha5qlx9s1bUbnw8skt1B4bfyvs8dxJam3dxJs8wZVj8u7aCd2M81TsP2S7GHXLXVr7xhr+r3MMOm27/ahbASJYzNJACFiHA3sh/vZycnms3U/wBobxrpMOs6PJpWht4n0/xXpWg5E8v2Ror5YmVs53b1EnTOKi8D/tEeNdY17SLfXNG0K3tLu+1jRC1vcSj/AEzT/MzMGZsLBJ5Zxu+Ze9LXddGv0ZPRp/1d2/Q+lVZgqg4LgchTxTlmJYDcp/hbac7TXxR4x/aT8deM/CPjrRdOfQbbV9Ki0+7i1GxWc24Se58p4yxI3FW+TevDdRzzXYaH8avFVj4y1TwfpOnaG3i+4vZmlnup7g2ZWK3ikd+WLAnzOg4pRi7sfwpP5fcfV1FfJkn7Wvi7VLO41XSNE0pNJ0zS4dT1D7W8jSyZm8mSOEKeMHnLV9S6Xff2hp9pdA8XESPj+7lc1TVh3L1FJS1FxhXkvir/AJOa+Gf/AGLHiP8A9KNIr1qvJfFX/JzXwz/7FjxH/wClGkU3tYDpdN+H1hpnjrW/FcNzNPf6jYwWU0L7CqrFnachSxb5j6/yrzS7/ZS02fWEuYvGGuW1nBcXk0Gnxpb+XbNcpiUA+Xk57E5I6KRXK/Er4e6R8Qvjn8QIdXRnuNO8IWt3p13HM6tYzE3AMkZDDaf3adPT3NcxoP7Y2r2i+HtOgtLfU/strp8d9C1pdy3d004QHymRdibc/wDLQHNNRbVkS5NOyPYm/Zf0STw/qekrrmp+TqGn2unyNGUAVYDlWAA4JPXGK7jwr4X1K30/X7HXL1tRtL28mW3jkA/d2pUKqZHJ78nn3r5l8EfGTxp4Ds9Siis9P1TS7zW9XjtYbqWX7WjQp5vznO0Jj5eOldcv7T2u+JtWsdO0DTNMW51I2FpZzX7yGNrmRHlnBCnO1AAPWm72SFGTl7z8zf1L9kvR9c0G70bUvEuualpkenTaTpEMgtwNJilGxzEVQFzs+XMm4gcDFdJq37Pmhar4muNeOqagk82oaXqTrG0QQSWG7yx9zODvbdz39q8W+D3xa8c2E2jeFtOsNN1DVtY1XXbm7m1OaURQC3nQERHPT5jx0rD+I37S/jTxN8P/AIp6VaSaLZ6nY+ErrV7XUtH+0OLVEkWOWMux2yyAMpDJ8tSrysn/AF1Hy6Wfp9+h7LY/sq6Jo9nYW+meI9YsL3SdKttNs722eIS2/kzyTq+3btLEykFWBVh1BrpfAPwivvh3q+jw2Gr3l9pb/b7zWHuxGGvLyeSN1kKKoUFW8wgKABnAGOK8s0340+IND8Raz4dg0/SZ/Gt9rOm6THeOZvsU80umLcs5UtvXZGhHBGTyeaoXn7WHjiVdei07QNBF34Y0m61HW47iaXl7e8lt5I4CpH3/ACyULdO9XGLu49/+HKtf3vJf5H17RWToGrf27oen6gh2i8gSdR/dDLkVrVLVnYmMuZXQV5L+1Z/ybb8Rv+wPc/yr1qvJf2rP+TbfiN/2B7n+VIo9aooooAKKKKACiiigAooooAKKKKACiiigDyX9nv8A48/HP/Y5a1/6U161Xkv7Pf8Ax5+Of+xy1r/0pr1qgAooooAKKKKACiiigAooooAK8l/aR/5Evw5/2Ofhj/09WdetV5L+0j/yJXhz/sdPDH/p6s6Vk9wL/wARPg/o3xM1TTb/AFWacpDpuo6V5ELApKl5GscpyVJBAUkNnA9Dxjg9N/Y+8K6P4TtvD9rqWppbWvh628OxybovN2wXLXKXBO0KZPMbPIwe4PNVv2iLXxBqPxf+DNjYSabJpf8Aal3f3VrqbyLvkhs3ZHyhA+XD4/2znpXC3H7UGseJtL8WaTrWlaFq6WFppmpR3GkvcR2/72+EJRnZsybSoO6M4NVDdKO//AK30/rdHqPhr9l/S9F8RJr+o+KNX1/Vjqf9qzXuoeQDO/2ZYAp8tFAUKhPAHWtb4Xfs92Hwv1bT76LXtU1dtPtJNPtob5Yj5cDyF1Tcqgnbk8kknPJryb4K/F7U9B1IaALa3vLPUdR8T3f2iR5DKn2W8by4QCeA248dquaT+1d4q1DTda12fw7pcPh3R9Is9RuZkkk86WS4TIjjGecetVJytd/1pYn4Gk+t/wAz0jUf2btJ1TxdLqp1nU00uXUP7ZfQ9sX2Zrzbt8zO3zOn8G7b3xmuH+LHwi1Pwv4f8L2HhGx8RalLplrdWK3miyWjzpHNnMc0c+EaM5PIG73rsvgB8aNT+K39sW+rWkcT2IhaLUdPtLiC3mSRM7P36hhJGfvEcc17V5KcHHIGN2efzqWnHT+thXUtT5g0T9j9dR8AaXZ6j4p1jQry70aysNXt9MeJ47mWBmeJy0iM3DO2QCA2fmzxXoOi/s96RpN34ek/tTUbqTRvEF5r8T3CxDzJriKdHQ4QfKPPbB/D0x6+sSqxI3dMcsSKGhRskjOfei75uYaDpT6TaKWkIKKKKBnk3w//AOS8fFn/AK5aR/6TyV6zXk3w/wD+S8fFn/rlpH/pPJXrNABRRRQAUUUUAFFFFABRRRQAUUUUAFeS/sof8m2fDL/sX7L/ANFCvWq8l/ZQ/wCTbPhl/wBi/Zf+ihQB61RRRQAUUUUAFFFFABTVp1NWmI8b/Z50xNc/Z40rTpXIS6S+hZlO0lTdzgjI5HHpXG2v7HK/6AbrxnqV9BY2lrYWsclrEqwwW86yxhcNx9xQe5xk55rrv2dNSttB/Z10S/upGNram+ZnUcsBeTiuSvP2mF8T+G7G+/sTXNGt57/TfssltJbN9tiuJtsWSWYRqT99DhxShe9kXa50upfs5wXGsXuuaR4kvdI12616TX4NRWGObymeyW1aLYw5BRS3I689avwfs92lv8CT8NJdYu7i1YSSNqTKPOaU3X2lWK9D83BXoRwQc15l8Pf2tNYi8G2cvifwxLeeIrnUdVENvFf2sY+yWt00byh3cDEYZUx95uo4Nexa/wDGjS9N+F+k+N7CGfV7HWlsv7Ls7UgTXUl0yCBE3HGSXqp8zXKQ46o4e3/ZcuodXvtbHju/Pia41hNch1RrOLMM62YtHUJnlGjAGOgHApNC/ZH0/S/D+rab/wAJJeXYv9FutIkuJI1DMJ7h5zIQBgkeZitXWf2iLvRYrKOTwBrT+IZory5n0nzIRNb29syrLKX3bHQF127Gbd2rJsf2uNI1jXpY7Dw5qt1o1vdWVpPrQmhEUb3cKTQjZv3nIZR92lq/w/HQlySXMdBffs36ZqWs/wBpNrN9EPtGn3AijiQjNpF5UfUH7w5qhffsq6TqGkaTp7a3qAj01b9U3RoVIu/v4BGBt7V5/wDEb9pe+uvFOhf2da6zpHhWQaqr6hG1u39oiGLBEWSduzkgnFRW/wC0Rr8njD7DqFjrdv4VEWkNa6nbz2hmJuEyvnL0O89duMUlqk+5rJNRv0PQ5P2Yre51rR2l8UahLoul3Vrew6a8QJWaCPYCtx94A/3Bhfak8G/sy2/hW+Etz4ivNZtYNM1DS4IpYFUxRXFwspUEcnaV78nPWmN+1VpEV3M0uiamdGmjum0rWPMgEWpSWys00US7ty4KNy3Ws1P2wNNXT5J7zwlqem38kdhcadYXEsCtex3mRC+8vsj6nO+k9V/XW6I5eV27EEP7Igk0XV9Nv/G19dw33htPDP8Ax5xKtvbxMWhYBTy6hjyfvfxZrZ/4ZrkjvbvVI/F13H4un1weII9ZFnEDHc/2dFp8g8rOCjxRFsE4BYEcqDXpvw/8Xf8ACbeGYNVNjNpMu50ns7wBpIZELI3zDhxkcOOGXkV1jQowwQcZz1P+cVcnJN/11uTHa/8AW1jwKw/ZR0fT9J1ywi1a5ibWdHj0ieZYkDMyzzTtO3HLM0ueTgduDW7+0lbix+BtxCRv8q+0kN+GoW3+FeweSnzcfe68+2K8o/aiYr8GtTYdTqGlD/yo21Lmk9GWlqbPxJ+Ftp8RL7S7m5u5rU2AuVHlwiTcJofLOMjtXC6t+yzpus2EFjJruoBItBXw+0ojQPIqzLMJTxgsMBfwqj+1V4wfwpq3w/t7nxxe+A9B1G+uIdQ1CxkSNygj3KuXRwOf9mmyftDaX8NdJ0G3Q6t4x8NyLGG8ZXFzbrE3mSYTqVaXA+95SHFKHl1Lle1/63NPWv2Z7W/16bWNO8QXui6sdVGqQ3UcMTiNvs/kFQrZHI5/pWRpf7IWmaf4N1/Q5/FN/Ouq6UdJlu/KQNHEZpZi3TkkSkHPXNc94X/aK1ifxVqw8WWuoaRpmneLbrT7S7tZ4HhlgS237JVBZgPcc+9dJ/w19p8MN9LqXhLVtMittFXXrbz5oT9stXmWKMjDfKWLKee1NXun/W3+RnN2jd/1r/mdVqn7Pun6p4g1HVW1S4D3niDTfEe3yUO2W0SNFTOOQyxoM9RjjknOdP8Asx6Ndafb2dxq15JbLq+tanLHtC+YNS8/zYjjn5fPHPX5ad4z/aS0/wAL6/qWiQ6LeajrUOqRaXDaC5ht1uZGtftW4SSEKgVODk89q7/4d/ECz+JXgvTfE2mrItpfxsRFKQHjKMVccZB2uCuR1xUxuk79/wCvwE/jX9bXPH4v2Rw1nq1tfeNdTv8A+0tGtNGAa0hURR2s/mW7hRx8h6j+LrWj/wAMzypeTazbeL7y38WSXUl2NUNnEx2vbpE6eSTjBEad+3uSfNE+IPiLTPEOo6zH411W/wBTh8dT6NB4W8yCS1ltQzARiJQGXaiht7PjIr0HVv2xNA0vwvpustoWqXP2qxW/ktYGiMtvum8oRsN3XdVR95XX9bP9RT0bXZv9V+ho2v7K2h6fpGradaaveQLqWiw6U7KBwI23GU+pZuea9M8E6RrejNqkOo3C3FosyixOF3GERgYO0D+L8a8tb9rDT7fXodNvvDGrWBjuILfUZZ5YEFjJN/qkZS+58/7ArJ8XftV6LdaP4m0yGx8QadqOkRSHU/sAhS403ZKiDBY7TvySuetNXkNqx9LHtS14zY/tHQH4o6d4K1Hw7qGmS6hLJbWd/cSRYnmiiaSQeQG81VwhwzLhu1ey1FmtSutha8l8Vf8AJzXwz/7FjxH/AOlGkV6zXknion/hpj4af9ix4j/9KNIp9bB1sUPiB8AtS8Z+ONX17T/GNxoEGsabDpWpafDYxSGaBGcnbIWyhIkcZHPPsKjn/Z00+HX2udH1690LSbg2zahpdoiqt39mxsy+Nw6DoRnvmuK/aZ+KXifwr8RvCVt4d1SbT9J0TytV8RJAit59vNMLZEYEHgHe1dhqH7T1jpnjS80Z/D2pvpVpqsek3Gu+ZB5MU0kW9QE3byMf7NEJc0FNdSft2/rv+hP/AMKM0vw3a2N9Jd6jfx6Tqd3rJtorcPJcidcNARn5gBx/hXDfBv8AZ0u7f4VwLNcXnhfxHJr02u2Fzc2wlubLLkKjoSeNhI2k7eelb0v7XWl2Gl6nqt94W1W102Oyn1HTLnzoT/asETYYxrvyp/66baTUv2utJ0mRUv8AwxqllbwwQ3d+1xNah7K3nGIZJIvMDMG/urk01+Yl8P3/ANfibHgj9myz8K32m3UmvXmqy2q6kWeVFUzm9cM/T7m0qMbcVzEP7INuuh32kX3jK/v9Jm8KXHhGG1e1jVbS0k24KkNkumxeTy2OSa0fGH7UmiLN4l0O3sNWTVdLtrya8W18oT21rHFvF2Nzbdr5CrkHLEDsa0Lz9oqDw94l8M6NeeHdTGm6w9nZw61cSQqHuJ0UpiLO5x8wDOgIDHFTG900XL3VzPvf7ncgb9muWaW71CbxbeN4nlv7PVINb+yRhobm3szZiQRA4O+Nmyp456Z5qOy/ZN0ew0/XIjrd017rmhXGkXtwqKpnmnkklmuGAHVnmJ29B2xwK95ESugz1we5qbyl4JHIGOv0/wAKq7u2TFvT0RxXgjQNY0PVb63urzztDhtLO205dqg/JFiQnAzy3rXcUwQoFIxweepp9LfUaVlYK8l/as/5Nt+I3/YHuf5V61Xkv7Vn/JtvxG/7A9z/ACoGetUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB5L+z3/AMefjn/scta/9Ka9aryX9nv/AI8/HP8A2OWtf+lNetUAFFFFABRRRQAUUUUAFFFFABXkv7SH/IleHf8AsdPDH/p6s69aryX9pH/kSvDn/Y5+GP8A09WdAG546+Flp448Q+F9Uu724g/sX7UBbwAbZhPbPbtn0wsjHj19hXkdv+x6q20VtdeMru5t4NGtdDij+wwxqlvbXCTwFQp42kODj727LZwK+lzCrIy5bDdcMQemOD2pfLX0pRvFpoR8/Xn7LEa+TLpXiu90jUY7vVZ/tUdskh2X8nmTRYbI4PRuo7EVo+FP2Z9G8N+GfEOkzateahbaxp9rp0skiqPJWCLaHUDjJPNe2/Z49zHbkscnPPOMfyp3lrx7ehxQ7uNg3km+lzz34Z/C+f4fjUJb3xFeeJL68SOLzruJIFVEGFUIg2j3OMnvmvRabsGCMYz1wadT3BKwUUUUDCiiigAooooA8m+H/wDyXj4s/wDXLSP/AEnkr1mvJvh//wAl4+LP/XLSP/SeSvWaACiiigAooooAKKKKACiiigAooooAK8l/ZQ/5Ns+GX/Yv2X/ooV61Xkv7KH/Jtnwy/wCxfsv/AEUKAPWqKKKACiiigAooooAKatOpFouI8T/Z3tpdQ/Z10e0tZ4rWe4F8kEjxCRFb7XPyVJIP0NeYaV+yl4u+1Wl3eT+G9JePUNPuJrDRZZ/sty1vP5z3ZRo0CzMONigL/t1s/AX4F+D/ABF8JNP1jUpfEaXVxLey3Elv4r1W3jOLyfJEcdyqL3+6BXd6f+z78P8AWdNS70++8UX9ncDzIpo/HOtPG4JycH7Ye/pRG8XdF35Vc8oj/ZO8UWdxZXpsfBuv3em3OrwWsGtRyTQPa310tyJWVoSPOjYBAvRlGN4FeueN/hLqOsfCjw54e027tBrfh250u8s7q6txHbSXFnJG43RxJ8iPtb7gG3Ixip2/Zi8D7QvneL9o3YH/AAnOt8Z6/wDL537+vepB+zJ4I3BzP4vZwMZbxzrZJGMYObznj1qudv3n0dydJM4fUvhH8Ubu8s/FY13QrrxhNY32m3tvPJMlna29zIsiRwyLEHk8nauN6IWxyUyayfDn7J+qeGPC+o6FZanataS6zpOoxPOXBEdrDCjKQByxMZxnge1drq3wH+Gmg2882qav4l062hiWWa4vPHusRCNW+QMZGvcY4Ocnmtc/sx+BZShMvi1tn3QfG+t4+uPtnX3pRly2t2S+53/O5LV42e55NrH7MvjrUrWy0KG+8Op4c03+0fsUzSzm5k+0jC+ZGY9owOuH596n1P8AZn8U3WtadLaahop0uO30lLz7Q8ySxvZjDGILFg7h03bcdq9Nuf2cfAdnbNc3F74shijUO0zeN9aAAHTJ+18/jWfa/A/4a6jcXtvba14ku7uyCSTwxePtYMtvxuXev23MfHrjPep5nypPoXzO1v63OGb9mfxNeWcGjzanojeHtIkv5dImEsv2mWW4DgiVdm2MLvf7rPnPPSruvfs5+KJbhLy2uvDl6raFpmlT6fq9sZbe7e3Pzo3yZCN2kHzDsor0Ufs0+ChJ5gufGHmYx5n/AAnOt7h+P2zOfekX9mTwOigCbxdtVtwX/hONbIB9h9spNyW3kEm5Suy38EvAuo/DX4ew6NqtyLy/W4nn8u2kd4rdZJWdYIml+YpGGwoboBjpivR/OHt/30K8uT9mXwRGxKz+Llz6eONbwPp/pnH4Uf8ADMvgf/nr4t/8LbWv/kyrbcndkRVlY9R84e3/AH0K8l/adcyfBnUAQSDqGkkyYCrzqVsM8nsOas/8My+B/wDnr4t/8LbWv/kyvMP2jv2efB+ifCXUbq1l8UGZdQ04AXHjDV50w99bI3ySXTLyvtx1HPNC3K1PW/H3w7l8ZePPA2sjyDaaHdzzzRzK26QNFtHGMferyr4zfs6+JvGfjLVNV0ceHbm2uvsP2aXWfN86waA5KwhYnCiQ9SMV2l18Afh5pt9a2k+reKIbm8Jit45/HWtebKVG4hM3mWwKj0v4F/DbV1kGma34lvfsUzW0n2Xx9rJMbjqjEXv3x79Kzi7JPt/mipfCcB4g/Z18SaprGqXN/d6P/YUutXGvGWGSZroh7PyJIzEY9pIb5h89ec+A/Deu/HWTXdGs9W0O4h07wYuh2+p2K3BhjnE6NGl2rxqRJiP54xnZjgmvpw/s0+Ccf6/xd97d/wAjvrfXGD/y+fpQv7MnglcYuPGA+bdx451vrz/0+f7R496uMmnb+trfqZ1Iqa5f63uePa1+zF4w8S+JtQ8W67aeCNb16XW4tUh0fURNc6bIgsPssiSu8JIKj50ITjp0r2H4c6Lr3gOTQPCbwWN1p1vpU0t3dafbC2jiumnBCoiqqhCHfphv3YJ5Jy3/AIZl8EbXUyeLNjNuK/8ACa61g/Ufa6bcfs3+B0hld7jxdtVvMb/iuNb5bB5P+me5/Opk202/60t/kNJaNf1qN+FnwR0nwHrniTXLzSNJuNd1TXL7U4tUiskN0kc7llQy7NxwCR174rwTwB8GZviVF8XLvQ9YtLnSNQ1uBNC1Dc4iFtDcx3E0YIycb/MTOO/WvbtH+Avw48R6XBqGl6t4n1KxnQTw3dn471p45Ay4BBS85GKgs/gf8NNViuruy1nxFcwwSOlxPb+PtXZIJFJDK5+2/Kc5z+tWpcjbXT/gA5Ozt1/4LOf179nHUbz4taj4gsLHwlNY6pcWt5cajqGmibUYGi/gg3RlQH9d4K9sVg69+y34x1J/G1/HrelHVfGdu0eqRzGbyldHBtzHgfwoAD9M+9ejaX8Afh34g0+G803VPEmo2bIRFNa+PNZkiYEc4K3hH5dK00/Zj8Drn994uOSrYbxxrbAEdMA3nHvjr3zQpSQuVatdTzDw1+zb4s0P4r+G/ETSeGZNO0jVbi/k1IeadSu4ZoGj8pm8raFj8xtqhsc8bcCvqHzh7f8AfQryz/hmHwMWDeb4u3DOD/wm+t8Z6/8AL537+venf8My+B/+evi3/wALfWv/AJMpXdrMfW56j5w9v++hXkviyQR/tN/DRNzNI3hfxEyKFGSBcaRuyc9eV/M1Z/4Zl8D/APPXxb/4W2tf/JleYeI/2efB9v8AtCfD7TUl8UC0udA166kz4w1cv5kdxpm0iQ3W5R+9fKggHIyDtXDDqbHj/wDZXtvilr/xG1nxNcbr3WraPT9Gez1C6hFnCkRCNIkbKrESs0nIPp04rNs/2a/FF54duLDVtS0sz3Ot2WozSQNJh4oYBG6kbfvt6iur1T4I/DLQbnTLDUNX8RWlzqcrW1nDN491eKS6deTGoN6PMb2FZup/DT4L6H4itvDeoeMtQ0/Xroq0Gl3XxG1OK7kPUMkTXoZyfUA9uKzj5bf8Ff8AAFvK/b9VY5S9/Zc8X614fi0nUtU0dbfRrK6sdFngeUzSieTJe4zF+6wvGF3itbxp+zHqOvePG12wtvC1015ZWVlPd6tYrcz6Ybfjfbb42DH67Kj0vTP2d9a1630Ox+KEl9rk8v2ePT7f4pak91JKePLMa3+4sf7mM+1devwF+GcmtXWkpqfiN9XWJZJ7L/hO9YMyxt/Fs+2bufX6VcXs/wCt3+rHH4Wv66L9DifFn7NPirXvE3i3X4te01NY8TafeaJqCShxEtl5f+iCMBesbkEjGDvbrVK//Zk8Xz+M4dbik8MX5g1bSdYhv74yteQi1ihSS0R/K+WFjGZAynk9RivWz+zD4FZVBbxUyqMAN401ogdc4/0vgnPJ6nj0FKP2Y/A2c+b4uJzuyfG+tnnsf+PzqOx7UoScdAesWvX9D05ZACvTp6ipPOHt/wB9CvLv+GZfA/8Az28W/wDhb61/8l0f8My+B/8Anr4t/wDC31r/AOTKd2Pokeo+cPb/AL6FHnD2/wC+hXl3/DMvgj/nr4t/8LfW/wD5Mo/4Zl8D/wDPXxb/AOFvrX/yZQB6j5w9v++hXkv7VDN/wzn8RdxJQaJchiFAG7HXk1Z/4Zl8D/8APXxb/wCFvrX/AMmV5h+0t+zx4P0f4C+O9TtpfFBu7XSbl4jceMNXnQHHUxvdFW/EGgD6g84e3/fQo84e3/fQry7/AIZl8D/89fFv/hb61/8AJlH/AAzL4H/56+Lf/C31r/5MoA9R84e3/fQo84e3/fQry7/hmXwP/wA9fFv/AIW+tf8AyZR/wzL4H/56+Lf/AAt9a/8AkygD1Hzh7f8AfQo84e3/AH0K8u/4Zl8D/wDPXxb/AOFvrX/yZR/wzL4H/wCevi3/AMLfWv8A5MoA9R84e3/fQo84e3/fQry7/hmXwP8A89fFv/hb61/8mUf8My+B/wDnr4t/8LfWv/kygD1Hzh7f99Cjzh7f99CvLv8AhmXwP/z18W/+FvrX/wAmUf8ADMvgf/nr4t/8LfWv/kygD1Hzh7f99Cjzh7f99CvLv+GZfA//AD18W/8Ahb61/wDJlH/DMvgf/nr4t/8AC31r/wCTKAIP2eXaTT/HrAH5PGesjhcZP2jtk9DXrHnD2/76FfMHwP8A2efB+s2fjP7VL4oPk+K9Wtk8nxhq8WI0uPlHyXQyR/ePJ7k16d/wzL4H/wCevi3/AMLfWv8A5MoA9R84e3/fQo84e3/fQry7/hmXwP8A89fFv/hb61/8mUf8My+B/wDnr4t/8LfWv/kygD1Hzh7f99Cjzh7f99CvLv8AhmXwP/z18W/+FvrX/wAmUf8ADMvgf/nr4t/8LfWv/kygD1Hzh7f99Cjzh7f99CvLv+GZfA//AD18W/8Ahb61/wDJlH/DMvgf/nr4t/8AC31r/wCTKAPUfOHt/wB9Cjzh7f8AfQry7/hmXwP/AM9fFv8A4W+tf/JlH/DMvgf/AJ6+Lf8Awt9a/wDkygD1Hzh7f99CvJf2kGb/AIQ7w4SxRP8AhMvDQK7QTu/tmzC9+mQfwPtVn/hmXwP/AM9fFv8A4W+tf/JleY/H39nnwfo3hPQLi1l8UCV/Fnh21ZpvGGrygxy6raxOMPdEZ2McN1UnIIPNAH0/5w9v++hR5w9v++hXl3/DMvgf/nr4t/8AC31r/wCTKP8AhmXwP/z18W/+FvrX/wAmUAeo+cPb/voUecPb/voV5d/wzL4H/wCevi3/AMLfWv8A5Mo/4Zl8D/8APXxb/wCFvrX/AMmUAeo+cPb/AL6FHnD2/wC+hXl3/DMvgf8A56+Lf/C31r/5Mo/4Zl8D/wDPXxb/AOFvrX/yZQB6j5w9v++hR5w9v++hXl3/AAzL4H/56+Lf/C31r/5Mo/4Zl8D/APPXxb/4W+tf/JlAHqPnD2/76FHnD2/76FeXf8My+B/+evi3/wALfWv/AJMo/wCGZfA//PXxb/4W+tf/ACZQB6j5w9v++hR5w9v++hXl3/DMvgf/AJ6+Lf8Awt9a/wDkyj/hmXwP/wA9fFv/AIW+tf8AyZQBB8PWZvj18W/vD5NGGwqMjNvJ0Oea9Y84e3/fQr5g8C/s7+Drn40fEyxkl8UG3s49LaHHjDVw4LW8m7Li63N/wInHavTv+GZfA/8Az18W/wDhb61/8mUAeo+cPb/voUecPb/voV5d/wAMy+B/+evi3/wt9a/+TKP+GZfA/wDz18W/+FvrX/yZQB6j5w9v++hR5w9v++hXl3/DMvgf/nr4t/8AC31r/wCTKP8AhmXwP/z18W/+FvrX/wAmUAeo+cPb/voUecPb/voV5d/wzL4H/wCevi3/AMLfWv8A5Mo/4Zl8D/8APXxb/wCFvrX/AMmUAeo+cPb/AL6FHnD2/wC+hXl3/DMvgf8A56+Lf/C31r/5Mo/4Zl8D/wDPXxb/AOFvrX/yZQB6j5w9v++hR5w9v++hXl3/AAzL4H/56+Lf/C31r/5Mo/4Zl8D/APPXxb/4W+tf/JlAHqPnD2/76FeVfsoEN+zb8Miv3f8AhHrLH/foVJ/wzL4H/wCevi3/AMLfWv8A5MqL9k1Qn7NXwxUcD/hHrL/0WKAPW6KKKACiiigAooooAKSlooA8N+B4/wCMX7bt/oupHg9/tE5r5y8G/ELx/oPw/lvNI8XXGj6P4U0TR7tNLTTrWSCUzPMJYpmaIyfMEXlGBGOMV9P/ALNFpFqH7P8AodtcJ5kEzX8TrkjKm7nBGR7VqWf7OfgOw02+sINGdbS+tbezuEa+uGLxQFjEuTJkbS7cggnPJNKnePNzdQlrFo+bfEX7THxH0O28R2Fref2nqvg601q41R1tIG+0MJok05XAUDBWcH5AmfKOc81pN8SPjRa6beaNLceJYZrfWrPzrqceHpPEhsntpnmW3tIGe2fbJFGyllMjRySBVYqGH0fN8DfA1xq3izU5fDdrJe+LLeO01uRi5+2xopVA67sAgMeQAenPArDT9mnwEmhrpAttSMq3Yv11JtavW1FZxGY1cXhm88ERsyDEmApKjjir0tb+t1+guq+f5f5nyvqnirxFPrOs/EOD4gX19fw/D+3uQy6ZZx2rSfbJocSwTW29GVkLMpORIXXO0AD0bWPi149l1a38Qw+LJtD0mLxiPDsugmwtXge3SJwzyO0ZmWR3AbKyBdvAUda9hv8A9mP4d30FrCdLmght9PbShHbahcwrLas24xShJB5wLZb95uO4lupJPnXij9mzVvFPxes9Sm0zT7Tw3BqserTXEGqXReYpbmJYzZH9wZOSPtGd5BwVIqe39fav+Qur/r7NvzPKde+Injnxb4d8Z6Le+LfEU+g3/hmXUrTUbqx0yxfck20G2iSN3SFhwFnZ5D2YVu+GfiF45tvF1l8ObPxhf232z+zYYtdk0+xa6to/sfmOqgQCJnbp86HHavedN/Za+HGkzSSW2mXQL2cmnlZNVu5EFu7bjEFaUgKDyoA+T+HFSL+zH8PxptzYmz1B2uGgZ7uTWb17sNCu2MrcGbzUIHGVcZ75qtLO/wDXvX/ILf18l+p8/wD/AAuL4l+ItQksU8d3mjHRdD1G6mmsdMsCNSntrlEVn86F9gZSQdm0HttrpPAfxl8e618SfDtx4h8QyaZomsTW8dpa2tnaTaRdiS2R/I85Fa4hu9xZtkjqu0pgc17jYfs/eBtLSJLXRRCI9Ol0kbbmbJtpXDyox3/MXYAsxyx7mq2k/s5+CND8S22t2Wm3EV3bmJoo21K6e3V40EaS+Q0piMgUBfMK7yAMk4ppq7/rq/0FNN2senLS0lLUdSwryT9qX/kjOp/9hHSv/TjbV63Xkn7Un/JGdT/7COlf+nG2oA5T9o2bxFbfEX4TS+GdN0fUtbW+vDDBrN69rbj9zjPmRwyuOD/crxTQPG3jfSND8TWljqGo6H4t1DxPqlxPpvg62tb95WRMttnvkVI40I+Y+Tvf+ELX2lrXg/Stb1nRtWv7Yz3mjvJLaS+c6iJnXax2hgGyP7wNcBdfAH4beN1a+S0mu47u7uL17uw1OeMSSyfJMC8cgJRu8ednHSlHSDTLck48p886H+0L8XvF1zY3umx38sWmWumS3It/7Gg0y7aZnM/2t7mZJ0yAFT7P0xzuNbOm+Pvidr3ijRYl+Jl7Y2WveINb0poINK09/sUNossiNCWgJZ8xlN8hZCvzFc817Zp/7Lnw40mTTWtdJniTT0jjht/7SumgZY2LRiWIylJdhJ2+YG29BgV0lj8F/B+m32mXltoyxXGm3tzqNq4nl+S4uFdZnI3YYsJHGGyBngDAq+aKm9DGV7O2/wDwH/wD5eH7QHxF8TfD3UvEcHin+wZvCfgSDxVdRxWNtLBrNwzXOYpGeMlYytrjEPltulB3YwtbOofFrx1r+qad4itfE82l6LfeNJvDcnhl7G2MItoreb5y5j84SNIgdj5mAuwBRkk+1Xf7Mvw7vbHSrOXR3+yaZarYpbx3twkc1urblhnVZAJ4ww3bJd65ycZJNeea9+znq3iT43WmvXGmadZeHrfVxrH2m31S533BFs0PlnT8eQshDFTcBg5GAVIAxF1dL+t1+htOUfsrT/7W35nkvwz+InjG0+CenHQvEMuh2HgvwVpeqNYrZW06arLKZGZJGljZgNkW1RGUJZs7u1TfDfxr4s8I6dN4ns9euH0vXvGOrWMvhyW0g8qMusk3nqdnmMQwH3nK7f4a+lZf2Y/h3LaaPbf2VMlvpNpHYRQx6hcoslvG++OKYLIPPRW+YCXeM81Nov7NfgDw/rtzq9npkyT3E09w8Ul/cSW4lmz5kiwtIY0c5I3KoIHAIHFbVJRk5W63/Mz6f12t+Z8z2fxo+JNx4Z1TX7XxfPbWWhWOlyf2YmlWYhnlmfEiyt5O4Aj/AJ5kY7Yr7ltZGmtoWJyWjyfrgV57F+zv4Eh0m80xNGZbC7hggmh+23GGSE5iGfMyCD3GCe5NejxxLCiogwqjAHtUNroNbW/rYfRRRUgJXkvir/k5r4af9ix4j/8ASjSK9aryXxV/yc18NM/9Cx4j/wDSjSKaF1Pm/wDbG8VadffFyOWS11W5vfAdja6jZSWekXd7FDczXJ81mkgjZIm8iPq7LgMCMHBrqPEl1ZaHqPiTxW1jpPjfwDqmrWl3qLQ3MlpqekXX7tAoK/6xQ5LEBgRkg7hX0DfeD/Buk3mtwXrW1tc+NJTBeRXd62+/YQiELGHb7wjVRhceuMnJ4q4+D/we0Ga71Oe6g02z0h4TqEM/iCeGxSSLBje6gMwidwAMNKueM5qKbSWv9bClvoTeE9KsD+0n4qxZwZTRLJ0/dj5TnqOOPwriPjZ8TPGmg+O/EWj6Fra6KAmjJbSfY7eYxia58uXJeNt25eOc47Yr1vwV4q+G3irxdfaz4U8R6DrWt3FpFFcSaZq6XRMC/dBVJCox6gZ9an1L4ZeCvH19da1Jaw6rdXRgjnngv5CjNbvvj+42AVbnjr3zQ94/1uVT0T5jwbw38SfiL4o8fXfw1PjrUbJ9O1W/R/FUOmWDXU8EEEEiRsrQmDJaYklIwSq4G0/NTfFHxg+Imhn4m6/YeOrTxDpfhDw5p93Z2+m6fa/ZNSup4Zszl/mYJ8iybRLt7bsZFe2+IP2cPAXiV7yS802ZJ7rUn1aW4tdQuLeb7S8Qhd1kjkVkDRgIyKQrAYINblv8F/BlrZatZx+H7cWWq2EOl3lqWdopbWJGSOLYW2qArsPlAPPJq+ZXtYh3ex82Q/FT4mQ28vhnUNd8YWOqXOoWy6bI9h4en8QXSPbSSyoUgd7O3iXy/M8yZN/lttCs2GrLsv2gviTqHhDwR4i1TxLdaLozaRb3Wo6lpmn2N0v2g3Lox1GFkMsUDxquJIFTDh87FAFfQo/Zl8Af2bDZG01B5Ybn7XHqD6zetfrJ5flHF2ZvO2mP5Cm/aV4xiq9n+yt8N9Pt7KG20y8t4LRfLjij1e8VGjDlxFIomxLGrE4jfcqgkAAHFTHT4io6J3PLPhR8aviX40+I2m6hcRal/wAInqOrXumypeHSbfTI0iz5bWuJPt0kvHIcEHsFr6w3OYxgrv8Afo1ecWH7P/g3RvEmo6/p+lNa6jctI6CO8n+zwvJ/rHig8zyonbuyIpPc11Pgvwy3hLwnp+kGeS/ezXaZZnLM/wCJp3T2Ek92dHXkv7Vn/JtvxG/7A9z/ACr1qvJf2rP+TbfiN/2B7n+VBR61RRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHkv7Pf/Hn45/7HLWv/SmvWq8l/Z7/AOPPxz/2OWtf+lNetUAFFFFABRRRQAUUUUAFFFFABXkv7SX/ACJXhz/sc/DH/p6s69aryX9pL/kSvDn/AGOfhj/09WdAHrVFFFABRRRQAUUUUAFFFFABRRRQAUUUUAeTfD//AJLx8Wf+uWkf+k8les15N8P/APkvHxZ/65aR/wCk8les0AFFFFABRRRQAUUUUAFFFFABRRRQAV5L+yh/ybZ8Mv8AsX7L/wBFCvWq8l/ZQ/5Ns+GX/Yv2X/ooUAetUUUUAFFFFABRRRQAUUUUAeS/st/8kK8O/wDXa+/9LJ69Z2/X868m/Zb/AOSFeHf+u19/6WT161QAUm0elLRQAm0elNMSllOMFemDin0UAJtHpRtGc45paKAE2/X86TYNu3t9adRQAUUUUAFeSftSf8kX1P8A7COlf+nG2r1uvJP2pP8Aki+p/wDYR0r/ANONtQBT+NHjLxDb+KvB3g/w5rKaJca99rkl1I2yTsq28YYoispXknnIyO1fMXw5+LXj3QPA3hvwz4Sg1Kb+z9NudSnuNN0+1miuT9rkH78zsNkWB95MH3r7G+KHgLwx4y0m0m8R3cmkwae7SxX8F59jeAsMMPMBGNw4I71xumfs2/DXUNE8OxaU00mm6dA8FvLp2pkrdwM5dkmZTiSMMSce/wCFXG3K0yptONluch4P+J3j7xZo+ueMZ/EtnodhY3FxaL4furS3ZH8u2SQGOUHc0hYk8krtP3a4hfjR8WF0H4b2C63qGt634o8OyeI57vQtGs3NuEWBRFtlKr5RabczY3DHBr35P2b/AATH4kl1lLK6SaWQztYreOLPzSgQyCL7ofYAu4DdjvSa58A/BmreHfDWkOt3p9voFuNPsbiwvHt5fJ2BDBvDbmVgBlSSDip0l96+6z/WxMLR+Ls/vPDG/aJ8dSeKPCV+mozTWVxqGi6XrekWtjbGws5rqCN5ka5+aR5R5m9TG3llSnPJrL1D9pTx94L0nXv7b1CeTxBOscdpoI0+2CwGTUYbeOaydcC4jCTjPmt94J6nPuEX7NPw+1bUINQ09bm1t7a7tpobXR9TaK0juLTy0ikEaEKJEEKqeOi7e2Kk0/8AZp+HaXGrWSx3OoKtq1ilhdam0qabDI6zbLaPP+j/ADIjArggqCCMVSst+/4WX63Dq/Rffrcm/Z78YeMPEOm+JbbxfDeibTdQFtbXGqQW1veTxtEjhpordikZG70HykGvZSoZcEcV5Zo/wTsfCt5os2iXt3HHb376hfzXV1LLcXhaDywJGLZfoPvZwBXqXPrUyavdERvsxdv1/OlpvNOqSwooopgJXkvir/k5r4af9ix4j/8ASjSK9aryXxV/yc18NM/9Cx4j/wDSjSKaF1PnH9snxZpFz8WrCe4muvtvgSys9Zg2WE08SyS3BEgkeJGEZ8lD9/bjfkdjXtvwNksfFHiT4qme3iuLC+1WJmt5AskZR7dDjIGGGSa7q6+H/hOxvvEsd9JGJ/GchS9hvLgA3GIhEEjUnsgHA+vUk1xOi/s6+A/DfiiO+0vxDr2n3Mc0cbWkHiCRYWlRAEVot2CwUDgj/Gs4NctvJ/oZzTlJcvRjv2T/AA/pml+Ar+e00+1tp21a8jMsUSq20SYC5Azj2ryax+LHj3Vvslhouvw6FC0OuahLcWumwSA/ZpysS7XjIG4H0r6s8IeDdN8D6U+n6TCYrZ5pLhlZ2bMjnLHJJPJ7dK4fR/hT4B0/UUWxnD3+L+2ECagxLeefMuEKbuCOv+z7UJPmXkbxlGMJcx5p8J/i147+LAi8Rt4psfDemaaumxXGlXFjD5N7JNBHLKGkLeYjN5u1AjABlwd1cha/Gj4t3nh/wg41vUdQu/FN1qkgbQdFs5ZbO3sppFURibbG5lBTduYkKmRgkk+6237M/gfT9X0W/trS8ik0qK3igtPt8hhnW3GLcyITh2j/AIWILDrmruofs9eEr7w5pmjpBe6dDpck8tld2N9JHdQtMztLiQc4YyPkZxg4xgADW8XqjPY+f/Fv7RHxItND8LatDd3FprFvY6NNrejWemW0lmklxdeTM1zOzM21hygt2yO+6rXiT9ozx34H8QeMLvVtSCCxXU2sNDk06NrK5jh/493t7pAG3D/lqkrAjtivX9e/ZV+H+u2sdsbW806yTT7Sw+z6XqElvGUtW3WxKqcM8Z5Vz8w9avf8Mz+CBqd1dTWV1cxXDXD/ANmzXrtZq0/+uZIydqs/cqAaUrO1i+ljA/Z38feOPEF1r9p4vj1T7Nbw29xa3WtW1lbXTNImXQRWzkBAfulhk9zXvPljCjnC9ME15Pp3wF0/wzZW0ehXuqx3Taja3lxf319JcTyJEMCNmZiSoH8J4r1qm7dDON1uFeS/tWf8m2/Eb/sD3P8AKvWq8l/as/5Nt+I3/YHuf5VJZ61RRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHkv7Pf/Hn45/7HLWv/AEpr1qvJf2e/+PPxz/2OWtf+lNetUAFFFFABRRRQAUUUUAFFFFABXkv7SX/IleHP+xz8Mf8Ap6s69aryX9pL/kSvDn/Y5+GP/T1Z0AetUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB5N8P/wDkvHxZ/wCuWkf+k8les15N8P8A/kvHxZ/65aR/6TyV6zQAUUUUAFFFFABRRRQAUUUUAFFFFABXkv7KH/Jtnwy/7F+y/wDRQr1qvJf2UP8Ak2z4Zf8AYv2X/ooUAetUUUUAFFFFABRRRQAUUUUAeS/st/8AJCvDv/Xa+/8ASyevWq8l/Zb/AOSFeHf+u19/6WT161QAUUUUAFFFFABRRRQAUUUUAFFFFABXkn7Un/JGNT/7COlf+nG2r1uvJP2pP+SMan/2EdK/9ONtSAzfjTAmufEv4a+Hb+0S+0a8urma5tpTujdo49yB1PDDPY8Vwmqa5L8OvGOleE/hjrVnZaPczanfalbmAXP2aWGPzHihXGI1PTbwB2Fe4/EXwLo/xC02yttRvrjTrmKdbmxvtOuEinjlAwTGzAhuDyCpHtWL4d+Bvhfw3dabeW7Xcl5ZfaCZrqcO9yZh+9Mx285/TtijV7CueE+DP2kvH+raPqes6m9xpejT6TNqFrqeqaGYLa0kEmyOMEPuuNwI+6B83tXPaz48+IfxG0/T9PvfEUul6hoXjzTLMT3WjR2080cqIU823LnDAseBwc85r32H9lfwUunalZvcatfWl/avZwxy3ikWcLP5jLb/ACjb8/zZOSD0IqFf2V/DP2PVIn1bxC82o31pqUl5Jdq1z9ptwAkm4ptyQBnIx9KcWlK78vzQqkXKnJLdp2+48L0/42fEZtJ15tB1PRdMj0fTPFGtlY9OQi7kstUkjReWO3euQ5GMZ9a6C8+Mfi7UfiadJ0Caz0CfWtd020udQSwW5kS3l0J7tic/eKOowT9Olev2v7M/hDTrTULaP+0THqGmalpM4NyctDezme5YccNvJII+nSrdv+zx4St/FFpr6Lc/b7XUIL5EM/7sPDZGzTPHIERJweC3Wr5ldvp/wWWn+8d9nf8AJfrc8Av/ANqD4g6hp+maXpcc0viGzsL261C40zR/tn2l7a6eBFkQFRAGMLFmyQN/GOK+vvCWsXeu+GdL1C7g+y3V3bRytD12MVzXmWqfs1eEJNJtoRc6rpttZi58ySG8ERninkMs0MxKY8okk4GMZNep2Mdpp9ta6dC+F8kiGPzMl41CgkEnOBuXnNLSzbM435V8zULU6mdSKd2rKJYtFJnilqgEryXxV/yc18NP+xY8R/8ApRpFet15L4q/5Oa+Gn/YseI//SjSKYdT5v8A2zvHOjW/xb0qW/1F7C78D2lnrdjHskAuJZbgiRcqCp/dIeGxjdnrzWT8QviRH4I8Wan4xj0+71Ap4zWeKGzXeWVrDcPwzzX2J/wqDQXbxu0sVzK3i4Aap5koYOBEIgIwfugIAMfj1JNcx4d/Zz8G6O9tJZzXtylvfreAS3AmBkSLyQrcdhx604K0Wuv/AAV/kZVE/iR498RP2gvHHhnRdL1TT/EVlqsyW8F5e2em6O0iKss20CVyx8pAOFPU45z1rntE+IWo+EvGXjK5sE02K5fWtbuEnmtw0ivHYoykMQSBkngcHPINezXf7HPge5tLmAXWtWNldRiGW1s7wBGQPujUDZwEPIArdX9mfwet3cXDDVGmuJbiaVpLpW3PPEIpTjGBlQBx07VaaUWuuv4tDl8NvT9Dw3Uv2jfiL4R05NOv7/8At7V9XsNHubG603RgZLd7ttsqpBn9+Afu8jPevoT4D+MfEvizwXLN4qtJ7TUbe/ms0mvLYWctzGv3JXgyfLZs/czxWXq37OvgzWWeDzb61u4dOsdMgksrkLNax2zF7eVcL8sgZW5YFTjkHpXaeBfAen/D3w//AGZYyXU+6V7ua6vZRJPcTPgvI7dCxwO1ZtpX9b/LQpReifZfkv1OuahVC4Azx05NV1mZvLbcpVuvPHtj1zVmjyGndDREq9Bjndwcc0+iikMK8l/as/5Nt+I3/YHuf5V61Xkv7Vn/ACbb8Rv+wPc/ypgetUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB5L+z3/x5+Of+xy1r/0pr1qvJf2e/wDjz8c/9jlrX/pTXrVABRRRQAUUUUAFFFFABRRRQAV5L+0l/wAiV4c/7HPwx/6erOvWq8l/aS/5Erw5/wBjn4Y/9PVnQB61RRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHk3w//wCS8fFn/rlpH/pPJXrNeTfD/wD5Lx8Wf+uWkf8ApPJXrNABRRRQAUUUUAFFFFABRRRQAUUUUAFeS/sof8m2fDL/ALF+y/8ARQr1qvJf2UP+TbPhl/2L9l/6KFAHrVFFFABRRRQAUUUUAFFFFAHkv7Lf/JCvDv8A12vv/SyevWq8l/Zb/wCSFeHf+u19/wClk9etUAFFFFABRRRQAUUUUAFFFFABRRRQAV5J+1J/yRfU/wDsI6V/6cbavW68k/ak/wCSMan/ANhHSv8A0421JgZvx18bz+DfEXg57axsbm7uEv2Sa+tmkaIxQb+CDxk15Hb/ALT3xE0u30u01S48PXOpeItHtb7T5oLR4EsZZrlIMTK0hMgGSf8AlnX0j42+F+j/ABCutJvr+W4jOnicQfZmVVYTKEbdlSTx0xjrXH337MfhPVIbG3kudZV7HRk0e3uFuEV40RxIkm4JkyhgDk/Lx0pU/dvzGjcWtDmfFHjr4s+FfEfhPw2+qeFby51Ka8e61aOwm2yQRRbxiAPlXx28xh/tVxfgn9qDxxr1nqOr3trFZaNdaRd6jBfar4ev9P0/S3jkRI42uH3C6ypLZj288V7L4V/Z38PeFdatdWXUNV1jW7Wa5uZb7UpY3e8lnj2M82yJQTt4+QL61lx/soeEZrPU7W51PxBf2t1bT2dnFdXSj+y4ppBJItuRGCMsAcybyMYBA4q2Yq55RZ/tKfEa40HX4ygM+j+ILXT7rXf+EZut1lZz2YmFzJpnm+cy7ii/eXCvvPAqO7/ar8dX99a2mjaeNZksdJs9RvBoegXmq22pvPLIHiS5gG212pGT+8BOT7NXqsP7KumwX13qUfjjxkmvTXtvqH9sG7tjcRTR2/2YHH2fy2V4TsdGUrjBABANPh/ZM8HWYs7e1vtc06xW1hs9R0+2uEaDVooppJ41uC0RbiSWQ5iMZIYqSV4ojo9QlzdDq/jxM83wG8dymIbjoF8Wjcnp9nc9u/FfP3xC8UXngGb4a69prRvqFj4Kv5Io7pT5UjKLfaW9z719J+H/AAXP/ZPiLTdfuv7XsNTu7iSKB5NwS1kXb5WQFOMEjqTz1ri7H9l7QI7W/tNQ8Q+I9aglsjplml9cwONPtztykOyBf7i8y+YeOtL+bzv+TX5sNXGK7b/ejyXVv2jPijo+uQaLHbprerWtjaahd22h+Fr6+S4E4XEKzRFlgwpZvMfcM8YrqLb9oPxavxu0TQ5Z7G+8PajqcmnSQWOkThbZhDuCG+dwjyKfvIqcetd/4l/Zz8O+Kbqylkv9ZsoIrWGyvbOznjW31CGLBjWbMRY4wOYihPQnFUrP9l/QrDxjpviGx8R+IrT+z9SbVLXSVuYDZxSuu2ZQDD5hV14IL+4xQ7XuEdEk/wCtD2n+GnUlLS6lBXkvir/k5r4Z/wDYseI//SjSK9ZrybxV/wAnNfDT/sWPEf8A6UaRTA4f4pfGDx34f8feLotEutFj8P8AhjTLTUJ7W5s3lmu/MZ/MUSCQBcIA3I615p8LPih4k+Hs2qay8ulz+F9W8V6sstgtnJ9rt22vNuWXdszgAeXtx716x4i+Ad140+OHibXtWvdT07w7c6fp8JisLiJY9Q8lpGaOVSryYBI+7sJHGSK6u1/Z38L2MUEKfb3t4dWuNX8tpYyPMmBDIfl5iwWG3rVRl7tyW+ZOKPHtS/aE+KGgaXYTPY6bq0viKx+36cum6ZLK+nxiXDF0VyZysfzDGzmr9h8bviF4vm8KaVoms+GZrvUpL/ztUjspXWRLePzIgsHmjy5G/iDvxXaQ/sneGllkabxH4knuoIhFptw95CX0dA2/bbnyemf+evmZHHTiuc179mG4Xxh4RGlaxr1vaxS317rXiCK7txetPLDsDOCmxt44IWHA68VMXzMmesdDyjRfjB4ubxb48+I2k/2RGsOiaO+r6XcWjymXE13DIkbKQEGQGy27OK7u6+O/i7UviVdeGLPV9Hn0jVBqtrbXNnotyYLKS3tmdP8ASHkRJ33K29ECqv8AfNel/wDDL/hBtP13TYZdSisdW06y0yaEToVjitmdo3TKH5maRyxJOc9uKbpf7MOg6V4s07WrfxD4hWLT727vbXRHuIHsomudyzoFMBcozOxBLZXPykDAp1LNWXVMLyd/kfOnhj48eOvhj+z38M7mPxDpetXUfhPTdXubH+xrm6vJ4ZCColkEgjt18tWC3DsfMcOBGMDHpXib9prxZ4N8Za//AGv9jtdLsY7uW10a4s3guL63jtzJFPb3ZJinJ2ksiKSuRn7rV0S/sW+F10GTQ4/FPi5LJtLTRp0W5tA01nG5e2iZvs+cQszFDnJyQ5fNb037K/hXUNUe51PVNf1jTWee5/sPUJY2s1nmieKaZdsIlVmSRwUEgT5idmeaucoyk+XuzXTmfbQzP2dfjR4x+I2qanB4i0+4GmpY29/bag/h680pQZN+6H/SP9aVwPmUKK+gq81+GXwc034d399dRa1q3iC/nhitPtWryQyPb20WfLtx5aIMDJ5ILHuxr0qlJroQr9QryX9qz/k234jf9ge5/lXrVeS/tWf8m2/Eb/sD3P8AKoKPWqKKKACiiigAooooAKKKKACiiigAooooA8l/Z7/48/HP/Y5a1/6U161Xkv7Pf/Hn45/7HLWv/SmvWqACiiigAooooAKKKKACiiigAryX9pL/AJErw5/2Ofhj/wBPVnXrVeS/tJf8iV4c/wCxz8Mf+nqzoA9aooooAKKKKACiiigAooooAKKKKACiiigDyb4f/wDJePiz/wBctI/9J5K9Zryb4f8A/JePiz/1y0j/ANJ5K9ZoAKKKKACiiigAooooAKKKKACiiigAryX9lD/k2z4Zf9i/Zf8AooV61Xkv7KH/ACbZ8Mv+xfsv/RQoA9aooooAKKKKACiiigAooooA8l/Zb/5IV4d/67X3/pZPXrVeS/st/wDJCvDv/Xa+/wDSyevWqACiiigAooooAKKKKACiiigAooooAK8k/ak/5Ivqf/YR0r/0421et15J+1J/yRfU/wDsI6V/6cbakwG/GP4gL4H8QeFHazu7yS4S+dFh1OW0j/dQhzvQDbJx03g47V5za/th6jbww/214DTT7zU9OjvtHt4daSfzzJJsWKU+Snl8918yvVPit8KW+I2o6PdLqIsBpouldfsxmL+fB5Yxgjp7V5/q/wCybNqMOkmHxR5N7pWiRaba3C2gzHdRz+ck2N+Ng+7sOSe7GnSXLfmLbVtDT1347+NfD+seGtG1H4bQRa/q8lzmAa8kltFFBHveVJRCGKkdmRW/2a5jwH+2np3xAv8AUbPR9O0nWJI7C71LSodL8TW1xcTx27YZLxWVFs3bqu53+XltprstG+Bmvf8ACU+H/EXiXxZFr2o6fJePcobZkhdp4fLEcAaRjCi/3ckH0rnJv2W9auvCmo+E7/xrEvh77BNp+lw2enmJ41eQOJLnMxW4MafKOE4o6mZlWP7aDXXh+6H9h6Bca1D4ig8PGW38TmTQw0sHnrM+o/ZRtXb8mBC2XKqC2c03xZ+3BYeDdT02y1PSdJ0uUabaahrVpq3iWG0vIRPMYgtnE0eLsqEZzgx5Upj5jtrSt/2dfG9veeIdQ/4TfTDqGr3VveXWnf2E50uby7eS3ljkt/Py8Tp5bKA25XUZLrxSeF/2T9W8Frp0fhvxnb6faz2VrY6rM2mlrk/Z5nkU2TrKv2f77RgHeBHjH3RilbqKSb2PpONlaMMCSDzySalKK3UZpiRLHGEUYUcYqWkwV+ozy067QT0yRzQY1YYI49O1PopFBRRRQAleTeKv+Tmvhp/2LPiP/wBKNIr1qvJfFX/JzXw0/wCxY8R/+lGkUvMDkviB8az8N/G3im3stBuNX1C1h0uC3s5NYaG0c3DOke1GRktyCOTjnjNQ2f7TniDVNQt/DWmeBbW58cNeXdvd6ZLrbRWcaW/+skju/sxMmf4Q0ae+2t3x5+z/ADeMPGWpa7/bkVkt4+lyGD7E0mw2kpbhhIv3s8ccd81i6h+zbrtj4k1DxH4X8XW+jeILu9vZVluNMM0aW9wuCu1ZEPmIfmVs7QeNuOKcfhSMndqVir4o/az1LwjqXi2PUfBSWGl+F7a2lvb7UNchiPmTJuWML5ZGP9rd05x2qrZ/tef2x4K1bUtNsPCd5eaTdrZ38ieMYRpFujxM6SrqAgJcELjasBIY4rduv2ZWu9N8Z2134jmu5fECWHl3k8IaaGe1XCSuzMfMLNz25qDVP2f/ABZrK6Xqd14zsZvE9lqUl4u/SXbToQ0Jj2xQCYFGVSWDF/vGr0WxrPV80djH8P8A7ZE/izV9CtNH8JW119vtoLyaKbWfJuvJe4MDtZw+S32sIUZ2+aM7SvHNafg/9sLQfGHxit/BEC6O1reale6RZtZ62lxqJuLZJGke4sRGGggPkyKshc5YLxhg1YNj+yT4kTQdM8O3/jjT9S0OCVWkabRmF1HsuWlElpIJtttK28oxw4IxgDAx2Ph/4H+IfA+rXR0vxLC/hyzvdS1bStJj09hMLu5EjsJ5BLsmjWWZ2RCqHO35vkXCdroi75Xc90VV29P1qRUVeAMD0HSsPwm2rnwzpP8AbgQ619kiN6IceWJ/LG8D23ZrdqXuOLuhNg54xnrjinUUUFBXkv7Vn/JtvxG/7A9z/KvWq8l/as/5Nt+I3/YHuf5UAetUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB5L+z3/wAefjn/ALHLWv8A0pr1qvJf2e/+PPxz/wBjlrX/AKU161QAUUUUAFFFFABRRRQAUUUUAFeS/tJf8iV4c/7HPwx/6erOvWq8l/aS/wCRK8Of9jn4Y/8AT1Z0AetUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB5N8P/APkvHxZ/65aR/wCk8les15N8P/8AkvHxZ/65aR/6TyV6zQAUUUUAFFFFABRRRQAUUUUAFFFFABXkv7KH/Jtnwy/7F+y/9FCvWq8l/ZQ/5Ns+GX/Yv2X/AKKFAHrVFFFABRRRQAUUUUAFFFFAHkv7Lf8AyQrw7/12vv8A0snr1qvJf2W/+SFeHf8Artff+lk9etUAFFFFABRRRQAUUUUAFFFFABRRRQAV5J+1J/yRjU/+wjpX/pxtq9bryT9qT/kjGp/9hHSv/TjbUAes+WpbdjmjyxgjnrnqfXNOopO/QBjRq2Qc9MdTmkSFI8bVCgcADoPp6VJRQr9QGGFGABXocj24xx6cUjwpIrKy7lYYKnofwqSimAm0UtFFABRRRQAUUUUAFeS+Kv8Ak5r4Z/8AYseI/wD0o0ivWa8l8Vf8nNfDT/sWPEf/AKUaRRurC6nhH7RXj7+wfit41iufFvijQLrTtGs5tFt9Inuha/aWLktOI/3IQkDPmkA/pWprnxavT8R9O09NS1i2u7fUbRNQWHUSLW+VtP8ANYQqPlTJ5PA55616D8Rfgp4x8ReN/F2qaDq2g22meJNJg0u6i1KxllnhEecmMhgrA7j1FY1r+ytf2niZbyLxBD9lW7t7gRurNJiKx+zHqTnJ5qqbXLdhKKloip4T/abum0y5t7Hwbql5Z6PpI1O8vr3V1dkjcuQjFgS78d81R+NH7Q2rFdDs/Denzxat9t0G7CQ33l/a4ruXm3Ygfd9fX8a6XwT+zTd+GdB8T6bd6va3Q1fR4dLUwxEbWTdlzuzk8muWuP2WvH2pYv7vxdocGrW66Slq1vYymKIWMu5eC24714yckUU2vaKUtk/8zOmtG/Jr56Gt4h/aat9NWy1C80TUrbU9Jk1SK/0e2vyYkkt7QyshXZiYFSuzGOea9D+E/wAZbv4g+ItX0TVvD3/CM6lY2VlqMcJvkuhNb3PmGM5UDDDym496841z9lDU9c0+S6vPEFlDrmoyalLqktvZOYXmu7VbVBEN2QiAD5m54zXpvgP4V3XhH4jav4klvLWWO/0HTNKSFUIKNaGfc2f9rzx/3zRHbXt+OpX+b+7Q9Q8tRjGeBjqakptOqS7WCiiigAryX9qz/k234jf9ge5/lXrVeS/tWf8AJtvxG/7A9z/KgD1qiiigAooooAKKKKACiiigAooooAKKKKAPJf2e/wDjz8c/9jlrX/pTXrVeS/s9/wDHn45/7HLWv/SmvWqACiiigAooooAKKKKACiiigAryX9pL/kSvDn/Y5+GP/T1Z161Xkv7SX/IleHP+xz8Mf+nqzoA9aooooAKKKKACiiigAooooAKKKKACiiigDyb4f/8AJePiz/1y0j/0nkr1mvJvh/8A8l4+LP8A1y0j/wBJ5K9ZoAKKKKACiiigAooooAKKKKACiiigAryX9lD/AJNs+GX/AGL9l/6KFetV5L+yh/ybZ8Mv+xfsv/RQoA9aooooAKKKKACiiigAooooA8l/Zb/5IV4d/wCu19/6WT161Xkv7Lf/ACQrw7/12vv/AEsnr1qgAooooAKKKKACiiigAooooAKKKKACvJP2pP8AkjGp/wDYR0r/ANONtXrdeSftSf8AJGNT/wCwjpX/AKcbagD1uiiigAooooAKKKKACiiigAooooAKKKKAErybxV/yc18NP+xY8R/+lGkV6zXk3ir/AJOa+Gn/AGLHiP8A9KNIoDqYnj3432/w+8aeKI/7M1rWLmyj02FbSKSNYXa5d1Xys9wVG6qdv+1FNf8Ak6fYeCdSvPFn2u6tLrQ4rmEy2wtz85L7sNntj1qf4jfAHVvGHjjUtct9Qs47e7m0iVbeZGOwWkxdwPTcGP1zWDefs8+MNJ8Xan4p8M61pdprU1/qEsRvkmaNLW4PbaOJF7Y64qI3SSMUpPmRr69+1daaDqOuWl34U1a2ttEtoZb++uHjjSJpVyic/wAftTrX9qZdS8Manf2fhS4udW06++w3enLqFsFiO3duNxv2fd44/i4qhq37M+qeI9L8f22ra/a6hc+Ik090kuIN6rNbRbS8i9BlueBWRf8A7Nvim+0+wuceDob6C/a8uNAgtPL0gqYfLCMViDSH/lpl0PPtWrsnZMuW6SN3Rf2uNO8SahpEOj+G77UBPbwXF/tnRZbVJJGj3KvWZVZW3bela3hn9p7QvFHxSi8LWtpILe6vLvTLTUjdRsk1zbB2mj8kfOuCkg3Hj5BXlun/ALJ/jex0PQ9Ln1Hw6YrFlKava+bDeacqXE0+bdkQbg/mAFWJX2rrPCn7POsfDrxRe6nZf8I3/Z9nqGpaxY3kdgTqlxJc+Y4hnfZnYrSN9xgW2gHIJFN8oL4ZX3PpVTxT6wvB97qWoeGdJn1a3Fpqs1nDLdwDpFMyAun4HNbLPtPJxWT0k0OO2pJRTeadTTuUFeS/tWf8m2/Eb/sD3P8AKvWq8l/as/5Nt+I3/YHuf5UwPWqKKKACiiigAooooAKKKKACiiigAooooA8l/Z7/AOPPxz/2OWtf+lNetV5L+z3/AMefjn/scta/9Ka9aoAKKKKACiiigAooooAKKKKACvJf2kv+RK8Of9jn4Y/9PVnXrVeS/tJf8iV4c/7HPwx/6erOgD1qiiigAooooAKKKKACiiigAooooAKKKKAPJvh//wAl4+LP/XLSP/SeSvWa8m+H/wDyXj4s/wDXLSP/AEnkr1mgAooooAKKKKACiiigAooooAKKKKACvJf2UP8Ak2z4Zf8AYv2X/ooV61Xkv7KH/Jtnwy/7F+y/9FCgD1qiiigAooooAKKKKACiiigDyX9lv/khXh3/AK7X3/pZPXrVeS/st/8AJCvDv/Xa+/8ASyevWqTdgCiiihO4BRRRTAKKKKACiiigAooooAK8k/ak/wCSMan/ANhHSv8A0421et15J+1J/wAkY1P/ALCOlf8ApxtqAPW6KKKACiiigAooooAKKKKACiiigAooooAK8l8Vf8nNfDT/ALFjxH/6UaRXrVeS+Kv+Tmvhp/2LHiP/ANKNIpAea/Fb9pKx+FfxK+I2j674qg0r7P4cgutFguwqD7QyTE7SVO7JReu7pXQeDf2m7S38G251fTNWuNYs10+1lXyola9e5QFJYwHwQSGJwK6DW/hHqupeL/iPqqTWMMPiTQYNLgXc+VkRJlLSkJyvzjnk4FeLf8K7DftH+AdGt9TtNRk8P+HFXxBZWMwk8ieBSLVuxQkMcbgM57UU4vW4pdOU9I0P9sDw/qWltq1/4b17Q9LmhuLiyur1IcX3kNtZYxHIxGT/AM9NtZPi/wDaUZrjw9HJDf8Age5tfEFnBrNlqgt3b7LLuxJvVmGw7DyOa80+HHwB8SfHP4O+G21uTSrDTdNgvjpElvcyvcPJJM5UyhogIxkDhWkFdp4m/ZT174sal/aPj0eHmnur/T31DStPu55YPsdtuwI5TDGxZt7ZUrt568VcqcElbe+oS1Wm52/ij9qKz8K+E7HxNP4O8RTaJNE13Jf5giihthLsMp3ygsT94RKDJs521z2j/tC3ui+KPHWlXen6l4mu28Tmx0XSLFYIpFtorC0llx5jouxSzEgnc3mcdeOI8afsk/EXxJoF9ok1z4X8SW0WmPpWkXWvXVwZbCMPuhlij8h1SYqPLZg+cfNntWnrX7J+u6p4suvEt3ovgnxfqbas9/HofiVpZtPWCXT7W2b52gkPmI9qrKdnzKOShJy0o6hHTc7W/wD2wtBhgS8svDeva3ozaTYa1NqdhFF5cEF48kUZYPIrE7ozwF3f7NaC/tEWeva1othNZa94c1IeI10W70jyLaaXe1nJcx+awZx5TR7HzES4xjPWuPuP2XfEQ0nxHYxaposiah4X0PRkeGEWUKS2dzPPIywwxbEjbzcKFUe/StTWf2cfEmq/EG816HUNLisrjxRDrUZ3v5yQLpX2Q5GzBk38jPAX0qrRu3/XQpdTvvAPx8t/HfjS98MT+HNa8N6jFafbYl1QQBng3Mu9kWRnibI+5IqmvWa+YvgT+z54r+GPj6z13UIPDSWsWknSrqTTbmdrm5kWYuLmQvCm9nDHKk/Lnhn4r6dqZW6Gcb3YV5L+1Z/ybb8Rv+wPc/yr1qvJf2rP+TbfiN/2B7n+VQWetUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB5L+z3/x5+Of+xy1r/0pr1qvJf2e/wDjz8c/9jlrX/pTXrVABRRRQAUUUUAFFFFABRRRQAV5L+0l/wAiV4c/7HPwx/6erOvWq8l/aS/5Erw5/wBjn4Y/9PVnQB61RRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHk3w//wCS8fFn/rlpH/pPJXrNeTfD/wD5Lx8Wf+uWkf8ApPJXrNABRRRQAUUUUAFFFFABRRRQAUUUUAFeS/sof8m2fDL/ALF+y/8ARQr1qvJf2UP+TbPhl/2L9l/6KFAHrVFFFABRRRQAUUUUAFFFFAHy18Cfh9r1x8GdJ1SD4y+KvDmmSS3kotra10U21qv2qcsFefT3fGecuxrofCUKfEG4uIfC/wC1DrfiSS3G+4j0WTwzdSQL2ZwmnNtH1pvwxH/GIt1/156sT74uLjr618+6P478S/Dvw94S8Wah4Z0vRLjS/AU93pP9n3RuzqTrGmBL+7j8s8ltv7wc/fpRald/1s3+hXLsfV//AAp/xl/0XTx7/wCC/wAPf/Kuj/hT/jL/AKLp49/8F/h7/wCVdeE2vxc+LsdnBpN3qmoaRc32t6LBBqevWemC+WG6dxPGLe2MiBQFHlsylj3Jqh4q+PHxEs/BmqWtl4x1GbxL4fm8QM/9n6PYmS8gsZisc13JMoiijVeGSFPMdvu4p9v66J/qQtW12/4P+R71b/DnxLfXlzZQ/H3xnJdWTLHcRw2Xh8yRsyhh5g/sw4yGXoBVv/hT/jL/AKLp49/8F/h7/wCVdcn8AdWfXviN8UNSuQqXN0+i3U6bWjCZ0yBzz35ryaX9ojx/Z/8ACR3Nl4l1DVtOuvD1zq+l6lfaVZW9ukkcyLm2ijDSPEATkysxPaqtrYiU1Cn7V7H0L/wp/wAZf9F08e/+C/w9/wDKuqmn/DbxNrCM1n8fvGl0sLmKV7ey8Pt869V/5BhryKP4tfEm08VReBn8WTXt5qWo2McWvf2faJNaxy2nnSxpH5QjYA8KzKSfWup+CN3qvhH4A+OL19RMusaff6pdfbmRMSSLyrbQNuOBxjHtSasmx8y5lHud/wD8Kf8AGX/RdPHv/gv8Pf8Ayrqpa/DfxJeahPaQfH3xtcXFrt+0W8dp4eLxbum7/iV14z4w+PHxIaw8OwaJ4gt7K+1XQdJvkmms4Zf3lxcokkjDYAF2kjHbtU+ueOviHpvxSl8HWXi77PNNren6bLrK6fa/aHja1uXLsvl7Sd0adu2OhNNq39en+YnNJ2/ra57V/wAKf8Zf9F08e/8Agv8AD3/yro/4U/4y/wCi6ePf/Bf4e/8AlXXz14k/aC+IsnwptdQ0zxPqDeItNt9eupU0/SbIi9isLt4UuLt5gEiiwAGSFd7N91lrZk+LXxR1K2+I/i2HxatppPhPVNNH9gQadbkNbG00+5u1eR4y4yss+whsjfyeBhxg5X8v87Gkvd0PbP8AhT/jL/ounj3/AMF/h7/5V15j+0T8L/FNl8J7+S8+MvjHUE+3aaDbXVloiREvf26Id0enK3ysQ3XnHORxXq3wK8bat8QtA1rxBe3v2nTbvWbtNJURIvl2kUhjTlQNwbYWycn5utVf2o/l+C+pbSy41DSgNpI66jbVHkyYy5ldDv8AhT/jL/ounj3/AMF/h7/5V0f8Kf8AGX/RdPHv/gv8Pf8Ayrr1iigo8n/4U/4y/wCi6ePf/Bf4e/8AlXR/wp/xl/0XTx7/AOC/w9/8q69YooA8n/4U/wCMv+i6ePf/AAX+Hv8A5V0f8Kf8Zf8ARdPHv/gv8Pf/ACrr1iigDyf/AIU/4y/6Lp49/wDBf4e/+VdH/Cn/ABl/0XTx7/4L/D3/AMq69YooA8n/AOFP+Mv+i6ePf/Bf4e/+VdH/AAp/xl/0XTx7/wCC/wAPf/KuvWKKAPJ/+FP+Mv8Aounj3/wX+Hv/AJV0f8Kf8Zf9F08e/wDgv8Pf/KuvWKKAPJ/+FP8AjL/ounj3/wAF/h7/AOVdeYeJPhf4qj/aK+H1pJ8ZfGUk8nh/XpEvjZaGJoFW40zMQA07YQ+9dzFSR5Sbdu5t31PXkvikbf2mfhqMtg+GPEWRk4P+kaT1/OgBD8F/F7Yz8dPHx/7cfD/POef+JZzR/wAKZ8X9B8cvHoGMACw8PgAf+CyvW6KAPJB8F/FwYn/heXj3Oc/8eHh/1J/6BnvSt8G/GDYB+Ofj046f6B4f/wDlZ1r1qigDyT/hS/i7Zt/4Xj4825z/AMg/w91znP8AyC+uefrS/wDCmfF//RcvHh5z/wAeHh7/AOVletUUAeSL8GPF6sCPjl49z0/48PD/AK5/6Bn/AOqkHwZ8XZJ/4Xn49yTk/wCgeH+v/gsr1yjaKYtTyT/hTPi/dn/heXjzOMf8g/w/09P+QX0p/wDwp/xl/wBF08e/+C/w9/8AKuvWMCikM8n/AOFP+Mv+i6ePf/Bf4e/+VdeZftKfC7xTp/wE8dXV38ZvGOo20elXDvZXVnoiw3CYztJi05ZAP91ga+pa8l/aqG39nL4iyKzLINFuVDKxBAxQA7/hT/jL/ounj3/wX+Hv/lXR/wAKf8Zf9F08e/8Agv8AD3/yrr1iigDyf/hT/jL/AKLp49/8F/h7/wCVdH/Cn/GX/RdPHv8A4L/D3/yrr1iigDyf/hT/AIy/6Lp49/8ABf4e/wDlXR/wp/xl/wBF08e/+C/w9/8AKuvWKKAPJ/8AhT/jL/ounj3/AMF/h7/5V0f8Kf8AGX/RdPHv/gv8Pf8Ayrr1iigDyf8A4U/4y/6Lp49/8F/h7/5V0f8ACn/GX/RdPHv/AIL/AA9/8q69YooA8n/4U/4y/wCi6ePf/Bf4e/8AlXR/wp/xl/0XTx7/AOC/w9/8q69YooA+WPgX8L/Fd9p/jR4fjJ4y07yvFmqwkWtnob+ewuOZT5mnHDv3UYUdgK9P/wCFP+Mv+i6ePf8AwX+Hv/lXTf2fV3WXjoEsQfGWtdWP/PzXrVAHk/8Awp/xl/0XTx7/AOC/w9/8q6P+FP8AjL/ounj3/wAF/h7/AOVdesUUAeT/APCn/GX/AEXTx7/4L/D3/wAq6P8AhT/jL/ounj3/AMF/h7/5V16xRQB5P/wp/wAZf9F08e/+C/w9/wDKuj/hT/jL/ounj3/wX+Hv/lXXrFFAHk//AAp/xl/0XTx7/wCC/wAPf/Kuj/hT/jL/AKLp49/8F/h7/wCVdesUUAeT/wDCn/GX/RdPHv8A4L/D3/yrrzH9oD4W+K7HwroL3Hxm8YX0TeK/D8aQ3Nnoi7WOq2qrIDHpoJdCVkVejMArAqcV9TV5J+0ig/4Q3w42Wz/wmXhkfeOOdZs+34D6UAP/AOFP+Mv+i6ePf/Bf4e/+VdH/AAp/xl/0XTx7/wCC/wAPf/KuvWKKAPJ/+FP+Mv8Aounj3/wX+Hv/AJV0f8Kf8Zf9F08e/wDgv8Pf/KuvWKKAPJ/+FP8AjL/ounj3/wAF/h7/AOVdH/Cn/GX/AEXTx7/4L/D3/wAq69YooA8n/wCFP+Mv+i6ePf8AwX+Hv/lXR/wp/wAZf9F08e/+C/w9/wDKuvWKKAPJ/wDhT/jL/ounj3/wX+Hv/lXR/wAKf8Zf9F08e/8Agv8AD3/yrr1iigDyf/hT/jL/AKLp49/8F/h7/wCVdH/Cn/GX/RdPHv8A4L/D3/yrr1iigD5Z8D/C7xXL8aPibAvxl8ZWskSaWHuls9Daa4DW8hHmA6cUXZ22gZ75r07/AIU/4y/6Lp49/wDBf4e/+VdJ8P0H/C+vi0ctzFo5I3HHFvJ2rqv+FpeEv+EnXw8fF2irrpfYNJ/tCH7Vv4+Qx7t2fmXjGaV9bAct/wAKf8Zf9F08e/8Agv8AD3/yro/4U/4y/wCi6ePf/Bf4e/8AlXXqcblhye1POaVwWp5T/wAKf8Zf9F08e/8Agv8AD3/yro/4U/4y/wCi6ePf/Bf4e/8AlXXora1bx6tDp0l3BHeTI8sduX/eOinBYDuASv51XbxTpa64NHfVbVNXEX2kacLiP7S0Pd/K+/tHqBTTvZ9x2OC/4U/4y/6Lp49/8F/h7/5V0f8ACn/GX/RdPHv/AIL/AA9/8q69B1jxNpug+V/aOo2mn+YGdftUyx5VRk/eI7flV63vI7yFZoZBLCyiRJIzkOp6UCPMP+FP+Mv+i6ePf/Bf4e/+VdH/AAp/xl/0XTx7/wCC/wAPf/KuvV6KL6XA8o/4U/4y/wCi6ePf/Bf4e/8AlXR/wp/xl/0XTx7/AOC/w9/8q69XPalpgeT/APCn/GX/AEXTx7/4L/D3/wAq6b+yYCP2afhiH5b/AIR6yz/37FetV5N+yiS37N3wyJ6/8I/Zf+ihQB61RRRQAUUUUAFFFFABTc8UtItLqI8b/Zz0q21z9nnSbC7j861ujqEM0e4ruRrucEZByOPSt25+B/g6/wBK0DTbrS1urPRdObTbNZJGYm2aERFH6b/lA5Oemetct8DfEKeEP2abTV5FMkOnDUZ3Ufxhbqc14d4g+J3imbxFqeu+K9L02WK58H2+o21naXM6QyRzXEIVM7siQbm6Y6/SiK5pWXf/ADInLlWv9ao+j9F/Z28G6PHHGlre3VxHd2t8Ly7vZZpzNbEmAmR2LEIScKSV9qpa5+y/4B15b77RYXsJv/tovDb6hNCblbxt1ykuxxvR25KNlQegFeb/APDWet6TdeMp9V0jS0t9HivWj0qN5I9RgaCTy42l3nbIk3VTGPl71Z1v9ojx9oOuW/hCfQtBvPGr65ptgy200i2f2W8t7qRZvmO7KPZygjvgY61Si3r/AF2LVoa/11Z7L4K+GXh/4eNdrpcd00l3DBDP9qunmMywwiGPlyeRHGB15xk81yNv+yd8PLXaIrC/CLZyaesbapOyLbyMGaIKWwFyAQAOO2K8f8V/GPxd4m8UfD3W9QttO0zw1p/ja802VbSWQzyyWtrexSsedpjdo5GTPTYN1TaR+2pr+seG9Z1Kw0Cw1WZbGLULCK1S5VIQ9wsXkXDugHmfOPmX5avpcTilaL2/4LPdde+AHg7xNcXNzdWN7HdTG3b7Rb3skMiGBdsRRkYFSo44Iz3zWr4N+FPhvwL4PufC2mW7tpU7StLDdzyTFzL/AKzLMxbn68dsV5BZ/tAePbf4mWPhnW9G8P6bua3zAzzLLcpMmd0EhOw7D95TzX0ttDdRUTT5fUGrOz3PGdL/AGUPh7pBBFlqNyQsSA3eqzz7UicPGq73OFDAHaOPUV0118HfCt14w/4SiWyZ9W+1R332jz5B++jjdEbbuxwsjjGMHPIyBXoAQD1/Ojy1Palre7/rYTj/AF8rHj2pfssfD/VrdIJLC+gi8u7hlW31GeLz47mYzXEcpRx5iPISxVsjJ4Apl98HbPwV8M/Gei+DtLa/u9egEdxDrGoyBJ3+yx2e9pXDn/UxIT2JXPU17H5anIx160n2dN+/b83rUtcykn1Vi+tzh/g98PY/hT8LfCvhKN/O/sixhtHlBJ3uqgFufUjNYH7Un/JF9T/7COlf+nG2r1dbdF5AOfck15R+1J/yRjU/+wjpX/pxtq0k+aTk93qTFcqset0UUVJQUUUUAFFFFABRRRQAUUUUAFFFFABXkvir/k5r4Z/9ix4j/wDSjSK9aryXxV/yc18M/wDsWPEf/pRpFAHrVFFFABRRRQAUUUUAFFFFABRRRQAV5L+1Z/ybb8Rv+wPc/wAq9aryX9qz/k234jf9ge5/lQB61RRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHkv7Pf8Ax5+Of+xy1r/0pr1qvJf2e/8Ajz8c/wDY5a1/6U161QAUUUUAFFFFABRRRQAUUUUAFeS/tJf8iV4c/wCxz8Mf+nqzr1qvJf2kv+RK8Of9jn4Y/wDT1Z0AetUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB5N8P8A/kvHxZ/65aR/6TyV8v69Jq6XfjknwxYjw5H8Qkmn8Vi6P2q1jP2fO2Py/u/7XmY/2a+oPh//AMl4+LP/AFy0j/0nkrVvPgb4XvdG1/TJbWZrPW74aldR+aQTcjbiTOcg/IvQ44ojo7/1un+g38Nup8xXH7THxQuIvEPiDTrTUIdHI1u3to7+wsltLZ7JZ/LaFxJ50rF4QrBlI56V0q/Gjxxodv4m0fVPGiXF+dN0DU7HUIdHgluEkv5Zo2tII02pIzGBvK3q33vmzXrt1+zP4Fvb7V7i4jvZY777QXtzfv5VoZ1KzGFM4jLgnJXB5z15q3rv7PvhTxFPeTXUF3b3NzZ2FsktveOHh+xu8luYzn5WR3Y7hycnJqla2vl+BL2dvP8AFqx4J8FPH+uePvjt4Jn8SvPJq2mWXirSnmuIY4Zpkh1DT4084Rqse8AZOxRhsgcEirvja71vwh8dvinrtv4uuNO8nTNItbeP+yortlaZ2CxRDbuJ+RsA8N/FmvbfA37PPg34f+JItd037c1/F9qKNfXzTBTcvG87AE4y7RRsT1yue5zd8V/Avwv4yutau9SguTeastss9xDOVeP7OWMJUg5UqXYgjnn6USfuwS6b/fcJXc5NbN6Hyn4o+L3i/wATfD+707xCq3N4Zdf02c31nbrdgQW/7svtQIjj+IKBXY6D8ZvFmg+BtdjtbyEQaHHoEVruhXES3EaGQOSMnqeueteuQfsp+AIbe5hlGpXCXMlxLN5+oyOXeddszEsSSWHBNLq37LPgbWtTt7uU6iqw/Z90MeoyLHJ5AAh3qDh9oA+8DnvmtFKNmmVP3opLfX8jxD/hePxTfQdIuE1a/wBUn8Ra5fWlonh/S7OWa2t7YO2UEoVGyFCtuYkY4r6S+CfizXPF/wAN9H1DxLC1jrk/mxyowiDEpIy7iI3ZQ2FG4A4DZ4FUtQ+APhW98N2ujiO+06G0upL63vLW+eK5imckuyyKcgMScqDg56V2vhnwrpng3QLXR9NtVt9Ptk2RW6klQMlj1JySSSSeSTk1lGyTTCWr08/zNlqdSUtIQV5L+yh/ybZ8Mv8AsX7L/wBFCvWq8l/ZQ/5Ns+GX/Yv2X/ooUAetUUUUAFFFFABRRRQAlItOpMYoEeKfs/6JB4m/ZxsdIulK290t/ayx4YEA3c4I556VzQ/ZHa8t7qDVfGl/qSyaPFoduJLOICCCOVZI2GDywCKuTzxkk13I/ZZ+Gis5j0K6gDyPMVg1m+jXc7s7HaswAyzsfxpW/Zb+G7PuOkaiW/7D2oeuf+e/rUxvGVxSipKzOL1T9kzT/EOoXv8Abvia81bSnt75LGOaCMTWxuv9YftAG5wvG1WyBWtpn7N4k1rT9b1vxHd634gg1a11abVPscdsZlt7aaCG32A8BfPkYEd2J61vj9l74ch939l6nnOf+Rg1Hr/4EUh/Zb+HB5/snUg2WO4a/qIbJAB58/PRR+VNXVv66jstfM5mT9mCBvGNne/8JHef8I5aazda9DoH2RNi3FzFNHOvnbskM07ttIwNxxioIv2WYW8MS+H73xpqV5YRWkVhpkTQoBbwRzrOEbH+v5RBubng+tdb/wAMu/Dgf8wnUv8Awf6h6Af89/RR+VO/4Zf+HXllP7L1Pb83/Mwaj3OT/wAt/WnrawPUyPE/7Pf/AAk/iyLVLvxRfLpP2m1vW0mWCOXZNCMb0mbJj3DqEAB75r2nd9fyP+FeVr+y78OVbd/ZmqFuOT4h1E9PrcUn/DLfw4/6BOpf+D/Uf/kijoN6yueq7vr+R/wo3fX8j/hXlX/DLfw4/wCgTqX/AIP9R/8Akij/AIZb+HH/AECdS/8AB/qP/wAkUAeq7vr+R/wo3fX8j/hXlX/DLfw4/wCgTqX/AIP9R/8Akij/AIZb+HH/AECdS/8AB/qP/wAkUAeq7vr+R/wryX9qBn/4U/qCbdyfb9JyzA5/5CVtk4A7AE1L/wAMt/Dj/oE6l/4P9R/+SKhvP2TfhdqULw3eg3lzEzrIY5tcv2UsrBgcGfsQDQB63u+v5H/Cjd9fyP8AhXlX/DLfw4/6BOpf+D/Uf/kij/hlv4cf9AnUv/B/qP8A8kUAeq7vr+R/wo3fX8j/AIV5V/wy38OP+gTqX/g/1H/5Io/4Zb+HH/QJ1L/wf6j/APJFAHqu76/kf8KN31/I/wCFeVf8Mt/Dj/oE6l/4P9R/+SKP+GW/hx/0CdS/8H+o/wDyRQB6ru+v5H/Cjd9fyP8AhXlX/DLfw4/6BOpf+D/Uf/kij/hlv4cf9AnUv/B/qP8A8kUAeq7vr+R/wo3fX8j/AIV5V/wy38OP+gTqX/g/1H/5Io/4Zb+HH/QJ1L/wf6j/APJFAHqu76/kf8KN31/I/wCFeVf8Mt/Dj/oE6l/4P9R/+SKP+GW/hx/0CdS/8H+o/wDyRQB6ru+v5H/CvI/FTsf2nvhltOV/4RjxEQMHJXz9Jznjg5K8e59Kn/4Zb+HH/QJ1L/wf6j/8kVDJ+yb8L5L6G9bQbxryFWSK4OuX+9FYqWAbz8gEouR32j0oA9b3fX8j/hRu+v5H/CvKv+GW/hx/0CdS/wDB/qP/AMkUf8Mt/Dj/AKBOpf8Ag/1H/wCSKAPVd31/I/4Ubvr+R/wryr/hlv4cf9AnUv8Awf6j/wDJFH/DLfw4/wCgTqX/AIP9R/8AkigD1Xd9fyP+FG76/kf8K8q/4Zb+HH/QJ1L/AMH+o/8AyRR/wy38OP8AoE6l/wCD/Uf/AJIoA9V3fX8j/hRu+v5H/CvKv+GW/hx/0CdS/wDB/qP/AMkUf8Mt/Dj/AKBOpf8Ag/1H/wCSKAPVd31/I/4Ubvr+R/wryr/hlv4cf9AnUv8Awf6j/wDJFH/DLfw4/wCgTqX/AIP9R/8AkigD1Xd9fyP+FeS/tWM6/s4fEUYGf7GmJ3Z28jkDAyal/wCGW/hx/wBAnUv/AAf6j/8AJFQ3v7Jvwv1K1e1u9BvLq1kzvgm1y/dGz1ypnwfxoA9b3fX8j/hRu+v5H/CvKv8Ahlv4cf8AQJ1L/wAH+o//ACRR/wAMt/Dj/oE6l/4P9R/+SKAPVd31/I/4Ubvr+R/wryr/AIZb+HH/AECdS/8AB/qP/wAkUf8ADLfw4/6BOpf+D/Uf/kigD1Xd9fyP+FG76/kf8K8q/wCGW/hx/wBAnUv/AAf6j/8AJFH/AAy38OP+gTqX/g/1H/5IoA9V3fX8j/hRu+v5H/CvKv8Ahlv4cf8AQJ1L/wAH+o//ACRR/wAMt/Dj/oE6l/4P9R/+SKAPVd31/I/4Ubvr+R/wryr/AIZb+HH/AECdS/8AB/qP/wAkUf8ADLfw4/6BOpf+D/Uf/kigD1Xd9fyP+FG76/kf8K8q/wCGW/hx/wBAnUv/AAf6j/8AJFH/AAy38OP+gTqX/g/1H/5IoAi/Z6kLWPjfOMjxlrQ4BG4/aTnqOletbvr+R/wryS0/ZN+F+nxypa6DeW6yytO4i1y/XdIzbmbifqTyfWpv+GW/hx/0CdS/8H+o/wDyRQB6ru+v5H/Cjd9fyP8AhXlX/DLfw4/6BOpf+D/Uf/kij/hlv4cf9AnUv/B/qP8A8kUAeq7vr+R/wo3fX8j/AIV5V/wy38OP+gTqX/g/1H/5Io/4Zb+HH/QJ1L/wf6j/APJFAHqu76/kf8KN31/I/wCFeVf8Mt/Dj/oE6l/4P9R/+SKP+GW/hx/0CdS/8H+o/wDyRQB6ru+v5H/Cjd9fyP8AhXlX/DLfw4/6BOpf+D/Uf/kij/hlv4cf9AnUv/B/qP8A8kUAeq7vr+R/wryP9o95G8F+GzgAN4z8M5BBJUjWbPA4HTIIJ9Dmp/8Ahlv4cf8AQJ1L/wAH+o//ACRUN5+yb8L9QjSO60G8uEWVJ1WXXL9sSIysrcz9QyqR7jNAHre76/kf8KN31/I/4V5V/wAMt/Dj/oE6l/4P9R/+SKP+GW/hx/0CdS/8H+o//JFAHqu76/kf8KN31/I/4V5V/wAMt/Dj/oE6l/4P9R/+SKP+GW/hx/0CdS/8H+o//JFAHqu76/kf8KN31/I/4V5V/wAMt/Dj/oE6l/4P9R/+SKP+GW/hx/0CdS/8H+o//JFAHqu76/kf8KN31/I/4V5V/wAMt/Dj/oE6l/4P9R/+SKP+GW/hx/0CdS/8H+o//JFAHqu76/kf8KN31/I/4V5V/wAMt/Dj/oE6l/4P9R/+SKP+GW/hx/0CdS/8H+o//JFAHqu76/kf8KN31/I/4V5V/wAMt/Dj/oE6l/4P9R/+SKP+GW/hx/0CdS/8H+o//JFAEXw/d/8AhfnxbVAH2rowbdkEA28mccc16wqqrMwBy3XrXk0f7Jvwuhurm6j0G8jubnZ50y65fh5NilVy3n5OASKm/wCGW/hx/wBAnUv/AAf6j/8AJFAHquec4Ofof8Kaqhc43ckk8nvXln/DLfw4/wCgTqX/AIP9R/8Akij/AIZb+HH/AECdS/8AB/qP/wAkUAeq7uc8/rSKqrnC4z146/pXlf8Awy38OP8AoE6l/wCD/Uf/AJIo/wCGW/hx/wBAnUv/AAf6j/8AJFAHqobHr+tJxuJwcnr1ryv/AIZb+HH/AECdS/8AB/qP/wAkUf8ADLfw4/6BOpf+D/Uf/kigD1Rfl6bvxyaXPOcHP0NeVf8ADLfw4/6BOpf+D/Uf/kij/hlv4cf9AnUv/B/qP/yRQB6ru+v5H/Cjd9fyP+FeVf8ADLfw4/6BOpf+D/Uf/kij/hlv4cf9AnUv/B/qP/yRQB6ru+v5H/CvJ/2T8t+zX8Mv4P8Ain7L/wBFCn/8Mt/Dj/oE6l/4P9R/+SK9C8L+FdL8GeG9M0DRrX7HpOm26Wtpb+Y7+XGgwq7mJY4HckmgDWooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigD//2Q==" alt="" width="769" height="1479" vspace="0" hspace="0" border="0" style="width:769px;height:1479px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /></p><p>NOS = Not otherwise specified</p><p>(*=combination therapy with rituximab)</p><p>&nbsp;</p><p><u>Description of selected adverse reactions</u></p><p>There have been isolated reports of necrosis after accidental extra-vascular administration and tumour lysis syndrome and</p><p>anaphylaxis.</p><p>The risk of myelodysplastic syndrome and acute myeloid leukaemias is increased in patients treated with alkylating agents</p><p>(including bendamustine). The secondary malignancy may develop several years after chemotherapy has been discontinued.</p><p>&nbsp;</p><p><u>Reporting of suspected adverse reactions</u></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued</p><p>monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected</p><p>adverse reactions via:</p><p>Reporting to National regulatory authority:</p><p><strong>The National Pharmacovigilance and Drug Safety Centre (NPC):</strong></p><p>Fax: +966-11-205-7662</p><p>Call NPC at +966-11-2038222, Ext 2317-2356-2340</p><p>Reporting hotline: 19999</p><p>E-mail: npc.drug@sfda.gov.sa</p><p>Website: www.sfda.gov.sa/npc</p><p><strong>OVERDOSE</strong></p><p>After application of a 30 min infusion of Bendamustine Hydrochloride once every 3 weeks the maximum tolerated dose</p><p>(MTD) was 280 mg/m2. Cardiac events of CTC grade 2 which were compatible with ischaemic ECG changes occurred which</p><p>were regarded as dose limiting.</p><p>&nbsp;</p><p>In a subsequent study with a 30 min infusion of Bendamustine Hydrochloride at day 1 and 2 every 3 weeks the MTD was</p><p>found to be 180 mg/m2. The dose limiting toxicity was grade 4 thrombocytopenia. Cardiac toxicity was not dose limiting with</p><p>this schedule.</p><p>&nbsp;</p><p><u>Counter measures</u></p><p>There is no specific antidote. Bone marrow transplantation and transfusions (platelets, concentrated erythrocytes) may be</p><p>made or haematological growth factors may be given as effective countermeasures to control haematological side effects.</p><p>Bendamustine hydrochloride and its metabolites are dialyzable to a small extent.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>STORAGE</strong></p><p>Do not store above 30&deg;C. Protect from light.</p><p><strong>SHELF-LIFE</strong></p><p>24 months from the date of manufacture.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>AVAILABILITY</strong></p><p>Pack size &ndash; 1 Vial in a carton.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Reconstituted and infusion solutions:
The powder should be reconstituted immediately with 0.9% sodium chloride solution after opening of the vial.
The reconstituted concentrate should be diluted immediately.
Solution for infusion
After reconstitution and dilution, chemical and physical stability has been demonstrated for 3.5 hours at 25°C and 48 hours
at 2°C to 8°C in polyethylene bags.
From a microbiological point of view, the solution should be used immediately. If not used immediately, in-use storage times
and conditions prior to use are the responsibility of the user.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Manufactured by:<br />Mylan Laboratories Limited [OTL],<br />Plot No. 284-B, Bommasandra &ndash; Jigani Link Road,<br />Industrial Area, Anekal Taluk, Bangalore &ndash; 560 105, India.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                DATE OF PUBLICATION/REVIEW
November, 2020

            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p><strong><u>ملخص خصائص المُنْتَج</u></strong></p><p dir="RTL"><strong><u>بنداموستين هيدروكلوريد للحقن </u></strong><strong><u>25</u></strong><strong><u> مج </u></strong><strong><u>/ </u></strong><strong><u>أمبول </u></strong><strong><u>&amp; 100</u></strong><strong><u> مج</u></strong><strong><u>/</u></strong><strong><u>أمبول</u></strong></p><p dir="RTL"><strong>[</strong><strong>SQUADAION</strong>]</p><p dir="RTL">1. اسم المُنْتَج الدوائي</p><p dir="RTL">بنداموستين هيدروكلوريد للحقن 25 مج / أمبول &amp; 100 مج/أمبول</p><p dir="RTL">التركيز</p><p dir="RTL">التركيز - 25 مج/أمبول &amp; 100 مج/أمبول</p><p dir="RTL">الشكل الصيدلاني</p><p dir="RTL">الشكل - مسحوق للحقن مُجَفَف بالتبريد</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">2. التركيب النوعي والكمي</p><p dir="RTL">يشتمل كل أمبول على: بنداموستين هيدروكلوريد 25 مج</p><p dir="RTL">يشتمل كل أمبول على: بنداموستين هيدروكلوريد 100 مج</p><p dir="RTL">للاطلاع على القائمة الكاملة للسواغات، راجع قسم قائمة السُواغات.</p><p dir="RTL">&nbsp;</p><p dir="RTL">3. الشكل الصيدلاني</p><p dir="RTL">مسحوق للحقن مُجَفَف بالتبريد. مسحوق أبيض أو أبيض فاتح مُجَفَف بالتبريد.</p><p dir="RTL">&nbsp;</p><p>4. الخصائص الإكلينيكية</p><p>4.1 دواعي الاستعمال العلاجية</p><p dir="RTL">الخط الأول في علاج سرطان الدم الليمفاوي المزمن (المرحلة البينية ب أو جـ)؛ وذلك بالنسبة للمرضى الذين لا يناسبهم العلاج الكيميائي باستعمال توليفة الفلودرابين.</p><p dir="RTL">كعلاج أحادي لأورام الغدد الليمفاوية غير الهودجكينية بطيئة الشفاء؛ وذلك بالنسبة للمرضى الذين حققوا تقدماً في أثناء العلاج باستعمال ريتوكسيماب، أو باستعمال أي من الأنظمة المحتوية على ريتوكسيماب؛ أو الذين حققوا تقدماً في خلال الستة أشهر التالية للعلاج.</p><p dir="RTL">الخط الأول في علاج الورم النِقْوِيٌّ المتعدد (دوري - سالمون المرحلة الثانية مع حدوث تقدم، أو المرحلة الثالثة)، في توليفة مع &quot;بريدنيزون&quot;؛ وذلك بالنسبة للمرضى الذين تجاوزا الــ 65عاماً، من غير المؤهلين لعملية زرع الخلايا الجذعية ذاتِيُّة المَنْشَأ، والذين يعانون من اعتلال الأعصاب السريري في وقت التشخيص، مع استبعاد استخدام الثاليدومايد، أو أي علاج آخر يحتوي على البورتيزوميب.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">2 الجرعات وطرق إعطاء الدواء</p><p dir="RTL">للتسريب الوريدي على مدى 30 - 60 دقيقة (راجع الاحتياطات الخاصة بالتخلص من المُنْتَج، وعمليات التداول الأخرى).</p><p dir="RTL">يجب أن تُجْرى عملية التسريب، تحت إشراف طبيب مؤهل من ذوي الخبرة في استعمال عوامل العلاج الكيميائي.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يرتبط ضعف وظائف نخاع العظام، بزيادة السمية الدموية الناجمة عن العلاج الكيميائي. يجب عدم بدء العلاج؛ وذلك إذا كان عدد كرات الدم البيضاء و/أو الصفائح الدموية أقل من 3000/ميكرولتر، أو أقل من 75000/ميكرولتر على التوالي (راجع قسم موانع الاستعمال).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>علاج&nbsp; أحادي لسرطان الدم الليمفاوي المزمن</u></p><p dir="RTL">100مج/م<sup>2</sup> من مساحة سطح الجسم، من بنداموستين هيدروكلوريد في اليوم الأول والثاني؛ كل أربعة أسابيع.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>علاج أحادي لأورام الغدد الليمفاوية غير الهودجكينية بطيئة الشفاء؛ المستعصية على العلاج باستعمال ريتوكسيماب</u></p><p dir="RTL">120مج/م<sup>2</sup> من مساحة سطح الجسم، من بنداموستين هيدروكلوريد في اليوم الأول والثاني؛ كل ثلاثة أسابيع.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>الورم النِقْوِيٌّ المتعدد</u></p><p dir="RTL">من 120 - 150 مج/م<sup>2</sup> من مساحة سطح الجسم، من بنداموستين هيدروكلوريد، في اليوم الأول والثاني؛ 60 مج/م<sup>2</sup> من مساحة سطح الجسم، من بريدنيزون عن طريق الحقن الوريدي، أو&nbsp; عن طريق الفم في اليوم الأول وحتى اليوم الرابع؛ كل أربعة أسابيع.</p><p dir="RTL">يجب إنهاء العلاج او تأخيره؛ وذلك في حالة انخفاض عدد كرات الدم البيضاء و/أو الصفائح الدموية، إلى أقل من 3000/ميكرولتر، أو أقل من 75000/ميكرولتر على التوالي (راجع قسم موانع الاستعمال). ومن الممكن الاستمرار في العلاج؛ وذلك بعد أن يصبح عدد كرات الدم البيضاء أكبر من 4000/ميكرولتر، وأن يصبح عدد الصفائح الدموية أكبر من 100000/ميكرولتر.</p><p dir="RTL">ويصل أقل عدد لكرات الدم البيضاء، وللصفائح الدموية، بعد مدة تتراوح ما بين 14 - 20 يوم؛ مع إعادة تولد الكرات الدموية البيضاء، والصفائح الدموية،&nbsp; بعد مرور فترة تتراوح ما بين 3 - 5 أسابيع. ويوصى في أثناء فترة العلاج، بإجراء متابعة صارمة، وعلى فترات غير محددة، لعدد مكونات الدم (راجع قسم التحذيرات الخاصة واحتياطات الاستعمال).</p><p dir="RTL">&nbsp;</p><p dir="RTL">ويجب - في حالة السُمية غير الدموية - أن يكون تخفبض الجرعة قائم على أساس أسوأ معايير السُمّيّة الشائعة&nbsp; &quot;سي.تي.سي&quot;، في الدورة العلاجية السابقة. يوصى بإجراء تخفيض الجرعة بنسبة 50%؛ وذلك في حالة معيار السُمّيّة الشائعة&nbsp; &quot;سي.تي.سي&quot; من الدرجة الثالثة. يوصى بإجراء تخفيض الجرعة بنسبة 50%؛ وذلك في حالة معيار السُمّيّة الشائعة&nbsp; &quot;سي.تي.سي&quot; من الدرجة الثالثة.</p><p dir="RTL">ويجب - في حال تطلبت حالة المريض تعديل الجرعة - أن يتم إعطاء الجرعة المخفضة المحسوبة وفقاً لكل حالة، في اليوم الأول والثاني من الدورة العلاجية المعنية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يرجى الرجوع إلى قسم الاحتياطات الخاصة بالتخلص من المُنْتَج، وعمليات التداول الأخرى؛ وذلك للحصول على التعليمات الخاصة بإعداد وإعطاء الدواء.</p><p dir="RTL"><u>الاختلال الكبدي</u></p><p dir="RTL">الأمر لا يتطلب إجراء أي تعديلات على الجرعة، بالنسبة للمرضى الذين يعانون من الاختلال الكبدي المعتدل (بيليروبين المصل أقل من 1.2 مج/ديسيلتر)؛ وذلك وفقاً لبيانات الحركية الدوائية. ويوصى بتخفيض الجرعة بنسبة 30%؛ وذلك بالنسبة للمرضى الذين يعانون من الاختلال الكبدي المتوسط (بيليروبين المصل يتراوح ما بين 1.2- 3.0 مج/ديسيلتر).</p><p dir="RTL">لا توجد بيانات فيما يتعلق بالمرضى الذين يعانون من الاختلال الكبدي الشديد (بيليروبين المصل أكبر من 3.0 مج/ديسيلتر) (راجع قسم موانع الاستعمال).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>الاختلال الكُلوي</u></p><p dir="RTL">الأمر لا يتطلب إجراء أي تعديلات على الجرعة، بالنسبة للمرضى ممن تتجاوز نسبة تصفية الكرياتينين 10 مليلتر/الدقيقة. هناك خبرات محدودة بالنسبة للمرضى الذين يعانون من الاختلال الكلوي الشديد.</p><p dir="RTL"><u>المرضى من الأطفال</u><u>:</u></p><p dir="RTL">لا تتوفر خبرات بالنسبة للأطفال والمراهقين؛ وذلك فيما يتعلق بالعلاج باستعمال بنداموستين هيدروكلوريد .</p><p dir="RTL"><u>المرضى المسنين</u><u>:</u></p><p dir="RTL">لا توجد أدلة على ضرورة ضبط الجرعة بالنسبة للمرضى من كبار السن (راجع قسم خصائص الحركية الدوائية).</p><p dir="RTL">طريقة الإدارة</p><p dir="RTL">.( انظر القسم اتجاه الاستخدام)&nbsp; للتسريب في الوريد لأكثر من 30 - 60 دقيقة</p><p dir="RTL">يجب أن تدار التسريب تحت إشراف طبيب مؤهل وذوي الخبرة في استخدام وكلاء العلاج الكيميائي.</p><p dir="RTL">يرتبط ضعف وظيفة النخاع العظمي بزيادة سمية الدم الناجمة عن العلاج الكيميائي. لا ينبغي أن يبدأ العلاج إذا انخفضت الكريات البيض و / أو قيم الصفائح الدموية إلى &lt;3000 / ميكرولتر أو أقل من 75000 / ميكروليتر ، على التوالي (انظر القسم CONTRAINDICATIONS).<br /><br />يجب إنهاء المعالجة أو تأخيرها إذا انخفضت قيم الكريات البيض و / أو الصفائح الدموية إلى &lt;3000 / ميكرولتر أو أقل من 75000 / ميكروليتر ، على التوالي. يمكن أن يستمر العلاج بعد زيادة قيم الكريات البيض إلى&gt; 4000 / ميكرولتر وقيم الصفائح الدموية إلى<br />&gt; 100،000 / ميكرولتر.<br /><br />يتم الوصول إلى الكريات البيض والصفائح الدموية نادر بعد 14-20 يوما مع تجديد بعد 3-5 أسابيع. أثناء فترات العلاج المجانية ، يوصى بمراقبة صارمة لتعداد الدم (انظر قسم التحذيرات والاحتياطات للاستخدام).<br /><br />في حالة التسمم بغير سمية دموية ، يجب أن تستند تخفيضات الجرعة إلى أسوأ درجات CTC في الدورة السابقة. يوصى بتخفيض الجرعة بنسبة 50 ٪ في حالة سمية CTC من الدرجة 3. يوصى بوقف العلاج في حالة سمية CTC من الدرجة 4.<br /><br />إذا كان المريض يحتاج إلى تعديل الجرعة ، فيجب إعطاء الجرعة المخفضة المحسوبة بشكل فردي في اليوم الأول والثاني من دورة العلاج المعنية.<br /><br />للحصول على إرشادات حول إعادة تكوين المنتج الطبي قبل تناوله ، انظر القسم &quot;اتجاه الاستخدام&quot;.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">3 موانع الاستعمال</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>الحساسية المفرطة تجاه المادة الفعالة في الدواء، أو لأي من السِوَاغات (راجع قسم قائمة السِوَاغات).<strong> </strong></p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>في أثناء الرضاعة الطبيعية</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>الاختلال الكبدي الشديد (بيليروبين المصل أكبر من 3.0 مج/ديسيلتر)</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>اصفرار لون الجلد ، واصفرار بياض العينين (اليرقان)</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>الكبت الشديد لنخاع العظام، والتغيرات الشديدة في عدد مكونات الدم (انخفاض كرات الدم البيضاء و/أو الصفائح الدموية إلى أقل من 3000 /ميكرولتر، أو أقل من 75000/ ميكرولتر على التوالي)</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>الجراحات الكبرى، أقل من 30 يوماً قبل البدء في تناول العلاج</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>العدوى، خاصة أنواع العدوى التي تنطوي على نقص كرات الدم البيضاء</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>لقاح الحمى الصفراء</p><p dir="RTL">&nbsp;</p><p dir="RTL">4.4 التحذيرات الخاصة واحتياطات الاستعمال</p><p dir="RTL"><u>الكَبْتُ النِّقْي </u></p><p dir="RTL">قد يتعرض المرضى الذي يعالجون باستعمال&nbsp; بنداموستين هيدروكلوريد للإصابة بالكَبْتُ النِّقْي.&nbsp; في حالة الإصابة بالكَبْتُ النِّقْي الناتج عن العلاج؛ فإنه يجب مراقبة عدد كرات الدم البيضاء، والصفائح الدموية، والهيموجلوبين والخلايا المتعادلة، وذلك بشكل أسبوعي على الأقل. يوصى بتوخي المعايير التالية، وذلك قبل بدء الدورة العلاجية التالية: أن تكون قيم كرات الدم البيضاء و/أو الصفائح الدموية أكبر من 4000/ميكرولتر، أو 100000/ميكرولتر على التوالي.</p><p dir="RTL"><u>حالات العدوى</u></p><p dir="RTL">وردت تقارير بخصوص العدوى؛ بما في ذلك&nbsp; عدوى الالتهاب الرئوي، وتَعَفُّن الدَّم. كما كانت العدوى - في حالات نادرة - مصحوبة بدخول المستشفى، والصدمة الإنتانية والموت. ويعتبر المرضى الذين يعانون من نقص الخلايا المتعادلة و/أو قِلَّةُ اللِّمْفاوِيَّات في أعقاب العلاج باستعمال بنداموستين هيدروكلوريد؛ هم الأكثر تعرضاً للعدوى. يجب إسداء النصح للمرضى الذين يعانون من الكَبْتُ النِّقْي، في أعقاب العلاج باستعمال&nbsp; بنداموستين هيدروكلوريد، بالاتصال بالطبيب؛ وذلك في حالة ملاحظتهم لأعراض أو علامات العدوى، بما في ذلك الحمى أو الأعراض ذات الصلة بالجهاز التنفسي.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>التفاعلات الجلدية</u></p><p dir="RTL">وردت تقارير بخصوص حدوث عدد من حالات التفاعلات الجلدية. ولقد اشتملت تلك الحالات على الطفح الجلدي، وتفاعلات الجلد السامة، والطفح الفقاعي. حدثت بعض الحالات عند إعطاء بنداموستين هيدروكلوريد، بالتزامن مع الأدوية الأخرى المضادة للسرطان؛ ومن ثم فإن العلاقة الدقيقة ليست مؤكدة. ومن الممكن - عند حدوث تفاعلات الجلد المذكورة - أن تتفاقم تلك التفاعلات، وتزداد شدتها مع تلقي المزيد من العلاج. يجب - في حالة تفاقم تفاعلات الجلد - حجب العلاج باستعمال بنداموستين هيدروكلوريد، أو عدم الاستمرار في العلاج. يجب عدم الاستمرار في العلاج باستعمال&nbsp; بنداموستين هيدروكلوريد؛ وذلك في حالة الشك في وجود علاقة بين تفاعلات الجلد الشديدة، وبين استعمال بنداموستين هيدروكلوريد.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>المرضى الذين يعانون من اضطرابات القلب</u></p><p dir="RTL">يجب - في اثناء العلاج باستعمال بنداموستين هيدروكلوريد - إجراء المتابعة الدقيقة لتركيز البوتاسيوم في الدم؛ كما يجب إعطاء مكملات البوتاسيوم، وذلك في حالة وصول تركيز&nbsp; K<sup>+</sup> إلى أقل من 3.5 مللي مكافئ/لتر؛ كما يجب أيضاً إجراء قياس مُخَطَّطُ كَهْرَبِيَّةِ القَلْب.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>الغثيان والقيء</u></p><p dir="RTL">يمكن إعطاء مضاد للقىء؛ وذلك لعلاج الأعراض ذات الصلة بالغثيان والقيء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>متلازمة انحلال الورم</u></p><p dir="RTL">وردت تقارير بخصوص ظهور حالات متلازمة انحلال الورم، المصاحبة للعلاج باستعمال بنداموستين هيدروكلوريد؛ وذلك في المرضى الخاضعين للتجارب الإكلينيكية. يبدأ ظهور الأعراض في خلال 48 ساعة من تناول الجرعة الأولى من بنداموستين هيدروكلوريد؛ كما أنها قد تؤدي - في حالة عدم التدخل - إلى الفشل الكلوي الحاد والوفاة. الإجراءات الوقائية بما في ذلك مراعاة حجم الدم في الدورة الدموية، والمتابعة الدقيقة لكيمياء الدم، وخاصة مستويات البوتاسيوم وحمض اليوريك. يمكن النظر بعين الاعتبار إلى استعمال ألوبيورينول، في أثناء الفترة من الأسبوع الأول إلى الأسبوع الثاني، من العلاج باستعمال بنداموستين هيدروكلوريد؛ وإن كان من غير الضروري أن يكون ذلك بشكل قياسي. وعلى كل حال؛ فقد وردت تقارير بخصوص ظهور حالات قليلة لمتلازمة ستيفن جونسون، وتقَشُّرُ أنسجة البشرة التسممي؛ وذلك عند إعطاء بنداموستين بالإضافة إلى ألوبيورينول بشكل متزامن.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>&nbsp;التَأَق </u><u>(</u><u>المظاهر الشديدة والفورية للحساسية</u><u>) </u></p><p dir="RTL">ظهرت حالات شائعة&nbsp; لحساسية التسريب (الحقن الوريدي البطيء) تجاه بنداموستين هيدروكلوريد؛ وذلك في أثناء التجارب الإكلينيكية. ولقد كانت الأعراض خفيفة بشكل عام؛ والتي اشتملت على الحمى، والقشعريرة، والحكة والطفح الجلدي. وقد وردت تقارير نادرة، بخصوص ظهور حالات تفاعلات تَأَقِيّ، وتفاعلات نوبات شبيهة بالتَّأَقي.&nbsp; يجب سؤال المرضى عن الأعراض، التي قد تكون مرتبطة بتفاعلات التسريب؛ وذلك بعد الدورة العلاجية الأولى.&nbsp;&nbsp; يجب النظر بعين الاعتبار إلى الإجراءات الواجب اتخاذها بغرض تجنب التفاعلات الشديدة؛ بما ذلك إعطاء المريض - في الدورات العلاجية التالية -&nbsp; الأدوية المضادة للهيستامين، والأدوية الخافضة للحرارة، والكورتيكوستيرويدات؛ وذلك بالنسبة للمرضى الذين تعرضوا من قبل لتفاعلات التسريب (الحقن الوريدي البطيء.</p><p dir="RTL">وفي العادة، لم تكن تتم إعادة محاولة العلاج باستعمال بنداموستين هيدروكلوريد؛ وذلك بالنسبة للمرضى الذين كانوا يعانون من تفاعلات الحساسية من الدرجة الثالثة، أو من الدرجات الأسوأ.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>وسائل منع الحمل</u></p><p dir="RTL">بنداموستين هيدروكلوريد هو أحد الأدوية الماسخة والمسببة للتشوهات الخلقية.</p><p dir="RTL">يجب على المرأة ألا تتعرض للحمل في أثناء فترة العلاج بهذا الدواء. يجب على المرضى من الذكور ألا يحاولوا الإنجاب؛ وذلك في أثناء فترة العلاج، ولغاية ستة أشهر بعد العلاج.&nbsp; ويجب على مثل هؤلاء المرضى، طلب المشورة بخصوص عملية حفظ السائل المنوي، قبل البدء في العلاج باستعمال بنداموستين هيدروكلوريد؛ وذلك بسبب احتمال التعرض للعقم الدائم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>التَسَرُّب </u></p><p dir="RTL">يجب التوقف الفوري في حالة الحقن خارج الوريد، ثم إزالة المِحْقَن (إبرة الحقن) بعد اخذ نفس قصير، حيث يتم بعد ذلك تبريد منطقة الأنسجة المتأثرة، كما يجب رفع الذراع إلى أعلى. لم يثبت وجود فائدة واضحة لاستخدام أي علاجات إضافية مثل استعمال الكورتيكوستيرويدات.</p><p dir="RTL">&nbsp;</p><p dir="RTL">4.5 التفاعل مع المنتجات الدوائية، والأشكال الأخرى من التفاعل</p><p dir="RTL">لم يتم إجراء أية دراسات في الأحياء؛ فيما يتعلق بمثل تلك التفاعلات.</p><p dir="RTL">قد يزداد تأثير بنداموستين هيدروكلوريد، و/أو المنتجات الدوائية المصاحبة، على نخاع العظام؛ وذلك عند إعطاء بنداموستين هيدروكلوريد، في توليفة مع العوامل الكابِتُة للنِّقْي. من الممكن أن يتسبب أي علاج يقلل من حالة أداء المريض، أو إضعاف وظيفة نخاع العظام؛ في زيادة درجة سُمِّية بنداموستين هيدروكلوريد.</p><p dir="RTL">من الممكن أن تتسبب توليفة من&nbsp; بنداموستين هيدروكلوريد، مع سيكلوسبورين أو تاكروليموس؛ في تثبيط المناعة بشكل مُفْرِط، مع خطر التعرض للاضطرابات التكاثرية اللمفية.</p><p dir="RTL">من الممكن أن يؤدي مُحِد النمو الخلوي، إلى الحد من تكوين الأجسام المضادة، في أعقاب التطعيم بالفيروسات الحية، مع زيادة خطر التعرض للعدوى، وهو ما قد يؤدي إلى نتائج مميتة.&nbsp; يزداد الخطر بالنسبة للأشخاص الذين يعانون بالفعل من التثبيط المناعي، وذلك كنتيجة لما هم مصابون به من أمراض كامنة.</p><p dir="RTL">ينطوي استقلاب بنداموستين على النَظِيْرٌ الإنزيمي &quot;سي.واي.بي. 1إيه2&quot;، من مجموعة إنزيمات السيتوكروم بيه450 &nbsp;(راجع خصائص الحركية الدوائية). ومن ثم، فإن هناك احتمال حدوث تفاعلات مع&nbsp; مثبطات &quot;سي.واي.بي. 1إيه2&quot;، مثل الفلوفوكسامين، والسيبروفلوكساسين، والأسيكلوفير والسيميتيدين.</p><p>سكان الأطفالوقد أجريت دراسات التفاعل في البالغين فقط.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">4.6 الخصوبة، والحمل والرضاعة</p><p dir="RTL"><u>الحمل</u></p><p dir="RTL">لا توجد بيانات كافية بخصوص استعمال بنداموستين هيدروكلوريد مع السيدات الحوامل. أظهرت الدراسات غير الإكلينيكية، أن بنداموستين هيدروكلوريد يعتبر دواءً محدثاً للسُمية الجينية، كما أنه يعتبر دواءً ماسخاً ومسبباً للتشوهات الخلقية، وللسُمية الجنينية (راجع قسم بيانات الأمان في المرحلة قبل الإكلينيكية). لا يجب استعمال بنداموستين هيدروكلوريد في أثناء فترة الحمل، ما لم تكن هناك ضرورة مُلِحَة لذلك؛ كما يجب إبلاغ الأم بالمخاطر التي قد يتعرض لها الجنين. إذا كان العلاج بنداموستين هيدروكلوريد أمراً حتمياً في أثناء فترة الحمل، أو في حالة حدوث الحمل في أثناء العلاج؛ فإنه يجب إبلاغ المريضة بالمخاطر التي قد يتعرض لها الجنين، بالإضافة إلى الالتزام بالمتابعة الدقيقة للأم.&nbsp;&nbsp; يجب النظر بعين الاعتبار إلى إمكانية اللجوء إلى الحصول على الاستشارة الجينية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>الخصوبة</u></p><p dir="RTL"><u>السيدات محتملة الإنجاب </u><u>/ </u><u>وسائل منع الحمل</u></p><p dir="RTL">يجب على السيدات محتملة الإنجاب، اللجوء إلى استعمال وسائل فعالة لمنع الحمل؛ وذلك قبل البدء في العلاج باستعمال بنداموستين هيدروكلوريد، وكذلك في أثناء العلاج.</p><p dir="RTL">يُنْصَح الرجال الذين يعالجون باستعمال بنداموستين هيدروكلوريد؛ بعدم محاولة الإنجاب في أثناء فترة العلاج، ولغاية ستة أشهر بعد إيقاف العلاج، كما يجب التفكير في حفظ السائل المنوي قبل بدء العلاج باستعمال بنداموستين هيدروكلوريد؛ وذلك بسبب احتمال التعرض للعقم الدائم، نتيجة العلاج باستعمال بنداموستين هيدروكلوريد.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>الرضاعة الطبيعية</u></p><p dir="RTL">من غير المعروف ما إذا كان بنداموستين هيدروكلوريد يمر إلى لبن الأم؛ ومن ثم فإنه يُحْظَر تناول بنداموستين هيدروكلوريد في أثناء فترة الرضاعة (راجع موانع الاستعمال). يجب إيقاف الرضاعة الطبيعية في أثناء فترة العلاج باستعمال بنداموستين هيدروكلوريد.</p><p dir="RTL">&nbsp;</p><p dir="RTL">4.7 التأثيرات في القدرة على القيادة، وعلى استخدام الماكينات</p><p dir="RTL">لم يتم إجراء أي دراسات تتعلق بتأثير تناول العقار على القدرة القيادة، أو تشغيل الماكينات. وعلى كل حال؛ فقد وردت تقارير بخصوص ظهور حالات من الترنح، والاعتلال العصبي الطرفي والنعاس؛ وذلك في أثناء العلاج باستعمال بنداموستين هيدروكلوريد (راجع التأثيرات غير المرغوبة). يجب إبلاغ المريض بضرورة تجنب القيام بالمهام التي يمكن أن تشكل خطراً بالنسبة له، مثل قيادة السيارات أو تشغيل الماكينات؛ وذلك في حالة شعوره بتلك الأعراض.</p><p dir="RTL">&nbsp;</p><p dir="RTL">4.8 التأثيرات غير المرغوبة</p><p dir="RTL">تتمثل غالبية التأثيرات الضارة، المصاحبة للعلاج باستعمال بنداموستين هيدروكلوريد، في التفاعلات الضارة ذات الصلة بالدم (نقص الصفائح الدموية، ونقص كرات الدم البيضاء)، والسمية الجلدية (تفاعلات الحساسية)، والأعراض البِنْيَوِيّ (الحُمى)، وأعراض الجهاز الهضمي (الغثيان والتقيؤ).</p><p dir="RTL">يعكس الجدول المبين أدناه، البيانات التي تم الحصول عليها، ذات الصلة باستعمال بنداموستين هيدروكلوريد في التجارب الإكلينيكية.</p><p dir="RTL">جدول 1: التفاعلات الضارة في المرضى الذين تلقوا العلاج باستعمال بنداموستين هيدروكلوريد.</p><table dir="rtl" border="1" cellspacing="0" cellpadding="0" style="width:718px"><tbody><tr><td style="vertical-align:top"><p dir="RTL">القاموس الطبي للأنشطة التنظيمية (<strong>MedDRA</strong>)</p></td><td style="vertical-align:top"><p dir="RTL">الأعراض الشائعة جداً&nbsp; &ge;</p><p dir="RTL">1<strong>/</strong>10</p></td><td style="vertical-align:top"><p dir="RTL">الأعراض الشائعة</p><p dir="RTL">(أكبر من أو يساوي 1<strong>/</strong>100 إلى أقل من 1<strong>/</strong>10)</p></td><td style="vertical-align:top"><p dir="RTL">الأعراض غير الشائعة</p><p dir="RTL">(أكبر من أو يساوي 1<strong>/</strong>1000 إلى أقل من 1<strong>/</strong>100)</p></td><td style="vertical-align:top"><p dir="RTL">الأعراض النادرة</p><p dir="RTL">(أكبر من أو يساوي 1<strong>/</strong>10000 إلى أقل من 1<strong>/</strong>1000)</p></td><td style="vertical-align:top"><p dir="RTL">الأعراض النادرة جداً:</p><p dir="RTL">أقل من 1<strong>/</strong>10000</p></td><td style="vertical-align:top"><p dir="RTL"><u>الآثار الجانبية غير المعروفة (لا يمكن تقدير مرات الحدوث من خلال البيانات المتاحة)</u></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">العدوى والإصابة بِالطُّفَيلِيَّات</p><p dir="RTL">&nbsp;وغير محدد (بما في ذلك الكيس والبول(</p><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">العدوى NOS</p><p dir="LTR">بما في ذلك</p><p dir="LTR">العدوى الانتھازیة</p><p dir="LTR">(مثل الھربس</p><p dir="LTR">النطاقي ،</p><p dir="LTR">الفیروس المضخم</p><p dir="LTR">للخلایا ، التھاب</p><p dir="RTL">(B الكب</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p dir="RTL">تَعَفُّن الدَّم.</p></td><td style="vertical-align:top"><p dir="RTL">الالتهاب الرئوي الابتدائي اللانمطي</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p dir="RTL">الأورام الحميدة، الخبيثة</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p dir="RTL">متلازمة انحلال الورم</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p dir="RTL">اضطرابات الدم والجهاز اللمفاوي</p></td><td style="vertical-align:top"><p dir="RTL">نقص كرات الدم البيضاء NOS، نقص الصفائح الدموية</p></td><td style="vertical-align:top"><p dir="RTL">النزيف وفقر الدم، نقص الخلايا المتعادلة</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p dir="RTL">انحلال الدم</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p dir="RTL">اضطرابات الجهاز المناعي</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p dir="RTL">فرط الحساسية NOS</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p dir="RTL">رد الفعل التحسسي، رد فعل التأقاني</p></td><td style="vertical-align:top"><p dir="RTL">صدمة الحساسية</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p dir="RTL">اضطرابات الجهاز العصبي</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p dir="RTL">الأرق</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p dir="RTL">نعاس، فقد الصوت</p></td><td style="vertical-align:top"><p dir="RTL">خلل التذوق، والمَذَل (التنميل)، والاعتلال العصبي الحسي الطرفي، متلازمة مضادات، والاضطرابات العصبية، والترنح، والتهاب الدماغ</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p dir="RTL">الاضطرابات القلبية</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p dir="RTL">الاختلال الوظيفي للقلب؛ مثل الخفقان، والذبحة الصدرية، عدم انتظام ضربات القلب</p></td><td style="vertical-align:top"><p dir="RTL">الانْصِبابٌ التأمُورِيّ</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p dir="RTL">عدم انتظام دقات القلب، واحتشاء عضلة القلب، فشل القلب</p></td><td style="vertical-align:top"><p dir="LTR">الرجفان</p><p dir="RTL">الأذیني</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">الاضطرابات الوعائية</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p dir="RTL">انخفاض ضغط الدم، ارتفاع ضغط الدم</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p dir="RTL">فشل الدورة الدموية الحاد</p></td><td style="vertical-align:top"><p dir="RTL">الالتهاب الوريدي</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p dir="RTL">اضطرابات الجهاز التنفسي، والصدر والرئتين</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p dir="RTL">الاختلال الوظيفي الرئوي</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p dir="RTL">التليف الرئوي</p></td><td style="vertical-align:top"><p dir="LTR">التھاب رئوي</p><p dir="LTR">النزف الرئوي</p><p dir="RTL">السنخي</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">الاضطرابات المَعِدِيَّةٌ المِعَوِيَّة</p></td><td style="vertical-align:top"><p dir="RTL">الغثيان والقيء</p></td><td style="vertical-align:top"><p dir="RTL">الإسهال، الإمساك، التهاب المعدة</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p dir="RTL">الْتِهابُ المَريء النزفي،النزف المعدي - المعوي</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p dir="RTL">اضطرابات الجلد والأنسجة تحت الجلد</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p dir="RTL">ثعلبة،</p><p dir="RTL">تساقط الشعر، اضطرابات الجلد NOS</p><p dir="RTL">الشرى</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p dir="RTL">الحمامي، التهاب الجلد، الحكة، الطفح البقعي، فرط التعرق</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p dir="LTR">متلازمة ستیفنز</p><p dir="LTR">جونسون ، انحلال البشرة</p><p dir="LTR">النخري السمي</p><p dir="LTR">(TEN)</p><p dir="LTR">التفاعل الدوائي</p><p dir="LTR">مع فرط</p><p dir="LTR">الحمضات</p><p dir="LTR">والأعراض</p><p dir="LTR">الجھازیة</p><p dir="RTL">* (DRESS)</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">اضطرابات الجهاز التناسلي الثدي</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p dir="RTL">إنحباس الطمث</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p dir="RTL">العقم</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p dir="RTL">الاضطرابات الكبدية الصفراوية</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p dir="RTL">الفشل الكبدي</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">الاضطرابات الصحية العامة وأحوال موضع إعطاء الدواء</p></td><td style="vertical-align:top"><p dir="RTL">التهاب الغشاء المخاطي، التعب، الحمى</p></td><td style="vertical-align:top"><p dir="RTL">الألم، القشعريرة، الجفاف، فقدان الشهية</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p dir="RTL">الفشل الجهازي المتعدد</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p dir="RTL">عمليات الاستقصاء</p></td><td style="vertical-align:top"><p dir="RTL">نقص الهيموجلوبين، زيادة الكرياتينين، زيادة اليوريا</p></td><td style="vertical-align:top"><p dir="RTL">زيادة ناقِلَةُ أَمينِ الأَسْبَارتات &quot;إيه.إس.تي&quot; ، زيادة ناقِلَةُ أَمينِ الأَلانين &quot;إيه.إل.تي&quot; ، زيادة الفوسفاتات القلوية في الدم، زيادة البيليروبين،&nbsp; نقص بوتاسيوم الدم</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p dir="RTL">الاضطرابات</p><p dir="RTL">الكلویة والبولیة</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p dir="RTL">الفشل الكلوي</p></td><td style="vertical-align:top">&nbsp;</td></tr></tbody></table><p dir="RTL">NOS = لم يتم تحديد خلاف ذلك</p><p dir="RTL">&nbsp;</p><p dir="RTL">وردت تقارير بخصوص ظهور عدد صغير من متلازمة ستيفن جونسونَ، وتَقَشُّرُ أنسجة البشرة الميتة التسممي؛ وذلك بالنسبة للمرضى الذين استعملوا بنداموستين، في توليفة مع ألوبيورينول، أو في توليفة مع&nbsp; ألوبيورينول وريتوكسيماب.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد تنخفض النسبة CD4/CD8. تلاحظ وجود انخفاض في عدد اللمفاويات. قد يزداد خطر العدوى (مثل العدوى بالهِرْبِسٌ النُطاقِيّ على سبيل المثال)؛ وذلك&nbsp; في المرضى الذين يعانون من كبت المناعة.</p><p dir="RTL">وردت تقارير منعزلة بخصوص حالات تَسَوُّسُ العِظَام (نخر) بعد الحقن - عن طريق الخطأ -&nbsp; خارج الأوعية الدموية؛ كما ظهرت حالات&nbsp; لتَقَشُّرُ أنسجة البشرة الميتة التسممي، ومتلازمة انحلال الورم، والتَأَق (المظاهر الشديدة والفورية للحساسية).</p><p dir="RTL">&nbsp;</p><p dir="RTL">وردت تقارير بخصوص ظهور حالات أورام ثانوية، والتي شملت متلازمة خلل التنسج النقوي (خَلَلُ التَّنَسُّجِ النُّخاعِيّ) ، وسرطان الدم النخاعي الحاد، وسرطان الشعب الهوائية.. لم يتم التحقق من ارتباط تلك الأمور، بالعلاج باستعمال بنداموستين هيدروكلوريد.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p>الإخطار عن ردود الفعلمن المهم عن ردود الفعل تمكن بمراقبة مستمرة لموازنة الفوائد / المخاطر للمنتج الطبي. طلب من المتخصصين في الرعاية الصحيةللإجابة عن أي أعراض جانبية:-</p><p dir="RTL">للإبلاغ عن أي أعراض جانبية:</p><p dir="RTL">-المركز الوطني للتيقظ والسلامة الدوائية (NPC)</p><p dir="RTL">فاكس: 7662 - 205 - 11 - 966+</p><p dir="RTL">اتصل بالمركز الوطني للتيقظ والسلامة الدوائية (NPC)على هاتف رقم2038222 - 11 - 966+ داخلي: 2340 - 2356 - 2317.</p><p dir="RTL">الخط الساخن للإبلاغ: 19999</p><p dir="RTL">البريد الإلكتروني: npc.drug@sfda.gov.sa</p><p dir="RTL">الموقع الإلكتروني: www.sfda.gov.sa/npc</p><p dir="RTL">&nbsp;</p><p dir="RTL">هذا دواء.</p><p dir="RTL">&bull; الدواء مستحضر يُؤثر على صحتك واستهلاكه خلافا للتعليمات يُعرضك للخطر.</p><p dir="RTL">&bull; اتبع بدقة وصفة الطبيب، وطريقة الاستعمال المنصوص عليها، وتعليمات الصيدلي الذي صرفها لك.</p><p dir="RTL">&bull; الطبيب والصيدلي خبيران في مجال الأدوية وفوائدها ومخاطرها.</p><p dir="RTL">&bull; لا تقطع مدة العلاج المحددة لك من تلقاء نفسك.</p><p dir="RTL">&bull; لا تكرر الوصفة الطبية نفسها بدون استشارة الطبيب.</p><p dir="RTL">&bull; احتفظ بجميع الأدوية بعيداً عن متناول الأطفال.</p><p dir="RTL">مجلس وزراء الصحة العرب</p><p dir="RTL">اتحاد الصيادلة العرب</p><p dir="RTL">&nbsp;</p><p dir="RTL">4.9 زيادة الجرعة</p><p dir="RTL">بعد استخدام تسريب بنداموستين هيدروكلوريد على مدار 30 دقيقة، مرة واحدة كل ثلاثة أسابيع؛ كانت أقصى جرعة محتملة (إم.تي.دي) هي 280 مج/م<sup>2</sup> . حدثت حالات قلبية خاصة بمعيار السُمّيّة الشائعة &quot;سي.تي.سي&quot; من الدرجة الثانية، والتي كانت متوافقة مع التغيرات في تروية القلب&nbsp; من خلال مُخَطَّطُ كَهْرَبِيَّةِ القَلْب، والتي كان يُنْظَر إليها كأمور تحد من الجرعة.</p><p dir="RTL">ولقد وُجِد في دراسة تالية، تم فيها تسريب بنداموستين هيدروكلوريد على مدار 30 دقيقة، في اليوم الأول والثاني كل ثلاثة أسابيع؛ أن أقصى جرعة محتملة (إم.تي.دي) كانت 180مج/م<sup>2</sup> . وكانت السمية المُحَددة للجرعة&nbsp; هي قلة الصفائح الدموية من الدرجة الرابعة. لم تكن السمية القلبية من العوامل المحددة للجرعة في هذا الجدول.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>التدابير المضادة</u></p><p dir="RTL">لا يوجد ترياق محدد. يمكن إجراء زرع للنخاع العظمي ونقل الدم (الصفائح الدموية، وكريات الدم الحمراء.المركزة)؛ كما يمكن إعطاء عوامل النمو الدموية، وذلك كتدابير مضادة فعالة، بغرض التحكم في الآثار الجانبية الدموية.</p><p dir="RTL">ويعتبر بنداموستين هيدروكلوريد ومُسْتَقْلَباته من الأدوية القابِلٌة للدِّيال إلى حدٍ بسيط.</p><p dir="RTL">&nbsp;</p><p dir="RTL">5 الخصائص الدوائية</p><p dir="RTL">5.1 الخصائص الديناميكية الدوائية</p><p dir="RTL">المجموعة الدوائية العلاجية: العوامل المضادة للأورام، والعوامل المُؤَلْكِلة، نظام التصنيف الكيماوي العلاجي التشريحي (إيه.تي.سي): L01AA09.</p><p dir="RTL">يعتبر بنداموستين هيدروكلوريد من العوامل&nbsp; المُؤَلْكِلة المضادة للسرطان، والتي تتميز بفعالية فريدة.&nbsp; ويعتمد التأثير المضاد للأورام والمبيد للخلايا&nbsp; لبنداموستين هيدروكلوريد بشكل أساسي؛ على الربط المتصالب للجدائل الفردية والمزدوجة للحمض النووي، وذلك من خلال عملية الألكلة. ونتيجة لذلك؛ فإن وظائف مصفوفة الحمض النووي، وتخليقه وإصلاحة تصاب بالضعف. ولقد ظهر تأثير بنداموستين هيدروكلوريد المضاد للورم في العديد من الدراسات التي أُجْريت على الأحياء، في خطوط مختلفة من خلايا الأورام البشرية (سرطان الثدي، وسرطان الرئة صغير الخلايا وغير صغير الخلايا، وسرطان المبيض بالإضافة إلى الأنواع المختلفة من اللوكيميا)؛ وكذلك في النماذج التجريبية المختلفة للورم في الأحياء، مع حالات سرطان الفم، وفي أعضاء الفيران والإنسان (سرطان الجلد، سرطان الثدي، والسركوما، وسرطان الغدد الليمفاوية وسرطان الرئة صغير الخلايا).</p><p dir="RTL">ولقد اظهر بنداموستين هيدروكلوريد فعالية مختلفة عن&nbsp; العوامل&nbsp; المُؤَلْكِلة الأخرى؛ وذلك فيما يتعلق بخطوط خلايا السرطان في الإنسان. لقد أظهرت المادة الفعالة مقاومة متصالبة&nbsp; منخفضة جداً - أو عدم وجود مقاومة على الإطلاق - وذلك فيما يتعلق بخطوط خلايا السرطان في الإنسان، ومع آليات المقاومة المختلفة، ولو بشكل جزئي على الأقل؛ وذلك نتيجة نتيجة لتفاعل الحمض النووي المستمر نسبياً. وبالإضافة إلى ذلك؛ فقد أظهرت الدراسات الإكلينيكية، عدم وجود مقاومة متصالبة كاملة لبنداموستين، وذلك مع الأنثراسيكلين، والعوامل المؤلكلة أو ريتوكسيماب. وعلى كل حال، فإن عدد المرضى الذين تم تقييم حالاتهم كان صغيراً</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><u>سرطان الدم الليمفاوي المزمن</u></p><p dir="RTL">لقد كانت دواعي الاستعمال في علاج سرطان الدم الليمفاوي المزمن؛ مدعومة بدراسة غير مُعَمَّاة، والتي تم فيها مقارنة البنداموستين مع الكلورامبوسيل.&nbsp; وقد تم في مجال الاحتمال، متعدد المراكز، في إحدى الدراسات العشوائية، تضمين 319 مريضاً ممن لم يتلقوا علاجاً مسبقاً، والذين كانوا يعانون من سرطان الدم الليمفاوي المزمن، في المرحلة البينية ب أو جـ، والذين كانت حالتهم تتطلب العلاج. ولقد تمت مقارنة الخط العلاجي الأول المكون من بنداموستين هيدروكلوريد 100 مج/م<sup>2</sup> عن طريق الحقن الوريد في اليوم الأول والثاني (BEN) ؛ بالكلورامبوسيل 0.8 مج/كج في اليوم، في اليوم الأول والخامس عشر(CLB) لمدة ست دورات علاجية في المجموعتين. المرضى الذين تلقوا ألوبيورينول بغرض منع متلازمة انحلال الورم.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">وقد اظهر مرضى الــ BEN، فترة بقاء أطول على قيد الحياة بشكل كبير، وخالية من أي تفاقم للمرض ؛ وذلك مقارنة بمرضى الــ CLB</p><p dir="RTL">العلاج (21.5 في مقابل 8.3 شهر، النسبة المئوية&nbsp; أقل من 0.0001 في المتابعة الأخيرة). لم تكن النسبة الشاملة للبقاء على قيد الحياة، مختلفة بشكل كبير من الناحية الإحصائية (لم تصل إلى المتوسط) كان متوسط فترة الخمود 19 شهراً بالنسبة لعلاج الــBEN ، و6 أشهر بالنسبة لعلاج الــCLB ( حيث النسبة المئوية &nbsp;أقل من 0.0001). لم تظهر عملية تقييم الأمان في مجموعتي العلاج، أي من التأثيرات غير المرغوبة، غير المتوقعة، سواء في طبيعة تلك التأثيرات أو في مدى تواترها.&nbsp; تم تخفيض جرعة علاج الــ BEN ، في 34% من المرضى. تم إيقاف علاج الــ BEN&nbsp; في 39% من المرضى؛ وذلك نتيجة لتفاعلات الحساسية.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><u>أورام الغدد الليمفاوية غير الهودجكينية بطيئة الشفاء</u></p><p dir="RTL">يعتمد المؤشر الخاص بأورام الغدد الليمفاوية غير الهودجكينية بطيئة الشفاء، على تجربتين من المرحلة الثانية غير متحكم فيهما.</p><p dir="RTL">وفي دراسة احتمالية محورية،مفتوحة ومتعددة المركز؛ تم إعطاء العلاج المتمثل في الــ BEN أحادي العامل، إلى 100 مريض ممن يعانون من أورام الغدد الليمفاوية غير الهودجكينية بطيئة الشفاء، المستعصية على ريتوكسيماب كعلاج أحادي أو في توليفة مع عوامل أخرى. وقد تلقى المرضى متوسط 3 دورات من العلاج الكيميائي أو العلاج البيولوجي. وقد كان متوسط الدورات العلاجية السابقة المحتوية على الريتوكسيماب هو دورتين. ولم يُظْهِر المرضى استجابة للعلاج، أو أنه قد حدث تقدم في خلال 6 شهور بعد العلاج باستعمال الريتوكسيماب . ولقد كان جرعة الــBEN هي 120 مج/م<sup>2</sup> عن طريق الحقن الوريدي،&nbsp; في اليوم الأول والثاني، والمخطط لها 6 دورات علاجية على الأقل. وتتوقف مدة استمرار العلاج على مدى استجابة المريض للعلاج (المخطط قائم على 6 دورات علاجية).&nbsp; كان المعدل الشامل للاستجابة هو 75%، بما في ذلك 17% استجابة كاملة (CR&nbsp; و CRu)، و 58% استجابة جزئية، وذلك وفقاً للتقييم الذي قامت به لجنة مراجعة مستقلة. كان متوسط فترة الخمود (انخفاض حدة الأعراض) 40 اسبوعاً. كان تحمل علاج الــBEN جيداً بشكل عام؛ وذلك عندما تم إعطاؤه بتلك الجرعة ووفقاً لهذا الجدول.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">وقد تم تدعيم المؤشر أيضاً، وذلك من خلال دراسة احتمالية أخرى،مفتوحة ومتعددة المركز، والتي اشتملت على 77 مريضاً. ولقد كانت شريحة المرضى اكثر تنوعاً حيث اشتملت على: أورام الغدد الليمفاوية الخلية - ب غير الهودجكينية بطيئة الشفاء أو المتحولة، المستعصية على العلاج باستعمال ريتوكسيماب كعلاج أحادي أو في توليفة مع عوامل أخرى. ولم يُظْهِر المرضى استجابة للعلاج، أو أنه قد حدث تقدم في خلال 6 شهور، أو أنه قد حدث رد فعل شديد تجاه العلاج السابق على استعمال الريتوكسيماب . وقد تلقى المرضى متوسط 3 دورات من العلاج الكيميائي أو العلاج البيولوجي. وقد كان متوسط الدورات العلاجية السابقة المحتوية على الريتوكسيماب هو دورتين. كان المعدل الشامل للاستجابة هو 76%، مع متوسط فترة استجابة 5 شهور(29 [95% CI 22.1، 43.1] أسبوع).</p><p dir="RTL"><u>الورم النِقْوِيٌّ المتعدد</u></p><p dir="RTL">وفي دراسة احتمالية، عشوائية، مفتوحة ومتعددة المركز؛ تم تضمين 131 مريض ممن كانوا يعانون من حالات الورم النِقْوِيٌّ المتعدد المتقدمة (دوري - سالمون المرحلة الثانية مع حدوث تقدم، أو المرحلة الثالثة). تمت مقارنة خط العلاج الأول المتمثل في استعمال بنداموستين هيدروكلوريد، في توليفة مع البريدنيزون (BP)؛ مع العلاج باستعمال الملفالان والبريدنيزون (MP).</p><p>كان التحمل في ذراعيه العلاج يتماشى مع ملف تعريف السلامة المعروفة من المنتجات الطبية المعنية مع تخفيضات جرعة أكبر بكثير في ذراع BP.</p><p>&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;كانت الجرعة 150 مج/م<sup>2</sup> عن طريق الحقن الوريدي من بنداموستين هيدروكلوريد في اليوم الأول والثاني؛ كل في توليفة مع البريدنيزون. &nbsp;اعتمدت فترة استمرار العلاج على مدى استجابة المريض للعلاج، والتي كان متوسطها 6.8 دورة علاجية، في مجموعة الــ BP، و 8.7 دورة علاجية في مجموعة الــMP .</p><p dir="RTL">حقق المرضى ممن تلقوا علاج الــ BP متوسط فترة بقاء أطول على قيد الحياة؛ وذلك مقارنة بالمرضى الذين تلقوا علاج الــ MP&nbsp; (15 [95% CI 12-21] مقابل12 [95% CI 10-14] شهراً) (النسبة المئوية 0.0566). كان متوسط الوقت لإخفاق العلاج هو 14 شهراً مع علاج الــ BP ، بينما كان 9 شهور مع علاج الــMP . كان استمرار فترة الخمود هو 18 شهراً مع علاج الــ BP، بينما كانت&nbsp;</p><p dir="RTL">12 شهراً مع علاج الــ MP.&nbsp;&nbsp; لم يكن الفرق في المعدل&nbsp; الشامل للبقاء على قيد الحياة كبيراً (35 شهراً مع علاج الــ BP مقابل 33 شهراً مع علاج الــ MP). كان مدى تحمل العلاج في مجموعتي العلاج، متوافقاً مع معدلات الأمان المعروفة، والخاصة بالمنتجات الدوائية المماثلة، مع ملاحظة التخفيض الكبير للجرعة في المجموعة التي كانت تتلقي علاج الــ .BP</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">5.2 خصائص الحركيات الدوائية</p><p dir="RTL"><u>التوزيع</u><u>:</u></p><p dir="RTL">كان العمر النصفي لإطراح الدواء t<sub>1/2</sub>&szlig;، بعد 30 دقيقة من التسريب الوريدي لــ 120 مج/م<sup>2</sup> ، لــ 12 مريض، هو 28.2 دقيقة.</p><p dir="RTL">كان الحجم الرئيسي للتوزيع 19.3 لتر، وذلك في الــ 30 دقيقة التالية لعملية التسريب الوريدي. كما كان الحجم الرئيسي للتوزيع&nbsp; يتراوح ما بين 15.8 &ndash; 20.5 لتر؛ وذلك في ظل الحالات المستقرة، التالية لعملية التسريب الوريدي للبُلعة.</p><p dir="RTL">كان أكثر من 95% من المادة مرتبطاً ببروتينات البلازما (الألبومين بشكل أساسي).</p><p dir="RTL"><u>الاستقلاب</u></p><p dir="RTL">تتمثل الوسيلة الأكبر لتصفية البنداموستين في التحلل المائي إلى أحادي هيدروكسي، وثنائي هيدروكسي البنداموستين.&nbsp; يشتمل تكوين N- ديسمسثيل-البنداموستين، وجاما-هيدروكسي-البنداموستين من خلال الاستقلاب الكبدي؛ على النَظِيْرٌ الإنزيمي &quot;سي.واي.بي. 1إيه2&quot;، من مجموعة إنزيمات السيتوكروم بيه 450. كما أن هناك وسيلة كبرى أخرى لاستقلاب البنداموستين؛ والتي تنطوي على الاقتران مع الجلوتاثيون.</p><p dir="RTL">لم تُظْهِر الدراسات المختبرية التي أجريت على البنداموستين، أنه لم يُثَبِّط أي من الإنزيمات &quot;سي.واي.بي.1إيه2&quot;، أو &quot;سي.واي.بي. 1إيه4&quot;، أو&nbsp; &quot;سي.واي.بي. 2سي9/10&quot;، أو &quot;سي.واي.بي. 2دي6&quot;، أو &quot;سي.واي.بي. 3إيه4&quot;.</p><p dir="RTL"><u>إطراح الدواء من الجسم</u></p><p dir="RTL">كان متوسط التصفية الكلية، بعد 30 دقيقة من التسريب الوريدي لــ120 مج/م<sup>2</sup> من مساحة سطح الجسم، لــ12 شخص، هو 639.4 مليلتر/الدقيقة. تم استعادة حوالي 20% من الجرعة التي تم إعطاؤها، خلال 24 ساعة عن طريق البول. كانت الكميات التي أُفْرِزَت في البول على النحو التالي أحادي هيدركسي - البنداموستين أكبر من البنداموستين&nbsp; أكبر من ثنائي هيدروكسي - البنداموستين أكبر من المُسْتَقْلَب المؤكسد أكبر من N- ديسميثيل البنداموستين.&nbsp;&nbsp; تم - في البراز - طرح المُسْتَقْلَبات القطبية بشكل أساسي.</p><p dir="RTL"><u>الاختلال الكبدي </u></p><p dir="RTL">لم تتغير سلوكيات الحركية الدوائية؛ وذلك بالنسبة للمرضى الذين كانوا يعانون من تفشي الورم الكبدي بنسبة تتراوح ما بين 30 - 70%، بالإضافة إلى الاختلال الكبدي المعتدل (بيليروبين المصل أقل من 1.2مج/ديسيلتر). لم يكن هناك فرق ملحوظ بالنسبة للمرضى الذين كانوا يتمتعون بوظائف كبد وكلى عادية، وذلك بالنسبة</p><p dir="RTL">لحجم توزيع وتصفية C<sub>max</sub>, t<sub>max, </sub>AUC, t<sub>1/2</sub>&szlig;.التوزيع والاسْتِحالَةُ البَيولوجِيَّة: يتناسب الــ AUC والتصفية الكلية للجسم بالنسبة لبنداموستين؛ تناسباً عكسياً مع بيليروبين المصل.</p><p dir="RTL"><u>الاختلال الكُلوي</u></p><p dir="RTL">بالنسبة للمرضى ممن لديهم تصفية الكرياتينين أكبر من 10 مليلتر/الدقيقة، بما في ذلك المرضى الذين يجرون عمليات الغسيل الدموي (الديال)؛ لم لاحظ وجود&nbsp; فرق كبير&nbsp; بالنسبة للمرضى الذين كانوا يتمتعون بوظائف كبد وكلى عادية؛ وذلك بالنسبة لحجم توزيع وتصفية .C<sub>max</sub>, t<sub>max, </sub>AUC, t<sub>1/2</sub></p><p dir="RTL"><u>الأشخاص كبار السن</u></p><p dir="RTL">تم تضمين الأشخاص لغاية 84 عاماً في الدراسات الخاصة بالحركية الدوائية. لم تؤثر المراحل العمرية الأكبر، على الحركية الدوائية للبنداموستين.</p><p dir="RTL">&nbsp;</p><p dir="RTL">5.3 بيانات الأمان في المرحلة قبل الإكلينيكية</p><p dir="RTL">لم يلاحظ حدوث أي تفاعلات ضارة في الدراسات الإكلينيكية؛ وإن كان قد تلاحظ وجودها بالنسبة للحيوانات، وذلك عند تعرضها لمستويات من العقار، مشابهة لمستويات التعرض الإكلينيكي، مع احتمال وجود علاقة للاستخدام الإكلينيكي على النحو التالي:</p><p dir="RTL">أظهرت الأبحاث الهيستولوجية في الكلاب، وجود فرط دموي ميكروسكوبي في الغشاء المخاطي، كما أظهرت وجود نزف في القناة الهضمية. كما أظهرت الأبحاث الهيستولوجية وجود تغيرات كبيرة في الأنسجة الليمفاوية، وهو ما يشير إلى وجود كبت مناعي، وإلى تغيرات أنبوبية في الكلى، وفي الخصيتين، وذلك بالإضافة إلى التغيرات التي تشمل الضمور والنخر في ظهارة البروستاتا.</p><p dir="RTL">وقد أظهرت الدراسات أن استعمال بنداموستين&nbsp; ينطوي على سُمية للجنين، كما أن له تأثيرات ماسخة للجنين.</p><p dir="RTL">يتسبب بنداموستين&nbsp; في إحداث انحرافات صبغية، كما أنه&nbsp; مُطَفِّر (مُحْدِث للتشوهات) سواء في الكائنات الحية أو في المختبرات. أثبتت الدراسات طويلة الأجل على أنثى الفئران، أن بنداموستين يسبب السرطان.</p><p dir="RTL">&nbsp;</p><p dir="RTL">6. التفاصيل الصيدلانية</p><p dir="RTL">6.1 قائمة السِوَاغات</p><p dir="RTL">المانيتول</p><p dir="RTL">ثلاثي بوتيل الكحول.</p><p dir="RTL">&nbsp;</p><p dir="RTL">6.2 عدم التوافق</p><p dir="RTL">يجب عدم مزج هذا المُنْتَج الطبي، مع منتجات طبية أخرى، وذلك فيما عدا تلك المنتجات المذكورة في قسم الاحتياطات الخاصة بالتخلص من المُنْتَج، وعمليات التداول الأخرى.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">6.3 مدة الصلاحية</p><p dir="RTL">24 شهر من تاريخ التصنيع.</p><p dir="RTL">يجب إعادة التركيب الفوري للمسحوق، باستخدام محلول كلوريد الصوديوم 0.9%، وذلك بعد فتح الأمبول.</p><p dir="RTL">يجب إجراء التخفيف الفوري، للمُرَكَّز المُعاد تركيبه؛ وذلك بعد تجهيزه مباشرة.</p><p dir="RTL"><u>محلول للحقن</u></p><p dir="RTL">أظهرت المحلول - بعد إعادة التركيب والتخفيف - ثباتاً فيزيائياً وكيميائياً لمدة 3.5 ساعات، عند درجة حرارة 25 درجة مئوية، ولمدة 48 ساعة عند درجة حرارة تتراوح ما بين 2 - 8 درجات مئوية، عند الحفظ في أكياس البولي إيثيلين.</p><p dir="RTL">يجب الاستخدام الفوري للمحلول؛ وذلك من وجهة النظر الميكروبيولوجية. تقع المسؤولية على المستخدم، فيما يتعلق بوقت التخزين، وبظروف المُنْتَج قبل الاستعمال؛ وذلك في حالة عدم الاستخدام الفوري للمحاليل.</p><p dir="RTL">4 الاحتياطات الخاصة بالتخزين</p><p dir="RTL">يجب عدم تخزين المُنْتَج في درجة حرارة تتجاوز 30 درجة مئوية، مع حماية المُنْتَج من الضوء.</p><p dir="RTL">فيما يتعلق يشروط التخزين بعد إعداد المُتْتَج الطبي للاستعمال، يرجي مراجعة قسم فترة الصلاحية.</p><p dir="RTL">يجب الاحتفاظ بالقارورة في الكرتونة الخارجية، وذلك بغرض حماية المُنْتَج من التعرض للضوء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">5 طبيعة ومحتويات العلبة</p><p dir="RTL">25 مج/أمبول:أمبول سعة 20 ملليلتر، من النوع رقم 1 من العنبر الأنبوبي، لأمبولات &quot;ليو&quot; مسطحة القاع، مزود بسدادات للقفل، مصنوعة من البروموبوتيل الرمادي، بالإضافة إلى مانع للتسريب 20 مم مصنوع من الألومنيوم.</p><p dir="RTL">100 مج/أمبول: أمبول سعة 50 ملليلتر، من النوع رقم 1 من أمبولات العنبر المصبوب،&nbsp; مزود بسدادات للقفل، مصنوعة من البروموبوتيل الرمادي، بالإضافة إلى مانع للتسريب 20 مم مصنوع من الألومنيوم.</p><p dir="RTL">حجم العبوة - 1 أمبول في كرتونة.</p><p dir="RTL">6 الاحتياطات الخاصة بالتخلص من المُنْتَج، وعمليات التداول الأخرى</p><p dir="RTL">يجب - عند مناولة بنداموستين هيدروكلوريد - تجنب استنشاقه، أو ملامسته للجلد، أو للأغشية المخاطية (يجب ارتداء قفاز وملابس واقية). يجب شطف الأجزاء الملوثة من الجسم بعناية، باستخدام الماء والصابون، كما يجب شطف العينين بمحلول ملحي فسيولوجي. يوصى - إذا سمحت الظروف - بالعمل على منضدة أمان خاصة (للتدفق السطحي)، مع أوراق ماصة للسوائل، وغير مُنْفِذَة لها. يجب إبعاد السيدات الحوامل من التعامل مع المواد المُحِدَة للنمو الخلوي.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يجب أن تتم إعادة تركيب المسحوق بماء الحقن، المخفف بمحلول كلوريد الصوديوم 9 مج/مل (0.9%)، يم يتم إعطاؤه عن طريق التسريب الوريدي.&nbsp; يجب استخدام تقنية مُطَهِّرَة.</p><p dir="RTL"><u>1. </u><u>إعادة التركيب</u></p><p dir="RTL">تتم إعادة تركیب كل أمبول بنداموستین ھیدروكلورید، الذي یحتوي 25 مج من بنداموستین ھیدروكلورید، في 10 مللیلتر ماء للحقن. ؛ عن طریق الرجرجة؛</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p dir="RTL">تتم إعادة تركیب كل أمبول بنداموستین ھیدروكلورید، الذي یحتوي 100 مج من بنداموستین ھیدروكلورید، في&nbsp; 40 مللیلتر ماء للحقن. ؛ عن طریق الرجرجة؛</p><p dir="RTL">&nbsp;</p><p dir="RTL">یحتوي المُرَكَّز المُعاد تركیبھ على 2.5 مج بنداموستین ھیدروكلورید، لكل مللیلتر، ویظھر على ھیئة محلول رائق عدیم</p><p dir="RTL">اللون</p><p dir="RTL">يحتوي المُرَكَّز المُعاد تركيبه على 2.5 مج بنداموستين هيدروكلوريد، لكل ملليلتر، ويظهر على هيئة محلول رائق عديم اللون.</p><p dir="RTL"><u>2. </u><u>التخفيف</u></p><p dir="RTL">بمجرد الحصول على محلول رائق عديم اللون (عادة بعد حوالي 5 - 10 دقائق)؛ يتم التخفيف&nbsp; الفوري للجرعة الكلية الموصى بها من بنداموستين هيدروكلوريد، بمحلول كلوريد الصوديوم 0.9%؛ وذلك للحصول على حجم نهائي حوالي 500 ملليلتر.</p><p dir="RTL">يجب تخفيف بنداموستين هيدروكلوريد بمحلول كلوريد الصوديوم 0.9%، وليس بأي محلول حقن آخر.</p><p dir="RTL"><u>3. </u><u>إعطاء الدواء</u></p><p dir="RTL">يتم إعطاء المحلول عن طريق التسريب الوريدي؛ وذلك على مدى 30 - 60 دقيقة.</p><p dir="RTL">الأمبول مخصص للاستخدام على مرة واحدة فقط.</p><p dir="RTL">يجب التخلص من أي مُنْتَج غير مستخدم أو نفايات؛ وذلك وفقاً للمتطلبات المحلية.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">7. اسم وعنوان جهة الصنع / والحاصل على ترخيص التسويق</p><p dir="RTL">ميلان لابوراتوريز ليمتد [أو.تي.إل].</p><p dir="RTL">القطعة رقم 284- ب،</p><p dir="RTL">بومّساندرا- جيجاني لينك رود،</p><p dir="RTL">المنطقة الصناعية، أنيكال تالوك،</p><p dir="RTL">بانجالورى - 560105</p><p dir="RTL">&nbsp;</p><p dir="RTL">8. رقم التسجيل/ رقم الوكالة الوطنية لإدارة الغذاء والدواء والرقابة</p><p dir="RTL">&nbsp;</p><p dir="RTL">9. فئة التوزيع</p><p dir="RTL">وصفة أدوية</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تاريخ النشر / تاريخ مراجعة النص
شهر نوفمبر 2020

        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                1.	NAME OF THE MEDICINAL PRODUCT
Bendamustine Hydrochloride for Injection 25 mg/vial & 100 mg/vial
Strength
Strength – 25 mg/vial & 100 mg/vial
Pharmaceutical Form
Form – Lyophilized Powder for Injection

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2.	QUALITATIVE AND QUANTITATIVE COMPOSITION Each vial contains: Bendamustine Hydrochloride 25 mg.
Each vial contains: Bendamustine Hydrochloride 100 mg. For the full list of excipients, see section List of Excipients.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3.	PHARMACEUTICAL FORM
Lyophilized powder for Injection. White to off-white lyophilized powder.


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>&nbsp;Therapeutic Indications</strong></p><p>First-line treatment of chronic lymphocytic leukaemia (Binet stage B or C) in patients for whom fludarabine combination chemotherapy is not appropriate.</p><p>Indolent non-Hodgkin&#39;s lymphomas as monotherapy in patients who have progressed during or within 6 months following treatment with rituximab or a rituximab containing regimen.</p><p>Front line treatment of multiple myeloma (Durie-Salmon stage II with progress or stage III) in combination with prednisone for patients older than 65 years who are not eligible for autologous stem cell transplantation and who have clinical neuropathy at time of diagnosis precluding the use of thalidomide or bortezomib containing treatment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>1.1&nbsp; Posology and method of administration</p><p>For intravenous infusion over 30 &ndash; 60 minutes (see section <strong>Special precautions for disposal and other handling).</strong></p><p>Infusion must be administered under the supervision of a physician qualified and experienced in the use of chemotherapeutic agents.</p><p>Poor bone marrow function is related to increased chemotherapy-induced haematological toxicity. Treatment should not be started if leukocyte and/or platelet values have dropped to &lt;3,000/&micro;L or</p><p>&lt;75,000/&micro;L, respectively (see section <strong>Contraindications).</strong></p><p><strong>&nbsp;</strong></p><p><u>Monotherapy for chronic lymphocytic leukaemia</u></p><p>100 mg/m2 body surface area bendamustine hydrochloride on days 1 and 2; every 4 weeks.</p><p>&nbsp;</p><p><u>Monotherapy for indolent non-Hodgkin&#39;s lymphomas refractory to rituximab</u></p><p>120 mg/m2 body surface area bendamustine hydrochloride on days 1 and 2; every 3 weeks.</p><p>&nbsp;</p><p><u>Multiple myeloma</u></p><p>120 &ndash; 150 mg/m2 body surface area bendamustine hydrochloride on days 1 and 2, 60 mg/m2 body surface area prednisone i.v. or per os on days 1 to 4; every 4 weeks.</p><p>Treatment should be terminated or delayed if leukocyte and/or platelet values have dropped to &lt;3,000/&micro;L or &lt;75,000/&micro;L, respectively. Treatment can be continued after leukocyte values have increased to</p><p>&gt;4,000/&micro;L and platelet values to &gt;100,000/&micro;L.</p><p>The leukocyte and platelet Nadir is reached after 14-20 days with regeneration after 3-5 weeks. During therapy free intervals strict monitoring of the blood count is recommended (see section <strong>Special warnings and Precautions for use</strong>).</p><p>In case of non-haematological toxicity dose reductions have to be based on the worst CTC grades in the preceding cycle. A 50% dose reduction is recommended in case of CTC grade 3 toxicity. An interruption of treatment is recommended in case of CTC grade 4 toxicity.</p><p>If a patient requires a dose modification the individually calculated reduced dose must be given on day 1 and 2 of the respective treatment cycle.</p><p>For preparation and administration instructions <strong>(</strong>see section <strong>Special precautions for disposal and other</strong></p><p>handling<strong>).</strong></p><p><u>Hepatic impairment</u></p><p>On the basis of pharmacokinetic data, no dose adjustment is necessary in patients with mild hepatic impairment (serum bilirubin &lt; 1.2 mg/dL). A 30% dose reduction is recommended in patients with moderate hepatic impairment (serum bilirubin 1.2 - 3.0 mg/dL).</p><p>No data is available in patients with severe hepatic impairment (serum bilirubin values of &gt; 3.0 mg/dL) (see section <strong>Contraindications).</strong></p><p><strong>&nbsp;</strong></p><p><u>Renal impairment</u></p><p>On the basis of pharmacokinetic data, no dose adjustment is necessary in patients with a creatinine clearance of &gt; 10 mL/min. Experience in patients with severe renal impairment is limited.</p><p><u>Paediatric patients</u></p><p>There is no experience in children and adolescents with Bendamustine Hydrochloride. <u>Elderly patients</u></p><p>There is no evidence that dose adjustments are necessary in elderly patients <strong>(</strong>see section <strong>Pharmacokinetic</strong></p><p>properties<strong>).</strong></p><p><u>Method of administration</u></p><p>For intravenous infusion over 30 - 60 minutes (see section <strong>Direction for use</strong>).</p><p>Infusion must be administered under the supervision of a physician qualified and experienced in the use of chemotherapeutic agents.</p><p>Poor bone marrow function is related to increased chemotherapy-induced haematological toxicity. Treatment should not be started if leukocyte and/or platelet values dropped to &lt; 3,000/&micro;l or &lt; 75,000/&micro;l, respectively (see section <strong>Contraindications</strong>).</p><p>Treatment should be terminated or delayed if leukocyte and/or platelet values dropped to &lt; 3,000/&micro;l or &lt; 75,000/&micro;l, respectively. Treatment can be continued after leukocyte values have increased to &gt; 4,000/&micro;l and platelet values to &gt; 100,000/&micro;l.</p><p>The leukocyte and platelet Nadir is reached after 14-20 days with regeneration after 3-5 weeks. During therapy free intervals strict monitoring of the blood count is recommended (see section <strong>Special warnings and Precautions for use</strong>).</p><p>In case of non-haematological toxicity dose reductions have to be based on the worst CTC grades in the preceding cycle. A 50% dose reduction is recommended in case of CTC grade 3 toxicity. An interruption of treatment is recommended in case of CTC grade 4 toxicity.</p><p>If a patient requires a dose modification the individually calculated reduced dose must be given on day 1 and 2 of the respective treatment cycle.</p><p>For instructions on reconstitution of the medicinal product before administration, see section <strong>Direction for use</strong>.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                4.3	Contraindications
•	Hypersensitivity to the active substance or to any of the excipients listed in section List of excipients.
•	During breast feeding
•	Severe hepatic impairment (serum bilirubin > 3.0 mg/dL)
•	Jaundice
•	Severe bone marrow suppression and severe blood count alterations (leukocyte and/or platelet values dropped to <3,000/µL or <75,000/µL, respectively)
•	Major surgery less than 30 days before start of treatment
•	Infections, especially involving leukocytopenia
•	Yellow fever vaccination

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>1.1&nbsp; Special warnings and precautions for use</p><p><u>Myelosuppression</u></p><p>Patients treated with bendamustine hydrochloride may experience myelosuppression. In the event of treatment-related myelosuppression, leukocytes, platelets, haemoglobin, and neutrophils must be monitored at least weekly. Prior to the initiation of the next cycle of therapy, the following parameters are recommended: Leukocyte and/or platelet values &gt;4,000/&micro;L or &gt;100,000/&micro;L, respectively.</p><p><u>Infections</u></p><p>Serious and fatal infections have occurred with bendamustine hydrochloride, including bacterial (sepsis, pneumonia) and opportunistic infections such as Pneumocystis jirovecii pneumonia (PJP), varicella zoster virus (VZV) and cytomegalovirus (CMV). Treatment with bendamustine hydrochloride may cause</p><p>&nbsp;</p><p>prolonged lymphocytopenia (&lt; 600/&mu;l) and low CD4-positive T-cell (T-helper cell) counts (&lt; 200/&mu;l) for at least 7&ndash;9 months after the completion of treatment. Lymphocytopenia and CD4-positive T-cell depletion are more pronounced when bendamustine is combined with rituximab Patients with lymphopenia and low CD4-positive T-cell count following treatment with bendamustine hydrochloride are more susceptible to (opportunistic) infections. In case of low CD4-positive T-cell counts (&lt; 200/&mu;l) Pneumocystis jirovecii pneumonia (PJP) prophylaxis should be considered. All patients should be monitored for respiratory signs and symptoms throughout treatment. Patients should be advised to report new signs of infection, including fever or respiratory symptoms promptly. Discontinuation of bendamustine hydrochloride should be considered if there are signs of (opportunistic) infections.</p><p>&nbsp;</p><p><u>Hepatitis B reactivation</u></p><p>Reactivation of hepatitis B in patients who are chronic carriers of this virus has occurred after these patients received bendamustine hydrochloride. Some cases resulted in acute hepatic failure or a fatal outcome. Patients should be tested for HBV infection before initiating treatment with bendamustine hydrochloride. Experts in liver disease and in the treatment of hepatitis B should be consulted before treatment is initiated in patients with positive hepatitis B tests (including those with active disease) and for patients who test positive for HBV infection during treatment. Carriers of HBV who require treatment with bendamustine hydrochloride should be closely monitored for signs and symptoms of active HBV infection throughout therapy and for several months following termination of therapy (see section <strong>Undesirable effects</strong>).</p><p>&nbsp;</p><p><u>Infections</u></p><p>Infection, including pneumonia and sepsis, has been reported. In rare cases, infection has been associated with hospitalization, septic shock and death. Patients with neutropenia and/or lymphopenia following treatment with bendamustine hydrochloride are more susceptible to infections. Patients with myelosuppression following bendamustine hydrochloride treatment should be advised to contact a physician if they have symptoms or signs of infection, including fever or respiratory symptoms.</p><p>&nbsp;</p><p><u>Skin reactions</u></p><p>A number of skin reactions have been reported. These events have included rash, toxic skin reactions and bullous exanthema. Some events occurred when bendamustine hydrochloride was given in combination with other anticancer agents, so the precise relationship is uncertain. Where skin reactions occur, they may</p><p>&nbsp;</p><p>be progressive and increase in severity with further treatment. If skin reactions are progressive, Bendamustine Hydrochloride should be withheld or discontinued. For severe skin reactions with suspected relationship to bendamustine hydrochloride, treatment should be discontinued.</p><p>&nbsp;</p><p><u>Patients with cardiac disorders</u></p><p>During treatment with bendamustine hydrochloride the concentration of potassium in the blood must be closely monitored and potassium supplement must be given when K+ &lt;3.5 mEq/L, and ECG measurement must be performed.</p><p>&nbsp;</p><p><u>Nausea, vomiting</u></p><p>An antiemetic may be given for the symptomatic treatment of nausea and vomiting.</p><p>&nbsp;</p><p><u>Tumour lysis syndrome</u></p><p>Tumour lysis syndrome (TLS) associated with Bendamustine Hydrochloride treatment has been reported in patients in clinical trials. The onset tends to be within 48 hours of the first dose of Bendamustine Hydrochloride and, without intervention, may lead to acute renal failure and death. Preventive measures include adequate volume status and close monitoring of blood chemistry, particularly potassium and uric acid levels. The use of allopurinol during the first one to two weeks of Bendamustine Hydrochloride therapy can be considered but not necessarily as standard. However, there have been a few cases of Stevens &ndash; Johnson syndrome and Toxic Epidermal Necrolysis reported when bendamustine and allopurinol were administered concomitantly.</p><p>&nbsp;</p><p><u>Anaphylaxis</u></p><p>Infusion reactions to bendamustine hydrochloride have occurred commonly in clinical trials. Symptoms are generally mild and include fever, chills, pruritus and rash. In rare instances severe anaphylactic and anaphylactoid reactions have occurred. Patients must be asked about symptoms suggestive of infusion reactions after their first cycle of therapy. Measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids must be considered in subsequent cycles in patients who have previously experienced infusion reactions.</p><p>Patients who experienced Grade 3 or worse allergic-type reactions were typically not re-challenged.</p><p>&nbsp;</p><p><u>Contraception</u></p><p>Bendamustine hydrochloride is teratogenic and mutagenic.</p><p>&nbsp;</p><p>Women should not become pregnant during treatment. Male patients should not father a child during and up to 6 months after treatment. They should seek advice about sperm conservation prior to treatment with bendamustine hydrochloride because of possible irreversible infertility.</p><p>&nbsp;</p><p><u>Extravasation</u></p><p>An extravasal injection should be stopped immediately. The needle should be removed after a short aspiration. Thereafter the affected area of tissue should be cooled. The arm should be elevated. Additional treatments like the use of corticosteroids are not of clear benefit.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>1.1&nbsp; Interaction with other medicinal products and other forms of interaction</p><p>No <em>in-vivo </em>interaction studies have been performed.</p><p>When Bendamustine Hydrochloride is combined with myelosuppressive agents, the effect of Bendamustine Hydrochloride and/or the co-administered medicinal products on the bone marrow may be potentiated. Any treatment reducing the patient&#39;s performance status or impairing bone marrow function can increase the toxicity of Bendamustine Hydrochloride.</p><p>Combination of Bendamustine Hydrochloride with cyclosporine or tacrolimus may result in excessive immunosuppression with risk of lymphoproliferation.</p><p>Cytostatics can reduce antibody formation following live-virus vaccination and increase the risk of infection which may lead to fatal outcome. This risk is increased in subjects who are already immunosuppressed by their underlying disease.</p><p>Bendamustine metabolism involves cytochrome P450 (CYP) 1A2 isoenzyme (see section <strong>Pharmacokinetic properties</strong>). Therefore, the potential for interaction with CYP1A2 inhibitors such as fluvoxamine, ciprofloxacin, acyclovir and cimetidine exists.</p><p>&nbsp;</p><p>Paediatric population</p><p>Interaction studies have only been performed in adults.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>1.1&nbsp; Fertility, pregnancy and lactation</p><p><u>Pregnancy</u></p><p>There are insufficient data from the use of Bendamustine Hydrochloride in pregnant women. In nonclinical studies bendamustine hydrochloride was embryo-/fetolethal, teratogenic and genotoxic (see section <strong>Preclinical safety data</strong>). During pregnancy Bendamustine Hydrochloride should not be used unless clearly necessary. The mother should be informed about the risk to the foetus. If treatment with</p><p>&nbsp;</p><p>Bendamustine Hydrochloride is absolutely necessary during pregnancy or if pregnancy occurs during treatment, the patient should be informed about the risks for the unborn child and be monitored carefully. The possibility of genetic counselling should be considered.</p><p>&nbsp;</p><p><u>Fertility</u></p><p><u>Women of childbearing potential/contraception</u></p><p>Women of childbearing potential must use effective methods of contraception both before and during Bendamustine Hydrochloride therapy.</p><p>Men being treated with Bendamustine Hydrochloride are advised not to father a child during and for up to 6 months following cessation of treatment. Advice on conservation of sperm should be sought prior to treatment because of the possibility of irreversible infertility due to therapy with Bendamustine Hydrochloride.</p><p>&nbsp;</p><p><u>Breast feeding</u></p><p>It is not known whether bendamustine passes into the breast milk, therefore, Bendamustine Hydrochloride is contraindicated during breast feeding (see section <strong>Contraindications</strong>). Breast feeding must be discontinued during treatment with Bendamustine Hydrochloride.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>1.1&nbsp; Effects on ability to drive and use machines</p><p>No studies on the effects on the ability to drive and use machines have been performed. However, ataxia, peripheral neuropathy and somnolence have been reported during treatment with Bendamustine Hydrochloride (see section <strong>Undesirable effects</strong>). Patients should be instructed that if they experience these symptoms they should avoid potentially hazardous tasks such as driving and using machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>1.1&nbsp; Undesirable effects</p><p>The most common adverse reactions with bendamustine hydrochloride are hematological adverse reactions (leukopenia, thrombopenia), dermatologic toxicities (allergic reactions), constitutional symptoms (fever), gastrointestinal symptoms (nausea, vomiting).</p><p>The table below reflects the data obtained with bendamustine hydrochloride.</p><p>Table 1: Adverse reactions in patients treated with bendamustine hydrochloride.</p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:710px"><tbody><tr><td style="vertical-align:top"><p><strong>MedDRA system</strong></p><p><strong>organ class</strong></p></td><td style="vertical-align:top"><p><strong>Very common &ge;</strong></p><p><strong>1/10</strong></p></td><td style="vertical-align:top"><p><strong>Common</strong></p><p><strong>&ge;1/100 to &lt;1/10</strong></p></td><td style="vertical-align:top"><p><strong>Uncommon</strong></p><p><strong>&ge;1/1,000 to</strong></p><p><strong>&lt;1/100</strong></p></td><td style="vertical-align:top"><p><strong>Rare</strong></p><p><strong>&ge;1/10,000 to</strong></p><p><strong>&lt;1/1, 000</strong></p></td><td style="vertical-align:top"><p><strong>Very rare</strong></p><p><strong>&lt;1/10, 000</strong></p></td><td style="vertical-align:top"><p><strong>Not known (cannot be estimated from the available data</strong></p></td></tr><tr><td style="vertical-align:top"><p>Infections and infestations</p></td><td style="vertical-align:top"><p>Infection NOS Including</p><p>Opportunistic infection (e.g. Herpes zoster, cytomegalovirus, hepatitis B)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Pneumocystis jirovecii pneumonia</p></td><td style="vertical-align:top"><p>Sepsis</p></td><td style="vertical-align:top"><p>Pneumonia primary atypical</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Neoplasms benign, malignant and unspecified (including cyst and polyp)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Tumour lysis syndrome</p></td><td style="vertical-align:top"><p>Myelodysplastic syndrome,</p><p>acute myeloid leukemia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Blood and lymphatic system disorders</p></td><td style="vertical-align:top"><p>Leukopenia NOS*, Thrombocytopenia</p></td><td style="vertical-align:top"><p>Haemorrhage, Anaemia, Neutropenia</p></td><td style="vertical-align:top"><p>Pancytopenia</p></td><td style="vertical-align:top"><p>Bone marrow failure</p></td><td style="vertical-align:top"><p>Haemolysis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Immune system disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hypersensitivity NOS*</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Anaphylactic reaction, Anaphylactoid reaction</p></td><td style="vertical-align:top"><p>Anaphylactic shock</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Insomnia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Somnolence, Aphonia</p></td><td style="vertical-align:top"><p>Dysgeusia, Paraesthesia, Peripheral sensory neuropathy, Anticholinergic syndrome, Neurological disorders, Ataxia, Encephalitis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Cardiac disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Cardiac dysfunction, such as palpitations, angina pectoris, Arrhythmia</p></td><td style="vertical-align:top"><p>Pericardial effusion</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Tachycardia, Myocardial infarction, Cardiac failure</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Vascular disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hypotension, Hypertension</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Acute circulatory failure</p></td><td style="vertical-align:top"><p>Phlebitis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Respiratory, thoracic and media-stinal disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Pulmonary dysfunction</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Pulmonary fibrosis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>Nausea, Vomiting</p></td><td style="vertical-align:top"><p>Diarrhoea, Constipation, Stomatitis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Haemorrhagic oesophagitis, Gastrointestinal haemorrhage</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Alopecia, Skin disorders NOS*</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Erythema, Dermatitis, Pruritus, Macular-papular rash, Hyperhidrosis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Reproductive system and breast disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Amenorrhea</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Infertility</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Hepatobiliary disorder</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hepatic failure</p></td></tr><tr><td style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top"><p>Mucosal inflammation, Fatigue, Pyrexia</p></td><td style="vertical-align:top"><p>Pain, Chills, Dehydration, Anorexia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Multi organ failure</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Investigations</p></td><td style="vertical-align:top"><p>Haemoglobin</p><p>decrease, Creatinine</p><p>increase, Urea</p><p>increase</p></td><td style="vertical-align:top"><p>AST increase,</p><p>ALT increase,</p><p>Alkaline</p><p>phosphatase</p><p>increase,</p><p>Bilirubin</p><p>increase,</p><p>Hypokalemia</p></td><td colspan="4" style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>NOS = Not otherwise specified</p><p>&nbsp;</p><p>A small number of cases of Stevens - Johnson syndrome and Toxic Epidermal Necrolysis have been reported in patients using bendamustine in combination with allopurinol or in combination with allopurinol and rituximab.</p><p>&nbsp;</p><p>The CD4/CD8 ratio may be reduced. A reduction of the lymphocyte count was seen. In immuno- suppressed patients, the risk of infection (e.g. with herpes zoster) may be increased.</p><p>There have been isolated reports of necrosis after accidental extra-vascular administration and toxic epidermal necrolysis, tumour lysis syndrome and anaphylaxis.</p><p>&nbsp;</p><p>There are reports of secondary tumours, including myelodysplastic syndrome, myeloproliferative disorders, acute myeloid leukaemia and bronchial carcinoma. The association with Bendamustine Hydrochloride therapy has not been determined.</p><p>&nbsp;</p><p>Reporting of suspected adverse reactions</p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via:</p><p>&nbsp;</p><p>Reporting to National regulatory authority:</p><p>The National Pharmacovigilance and Drug Safety Centre (NPC):</p><p>Fax: +966-11-205-7662</p><p>Call NPC at +966-11-2038222, Ext 2317-2356-2340</p><p>Reporting hotline: 19999</p><p>E-mail: npc.drug@sfda.gov.sa Website: www.sfda.gov.sa/npc</p><p>This is a medicament</p><p>&bull;&nbsp; A medicament is a product which affects your health and its consumption contrary to instructions is dangerous for you.</p><p>&bull;&nbsp; Follow strictly the doctor&rsquo;s prescription, the method of use and the instructions of the pharmacist who sold the medicament.</p><p>&bull;&nbsp; The doctor and the pharmacist are experts in medicines, its benefits and risks.</p><p>&bull;&nbsp; Do not by yourself interrupt the period of treatment prescribed for you.</p><p>&bull;&nbsp; Do not repeat the same prescription without consulting your doctor.</p><p>&bull;&nbsp; Keep all medicaments out of reach of children. COUNCIL OF ARAB HEALTH MINISTERS UNION OF ARAB PHARMACISTS</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>1.1&nbsp; Overdose</p><p>After application of a 30 min infusion of Bendamustine Hydrochloride once every 3 weeks the maximum tolerated dose (MTD) was 280 mg/m2. Cardiac events of CTC grade 2 which were compatible with ischaemic ECG changes occurred which were regarded as dose limiting.</p><p>In a subsequent study with a 30 min infusion of Bendamustine Hydrochloride at day 1 and 2 every 3 weeks the MTD was found to be 180 mg/m2. The dose limiting toxicity was grade 4 thrombocytopenia. Cardiac toxicity was not dose limiting with this schedule.</p><p>&nbsp;</p><p><u>Counter measures</u></p><p>There is no specific antidote. Bone marrow transplantation and transfusions (platelets, concentrated erythrocytes) may be made or haematological growth factors may be given as effective countermeasures to control haematological side effects.</p><p>Bendamustine hydrochloride and its metabolites are dialyzable to a small extent.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Pharmacodynamic properties</strong></p><p>Pharmacotherapeutic group: Antineoplastic agents, alkylating agents, ATC code: L01AA09. Bendamustine hydrochloride is an alkylating antitumour agent with unique activity. The antineoplastic and cytocidal effect of bendamustine hydrochloride is based essentially on a cross-linking of DNA single and double strands by alkylation. As a result, DNA matrix functions and DNA synthesis and repair are impaired. The antitumour effect of bendamustine hydrochloride has been demonstrated by several <em>in vitro </em>studies in different human tumour cell lines (breast cancer, non-small cell and small cell lung cancer, ovarian carcinoma and different leukaemia) and <em>in vivo </em>in different experimental tumour models with tumours of mouse, rat and human origin (melanoma, breast cancer, sarcoma, lymphoma, leukaemia and small cell lung cancer).</p><p>Bendamustine hydrochloride showed an activity profile in human tumour cell lines different to that of other alkylating agents. The active substance revealed no or very low cross-resistance in human tumour cell lines with different resistance mechanisms at least in part due to a comparatively persistent DNA interaction. Additionally, it was shown in clinical studies that there is no complete cross-resistance of bendamustine with anthracyclines, alkylating agents or rituximab. However, the number of assessed patients is small.</p><p>&nbsp;</p><p><u>Chronic lymphocytic leukaemia</u></p><p>The indication for use in chronic lymphocytic leukaemia is supported by a single open label study comparing bendamustine with chlorambucil. In the prospective, multi-centre, randomised study, 319 previously untreated patients with chronic lymphocytic leukaemia stage Binet B or C requiring therapy were included. The first line therapy with bendamustine hydrochloride 100 mg/m2 i.v. on days 1 and 2 (BEN) was compared to treatment with chlorambucil 0.8 mg/kg days 1 and 15 (CLB) for 6 cycles in both arms. Patients received allopurinol in order to prevent tumour lysis syndrome.</p><p>&nbsp;</p><p>Patients with BEN had a significantly longer median progression free survival than patients with CLB treatment (21.5 versus 8.3 months, p &lt; 0.0001 in the latest follow-up). Overall survival was not statistically significantly different (median not reached). The median duration of remission was 19 months with BEN and 6 months with CLB treatment (p &lt; 0.0001). The safety evaluation in both treatment arms did not reveal any unexpected undesirable effects in nature and frequency. The dose of BEN was reduced in 34% of the patients. Treatment with BEN was discontinued in 3.9% of patients due to allergic reactions.</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Indolent non-Hodgkin&#39;s lymphomas</u></p><p>The indication for indolent non-Hodgkin&#39;s lymphomas relied on two uncontrolled phase II trials.</p><p>In the pivotal prospective, multi-centre, open study 100 patients with indolent B-cell non-Hodgkin&acute;s lymphomas refractory to rituximab mono- or combination therapy were treated with BEN single agent. Patients had received a median of 3 previous chemotherapy or biological therapy courses. The median number of previous rituximab-containing courses was 2. The patients had no response or there had been progression within 6 months after rituximab treatment. The dose of BEN was 120 mg/m2 i.v. on days 1 and 2 planned for at least 6 cycles. Duration of treatment depended on response (6 cycles planned). The overall response rate was 75% including 17% complete (CR and CRu) and 58% partial response as assessed by independent review committee. The median duration of remission was 40 weeks. BEN was generally well tolerated when given in this dose and schedule.</p><p>&nbsp;</p><p>The indication is further supported by another prospective, multi-centre, open study including 77 patients. The patient population was more heterogeneous including: indolent or transformed B-cell non-Hodgkin&#39;s lymphomas refractory to rituximab mono- or combination therapy. The patients had no response or there had been progression within 6 months or had had an untoward reaction to prior rituximab treatment. Patients had received a median of 3 previous chemotherapy or biological therapy courses. The median number of previous rituximab-containing courses had been 2. The overall response rate was 76% with a median duration of response of 5 months (29 [95% CI 22.1, 43.1] weeks).</p><p><u>Multiple myeloma</u></p><p>In a prospective, multi-centre, randomised, open study 131 patients with advanced multiple myeloma (Durie-Salmon stage II with progression or stage III) were included. The first line therapy with bendamustine hydrochloride in combination with prednisone (BP) was compared to treatment with melphalan and prednisone (MP). Tolerability in both treatment arms was in line with the known safety profile of the respective medicinal products with significantly more dose reductions in the BP arm. The dose was bendamustine hydrochloride 150 mg/m2 i.v. on days 1 and 2 or melphalan 15 mg/m2 i.v. on day 1 each in combination with prednisone. Duration of treatment depended on response and averaged 6.8 cycles in the BP and 8.7 cycles in the MP group.</p><p>Patients with BP treatment had a longer median progression free survival than patients with MP (15 [95% CI 12-21] versus 12 [95% CI 10-14] months) (p=0.0566). The median time to treatment failure was 14 months with BP and 9 months with MP treatment. The duration of remission was 18 months with BP and</p><p>&nbsp;</p><p>12 months with MP treatment. The difference in overall survival was not significantly different (35 months BP versus 33 months MP). Tolerability in both treatment arms was in line with the known safety profile of the respective medicinal products with significantly more dose reductions in the BP arm.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;Pharmacokinetic properties</p><p><u>Distribution</u></p><p>The elimination half-life t1/2 &szlig; after 30 min i.v. infusion of 120 mg/m<sup>2</sup> area to 12 subjects was 28.2 minutes. Following 30 min i.v. infusion the central volume of distribution was 19.3 L. Under steady-state conditions following i.v. bolus injection the volume of distribution was 15.8-20.5 I.</p><p>More than 95% of the substance is bound to plasma proteins (primarily albumin). <u>Metabolism</u></p><p>A major route of clearance of bendamustine is the hydrolysis to monohydroxy- and dihydroxy- bendamustine. Formation of N-desmethyl-bendamustine and gamma-hydroxy-bendamustine by hepatic metabolism involves cytochrome P450 (CYP) 1A2 isoenzyme. Another major route of bendamustine metabolism involves conjugation with glutathione.</p><p><em>In-vitro </em>bendamustine does not inhibit CYP 1A4, CYP 2C9/10, CYP 2D6, CYP 2E1 or CYP 3A4. <u>Elimination</u></p><p>The mean total clearance after 30 min i.v. infusion of 120 mg/m2 body surface area to 12 subjects was</p><p>639.4 mL/minute. About 20% of the administered dose was recovered in urine within 24 hours. Amounts excreted in urine were in the order monohydroxy-bendamustine &gt; bendamustine &gt; dihydroxy- bendamustine &gt; oxidised metabolite &gt; N-desmethyl bendamustine. In the bile, primarily polar metabolites are eliminated.</p><p><u>Hepatic impairment</u></p><p>In patients with 30 - 70% tumour infestation of the liver and mild hepatic impairment (serum bilirubin &lt;</p><p>1.2 mg/dL) the pharmacokinetic behaviour was not changed. There was no significant difference to patients with normal liver and kidney function with respect to Cmax, tmax, AUC, t1/2 &szlig;, volume of&nbsp;distribution and clearance. AUC and total body clearance of bendamustine correlate inversely with serum bilirubin.</p><p><u>Renal impairment</u></p><p>In patients with creatinine clearance &gt;10 mL/min including dialysis dependent patients, no significant difference to patients with normal liver and kidney function was observed with respect to Cmax, tmax, AUC, t1/2&szlig;, volume of distribution and clearance.</p><p>&nbsp;</p><p><u>Elderly subjects</u></p><p>Subjects up to 84 years of age were included in pharmacokinetic studies. Higher age does not influence the pharmacokinetics of bendamustine.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Preclinical safety data</p><p>Adverse reactions not observed in clinical studies, but seen in animals at exposure levels similar to clinical exposure levels and with possible relevance to clinical use were as follows:</p><p>Histological investigations in dogs showed macroscopic visible hyperaemia of the mucosa and haemorrhagia in the gastrointestinal tract. Microscopic investigations showed extensive changes of the lymphatic tissue indicating an immunosuppression and tubular changes of kidneys and testis, as well as atrophic, necrotic changes of the prostate epithelium.</p><p>Animal studies showed that bendamustine is embryotoxic and teratogenic.</p><p>Bendamustine induces aberrations of the chromosomes and is mutagenic <em>in vivo </em>as well as <em>in vitro</em>. In long-term studies in female mice bendamustine is carcinogenic.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>1.1&nbsp; </strong><strong>List of Excipients</strong></p><p>Mannitol</p><p>Tertiary butyl alcohol</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>1.1&nbsp; Incompatibilities</p><p>This medicinal product must not be mixed with other medicinal products except those mentioned in section <strong>Special precautions for disposal and other handling</strong>.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                6.3	Shelf-life
24months from the date of manufacture.
The powder should be reconstituted immediately with 0.9% sodium chloride solution after opening of the vial.
The reconstituted concentrate should be diluted immediately. Solution for infusion
After reconstitution and dilution, chemical and physical stability has been demonstrated for 3.5 hours at 25°C and 48 hours at 2°C to 8°C in polyethylene bags.
 
From a microbiological point of view, the solution should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Special precautions for storage</p><p>Do not store above 30&deg;C. Protect from light.</p><p>For storage conditions after reconstitution of the medicinal product, see section <strong>Shelf-life</strong>. Keep the vial in the outer carton in order to protect from light.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Nature and contents of container</p><p><strong>24&nbsp; </strong><strong>mg/vial: </strong>20 mL type I amber tubular for lyo flat bottom vials and 20 mm dark grey bromobutyl lyo rubber closures and 20 mm aluminium seals.</p><p><strong>100 mg/vial: </strong>50 mL type I moulded amber vials and 20 mm dark grey bromobutyl lyo rubber closures and 20 mm aluminium seals.</p><p>Pack size &ndash; 1 Vial in a carton</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Special precautions for disposal and other handling</p><p>When handling Bendamustine Hydrochloride, inhalation, skin contact or contact with mucous membranes should be avoided (wear gloves and protective clothes). Contaminated body parts should be carefully rinsed with water and soap, the eyes should be rinsed with physiological saline solution. If possible it is recommended to work on special safety workbenches (laminar flow) with liquid-impermeable, absorbent disposable foil. Pregnant personnel should be excluded from handling cytostatics.</p><p>The powder has to be reconstituted with water for injection, diluted with sodium chloride 9 mg/mL (0.9%) solution for injection and then administered by intravenous infusion. Aseptic technique is to be used.</p><p>1.&nbsp; <u>Reconstitution</u></p><p>Reconstitute each vial of Bendamustine Hydrochloride containing 25 mg bendamustine hydrochloride in 10 ml water for injection by shaking;</p><p>&nbsp;</p><p>Reconstitute each vial of Bendamustine Hydrochloride containing 100 mg bendamustine hydrochloride in 40 ml water for injection by shaking.</p><p>The reconstituted concentrate contains 2.5 mg bendamustine hydrochloride per mL and appears as a clear colourless solution.</p><p>2.&nbsp; <u>Dilution</u></p><p>&nbsp;</p><p>As soon as a clear solution is obtained (usually after 5-10 minutes) dilute the total recommended dose of Bendamustine Hydrochloride immediately with 0.9% NaCl solution to produce a final volume of about 500 mL.</p><p>Bendamustine Hydrochloride must be diluted with 0.9% NaCl solution and not with any other injectable solution.</p><p>3.&nbsp; <u>Administration</u></p><p>The solution is administered by intravenous infusion over 30-60 min. The vials are for single use only.</p><p>Any unused product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                7.	NAME AND ADDRESS OF THE MANUFACTURER/MARKETING AUTHORISATION HOLDER
Manufactured by:
Mylan Laboratories Limited [OTL],
Plot No. 284-B,
Bommasandra – Jigani Link Road, Industrial Area, Anekal Taluk, Bangalore – 560 105

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                November, 2020
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>